data_6hpj_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6hpj _Structure_validation_residue.Date_analyzed 2020-11-20 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.1 m . . . . . 0 CA--C 1.533 0.306 0 N-CA-C 111.797 0.295 . . . . 0.0 111.797 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 33.9 mtt180 -84.5 149.7 25.76 Favored 'General case' 0 C--O 1.232 0.135 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -176.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 16.6 pt -140.62 174.48 7.8 Favored 'Isoleucine or valine' 0 C--O 1.23 0.07 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.917 173.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -109.0 150.39 27.83 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 114.497 1.295 . . . . 0.0 114.497 -177.64 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t -137.4 142.43 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.19 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.221 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.92 179.45 29.35 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -178.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 61.9 t30 56.23 39.42 30.25 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 123.666 0.787 . . . . 0.0 110.899 -174.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 84.8 mt . . . . . 0 CA--C 1.533 0.295 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.392 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 52.7 tptt . . . . . 0 N--CA 1.454 -0.257 0 N-CA-C 110.83 -0.063 . . . . 0.0 110.83 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 59.2 m-20 -64.6 -28.4 69.6 Favored 'General case' 0 C--O 1.231 0.124 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -176.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 31.3 mm -78.12 -23.41 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 177.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.4 mt-10 -86.74 -11.44 51.1 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.921 -0.127 . . . . 0.0 110.823 179.083 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 79.0 m-20 -101.33 -66.06 0.94 Allowed 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 177.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 41.4 t -73.84 -53.95 16.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.21 0 CA-C-N 116.756 -0.202 . . . . 0.0 111.04 -174.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 63.3 m-85 -69.16 -21.38 64.0 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -179.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 45.5 t -74.28 -32.18 62.81 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 175.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -68.85 -29.71 68.08 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 174.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 20.3 m-85 -82.69 -20.17 36.65 Favored 'General case' 0 CA--C 1.528 0.129 0 N-CA-C 116.352 1.982 . . . . 0.0 116.352 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.73 20.52 0.05 OUTLIER Glycine 0 CA--C 1.527 0.782 0 C-N-CA 119.66 -1.257 . . . . 0.0 114.775 -175.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 47.65 59.81 3.92 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 118.203 1.002 . . . . 0.0 111.667 174.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 29.2 mm -44.96 132.8 1.83 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 C-N-CA 123.597 0.759 . . . . 0.0 111.496 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -86.64 -37.29 18.18 Favored 'General case' 0 N--CA 1.456 -0.161 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.384 177.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 -147.86 150.06 33.44 Favored 'General case' 0 C--O 1.231 0.09 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -176.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -109.15 149.91 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 176.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -148.11 64.63 1.1 Allowed 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 77.7 mt -63.47 138.12 58.39 Favored 'General case' 0 C--O 1.232 0.156 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 49.3 mttp -130.64 51.76 2.09 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 123.974 0.91 . . . . 0.0 109.832 177.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 76.8 m-20 . . . . . 0 N--CA 1.452 -0.329 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.425 174.048 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo . . . . . 0 N--CA 1.45 -1.08 0 N-CA-C 110.535 -0.602 . . . . 0.0 110.535 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -166.32 -178.45 4.54 Favored 'General case' 0 CA--C 1.528 0.127 0 N-CA-C 105.974 -1.862 . . . . 0.0 105.974 176.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -158.11 166.39 32.59 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.373 0.606 . . . . 0.0 112.081 -177.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -121.32 157.82 29.55 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.575 171.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 75.7 t -138.9 137.21 42.76 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.134 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -178.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 69.0 tt0 -116.91 114.04 23.29 Favored 'General case' 0 CA--C 1.529 0.142 0 CA-C-O 120.666 0.27 . . . . 0.0 110.814 -176.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -82.11 168.56 17.62 Favored 'General case' 0 N--CA 1.457 -0.095 0 N-CA-C 115.872 1.804 . . . . 0.0 115.872 -176.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 48.7 tp10 -64.74 -35.73 82.01 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 174.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 26.1 p30 -159.19 162.92 25.17 Favored Pre-proline 0 CA--C 1.532 0.275 0 C-N-CA 123.536 0.734 . . . . 0.0 110.359 175.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -63.61 -18.15 63.05 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 123.116 2.544 . . . . 0.0 112.322 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 4.3 ttp85 -78.44 -40.93 34.29 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 117.849 0.295 . . . . 0.0 110.765 -175.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 79.5 m-20 -71.78 -24.35 61.73 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 178.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.59 -28.88 68.14 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 44.5 tp10 -68.77 -34.11 75.02 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 110.492 -0.188 . . . . 0.0 110.492 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -73.85 -33.99 64.33 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 178.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.86 -33.33 64.04 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 177.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 13.7 t -71.22 -45.23 71.81 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 48.2 t -69.79 -16.65 63.33 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 122.309 -0.244 . . . . 0.0 111.487 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.86 -8.75 41.69 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-O 119.119 -0.823 . . . . 0.0 113.711 -174.155 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -140.25 -12.26 1.07 Allowed 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 118.905 1.352 . . . . 0.0 113.277 -174.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -76.61 146.34 38.29 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 118.516 0.598 . . . . 0.0 110.12 -176.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.25 39.96 97.92 Favored Glycine 0 CA--C 1.527 0.836 0 CA-C-O 119.526 -0.597 . . . . 0.0 112.068 171.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 42.3 t80 -95.67 131.18 42.18 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -174.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -61.29 105.87 0.55 Allowed 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 123.663 0.785 . . . . 0.0 112.477 -178.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.427 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 46.3 t80 -112.88 169.45 8.9 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 123.738 0.815 . . . . 0.0 111.619 177.691 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.427 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 19.0 t0 -61.02 98.62 0.08 Allowed 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -179.249 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.59 -5.14 61.75 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 123.441 0.543 . . . . 0.0 112.677 177.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -141.3 -171.12 3.22 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 117.855 0.828 . . . . 0.0 112.954 -178.323 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 40.5 ttt180 -147.24 128.34 14.64 Favored 'General case' 0 C--O 1.231 0.113 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 -177.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -63.92 147.49 51.84 Favored 'General case' 0 N--CA 1.461 0.102 0 C-N-CA 122.694 0.398 . . . . 0.0 110.205 -174.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -118.57 119.82 35.65 Favored 'General case' 0 CA--C 1.521 -0.15 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 175.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.7 t -145.55 80.11 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 C-N-CA 122.878 0.471 . . . . 0.0 109.84 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -149.33 159.2 44.48 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.692 0.282 . . . . 0.0 110.807 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -74.16 156.04 87.83 Favored Pre-proline 0 CA--C 1.531 0.223 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo . . . . . 0 C--O 1.252 1.187 0 C-N-CA 123.669 2.913 . . . . 0.0 111.727 175.807 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.7 m . . . . . 0 CA--C 1.528 0.106 0 N-CA-C 110.591 -0.151 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . 0.441 ' HA ' ' HA ' ' B' ' 60' ' ' GLU . 32.6 ttp-105 -102.81 148.83 25.14 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.324 0.65 . . . . 0.0 110.686 -177.398 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 20.8 pt -131.67 179.23 4.54 Favored 'Isoleucine or valine' 0 C--O 1.23 0.063 0 C-N-CA 123.277 0.631 . . . . 0.0 109.835 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -118.82 156.87 28.67 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 114.248 1.203 . . . . 0.0 114.248 -175.674 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 12.7 t -134.37 123.92 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 C-N-CA 122.917 0.487 . . . . 0.0 110.705 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -130.22 166.61 22.14 Favored Glycine 0 CA--C 1.53 1.02 0 N-CA-C 111.688 -0.565 . . . . 0.0 111.688 -177.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 60.5 t30 63.65 28.61 15.06 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 124.648 1.179 . . . . 0.0 111.765 -176.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 87.7 mt . . . . . 0 CA--C 1.532 0.287 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 174.996 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 21.6 tptm . . . . . 0 CA--C 1.533 0.322 0 CA-C-O 120.462 0.173 . . . . 0.0 110.722 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -67.24 -30.38 70.27 Favored 'General case' 0 CA--C 1.528 0.131 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -178.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.3 mt -75.28 -33.09 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 99.3 mt-10 -75.34 -15.49 60.48 Favored 'General case' 0 N--CA 1.456 -0.173 0 C-N-CA 122.451 0.301 . . . . 0.0 110.986 -178.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -91.51 -52.18 4.91 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 112.924 0.712 . . . . 0.0 112.924 174.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 93.9 t -71.22 -50.91 38.26 Favored 'Isoleucine or valine' 0 C--N 1.34 0.172 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 -174.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -68.09 -31.9 71.84 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -177.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 43.8 t -66.45 -29.12 69.18 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 110.539 -0.171 . . . . 0.0 110.539 177.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -71.23 -31.03 67.07 Favored 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 174.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -79.0 -20.88 47.96 Favored 'General case' 0 C--O 1.233 0.219 0 N-CA-C 115.79 1.774 . . . . 0.0 115.79 176.376 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 169.81 -177.11 43.43 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 118.388 0.54 . . . . 0.0 112.289 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.37 95.99 8.92 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 122.838 0.455 . . . . 0.0 110.68 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.8 mp -80.28 149.6 5.13 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 C-N-CA 122.733 0.413 . . . . 0.0 110.225 175.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 29.1 mtp-105 -115.0 -34.06 5.2 Favored 'General case' 0 CA--C 1.528 0.119 0 C-N-CA 123.657 0.783 . . . . 0.0 111.313 177.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.8 m-20 -146.61 155.8 42.74 Favored 'General case' 0 N--CA 1.457 -0.105 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -176.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 4.1 mp -136.1 150.48 28.1 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.137 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 177.248 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -138.96 48.81 1.88 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 120.792 0.33 . . . . 0.0 111.072 179.167 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.6 tp -63.78 124.48 21.6 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 173.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 24.4 pttm -152.35 161.72 42.19 Favored 'General case' 0 N--CA 1.458 -0.062 0 C-N-CA 122.53 0.332 . . . . 0.0 110.666 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 18.8 p30 . . . . . 0 N--CA 1.455 -0.22 0 CA-C-O 120.891 0.377 . . . . 0.0 111.061 -177.201 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_exo . . . . . 0 N--CA 1.455 -0.745 0 N-CA-C 113.824 0.663 . . . . 0.0 113.824 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -147.61 163.4 36.75 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 104.385 -2.45 . . . . 0.0 104.385 175.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -149.93 163.59 37.67 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 119.997 -0.681 . . . . 0.0 112.737 -171.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -122.15 154.67 37.11 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.09 169.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 71.9 t -140.12 132.37 33.2 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.266 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . 0.441 ' HA ' ' HA ' ' B' ' 17' ' ' ARG . 68.2 tt0 -117.28 132.54 56.6 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.811 0.339 . . . . 0.0 111.252 -174.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -98.47 160.55 14.21 Favored 'General case' 0 C--O 1.231 0.12 0 N-CA-C 114.826 1.417 . . . . 0.0 114.826 -175.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -81.89 -17.4 47.36 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.857 0.463 . . . . 0.0 110.382 171.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -152.74 120.58 3.13 Favored Pre-proline 0 C--O 1.233 0.206 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -178.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.52 -14.33 44.3 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 123.066 2.51 . . . . 0.0 111.948 -175.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 86.7 mtm180 -71.69 -24.49 61.83 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 117.944 0.338 . . . . 0.0 110.669 176.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -87.74 -27.07 22.59 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-O 120.75 0.309 . . . . 0.0 110.751 176.016 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.03 -25.23 65.27 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 177.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -69.86 -31.08 68.73 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 122.218 0.207 . . . . 0.0 110.523 178.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -76.48 -35.33 58.45 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 112.308 0.485 . . . . 0.0 112.308 179.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.33 -27.72 66.52 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 122.634 0.373 . . . . 0.0 110.059 177.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 39.6 t -87.52 -44.09 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.2 t -65.98 -21.56 66.42 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-N 117.552 0.16 . . . . 0.0 111.127 -176.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -90.29 -15.36 57.4 Favored Glycine 0 CA--C 1.53 0.977 0 CA-C-O 119.455 -0.636 . . . . 0.0 113.004 -177.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 61.0 mtm180 -146.22 19.57 1.39 Allowed 'General case' 0 C--N 1.342 0.282 0 CA-C-N 118.24 1.02 . . . . 0.0 113.146 -170.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 18.8 p30 -70.81 -1.42 11.56 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.105 0.779 . . . . 0.0 113.105 178.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.82 90.69 0.08 OUTLIER Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -120.58 137.77 54.23 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 176.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -68.94 92.26 0.5 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.442 0.697 . . . . 0.0 111.953 -176.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -84.68 -175.92 5.99 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -67.89 82.79 0.2 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 123.557 0.743 . . . . 0.0 112.298 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.7 2.83 89.81 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 112.148 -0.381 . . . . 0.0 112.148 178.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -137.86 -174.57 3.82 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -179.081 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 70.5 ttp85 -140.39 135.06 31.71 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.85 151.42 45.55 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 122.666 0.387 . . . . 0.0 110.18 -179.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 51.5 mtm180 -134.54 55.71 1.88 Allowed 'General case' 0 C--O 1.231 0.103 0 C-N-CA 122.435 0.294 . . . . 0.0 110.849 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 20.1 t -82.95 94.83 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.188 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 174.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -152.31 161.47 42.56 Favored 'General case' 0 C--O 1.226 -0.174 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -76.6 156.05 83.2 Favored Pre-proline 0 CA--C 1.532 0.268 0 N-CA-C 114.666 1.358 . . . . 0.0 114.666 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo . . . . . 0 C--O 1.25 1.119 0 C-N-CA 123.789 2.993 . . . . 0.0 111.723 175.434 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 95.9 m . . . . . 0 CA--C 1.534 0.327 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 84.2 mtt-85 -83.38 146.9 28.21 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 118.272 0.487 . . . . 0.0 111.737 176.195 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 26.9 pt -131.45 172.29 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 173.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -120.74 149.72 42.1 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 114.185 1.18 . . . . 0.0 114.185 -178.029 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 19.7 t -137.53 141.83 38.36 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 C-N-CA 123.449 0.699 . . . . 0.0 109.728 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -150.43 171.84 30.26 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -176.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 65.6 t30 59.73 30.91 20.51 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.213 1.005 . . . . 0.0 111.688 -175.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.9 mt . . . . . 0 N--CA 1.454 -0.257 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 174.892 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 55.0 tptt . . . . . 0 N--CA 1.456 -0.129 0 N-CA-C 111.139 0.051 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -64.53 -29.78 70.81 Favored 'General case' 0 N--CA 1.455 -0.175 0 N-CA-C 112.106 0.409 . . . . 0.0 112.106 -177.089 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 mm -74.69 -21.2 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.18 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 90.2 mt-10 -78.47 -48.74 14.76 Favored 'General case' 0 C--O 1.223 -0.324 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -65.86 -44.7 84.63 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -174.312 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 99.0 t -69.84 -53.04 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.099 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -176.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -75.28 -24.1 57.49 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 113.546 0.943 . . . . 0.0 113.546 -174.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 41.8 t -68.89 -31.79 70.96 Favored 'General case' 0 C--N 1.342 0.265 0 CA-C-N 118.008 0.367 . . . . 0.0 110.054 173.149 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 58.3 tptt -68.36 -30.76 69.78 Favored 'General case' 0 C--N 1.341 0.212 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 174.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . 0.401 ' CD2' ' HA ' ' B' ' 70' ' ' ALA . 39.6 m-85 -74.75 -20.36 59.85 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 115.457 1.651 . . . . 0.0 115.457 174.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 159.52 -178.0 35.81 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.835 -0.506 . . . . 0.0 111.835 176.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -73.79 122.19 22.04 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.65 0.262 . . . . 0.0 110.36 -178.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 73.8 mt -92.65 140.0 17.01 Favored 'Isoleucine or valine' 0 C--O 1.233 0.237 0 C-N-CA 122.937 0.495 . . . . 0.0 111.201 -178.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -94.14 -38.19 11.21 Favored 'General case' 0 N--CA 1.458 -0.071 0 C-N-CA 123.093 0.557 . . . . 0.0 110.361 170.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -155.94 156.76 35.12 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 120.713 0.292 . . . . 0.0 111.101 -173.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mt -133.28 143.3 39.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 C-N-CA 124.186 0.994 . . . . 0.0 108.854 175.281 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -144.74 64.88 1.28 Allowed 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 120.644 0.259 . . . . 0.0 111.54 -174.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 57.7 tp -58.23 134.75 56.8 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 169.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 54.8 tttp -143.23 164.23 30.78 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.841 0.353 . . . . 0.0 111.238 -168.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 44.8 p30 . . . . . 0 CA--C 1.535 0.387 0 C-N-CA 123.383 0.673 . . . . 0.0 110.694 -173.312 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo . . . . . 0 N--CA 1.452 -0.963 0 N-CA-C 110.658 -0.555 . . . . 0.0 110.658 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 3.8 p90 -152.92 173.3 15.55 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 106.281 -1.748 . . . . 0.0 106.281 -175.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.64 168.31 27.78 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 -174.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 80.7 m-85 -127.23 157.11 40.7 Favored 'General case' 0 C--O 1.234 0.282 0 C-N-CA 123.618 0.767 . . . . 0.0 110.056 171.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 56.0 t -143.76 142.03 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -119.18 125.26 48.78 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 177.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -89.49 161.68 16.11 Favored 'General case' 0 C--O 1.231 0.114 0 N-CA-C 115.272 1.582 . . . . 0.0 115.272 174.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 37.3 tp10 -72.18 -23.97 61.35 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.559 175.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 48.4 m-20 -144.47 151.86 51.85 Favored Pre-proline 0 N--CA 1.455 -0.176 0 C-N-CA 124.192 0.997 . . . . 0.0 112.292 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -68.6 -18.29 42.9 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.877 2.384 . . . . 0.0 110.615 178.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 73.0 ttt-85 -68.84 -40.04 79.63 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 177.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -76.07 -26.12 56.22 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 120.739 0.304 . . . . 0.0 111.664 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.87 -36.24 70.05 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 176.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 41.7 tp10 -69.35 -32.09 70.93 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 110.388 -0.227 . . . . 0.0 110.388 178.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -70.94 -35.9 72.4 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . 0.401 ' HA ' ' CD2' ' B' ' 39' ' ' TYR . . . -71.43 -32.73 68.71 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 178.305 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 59.1 t -80.14 -30.48 12.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 45.7 t -79.97 -9.33 59.68 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 122.715 0.406 . . . . 0.0 110.656 178.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -66.57 -77.06 0.31 Allowed Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.217 -0.753 . . . . 0.0 111.217 -178.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 4.0 tpm_? -156.69 132.06 9.28 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 51.3 p-10 -153.15 168.79 24.78 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.506 0.722 . . . . 0.0 109.09 176.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 58.67 40.8 95.26 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 174.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -98.42 132.93 43.47 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 113.832 1.049 . . . . 0.0 113.832 -172.411 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -62.45 106.69 0.8 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.639 0.776 . . . . 0.0 112.35 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.437 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 50.1 t80 -114.31 170.31 8.39 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 123.585 0.754 . . . . 0.0 111.39 178.341 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.437 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 21.3 t0 -60.0 100.54 0.09 Allowed 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.33 -5.6 42.49 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-O 119.746 -0.474 . . . . 0.0 112.912 178.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 88.1 m-85 -140.34 -170.51 3.0 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 117.871 0.836 . . . . 0.0 113.241 -178.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 40.0 ttt180 -148.61 129.9 14.67 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 123.673 0.789 . . . . 0.0 108.953 -177.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -67.51 149.59 49.97 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -176.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -129.67 130.35 45.44 Favored 'General case' 0 C--N 1.34 0.181 0 CA-C-O 120.624 0.25 . . . . 0.0 110.52 172.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.6 t -145.3 80.36 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.099 0 C-N-CA 123.96 0.904 . . . . 0.0 109.298 173.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -144.63 168.36 20.34 Favored 'General case' 0 C--O 1.226 -0.132 0 C-N-CA 122.595 0.358 . . . . 0.0 111.047 -175.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 69.9 m-85 -63.67 153.24 84.17 Favored Pre-proline 0 C--O 1.235 0.307 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 179.03 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 C--O 1.251 1.168 0 C-N-CA 123.705 2.937 . . . . 0.0 110.932 175.168 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 69.8 m . . . . . 0 CA--C 1.533 0.292 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 66.1 mtm-85 -71.29 143.86 50.19 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 117.769 0.259 . . . . 0.0 110.796 172.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.6 pt -139.16 171.2 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.102 0 C-N-CA 123.302 0.641 . . . . 0.0 109.4 177.188 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -113.75 151.37 32.03 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 44.1 t -137.38 144.64 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 123.251 0.62 . . . . 0.0 109.462 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -156.2 177.15 33.39 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -177.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 62.1 t30 62.75 169.68 0.14 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.604 1.161 . . . . 0.0 111.406 -172.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 85.3 mt . . . . . 0 N--CA 1.454 -0.251 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 177.631 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 47.7 tptt . . . . . 0 CA--C 1.532 0.265 0 CA-C-O 120.554 0.216 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -53.35 -44.66 68.71 Favored 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -177.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.3 tt -78.55 -5.26 7.69 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 C-N-CA 122.898 0.479 . . . . 0.0 110.819 -176.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 84.5 mt-10 -116.85 1.43 12.7 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 122.55 0.34 . . . . 0.0 111.236 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 11.1 t0 -125.29 -54.04 1.59 Allowed 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 87.2 t -69.7 -41.99 80.2 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.042 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -178.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 45.4 m-85 -67.86 -27.85 67.04 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 176.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 67.2 m -72.65 -21.88 61.02 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.443 177.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 24.7 ttmm -77.75 -30.82 51.75 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 109.684 -0.488 . . . . 0.0 109.684 173.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -70.86 -23.13 62.26 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 114.39 1.256 . . . . 0.0 114.39 173.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 164.01 174.34 33.71 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 174.138 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -71.53 125.13 26.26 Favored 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 17.1 mt -99.33 138.97 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.164 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 77.8 mtp85 -86.31 -43.1 13.18 Favored 'General case' 0 C--N 1.333 -0.148 0 C-N-CA 122.897 0.479 . . . . 0.0 110.065 174.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -152.6 159.13 43.25 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -176.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.9 mp -130.02 148.68 33.18 Favored 'Isoleucine or valine' 0 C--N 1.339 0.136 0 C-N-CA 124.172 0.989 . . . . 0.0 109.627 177.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 21.2 t0 -140.72 63.97 1.44 Allowed 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.296 0.238 . . . . 0.0 111.255 176.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 61.2 tp -59.81 133.61 56.26 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 170.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 15.7 ttmm -143.62 152.2 41.08 Favored 'General case' 0 C--N 1.342 0.24 0 CA-C-O 120.74 0.305 . . . . 0.0 111.024 -173.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 . . . . . 0 N--CA 1.455 -0.222 0 C-N-CA 122.996 0.518 . . . . 0.0 110.563 178.891 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo . . . . . 0 N--CA 1.453 -0.883 0 N-CA-C 111.615 -0.187 . . . . 0.0 111.615 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -150.72 169.12 22.38 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 179.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -157.96 170.7 21.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 120.916 0.389 . . . . 0.0 111.527 -174.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -123.59 154.68 38.95 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.909 169.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 71.7 t -137.73 139.85 42.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -178.127 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -121.91 108.32 13.29 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -79.21 160.59 26.84 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 115.004 1.483 . . . . 0.0 115.004 177.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 41.1 tp10 -75.76 -31.85 59.71 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.542 175.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -133.05 150.75 76.42 Favored Pre-proline 0 CA--C 1.532 0.275 0 C-N-CA 123.707 0.803 . . . . 0.0 112.365 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -70.11 -21.6 31.62 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 123.203 2.602 . . . . 0.0 110.885 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 81.2 mtt85 -72.67 -27.89 62.37 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 178.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -79.76 -31.39 40.95 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 122.039 0.136 . . . . 0.0 111.318 179.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.97 -36.68 69.91 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 110.511 -0.181 . . . . 0.0 110.511 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 43.4 tp10 -68.12 -34.29 76.1 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -72.28 -35.23 68.68 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.1 -29.52 64.18 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.2 t -75.21 -50.97 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 88.0 p -73.5 -10.22 59.49 Favored 'General case' 0 C--O 1.233 0.217 0 O-C-N 122.199 -0.313 . . . . 0.0 111.661 -176.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -98.62 -10.38 50.44 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-O 119.167 -0.796 . . . . 0.0 113.371 -173.49 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -151.51 -13.02 0.2 Allowed 'General case' 0 C--N 1.34 0.159 0 CA-C-N 119.04 1.42 . . . . 0.0 113.206 -173.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -66.61 143.9 56.73 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.421 0.555 . . . . 0.0 110.146 -177.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 60.22 39.92 96.62 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 173.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 41.2 t80 -99.13 133.42 43.44 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 113.635 0.976 . . . . 0.0 113.635 -173.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.2 t0 -62.1 105.69 0.62 Allowed 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 123.574 0.749 . . . . 0.0 112.372 -178.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.423 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 51.5 t80 -111.26 169.92 8.46 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 123.829 0.852 . . . . 0.0 111.389 178.23 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.423 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 21.0 t0 -61.0 97.41 0.06 Allowed 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.375 0.509 . . . . 0.0 112.375 -179.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 80.68 -4.06 71.25 Favored Glycine 0 CA--C 1.53 0.994 0 CA-C-O 119.379 -0.678 . . . . 0.0 112.722 177.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -142.46 -170.72 3.25 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 118.142 0.971 . . . . 0.0 112.793 -177.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 36.0 ttt180 -145.89 130.22 17.66 Favored 'General case' 0 C--O 1.231 0.095 0 C-N-CA 123.466 0.706 . . . . 0.0 109.292 -178.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -63.86 152.92 38.33 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 122.952 0.501 . . . . 0.0 111.078 -174.088 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 53.1 mmm-85 -124.92 117.36 23.9 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 173.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 19.2 t -145.25 81.31 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.522 -0.103 0 C-N-CA 122.75 0.42 . . . . 0.0 110.252 178.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.9 pt-20 -142.8 168.49 19.6 Favored 'General case' 0 C--N 1.333 -0.112 0 C-N-CA 122.429 0.291 . . . . 0.0 111.066 -175.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 54.3 m-85 -65.15 151.66 93.27 Favored Pre-proline 0 CA--C 1.532 0.257 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo . . . . . 0 N--CA 1.448 -1.186 0 C-N-CA 123.894 3.063 . . . . 0.0 110.72 175.719 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 85.3 m . . . . . 0 CA--C 1.531 0.236 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 79.6 mtt180 -76.78 147.41 37.28 Favored 'General case' 0 CA--C 1.528 0.108 0 CA-C-N 117.889 0.313 . . . . 0.0 110.668 177.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 pt -135.57 167.87 24.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.107 0 C-N-CA 123.216 0.607 . . . . 0.0 109.364 173.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -108.61 148.65 30.03 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 114.694 1.368 . . . . 0.0 114.694 -173.309 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 21.7 t -137.13 139.05 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 C-N-CA 123.839 0.856 . . . . 0.0 110.001 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.76 175.65 30.45 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -177.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 54.2 t30 59.68 26.07 15.11 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.807 0.843 . . . . 0.0 111.42 -175.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 97.3 mt . . . . . 0 N--CA 1.455 -0.218 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 176.455 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.1 tptt . . . . . 0 N--CA 1.454 -0.234 0 CA-C-O 120.019 -0.038 . . . . 0.0 110.974 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 -67.45 -22.92 65.47 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 112.401 0.519 . . . . 0.0 112.401 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 6.4 tp -71.31 -18.18 20.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 C-N-CA 122.64 0.376 . . . . 0.0 110.188 176.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -96.16 -26.63 15.39 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 176.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -64.93 -49.91 68.54 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.625 0.25 . . . . 0.0 111.67 -177.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 99.7 t -67.63 -43.56 86.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -178.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -74.6 -32.45 62.36 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 114.52 1.304 . . . . 0.0 114.52 -177.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 90.0 p -69.74 -22.48 63.37 Favored 'General case' 0 C--O 1.231 0.107 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.87 175.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -72.26 -34.02 67.92 Favored 'General case' 0 C--N 1.34 0.193 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 173.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 49.4 m-85 -68.87 -19.1 64.23 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 170.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.76 169.3 33.14 Favored Glycine 0 CA--C 1.532 1.119 0 C-N-CA 123.183 0.42 . . . . 0.0 112.996 171.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 59.56 20.28 8.8 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 124.762 1.225 . . . . 0.0 113.68 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.5 mp -76.51 140.15 17.67 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 173.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 20.4 mmt180 -120.3 -21.92 6.74 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 122.488 0.315 . . . . 0.0 111.502 173.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -158.13 149.6 21.33 Favored 'General case' 0 C--N 1.339 0.137 0 N-CA-C 113.919 1.081 . . . . 0.0 113.919 176.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -120.4 152.24 23.31 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 171.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 45.1 t0 -145.16 79.07 1.58 Allowed 'General case' 0 N--CA 1.449 -0.496 0 CA-C-O 120.947 0.404 . . . . 0.0 111.374 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 55.9 tp -66.04 135.73 55.05 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 171.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 14.5 ttmm -151.86 168.29 25.58 Favored 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 -173.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 54.3 t30 . . . . . 0 N--CA 1.452 -0.325 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 175.496 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo . . . . . 0 N--CA 1.452 -0.955 0 N-CA-C 111.184 -0.352 . . . . 0.0 111.184 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -149.11 171.76 15.9 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 104.977 -2.231 . . . . 0.0 104.977 177.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.76 169.03 25.32 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.289 0.566 . . . . 0.0 111.941 -174.566 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -121.88 156.95 32.22 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.881 171.228 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 96.8 t -134.8 140.29 45.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -124.1 115.94 21.98 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.019 0.437 . . . . 0.0 110.538 -174.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 38.5 m-85 -91.3 161.74 14.91 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 114.256 1.206 . . . . 0.0 114.256 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -75.65 -28.23 58.67 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 170.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 17.2 p30 -154.8 152.55 25.87 Favored Pre-proline 0 CA--C 1.534 0.333 0 C-N-CA 123.326 0.651 . . . . 0.0 111.675 176.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.09 -7.85 22.27 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 123.24 2.626 . . . . 0.0 111.429 179.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 45.3 ttm105 -65.24 -38.9 91.8 Favored 'General case' 0 C--N 1.339 0.122 0 C-N-CA 122.444 0.298 . . . . 0.0 111.331 -177.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -94.52 -17.81 22.04 Favored 'General case' 0 C--O 1.232 0.177 0 N-CA-C 112.859 0.688 . . . . 0.0 112.859 179.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.7 -27.21 67.46 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -69.05 -30.36 68.68 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 110.423 -0.214 . . . . 0.0 110.423 178.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -75.98 -36.81 59.09 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 112.165 0.431 . . . . 0.0 112.165 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.01 -28.01 64.1 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 110.263 -0.273 . . . . 0.0 110.263 176.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 16.6 t -77.29 -50.18 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.177 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 71.1 m -73.59 -7.6 52.59 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 111.656 0.243 . . . . 0.0 111.656 -175.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -99.67 -8.05 52.58 Favored Glycine 0 CA--C 1.53 1.023 0 CA-C-O 119.07 -0.85 . . . . 0.0 113.423 -175.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 13.6 tpp180 -152.04 -13.73 0.19 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 118.489 1.145 . . . . 0.0 113.332 -174.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -66.65 141.86 57.64 Favored 'General case' 0 N--CA 1.456 -0.168 0 O-C-N 121.933 -0.479 . . . . 0.0 110.118 -177.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.49 43.87 97.5 Favored Glycine 0 CA--C 1.53 0.988 0 N-CA-C 111.921 -0.472 . . . . 0.0 111.921 174.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -101.86 137.5 40.07 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 114.132 1.16 . . . . 0.0 114.132 -173.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 11.3 t0 -63.23 109.07 1.43 Allowed 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 123.62 0.768 . . . . 0.0 112.491 -176.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.41 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 42.3 t80 -116.27 168.11 10.42 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 123.662 0.785 . . . . 0.0 111.524 175.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.41 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.5 t0 -58.99 98.5 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.98 -5.79 61.31 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-O 119.476 -0.624 . . . . 0.0 112.6 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -141.54 -169.32 2.85 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.007 0.904 . . . . 0.0 113.174 -177.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 42.3 ttp-105 -145.26 131.05 19.04 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 123.492 0.717 . . . . 0.0 109.48 -178.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -63.41 152.07 39.24 Favored 'General case' 0 N--CA 1.461 0.086 0 C-N-CA 122.782 0.433 . . . . 0.0 110.372 -177.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 92.1 mtm-85 -127.98 121.3 29.51 Favored 'General case' 0 CA--C 1.52 -0.177 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 173.302 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 24.2 t -142.46 81.45 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -141.54 164.26 30.71 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 111.798 0.295 . . . . 0.0 111.798 -174.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . 0.414 ' CD1' ' HD2' ' B' ' 89' ' ' PRO . 17.0 t80 -72.37 136.14 81.5 Favored Pre-proline 0 CA--C 1.534 0.341 0 N-CA-C 113.365 0.876 . . . . 0.0 113.365 178.494 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . 0.414 ' HD2' ' CD1' ' B' ' 88' ' ' PHE . 47.6 Cg_endo . . . . . 0 C--O 1.25 1.081 0 C-N-CA 123.706 2.937 . . . . 0.0 111.076 -179.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 72.3 m . . . . . 0 CA--C 1.533 0.291 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 52.8 mtm180 -75.38 151.65 38.15 Favored 'General case' 0 N--CA 1.456 -0.138 0 C-N-CA 122.713 0.405 . . . . 0.0 111.781 178.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 pt -136.9 175.52 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 170.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -124.76 148.25 48.21 Favored 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 114.541 1.312 . . . . 0.0 114.541 -177.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.2 t -135.33 140.89 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.643 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.0 179.38 27.75 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 -178.038 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 57.4 t30 60.09 22.23 11.44 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.724 0.81 . . . . 0.0 111.251 -174.093 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 92.8 mt . . . . . 0 N--CA 1.451 -0.377 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 177.763 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.528 0.119 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -70.63 -26.69 63.59 Favored 'General case' 0 C--N 1.333 -0.124 0 O-C-N 121.966 -0.459 . . . . 0.0 110.365 178.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 81.0 mt -77.93 -24.03 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -80.24 -14.39 58.46 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 178.227 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -94.36 -71.45 0.66 Allowed 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 122.865 0.466 . . . . 0.0 111.858 174.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 53.5 t -64.12 -55.65 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.254 -171.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -68.01 -18.18 64.63 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -177.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.8 t -73.33 -31.57 64.07 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 175.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -73.08 -27.05 61.5 Favored 'General case' 0 C--N 1.343 0.314 0 O-C-N 122.071 -0.393 . . . . 0.0 110.609 172.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -79.07 -18.11 54.0 Favored 'General case' 0 N--CA 1.456 -0.153 0 N-CA-C 115.253 1.575 . . . . 0.0 115.253 176.1 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.35 167.26 32.9 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.608 -0.597 . . . . 0.0 111.608 177.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -75.86 105.57 6.97 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 80.6 mt -79.73 142.29 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.544 -178.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -105.94 -32.28 8.4 Favored 'General case' 0 N--CA 1.456 -0.128 0 C-N-CA 122.862 0.465 . . . . 0.0 109.869 172.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -152.38 155.46 37.65 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 114.271 1.211 . . . . 0.0 114.271 178.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 3.3 mp -117.06 149.95 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 175.191 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -146.28 52.88 1.13 Allowed 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 121.086 0.47 . . . . 0.0 109.801 -178.28 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.0 tp -63.06 135.2 57.11 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 122.678 0.391 . . . . 0.0 110.059 173.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 59.0 mttp -127.06 144.83 50.93 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 123.214 0.606 . . . . 0.0 110.645 178.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 66.8 m-20 . . . . . 0 C--O 1.232 0.139 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 171.35 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo . . . . . 0 N--CA 1.449 -1.105 0 N-CA-C 110.997 -0.424 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -152.82 165.66 34.69 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 -177.303 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.13 169.64 23.09 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 121.216 0.531 . . . . 0.0 111.46 -172.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -132.17 158.19 42.35 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 171.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 73.5 t -140.15 135.05 36.78 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.309 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -178.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 64.4 tt0 -110.58 112.03 23.66 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -80.73 162.4 24.13 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 176.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 89.2 tt0 -74.36 -37.8 63.38 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 174.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -125.24 147.48 57.53 Favored Pre-proline 0 CA--C 1.529 0.17 0 C-N-CA 123.602 0.761 . . . . 0.0 109.917 179.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.48 -16.57 30.7 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 123.367 2.711 . . . . 0.0 111.576 -178.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 23.3 ptt85 -71.74 -15.92 62.2 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 122.7 0.4 . . . . 0.0 111.314 -177.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.65 -21.31 60.32 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 179.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -70.79 -18.1 62.76 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -73.93 -17.81 60.97 Favored 'General case' 0 N--CA 1.454 -0.226 0 O-C-N 122.274 -0.266 . . . . 0.0 110.469 179.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 -97.85 -39.69 8.89 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.567 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -74.68 -31.35 61.88 Favored 'General case' 0 N--CA 1.453 -0.283 0 O-C-N 122.274 -0.267 . . . . 0.0 110.783 -178.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 48.2 t -87.99 6.33 3.54 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 122.836 0.455 . . . . 0.0 111.6 -174.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.8 t -139.14 -23.04 0.91 Allowed 'General case' 0 C--O 1.232 0.146 0 O-C-N 121.819 -0.551 . . . . 0.0 111.722 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -96.22 -4.2 59.9 Favored Glycine 0 CA--C 1.526 0.737 0 CA-C-O 119.449 -0.639 . . . . 0.0 112.443 -178.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 3.9 tpp180 -147.48 -18.5 0.38 Allowed 'General case' 0 CA--C 1.529 0.161 0 CA-C-N 118.219 1.01 . . . . 0.0 111.993 -176.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -68.46 146.15 53.43 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.56 42.36 99.75 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-O 119.691 -0.505 . . . . 0.0 112.092 174.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 30.7 t80 -87.62 129.13 35.23 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 117.806 0.803 . . . . 0.0 113.028 -177.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -69.38 87.42 0.44 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 123.378 0.671 . . . . 0.0 111.442 -177.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 36.7 t80 -81.13 -177.63 6.54 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 31.1 t0 -69.7 85.2 0.46 Allowed 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.144 179.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.72 3.45 89.5 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-O 119.843 -0.42 . . . . 0.0 112.113 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 -133.67 -179.1 5.32 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 113.791 1.034 . . . . 0.0 113.791 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -143.19 117.85 9.82 Favored 'General case' 0 N--CA 1.456 -0.13 0 C-N-CA 123.346 0.658 . . . . 0.0 109.357 -176.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.77 154.08 37.97 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 122.569 0.348 . . . . 0.0 110.642 -177.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -124.35 118.93 27.85 Favored 'General case' 0 CA--C 1.516 -0.352 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 176.143 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 19.9 t -142.52 84.99 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 123.028 0.531 . . . . 0.0 110.109 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -143.58 161.11 39.35 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.175 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.7 p90 -77.74 152.26 80.27 Favored Pre-proline 0 CA--C 1.528 0.116 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 178.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo . . . . . 0 C--O 1.251 1.133 0 C-N-CA 123.526 2.817 . . . . 0.0 110.653 177.676 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 78.9 m . . . . . 0 N--CA 1.453 -0.304 0 N-CA-C 110.432 -0.21 . . . . 0.0 110.432 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 41.5 ttm105 -78.51 145.69 34.79 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 123.513 0.725 . . . . 0.0 110.385 -178.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.0 pt -142.76 172.87 7.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 CA-C-O 121.087 0.47 . . . . 0.0 110.92 -177.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -109.81 153.93 23.71 Favored 'General case' 0 C--O 1.233 0.221 0 C-N-CA 124.909 1.283 . . . . 0.0 113.602 -178.08 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 22.5 t -137.07 139.74 43.81 Favored 'Isoleucine or valine' 0 C--O 1.232 0.17 0 C-N-CA 123.367 0.667 . . . . 0.0 110.701 179.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -159.7 -177.7 33.03 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 40.2 t30 56.53 26.37 10.9 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.668 0.787 . . . . 0.0 111.107 -173.265 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 91.4 mt . . . . . 0 N--CA 1.454 -0.253 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 177.524 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.4 tptt . . . . . 0 CA--C 1.529 0.139 0 N-CA-C 111.492 0.182 . . . . 0.0 111.492 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -65.35 -24.5 67.27 Favored 'General case' 0 N--CA 1.456 -0.133 0 N-CA-C 112.674 0.62 . . . . 0.0 112.674 -179.099 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 6.9 tp -72.11 -20.93 20.33 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -90.37 -28.87 18.4 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.32 -32.46 64.6 Favored 'General case' 0 C--N 1.337 0.044 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -178.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 53.7 t -71.75 -45.29 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 177.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 35.5 m-85 -72.08 -30.41 65.09 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 47.1 t -68.33 -25.58 65.18 Favored 'General case' 0 C--N 1.34 0.179 0 CA-C-N 116.953 -0.112 . . . . 0.0 110.857 174.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -75.98 -32.64 59.56 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 176.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 14.6 m-85 -78.57 -15.76 58.2 Favored 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 115.534 1.679 . . . . 0.0 115.534 176.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 170.64 178.89 41.64 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 177.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.41 113.78 19.72 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 122.779 -0.247 . . . . 0.0 110.592 -178.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.6 mp -86.29 140.97 15.06 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 122.731 0.412 . . . . 0.0 109.9 176.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . 0.449 ' HA ' ' HE ' ' B' ' 43' ' ' ARG . 1.7 mmp_? -108.05 -31.85 7.78 Favored 'General case' 0 N--CA 1.456 -0.13 0 C-N-CA 122.969 0.508 . . . . 0.0 110.012 174.273 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -151.32 158.8 44.28 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . 0.523 HG23 ' H ' ' B' ' 47' ' ' LEU . 29.9 mm -140.2 151.03 21.32 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 124.153 0.981 . . . . 0.0 109.037 179.271 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -135.62 51.9 2.03 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 175.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . 0.523 ' H ' HG23 ' B' ' 45' ' ' ILE . 51.0 tp -53.38 130.52 35.54 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.101 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 18.3 ttmm -146.46 151.33 37.22 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -172.243 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 . . . . . 0 CA--C 1.532 0.26 0 C-N-CA 122.271 0.229 . . . . 0.0 111.544 -179.304 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo . . . . . 0 N--CA 1.452 -0.918 0 CA-C-O 121.111 0.379 . . . . 0.0 111.807 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -146.9 146.63 30.22 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 124.178 0.991 . . . . 0.0 112.307 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -160.43 157.05 27.05 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -175.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -112.69 151.57 30.06 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.854 167.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.6 t -135.2 136.63 51.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -176.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 78.8 tt0 -124.25 112.66 17.28 Favored 'General case' 0 N--CA 1.455 -0.176 0 CA-C-O 120.747 0.308 . . . . 0.0 110.637 -177.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -84.32 159.29 20.93 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 177.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 33.2 tp10 -78.14 -30.33 49.21 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.439 174.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -129.09 150.15 74.58 Favored Pre-proline 0 C--O 1.232 0.151 0 C-N-CA 123.573 0.749 . . . . 0.0 112.538 -178.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.99 -24.47 24.0 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 123.431 2.754 . . . . 0.0 110.921 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 38.6 mmt180 -76.52 -24.83 53.71 Favored 'General case' 0 C--N 1.339 0.131 0 C-N-CA 121.962 0.105 . . . . 0.0 110.757 179.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -75.19 -34.16 61.5 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-O 120.416 0.151 . . . . 0.0 111.271 175.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -73.04 -32.54 65.13 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 176.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -65.81 -33.87 76.86 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.151 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -76.06 -35.62 59.35 Favored 'General case' 0 N--CA 1.457 -0.125 0 N-CA-C 113.249 0.833 . . . . 0.0 113.249 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.73 -29.16 63.13 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 122.365 -0.21 . . . . 0.0 110.505 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 55.9 t -81.43 -52.47 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.0 t -70.29 -17.27 63.09 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -174.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.03 -1.76 45.28 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-O 119.161 -0.799 . . . . 0.0 113.868 -173.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 30.1 ttp-105 -153.23 -14.02 0.15 Allowed 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 119.003 1.402 . . . . 0.0 113.19 -175.048 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -69.28 146.71 52.04 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 118.673 0.67 . . . . 0.0 110.037 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.75 38.25 95.63 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-O 119.562 -0.577 . . . . 0.0 112.313 172.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 37.8 t80 -88.24 130.04 35.19 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 118.089 0.945 . . . . 0.0 112.968 -176.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 29.6 t0 -68.75 89.37 0.39 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.369 0.668 . . . . 0.0 111.091 -178.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 35.7 t80 -81.17 -174.62 4.99 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -69.49 74.05 0.37 Allowed 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 123.765 0.826 . . . . 0.0 111.997 178.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.47 6.83 70.17 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 -179.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -133.19 -179.31 5.42 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -179.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 9.5 tpp180 -143.08 114.38 7.88 Favored 'General case' 0 CA--C 1.528 0.132 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -175.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -61.9 153.13 29.99 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.811 0.444 . . . . 0.0 110.245 -177.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 74.8 mtt180 -129.11 115.31 17.52 Favored 'General case' 0 CA--C 1.52 -0.185 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 177.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 38.7 t -143.14 85.14 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.183 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -148.58 165.3 31.66 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.641 0.258 . . . . 0.0 110.589 -174.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -81.79 156.82 70.0 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 113.755 1.021 . . . . 0.0 113.755 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo . . . . . 0 C--O 1.252 1.215 0 C-N-CA 123.895 3.064 . . . . 0.0 111.639 177.684 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 80.9 m . . . . . 0 CA--C 1.53 0.191 0 N-CA-C 111.598 0.221 . . . . 0.0 111.598 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . 0.437 ' HA ' ' HA ' ' B' ' 60' ' ' GLU . 27.5 ttm180 -74.38 149.61 40.43 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 122.831 0.452 . . . . 0.0 111.239 -175.002 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.3 pt -131.08 -178.8 2.84 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.09 0 C-N-CA 123.876 0.87 . . . . 0.0 109.645 178.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -120.66 150.2 41.3 Favored 'General case' 0 C--O 1.231 0.12 0 N-CA-C 114.462 1.282 . . . . 0.0 114.462 -173.657 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 46.3 t -141.05 142.29 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 C-N-CA 123.928 0.891 . . . . 0.0 109.019 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.54 -178.95 33.03 Favored Glycine 0 C--N 1.338 0.665 0 C-N-CA 121.277 -0.487 . . . . 0.0 112.515 -175.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 48.5 t30 56.48 25.96 10.32 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.245 1.018 . . . . 0.0 111.376 -176.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.8 mt . . . . . 0 CA--C 1.531 0.223 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.727 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 58.2 tptt . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 111.132 0.049 . . . . 0.0 111.132 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -65.61 -23.07 66.74 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 122.118 -0.364 . . . . 0.0 111.451 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mp -70.86 -22.47 23.1 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 178.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -96.45 -38.4 10.04 Favored 'General case' 0 N--CA 1.453 -0.305 0 O-C-N 122.359 -0.213 . . . . 0.0 110.824 -178.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -67.62 -45.71 74.64 Favored 'General case' 0 N--CA 1.458 -0.057 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -175.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 91.1 t -72.26 -42.37 66.06 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -178.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -75.32 -26.68 58.85 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -177.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.2 t -70.73 -31.0 67.69 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-O 120.557 0.218 . . . . 0.0 110.43 174.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 28.9 tptp -70.82 -31.33 68.02 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -85.22 -13.0 51.28 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 116.082 1.882 . . . . 0.0 116.082 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.18 171.98 38.32 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.303 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -79.1 104.46 9.74 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 122.669 0.387 . . . . 0.0 110.406 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 83.5 mt -75.58 147.27 8.25 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.145 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 176.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -131.02 -19.41 2.87 Favored 'General case' 0 C--N 1.34 0.168 0 C-N-CA 122.523 0.329 . . . . 0.0 111.12 175.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -153.7 156.03 37.08 Favored 'General case' 0 CA--C 1.528 0.102 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 174.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 18.9 mm -136.19 152.85 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.122 0 C-N-CA 123.737 0.815 . . . . 0.0 109.253 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -145.72 46.73 1.27 Allowed 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 178.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 28.6 tp -58.27 133.99 56.16 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 174.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 56.0 mttp -127.56 145.49 50.84 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 123.655 0.782 . . . . 0.0 110.608 178.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.4 p-10 . . . . . 0 CA--C 1.533 0.289 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 171.899 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo . . . . . 0 N--CA 1.454 -0.838 0 CA-C-O 120.79 0.246 . . . . 0.0 112.065 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -157.74 166.47 32.68 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.14 172.68 18.02 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-O 121.174 0.512 . . . . 0.0 112.089 -172.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -131.67 146.58 52.25 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 171.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 96.6 t -132.41 132.41 60.37 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.265 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -174.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . 0.437 ' HA ' ' HA ' ' B' ' 17' ' ' ARG . 76.2 tt0 -116.36 120.39 38.71 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 120.581 0.229 . . . . 0.0 111.433 -175.525 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -90.49 161.7 15.39 Favored 'General case' 0 C--O 1.232 0.16 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 177.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -71.6 -33.4 68.98 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 174.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -128.96 150.39 75.12 Favored Pre-proline 0 CA--C 1.53 0.189 0 C-N-CA 123.689 0.795 . . . . 0.0 111.795 -178.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.86 -13.89 32.23 Favored 'Trans proline' 0 N--CA 1.452 -0.913 0 C-N-CA 123.214 2.609 . . . . 0.0 110.364 176.499 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 32.5 ttp-105 -65.26 -38.25 89.72 Favored 'General case' 0 CA--C 1.528 0.124 0 C-N-CA 123.323 0.649 . . . . 0.0 110.545 178.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -77.67 -20.3 53.96 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -176.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.79 -29.94 65.0 Favored 'General case' 0 N--CA 1.452 -0.364 0 O-C-N 122.527 -0.108 . . . . 0.0 110.711 -177.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -72.89 -27.24 61.77 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.327 -0.233 . . . . 0.0 110.61 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -80.1 -36.45 35.41 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -178.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -76.55 -28.39 56.26 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 110.572 -0.158 . . . . 0.0 110.572 -178.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.5 t -79.33 -58.66 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 69.9 m -73.5 -3.33 26.95 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -175.537 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -85.41 -19.94 57.67 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 119.32 -0.711 . . . . 0.0 112.828 -176.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 24.7 ptt-85 -161.64 18.45 0.11 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 118.604 1.202 . . . . 0.0 113.009 -174.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -66.9 140.96 57.8 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.97 0.73 . . . . 0.0 112.97 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 60.28 70.87 0.89 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.828 -0.509 . . . . 0.0 111.828 174.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 59.6 t80 -110.73 137.91 47.79 Favored 'General case' 0 C--N 1.339 0.138 0 N-CA-C 113.571 0.952 . . . . 0.0 113.571 179.215 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -64.42 108.47 1.64 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 124.392 1.077 . . . . 0.0 112.988 -175.086 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.412 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.9 t80 -113.9 169.3 9.1 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.849 0.86 . . . . 0.0 111.26 175.266 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.412 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 75.7 m-20 -59.81 97.18 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -179.193 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 80.08 -5.65 62.07 Favored Glycine 0 CA--C 1.534 1.281 0 CA-C-O 119.315 -0.714 . . . . 0.0 112.643 177.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -139.4 -171.02 3.03 Favored 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 118.296 1.048 . . . . 0.0 113.362 -177.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -142.04 128.96 20.67 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -177.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.6 mp -63.39 150.09 44.34 Favored 'General case' 0 C--N 1.335 -0.049 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -123.11 124.87 44.05 Favored 'General case' 0 CA--C 1.52 -0.194 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.184 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.3 t -147.29 79.73 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.088 0 C-N-CA 123.603 0.761 . . . . 0.0 109.269 178.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.9 pt-20 -147.08 165.03 31.17 Favored 'General case' 0 C--O 1.226 -0.155 0 C-N-CA 122.667 0.387 . . . . 0.0 110.442 -177.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.7 p90 -80.01 153.72 74.96 Favored Pre-proline 0 C--O 1.234 0.275 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 176.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo . . . . . 0 C--O 1.249 1.051 0 C-N-CA 123.746 2.964 . . . . 0.0 111.728 175.967 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.7 m . . . . . 0 CA--C 1.531 0.247 0 N-CA-C 111.412 0.153 . . . . 0.0 111.412 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 39.9 ttm180 -75.87 148.6 38.19 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 123.943 0.897 . . . . 0.0 110.49 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 14.2 pt -129.6 176.26 8.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 C-N-CA 122.897 0.479 . . . . 0.0 109.923 178.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -115.49 153.42 31.16 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -173.297 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 79.2 t -138.09 100.26 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -82.66 160.03 38.96 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 175.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 40.8 t30 60.51 -171.56 0.14 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.153 0.581 . . . . 0.0 110.25 -176.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.6 tp . . . . . 0 CA--C 1.533 0.314 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.645 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.2 tptt . . . . . 0 CA--C 1.528 0.132 0 N-CA-C 111.298 0.11 . . . . 0.0 111.298 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 71.1 m-20 -67.93 -19.76 65.01 Favored 'General case' 0 N--CA 1.457 -0.123 0 O-C-N 122.389 -0.195 . . . . 0.0 111.455 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 7.9 tp -73.19 -14.3 16.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 177.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -103.55 -21.25 13.78 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -71.09 -51.46 25.01 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.432 0.293 . . . . 0.0 111.585 -177.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 m -67.91 -33.42 61.25 Favored 'Isoleucine or valine' 0 C--N 1.338 0.082 0 CA-C-O 120.515 0.198 . . . . 0.0 110.929 -179.026 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -74.42 -35.15 63.39 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 176.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.4 t -66.66 -25.55 66.62 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.575 0.226 . . . . 0.0 110.599 175.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 29.2 tptp -77.72 -33.1 53.16 Favored 'General case' 0 N--CA 1.456 -0.149 0 N-CA-C 110.275 -0.268 . . . . 0.0 110.275 177.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -85.44 -9.24 57.77 Favored 'General case' 0 CA--C 1.53 0.184 0 N-CA-C 116.394 1.998 . . . . 0.0 116.394 179.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.42 178.54 44.4 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.73 177.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -79.41 43.26 0.54 Allowed 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.937 0.895 . . . . 0.0 110.99 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.8 mp -55.77 138.25 16.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 122.695 0.398 . . . . 0.0 110.089 179.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 56.7 mmm-85 -94.69 -54.64 3.42 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.175 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -133.44 150.62 51.76 Favored 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -170.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -112.52 151.04 14.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.203 0 C-N-CA 124.596 1.158 . . . . 0.0 108.26 173.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -143.7 68.74 1.28 Allowed 'General case' 0 N--CA 1.452 -0.329 0 CA-C-O 120.694 0.283 . . . . 0.0 111.164 178.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 44.1 tp -70.91 129.54 39.31 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.178 174.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -114.41 140.28 48.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 123.089 0.556 . . . . 0.0 110.085 178.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 46.0 p-10 . . . . . 0 CA--C 1.532 0.28 0 C-N-CA 123.877 0.871 . . . . 0.0 111.179 -178.326 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo . . . . . 0 N--CA 1.448 -1.172 0 N-CA-C 110.242 -0.715 . . . . 0.0 110.242 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -157.59 162.98 38.77 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -146.62 173.68 12.12 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-O 121.083 0.468 . . . . 0.0 111.387 -172.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -138.68 160.67 39.06 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.336 175.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 81.9 t -137.76 134.75 45.85 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 55.1 tt0 -115.52 127.23 55.14 Favored 'General case' 0 N--CA 1.453 -0.295 0 CA-C-O 120.773 0.32 . . . . 0.0 110.741 -174.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -95.17 151.52 19.14 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 115.314 1.598 . . . . 0.0 115.314 -172.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 49.8 tp10 -80.49 -26.24 38.33 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 168.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -153.05 117.54 2.85 Favored Pre-proline 0 N--CA 1.453 -0.294 0 C-N-CA 124.125 0.97 . . . . 0.0 109.468 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -66.86 -6.1 14.94 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 123.225 2.616 . . . . 0.0 112.429 -174.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 60.1 ttt85 -65.36 -28.88 69.6 Favored 'General case' 0 N--CA 1.456 -0.159 0 CA-C-N 118.022 0.374 . . . . 0.0 110.576 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -78.7 -15.8 58.03 Favored 'General case' 0 CA--C 1.531 0.213 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.21 -20.47 63.97 Favored 'General case' 0 N--CA 1.451 -0.411 0 O-C-N 122.198 -0.314 . . . . 0.0 110.428 -177.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -64.75 -26.95 68.58 Favored 'General case' 0 CA--C 1.532 0.266 0 O-C-N 122.055 -0.403 . . . . 0.0 110.336 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -90.88 -36.56 14.1 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 112.561 0.578 . . . . 0.0 112.561 178.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.67 -28.44 62.71 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 122.41 0.284 . . . . 0.0 110.723 -177.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 49.7 t -75.24 0.0 2.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 32.5 t -135.35 5.49 3.23 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.763 -0.586 . . . . 0.0 110.943 178.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -77.94 -28.87 55.77 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-O 119.694 -0.503 . . . . 0.0 112.129 -177.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 50.1 ttt180 -158.45 13.46 0.18 Allowed 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 117.624 0.712 . . . . 0.0 110.89 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 29.9 t0 -69.55 150.07 47.52 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 122.102 -0.374 . . . . 0.0 110.246 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.28 38.13 95.97 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 111.803 -0.519 . . . . 0.0 111.803 175.538 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 31.0 t80 -98.97 132.78 44.03 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 113.149 0.796 . . . . 0.0 113.149 -173.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -61.62 104.35 0.42 Allowed 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 123.559 0.744 . . . . 0.0 112.149 -179.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.496 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 66.2 t80 -110.35 173.44 6.33 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 123.586 0.754 . . . . 0.0 111.803 178.617 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.496 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.7 t0 -62.43 100.03 0.17 Allowed 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.67 -8.22 29.15 Favored Glycine 0 CA--C 1.531 1.076 0 C-N-CA 123.435 0.541 . . . . 0.0 112.936 177.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -138.9 -169.92 2.74 Favored 'General case' 0 C--N 1.34 0.172 0 N-CA-C 113.133 0.79 . . . . 0.0 113.133 -178.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 38.3 ttt180 -145.46 134.68 22.87 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -177.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -62.71 144.34 56.48 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -178.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 56.7 mtm180 -132.43 71.97 1.48 Allowed 'General case' 0 C--N 1.339 0.127 0 C-N-CA 122.728 0.411 . . . . 0.0 110.809 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.83 92.31 3.81 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.103 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 177.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.5 pt-20 -151.04 159.72 44.36 Favored 'General case' 0 C--N 1.334 -0.102 0 C-N-CA 122.658 0.383 . . . . 0.0 110.827 178.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -73.65 153.4 89.51 Favored Pre-proline 0 C--O 1.235 0.303 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo . . . . . 0 C--O 1.251 1.173 0 C-N-CA 123.839 3.026 . . . . 0.0 110.543 176.138 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 93.7 m . . . . . 0 CA--C 1.533 0.309 0 CA-C-O 120.483 0.182 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 49.2 mtt180 -73.12 156.61 38.49 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.448 0.699 . . . . 0.0 112.57 -179.128 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.0 pt -132.41 175.96 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.068 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 173.089 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -119.3 147.63 44.08 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -174.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 24.8 t -132.42 138.5 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 C-N-CA 123.312 0.645 . . . . 0.0 110.368 -179.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -143.6 -179.43 20.18 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -177.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 64.4 t30 59.48 24.4 13.07 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.812 0.845 . . . . 0.0 111.325 -173.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 96.1 mt . . . . . 0 CA--C 1.533 0.309 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 176.594 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.456 -0.162 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -75.55 -39.26 58.48 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 117.774 0.261 . . . . 0.0 111.109 179.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 12.6 tt -78.18 -21.28 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 CA-C-N 116.688 -0.233 . . . . 0.0 110.667 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.4 mt-10 -77.29 -39.39 48.19 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.108 -0.37 . . . . 0.0 110.494 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -74.3 -33.64 63.27 Favored 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -179.287 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 41.3 t -71.3 -48.14 55.86 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -74.58 -31.79 62.18 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 39.1 t -67.81 -30.73 70.22 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.933 177.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -77.66 -26.79 50.64 Favored 'General case' 0 C--O 1.232 0.138 0 O-C-N 122.366 -0.209 . . . . 0.0 111.075 175.529 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -87.45 -8.31 56.63 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 116.435 2.013 . . . . 0.0 116.435 177.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 175.37 174.17 41.73 Favored Glycine 0 CA--C 1.524 0.599 0 C-N-CA 121.1 -0.571 . . . . 0.0 112.483 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.46 40.44 0.57 Allowed 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 123.767 0.827 . . . . 0.0 111.348 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.9 mp -52.8 136.07 13.97 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.066 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 18.8 mmt85 -93.61 -35.18 13.0 Favored 'General case' 0 C--O 1.23 0.073 0 CA-C-O 119.492 -0.289 . . . . 0.0 111.691 -175.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -148.54 150.34 33.19 Favored 'General case' 0 C--O 1.232 0.147 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -177.794 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -115.15 151.8 16.84 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 C-N-CA 124.344 1.057 . . . . 0.0 108.278 174.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 61.6 t0 -148.16 75.12 1.32 Allowed 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.136 0.493 . . . . 0.0 110.221 179.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 53.9 tp -71.05 146.03 49.57 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.526 176.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 25.1 ttmm -146.41 141.09 26.82 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 176.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 45.8 p30 . . . . . 0 CA--C 1.53 0.174 0 N-CA-C 111.832 0.308 . . . . 0.0 111.832 -176.048 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_exo . . . . . 0 N--CA 1.451 -0.981 0 CA-C-O 120.839 0.266 . . . . 0.0 112.164 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -162.61 169.4 20.22 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -151.78 159.24 43.99 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.184 0.516 . . . . 0.0 111.68 -174.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -112.72 151.05 30.69 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.11 172.106 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.2 t -135.96 132.33 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.148 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -178.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 69.9 tt0 -110.57 116.27 31.07 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 122.445 0.298 . . . . 0.0 111.155 -173.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -92.51 154.8 18.24 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -80.71 -29.97 36.38 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 171.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -159.93 151.17 16.14 Favored Pre-proline 0 CA--C 1.531 0.212 0 C-N-CA 125.267 1.427 . . . . 0.0 111.589 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.39 -3.04 12.2 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 123.6 2.867 . . . . 0.0 112.484 -176.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -63.52 -25.49 68.27 Favored 'General case' 0 CA--C 1.529 0.152 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -176.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -89.58 -5.15 57.46 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -177.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.15 -14.2 62.85 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 122.408 -0.183 . . . . 0.0 110.818 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -65.86 -17.33 64.57 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 122.419 -0.176 . . . . 0.0 111.17 -178.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -123.5 -37.43 2.66 Favored 'General case' 0 C--O 1.231 0.122 0 C-N-CA 122.975 0.51 . . . . 0.0 112.142 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -79.76 -9.92 59.72 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 122.58 0.352 . . . . 0.0 111.634 -175.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 60.4 t -131.79 -53.69 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 C-N-CA 122.374 0.27 . . . . 0.0 110.724 -178.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 70.5 m -70.71 -6.53 38.0 Favored 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 122.208 0.203 . . . . 0.0 111.343 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -116.09 10.44 17.79 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 119.543 -0.587 . . . . 0.0 111.764 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . 0.401 HH11 ' HD2' ' B' ' 74' ' ' ARG . 46.0 ttm180 -145.05 -20.41 0.5 Allowed 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 117.933 0.866 . . . . 0.0 111.984 -176.096 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -68.89 136.16 52.18 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 67.7 27.49 73.6 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 119.779 -0.456 . . . . 0.0 112.068 176.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 50.4 t80 -79.95 140.62 36.58 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 -172.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.7 t0 -59.34 102.52 0.14 Allowed 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -175.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.414 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 73.9 t80 -111.8 172.26 7.0 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 123.71 0.804 . . . . 0.0 110.743 176.026 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.414 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 17.6 t0 -62.4 98.35 0.11 Allowed 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.58 -5.8 55.42 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 119.599 -0.556 . . . . 0.0 112.887 177.347 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -142.2 -175.56 4.48 Favored 'General case' 0 CA--C 1.527 0.072 0 CA-C-N 117.945 0.872 . . . . 0.0 112.882 -178.083 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 93.1 mtt-85 -131.87 138.46 48.45 Favored 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 124.191 0.996 . . . . 0.0 109.829 176.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -59.85 154.38 18.64 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 178.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 1.3 tpm_? -122.42 116.45 24.0 Favored 'General case' 0 CA--C 1.518 -0.255 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 176.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 15.2 t -135.1 89.48 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 O-C-N 123.378 0.424 . . . . 0.0 110.063 178.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -146.89 158.18 43.85 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.361 178.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -76.56 155.09 83.69 Favored Pre-proline 0 CA--C 1.532 0.276 0 N-CA-C 114.224 1.194 . . . . 0.0 114.224 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo . . . . . 0 C--O 1.251 1.14 0 C-N-CA 123.702 2.934 . . . . 0.0 111.46 175.29 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 8.2 p . . . . . 0 C--O 1.233 0.234 0 N-CA-C 111.669 0.248 . . . . 0.0 111.669 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -63.11 144.71 56.66 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 122.857 0.463 . . . . 0.0 111.808 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.7 pt -131.67 173.16 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.885 174.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -111.97 150.62 30.29 Favored 'General case' 0 N--CA 1.457 -0.115 0 C-N-CA 124.356 1.062 . . . . 0.0 113.383 -177.667 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 25.9 t -133.32 91.71 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.145 0 C-N-CA 122.964 0.506 . . . . 0.0 110.35 -176.54 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -91.49 165.73 30.06 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 111.594 -0.602 . . . . 0.0 111.594 179.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 62.9 t30 59.96 21.09 10.13 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.026 0.93 . . . . 0.0 111.669 -176.398 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 21.0 tp . . . . . 0 CA--C 1.535 0.367 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.204 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.0 tptm . . . . . 0 C--O 1.227 -0.096 0 CA-C-O 119.916 -0.088 . . . . 0.0 111.129 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 -63.71 -19.1 64.66 Favored 'General case' 0 N--CA 1.456 -0.167 0 O-C-N 122.048 -0.407 . . . . 0.0 110.532 175.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 tt -67.43 -16.1 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 123.028 0.531 . . . . 0.0 110.908 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -130.66 -22.33 2.69 Favored 'General case' 0 C--N 1.341 0.198 0 CA-C-N 118.162 0.437 . . . . 0.0 111.915 177.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 66.4 m-20 -70.9 -29.76 65.92 Favored 'General case' 0 C--O 1.232 0.151 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 176.464 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 52.4 t -67.93 -40.8 84.02 Favored 'Isoleucine or valine' 0 C--N 1.34 0.156 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 174.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -67.6 -32.04 72.5 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 113.086 0.772 . . . . 0.0 113.086 176.13 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 54.5 m -65.75 -24.64 67.0 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.993 -0.094 . . . . 0.0 110.819 175.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 14.3 tmtt? -74.5 -34.56 63.09 Favored 'General case' 0 CA--C 1.531 0.25 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 173.091 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . 0.42 ' CD1' ' HA ' ' B' ' 70' ' ' ALA . 40.0 m-85 -72.04 -20.86 61.62 Favored 'General case' 0 CA--C 1.529 0.169 0 N-CA-C 115.582 1.697 . . . . 0.0 115.582 175.496 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 161.72 -169.43 37.17 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 178.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.41 108.51 17.26 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 120.778 0.323 . . . . 0.0 111.174 -177.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.55 147.66 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.157 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 173.308 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -115.3 -24.05 8.63 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 119.384 -0.341 . . . . 0.0 111.209 177.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -151.38 158.78 44.2 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 114.071 1.137 . . . . 0.0 114.071 -179.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 10.9 tp -124.28 159.67 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 176.318 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -153.19 63.28 0.76 Allowed 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.826 0.346 . . . . 0.0 110.752 -177.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.1 tp -63.37 135.89 57.28 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 175.198 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . 0.524 ' HE2' ' CZ ' ' B' ' 56' ' ' PHE . 35.5 mtmm -141.09 176.43 8.83 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 123.795 0.838 . . . . 0.0 111.239 -178.327 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.5 p30 . . . . . 0 C--O 1.233 0.21 0 C-N-CA 122.928 0.491 . . . . 0.0 110.661 -178.962 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo . . . . . 0 N--CA 1.451 -1.012 0 N-CA-C 110.435 -0.64 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . 0.524 ' CZ ' ' HE2' ' B' ' 48' ' ' LYS . 3.1 p90 -155.34 167.34 30.69 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -146.83 156.98 43.54 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.133 0.492 . . . . 0.0 111.74 -175.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -106.78 150.85 25.9 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 115.179 -0.919 . . . . 0.0 112.332 170.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 72.8 t -131.82 137.98 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.264 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 -179.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -122.17 118.42 28.59 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.69 0.281 . . . . 0.0 110.557 -177.234 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -85.52 151.85 23.63 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 115.39 1.626 . . . . 0.0 115.39 -177.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 40.3 tp10 -78.53 -18.4 54.78 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.379 0.672 . . . . 0.0 109.851 173.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -148.44 119.53 4.32 Favored Pre-proline 0 CA--C 1.532 0.269 0 C-N-CA 123.482 0.713 . . . . 0.0 110.072 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_exo -55.08 -20.5 24.0 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.411 2.741 . . . . 0.0 113.324 -177.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 53.3 tpt85 -69.54 -32.55 71.43 Favored 'General case' 0 C--N 1.342 0.243 0 CA-C-N 118.295 0.498 . . . . 0.0 110.971 179.578 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -74.05 -24.39 59.52 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -179.867 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.46 -24.11 64.67 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.239 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -73.79 -27.71 61.27 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 178.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 77.4 m-20 -78.04 -38.43 44.61 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 112.386 0.513 . . . . 0.0 112.386 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . 0.42 ' HA ' ' CD1' ' B' ' 39' ' ' TYR . . . -70.77 -31.05 67.71 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 110.343 -0.243 . . . . 0.0 110.343 178.389 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 37.3 t -80.6 -43.91 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 46.0 t -66.27 -20.97 66.26 Favored 'General case' 0 CA--C 1.533 0.29 0 O-C-N 122.197 -0.315 . . . . 0.0 111.127 -177.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -91.03 -15.27 56.43 Favored Glycine 0 CA--C 1.529 0.938 0 CA-C-O 119.307 -0.718 . . . . 0.0 113.17 -177.001 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 62.7 mtt180 -147.62 21.54 1.16 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.448 1.124 . . . . 0.0 113.045 -172.275 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 16.5 p30 -69.32 1.71 3.58 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 177.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.24 90.44 0.08 OUTLIER Glycine 0 C--N 1.336 0.582 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -125.53 139.49 53.56 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 178.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -64.39 106.5 1.13 Allowed 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.628 0.771 . . . . 0.0 112.65 -177.066 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.444 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.0 t80 -111.46 170.35 8.18 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 123.677 0.791 . . . . 0.0 111.446 177.348 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.444 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.1 t0 -59.15 100.9 0.08 Allowed 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -179.198 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 75.81 -5.28 40.32 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-O 119.661 -0.522 . . . . 0.0 112.888 177.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -141.43 -169.49 2.88 Favored 'General case' 0 C--O 1.232 0.161 0 N-CA-C 113.513 0.931 . . . . 0.0 113.513 -177.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 42.2 ttp-105 -142.04 139.31 32.29 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.672 0.789 . . . . 0.0 109.162 179.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.72 151.15 45.85 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 -178.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 90.1 mtm-85 -133.61 56.17 1.86 Allowed 'General case' 0 C--N 1.339 0.135 0 CA-C-O 120.75 0.31 . . . . 0.0 110.799 177.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 23.1 t -82.21 93.95 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 175.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.9 pt-20 -151.9 162.72 40.6 Favored 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 122.51 0.324 . . . . 0.0 110.205 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.4 p90 -78.09 157.56 78.4 Favored Pre-proline 0 N--CA 1.453 -0.306 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 177.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo . . . . . 0 C--O 1.252 1.219 0 C-N-CA 123.903 3.069 . . . . 0.0 111.658 177.45 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 75.2 m . . . . . 0 CA--C 1.531 0.244 0 N-CA-C 111.34 0.126 . . . . 0.0 111.34 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 48.8 mtt-85 -78.51 151.1 32.73 Favored 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 112.705 0.631 . . . . 0.0 112.705 -177.164 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.4 pt -139.14 171.59 14.44 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 C-N-CA 123.507 0.723 . . . . 0.0 109.524 174.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . 0.4 ' HB2' ' CZ ' ' B' ' 58' ' ' PHE . 0.3 OUTLIER -113.21 153.12 28.86 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -175.99 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 58.7 t -136.77 140.89 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.317 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -146.87 174.62 26.63 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.925 -0.47 . . . . 0.0 111.925 -176.504 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 66.3 t30 62.91 157.35 0.06 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.772 1.229 . . . . 0.0 111.463 -172.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.2 tp . . . . . 0 N--CA 1.453 -0.306 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.734 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . 0.427 ' HE3' ' HB2' ' B' ' 30' ' ' LYS . 0.0 OUTLIER . . . . . 0 CA--C 1.527 0.085 0 N-CA-C 111.427 0.158 . . . . 0.0 111.427 . . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -64.65 -19.75 65.89 Favored 'General case' 0 N--CA 1.457 -0.112 0 O-C-N 122.116 -0.365 . . . . 0.0 111.979 178.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 7.5 tp -71.64 -17.69 19.59 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 175.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 81.6 mt-10 -94.96 -36.52 11.55 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -69.52 -39.97 77.2 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -177.023 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 77.1 t -72.14 -41.89 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.075 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 39.0 m-85 -74.06 -37.78 64.16 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 114.02 1.119 . . . . 0.0 114.02 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 91.7 p -69.21 -22.12 63.9 Favored 'General case' 0 C--N 1.34 0.175 0 CA-C-N 117.729 0.241 . . . . 0.0 110.422 177.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -74.73 -34.06 62.49 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -81.22 -13.26 58.72 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 115.926 1.825 . . . . 0.0 115.926 177.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.16 175.37 43.47 Favored Glycine 0 CA--C 1.527 0.819 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.053 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -82.27 80.02 8.58 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.097 0.559 . . . . 0.0 110.601 -178.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.7 mp -65.51 140.22 20.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.105 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 174.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . 0.407 ' HA ' ' HE ' ' B' ' 43' ' ' ARG . 1.7 mmp_? -109.76 -27.84 9.12 Favored 'General case' 0 N--CA 1.457 -0.082 0 C-N-CA 122.869 0.467 . . . . 0.0 110.739 177.361 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -151.79 163.43 39.18 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 113.815 1.042 . . . . 0.0 113.815 -179.223 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 7.6 tp -142.17 160.56 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -177.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -153.95 68.55 0.76 Allowed 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 176.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 49.0 tp -69.3 133.31 47.71 Favored 'General case' 0 CA--C 1.529 0.141 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 175.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . 0.461 ' HD2' ' CZ ' ' B' ' 56' ' ' PHE . 67.3 mttm -126.5 128.84 47.55 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 122.559 0.344 . . . . 0.0 110.542 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 10.1 p30 . . . . . 0 CA--C 1.533 0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.124 175.879 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo . . . . . 0 N--CA 1.449 -1.142 0 N-CA-C 110.247 -0.713 . . . . 0.0 110.247 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . 0.461 ' CZ ' ' HD2' ' B' ' 48' ' ' LYS . 3.3 p90 -161.58 171.69 17.6 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 178.097 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.38 164.37 38.37 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.213 0.53 . . . . 0.0 111.691 -175.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . 0.4 ' CZ ' ' HB2' ' B' ' 19' ' ' TYR . 9.7 m-85 -116.81 151.62 36.11 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.372 -0.831 . . . . 0.0 113.073 169.396 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 48.2 t -133.41 142.23 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 C-N-CA 123.189 0.596 . . . . 0.0 109.62 -177.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -123.99 117.82 25.62 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 110.444 -0.206 . . . . 0.0 110.444 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 49.3 m-85 -90.33 158.27 17.22 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 113.774 1.027 . . . . 0.0 113.774 177.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -70.77 -24.28 62.56 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 174.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -152.64 155.52 32.64 Favored Pre-proline 0 CA--C 1.533 0.314 0 C-N-CA 123.367 0.667 . . . . 0.0 111.952 178.511 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -71.92 -7.74 21.65 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 123.054 2.502 . . . . 0.0 111.359 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.28 -53.93 14.77 Favored 'General case' 0 C--N 1.339 0.12 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -177.112 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -70.75 -20.22 62.65 Favored 'General case' 0 C--O 1.233 0.185 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -177.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.05 -23.92 65.93 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 45.6 tp10 -72.77 -32.48 65.64 Favored 'General case' 0 N--CA 1.455 -0.2 0 O-C-N 122.273 -0.267 . . . . 0.0 110.318 179.539 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 62.0 m-20 -73.49 -36.8 65.84 Favored 'General case' 0 CA--C 1.522 -0.116 0 N-CA-C 111.979 0.362 . . . . 0.0 111.979 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.8 -27.92 63.26 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 122.164 0.186 . . . . 0.0 110.557 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 42.6 t -83.19 -54.32 9.49 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.2 t -70.68 -18.91 62.83 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 -174.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -101.31 0.54 53.91 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-O 119.031 -0.872 . . . . 0.0 113.585 -173.04 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 28.9 ttp-105 -153.78 -13.18 0.14 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-N 118.846 1.323 . . . . 0.0 113.393 -175.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -67.68 145.69 54.53 Favored 'General case' 0 C--O 1.233 0.226 0 O-C-N 121.465 -0.772 . . . . 0.0 110.315 179.485 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.51 55.17 26.95 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.554 -0.618 . . . . 0.0 111.554 175.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 39.2 t80 -105.96 140.38 39.06 Favored 'General case' 0 N--CA 1.453 -0.288 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -178.094 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -62.91 110.55 1.81 Allowed 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 124.2 1.0 . . . . 0.0 113.012 -175.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.421 ' CD2' ' N ' ' B' ' 80' ' ' ASP . 25.6 t80 -118.88 165.93 13.45 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 123.66 0.784 . . . . 0.0 111.941 174.756 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.421 ' N ' ' CD2' ' B' ' 79' ' ' TYR . 19.4 t0 -59.07 98.09 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.436 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -178.661 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.9 -4.91 63.79 Favored Glycine 0 CA--C 1.535 1.285 0 CA-C-O 119.747 -0.474 . . . . 0.0 112.677 177.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -140.56 -170.22 2.96 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 117.952 0.876 . . . . 0.0 113.15 -178.185 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 -141.38 133.35 27.59 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 -178.158 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -65.13 152.03 44.6 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.27 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -125.72 126.92 45.39 Favored 'General case' 0 CA--C 1.52 -0.173 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 175.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 38.9 t -143.95 81.26 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.245 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 176.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -139.8 158.22 44.45 Favored 'General case' 0 C--O 1.224 -0.281 0 C-N-CA 122.664 0.386 . . . . 0.0 110.551 -175.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.0 p90 -74.54 154.79 87.64 Favored Pre-proline 0 N--CA 1.454 -0.269 0 N-CA-C 114.73 1.381 . . . . 0.0 114.73 179.245 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo . . . . . 0 C--O 1.253 1.255 0 C-N-CA 123.646 2.897 . . . . 0.0 110.877 176.937 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 86.6 m . . . . . 0 CA--C 1.533 0.322 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 68.5 mtm-85 -87.76 138.21 31.66 Favored 'General case' 0 N--CA 1.453 -0.316 0 O-C-N 122.1 -0.375 . . . . 0.0 111.336 178.618 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.6 pp -138.05 168.89 19.48 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 C-N-CA 123.148 0.579 . . . . 0.0 110.072 176.128 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -113.33 153.31 28.71 Favored 'General case' 0 CA--C 1.528 0.104 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -177.228 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 93.0 t -133.99 115.21 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -117.56 169.95 13.38 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 177.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 61.1 t30 57.99 23.68 10.21 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.704 0.801 . . . . 0.0 111.113 -175.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 21.2 tp . . . . . 0 CA--C 1.535 0.374 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 178.95 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 4.2 ttpt . . . . . 0 C--O 1.226 -0.144 0 N-CA-C 110.714 -0.106 . . . . 0.0 110.714 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -69.23 -31.79 70.58 Favored 'General case' 0 C--O 1.233 0.189 0 O-C-N 122.169 -0.332 . . . . 0.0 111.581 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.4 tt -76.48 -11.24 13.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 O-C-N 123.169 0.293 . . . . 0.0 110.99 -178.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -118.97 -0.56 11.14 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 117.833 0.288 . . . . 0.0 110.807 177.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -94.49 -62.41 1.33 Allowed 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 122.551 0.34 . . . . 0.0 111.674 177.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 62.9 t -65.4 -41.12 90.4 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 -178.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -62.94 -31.03 72.03 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.4 t -68.07 -30.8 70.08 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 110.228 -0.286 . . . . 0.0 110.228 177.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 47.1 mmtm -69.35 -28.28 66.08 Favored 'General case' 0 C--N 1.338 0.082 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 173.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -80.18 -19.11 47.86 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 116.665 2.098 . . . . 0.0 116.665 176.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.49 20.24 0.03 OUTLIER Glycine 0 CA--C 1.53 0.99 0 C-N-CA 119.584 -1.293 . . . . 0.0 114.64 -177.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 50.85 66.69 1.1 Allowed 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 118.279 1.039 . . . . 0.0 111.987 176.423 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.7 mp -56.02 141.95 11.83 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 C-N-CA 122.951 0.5 . . . . 0.0 110.447 178.054 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . 0.409 HH11 ' HD3' ' B' ' 43' ' ' ARG . 10.6 mmm180 -107.05 -24.7 11.88 Favored 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 122.603 0.361 . . . . 0.0 111.262 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -146.59 155.25 42.34 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . 0.4 HG22 ' H ' ' B' ' 47' ' ' LEU . 17.7 mm -139.13 154.36 25.5 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 C-N-CA 124.203 1.001 . . . . 0.0 109.407 -178.21 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -142.38 47.67 1.58 Allowed 'General case' 0 CA--C 1.531 0.233 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 177.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . 0.4 ' H ' HG22 ' B' ' 45' ' ' ILE . 58.7 tp -61.5 128.21 35.19 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.55 177.626 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . 0.535 ' HE2' ' CZ ' ' B' ' 56' ' ' PHE . 23.2 pttm -157.74 173.14 17.27 Favored 'General case' 0 CA--C 1.528 0.102 0 C-N-CA 123.551 0.74 . . . . 0.0 109.691 179.04 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 50.8 p30 . . . . . 0 CA--C 1.531 0.219 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -174.445 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo . . . . . 0 N--CA 1.452 -0.923 0 N-CA-C 110.945 -0.444 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . 0.535 ' CZ ' ' HE2' ' B' ' 48' ' ' LYS . 4.2 p90 -157.24 163.07 39.17 Favored 'General case' 0 C--O 1.234 0.25 0 N-CA-C 104.696 -2.335 . . . . 0.0 104.696 174.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.17 152.88 29.94 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 119.713 -0.795 . . . . 0.0 112.611 -172.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -96.5 148.24 23.02 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.707 166.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 58.5 t -133.98 143.8 37.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -178.439 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -132.21 118.39 19.47 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 120.956 0.408 . . . . 0.0 110.763 -176.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 34.5 m-85 -86.96 161.97 17.93 Favored 'General case' 0 C--N 1.333 -0.115 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -177.436 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -79.98 -27.92 39.59 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.425 174.36 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -138.51 143.51 38.62 Favored Pre-proline 0 C--N 1.34 0.182 0 C-N-CA 123.85 0.86 . . . . 0.0 112.006 179.055 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -73.83 -19.7 20.64 Favored 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 123.281 2.654 . . . . 0.0 111.257 -177.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 78.7 mtt85 -74.18 -25.23 59.59 Favored 'General case' 0 N--CA 1.456 -0.136 0 C-N-CA 122.398 0.279 . . . . 0.0 111.381 -178.154 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -91.96 -21.89 20.3 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.642 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.73 -27.06 66.48 Favored 'General case' 0 N--CA 1.453 -0.276 0 O-C-N 122.274 -0.267 . . . . 0.0 110.282 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -73.55 -26.66 60.95 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 121.9 0.08 . . . . 0.0 110.848 179.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -77.25 -36.23 54.67 Favored 'General case' 0 CA--C 1.521 -0.14 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.84 -29.06 61.92 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 122.259 0.224 . . . . 0.0 110.439 177.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 17.2 t -80.94 -42.81 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 43.8 t -66.97 -21.83 65.95 Favored 'General case' 0 CA--C 1.528 0.108 0 O-C-N 122.177 -0.327 . . . . 0.0 111.063 -178.156 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -89.66 -2.88 75.15 Favored Glycine 0 CA--C 1.531 1.071 0 CA-C-O 119.387 -0.674 . . . . 0.0 112.92 -178.361 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 80.3 mtt85 -141.93 -8.48 0.92 Allowed 'General case' 0 C--N 1.341 0.211 0 CA-C-N 118.181 0.99 . . . . 0.0 112.827 -174.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -67.3 118.64 10.95 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -179.286 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.81 45.37 96.35 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 175.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 53.9 t80 -95.97 135.94 37.06 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -172.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.6 t0 -63.51 105.33 0.76 Allowed 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.52 0.728 . . . . 0.0 112.557 -177.506 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.434 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 62.8 t80 -111.72 171.05 7.72 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.733 0.813 . . . . 0.0 111.301 177.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.434 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 19.7 t0 -60.5 98.83 0.07 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -179.464 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 77.88 -4.69 56.57 Favored Glycine 0 CA--C 1.536 1.35 0 CA-C-O 119.474 -0.626 . . . . 0.0 112.938 177.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -140.93 -171.14 3.19 Favored 'General case' 0 N--CA 1.462 0.148 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 41.7 ttp-105 -145.08 131.07 19.24 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.86 0.864 . . . . 0.0 109.334 -178.107 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.9 mp -66.62 153.79 42.18 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-O 120.923 0.392 . . . . 0.0 110.477 -175.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 52.8 mtm180 -129.47 47.27 2.51 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.457 0.703 . . . . 0.0 110.167 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 88.3 t -77.32 98.43 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 175.088 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -151.09 162.49 40.75 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.629 0.252 . . . . 0.0 110.655 179.178 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -73.05 152.51 90.71 Favored Pre-proline 0 C--O 1.234 0.24 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 178.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo . . . . . 0 C--O 1.251 1.15 0 C-N-CA 123.739 2.959 . . . . 0.0 110.735 177.836 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 76.4 m . . . . . 0 CA--C 1.532 0.28 0 N-CA-C 110.732 -0.099 . . . . 0.0 110.732 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 18.4 ttm180 -84.25 152.65 24.05 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 178.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 15.3 pt -136.17 -178.77 2.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.141 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 175.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -122.58 148.76 44.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.452 -0.794 . . . . 0.0 112.762 177.226 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 21.2 t -137.9 90.47 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 120.451 0.167 . . . . 0.0 110.755 -176.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -80.8 146.5 27.0 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 174.658 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 44.7 t30 58.28 -171.12 0.11 Allowed 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 122.786 0.434 . . . . 0.0 110.292 -174.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 2.1 pt? . . . . . 0 CA--C 1.534 0.338 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 177.107 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . 0.42 ' HE3' ' HB2' ' B' ' 34' ' ' ASP . 30.8 ttpt . . . . . 0 CA--C 1.529 0.165 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -58.83 -23.67 60.91 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -179.004 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 27.7 mm -74.8 -17.49 16.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 122.653 0.381 . . . . 0.0 110.636 179.565 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -126.42 13.53 7.63 Favored 'General case' 0 C--N 1.34 0.159 0 CA-C-N 117.772 0.26 . . . . 0.0 111.052 178.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . 0.42 ' HB2' ' HE3' ' B' ' 30' ' ' LYS . 22.0 t0 -127.93 -60.86 1.14 Allowed 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 173.011 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 95.1 t -69.55 -53.18 26.03 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -65.14 -19.3 65.92 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 175.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 47.5 t -71.57 -28.94 64.19 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 175.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -74.82 -26.93 60.06 Favored 'General case' 0 CA--C 1.529 0.144 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 171.154 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -73.55 -23.78 60.03 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 115.928 1.825 . . . . 0.0 115.928 174.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.57 16.48 0.03 OUTLIER Glycine 0 CA--C 1.53 1.026 0 C-N-CA 120.219 -0.991 . . . . 0.0 114.074 -177.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.21 77.28 0.14 Allowed 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 117.886 0.843 . . . . 0.0 112.191 176.774 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.8 mp -60.07 142.32 15.56 Favored 'Isoleucine or valine' 0 C--O 1.232 0.138 0 C-N-CA 122.742 0.417 . . . . 0.0 110.225 177.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . 0.485 ' HE ' ' HA ' ' B' ' 62' ' ' GLU . 48.6 mtm105 -102.96 -30.99 10.45 Favored 'General case' 0 CA--C 1.523 -0.063 0 C-N-CA 122.393 0.277 . . . . 0.0 111.177 176.272 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -149.67 158.26 44.0 Favored 'General case' 0 C--O 1.232 0.134 0 N-CA-C 114.002 1.112 . . . . 0.0 114.002 -177.057 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 53.4 mt -125.59 150.8 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.149 0 C-N-CA 123.7 0.8 . . . . 0.0 109.098 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -141.01 50.71 1.63 Allowed 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 54.8 tp -60.55 135.58 57.8 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.099 177.034 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 25.3 ttmm -143.77 152.36 41.14 Favored 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 122.886 0.475 . . . . 0.0 110.116 -179.095 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 44.4 p30 . . . . . 0 CA--C 1.534 0.336 0 C-N-CA 122.61 0.364 . . . . 0.0 111.949 -178.345 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo . . . . . 0 N--CA 1.449 -1.097 0 N-CA-C 110.918 -0.455 . . . . 0.0 110.918 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -154.11 164.5 38.39 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 175.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -153.11 165.5 35.44 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-O 120.935 0.398 . . . . 0.0 111.883 -173.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -121.37 79.52 1.55 Allowed 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.471 175.02 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.5 t -67.49 147.48 12.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 C-N-CA 123.23 0.612 . . . . 0.0 110.19 -174.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -123.84 122.32 37.7 Favored 'General case' 0 CA--C 1.529 0.161 0 CA-C-O 120.825 0.345 . . . . 0.0 110.804 -178.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -94.58 164.92 12.78 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 115.464 1.653 . . . . 0.0 115.464 -175.322 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . 0.485 ' HA ' ' HE ' ' B' ' 43' ' ' ARG . 85.0 tt0 -73.58 -32.18 63.99 Favored 'General case' 0 C--N 1.34 0.183 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.661 174.332 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -141.59 145.82 39.02 Favored Pre-proline 0 CA--C 1.529 0.149 0 C-N-CA 123.771 0.828 . . . . 0.0 111.955 179.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -73.77 -19.58 20.92 Favored 'Trans proline' 0 N--CA 1.452 -0.941 0 C-N-CA 123.179 2.586 . . . . 0.0 110.841 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.74 -35.43 57.77 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 122.122 0.169 . . . . 0.0 110.838 -178.569 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -77.51 -17.72 57.71 Favored 'General case' 0 CA--C 1.527 0.083 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 178.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.53 -20.95 64.59 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 177.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -70.31 -34.25 72.48 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 177.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -75.83 -34.12 60.1 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.03 -31.69 64.6 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 178.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 7.5 t -73.69 -42.37 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 67.0 m -74.78 -0.49 18.43 Favored 'General case' 0 C--O 1.232 0.152 0 C-N-CA 122.136 0.175 . . . . 0.0 111.056 179.278 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -73.16 -35.66 57.02 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 119.487 -0.619 . . . . 0.0 112.756 -175.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 23.6 ttt180 -163.15 30.39 0.09 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.194 0.997 . . . . 0.0 111.631 -176.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -65.0 144.29 57.39 Favored 'General case' 0 C--O 1.232 0.14 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -179.607 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 57.78 46.47 92.27 Favored Glycine 0 C--N 1.338 0.656 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 174.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . 0.541 ' H ' ' HB2' ' B' ' 84' ' ' LEU . 16.7 t80 -98.67 137.42 37.33 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.673 0.736 . . . . 0.0 112.853 -173.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -67.95 83.35 0.21 Allowed 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 124.29 1.036 . . . . 0.0 112.059 -177.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.449 ' CD2' ' N ' ' B' ' 80' ' ' ASP . 54.2 t80 -82.89 171.31 14.02 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 123.199 0.6 . . . . 0.0 111.218 177.532 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.449 ' N ' ' CD2' ' B' ' 79' ' ' TYR . 24.9 t0 -64.5 93.84 0.11 Allowed 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.96 -1.81 88.33 Favored Glycine 0 CA--C 1.53 0.997 0 CA-C-O 119.762 -0.465 . . . . 0.0 112.615 177.244 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -141.93 -172.69 3.62 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 117.876 0.838 . . . . 0.0 112.669 -179.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 4.6 tpt180 -137.59 133.78 34.81 Favored 'General case' 0 C--O 1.232 0.143 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . 0.541 ' HB2' ' H ' ' B' ' 77' ' ' TYR . 4.2 mm? -64.66 139.23 58.74 Favored 'General case' 0 C--N 1.333 -0.117 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 95.3 mtm-85 -129.04 54.98 1.76 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 122.701 0.4 . . . . 0.0 110.288 175.517 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 2.7 p -81.28 97.64 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 175.017 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -153.68 169.49 23.18 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 122.875 0.47 . . . . 0.0 110.686 -179.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -65.26 151.72 93.32 Favored Pre-proline 0 CA--C 1.53 0.203 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo . . . . . 0 C--O 1.25 1.107 0 C-N-CA 123.678 2.918 . . . . 0.0 110.761 177.221 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 73.9 m . . . . . 0 CA--C 1.532 0.26 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 54.6 mtm180 -82.16 145.26 30.2 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 118.422 0.555 . . . . 0.0 111.305 175.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 22.8 pt -138.62 175.73 7.77 Favored 'Isoleucine or valine' 0 C--O 1.231 0.095 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 170.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -119.34 148.82 42.75 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 114.553 1.316 . . . . 0.0 114.553 -177.839 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 60.7 t -132.88 136.58 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 123.226 0.61 . . . . 0.0 109.634 179.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -140.52 172.15 23.69 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 51.2 t30 57.07 19.74 4.95 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.729 0.812 . . . . 0.0 111.41 -174.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.7 tp . . . . . 0 N--CA 1.454 -0.258 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.723 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt . . . . . 0 CA--C 1.532 0.281 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -58.84 -25.48 63.27 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 179.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.9 tt -76.27 -17.87 15.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 C-N-CA 122.335 0.254 . . . . 0.0 110.511 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.1 mt-10 -93.41 -31.04 14.78 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -74.13 -37.26 64.13 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 -177.655 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 62.4 t -69.71 -46.1 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.353 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -68.79 -35.4 76.99 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 113.615 0.969 . . . . 0.0 113.615 178.064 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 33.5 t -60.9 -33.5 73.21 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 178.283 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 16.7 tppt? -73.76 -33.43 64.29 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 122.2 0.2 . . . . 0.0 110.769 177.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -87.04 -13.83 43.28 Favored 'General case' 0 C--O 1.233 0.206 0 N-CA-C 116.739 2.125 . . . . 0.0 116.739 -178.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.08 13.83 0.03 OUTLIER Glycine 0 CA--C 1.527 0.843 0 C-N-CA 119.906 -1.14 . . . . 0.0 114.254 -177.447 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.62 40.54 27.44 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 118.227 1.013 . . . . 0.0 111.806 177.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . 0.407 HD12 ' CE2' ' B' ' 61' ' ' PHE . 1.7 mp -44.25 138.33 0.97 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.182 0 C-N-CA 123.719 0.808 . . . . 0.0 111.114 179.087 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 29.8 mtp-105 -85.51 -38.91 18.03 Favored 'General case' 0 CA--C 1.523 -0.08 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.748 -178.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -144.5 159.48 42.7 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -176.439 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 8.7 tp -137.32 161.74 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -178.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -147.78 70.44 1.16 Allowed 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 177.013 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -64.14 125.53 24.8 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 176.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 39.4 mttp -139.11 164.14 30.57 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 123.547 0.739 . . . . 0.0 111.054 -178.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 51.9 t-20 . . . . . 0 N--CA 1.454 -0.272 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 170.703 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo . . . . . 0 N--CA 1.449 -1.134 0 CA-C-O 121.179 0.408 . . . . 0.0 111.629 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -150.67 165.2 34.14 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 104.884 -2.265 . . . . 0.0 104.884 175.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -157.03 163.7 38.78 Favored 'General case' 0 N--CA 1.453 -0.304 0 O-C-N 121.721 -0.612 . . . . 0.0 111.922 -174.409 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -113.2 151.62 30.75 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 171.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 41.5 t -131.1 136.4 57.95 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 -175.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -120.55 111.68 17.98 Favored 'General case' 0 N--CA 1.455 -0.205 0 CA-C-O 120.865 0.364 . . . . 0.0 110.481 -177.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.407 ' CE2' HD12 ' B' ' 42' ' ' ILE . 37.1 m-85 -81.15 159.38 24.66 Favored 'General case' 0 CA--C 1.528 0.125 0 N-CA-C 115.347 1.61 . . . . 0.0 115.347 -176.583 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -87.73 -26.66 22.82 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 169.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -155.44 118.95 2.42 Favored Pre-proline 0 CA--C 1.532 0.258 0 C-N-CA 123.635 0.774 . . . . 0.0 109.691 -179.196 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.52 -10.54 29.08 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.31 2.673 . . . . 0.0 111.942 -174.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 41.0 ttm105 -67.45 -29.29 68.72 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 117.887 0.312 . . . . 0.0 110.542 177.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 -81.24 -16.07 53.72 Favored 'General case' 0 CA--C 1.53 0.176 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.77 -16.43 63.3 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 120.39 0.138 . . . . 0.0 110.75 -179.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -66.7 -20.27 65.93 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 122.363 -0.21 . . . . 0.0 110.6 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -104.29 -33.16 8.76 Favored 'General case' 0 C--N 1.339 0.125 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 178.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.92 -31.49 64.67 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.012 0.525 . . . . 0.0 110.571 -178.614 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 98.0 t -87.44 -48.58 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 36.0 t -67.45 -14.87 63.32 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 122.474 -0.141 . . . . 0.0 111.2 -175.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -79.19 -14.24 81.96 Favored Glycine 0 CA--C 1.529 0.958 0 CA-C-O 119.345 -0.697 . . . . 0.0 112.652 -176.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 23.4 ptt-85 -158.13 3.92 0.11 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 118.623 1.212 . . . . 0.0 113.52 -175.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -73.16 143.39 47.28 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 118.757 0.708 . . . . 0.0 110.11 176.207 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 62.22 35.64 91.86 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.697 -0.561 . . . . 0.0 111.697 175.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 49.8 t80 -96.98 137.51 35.94 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -172.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -64.03 103.86 0.65 Allowed 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 123.382 0.673 . . . . 0.0 112.361 -178.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.457 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 75.7 t80 -109.75 173.33 6.37 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.91 0.884 . . . . 0.0 111.191 179.085 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.457 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 77.2 m-20 -59.88 98.66 0.06 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -179.575 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.58 -5.89 42.54 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-O 119.666 -0.519 . . . . 0.0 112.938 177.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -139.99 -169.33 2.71 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.964 0.882 . . . . 0.0 113.344 -177.36 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 41.6 ttp-105 -143.92 133.96 24.16 Favored 'General case' 0 N--CA 1.457 -0.12 0 C-N-CA 123.615 0.766 . . . . 0.0 109.016 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -62.55 147.96 47.47 Favored 'General case' 0 C--N 1.335 -0.063 0 C-N-CA 122.571 0.348 . . . . 0.0 110.18 -178.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 57.7 ttt180 -130.86 113.74 14.43 Favored 'General case' 0 CA--C 1.517 -0.313 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 37.5 t -132.52 92.57 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.632 178.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 24.0 pt-20 -145.29 159.49 42.96 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.703 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -74.04 153.57 88.69 Favored Pre-proline 0 N--CA 1.454 -0.229 0 N-CA-C 114.854 1.427 . . . . 0.0 114.854 -179.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo . . . . . 0 C--O 1.25 1.118 0 C-N-CA 123.911 3.074 . . . . 0.0 110.714 175.98 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 98.6 m . . . . . 0 CA--C 1.532 0.273 0 N-CA-C 111.491 0.182 . . . . 0.0 111.491 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 92.8 mtt-85 -73.3 147.88 44.07 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-O 120.879 0.371 . . . . 0.0 111.854 179.462 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 20.8 pt -138.67 177.76 4.77 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 C-N-CA 123.852 0.861 . . . . 0.0 108.754 172.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -116.9 150.54 38.3 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 114.344 1.238 . . . . 0.0 114.344 -177.285 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 47.4 t -138.65 143.3 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 C-N-CA 123.519 0.728 . . . . 0.0 109.187 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.35 178.81 34.43 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.954 -0.459 . . . . 0.0 111.954 -176.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 54.2 t30 58.54 25.52 13.21 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.195 0.998 . . . . 0.0 111.606 -176.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.6 mt . . . . . 0 N--CA 1.454 -0.23 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.94 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 48.1 mtpt . . . . . 0 CA--C 1.528 0.112 0 N-CA-C 113.175 0.805 . . . . 0.0 113.175 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -62.5 -32.74 73.71 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 118.641 0.655 . . . . 0.0 112.088 175.596 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.9 tt -75.82 -16.81 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 122.787 0.435 . . . . 0.0 110.576 178.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 72.9 mt-10 -97.31 -13.67 21.79 Favored 'General case' 0 C--N 1.34 0.18 0 C-N-CA 122.181 0.193 . . . . 0.0 110.684 -179.456 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -103.17 -67.69 0.87 Allowed 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -175.566 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 3.7 p -73.81 -37.27 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 N-CA-C 112.493 0.553 . . . . 0.0 112.493 -172.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 70.7 m-85 -73.15 -25.98 61.03 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 112.773 0.656 . . . . 0.0 112.773 177.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 42.8 t -72.37 -30.27 64.54 Favored 'General case' 0 N--CA 1.456 -0.166 0 N-CA-C 110.305 -0.257 . . . . 0.0 110.305 176.348 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . 0.583 ' HZ2' ' HB2' ' B' ' 38' ' ' LYS . 0.2 OUTLIER -73.37 -29.48 62.66 Favored 'General case' 0 N--CA 1.455 -0.208 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 174.72 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -81.01 -20.4 41.84 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 116.144 1.905 . . . . 0.0 116.144 179.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.1 14.4 0.76 Allowed Glycine 0 CA--C 1.527 0.783 0 C-N-CA 120.707 -0.758 . . . . 0.0 113.851 -175.113 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.67 38.49 22.88 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 117.858 0.829 . . . . 0.0 111.261 178.002 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 81.8 mt -45.47 138.67 1.3 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.151 0 C-N-CA 123.338 0.655 . . . . 0.0 111.387 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 28.6 mmt180 -104.63 -22.56 13.22 Favored 'General case' 0 N--CA 1.455 -0.204 0 C-N-CA 122.884 0.474 . . . . 0.0 111.668 -178.141 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -152.4 154.16 35.04 Favored 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 118.352 0.524 . . . . 0.0 112.112 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 2.8 mp -136.52 148.03 27.32 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.085 0 C-N-CA 123.884 0.874 . . . . 0.0 109.326 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -140.95 57.2 1.56 Allowed 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 122.694 0.398 . . . . 0.0 110.278 179.297 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 57.8 tp -60.16 129.25 40.79 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.154 175.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 43.0 mttp -120.13 143.59 48.1 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 123.634 0.774 . . . . 0.0 110.672 179.204 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 49.7 p30 . . . . . 0 N--CA 1.453 -0.307 0 C-N-CA 123.402 0.681 . . . . 0.0 110.473 179.871 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo . . . . . 0 N--CA 1.452 -0.96 0 N-CA-C 111.197 -0.347 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -160.87 173.86 14.7 Favored 'General case' 0 CA--C 1.53 0.178 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -173.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.28 166.11 34.39 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 120.801 0.334 . . . . 0.0 111.668 -175.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -121.17 154.82 35.72 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 168.581 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 70.5 t -144.2 133.03 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -174.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -106.76 117.97 35.45 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 -85.59 154.65 21.58 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 115.12 1.526 . . . . 0.0 115.12 179.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 38.1 tp10 -75.54 -30.27 59.7 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 172.305 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 58.3 t0 -157.59 117.72 1.97 Allowed Pre-proline 0 N--CA 1.451 -0.415 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.3 -10.3 26.97 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 123.194 2.596 . . . . 0.0 112.112 -176.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 77.4 mtt85 -72.17 -16.16 61.97 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 117.85 0.295 . . . . 0.0 111.026 178.059 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -77.97 -2.73 38.4 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 177.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -64.52 -14.67 58.52 Favored 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 122.435 0.294 . . . . 0.0 111.163 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -65.96 -15.85 63.35 Favored 'General case' 0 CA--C 1.529 0.168 0 O-C-N 122.173 -0.329 . . . . 0.0 111.333 -179.319 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -123.39 -38.28 2.57 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 123.001 0.52 . . . . 0.0 112.181 177.166 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -81.82 -9.57 59.57 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.08 0.552 . . . . 0.0 112.187 -175.486 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 99.5 t -130.99 -49.76 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 CA-C-N 117.729 0.24 . . . . 0.0 110.526 -177.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 69.2 m -66.23 -10.96 46.98 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 117.646 0.203 . . . . 0.0 111.145 -179.462 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.2 -1.16 69.87 Favored Glycine 0 CA--C 1.53 0.975 0 CA-C-O 119.436 -0.646 . . . . 0.0 112.73 -178.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 12.1 tpp180 -151.72 -16.88 0.19 Allowed 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 118.466 1.133 . . . . 0.0 112.705 -176.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 32.9 t0 -65.11 138.34 58.24 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 118.267 0.485 . . . . 0.0 110.634 -178.128 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.51 41.57 99.2 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 111.794 -0.522 . . . . 0.0 111.794 174.091 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -98.61 133.47 42.91 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -174.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.6 t0 -62.63 106.52 0.8 Allowed 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 123.781 0.832 . . . . 0.0 112.341 -177.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.439 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.9 t80 -112.88 171.28 7.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 123.804 0.842 . . . . 0.0 111.445 177.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.439 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 20.6 t0 -60.53 99.82 0.09 Allowed 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.066 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 77.99 -6.32 49.51 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 123.553 0.597 . . . . 0.0 112.761 177.46 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 87.9 m-85 -140.56 -169.54 2.81 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 117.996 0.898 . . . . 0.0 113.269 -177.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 36.1 ttt180 -147.46 129.53 15.48 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.439 0.696 . . . . 0.0 109.474 -177.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -62.57 147.79 48.02 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 122.847 0.459 . . . . 0.0 110.502 -175.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 -120.68 127.68 52.26 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 175.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 11.8 t -145.27 82.02 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.131 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 173.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -148.33 160.7 42.73 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 122.75 0.42 . . . . 0.0 110.43 -175.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -75.25 156.57 85.58 Favored Pre-proline 0 CA--C 1.533 0.324 0 N-CA-C 114.228 1.196 . . . . 0.0 114.228 179.211 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo . . . . . 0 C--O 1.25 1.077 0 C-N-CA 123.739 2.96 . . . . 0.0 111.867 177.349 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 87.6 m . . . . . 0 N--CA 1.456 -0.137 0 N-CA-C 111.334 0.124 . . . . 0.0 111.334 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 73.0 mtm180 -69.03 146.99 52.2 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 122.831 0.452 . . . . 0.0 110.818 -178.546 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.1 pt -132.56 170.06 20.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-O 120.964 0.412 . . . . 0.0 110.08 172.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -114.99 151.02 34.89 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -176.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 59.3 t -138.45 143.61 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -157.36 -178.76 31.73 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 111.934 -0.466 . . . . 0.0 111.934 -177.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 36.3 t30 56.8 23.99 8.65 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 123.825 0.85 . . . . 0.0 111.645 -177.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 93.4 mt . . . . . 0 CA--C 1.53 0.207 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -179.992 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 6.4 ttpt . . . . . 0 N--CA 1.456 -0.126 0 CA-C-O 120.449 0.166 . . . . 0.0 111.074 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 -70.72 -36.14 73.06 Favored 'General case' 0 N--CA 1.454 -0.227 0 O-C-N 122.1 -0.375 . . . . 0.0 111.261 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 15.2 tt -75.85 -14.09 15.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.377 -176.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -104.28 -21.85 13.46 Favored 'General case' 0 C--N 1.34 0.164 0 CA-C-N 118.714 0.688 . . . . 0.0 110.687 178.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -74.33 -49.88 21.07 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 178.161 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 m -72.86 -30.8 33.81 Favored 'Isoleucine or valine' 0 C--N 1.338 0.101 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.095 -178.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -75.92 -42.87 47.57 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 177.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 96.7 p -67.58 -21.45 65.42 Favored 'General case' 0 C--N 1.34 0.164 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.49 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 23.7 tptm -73.98 -36.88 64.58 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 173.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -82.12 -11.61 58.66 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 116.659 2.096 . . . . 0.0 116.659 178.175 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.98 179.27 48.92 Favored Glycine 0 C--N 1.338 0.645 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.044 -179.364 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.94 53.7 2.27 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 124.06 0.944 . . . . 0.0 111.626 -177.597 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 2.1 mp -68.75 144.24 14.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.24 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 35.0 mmt180 -124.81 -36.1 2.62 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 119.42 -0.324 . . . . 0.0 111.149 178.246 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 39.9 m-20 -122.38 150.16 42.8 Favored 'General case' 0 N--CA 1.462 0.126 0 N-CA-C 113.944 1.091 . . . . 0.0 113.944 -178.385 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -136.18 150.08 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 C-N-CA 124.236 1.014 . . . . 0.0 109.169 178.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 59.2 t0 -146.9 63.5 1.18 Allowed 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 49.6 tp -64.35 129.06 38.43 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 173.345 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -120.39 146.69 45.94 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 123.698 0.799 . . . . 0.0 109.966 178.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 . . . . . 0 C--N 1.334 -0.104 0 C-N-CA 122.891 0.476 . . . . 0.0 111.11 -176.183 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo . . . . . 0 N--CA 1.452 -0.927 0 N-CA-C 110.414 -0.648 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -150.85 167.71 26.68 Favored 'General case' 0 C--O 1.232 0.162 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 -179.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -152.87 166.06 33.48 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.295 0.569 . . . . 0.0 112.426 -171.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -120.56 153.67 36.43 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 124.042 0.937 . . . . 0.0 112.813 170.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 88.9 t -141.1 144.39 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 108.685 -0.858 . . . . 0.0 108.685 -178.17 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 11.7 tp10 -131.14 125.59 33.46 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 122.578 0.351 . . . . 0.0 111.174 -177.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -91.57 151.56 20.68 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 113.974 1.101 . . . . 0.0 113.974 -178.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -82.46 -24.69 34.14 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 169.045 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 36.6 t0 -152.26 114.94 2.9 Favored Pre-proline 0 CA--C 1.534 0.355 0 C-N-CA 123.352 0.661 . . . . 0.0 109.944 -176.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -74.77 -1.37 11.06 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 123.566 2.844 . . . . 0.0 112.742 -173.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 79.5 mtt85 -68.27 -0.49 4.81 Favored 'General case' 0 CA--C 1.53 0.197 0 N-CA-C 112.998 0.74 . . . . 0.0 112.998 -176.212 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 20.4 p30 -134.35 3.12 3.33 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 112.173 0.434 . . . . 0.0 112.173 173.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.76 -22.03 64.33 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 178.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -70.25 -28.45 65.25 Favored 'General case' 0 N--CA 1.456 -0.127 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 178.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -79.63 -35.18 39.8 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 122.337 0.255 . . . . 0.0 111.381 178.025 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.96 -24.72 63.38 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.231 176.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 10.0 t -85.69 -59.03 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.5 t -71.28 -17.6 62.46 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -172.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -93.12 4.07 73.9 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-O 119.247 -0.751 . . . . 0.0 112.588 -177.089 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 46.6 ttm180 -150.19 -16.55 0.25 Allowed 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 118.516 1.158 . . . . 0.0 112.555 -174.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 50.7 p-10 -71.3 156.64 39.29 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.277 0.561 . . . . 0.0 112.306 -176.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 58.85 41.8 96.29 Favored Glycine 0 CA--C 1.526 0.725 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.683 169.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 43.4 t80 -92.38 130.83 37.95 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 118.226 1.013 . . . . 0.0 113.714 -175.153 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -66.12 101.81 0.75 Allowed 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 123.044 0.538 . . . . 0.0 112.025 -178.441 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.515 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 71.4 t80 -93.02 177.98 5.9 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.406 0.682 . . . . 0.0 112.127 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.515 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 74.1 m-20 -66.66 21.84 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.537 0 N-CA-C 114.934 1.457 . . . . 0.0 114.934 -177.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . 0.42 ' H ' ' C ' ' B' ' 79' ' ' TYR . . . 161.5 -10.82 0.12 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-O 119.618 -0.546 . . . . 0.0 112.425 -179.137 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -140.95 -167.05 2.29 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 117.731 0.766 . . . . 0.0 110.893 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 33.8 ttt180 -138.93 122.96 17.89 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -59.81 153.39 20.79 Favored 'General case' 0 N--CA 1.458 -0.043 0 C-N-CA 123.421 0.688 . . . . 0.0 111.096 -176.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 24.0 mtp180 -128.08 125.21 38.81 Favored 'General case' 0 CA--C 1.521 -0.164 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.593 175.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 48.2 t -142.99 82.01 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.171 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 175.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -140.28 160.57 39.67 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.219 0.533 . . . . 0.0 111.809 -173.09 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . 0.468 ' CD1' ' HD2' ' B' ' 89' ' ' PRO . 18.2 t80 -71.84 138.9 82.67 Favored Pre-proline 0 CA--C 1.534 0.335 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . 0.468 ' HD2' ' CD1' ' B' ' 88' ' ' PHE . 43.9 Cg_endo . . . . . 0 C--O 1.248 1.018 0 C-N-CA 123.824 3.016 . . . . 0.0 111.303 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 61.3 m . . . . . 0 C--O 1.231 0.093 0 N-CA-C 110.473 -0.195 . . . . 0.0 110.473 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 31.4 ttm180 -101.02 147.89 25.67 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 123.046 0.539 . . . . 0.0 109.815 -178.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.5 pt -133.53 174.78 12.67 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.081 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 176.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -118.92 150.32 40.09 Favored 'General case' 0 C--O 1.231 0.122 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -175.838 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 60.5 t -139.22 142.84 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 C-N-CA 123.509 0.724 . . . . 0.0 109.437 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.81 168.76 31.78 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -178.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 59.4 t30 60.55 36.89 19.81 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 124.073 0.949 . . . . 0.0 111.379 -174.205 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 84.0 mt . . . . . 0 CA--C 1.532 0.285 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 176.492 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.8 tptt . . . . . 0 N--CA 1.456 -0.174 0 N-CA-C 111.218 0.081 . . . . 0.0 111.218 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -63.79 -28.39 69.83 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.593 0.235 . . . . 0.0 110.43 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.0 tt -72.1 -13.78 16.9 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.349 -178.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -116.98 -9.94 11.02 Favored 'General case' 0 N--CA 1.456 -0.156 0 CA-C-N 118.291 0.496 . . . . 0.0 110.722 174.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -71.27 -55.3 8.34 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-O 121.025 0.44 . . . . 0.0 110.57 178.016 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 10.0 p -67.68 -34.65 69.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 O-C-N 122.241 -0.287 . . . . 0.0 110.886 179.392 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -69.88 -32.86 71.43 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 113.38 0.882 . . . . 0.0 113.38 176.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 39.2 t -67.48 -28.0 67.48 Favored 'General case' 0 C--N 1.342 0.28 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 176.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -70.68 -34.26 71.8 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 174.532 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -81.68 -15.61 53.95 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 116.225 1.935 . . . . 0.0 116.225 177.124 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.46 179.21 44.92 Favored Glycine 0 C--N 1.338 0.656 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.584 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -83.85 84.61 7.51 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 122.992 0.517 . . . . 0.0 111.249 -178.431 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.7 mp -73.09 150.39 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.123 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 174.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 85.3 mmt-85 -128.35 -25.64 2.91 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 119.25 -0.405 . . . . 0.0 111.972 176.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -150.55 161.43 42.56 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 178.609 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . 0.454 HG23 ' H ' ' B' ' 47' ' ' LEU . 30.8 mm -132.43 156.46 42.42 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.061 0 C-N-CA 124.289 1.036 . . . . 0.0 109.279 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -143.2 55.25 1.36 Allowed 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 175.316 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . 0.454 ' H ' HG23 ' B' ' 45' ' ' ILE . 59.9 tp -55.79 133.13 50.88 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.223 174.468 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -133.79 158.53 43.13 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 123.735 0.814 . . . . 0.0 111.415 -177.483 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 43.0 p30 . . . . . 0 CA--C 1.533 0.302 0 C-N-CA 123.442 0.697 . . . . 0.0 110.698 177.692 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo . . . . . 0 N--CA 1.45 -1.038 0 N-CA-C 110.195 -0.733 . . . . 0.0 110.195 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 6.1 p90 -153.29 171.38 18.65 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 106.414 -1.699 . . . . 0.0 106.414 -176.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -159.61 174.62 14.31 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.242 0.544 . . . . 0.0 111.371 -174.089 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -131.81 155.94 46.9 Favored 'General case' 0 N--CA 1.452 -0.355 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 172.04 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 66.8 t -132.87 134.24 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -178.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -111.17 123.95 51.23 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 122.465 0.306 . . . . 0.0 110.562 -177.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -97.43 154.95 17.14 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 42.3 tp10 -78.7 -23.63 45.45 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 170.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -152.51 118.87 3.05 Favored Pre-proline 0 CA--C 1.534 0.365 0 C-N-CA 123.162 0.585 . . . . 0.0 109.785 -178.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -66.65 -8.11 20.13 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.188 2.592 . . . . 0.0 112.505 -176.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 72.3 ttt-85 -61.94 -36.05 80.26 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-N 118.111 0.414 . . . . 0.0 110.172 177.19 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 52.8 m-20 -89.87 -16.3 30.36 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-O 120.582 0.23 . . . . 0.0 111.57 -178.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.97 -25.3 64.47 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -71.81 -28.59 63.7 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 177.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 -75.16 -35.48 61.61 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 178.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.97 -29.91 67.13 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 110.279 -0.267 . . . . 0.0 110.279 177.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.93 -30.02 17.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.306 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.368 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 41.5 t -85.79 -12.34 51.19 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 122.587 0.355 . . . . 0.0 111.54 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -68.56 -46.06 64.22 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.609 -0.596 . . . . 0.0 111.609 -175.518 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 38.2 ttt180 -163.08 122.1 2.11 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.274 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -164.24 149.27 10.2 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 123.066 0.229 . . . . 0.0 110.574 -178.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.94 88.88 0.3 Allowed Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.481 0.562 . . . . 0.0 112.857 170.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . 0.443 ' HA ' ' HA ' ' B' ' 83' ' ' ARG . 13.6 t80 60.31 103.09 0.02 OUTLIER 'General case' 0 N--CA 1.457 -0.104 0 N-CA-C 116.478 2.029 . . . . 0.0 116.478 169.579 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -164.71 31.09 0.07 Allowed 'General case' 0 N--CA 1.444 -0.733 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -131.62 178.09 7.01 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -88.89 107.38 18.97 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 114.892 -1.049 . . . . 0.0 111.228 179.378 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 72.11 -2.26 28.26 Favored Glycine 0 CA--C 1.531 1.092 0 N-CA-C 111.522 -0.631 . . . . 0.0 111.522 -178.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 45.1 m-85 -131.47 169.81 15.55 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 124.001 0.92 . . . . 0.0 113.455 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . 0.443 ' HA ' ' HA ' ' B' ' 77' ' ' TYR . 0.0 OUTLIER -135.15 135.83 41.4 Favored 'General case' 0 N--CA 1.44 -0.949 0 CA-C-O 120.803 0.335 . . . . 0.0 111.282 -178.58 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . 0.45 ' CD2' ' N ' ' B' ' 84' ' ' LEU . 2.4 mm? -73.85 142.92 46.06 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 178.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 59.1 mtm180 -132.48 114.57 14.45 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-O 120.943 0.401 . . . . 0.0 110.222 175.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 42.4 t -136.4 86.08 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 C-N-CA 123.543 0.737 . . . . 0.0 109.055 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -149.8 163.21 38.61 Favored 'General case' 0 C--N 1.334 -0.103 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.534 -178.655 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.5 p90 -74.0 152.23 88.62 Favored Pre-proline 0 CA--C 1.531 0.229 0 N-CA-C 114.626 1.343 . . . . 0.0 114.626 179.433 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo . . . . . 0 C--O 1.253 1.266 0 C-N-CA 123.837 3.025 . . . . 0.0 110.781 176.312 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 98.3 m . . . . . 0 C--O 1.231 0.083 0 N-CA-C 111.501 0.185 . . . . 0.0 111.501 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -88.86 155.21 19.67 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 120.847 0.356 . . . . 0.0 111.255 -177.733 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 12.2 pt -127.62 -177.29 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 C-N-CA 123.223 0.609 . . . . 0.0 109.477 177.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -142.94 151.29 40.79 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -178.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 62.8 t -142.84 101.15 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.149 0 N-CA-C 110.465 -0.198 . . . . 0.0 110.465 -176.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -92.59 166.95 29.47 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 171.682 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 66.2 t30 55.43 29.37 13.07 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 122.824 0.45 . . . . 0.0 110.725 -177.028 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 23.0 tp . . . . . 0 CA--C 1.536 0.405 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.911 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . 0.421 ' HE2' ' OD1' ' B' ' 34' ' ' ASP . 23.4 tptm . . . . . 0 N--CA 1.455 -0.2 0 CA-C-O 120.221 0.058 . . . . 0.0 110.957 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -63.87 -24.01 67.58 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 175.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.6 tt -69.51 -15.99 20.06 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 C-N-CA 123.15 0.58 . . . . 0.0 110.902 -179.584 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -125.45 4.35 7.65 Favored 'General case' 0 CA--C 1.53 0.205 0 O-C-N 122.053 -0.404 . . . . 0.0 111.367 179.056 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . 0.421 ' OD1' ' HE2' ' B' ' 30' ' ' LYS . 79.1 m-20 -97.06 -61.93 1.33 Allowed 'General case' 0 C--O 1.233 0.197 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 172.215 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 p -74.84 -41.53 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.087 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -172.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -75.39 -21.49 58.22 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -179.019 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 43.3 t -72.26 -30.18 64.6 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 175.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 29.7 ttpp -72.92 -28.59 62.55 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.638 -0.505 . . . . 0.0 109.638 174.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -79.33 -20.73 47.15 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 116.26 1.948 . . . . 0.0 116.26 177.413 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.88 20.58 0.17 Allowed Glycine 0 CA--C 1.53 0.984 0 C-N-CA 119.887 -1.149 . . . . 0.0 114.717 -175.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 48.7 49.14 19.19 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 117.938 0.869 . . . . 0.0 111.475 175.186 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 75.6 mt -48.97 137.02 5.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.144 0.577 . . . . 0.0 111.008 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 48.0 mtm105 -98.9 -32.14 11.48 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 122.891 0.477 . . . . 0.0 111.527 179.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 32.3 m-20 -148.94 157.01 43.1 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 113.835 1.05 . . . . 0.0 113.835 -177.449 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 3.2 mp -126.78 151.95 34.07 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -148.6 48.02 1.02 Allowed 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -177.032 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 54.0 tp -68.75 110.45 4.32 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 177.632 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 48.1 mttm -93.88 146.57 23.8 Favored 'General case' 0 N--CA 1.456 -0.145 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 175.475 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 31.9 p30 . . . . . 0 CA--C 1.532 0.266 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.003 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo . . . . . 0 N--CA 1.454 -0.815 0 CA-C-O 120.78 0.242 . . . . 0.0 112.163 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -164.13 167.22 20.46 Favored 'General case' 0 N--CA 1.455 -0.195 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 178.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -144.25 161.01 39.98 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -171.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -119.71 60.52 0.85 Allowed 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 124.152 0.981 . . . . 0.0 112.769 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 83.7 t -58.34 143.26 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.108 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -177.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 73.1 tt0 -120.79 120.4 35.49 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.918 0.389 . . . . 0.0 110.956 -175.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -91.53 166.43 12.84 Favored 'General case' 0 N--CA 1.455 -0.179 0 N-CA-C 115.984 1.846 . . . . 0.0 115.984 -174.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 30.4 tp10 -70.99 -35.22 72.01 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 122.757 0.423 . . . . 0.0 110.138 173.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -149.21 148.22 26.03 Favored Pre-proline 0 CA--C 1.527 0.093 0 C-N-CA 124.387 1.075 . . . . 0.0 112.021 178.084 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.1 -17.27 31.73 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.181 2.588 . . . . 0.0 111.089 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 51.9 mmm-85 -77.76 -13.42 59.9 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 122.435 0.294 . . . . 0.0 111.606 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -76.5 -10.31 59.3 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 111.953 0.353 . . . . 0.0 111.953 177.552 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.48 -11.05 60.68 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.592 0.357 . . . . 0.0 111.101 179.563 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -67.93 -17.72 64.54 Favored 'General case' 0 C--O 1.232 0.155 0 O-C-N 122.135 -0.353 . . . . 0.0 111.032 -179.286 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -123.84 -36.24 2.76 Favored 'General case' 0 CA--C 1.528 0.125 0 C-N-CA 123.183 0.593 . . . . 0.0 112.433 178.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -84.28 -8.86 58.9 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -175.605 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 47.3 t -132.68 -46.25 0.64 Allowed 'Isoleucine or valine' 0 C--O 1.228 -0.036 0 CA-C-N 118.062 0.392 . . . . 0.0 110.906 -175.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.3 t -69.5 -15.19 63.2 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-O 120.502 0.192 . . . . 0.0 110.977 -179.282 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.94 -5.82 88.8 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-O 119.647 -0.529 . . . . 0.0 112.711 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 70.2 mtm-85 -138.86 6.07 2.41 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 118.078 0.939 . . . . 0.0 111.869 -178.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -67.3 123.51 20.55 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 117.823 0.283 . . . . 0.0 111.307 -179.101 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 65.19 34.45 89.63 Favored Glycine 0 C--N 1.338 0.669 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 177.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 56.2 t80 -75.91 137.77 40.6 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -173.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 28.2 t0 -66.15 81.02 0.08 Allowed 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.295 1.038 . . . . 0.0 111.964 -177.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . 0.4 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 68.2 t80 -85.03 -179.94 7.15 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 177.784 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.4 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 71.4 m-20 -66.38 91.9 0.18 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 123.246 0.618 . . . . 0.0 112.43 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.73 -2.12 69.81 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-O 119.606 -0.552 . . . . 0.0 112.399 177.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -138.41 176.68 8.49 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 -178.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -125.15 140.1 53.17 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 123.846 0.858 . . . . 0.0 109.376 176.652 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -67.22 152.51 45.6 Favored 'General case' 0 N--CA 1.455 -0.204 0 C-N-CA 122.626 0.37 . . . . 0.0 110.426 177.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -118.43 48.26 1.46 Allowed 'General case' 0 C--N 1.338 0.068 0 C-N-CA 123.3 0.64 . . . . 0.0 109.828 172.012 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 74.7 t -76.43 95.1 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -154.02 158.63 40.86 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.845 178.51 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 8.1 p90 -87.23 145.77 38.64 Favored Pre-proline 0 N--CA 1.456 -0.161 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 177.419 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 C--O 1.253 1.245 0 C-N-CA 123.614 2.876 . . . . 0.0 110.737 175.565 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 74.2 m . . . . . 0 CA--C 1.531 0.225 0 N-CA-C 112.53 0.567 . . . . 0.0 112.53 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 86.3 mtt180 -99.79 148.81 24.01 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 117.96 0.346 . . . . 0.0 111.741 177.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 19.9 pt -134.66 -177.26 1.95 Allowed 'Isoleucine or valine' 0 CA--C 1.524 -0.034 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -119.0 146.64 44.86 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -177.288 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 41.7 t -140.17 139.97 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.54 177.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -143.27 169.75 25.7 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -176.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 59.7 t30 61.07 31.56 19.79 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.741 0.817 . . . . 0.0 111.483 -175.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 81.3 mt . . . . . 0 CA--C 1.533 0.301 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.664 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 30' ' ' LYS . . . . . 0.411 ' HE2' ' OD2' ' B' ' 34' ' ' ASP . 24.0 tptm . . . . . 0 C--O 1.227 -0.12 0 CA-C-O 119.915 -0.088 . . . . 0.0 111.004 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 31.2 m-20 -64.06 -19.94 65.59 Favored 'General case' 0 CA--C 1.528 0.103 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 174.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 tt -69.29 -14.14 18.09 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 C-N-CA 123.336 0.654 . . . . 0.0 111.059 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -129.02 -10.32 4.81 Favored 'General case' 0 CA--C 1.529 0.173 0 CA-C-N 118.514 0.597 . . . . 0.0 111.677 176.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . 0.411 ' OD2' ' HE2' ' B' ' 30' ' ' LYS . 77.7 m-20 -74.13 -46.48 42.33 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 113.024 0.75 . . . . 0.0 113.024 174.166 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.6 p -71.91 -30.52 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.117 0 CA-C-O 120.656 0.265 . . . . 0.0 111.045 178.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -75.48 -30.82 60.01 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 177.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 41.4 t -70.37 -30.65 67.63 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 174.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 3.6 tppp? -73.38 -30.81 63.53 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 122.121 0.168 . . . . 0.0 110.672 177.257 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -84.03 -19.18 34.88 Favored 'General case' 0 C--N 1.338 0.103 0 N-CA-C 116.316 1.969 . . . . 0.0 116.316 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.14 22.31 0.07 OUTLIER Glycine 0 CA--C 1.528 0.88 0 C-N-CA 120.035 -1.078 . . . . 0.0 113.531 -177.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 52.32 30.15 7.67 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 117.64 0.72 . . . . 0.0 111.296 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 42' ' ' ILE . . . . . 0.408 HD11 ' CZ ' ' B' ' 61' ' ' PHE . 17.8 mt -50.72 137.37 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 123.191 0.597 . . . . 0.0 110.131 178.099 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 14.9 mmt180 -105.26 -19.02 13.93 Favored 'General case' 0 N--CA 1.457 -0.078 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -172.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 40.9 t0 -154.94 156.66 36.45 Favored 'General case' 0 C--O 1.233 0.201 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.962 178.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 15.5 mm -131.96 114.86 25.38 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 174.305 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 46' ' ' ASP . . . . . 0.401 ' HB3' ' H ' ' B' ' 58' ' ' PHE . 41.3 t0 -84.53 51.91 2.24 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 177.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 50.8 tp -54.18 120.88 7.09 Favored 'General case' 0 C--O 1.231 0.114 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 175.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . 0.499 ' HZ2' ' HB3' ' B' ' 48' ' ' LYS . 7.0 ttpm? -145.08 146.51 31.88 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-O 120.829 0.347 . . . . 0.0 111.02 -173.407 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 73.9 m-20 . . . . . 0 N--CA 1.454 -0.249 0 C-N-CA 122.951 0.501 . . . . 0.0 110.992 -179.198 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo . . . . . 0 N--CA 1.45 -1.079 0 N-CA-C 110.564 -0.591 . . . . 0.0 110.564 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -149.34 170.16 19.16 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 105.634 -1.987 . . . . 0.0 105.634 -178.141 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.83 155.2 33.98 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-O 120.756 0.312 . . . . 0.0 111.731 -175.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 58' ' ' PHE . . . . . 0.401 ' H ' ' HB3' ' B' ' 46' ' ' ASP . 86.4 m-85 -108.93 107.79 18.3 Favored 'General case' 0 N--CA 1.457 -0.12 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.944 169.395 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 91.2 t -80.54 141.9 14.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -177.685 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -120.09 120.17 35.47 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-O 120.652 0.263 . . . . 0.0 110.424 178.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.408 ' CZ ' HD11 ' B' ' 42' ' ' ILE . 37.0 m-85 -88.08 158.1 18.68 Favored 'General case' 0 N--CA 1.456 -0.148 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -178.441 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -86.3 -29.6 22.91 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 167.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -155.61 110.28 2.19 Favored Pre-proline 0 CA--C 1.535 0.376 0 C-N-CA 123.655 0.782 . . . . 0.0 109.598 178.349 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -58.6 -11.51 11.67 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 124.04 3.16 . . . . 0.0 113.801 -177.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.66 -25.4 67.93 Favored 'General case' 0 CA--C 1.528 0.1 0 CA-C-N 118.191 0.451 . . . . 0.0 110.862 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 78.4 m-20 -76.2 2.7 12.44 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -179.587 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.97 -8.01 26.61 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.538 0.335 . . . . 0.0 111.341 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -62.73 -24.98 67.95 Favored 'General case' 0 N--CA 1.454 -0.26 0 O-C-N 122.149 -0.344 . . . . 0.0 110.969 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -120.78 -34.4 3.58 Favored 'General case' 0 C--O 1.228 -0.063 0 N-CA-C 112.731 0.641 . . . . 0.0 112.731 178.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -79.74 -9.09 59.6 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 123.346 0.658 . . . . 0.0 111.642 -176.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 58.2 t -136.2 -43.99 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 CA-C-N 117.623 0.192 . . . . 0.0 111.111 -177.225 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 68.7 m -83.82 -2.41 56.32 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.985 -0.098 . . . . 0.0 111.197 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -76.61 -30.18 56.72 Favored Glycine 0 C--N 1.34 0.796 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 -178.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 56.2 ttm-85 -162.76 131.8 4.16 Favored 'General case' 0 C--N 1.338 0.07 0 CA-C-N 117.376 0.588 . . . . 0.0 110.762 177.626 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 26.0 p30 -160.11 153.52 22.22 Favored 'General case' 0 C--O 1.232 0.165 0 C-N-CA 123.61 0.764 . . . . 0.0 110.89 175.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 56.37 41.49 87.73 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.71 -0.556 . . . . 0.0 111.71 175.455 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 46.3 t80 -92.71 136.61 33.08 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 -173.102 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -67.51 91.75 0.29 Allowed 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 124.042 0.937 . . . . 0.0 112.224 -177.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -85.09 -175.31 5.69 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.393 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -68.73 77.05 0.3 Allowed 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 123.678 0.791 . . . . 0.0 112.379 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 86.88 5.61 80.79 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 178.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -135.21 -176.86 4.4 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.351 0.66 . . . . 0.0 112.431 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 2.3 tpt180 -139.7 129.08 24.1 Favored 'General case' 0 CA--C 1.522 -0.123 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -179.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.7 mp -70.01 148.33 48.99 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 178.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 43.0 mtp85 -131.12 125.72 33.84 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 173.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 13.8 t -139.65 82.78 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.148 0 C-N-CA 123.562 0.745 . . . . 0.0 109.84 176.235 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -147.37 161.47 40.94 Favored 'General case' 0 C--N 1.333 -0.118 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.038 -177.627 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 6.0 p90 -76.16 151.99 83.95 Favored Pre-proline 0 CA--C 1.53 0.205 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 177.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo . . . . . 0 C--O 1.251 1.128 0 C-N-CA 123.455 2.77 . . . . 0.0 111.015 177.203 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 3.0 m . . . . . 0 N--CA 1.479 1.016 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 85.9 mt -70.75 140.24 18.71 Favored 'Isoleucine or valine' 0 C--O 1.232 0.181 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 178.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 17.6 tpp85 -159.69 167.28 28.75 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 122.538 0.335 . . . . 0.0 110.313 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . 0.422 ' N ' ' C2 ' ' A' ' 93' ' ' ' A' . . . -74.15 -123.11 0.1 OUTLIER Glycine 0 CA--C 1.531 1.09 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 176.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -71.75 -162.82 0.12 Allowed 'Trans proline' 0 N--CA 1.45 -1.06 0 C-N-CA 123.396 2.73 . . . . 0.0 109.502 172.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.7 7.49 0.35 Allowed 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -177.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -74.99 70.08 1.82 Allowed Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 177.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 72.3 m-20 -80.58 0.42 34.07 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.183 0.593 . . . . 0.0 112.165 -177.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 79.6 m-20 -68.1 152.97 44.68 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 122.253 -0.279 . . . . 0.0 110.624 -178.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 20.1 p30 -80.76 3.25 22.97 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -179.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.1 m -78.33 3.64 15.05 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 122.93 0.492 . . . . 0.0 111.797 -178.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 33.9 mtt180 -84.5 149.7 25.76 Favored 'General case' 0 C--O 1.232 0.135 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -176.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 16.6 pt -140.62 174.48 7.8 Favored 'Isoleucine or valine' 0 C--O 1.23 0.07 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.917 173.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.436 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.6 OUTLIER -109.0 150.39 27.83 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 114.497 1.295 . . . . 0.0 114.497 -177.64 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t -137.4 142.43 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.19 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.221 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.92 179.45 29.35 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -178.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 61.9 t30 56.23 39.42 30.25 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 123.666 0.787 . . . . 0.0 110.899 -174.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 84.8 mt -60.27 139.59 91.65 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.392 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -70.47 159.47 52.75 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 123.441 2.761 . . . . 0.0 110.885 -178.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -62.1 -5.87 7.11 Favored 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 123.957 3.104 . . . . 0.0 113.302 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -129.21 25.3 5.51 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -177.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 7.3 tp -57.71 150.8 3.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 122.504 0.322 . . . . 0.0 110.178 178.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . 0.449 ' HG2' ' H ' ' B' ' 30' ' ' LYS . 38.1 ttm105 -143.26 145.68 32.95 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -177.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -60.66 -26.66 67.24 Favored 'General case' 0 C--N 1.333 -0.118 0 N-CA-C 114.173 1.175 . . . . 0.0 114.173 -178.474 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.449 ' H ' ' HG2' ' B' ' 28' ' ' ARG . 52.7 tptt -81.02 -19.17 44.5 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 122.269 0.228 . . . . 0.0 110.83 -178.081 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 59.2 m-20 -64.6 -28.4 69.6 Favored 'General case' 0 C--O 1.231 0.124 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -176.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 31.3 mm -78.12 -23.41 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 177.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.4 mt-10 -86.74 -11.44 51.1 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.921 -0.127 . . . . 0.0 110.823 179.083 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 79.0 m-20 -101.33 -66.06 0.94 Allowed 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 177.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 41.4 t -73.84 -53.95 16.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.21 0 CA-C-N 116.756 -0.202 . . . . 0.0 111.04 -174.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 63.3 m-85 -69.16 -21.38 64.0 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -179.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 45.5 t -74.28 -32.18 62.81 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 175.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -68.85 -29.71 68.08 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 174.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 20.3 m-85 -82.69 -20.17 36.65 Favored 'General case' 0 CA--C 1.528 0.129 0 N-CA-C 116.352 1.982 . . . . 0.0 116.352 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.73 20.52 0.05 OUTLIER Glycine 0 CA--C 1.527 0.782 0 C-N-CA 119.66 -1.257 . . . . 0.0 114.775 -175.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 47.65 59.81 3.92 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 118.203 1.002 . . . . 0.0 111.667 174.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 29.2 mm -44.96 132.8 1.83 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 C-N-CA 123.597 0.759 . . . . 0.0 111.496 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -86.64 -37.29 18.18 Favored 'General case' 0 N--CA 1.456 -0.161 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.384 177.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 -147.86 150.06 33.44 Favored 'General case' 0 C--O 1.231 0.09 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -176.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -109.15 149.91 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 176.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -148.11 64.63 1.1 Allowed 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 77.7 mt -63.47 138.12 58.39 Favored 'General case' 0 C--O 1.232 0.156 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 49.3 mttp -130.64 51.76 2.09 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 123.974 0.91 . . . . 0.0 109.832 177.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 76.8 m-20 -80.84 5.18 16.77 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.425 174.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 58.8 ttt180 -58.8 150.5 23.7 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 123.755 0.822 . . . . 0.0 110.623 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.95 170.08 5.95 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.136 0.574 . . . . 0.0 110.987 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.98 -2.12 65.88 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 111.273 -0.731 . . . . 0.0 111.273 -179.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -175.42 175.75 47.25 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 178.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -67.79 148.19 76.68 Favored 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 123.652 2.901 . . . . 0.0 110.067 178.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.9 138.5 34.34 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 123.167 2.578 . . . . 0.0 110.535 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . 0.454 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 2.9 p90 -166.32 -178.45 4.54 Favored 'General case' 0 CA--C 1.528 0.127 0 N-CA-C 105.974 -1.862 . . . . 0.0 105.974 176.001 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -158.11 166.39 32.59 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.373 0.606 . . . . 0.0 112.081 -177.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . 0.425 ' CE1' ' C4 ' ' A' ' 93' ' ' ' A' . 85.2 m-85 -121.32 157.82 29.55 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.575 171.034 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 75.7 t -138.9 137.21 42.76 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.134 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -178.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 69.0 tt0 -116.91 114.04 23.29 Favored 'General case' 0 CA--C 1.529 0.142 0 CA-C-O 120.666 0.27 . . . . 0.0 110.814 -176.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -82.11 168.56 17.62 Favored 'General case' 0 N--CA 1.457 -0.095 0 N-CA-C 115.872 1.804 . . . . 0.0 115.872 -176.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 48.7 tp10 -64.74 -35.73 82.01 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 174.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 26.1 p30 -159.19 162.92 25.17 Favored Pre-proline 0 CA--C 1.532 0.275 0 C-N-CA 123.536 0.734 . . . . 0.0 110.359 175.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -63.61 -18.15 63.05 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 123.116 2.544 . . . . 0.0 112.322 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 4.3 ttp85 -78.44 -40.93 34.29 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 117.849 0.295 . . . . 0.0 110.765 -175.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 79.5 m-20 -71.78 -24.35 61.73 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 178.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.59 -28.88 68.14 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 44.5 tp10 -68.77 -34.11 75.02 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 110.492 -0.188 . . . . 0.0 110.492 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -73.85 -33.99 64.33 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 178.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.86 -33.33 64.04 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 177.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 13.7 t -71.22 -45.23 71.81 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 48.2 t -69.79 -16.65 63.33 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 122.309 -0.244 . . . . 0.0 111.487 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.86 -8.75 41.69 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-O 119.119 -0.823 . . . . 0.0 113.711 -174.155 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -140.25 -12.26 1.07 Allowed 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 118.905 1.352 . . . . 0.0 113.277 -174.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -76.61 146.34 38.29 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 118.516 0.598 . . . . 0.0 110.12 -176.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.25 39.96 97.92 Favored Glycine 0 CA--C 1.527 0.836 0 CA-C-O 119.526 -0.597 . . . . 0.0 112.068 171.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 42.3 t80 -95.67 131.18 42.18 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -174.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -61.29 105.87 0.55 Allowed 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 123.663 0.785 . . . . 0.0 112.477 -178.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.427 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 46.3 t80 -112.88 169.45 8.9 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 123.738 0.815 . . . . 0.0 111.619 177.691 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.427 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 19.0 t0 -61.02 98.62 0.08 Allowed 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -179.249 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.59 -5.14 61.75 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 123.441 0.543 . . . . 0.0 112.677 177.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -141.3 -171.12 3.22 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 117.855 0.828 . . . . 0.0 112.954 -178.323 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 40.5 ttt180 -147.24 128.34 14.64 Favored 'General case' 0 C--O 1.231 0.113 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 -177.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -63.92 147.49 51.84 Favored 'General case' 0 N--CA 1.461 0.102 0 C-N-CA 122.694 0.398 . . . . 0.0 110.205 -174.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -118.57 119.82 35.65 Favored 'General case' 0 CA--C 1.521 -0.15 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 175.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.7 t -145.55 80.11 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 C-N-CA 122.878 0.471 . . . . 0.0 109.84 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -149.33 159.2 44.48 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.692 0.282 . . . . 0.0 110.807 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -74.16 156.04 87.83 Favored Pre-proline 0 CA--C 1.531 0.223 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo . . . . . 0 C--O 1.252 1.187 0 C-N-CA 123.669 2.913 . . . . 0.0 111.727 175.807 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.884 0 C5'-C4'-C3' 110.058 -3.628 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.623 1 O4'-C1'-N19 113.215 5.015 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.454 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.378 0 O4'-C1'-N19 111.594 3.394 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.425 ' C4 ' ' CE1' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.421 -2.663 0 C5'-C4'-C3' 109.922 -3.719 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.69 1 O4'-C1'-N19 112.443 4.243 . 0.01 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.563 0 C5'-C4'-C3' 111.391 -2.739 . 0.0 OUTLIER delta 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 N--CA 1.477 0.924 0 N-CA-C 111.406 0.15 . . . . 0.0 111.406 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 84.0 mt -69.26 142.77 15.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 4.4 tmm_? -70.9 133.75 46.7 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 122.686 0.394 . . . . 0.0 110.396 179.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 57.78 -159.54 12.77 Favored Glycine 0 CA--C 1.528 0.905 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 175.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -72.96 164.6 35.11 Favored 'Trans proline' 0 N--CA 1.449 -1.118 0 C-N-CA 123.249 2.633 . . . . 0.0 109.704 175.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.57 -6.34 43.35 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 122.319 0.248 . . . . 0.0 111.648 -178.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -77.08 168.26 54.64 Favored Glycine 0 CA--C 1.529 0.913 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 76.8 m-20 -76.87 148.67 36.35 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 122.553 0.341 . . . . 0.0 111.031 -178.381 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -76.92 -9.62 58.81 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 122.504 0.322 . . . . 0.0 110.456 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -70.43 -9.12 55.55 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 -176.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.7 m -133.37 9.67 4.05 Favored 'General case' 0 CA--C 1.528 0.106 0 C-N-CA 122.746 0.419 . . . . 0.0 110.591 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . 0.441 ' HA ' ' HA ' ' B' ' 60' ' ' GLU . 32.6 ttp-105 -102.81 148.83 25.14 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.324 0.65 . . . . 0.0 110.686 -177.398 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 20.8 pt -131.67 179.23 4.54 Favored 'Isoleucine or valine' 0 C--O 1.23 0.063 0 C-N-CA 123.277 0.631 . . . . 0.0 109.835 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.44 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.7 OUTLIER -118.82 156.87 28.67 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 114.248 1.203 . . . . 0.0 114.248 -175.674 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 12.7 t -134.37 123.92 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 C-N-CA 122.917 0.487 . . . . 0.0 110.705 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -130.22 166.61 22.14 Favored Glycine 0 CA--C 1.53 1.02 0 N-CA-C 111.688 -0.565 . . . . 0.0 111.688 -177.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 60.5 t30 63.65 28.61 15.06 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 124.648 1.179 . . . . 0.0 111.765 -176.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 87.7 mt -69.38 143.11 92.99 Favored Pre-proline 0 CA--C 1.532 0.287 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -60.46 157.36 36.65 Favored 'Trans proline' 0 N--CA 1.452 -0.96 0 C-N-CA 123.247 2.632 . . . . 0.0 110.783 174.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.99 -18.99 35.59 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 123.377 2.718 . . . . 0.0 110.537 177.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -96.37 14.11 25.48 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.727 0.639 . . . . 0.0 112.727 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 7.8 tp -61.24 153.09 5.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 122.546 0.338 . . . . 0.0 110.691 -177.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 22.9 tpp85 -143.29 149.95 38.55 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.34 -26.19 62.83 Favored 'General case' 0 C--N 1.333 -0.14 0 N-CA-C 114.64 1.348 . . . . 0.0 114.64 -174.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 21.6 tptm -71.94 -29.82 64.67 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 122.364 -0.21 . . . . 0.0 110.722 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -67.24 -30.38 70.27 Favored 'General case' 0 CA--C 1.528 0.131 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -178.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.3 mt -75.28 -33.09 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 99.3 mt-10 -75.34 -15.49 60.48 Favored 'General case' 0 N--CA 1.456 -0.173 0 C-N-CA 122.451 0.301 . . . . 0.0 110.986 -178.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -91.51 -52.18 4.91 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 112.924 0.712 . . . . 0.0 112.924 174.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 93.9 t -71.22 -50.91 38.26 Favored 'Isoleucine or valine' 0 C--N 1.34 0.172 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 -174.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -68.09 -31.9 71.84 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -177.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 43.8 t -66.45 -29.12 69.18 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 110.539 -0.171 . . . . 0.0 110.539 177.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -71.23 -31.03 67.07 Favored 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 174.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -79.0 -20.88 47.96 Favored 'General case' 0 C--O 1.233 0.219 0 N-CA-C 115.79 1.774 . . . . 0.0 115.79 176.376 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 169.81 -177.11 43.43 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 118.388 0.54 . . . . 0.0 112.289 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.37 95.99 8.92 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 122.838 0.455 . . . . 0.0 110.68 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.8 mp -80.28 149.6 5.13 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 C-N-CA 122.733 0.413 . . . . 0.0 110.225 175.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 29.1 mtp-105 -115.0 -34.06 5.2 Favored 'General case' 0 CA--C 1.528 0.119 0 C-N-CA 123.657 0.783 . . . . 0.0 111.313 177.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.8 m-20 -146.61 155.8 42.74 Favored 'General case' 0 N--CA 1.457 -0.105 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -176.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 4.1 mp -136.1 150.48 28.1 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.137 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 177.248 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -138.96 48.81 1.88 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 120.792 0.33 . . . . 0.0 111.072 179.167 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.6 tp -63.78 124.48 21.6 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 173.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 24.4 pttm -152.35 161.72 42.19 Favored 'General case' 0 N--CA 1.458 -0.062 0 C-N-CA 122.53 0.332 . . . . 0.0 110.666 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 18.8 p30 -69.74 158.06 36.13 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-O 120.891 0.377 . . . . 0.0 111.061 -177.201 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 28.7 ttm-85 -96.65 76.96 2.86 Favored 'General case' 0 N--CA 1.457 -0.11 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 18.7 mmt-85 56.36 26.39 10.59 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 122.761 0.424 . . . . 0.0 110.32 -174.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.2 -8.97 61.04 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 123.777 0.703 . . . . 0.0 111.733 -177.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -86.65 -168.09 44.42 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 176.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -52.68 119.41 5.92 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 124.232 3.288 . . . . 0.0 110.944 -179.056 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_exo -56.45 163.05 7.17 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 124.09 3.193 . . . . 0.0 113.824 -174.011 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -147.61 163.4 36.75 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 104.385 -2.45 . . . . 0.0 104.385 175.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -149.93 163.59 37.67 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 119.997 -0.681 . . . . 0.0 112.737 -171.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . 0.445 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 88.6 m-85 -122.15 154.67 37.11 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.09 169.078 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 71.9 t -140.12 132.37 33.2 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.266 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . 0.441 ' HA ' ' HA ' ' B' ' 17' ' ' ARG . 68.2 tt0 -117.28 132.54 56.6 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.811 0.339 . . . . 0.0 111.252 -174.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -98.47 160.55 14.21 Favored 'General case' 0 C--O 1.231 0.12 0 N-CA-C 114.826 1.417 . . . . 0.0 114.826 -175.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -81.89 -17.4 47.36 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.857 0.463 . . . . 0.0 110.382 171.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -152.74 120.58 3.13 Favored Pre-proline 0 C--O 1.233 0.206 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -178.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.52 -14.33 44.3 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 123.066 2.51 . . . . 0.0 111.948 -175.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 86.7 mtm180 -71.69 -24.49 61.83 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 117.944 0.338 . . . . 0.0 110.669 176.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -87.74 -27.07 22.59 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-O 120.75 0.309 . . . . 0.0 110.751 176.016 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.03 -25.23 65.27 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 177.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -69.86 -31.08 68.73 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 122.218 0.207 . . . . 0.0 110.523 178.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -76.48 -35.33 58.45 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 112.308 0.485 . . . . 0.0 112.308 179.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.33 -27.72 66.52 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 122.634 0.373 . . . . 0.0 110.059 177.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 39.6 t -87.52 -44.09 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.2 t -65.98 -21.56 66.42 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-N 117.552 0.16 . . . . 0.0 111.127 -176.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -90.29 -15.36 57.4 Favored Glycine 0 CA--C 1.53 0.977 0 CA-C-O 119.455 -0.636 . . . . 0.0 113.004 -177.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 61.0 mtm180 -146.22 19.57 1.39 Allowed 'General case' 0 C--N 1.342 0.282 0 CA-C-N 118.24 1.02 . . . . 0.0 113.146 -170.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 18.8 p30 -70.81 -1.42 11.56 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.105 0.779 . . . . 0.0 113.105 178.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.82 90.69 0.08 OUTLIER Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -120.58 137.77 54.23 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 176.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -68.94 92.26 0.5 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.442 0.697 . . . . 0.0 111.953 -176.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -84.68 -175.92 5.99 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -67.89 82.79 0.2 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 123.557 0.743 . . . . 0.0 112.298 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.7 2.83 89.81 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 112.148 -0.381 . . . . 0.0 112.148 178.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -137.86 -174.57 3.82 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -179.081 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 70.5 ttp85 -140.39 135.06 31.71 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.85 151.42 45.55 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 122.666 0.387 . . . . 0.0 110.18 -179.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 51.5 mtm180 -134.54 55.71 1.88 Allowed 'General case' 0 C--O 1.231 0.103 0 C-N-CA 122.435 0.294 . . . . 0.0 110.849 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 20.1 t -82.95 94.83 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.188 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 174.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -152.31 161.47 42.56 Favored 'General case' 0 C--O 1.226 -0.174 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -76.6 156.05 83.2 Favored Pre-proline 0 CA--C 1.532 0.268 0 N-CA-C 114.666 1.358 . . . . 0.0 114.666 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo . . . . . 0 C--O 1.25 1.119 0 C-N-CA 123.789 2.993 . . . . 0.0 111.723 175.434 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.426 -2.287 0 C5'-C4'-C3' 110.589 -3.274 OUTLIER-DELTA 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.948 1 C5'-C4'-C3' 108.908 -4.395 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.44 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.323 0 C5'-C4'-C3' 110.337 -3.442 . 0.259 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.445 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.426 -2.241 1 C5'-C4'-C3' 109.102 -4.266 . 0.01 6n . 0.0 . . . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.568 1 O4'-C1'-N19 112.762 4.562 . 0.01 5z . 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.601 0 C5'-C4'-C3' 109.838 -3.775 . 0.0 OUTLIER delta 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 11.8 t . . . . . 0 N--CA 1.476 0.833 0 N-CA-C 111.302 0.112 . . . . 0.0 111.302 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 1.8 mp -68.07 153.13 9.08 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.58 172.21 2.81 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.078 0.466 . . . . 0.0 112.2 -176.643 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . 0.528 ' N ' ' CD ' ' B' ' 10' ' ' PRO . . . 70.99 27.66 71.8 Favored Glycine 0 CA--C 1.535 1.318 0 CA-C-O 118.232 -1.315 . . . . 0.0 114.695 175.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . 0.528 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 61.5 Cg_endo -70.54 -25.02 25.44 Favored 'Trans proline' 0 N--CA 1.454 -0.8 0 CA-C-N 120.489 2.145 . . . . 0.0 110.334 179.259 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -161.1 158.71 28.1 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 123.371 0.669 . . . . 0.0 109.909 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -81.71 -6.04 89.38 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.928 -0.469 . . . . 0.0 111.928 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 35.9 p30 -87.04 8.76 22.07 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 117.408 0.604 . . . . 0.0 111.804 -177.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -65.05 148.61 51.35 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -178.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 82.5 m-20 -78.67 148.98 32.94 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -174.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 95.9 m 58.22 2.4 0.2 Allowed 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 125.152 1.381 . . . . 0.0 114.343 174.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 84.2 mtt-85 -83.38 146.9 28.21 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 118.272 0.487 . . . . 0.0 111.737 176.195 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 26.9 pt -131.45 172.29 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 173.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.442 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.4 OUTLIER -120.74 149.72 42.1 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 114.185 1.18 . . . . 0.0 114.185 -178.029 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 19.7 t -137.53 141.83 38.36 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 C-N-CA 123.449 0.699 . . . . 0.0 109.728 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -150.43 171.84 30.26 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -176.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 65.6 t30 59.73 30.91 20.51 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.213 1.005 . . . . 0.0 111.688 -175.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.9 mt -64.17 149.15 94.66 Favored Pre-proline 0 N--CA 1.454 -0.257 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 174.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -65.29 155.45 68.51 Favored 'Trans proline' 0 N--CA 1.452 -0.944 0 C-N-CA 122.996 2.464 . . . . 0.0 111.218 -177.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -62.85 -3.21 4.31 Favored 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 124.271 3.314 . . . . 0.0 113.191 -179.495 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -136.52 30.61 2.89 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -176.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 6.3 tp -61.56 137.39 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 177.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 47.2 mtm180 -97.55 153.93 17.84 Favored 'General case' 0 N--CA 1.457 -0.124 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.6 p -68.24 -22.0 64.8 Favored 'General case' 0 C--O 1.232 0.155 0 N-CA-C 112.914 0.709 . . . . 0.0 112.914 177.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -82.02 -26.47 33.78 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 122.798 0.439 . . . . 0.0 111.139 -179.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -64.53 -29.78 70.81 Favored 'General case' 0 N--CA 1.455 -0.175 0 N-CA-C 112.106 0.409 . . . . 0.0 112.106 -177.089 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 mm -74.69 -21.2 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.18 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 90.2 mt-10 -78.47 -48.74 14.76 Favored 'General case' 0 C--O 1.223 -0.324 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -65.86 -44.7 84.63 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -174.312 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 99.0 t -69.84 -53.04 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.099 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -176.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -75.28 -24.1 57.49 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 113.546 0.943 . . . . 0.0 113.546 -174.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 41.8 t -68.89 -31.79 70.96 Favored 'General case' 0 C--N 1.342 0.265 0 CA-C-N 118.008 0.367 . . . . 0.0 110.054 173.149 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 58.3 tptt -68.36 -30.76 69.78 Favored 'General case' 0 C--N 1.341 0.212 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 174.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . 0.401 ' CD2' ' HA ' ' B' ' 70' ' ' ALA . 39.6 m-85 -74.75 -20.36 59.85 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 115.457 1.651 . . . . 0.0 115.457 174.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 159.52 -178.0 35.81 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.835 -0.506 . . . . 0.0 111.835 176.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -73.79 122.19 22.04 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.65 0.262 . . . . 0.0 110.36 -178.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 73.8 mt -92.65 140.0 17.01 Favored 'Isoleucine or valine' 0 C--O 1.233 0.237 0 C-N-CA 122.937 0.495 . . . . 0.0 111.201 -178.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -94.14 -38.19 11.21 Favored 'General case' 0 N--CA 1.458 -0.071 0 C-N-CA 123.093 0.557 . . . . 0.0 110.361 170.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -155.94 156.76 35.12 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 120.713 0.292 . . . . 0.0 111.101 -173.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mt -133.28 143.3 39.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 C-N-CA 124.186 0.994 . . . . 0.0 108.854 175.281 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -144.74 64.88 1.28 Allowed 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 120.644 0.259 . . . . 0.0 111.54 -174.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 57.7 tp -58.23 134.75 56.8 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 169.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 54.8 tttp -143.23 164.23 30.78 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.841 0.353 . . . . 0.0 111.238 -168.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 44.8 p30 -142.67 -155.97 0.64 Allowed 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 123.383 0.673 . . . . 0.0 110.694 -173.312 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 55.0 mtm180 63.61 175.31 0.17 Allowed 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.837 1.255 . . . . 0.0 111.618 -172.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 61.81 159.18 0.06 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.659 1.184 . . . . 0.0 110.789 -170.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -67.01 170.9 32.58 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.07 -176.77 53.01 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 111.449 -0.66 . . . . 0.0 111.449 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -68.33 161.24 45.59 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 124.348 3.365 . . . . 0.0 111.122 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -64.8 167.21 16.09 Favored 'Trans proline' 0 N--CA 1.452 -0.963 0 C-N-CA 123.684 2.922 . . . . 0.0 110.658 177.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . 0.479 ' CE1' " H4'" ' A' ' 92' ' ' ' C' . 3.8 p90 -152.92 173.3 15.55 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 106.281 -1.748 . . . . 0.0 106.281 -175.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.64 168.31 27.78 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 -174.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . 0.498 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 80.7 m-85 -127.23 157.11 40.7 Favored 'General case' 0 C--O 1.234 0.282 0 C-N-CA 123.618 0.767 . . . . 0.0 110.056 171.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 56.0 t -143.76 142.03 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -119.18 125.26 48.78 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 177.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -89.49 161.68 16.11 Favored 'General case' 0 C--O 1.231 0.114 0 N-CA-C 115.272 1.582 . . . . 0.0 115.272 174.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 37.3 tp10 -72.18 -23.97 61.35 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.559 175.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 48.4 m-20 -144.47 151.86 51.85 Favored Pre-proline 0 N--CA 1.455 -0.176 0 C-N-CA 124.192 0.997 . . . . 0.0 112.292 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -68.6 -18.29 42.9 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.877 2.384 . . . . 0.0 110.615 178.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 73.0 ttt-85 -68.84 -40.04 79.63 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 177.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -76.07 -26.12 56.22 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 120.739 0.304 . . . . 0.0 111.664 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.87 -36.24 70.05 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 176.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 41.7 tp10 -69.35 -32.09 70.93 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 110.388 -0.227 . . . . 0.0 110.388 178.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -70.94 -35.9 72.4 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . 0.401 ' HA ' ' CD2' ' B' ' 39' ' ' TYR . . . -71.43 -32.73 68.71 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 178.305 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 59.1 t -80.14 -30.48 12.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 45.7 t -79.97 -9.33 59.68 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 122.715 0.406 . . . . 0.0 110.656 178.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -66.57 -77.06 0.31 Allowed Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.217 -0.753 . . . . 0.0 111.217 -178.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 4.0 tpm_? -156.69 132.06 9.28 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 51.3 p-10 -153.15 168.79 24.78 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.506 0.722 . . . . 0.0 109.09 176.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 58.67 40.8 95.26 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 174.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -98.42 132.93 43.47 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 113.832 1.049 . . . . 0.0 113.832 -172.411 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -62.45 106.69 0.8 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.639 0.776 . . . . 0.0 112.35 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.437 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 50.1 t80 -114.31 170.31 8.39 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 123.585 0.754 . . . . 0.0 111.39 178.341 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.437 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 21.3 t0 -60.0 100.54 0.09 Allowed 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.33 -5.6 42.49 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-O 119.746 -0.474 . . . . 0.0 112.912 178.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 88.1 m-85 -140.34 -170.51 3.0 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 117.871 0.836 . . . . 0.0 113.241 -178.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 40.0 ttt180 -148.61 129.9 14.67 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 123.673 0.789 . . . . 0.0 108.953 -177.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -67.51 149.59 49.97 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -176.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -129.67 130.35 45.44 Favored 'General case' 0 C--N 1.34 0.181 0 CA-C-O 120.624 0.25 . . . . 0.0 110.52 172.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.6 t -145.3 80.36 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.099 0 C-N-CA 123.96 0.904 . . . . 0.0 109.298 173.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -144.63 168.36 20.34 Favored 'General case' 0 C--O 1.226 -0.132 0 C-N-CA 122.595 0.358 . . . . 0.0 111.047 -175.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 69.9 m-85 -63.67 153.24 84.17 Favored Pre-proline 0 C--O 1.235 0.307 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 179.03 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 C--O 1.251 1.168 0 C-N-CA 123.705 2.937 . . . . 0.0 110.932 175.168 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.664 0 C5'-C4'-C3' 109.925 -3.717 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.472 1 O4'-C1'-N19 112.32 4.12 . 0.344 2[ . 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.479 " H4'" ' CE1' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.42 -2.732 0 O4'-C1'-N19 111.112 2.912 . 0.687 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.498 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.385 0 C5'-C4'-C3' 110.111 -3.593 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.42 -2.743 0 O4'-C1'-N19 111.496 3.296 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.479 1 C5'-C4'-C3' 109.402 -4.065 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.476 0.825 0 N-CA-C 111.79 0.293 . . . . 0.0 111.79 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 32.3 mm -71.14 149.4 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 2.4 tmm_? -62.71 -47.33 84.07 Favored 'General case' 0 C--N 1.337 0.062 0 C-N-CA 122.723 0.409 . . . . 0.0 111.059 -179.214 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . -157.92 -161.5 10.99 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 -172.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.52 -28.1 53.3 Favored 'Trans proline' 0 N--CA 1.452 -0.957 0 C-N-CA 123.933 3.088 . . . . 0.0 111.853 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 53.62 19.39 1.76 Allowed 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 123.91 0.884 . . . . 0.0 113.109 175.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.1 152.52 50.13 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -73.85 -15.1 61.17 Favored 'General case' 0 N--CA 1.457 -0.114 0 CA-C-N 116.773 0.286 . . . . 0.0 111.709 -178.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 63.4 t30 -88.22 160.83 17.54 Favored 'General case' 0 N--CA 1.456 -0.125 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 50.1 m-20 -82.4 -139.62 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 172.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 69.8 m 62.58 15.33 7.85 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 123.554 0.742 . . . . 0.0 112.855 175.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 66.1 mtm-85 -71.29 143.86 50.19 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 117.769 0.259 . . . . 0.0 110.796 172.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.6 pt -139.16 171.2 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.102 0 C-N-CA 123.302 0.641 . . . . 0.0 109.4 177.188 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.424 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.2 OUTLIER -113.75 151.37 32.03 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -179.327 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 44.1 t -137.38 144.64 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 123.251 0.62 . . . . 0.0 109.462 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -156.2 177.15 33.39 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -177.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 62.1 t30 62.75 169.68 0.14 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.604 1.161 . . . . 0.0 111.406 -172.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 85.3 mt -61.36 146.26 89.41 Favored Pre-proline 0 N--CA 1.454 -0.251 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 177.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -69.31 159.87 52.05 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 C-N-CA 123.553 2.835 . . . . 0.0 110.838 -176.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.42 -9.06 25.06 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 124.104 3.202 . . . . 0.0 110.775 178.182 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 55.5 t0 -149.94 133.65 16.78 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 177.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 3.0 tp -80.01 80.21 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-O 121.618 0.723 . . . . 0.0 111.344 -172.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 16.3 ptt180 -159.17 145.91 16.91 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.665 171.443 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.8 p -71.81 -13.7 61.77 Favored 'General case' 0 C--O 1.231 0.086 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -179.121 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 47.7 tptt -82.24 -5.27 58.4 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.577 0.351 . . . . 0.0 110.517 179.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -53.35 -44.66 68.71 Favored 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -177.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.3 tt -78.55 -5.26 7.69 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 C-N-CA 122.898 0.479 . . . . 0.0 110.819 -176.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 84.5 mt-10 -116.85 1.43 12.7 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 122.55 0.34 . . . . 0.0 111.236 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 11.1 t0 -125.29 -54.04 1.59 Allowed 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 87.2 t -69.7 -41.99 80.2 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.042 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -178.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 45.4 m-85 -67.86 -27.85 67.04 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 176.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 67.2 m -72.65 -21.88 61.02 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.443 177.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 24.7 ttmm -77.75 -30.82 51.75 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 109.684 -0.488 . . . . 0.0 109.684 173.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -70.86 -23.13 62.26 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 114.39 1.256 . . . . 0.0 114.39 173.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 164.01 174.34 33.71 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 174.138 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -71.53 125.13 26.26 Favored 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 17.1 mt -99.33 138.97 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.164 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 77.8 mtp85 -86.31 -43.1 13.18 Favored 'General case' 0 C--N 1.333 -0.148 0 C-N-CA 122.897 0.479 . . . . 0.0 110.065 174.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -152.6 159.13 43.25 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -176.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.9 mp -130.02 148.68 33.18 Favored 'Isoleucine or valine' 0 C--N 1.339 0.136 0 C-N-CA 124.172 0.989 . . . . 0.0 109.627 177.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 21.2 t0 -140.72 63.97 1.44 Allowed 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.296 0.238 . . . . 0.0 111.255 176.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 61.2 tp -59.81 133.61 56.26 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 170.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 15.7 ttmm -143.62 152.2 41.08 Favored 'General case' 0 C--N 1.342 0.24 0 CA-C-O 120.74 0.305 . . . . 0.0 111.024 -173.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -75.96 159.77 30.54 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 122.996 0.518 . . . . 0.0 110.563 178.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 9.2 tpt180 -148.69 146.7 28.26 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.381 0.672 . . . . 0.0 109.767 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 55.7 mtt180 -106.07 149.37 26.78 Favored 'General case' 0 C--O 1.231 0.099 0 C-N-CA 122.888 0.475 . . . . 0.0 110.198 -179.542 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.59 6.55 62.81 Favored Glycine 0 CA--C 1.532 1.116 0 N-CA-C 112.357 -0.297 . . . . 0.0 112.357 176.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -173.67 174.63 46.24 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_exo -59.08 157.63 28.82 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.981 3.12 . . . . 0.0 111.633 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -58.63 168.53 4.02 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.828 3.019 . . . . 0.0 111.615 175.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . 0.453 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 2.9 p90 -150.72 169.12 22.38 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 179.211 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -157.96 170.7 21.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 120.916 0.389 . . . . 0.0 111.527 -174.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -123.59 154.68 38.95 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.909 169.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 71.7 t -137.73 139.85 42.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -178.127 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -121.91 108.32 13.29 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -79.21 160.59 26.84 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 115.004 1.483 . . . . 0.0 115.004 177.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 41.1 tp10 -75.76 -31.85 59.71 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.542 175.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -133.05 150.75 76.42 Favored Pre-proline 0 CA--C 1.532 0.275 0 C-N-CA 123.707 0.803 . . . . 0.0 112.365 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -70.11 -21.6 31.62 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 123.203 2.602 . . . . 0.0 110.885 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 81.2 mtt85 -72.67 -27.89 62.37 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 178.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -79.76 -31.39 40.95 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 122.039 0.136 . . . . 0.0 111.318 179.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.97 -36.68 69.91 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 110.511 -0.181 . . . . 0.0 110.511 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 43.4 tp10 -68.12 -34.29 76.1 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -72.28 -35.23 68.68 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.1 -29.52 64.18 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.2 t -75.21 -50.97 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 88.0 p -73.5 -10.22 59.49 Favored 'General case' 0 C--O 1.233 0.217 0 O-C-N 122.199 -0.313 . . . . 0.0 111.661 -176.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -98.62 -10.38 50.44 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-O 119.167 -0.796 . . . . 0.0 113.371 -173.49 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -151.51 -13.02 0.2 Allowed 'General case' 0 C--N 1.34 0.159 0 CA-C-N 119.04 1.42 . . . . 0.0 113.206 -173.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -66.61 143.9 56.73 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.421 0.555 . . . . 0.0 110.146 -177.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 60.22 39.92 96.62 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 173.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 41.2 t80 -99.13 133.42 43.44 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 113.635 0.976 . . . . 0.0 113.635 -173.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.2 t0 -62.1 105.69 0.62 Allowed 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 123.574 0.749 . . . . 0.0 112.372 -178.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.423 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 51.5 t80 -111.26 169.92 8.46 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 123.829 0.852 . . . . 0.0 111.389 178.23 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.423 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 21.0 t0 -61.0 97.41 0.06 Allowed 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.375 0.509 . . . . 0.0 112.375 -179.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 80.68 -4.06 71.25 Favored Glycine 0 CA--C 1.53 0.994 0 CA-C-O 119.379 -0.678 . . . . 0.0 112.722 177.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -142.46 -170.72 3.25 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 118.142 0.971 . . . . 0.0 112.793 -177.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 36.0 ttt180 -145.89 130.22 17.66 Favored 'General case' 0 C--O 1.231 0.095 0 C-N-CA 123.466 0.706 . . . . 0.0 109.292 -178.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -63.86 152.92 38.33 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 122.952 0.501 . . . . 0.0 111.078 -174.088 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 53.1 mmm-85 -124.92 117.36 23.9 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 173.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 19.2 t -145.25 81.31 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.522 -0.103 0 C-N-CA 122.75 0.42 . . . . 0.0 110.252 178.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.9 pt-20 -142.8 168.49 19.6 Favored 'General case' 0 C--N 1.333 -0.112 0 C-N-CA 122.429 0.291 . . . . 0.0 111.066 -175.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 54.3 m-85 -65.15 151.66 93.27 Favored Pre-proline 0 CA--C 1.532 0.257 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo . . . . . 0 N--CA 1.448 -1.186 0 C-N-CA 123.894 3.063 . . . . 0.0 110.72 175.719 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.529 0 O4'-C1'-N19 111.414 3.214 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.293 0 C5'-C4'-C3' 111.623 -2.585 OUTLIER-DELTA 0.072 8d . 0.0 . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.453 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.423 -2.528 0 C5'-C4'-C3' 111.559 -2.627 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.643 0 C5'-C4'-C3' 109.634 -3.911 . 0.01 6n . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.42 -2.721 0 C5'-C4'-C3' 109.825 -3.784 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.354 0 O4'-C1'-N19 111.954 3.754 . 0.13 2u . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 12.4 t . . . . . 0 N--CA 1.477 0.878 0 N-CA-C 111.499 0.185 . . . . 0.0 111.499 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 44.9 mm -66.02 149.21 11.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.009 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 41.0 ttm-85 -68.42 142.79 55.28 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.95 -73.2 0.23 Allowed Glycine 0 CA--C 1.527 0.817 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -58.1 -10.97 9.07 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 123.777 2.984 . . . . 0.0 112.176 174.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -147.51 160.45 42.59 Favored 'General case' 0 C--O 1.234 0.279 0 C-N-CA 123.112 0.565 . . . . 0.0 109.976 177.339 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.39 179.93 43.55 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 13.3 m120 -139.49 3.54 2.11 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 122.749 0.42 . . . . 0.0 110.919 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -144.82 147.59 33.04 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -95.73 8.93 42.08 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.038 0.535 . . . . 0.0 112.326 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 85.3 m -76.46 8.67 3.26 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -176.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 79.6 mtt180 -76.78 147.41 37.28 Favored 'General case' 0 CA--C 1.528 0.108 0 CA-C-N 117.889 0.313 . . . . 0.0 110.668 177.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 pt -135.57 167.87 24.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.107 0 C-N-CA 123.216 0.607 . . . . 0.0 109.364 173.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.423 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.6 OUTLIER -108.61 148.65 30.03 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 114.694 1.368 . . . . 0.0 114.694 -173.309 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 21.7 t -137.13 139.05 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 C-N-CA 123.839 0.856 . . . . 0.0 110.001 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.76 175.65 30.45 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -177.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 54.2 t30 59.68 26.07 15.11 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.807 0.843 . . . . 0.0 111.42 -175.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 97.3 mt -64.9 152.25 91.22 Favored Pre-proline 0 N--CA 1.455 -0.218 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 176.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . 0.406 ' HA ' ' HD3' ' B' ' 25' ' ' PRO . 48.8 Cg_exo -53.47 140.8 63.6 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.247 2.631 . . . . 0.0 111.388 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' B' ' 24' ' ' PRO . 32.9 Cg_exo -60.32 -7.26 6.47 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 123.694 2.93 . . . . 0.0 112.579 177.374 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 27.5 p30 -135.73 26.56 3.36 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 123.448 0.699 . . . . 0.0 111.879 -177.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 7.2 tp -54.96 141.69 10.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . 0.428 ' C ' ' H ' ' B' ' 30' ' ' LYS . 41.8 ttt-85 -80.44 147.55 30.9 Favored 'General case' 0 N--CA 1.455 -0.19 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 -176.698 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.82 17.36 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 114.908 1.447 . . . . 0.0 114.908 -178.303 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.428 ' H ' ' C ' ' B' ' 28' ' ' ARG . 57.1 tptt -146.0 -22.2 0.45 Allowed 'General case' 0 N--CA 1.454 -0.234 0 C-N-CA 122.968 0.507 . . . . 0.0 110.974 -178.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 -67.45 -22.92 65.47 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 112.401 0.519 . . . . 0.0 112.401 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 6.4 tp -71.31 -18.18 20.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 C-N-CA 122.64 0.376 . . . . 0.0 110.188 176.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -96.16 -26.63 15.39 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 176.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -64.93 -49.91 68.54 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.625 0.25 . . . . 0.0 111.67 -177.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 99.7 t -67.63 -43.56 86.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -178.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -74.6 -32.45 62.36 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 114.52 1.304 . . . . 0.0 114.52 -177.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 90.0 p -69.74 -22.48 63.37 Favored 'General case' 0 C--O 1.231 0.107 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.87 175.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -72.26 -34.02 67.92 Favored 'General case' 0 C--N 1.34 0.193 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 173.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 49.4 m-85 -68.87 -19.1 64.23 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 170.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.76 169.3 33.14 Favored Glycine 0 CA--C 1.532 1.119 0 C-N-CA 123.183 0.42 . . . . 0.0 112.996 171.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 59.56 20.28 8.8 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 124.762 1.225 . . . . 0.0 113.68 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.5 mp -76.51 140.15 17.67 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 173.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 20.4 mmt180 -120.3 -21.92 6.74 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 122.488 0.315 . . . . 0.0 111.502 173.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -158.13 149.6 21.33 Favored 'General case' 0 C--N 1.339 0.137 0 N-CA-C 113.919 1.081 . . . . 0.0 113.919 176.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -120.4 152.24 23.31 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 171.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 45.1 t0 -145.16 79.07 1.58 Allowed 'General case' 0 N--CA 1.449 -0.496 0 CA-C-O 120.947 0.404 . . . . 0.0 111.374 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 55.9 tp -66.04 135.73 55.05 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 171.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 14.5 ttmm -151.86 168.29 25.58 Favored 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 -173.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 54.3 t30 -155.12 156.89 36.6 Favored 'General case' 0 N--CA 1.452 -0.325 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 175.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 11.0 tpp180 -151.98 6.08 0.44 Allowed 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.274 0.63 . . . . 0.0 110.325 -178.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 6.5 ptp85 -150.18 166.16 30.69 Favored 'General case' 0 CA--C 1.529 0.136 0 O-C-N 122.035 -0.415 . . . . 0.0 110.891 -172.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -78.4 -9.54 86.92 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 178.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -78.1 -172.4 39.63 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.096 -0.801 . . . . 0.0 111.096 176.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -57.22 151.13 53.42 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 123.822 3.015 . . . . 0.0 111.621 179.019 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.07 172.88 13.83 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.753 2.969 . . . . 0.0 111.184 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . 0.508 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 1.9 p90 -149.11 171.76 15.9 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 104.977 -2.231 . . . . 0.0 104.977 177.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.76 169.03 25.32 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.289 0.566 . . . . 0.0 111.941 -174.566 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . 0.534 ' CE1' ' C4 ' ' A' ' 93' ' ' ' A' . 90.9 m-85 -121.88 156.95 32.22 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.881 171.228 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 96.8 t -134.8 140.29 45.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -124.1 115.94 21.98 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.019 0.437 . . . . 0.0 110.538 -174.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 38.5 m-85 -91.3 161.74 14.91 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 114.256 1.206 . . . . 0.0 114.256 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -75.65 -28.23 58.67 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 170.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 17.2 p30 -154.8 152.55 25.87 Favored Pre-proline 0 CA--C 1.534 0.333 0 C-N-CA 123.326 0.651 . . . . 0.0 111.675 176.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.09 -7.85 22.27 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 123.24 2.626 . . . . 0.0 111.429 179.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 45.3 ttm105 -65.24 -38.9 91.8 Favored 'General case' 0 C--N 1.339 0.122 0 C-N-CA 122.444 0.298 . . . . 0.0 111.331 -177.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -94.52 -17.81 22.04 Favored 'General case' 0 C--O 1.232 0.177 0 N-CA-C 112.859 0.688 . . . . 0.0 112.859 179.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.7 -27.21 67.46 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -69.05 -30.36 68.68 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 110.423 -0.214 . . . . 0.0 110.423 178.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -75.98 -36.81 59.09 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 112.165 0.431 . . . . 0.0 112.165 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.01 -28.01 64.1 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 110.263 -0.273 . . . . 0.0 110.263 176.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 16.6 t -77.29 -50.18 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.177 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 71.1 m -73.59 -7.6 52.59 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 111.656 0.243 . . . . 0.0 111.656 -175.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -99.67 -8.05 52.58 Favored Glycine 0 CA--C 1.53 1.023 0 CA-C-O 119.07 -0.85 . . . . 0.0 113.423 -175.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 13.6 tpp180 -152.04 -13.73 0.19 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 118.489 1.145 . . . . 0.0 113.332 -174.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -66.65 141.86 57.64 Favored 'General case' 0 N--CA 1.456 -0.168 0 O-C-N 121.933 -0.479 . . . . 0.0 110.118 -177.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.49 43.87 97.5 Favored Glycine 0 CA--C 1.53 0.988 0 N-CA-C 111.921 -0.472 . . . . 0.0 111.921 174.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -101.86 137.5 40.07 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 114.132 1.16 . . . . 0.0 114.132 -173.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 11.3 t0 -63.23 109.07 1.43 Allowed 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 123.62 0.768 . . . . 0.0 112.491 -176.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.41 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 42.3 t80 -116.27 168.11 10.42 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 123.662 0.785 . . . . 0.0 111.524 175.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.41 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.5 t0 -58.99 98.5 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.98 -5.79 61.31 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-O 119.476 -0.624 . . . . 0.0 112.6 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -141.54 -169.32 2.85 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.007 0.904 . . . . 0.0 113.174 -177.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 42.3 ttp-105 -145.26 131.05 19.04 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 123.492 0.717 . . . . 0.0 109.48 -178.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -63.41 152.07 39.24 Favored 'General case' 0 N--CA 1.461 0.086 0 C-N-CA 122.782 0.433 . . . . 0.0 110.372 -177.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 92.1 mtm-85 -127.98 121.3 29.51 Favored 'General case' 0 CA--C 1.52 -0.177 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 173.302 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 24.2 t -142.46 81.45 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -141.54 164.26 30.71 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 111.798 0.295 . . . . 0.0 111.798 -174.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . 0.414 ' CD1' ' HD2' ' B' ' 89' ' ' PRO . 17.0 t80 -72.37 136.14 81.5 Favored Pre-proline 0 CA--C 1.534 0.341 0 N-CA-C 113.365 0.876 . . . . 0.0 113.365 178.494 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . 0.414 ' HD2' ' CD1' ' B' ' 88' ' ' PHE . 47.6 Cg_endo . . . . . 0 C--O 1.25 1.081 0 C-N-CA 123.706 2.937 . . . . 0.0 111.076 -179.073 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.087 0 C3'-C2'-C1' 104.832 3.702 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.63 0 O4'-C1'-N19 111.428 3.228 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.508 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.421 -2.701 0 O4'-C1'-N19 111.235 3.035 . 0.057 2z . 0.0 . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.534 ' C4 ' ' CE1' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.427 -2.172 1 O4'-C1'-N19 112.699 4.499 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . 0.401 H5'' " H3'" ' A' ' 93' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.422 -2.604 0 O4'-C1'-N19 111.582 3.382 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.859 0 C5'-C4'-C3' 110.158 -3.561 . 0.282 2u . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m . . . . . 0 N--CA 1.477 0.925 0 N-CA-C 111.531 0.197 . . . . 0.0 111.531 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 8.7 pt -72.77 166.04 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 C-N-CA 122.846 0.458 . . . . 0.0 110.214 -178.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 33.0 ttm105 -67.68 138.7 56.52 Favored 'General case' 0 N--CA 1.457 -0.086 0 C-N-CA 122.921 0.488 . . . . 0.0 110.598 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.77 -66.84 0.31 Allowed Glycine 0 CA--C 1.529 0.946 0 CA-C-O 119.324 -0.709 . . . . 0.0 111.896 174.613 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.23 -6.78 3.14 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 124.073 3.182 . . . . 0.0 113.309 178.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -147.65 155.88 42.22 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 118.01 0.368 . . . . 0.0 110.773 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -84.29 22.18 9.03 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 111.624 -0.59 . . . . 0.0 111.624 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -71.27 3.14 3.88 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.353 0.577 . . . . 0.0 112.25 -176.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -133.25 138.24 46.39 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 122.46 0.304 . . . . 0.0 110.824 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -113.25 177.52 4.6 Favored 'General case' 0 C--N 1.334 -0.074 0 C-N-CA 123.883 0.873 . . . . 0.0 111.008 -178.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 72.3 m 57.31 16.95 3.39 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 123.657 0.783 . . . . 0.0 112.641 177.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 52.8 mtm180 -75.38 151.65 38.15 Favored 'General case' 0 N--CA 1.456 -0.138 0 C-N-CA 122.713 0.405 . . . . 0.0 111.781 178.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 pt -136.9 175.52 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 170.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.417 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.5 OUTLIER -124.76 148.25 48.21 Favored 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 114.541 1.312 . . . . 0.0 114.541 -177.715 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.2 t -135.33 140.89 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.643 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.0 179.38 27.75 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 -178.038 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 57.4 t30 60.09 22.23 11.44 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.724 0.81 . . . . 0.0 111.251 -174.093 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 92.8 mt -68.39 147.01 98.17 Favored Pre-proline 0 N--CA 1.451 -0.377 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 177.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -71.59 156.62 57.51 Favored 'Trans proline' 0 N--CA 1.452 -0.938 0 C-N-CA 123.257 2.638 . . . . 0.0 110.218 178.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_exo -60.02 -20.72 62.0 Favored 'Trans proline' 0 N--CA 1.453 -0.906 0 C-N-CA 123.217 2.611 . . . . 0.0 111.622 176.17 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -85.3 8.56 18.15 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.077 0.769 . . . . 0.0 113.077 -179.1 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 8.1 tp -59.98 150.47 6.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.237 0 CA-C-O 120.828 0.347 . . . . 0.0 110.528 -179.1 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 53.1 ttt180 -144.05 150.93 38.96 Favored 'General case' 0 N--CA 1.456 -0.137 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 177.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -57.49 -28.92 63.83 Favored 'General case' 0 CA--C 1.527 0.059 0 N-CA-C 114.908 1.447 . . . . 0.0 114.908 -173.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -79.91 -13.74 59.15 Favored 'General case' 0 CA--C 1.528 0.119 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -177.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -70.63 -26.69 63.59 Favored 'General case' 0 C--N 1.333 -0.124 0 O-C-N 121.966 -0.459 . . . . 0.0 110.365 178.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 81.0 mt -77.93 -24.03 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -80.24 -14.39 58.46 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 178.227 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -94.36 -71.45 0.66 Allowed 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 122.865 0.466 . . . . 0.0 111.858 174.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 53.5 t -64.12 -55.65 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.254 -171.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -68.01 -18.18 64.63 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -177.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.8 t -73.33 -31.57 64.07 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 175.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -73.08 -27.05 61.5 Favored 'General case' 0 C--N 1.343 0.314 0 O-C-N 122.071 -0.393 . . . . 0.0 110.609 172.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -79.07 -18.11 54.0 Favored 'General case' 0 N--CA 1.456 -0.153 0 N-CA-C 115.253 1.575 . . . . 0.0 115.253 176.1 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.35 167.26 32.9 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.608 -0.597 . . . . 0.0 111.608 177.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -75.86 105.57 6.97 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 80.6 mt -79.73 142.29 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.544 -178.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -105.94 -32.28 8.4 Favored 'General case' 0 N--CA 1.456 -0.128 0 C-N-CA 122.862 0.465 . . . . 0.0 109.869 172.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -152.38 155.46 37.65 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 114.271 1.211 . . . . 0.0 114.271 178.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 3.3 mp -117.06 149.95 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 175.191 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -146.28 52.88 1.13 Allowed 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 121.086 0.47 . . . . 0.0 109.801 -178.28 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.0 tp -63.06 135.2 57.11 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 122.678 0.391 . . . . 0.0 110.059 173.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.484 ' HE3' ' C2 ' ' A' ' 94' ' ' ' A' . 59.0 mttp -127.06 144.83 50.93 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 123.214 0.606 . . . . 0.0 110.645 178.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 66.8 m-20 -76.51 169.21 18.68 Favored 'General case' 0 C--O 1.232 0.139 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 171.35 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 18.6 tpt85 -156.0 152.16 27.79 Favored 'General case' 0 C--O 1.231 0.105 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 82.2 mtt85 -119.56 151.8 38.04 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 123.938 0.895 . . . . 0.0 109.365 178.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.49 5.57 60.27 Favored Glycine 0 CA--C 1.533 1.162 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 -178.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -176.34 175.93 47.62 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -179.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -68.44 157.28 62.5 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 123.886 3.057 . . . . 0.0 111.012 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.13 167.81 17.26 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 123.869 3.046 . . . . 0.0 110.997 177.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . 0.467 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 3.9 p90 -152.82 165.66 34.69 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 -177.303 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.13 169.64 23.09 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 121.216 0.531 . . . . 0.0 111.46 -172.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -132.17 158.19 42.35 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 171.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 73.5 t -140.15 135.05 36.78 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.309 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -178.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 64.4 tt0 -110.58 112.03 23.66 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -80.73 162.4 24.13 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 176.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 89.2 tt0 -74.36 -37.8 63.38 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 174.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -125.24 147.48 57.53 Favored Pre-proline 0 CA--C 1.529 0.17 0 C-N-CA 123.602 0.761 . . . . 0.0 109.917 179.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.48 -16.57 30.7 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 123.367 2.711 . . . . 0.0 111.576 -178.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 23.3 ptt85 -71.74 -15.92 62.2 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 122.7 0.4 . . . . 0.0 111.314 -177.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.65 -21.31 60.32 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 179.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -70.79 -18.1 62.76 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -73.93 -17.81 60.97 Favored 'General case' 0 N--CA 1.454 -0.226 0 O-C-N 122.274 -0.266 . . . . 0.0 110.469 179.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 -97.85 -39.69 8.89 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.567 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -74.68 -31.35 61.88 Favored 'General case' 0 N--CA 1.453 -0.283 0 O-C-N 122.274 -0.267 . . . . 0.0 110.783 -178.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 48.2 t -87.99 6.33 3.54 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 122.836 0.455 . . . . 0.0 111.6 -174.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.8 t -139.14 -23.04 0.91 Allowed 'General case' 0 C--O 1.232 0.146 0 O-C-N 121.819 -0.551 . . . . 0.0 111.722 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -96.22 -4.2 59.9 Favored Glycine 0 CA--C 1.526 0.737 0 CA-C-O 119.449 -0.639 . . . . 0.0 112.443 -178.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 3.9 tpp180 -147.48 -18.5 0.38 Allowed 'General case' 0 CA--C 1.529 0.161 0 CA-C-N 118.219 1.01 . . . . 0.0 111.993 -176.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -68.46 146.15 53.43 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.56 42.36 99.75 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-O 119.691 -0.505 . . . . 0.0 112.092 174.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 30.7 t80 -87.62 129.13 35.23 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 117.806 0.803 . . . . 0.0 113.028 -177.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -69.38 87.42 0.44 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 123.378 0.671 . . . . 0.0 111.442 -177.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 36.7 t80 -81.13 -177.63 6.54 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 31.1 t0 -69.7 85.2 0.46 Allowed 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.144 179.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.72 3.45 89.5 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-O 119.843 -0.42 . . . . 0.0 112.113 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 -133.67 -179.1 5.32 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 113.791 1.034 . . . . 0.0 113.791 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -143.19 117.85 9.82 Favored 'General case' 0 N--CA 1.456 -0.13 0 C-N-CA 123.346 0.658 . . . . 0.0 109.357 -176.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.77 154.08 37.97 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 122.569 0.348 . . . . 0.0 110.642 -177.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -124.35 118.93 27.85 Favored 'General case' 0 CA--C 1.516 -0.352 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 176.143 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 19.9 t -142.52 84.99 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 123.028 0.531 . . . . 0.0 110.109 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -143.58 161.11 39.35 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.175 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.7 p90 -77.74 152.26 80.27 Favored Pre-proline 0 CA--C 1.528 0.116 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 178.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo . . . . . 0 C--O 1.251 1.133 0 C-N-CA 123.526 2.817 . . . . 0.0 110.653 177.676 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -2.985 0 C3'-C2'-C1' 104.823 3.692 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.821 1 C5'-C4'-C3' 109.014 -4.324 OUTLIER-DELTA 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.467 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.379 0 C5'-C4'-C3' 110.64 -3.24 . 0.01 2z . 0.0 . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.426 -2.248 1 C5'-C4'-C3' 108.97 -4.354 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . 0.484 ' C2 ' ' HE3' ' B' ' 48' ' ' LYS . . . . . . . . 0 O4'--C4' 1.425 -2.324 1 O4'-C1'-N19 112.721 4.521 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.825 0 C5'-C4'-C3' 110.282 -3.479 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.3 t . . . . . 0 N--CA 1.477 0.878 0 CA-C-O 120.772 0.32 . . . . 0.0 111.569 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 93.2 mt -68.18 144.84 13.98 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 2.1 tmm_? -152.62 127.4 9.53 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 116.907 -0.133 . . . . 0.0 110.792 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.13 -170.59 5.41 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 123.62 0.629 . . . . 0.0 112.664 172.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.38 -28.82 3.39 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.534 2.822 . . . . 0.0 110.631 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -165.24 166.83 18.55 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 123.244 0.618 . . . . 0.0 109.958 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -89.7 -168.49 43.23 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 176.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 34.3 t30 57.95 -176.26 0.07 Allowed 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 123.87 0.868 . . . . 0.0 111.222 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 30.3 t-20 63.09 162.04 0.1 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.404 1.081 . . . . 0.0 111.342 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 19.1 p30 -139.51 -0.74 1.74 Allowed 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 123.358 0.663 . . . . 0.0 112.113 179.325 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 78.9 m -77.26 0.31 22.5 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 122.686 0.395 . . . . 0.0 110.432 174.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 41.5 ttm105 -78.51 145.69 34.79 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 123.513 0.725 . . . . 0.0 110.385 -178.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.0 pt -142.76 172.87 7.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 CA-C-O 121.087 0.47 . . . . 0.0 110.92 -177.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -109.81 153.93 23.71 Favored 'General case' 0 C--O 1.233 0.221 0 C-N-CA 124.909 1.283 . . . . 0.0 113.602 -178.08 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 22.5 t -137.07 139.74 43.81 Favored 'Isoleucine or valine' 0 C--O 1.232 0.17 0 C-N-CA 123.367 0.667 . . . . 0.0 110.701 179.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -159.7 -177.7 33.03 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 40.2 t30 56.53 26.37 10.9 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.668 0.787 . . . . 0.0 111.107 -173.265 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 91.4 mt -63.97 152.59 86.97 Favored Pre-proline 0 N--CA 1.454 -0.253 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 177.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -64.34 159.74 42.35 Favored 'Trans proline' 0 N--CA 1.45 -1.066 0 C-N-CA 123.461 2.774 . . . . 0.0 110.805 -177.1 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.53 -2.15 9.51 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 124.218 3.279 . . . . 0.0 111.563 -178.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -146.12 116.94 7.68 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 122.695 0.398 . . . . 0.0 111.415 178.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 8.1 tp -157.79 147.33 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.177 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 15.0 mmp_? -80.58 158.08 25.84 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 120.783 0.325 . . . . 0.0 110.365 -179.03 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.5 p -72.57 10.24 0.88 Allowed 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 114.168 1.173 . . . . 0.0 114.168 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.4 tptt -140.1 -22.75 0.84 Allowed 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 122.473 0.309 . . . . 0.0 111.492 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -65.35 -24.5 67.27 Favored 'General case' 0 N--CA 1.456 -0.133 0 N-CA-C 112.674 0.62 . . . . 0.0 112.674 -179.099 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 6.9 tp -72.11 -20.93 20.33 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -90.37 -28.87 18.4 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.32 -32.46 64.6 Favored 'General case' 0 C--N 1.337 0.044 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -178.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 53.7 t -71.75 -45.29 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 177.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 35.5 m-85 -72.08 -30.41 65.09 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 47.1 t -68.33 -25.58 65.18 Favored 'General case' 0 C--N 1.34 0.179 0 CA-C-N 116.953 -0.112 . . . . 0.0 110.857 174.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -75.98 -32.64 59.56 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 176.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 14.6 m-85 -78.57 -15.76 58.2 Favored 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 115.534 1.679 . . . . 0.0 115.534 176.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 170.64 178.89 41.64 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 177.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.41 113.78 19.72 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 122.779 -0.247 . . . . 0.0 110.592 -178.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.6 mp -86.29 140.97 15.06 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 122.731 0.412 . . . . 0.0 109.9 176.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . 0.449 ' HA ' ' HE ' ' B' ' 43' ' ' ARG . 1.7 mmp_? -108.05 -31.85 7.78 Favored 'General case' 0 N--CA 1.456 -0.13 0 C-N-CA 122.969 0.508 . . . . 0.0 110.012 174.273 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -151.32 158.8 44.28 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . 0.523 HG23 ' H ' ' B' ' 47' ' ' LEU . 29.9 mm -140.2 151.03 21.32 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 124.153 0.981 . . . . 0.0 109.037 179.271 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -135.62 51.9 2.03 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 175.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . 0.523 ' H ' HG23 ' B' ' 45' ' ' ILE . 51.0 tp -53.38 130.52 35.54 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.101 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 18.3 ttmm -146.46 151.33 37.22 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -172.243 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 -141.29 -1.08 1.37 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 122.271 0.229 . . . . 0.0 111.544 -179.304 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . 0.41 HH22 ' P ' ' A' ' 93' ' ' ' A' . 44.8 ttm105 49.11 -102.97 0.1 Allowed 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 123.709 0.804 . . . . 0.0 111.235 179.334 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . 0.401 HH11 ' HD3' ' B' ' 51' ' ' ARG . 54.8 mtt180 -142.71 4.52 1.52 Allowed 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 123.077 0.551 . . . . 0.0 111.302 -178.525 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 167.71 -176.49 42.38 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.488 -0.645 . . . . 0.0 111.488 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.03 178.41 48.98 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -178.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.58 154.1 74.46 Favored 'Trans proline' 0 N--CA 1.451 -0.983 0 C-N-CA 123.4 2.733 . . . . 0.0 109.882 178.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -60.38 153.17 62.05 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 122.956 2.438 . . . . 0.0 111.807 -179.544 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -146.9 146.63 30.22 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 124.178 0.991 . . . . 0.0 112.307 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -160.43 157.05 27.05 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -175.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -112.69 151.57 30.06 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.854 167.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.6 t -135.2 136.63 51.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -176.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 78.8 tt0 -124.25 112.66 17.28 Favored 'General case' 0 N--CA 1.455 -0.176 0 CA-C-O 120.747 0.308 . . . . 0.0 110.637 -177.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -84.32 159.29 20.93 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 177.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 33.2 tp10 -78.14 -30.33 49.21 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.439 174.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -129.09 150.15 74.58 Favored Pre-proline 0 C--O 1.232 0.151 0 C-N-CA 123.573 0.749 . . . . 0.0 112.538 -178.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.99 -24.47 24.0 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 123.431 2.754 . . . . 0.0 110.921 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 38.6 mmt180 -76.52 -24.83 53.71 Favored 'General case' 0 C--N 1.339 0.131 0 C-N-CA 121.962 0.105 . . . . 0.0 110.757 179.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -75.19 -34.16 61.5 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-O 120.416 0.151 . . . . 0.0 111.271 175.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -73.04 -32.54 65.13 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 176.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -65.81 -33.87 76.86 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.151 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -76.06 -35.62 59.35 Favored 'General case' 0 N--CA 1.457 -0.125 0 N-CA-C 113.249 0.833 . . . . 0.0 113.249 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.73 -29.16 63.13 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 122.365 -0.21 . . . . 0.0 110.505 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 55.9 t -81.43 -52.47 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.0 t -70.29 -17.27 63.09 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -174.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.03 -1.76 45.28 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-O 119.161 -0.799 . . . . 0.0 113.868 -173.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 30.1 ttp-105 -153.23 -14.02 0.15 Allowed 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 119.003 1.402 . . . . 0.0 113.19 -175.048 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -69.28 146.71 52.04 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 118.673 0.67 . . . . 0.0 110.037 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.75 38.25 95.63 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-O 119.562 -0.577 . . . . 0.0 112.313 172.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 37.8 t80 -88.24 130.04 35.19 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 118.089 0.945 . . . . 0.0 112.968 -176.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 29.6 t0 -68.75 89.37 0.39 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.369 0.668 . . . . 0.0 111.091 -178.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 35.7 t80 -81.17 -174.62 4.99 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -69.49 74.05 0.37 Allowed 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 123.765 0.826 . . . . 0.0 111.997 178.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.47 6.83 70.17 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 -179.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -133.19 -179.31 5.42 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -179.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 9.5 tpp180 -143.08 114.38 7.88 Favored 'General case' 0 CA--C 1.528 0.132 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -175.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -61.9 153.13 29.99 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.811 0.444 . . . . 0.0 110.245 -177.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 74.8 mtt180 -129.11 115.31 17.52 Favored 'General case' 0 CA--C 1.52 -0.185 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 177.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 38.7 t -143.14 85.14 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.183 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -148.58 165.3 31.66 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.641 0.258 . . . . 0.0 110.589 -174.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -81.79 156.82 70.0 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 113.755 1.021 . . . . 0.0 113.755 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo . . . . . 0 C--O 1.252 1.215 0 C-N-CA 123.895 3.064 . . . . 0.0 111.639 177.684 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.649 1 O4'-C1'-N19 112.447 4.247 . 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.46 1 C5'-C4'-C3' 109.311 -4.126 . 0.118 6n . 0.0 . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.547 0 O4'-C1'-N19 111.91 3.71 . 0.078 1z . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.492 H5'' ' C8 ' ' A' ' 93' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.421 -2.654 1 C3'-C2'-C1' 105.188 4.098 OUTLIER-DELTA 0.0 OUTLIER . 0.0 . . . . . . . . . . 4 4 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.845 0 O4'-C1'-N19 111.558 3.358 . 0.142 2u . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.417 2 C5'-C4'-C3' 109.421 -4.052 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 11.1 t . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 111.535 0.198 . . . . 0.0 111.535 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 73.3 mt -68.53 150.51 10.75 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.48 ' HD3' ' N ' ' B' ' 9' ' ' GLY . 3.0 tmt_? -144.0 158.34 43.77 Favored 'General case' 0 N--CA 1.457 -0.097 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . 0.48 ' N ' ' HD3' ' B' ' 8' ' ' ARG . . . -45.45 145.33 2.73 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 178.271 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.73 176.88 6.89 Favored 'Trans proline' 0 N--CA 1.452 -0.93 0 C-N-CA 123.766 2.977 . . . . 0.0 111.769 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 62.39 15.63 7.89 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.481 1.112 . . . . 0.0 113.492 176.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 166.33 160.99 14.37 Favored Glycine 0 CA--C 1.527 0.808 0 CA-C-N 118.41 0.55 . . . . 0.0 112.304 174.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 73.5 m-80 -137.44 -5.81 1.79 Allowed 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 123.525 0.73 . . . . 0.0 110.525 176.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -155.48 106.64 2.55 Favored 'General case' 0 N--CA 1.456 -0.14 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 176.173 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . 0.414 ' C ' ' H ' ' B' ' 17' ' ' ARG . 6.7 p30 -160.69 176.38 11.59 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -169.385 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 80.9 m -75.47 18.67 0.21 Allowed 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 123.321 0.649 . . . . 0.0 111.598 177.377 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . 0.437 ' HA ' ' HA ' ' B' ' 60' ' ' GLU . 27.5 ttm180 -74.38 149.61 40.43 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 122.831 0.452 . . . . 0.0 111.239 -175.002 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.3 pt -131.08 -178.8 2.84 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.09 0 C-N-CA 123.876 0.87 . . . . 0.0 109.645 178.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -120.66 150.2 41.3 Favored 'General case' 0 C--O 1.231 0.12 0 N-CA-C 114.462 1.282 . . . . 0.0 114.462 -173.657 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 46.3 t -141.05 142.29 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 C-N-CA 123.928 0.891 . . . . 0.0 109.019 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.54 -178.95 33.03 Favored Glycine 0 C--N 1.338 0.665 0 C-N-CA 121.277 -0.487 . . . . 0.0 112.515 -175.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 48.5 t30 56.48 25.96 10.32 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.245 1.018 . . . . 0.0 111.376 -176.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.8 mt -66.32 127.34 93.22 Favored Pre-proline 0 CA--C 1.531 0.223 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -57.73 152.64 47.94 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 123.302 2.668 . . . . 0.0 110.905 174.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -69.24 -14.83 38.42 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.527 2.818 . . . . 0.0 111.194 -179.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 -82.5 -6.66 59.45 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 112.921 0.711 . . . . 0.0 112.921 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 19.5 mm -71.59 138.77 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 C-N-CA 122.421 0.288 . . . . 0.0 110.517 -178.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 65.9 mtm180 -88.06 154.53 20.41 Favored 'General case' 0 C--N 1.334 -0.065 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 177.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 2.7 p -65.74 -18.1 65.09 Favored 'General case' 0 C--N 1.333 -0.147 0 N-CA-C 113.246 0.832 . . . . 0.0 113.246 179.227 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 58.2 tptt -87.71 -21.09 25.4 Favored 'General case' 0 C--N 1.342 0.25 0 C-N-CA 122.669 0.388 . . . . 0.0 111.132 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -65.61 -23.07 66.74 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 122.118 -0.364 . . . . 0.0 111.451 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mp -70.86 -22.47 23.1 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 178.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -96.45 -38.4 10.04 Favored 'General case' 0 N--CA 1.453 -0.305 0 O-C-N 122.359 -0.213 . . . . 0.0 110.824 -178.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -67.62 -45.71 74.64 Favored 'General case' 0 N--CA 1.458 -0.057 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -175.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 91.1 t -72.26 -42.37 66.06 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -178.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -75.32 -26.68 58.85 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -177.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.2 t -70.73 -31.0 67.69 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-O 120.557 0.218 . . . . 0.0 110.43 174.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 28.9 tptp -70.82 -31.33 68.02 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -85.22 -13.0 51.28 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 116.082 1.882 . . . . 0.0 116.082 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.18 171.98 38.32 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.303 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -79.1 104.46 9.74 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 122.669 0.387 . . . . 0.0 110.406 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 83.5 mt -75.58 147.27 8.25 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.145 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 176.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -131.02 -19.41 2.87 Favored 'General case' 0 C--N 1.34 0.168 0 C-N-CA 122.523 0.329 . . . . 0.0 111.12 175.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -153.7 156.03 37.08 Favored 'General case' 0 CA--C 1.528 0.102 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 174.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 18.9 mm -136.19 152.85 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.122 0 C-N-CA 123.737 0.815 . . . . 0.0 109.253 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -145.72 46.73 1.27 Allowed 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 178.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 28.6 tp -58.27 133.99 56.16 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 174.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 56.0 mttp -127.56 145.49 50.84 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 123.655 0.782 . . . . 0.0 110.608 178.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.4 p-10 -81.38 -12.77 58.87 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 171.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 52.1 ttt85 62.4 154.56 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 125.437 1.495 . . . . 0.0 112.125 -177.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 33.3 ttp-105 -72.8 -11.18 60.5 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.185 0.594 . . . . 0.0 111.155 -178.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.41 162.69 33.05 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.93 -176.86 42.83 Favored Glycine 0 CA--C 1.53 0.978 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -177.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -66.76 157.64 60.17 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 123.798 2.998 . . . . 0.0 111.055 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -59.81 160.08 22.68 Favored 'Trans proline' 0 N--CA 1.454 -0.838 0 C-N-CA 123.808 3.005 . . . . 0.0 112.065 177.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . 0.432 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 1.8 p90 -157.74 166.47 32.68 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.705 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.14 172.68 18.02 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-O 121.174 0.512 . . . . 0.0 112.089 -172.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -131.67 146.58 52.25 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 171.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 96.6 t -132.41 132.41 60.37 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.265 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -174.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . 0.437 ' HA ' ' HA ' ' B' ' 17' ' ' ARG . 76.2 tt0 -116.36 120.39 38.71 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 120.581 0.229 . . . . 0.0 111.433 -175.525 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -90.49 161.7 15.39 Favored 'General case' 0 C--O 1.232 0.16 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 177.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -71.6 -33.4 68.98 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 174.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -128.96 150.39 75.12 Favored Pre-proline 0 CA--C 1.53 0.189 0 C-N-CA 123.689 0.795 . . . . 0.0 111.795 -178.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.86 -13.89 32.23 Favored 'Trans proline' 0 N--CA 1.452 -0.913 0 C-N-CA 123.214 2.609 . . . . 0.0 110.364 176.499 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 32.5 ttp-105 -65.26 -38.25 89.72 Favored 'General case' 0 CA--C 1.528 0.124 0 C-N-CA 123.323 0.649 . . . . 0.0 110.545 178.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -77.67 -20.3 53.96 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -176.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.79 -29.94 65.0 Favored 'General case' 0 N--CA 1.452 -0.364 0 O-C-N 122.527 -0.108 . . . . 0.0 110.711 -177.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -72.89 -27.24 61.77 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.327 -0.233 . . . . 0.0 110.61 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -80.1 -36.45 35.41 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -178.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -76.55 -28.39 56.26 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 110.572 -0.158 . . . . 0.0 110.572 -178.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.5 t -79.33 -58.66 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 69.9 m -73.5 -3.33 26.95 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -175.537 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -85.41 -19.94 57.67 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 119.32 -0.711 . . . . 0.0 112.828 -176.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 24.7 ptt-85 -161.64 18.45 0.11 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 118.604 1.202 . . . . 0.0 113.009 -174.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -66.9 140.96 57.8 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.97 0.73 . . . . 0.0 112.97 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 60.28 70.87 0.89 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.828 -0.509 . . . . 0.0 111.828 174.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 59.6 t80 -110.73 137.91 47.79 Favored 'General case' 0 C--N 1.339 0.138 0 N-CA-C 113.571 0.952 . . . . 0.0 113.571 179.215 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -64.42 108.47 1.64 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 124.392 1.077 . . . . 0.0 112.988 -175.086 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.412 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.9 t80 -113.9 169.3 9.1 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.849 0.86 . . . . 0.0 111.26 175.266 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.412 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 75.7 m-20 -59.81 97.18 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -179.193 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 80.08 -5.65 62.07 Favored Glycine 0 CA--C 1.534 1.281 0 CA-C-O 119.315 -0.714 . . . . 0.0 112.643 177.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -139.4 -171.02 3.03 Favored 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 118.296 1.048 . . . . 0.0 113.362 -177.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -142.04 128.96 20.67 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -177.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.6 mp -63.39 150.09 44.34 Favored 'General case' 0 C--N 1.335 -0.049 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -123.11 124.87 44.05 Favored 'General case' 0 CA--C 1.52 -0.194 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.184 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.3 t -147.29 79.73 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.088 0 C-N-CA 123.603 0.761 . . . . 0.0 109.269 178.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.9 pt-20 -147.08 165.03 31.17 Favored 'General case' 0 C--O 1.226 -0.155 0 C-N-CA 122.667 0.387 . . . . 0.0 110.442 -177.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.7 p90 -80.01 153.72 74.96 Favored Pre-proline 0 C--O 1.234 0.275 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 176.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo . . . . . 0 C--O 1.249 1.051 0 C-N-CA 123.746 2.964 . . . . 0.0 111.728 175.967 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.472 2 O4'-C1'-N19 112.967 4.767 . 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . 0.41 " H4'" " H5'" ' A' ' 92' ' ' ' C' . . . . . . . . 0 O4'--C4' 1.424 -2.433 0 C5'-C4'-C3' 110.304 -3.464 OUTLIER-DELTA 0.0 OUTLIER delta 0.0 . . . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.432 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.42 -2.747 0 C5'-C4'-C3' 109.756 -3.829 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.515 1 C3'-C2'-C1' 105.21 4.122 . 0.145 4b . 0.0 . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.563 1 O4'-C1'-N19 112.564 4.364 OUTLIER-EPSILON 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.895 0 C5'-C4'-C3' 109.585 -3.943 . 0.0 OUTLIER epsilon-1 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 4.6 p . . . . . 0 N--CA 1.48 1.037 0 N-CA-C 111.862 0.319 . . . . 0.0 111.862 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 44.3 mm -71.49 152.89 8.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 36.5 ttm-85 -62.85 145.5 54.91 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 122.666 0.387 . . . . 0.0 110.711 -179.149 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . 0.698 ' HA2' ' C2 ' ' A' ' 93' ' ' ' A' . . . 148.56 -25.71 1.35 Allowed Glycine 0 CA--C 1.533 1.185 0 CA-C-O 118.312 -1.271 . . . . 0.0 113.641 172.266 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . 0.531 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 32.4 Cg_exo -58.07 161.32 13.64 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 CA-C-N 120.111 1.956 . . . . 0.0 111.01 169.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.77 155.55 40.63 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.021 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 154.88 173.61 23.88 Favored Glycine 0 C--N 1.337 0.599 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 52.77 42.7 31.88 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.098 0.559 . . . . 0.0 111.28 179.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 68.0 m-20 57.17 20.37 5.59 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.792 0.837 . . . . 0.0 112.398 179.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 53.86 34.3 19.03 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 177.196 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.7 m -68.92 -1.08 6.47 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 122.739 0.416 . . . . 0.0 111.412 177.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 39.9 ttm180 -75.87 148.6 38.19 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 123.943 0.897 . . . . 0.0 110.49 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 14.2 pt -129.6 176.26 8.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 C-N-CA 122.897 0.479 . . . . 0.0 109.923 178.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.478 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 1.0 OUTLIER -115.49 153.42 31.16 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -173.297 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 79.2 t -138.09 100.26 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -82.66 160.03 38.96 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 175.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 40.8 t30 60.51 -171.56 0.14 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.153 0.581 . . . . 0.0 110.25 -176.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.6 tp -144.52 132.62 10.74 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -68.64 157.67 60.89 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.23 2.62 . . . . 0.0 111.501 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.59 -4.5 15.34 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 124.337 3.358 . . . . 0.0 111.821 -175.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 9.9 p30 -126.82 25.19 6.39 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -177.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 5.5 tp -58.78 139.97 17.75 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 C-N-CA 122.855 0.462 . . . . 0.0 110.95 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 39.0 ttm105 -155.83 160.56 40.32 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 175.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.05 3.68 0.16 Allowed 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 116.279 1.955 . . . . 0.0 116.279 -173.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -148.72 -22.49 0.32 Allowed 'General case' 0 CA--C 1.528 0.132 0 O-C-N 122.092 -0.38 . . . . 0.0 111.298 177.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 71.1 m-20 -67.93 -19.76 65.01 Favored 'General case' 0 N--CA 1.457 -0.123 0 O-C-N 122.389 -0.195 . . . . 0.0 111.455 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 7.9 tp -73.19 -14.3 16.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 177.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -103.55 -21.25 13.78 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -71.09 -51.46 25.01 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.432 0.293 . . . . 0.0 111.585 -177.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 m -67.91 -33.42 61.25 Favored 'Isoleucine or valine' 0 C--N 1.338 0.082 0 CA-C-O 120.515 0.198 . . . . 0.0 110.929 -179.026 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -74.42 -35.15 63.39 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 176.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.4 t -66.66 -25.55 66.62 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.575 0.226 . . . . 0.0 110.599 175.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 29.2 tptp -77.72 -33.1 53.16 Favored 'General case' 0 N--CA 1.456 -0.149 0 N-CA-C 110.275 -0.268 . . . . 0.0 110.275 177.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -85.44 -9.24 57.77 Favored 'General case' 0 CA--C 1.53 0.184 0 N-CA-C 116.394 1.998 . . . . 0.0 116.394 179.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.42 178.54 44.4 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.73 177.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -79.41 43.26 0.54 Allowed 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.937 0.895 . . . . 0.0 110.99 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.8 mp -55.77 138.25 16.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 122.695 0.398 . . . . 0.0 110.089 179.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 56.7 mmm-85 -94.69 -54.64 3.42 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.175 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -133.44 150.62 51.76 Favored 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -170.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -112.52 151.04 14.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.203 0 C-N-CA 124.596 1.158 . . . . 0.0 108.26 173.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -143.7 68.74 1.28 Allowed 'General case' 0 N--CA 1.452 -0.329 0 CA-C-O 120.694 0.283 . . . . 0.0 111.164 178.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 44.1 tp -70.91 129.54 39.31 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.178 174.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.562 ' HE3' " H1'" ' A' ' 93' ' ' ' A' . 68.8 mttm -114.41 140.28 48.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 123.089 0.556 . . . . 0.0 110.085 178.225 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 46.0 p-10 -81.53 -163.81 0.68 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 123.877 0.871 . . . . 0.0 111.179 -178.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 22.7 tpp85 -49.6 131.06 21.31 Favored 'General case' 0 C--N 1.339 0.114 0 C-N-CA 123.182 0.593 . . . . 0.0 109.883 177.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 57.6 ttt-85 -150.39 42.32 0.82 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 122.86 0.464 . . . . 0.0 110.049 -174.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.7 6.09 83.41 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -176.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -167.03 -172.09 33.87 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 -179.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -63.97 159.05 44.2 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 123.158 2.572 . . . . 0.0 110.348 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -65.36 152.07 83.17 Favored 'Trans proline' 0 N--CA 1.448 -1.172 0 C-N-CA 123.086 2.524 . . . . 0.0 110.242 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . 0.495 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 2.1 p90 -157.59 162.98 38.77 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -178.301 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -146.62 173.68 12.12 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-O 121.083 0.468 . . . . 0.0 111.387 -172.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . 0.411 ' CD2' ' C2 ' ' A' ' 93' ' ' ' A' . 94.5 m-85 -138.68 160.67 39.06 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.336 175.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 81.9 t -137.76 134.75 45.85 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 55.1 tt0 -115.52 127.23 55.14 Favored 'General case' 0 N--CA 1.453 -0.295 0 CA-C-O 120.773 0.32 . . . . 0.0 110.741 -174.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -95.17 151.52 19.14 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 115.314 1.598 . . . . 0.0 115.314 -172.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 49.8 tp10 -80.49 -26.24 38.33 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 168.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -153.05 117.54 2.85 Favored Pre-proline 0 N--CA 1.453 -0.294 0 C-N-CA 124.125 0.97 . . . . 0.0 109.468 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -66.86 -6.1 14.94 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 123.225 2.616 . . . . 0.0 112.429 -174.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 60.1 ttt85 -65.36 -28.88 69.6 Favored 'General case' 0 N--CA 1.456 -0.159 0 CA-C-N 118.022 0.374 . . . . 0.0 110.576 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -78.7 -15.8 58.03 Favored 'General case' 0 CA--C 1.531 0.213 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.21 -20.47 63.97 Favored 'General case' 0 N--CA 1.451 -0.411 0 O-C-N 122.198 -0.314 . . . . 0.0 110.428 -177.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -64.75 -26.95 68.58 Favored 'General case' 0 CA--C 1.532 0.266 0 O-C-N 122.055 -0.403 . . . . 0.0 110.336 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -90.88 -36.56 14.1 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 112.561 0.578 . . . . 0.0 112.561 178.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.67 -28.44 62.71 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 122.41 0.284 . . . . 0.0 110.723 -177.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 49.7 t -75.24 0.0 2.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 32.5 t -135.35 5.49 3.23 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.763 -0.586 . . . . 0.0 110.943 178.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -77.94 -28.87 55.77 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-O 119.694 -0.503 . . . . 0.0 112.129 -177.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 50.1 ttt180 -158.45 13.46 0.18 Allowed 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 117.624 0.712 . . . . 0.0 110.89 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 29.9 t0 -69.55 150.07 47.52 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 122.102 -0.374 . . . . 0.0 110.246 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.28 38.13 95.97 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 111.803 -0.519 . . . . 0.0 111.803 175.538 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 31.0 t80 -98.97 132.78 44.03 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 113.149 0.796 . . . . 0.0 113.149 -173.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -61.62 104.35 0.42 Allowed 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 123.559 0.744 . . . . 0.0 112.149 -179.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.496 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 66.2 t80 -110.35 173.44 6.33 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 123.586 0.754 . . . . 0.0 111.803 178.617 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.496 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.7 t0 -62.43 100.03 0.17 Allowed 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.67 -8.22 29.15 Favored Glycine 0 CA--C 1.531 1.076 0 C-N-CA 123.435 0.541 . . . . 0.0 112.936 177.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -138.9 -169.92 2.74 Favored 'General case' 0 C--N 1.34 0.172 0 N-CA-C 113.133 0.79 . . . . 0.0 113.133 -178.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 38.3 ttt180 -145.46 134.68 22.87 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -177.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -62.71 144.34 56.48 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -178.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 56.7 mtm180 -132.43 71.97 1.48 Allowed 'General case' 0 C--N 1.339 0.127 0 C-N-CA 122.728 0.411 . . . . 0.0 110.809 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.83 92.31 3.81 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.103 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 177.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.5 pt-20 -151.04 159.72 44.36 Favored 'General case' 0 C--N 1.334 -0.102 0 C-N-CA 122.658 0.383 . . . . 0.0 110.827 178.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -73.65 153.4 89.51 Favored Pre-proline 0 C--O 1.235 0.303 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo . . . . . 0 C--O 1.251 1.173 0 C-N-CA 123.839 3.026 . . . . 0.0 110.543 176.138 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.443 0 C5'-C4'-C3' 112.174 -2.218 OUTLIER-DELTA 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.619 0 O4'-C1'-N19 111.882 3.682 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.495 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.422 -2.608 0 O4'-C1'-N19 111.391 3.191 . 0.202 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.698 ' C2 ' ' HA2' ' B' ' 9' ' ' GLY . . . . . . . . 0 O4'--C4' 1.422 -2.605 0 C5'-C4'-C3' 110.2 -3.534 . 0.14 6n . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . 0.508 " C5'" HO2' ' A' ' 93' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.421 -2.662 0 C5'-C4'-C3' 110.337 -3.442 OUTLIER-DELTA 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.42 -2.739 0 C3'-C2'-C1' 104.523 3.359 . 0.0 OUTLIER '7D dist 2[' 0.0 . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.419 ' C ' ' H ' ' B' ' 8' ' ' ARG . 14.1 t . . . . . 0 N--CA 1.477 0.894 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 15.8 mt 61.91 -38.96 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 C-N-CA 125.777 1.631 . . . . 0.0 113.364 -176.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.419 ' H ' ' C ' ' B' ' 6' ' ' VAL . 0.0 OUTLIER -160.87 -31.87 0.05 Allowed 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.254 0.621 . . . . 0.0 110.481 178.478 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . -171.43 -56.0 0.04 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-O 119.482 -0.621 . . . . 0.0 112.209 -174.488 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -59.31 135.77 67.66 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 123.666 2.911 . . . . 0.0 112.859 -176.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 57.47 170.71 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.901 1.28 . . . . 0.0 113.562 176.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.58 172.41 32.05 Favored Glycine 0 CA--C 1.525 0.711 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.22 178.057 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -77.81 162.73 26.68 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.764 0.426 . . . . 0.0 110.351 178.062 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -73.84 144.98 45.26 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 120.696 0.284 . . . . 0.0 110.641 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . 0.466 ' C ' ' H ' ' B' ' 17' ' ' ARG . 68.0 m-20 -87.08 -157.73 0.4 Allowed 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.496 0.719 . . . . 0.0 109.826 174.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 93.7 m -68.36 8.72 0.41 Allowed 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 122.608 0.363 . . . . 0.0 111.18 174.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . 0.466 ' H ' ' C ' ' B' ' 15' ' ' ASP . 49.2 mtt180 -73.12 156.61 38.49 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.448 0.699 . . . . 0.0 112.57 -179.128 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.0 pt -132.41 175.96 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.068 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 173.089 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.435 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.7 OUTLIER -119.3 147.63 44.08 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -174.981 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 24.8 t -132.42 138.5 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 C-N-CA 123.312 0.645 . . . . 0.0 110.368 -179.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -143.6 -179.43 20.18 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -177.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 64.4 t30 59.48 24.4 13.07 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.812 0.845 . . . . 0.0 111.325 -173.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 96.1 mt -71.5 142.04 86.06 Favored Pre-proline 0 CA--C 1.533 0.309 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 176.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -59.68 157.82 30.89 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 123.256 2.638 . . . . 0.0 111.116 176.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -69.97 -17.57 36.55 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.269 2.646 . . . . 0.0 110.58 177.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 79.1 m-20 -88.93 11.9 16.81 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 123.385 0.674 . . . . 0.0 112.724 178.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 7.7 tp -59.75 151.29 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 C-N-CA 122.63 0.372 . . . . 0.0 110.507 -178.303 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 16.1 ttp180 -142.68 147.69 36.11 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -59.78 -28.39 67.38 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -176.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -83.01 -19.62 36.63 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -75.55 -39.26 58.48 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 117.774 0.261 . . . . 0.0 111.109 179.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 12.6 tt -78.18 -21.28 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 CA-C-N 116.688 -0.233 . . . . 0.0 110.667 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.4 mt-10 -77.29 -39.39 48.19 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.108 -0.37 . . . . 0.0 110.494 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -74.3 -33.64 63.27 Favored 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -179.287 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 41.3 t -71.3 -48.14 55.86 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -74.58 -31.79 62.18 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 39.1 t -67.81 -30.73 70.22 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.933 177.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -77.66 -26.79 50.64 Favored 'General case' 0 C--O 1.232 0.138 0 O-C-N 122.366 -0.209 . . . . 0.0 111.075 175.529 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -87.45 -8.31 56.63 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 116.435 2.013 . . . . 0.0 116.435 177.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 175.37 174.17 41.73 Favored Glycine 0 CA--C 1.524 0.599 0 C-N-CA 121.1 -0.571 . . . . 0.0 112.483 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.46 40.44 0.57 Allowed 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 123.767 0.827 . . . . 0.0 111.348 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.9 mp -52.8 136.07 13.97 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.066 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 18.8 mmt85 -93.61 -35.18 13.0 Favored 'General case' 0 C--O 1.23 0.073 0 CA-C-O 119.492 -0.289 . . . . 0.0 111.691 -175.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -148.54 150.34 33.19 Favored 'General case' 0 C--O 1.232 0.147 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -177.794 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -115.15 151.8 16.84 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 C-N-CA 124.344 1.057 . . . . 0.0 108.278 174.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 61.6 t0 -148.16 75.12 1.32 Allowed 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.136 0.493 . . . . 0.0 110.221 179.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 53.9 tp -71.05 146.03 49.57 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.526 176.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 25.1 ttmm -146.41 141.09 26.82 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 176.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 45.8 p30 -147.42 15.12 1.12 Allowed 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 111.832 0.308 . . . . 0.0 111.832 -176.048 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . 0.474 ' C ' ' H ' ' B' ' 52' ' ' GLY . 35.3 ptt-85 -154.7 165.68 35.8 Favored 'General case' 0 CA--C 1.52 -0.176 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -178.397 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 64.35 -28.85 0.1 Allowed 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 125.144 1.378 . . . . 0.0 112.734 -176.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . 0.474 ' H ' ' C ' ' B' ' 50' ' ' ARG . . . -102.75 -155.07 25.13 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 175.55 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -74.85 -156.84 5.41 Favored Glycine 0 CA--C 1.534 1.277 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 176.421 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -63.48 164.91 19.16 Favored 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 123.618 2.879 . . . . 0.0 110.191 178.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_exo -50.5 131.47 32.62 Favored 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 123.569 2.846 . . . . 0.0 112.164 -173.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -162.61 169.4 20.22 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -151.78 159.24 43.99 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.184 0.516 . . . . 0.0 111.68 -174.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . 0.513 ' CE1' ' C4 ' ' A' ' 93' ' ' ' A' . 86.2 m-85 -112.72 151.05 30.69 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.11 172.106 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.2 t -135.96 132.33 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.148 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -178.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 69.9 tt0 -110.57 116.27 31.07 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 122.445 0.298 . . . . 0.0 111.155 -173.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -92.51 154.8 18.24 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -80.71 -29.97 36.38 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 171.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -159.93 151.17 16.14 Favored Pre-proline 0 CA--C 1.531 0.212 0 C-N-CA 125.267 1.427 . . . . 0.0 111.589 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.39 -3.04 12.2 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 123.6 2.867 . . . . 0.0 112.484 -176.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -63.52 -25.49 68.27 Favored 'General case' 0 CA--C 1.529 0.152 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -176.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -89.58 -5.15 57.46 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -177.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.15 -14.2 62.85 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 122.408 -0.183 . . . . 0.0 110.818 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -65.86 -17.33 64.57 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 122.419 -0.176 . . . . 0.0 111.17 -178.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -123.5 -37.43 2.66 Favored 'General case' 0 C--O 1.231 0.122 0 C-N-CA 122.975 0.51 . . . . 0.0 112.142 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -79.76 -9.92 59.72 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 122.58 0.352 . . . . 0.0 111.634 -175.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 60.4 t -131.79 -53.69 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 C-N-CA 122.374 0.27 . . . . 0.0 110.724 -178.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 70.5 m -70.71 -6.53 38.0 Favored 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 122.208 0.203 . . . . 0.0 111.343 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -116.09 10.44 17.79 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 119.543 -0.587 . . . . 0.0 111.764 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . 0.401 HH11 ' HD2' ' B' ' 74' ' ' ARG . 46.0 ttm180 -145.05 -20.41 0.5 Allowed 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 117.933 0.866 . . . . 0.0 111.984 -176.096 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -68.89 136.16 52.18 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 67.7 27.49 73.6 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 119.779 -0.456 . . . . 0.0 112.068 176.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 50.4 t80 -79.95 140.62 36.58 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 -172.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.7 t0 -59.34 102.52 0.14 Allowed 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -175.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.414 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 73.9 t80 -111.8 172.26 7.0 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 123.71 0.804 . . . . 0.0 110.743 176.026 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.414 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 17.6 t0 -62.4 98.35 0.11 Allowed 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.58 -5.8 55.42 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 119.599 -0.556 . . . . 0.0 112.887 177.347 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -142.2 -175.56 4.48 Favored 'General case' 0 CA--C 1.527 0.072 0 CA-C-N 117.945 0.872 . . . . 0.0 112.882 -178.083 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 93.1 mtt-85 -131.87 138.46 48.45 Favored 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 124.191 0.996 . . . . 0.0 109.829 176.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -59.85 154.38 18.64 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 178.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 1.3 tpm_? -122.42 116.45 24.0 Favored 'General case' 0 CA--C 1.518 -0.255 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 176.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 15.2 t -135.1 89.48 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 O-C-N 123.378 0.424 . . . . 0.0 110.063 178.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -146.89 158.18 43.85 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.361 178.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -76.56 155.09 83.69 Favored Pre-proline 0 CA--C 1.532 0.276 0 N-CA-C 114.224 1.194 . . . . 0.0 114.224 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo . . . . . 0 C--O 1.251 1.14 0 C-N-CA 123.702 2.934 . . . . 0.0 111.46 175.29 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.036 0 O4'-C1'-N19 111.689 3.489 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.891 0 C5'-C4'-C3' 111.221 -2.853 . 0.571 6n . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.435 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.422 -2.585 0 C5'-C4'-C3' 110.537 -3.308 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.513 ' C4 ' ' CE1' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.426 -2.238 2 C5'-C4'-C3' 109.095 -4.27 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.319 0 C5'-C4'-C3' 112.531 -1.979 OUTLIER-DELTA 0.0 OUTLIER '7D dist 8d' 0.0 . . . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.319 0 O4'-C1'-N19 111.853 3.653 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.477 0.896 0 CA-C-O 120.567 0.222 . . . . 0.0 111.303 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 85.7 mt -74.35 147.1 9.13 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.144 0 C-N-CA 122.845 0.458 . . . . 0.0 110.496 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 53.52 -98.05 0.07 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.431 1.092 . . . . 0.0 112.427 178.126 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . 0.462 ' HA3' ' C4 ' ' A' ' 93' ' ' ' A' . . . -79.01 132.2 11.3 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 111.932 -0.467 . . . . 0.0 111.932 -169.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -75.03 175.41 11.28 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 123.919 3.079 . . . . 0.0 110.265 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.27 -12.28 61.53 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 122.201 0.201 . . . . 0.0 110.674 176.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 169.39 151.51 7.34 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 110.104 -1.199 . . . . 0.0 110.104 177.136 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 31.1 p-10 -159.3 174.74 14.32 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 116.855 0.327 . . . . 0.0 110.659 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 41.8 p30 -135.62 26.99 3.38 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 123.377 0.671 . . . . 0.0 110.366 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -69.63 -177.67 1.28 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.352 0.661 . . . . 0.0 110.024 -179.38 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 8.2 p -64.06 -9.77 18.16 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 122.62 0.368 . . . . 0.0 111.669 176.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -63.11 144.71 56.66 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 122.857 0.463 . . . . 0.0 111.808 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.7 pt -131.67 173.16 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.885 174.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -111.97 150.62 30.29 Favored 'General case' 0 N--CA 1.457 -0.115 0 C-N-CA 124.356 1.062 . . . . 0.0 113.383 -177.667 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 25.9 t -133.32 91.71 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.145 0 C-N-CA 122.964 0.506 . . . . 0.0 110.35 -176.54 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -91.49 165.73 30.06 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 111.594 -0.602 . . . . 0.0 111.594 179.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 62.9 t30 59.96 21.09 10.13 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.026 0.93 . . . . 0.0 111.669 -176.398 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 21.0 tp -67.35 118.7 59.03 Favored Pre-proline 0 CA--C 1.535 0.367 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.36 146.95 46.15 Favored 'Trans proline' 0 N--CA 1.45 -1.039 0 C-N-CA 122.658 2.239 . . . . 0.0 110.26 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.41 -14.47 30.97 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 123.401 2.734 . . . . 0.0 110.881 178.219 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 78.1 m-20 -80.13 0.8 30.61 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 113.479 0.918 . . . . 0.0 113.479 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 tp -64.98 144.3 14.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 24.7 ttp85 -73.91 155.66 38.46 Favored 'General case' 0 C--O 1.231 0.127 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.8 p -66.01 7.82 0.25 Allowed 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 114.537 1.31 . . . . 0.0 114.537 -178.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.0 tptm -142.02 -29.43 0.6 Allowed 'General case' 0 C--O 1.227 -0.096 0 C-N-CA 122.354 0.262 . . . . 0.0 111.129 -179.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 -63.71 -19.1 64.66 Favored 'General case' 0 N--CA 1.456 -0.167 0 O-C-N 122.048 -0.407 . . . . 0.0 110.532 175.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 tt -67.43 -16.1 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 123.028 0.531 . . . . 0.0 110.908 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -130.66 -22.33 2.69 Favored 'General case' 0 C--N 1.341 0.198 0 CA-C-N 118.162 0.437 . . . . 0.0 111.915 177.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 66.4 m-20 -70.9 -29.76 65.92 Favored 'General case' 0 C--O 1.232 0.151 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 176.464 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 52.4 t -67.93 -40.8 84.02 Favored 'Isoleucine or valine' 0 C--N 1.34 0.156 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 174.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -67.6 -32.04 72.5 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 113.086 0.772 . . . . 0.0 113.086 176.13 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 54.5 m -65.75 -24.64 67.0 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.993 -0.094 . . . . 0.0 110.819 175.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 14.3 tmtt? -74.5 -34.56 63.09 Favored 'General case' 0 CA--C 1.531 0.25 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 173.091 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . 0.42 ' CD1' ' HA ' ' B' ' 70' ' ' ALA . 40.0 m-85 -72.04 -20.86 61.62 Favored 'General case' 0 CA--C 1.529 0.169 0 N-CA-C 115.582 1.697 . . . . 0.0 115.582 175.496 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 161.72 -169.43 37.17 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 178.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.41 108.51 17.26 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 120.778 0.323 . . . . 0.0 111.174 -177.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.55 147.66 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.157 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 173.308 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -115.3 -24.05 8.63 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 119.384 -0.341 . . . . 0.0 111.209 177.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -151.38 158.78 44.2 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 114.071 1.137 . . . . 0.0 114.071 -179.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 10.9 tp -124.28 159.67 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 176.318 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -153.19 63.28 0.76 Allowed 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.826 0.346 . . . . 0.0 110.752 -177.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.1 tp -63.37 135.89 57.28 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 175.198 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.524 ' HE2' ' CZ ' ' B' ' 56' ' ' PHE . 35.5 mtmm -141.09 176.43 8.83 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 123.795 0.838 . . . . 0.0 111.239 -178.327 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -144.16 177.85 8.3 Favored 'General case' 0 C--O 1.233 0.21 0 C-N-CA 122.928 0.491 . . . . 0.0 110.661 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 52.6 ttp180 -146.88 161.17 41.27 Favored 'General case' 0 C--O 1.232 0.171 0 C-N-CA 123.15 0.58 . . . . 0.0 109.601 -177.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 23.1 mmm180 -69.14 1.0 3.98 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 123.259 0.624 . . . . 0.0 112.218 -178.258 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -167.28 158.77 31.86 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 178.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.54 178.97 37.6 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 111.641 -0.584 . . . . 0.0 111.641 -178.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.82 160.59 49.12 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 123.649 2.9 . . . . 0.0 110.684 178.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.12 172.74 12.42 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 123.837 3.025 . . . . 0.0 110.435 176.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . 0.524 ' CZ ' ' HE2' ' B' ' 48' ' ' LYS . 3.1 p90 -155.34 167.34 30.69 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -146.83 156.98 43.54 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.133 0.492 . . . . 0.0 111.74 -175.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -106.78 150.85 25.9 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 115.179 -0.919 . . . . 0.0 112.332 170.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 72.8 t -131.82 137.98 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.264 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 -179.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -122.17 118.42 28.59 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.69 0.281 . . . . 0.0 110.557 -177.234 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -85.52 151.85 23.63 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 115.39 1.626 . . . . 0.0 115.39 -177.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 40.3 tp10 -78.53 -18.4 54.78 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.379 0.672 . . . . 0.0 109.851 173.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -148.44 119.53 4.32 Favored Pre-proline 0 CA--C 1.532 0.269 0 C-N-CA 123.482 0.713 . . . . 0.0 110.072 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_exo -55.08 -20.5 24.0 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.411 2.741 . . . . 0.0 113.324 -177.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 53.3 tpt85 -69.54 -32.55 71.43 Favored 'General case' 0 C--N 1.342 0.243 0 CA-C-N 118.295 0.498 . . . . 0.0 110.971 179.578 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -74.05 -24.39 59.52 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -179.867 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.46 -24.11 64.67 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.239 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -73.79 -27.71 61.27 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 178.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 77.4 m-20 -78.04 -38.43 44.61 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 112.386 0.513 . . . . 0.0 112.386 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . 0.42 ' HA ' ' CD1' ' B' ' 39' ' ' TYR . . . -70.77 -31.05 67.71 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 110.343 -0.243 . . . . 0.0 110.343 178.389 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 37.3 t -80.6 -43.91 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 46.0 t -66.27 -20.97 66.26 Favored 'General case' 0 CA--C 1.533 0.29 0 O-C-N 122.197 -0.315 . . . . 0.0 111.127 -177.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -91.03 -15.27 56.43 Favored Glycine 0 CA--C 1.529 0.938 0 CA-C-O 119.307 -0.718 . . . . 0.0 113.17 -177.001 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 62.7 mtt180 -147.62 21.54 1.16 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.448 1.124 . . . . 0.0 113.045 -172.275 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 16.5 p30 -69.32 1.71 3.58 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 177.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.24 90.44 0.08 OUTLIER Glycine 0 C--N 1.336 0.582 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -125.53 139.49 53.56 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 178.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -64.39 106.5 1.13 Allowed 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.628 0.771 . . . . 0.0 112.65 -177.066 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.444 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.0 t80 -111.46 170.35 8.18 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 123.677 0.791 . . . . 0.0 111.446 177.348 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.444 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.1 t0 -59.15 100.9 0.08 Allowed 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -179.198 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 75.81 -5.28 40.32 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-O 119.661 -0.522 . . . . 0.0 112.888 177.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -141.43 -169.49 2.88 Favored 'General case' 0 C--O 1.232 0.161 0 N-CA-C 113.513 0.931 . . . . 0.0 113.513 -177.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 42.2 ttp-105 -142.04 139.31 32.29 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.672 0.789 . . . . 0.0 109.162 179.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.72 151.15 45.85 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 -178.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 90.1 mtm-85 -133.61 56.17 1.86 Allowed 'General case' 0 C--N 1.339 0.135 0 CA-C-O 120.75 0.31 . . . . 0.0 110.799 177.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 23.1 t -82.21 93.95 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 175.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.9 pt-20 -151.9 162.72 40.6 Favored 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 122.51 0.324 . . . . 0.0 110.205 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.4 p90 -78.09 157.56 78.4 Favored Pre-proline 0 N--CA 1.453 -0.306 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 177.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo . . . . . 0 C--O 1.252 1.219 0 C-N-CA 123.903 3.069 . . . . 0.0 111.658 177.45 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.379 1 O4'-C1'-N19 112.554 4.354 . 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.908 0 O4'-C1'-N19 111.828 3.628 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.469 " H4'" ' CE1' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.421 -2.643 0 O4'-C1'-N19 111.395 3.195 . 0.133 2z . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.462 ' C4 ' ' HA3' ' B' ' 9' ' ' GLY . . . . . . . . 0 O4'--C4' 1.42 -2.75 0 O4'-C1'-N19 111.098 2.898 . 0.368 4g . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.298 0 C5'-C4'-C3' 110.208 -3.528 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.025 0 C5'-C4'-C3' 109.924 -3.717 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 4.6 p . . . . . 0 N--CA 1.477 0.909 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 1.7 mt -86.05 -2.16 7.75 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 C-N-CA 122.61 0.364 . . . . 0.0 111.24 -177.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 1.2 tmm_? -60.79 141.8 56.64 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 122.474 0.31 . . . . 0.0 110.457 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 57.8 -145.88 39.35 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 176.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -76.31 43.24 1.14 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 124.27 3.313 . . . . 0.0 110.273 175.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 59.39 13.36 3.14 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 124.2 1.0 . . . . 0.0 112.064 -173.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -93.15 175.95 36.88 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 176.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -154.86 125.46 6.96 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 122.404 -0.468 . . . . 0.0 110.168 178.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 56.4 t-20 -163.61 139.41 6.58 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 177.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -77.52 -11.07 59.81 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.074 0.398 . . . . 0.0 112.074 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 75.2 m -79.24 1.76 23.6 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 122.835 0.454 . . . . 0.0 111.34 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 48.8 mtt-85 -78.51 151.1 32.73 Favored 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 112.705 0.631 . . . . 0.0 112.705 -177.164 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.4 pt -139.14 171.59 14.44 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 C-N-CA 123.507 0.723 . . . . 0.0 109.524 174.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.441 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.3 OUTLIER -113.21 153.12 28.86 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -175.99 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 58.7 t -136.77 140.89 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.317 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -146.87 174.62 26.63 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.925 -0.47 . . . . 0.0 111.925 -176.504 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 66.3 t30 62.91 157.35 0.06 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.772 1.229 . . . . 0.0 111.463 -172.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.2 tp -81.65 130.41 61.49 Favored Pre-proline 0 N--CA 1.453 -0.306 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -69.93 165.17 32.07 Favored 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.344 2.696 . . . . 0.0 110.822 176.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -56.59 -26.16 63.01 Favored 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 123.737 2.958 . . . . 0.0 111.894 179.022 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 40.4 p-10 -157.14 162.85 39.39 Favored 'General case' 0 C--O 1.233 0.192 0 C-N-CA 123.368 0.667 . . . . 0.0 110.457 175.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 6.4 tp -151.99 142.63 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 110.105 -0.332 . . . . 0.0 110.105 -179.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 81.8 mtt85 -140.02 31.15 1.99 Allowed 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 123.558 0.743 . . . . 0.0 110.135 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . 0.25 1.0 OUTLIER 59.59 7.78 1.1 Allowed 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 115.749 1.759 . . . . 0.0 115.749 -178.916 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.427 ' HE3' ' HB2' ' B' ' 30' ' ' LYS . 0.0 OUTLIER -151.43 -6.6 0.25 Allowed 'General case' 0 C--N 1.339 0.126 0 O-C-N 122.435 -0.166 . . . . 0.0 111.427 177.359 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -64.65 -19.75 65.89 Favored 'General case' 0 N--CA 1.457 -0.112 0 O-C-N 122.116 -0.365 . . . . 0.0 111.979 178.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 7.5 tp -71.64 -17.69 19.59 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 175.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 81.6 mt-10 -94.96 -36.52 11.55 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -69.52 -39.97 77.2 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -177.023 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 77.1 t -72.14 -41.89 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.075 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 39.0 m-85 -74.06 -37.78 64.16 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 114.02 1.119 . . . . 0.0 114.02 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 91.7 p -69.21 -22.12 63.9 Favored 'General case' 0 C--N 1.34 0.175 0 CA-C-N 117.729 0.241 . . . . 0.0 110.422 177.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -74.73 -34.06 62.49 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -81.22 -13.26 58.72 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 115.926 1.825 . . . . 0.0 115.926 177.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.16 175.37 43.47 Favored Glycine 0 CA--C 1.527 0.819 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.053 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -82.27 80.02 8.58 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.097 0.559 . . . . 0.0 110.601 -178.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.7 mp -65.51 140.22 20.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.105 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 174.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . 0.407 ' HA ' ' HE ' ' B' ' 43' ' ' ARG . 1.7 mmp_? -109.76 -27.84 9.12 Favored 'General case' 0 N--CA 1.457 -0.082 0 C-N-CA 122.869 0.467 . . . . 0.0 110.739 177.361 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -151.79 163.43 39.18 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 113.815 1.042 . . . . 0.0 113.815 -179.223 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 7.6 tp -142.17 160.56 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -177.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -153.95 68.55 0.76 Allowed 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 176.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 49.0 tp -69.3 133.31 47.71 Favored 'General case' 0 CA--C 1.529 0.141 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 175.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.461 ' HD2' ' CZ ' ' B' ' 56' ' ' PHE . 67.3 mttm -126.5 128.84 47.55 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 122.559 0.344 . . . . 0.0 110.542 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -161.2 -36.41 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.124 175.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 51.5 tpt85 -84.03 -21.16 31.71 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 122.719 0.408 . . . . 0.0 110.62 177.2 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 82.9 mtm180 -82.89 14.12 3.47 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.263 0.625 . . . . 0.0 111.621 179.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.73 174.57 44.32 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 111.671 -0.572 . . . . 0.0 111.671 176.37 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.53 176.47 32.81 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.504 -0.639 . . . . 0.0 111.504 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.24 161.3 45.2 Favored 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 123.639 2.892 . . . . 0.0 109.772 176.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -68.0 120.82 7.8 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 123.021 2.48 . . . . 0.0 110.247 178.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . 0.461 ' CZ ' ' HD2' ' B' ' 48' ' ' LYS . 3.3 p90 -161.58 171.69 17.6 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 178.097 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.38 164.37 38.37 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.213 0.53 . . . . 0.0 111.691 -175.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . 0.4 ' CZ ' ' HB2' ' B' ' 19' ' ' TYR . 9.7 m-85 -116.81 151.62 36.11 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.372 -0.831 . . . . 0.0 113.073 169.396 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 48.2 t -133.41 142.23 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 C-N-CA 123.189 0.596 . . . . 0.0 109.62 -177.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -123.99 117.82 25.62 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 110.444 -0.206 . . . . 0.0 110.444 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 49.3 m-85 -90.33 158.27 17.22 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 113.774 1.027 . . . . 0.0 113.774 177.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -70.77 -24.28 62.56 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 174.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -152.64 155.52 32.64 Favored Pre-proline 0 CA--C 1.533 0.314 0 C-N-CA 123.367 0.667 . . . . 0.0 111.952 178.511 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -71.92 -7.74 21.65 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 123.054 2.502 . . . . 0.0 111.359 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.28 -53.93 14.77 Favored 'General case' 0 C--N 1.339 0.12 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -177.112 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -70.75 -20.22 62.65 Favored 'General case' 0 C--O 1.233 0.185 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -177.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.05 -23.92 65.93 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 45.6 tp10 -72.77 -32.48 65.64 Favored 'General case' 0 N--CA 1.455 -0.2 0 O-C-N 122.273 -0.267 . . . . 0.0 110.318 179.539 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 62.0 m-20 -73.49 -36.8 65.84 Favored 'General case' 0 CA--C 1.522 -0.116 0 N-CA-C 111.979 0.362 . . . . 0.0 111.979 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.8 -27.92 63.26 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 122.164 0.186 . . . . 0.0 110.557 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 42.6 t -83.19 -54.32 9.49 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.2 t -70.68 -18.91 62.83 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 -174.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -101.31 0.54 53.91 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-O 119.031 -0.872 . . . . 0.0 113.585 -173.04 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 28.9 ttp-105 -153.78 -13.18 0.14 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-N 118.846 1.323 . . . . 0.0 113.393 -175.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -67.68 145.69 54.53 Favored 'General case' 0 C--O 1.233 0.226 0 O-C-N 121.465 -0.772 . . . . 0.0 110.315 179.485 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.51 55.17 26.95 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.554 -0.618 . . . . 0.0 111.554 175.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 39.2 t80 -105.96 140.38 39.06 Favored 'General case' 0 N--CA 1.453 -0.288 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -178.094 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -62.91 110.55 1.81 Allowed 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 124.2 1.0 . . . . 0.0 113.012 -175.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.421 ' CD2' ' N ' ' B' ' 80' ' ' ASP . 25.6 t80 -118.88 165.93 13.45 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 123.66 0.784 . . . . 0.0 111.941 174.756 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.421 ' N ' ' CD2' ' B' ' 79' ' ' TYR . 19.4 t0 -59.07 98.09 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.436 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -178.661 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.9 -4.91 63.79 Favored Glycine 0 CA--C 1.535 1.285 0 CA-C-O 119.747 -0.474 . . . . 0.0 112.677 177.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -140.56 -170.22 2.96 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 117.952 0.876 . . . . 0.0 113.15 -178.185 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 -141.38 133.35 27.59 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 -178.158 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -65.13 152.03 44.6 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.27 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -125.72 126.92 45.39 Favored 'General case' 0 CA--C 1.52 -0.173 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 175.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 38.9 t -143.95 81.26 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.245 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 176.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -139.8 158.22 44.45 Favored 'General case' 0 C--O 1.224 -0.281 0 C-N-CA 122.664 0.386 . . . . 0.0 110.551 -175.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.0 p90 -74.54 154.79 87.64 Favored Pre-proline 0 N--CA 1.454 -0.269 0 N-CA-C 114.73 1.381 . . . . 0.0 114.73 179.245 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo . . . . . 0 C--O 1.253 1.255 0 C-N-CA 123.646 2.897 . . . . 0.0 110.877 176.937 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -2.987 0 C3'-C2'-C1' 104.46 3.289 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.063 0 C3'-C2'-C1' 104.673 3.525 . 0.171 0b . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.446 " H4'" ' CE1' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.422 -2.607 0 C5'-C4'-C3' 110.752 -3.165 . 0.048 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.358 0 C5'-C4'-C3' 110.079 -3.614 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.518 0 O4'-C1'-N19 110.745 2.545 OUTLIER-DELTA 0.0 OUTLIER delta 0.0 . . . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.792 0 C5'-C4'-C3' 110.208 -3.528 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.2 t . . . . . 0 N--CA 1.476 0.87 0 N-CA-C 111.585 0.217 . . . . 0.0 111.585 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 85.7 mt -66.4 -31.69 54.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 122.261 0.224 . . . . 0.0 111.438 -175.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 7.0 tpp180 -158.25 159.5 36.08 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 122.436 0.294 . . . . 0.0 110.267 -178.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . -64.12 167.91 25.9 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 176.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.42 149.4 84.71 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 123.292 2.661 . . . . 0.0 109.433 174.337 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -156.94 164.35 38.13 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-O 120.878 0.37 . . . . 0.0 111.442 -176.21 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -157.65 5.86 0.17 Allowed Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 177.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 59.4 t30 -148.1 158.88 44.31 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.895 0.878 . . . . 0.0 109.364 -179.175 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 74.8 m-20 -73.66 140.95 46.46 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 178.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 40.75 -134.05 0.26 Allowed 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.876 0.695 . . . . 0.0 112.876 -178.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 86.6 m 59.27 7.58 0.94 Allowed 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 178.085 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 68.5 mtm-85 -87.76 138.21 31.66 Favored 'General case' 0 N--CA 1.453 -0.316 0 O-C-N 122.1 -0.375 . . . . 0.0 111.336 178.618 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.6 pp -138.05 168.89 19.48 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 C-N-CA 123.148 0.579 . . . . 0.0 110.072 176.128 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.439 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.4 OUTLIER -113.33 153.31 28.71 Favored 'General case' 0 CA--C 1.528 0.104 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -177.228 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 93.0 t -133.99 115.21 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -117.56 169.95 13.38 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 177.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 61.1 t30 57.99 23.68 10.21 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.704 0.801 . . . . 0.0 111.113 -175.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 21.2 tp -65.39 127.05 92.61 Favored Pre-proline 0 CA--C 1.535 0.374 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 178.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -71.21 154.46 61.76 Favored 'Trans proline' 0 N--CA 1.451 -0.98 0 C-N-CA 123.075 2.516 . . . . 0.0 110.824 -178.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -71.26 -12.52 30.03 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 123.44 2.76 . . . . 0.0 111.233 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 -77.56 -1.91 33.04 Favored 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 178.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 9.1 tp -67.12 158.62 5.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 C-N-CA 122.596 0.358 . . . . 0.0 110.321 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 76.5 mtt85 -132.19 152.58 51.22 Favored 'General case' 0 N--CA 1.457 -0.09 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 176.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.43 -17.78 60.15 Favored 'General case' 0 C--N 1.334 -0.101 0 N-CA-C 114.262 1.208 . . . . 0.0 114.262 -177.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 4.2 ttpt -97.03 -30.56 12.99 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 122.329 0.251 . . . . 0.0 110.714 178.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -69.23 -31.79 70.58 Favored 'General case' 0 C--O 1.233 0.189 0 O-C-N 122.169 -0.332 . . . . 0.0 111.581 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.4 tt -76.48 -11.24 13.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 O-C-N 123.169 0.293 . . . . 0.0 110.99 -178.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -118.97 -0.56 11.14 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 117.833 0.288 . . . . 0.0 110.807 177.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -94.49 -62.41 1.33 Allowed 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 122.551 0.34 . . . . 0.0 111.674 177.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 62.9 t -65.4 -41.12 90.4 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 -178.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -62.94 -31.03 72.03 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.4 t -68.07 -30.8 70.08 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 110.228 -0.286 . . . . 0.0 110.228 177.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 47.1 mmtm -69.35 -28.28 66.08 Favored 'General case' 0 C--N 1.338 0.082 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 173.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -80.18 -19.11 47.86 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 116.665 2.098 . . . . 0.0 116.665 176.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.49 20.24 0.03 OUTLIER Glycine 0 CA--C 1.53 0.99 0 C-N-CA 119.584 -1.293 . . . . 0.0 114.64 -177.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 50.85 66.69 1.1 Allowed 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 118.279 1.039 . . . . 0.0 111.987 176.423 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.7 mp -56.02 141.95 11.83 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 C-N-CA 122.951 0.5 . . . . 0.0 110.447 178.054 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . 0.409 HH11 ' HD3' ' B' ' 43' ' ' ARG . 10.6 mmm180 -107.05 -24.7 11.88 Favored 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 122.603 0.361 . . . . 0.0 111.262 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -146.59 155.25 42.34 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . 0.4 HG22 ' H ' ' B' ' 47' ' ' LEU . 17.7 mm -139.13 154.36 25.5 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 C-N-CA 124.203 1.001 . . . . 0.0 109.407 -178.21 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -142.38 47.67 1.58 Allowed 'General case' 0 CA--C 1.531 0.233 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 177.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . 0.4 ' H ' HG22 ' B' ' 45' ' ' ILE . 58.7 tp -61.5 128.21 35.19 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.55 177.626 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.535 ' HE2' ' CZ ' ' B' ' 56' ' ' PHE . 23.2 pttm -157.74 173.14 17.27 Favored 'General case' 0 CA--C 1.528 0.102 0 C-N-CA 123.551 0.74 . . . . 0.0 109.691 179.04 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 50.8 p30 -146.78 11.28 1.08 Allowed 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -174.445 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 19.5 mtp180 50.53 24.46 1.63 Allowed 'General case' 0 C--N 1.341 0.219 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -179.054 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 63.6 mtm-85 56.1 19.93 4.07 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.399 0.68 . . . . 0.0 112.586 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.88 145.42 7.91 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.43 -179.03 49.15 Favored Glycine 0 CA--C 1.53 0.97 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -176.39 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -68.0 147.16 73.35 Favored 'Trans proline' 0 N--CA 1.451 -1.001 0 C-N-CA 123.665 2.91 . . . . 0.0 110.397 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.22 164.69 34.87 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 123.362 2.708 . . . . 0.0 110.945 -179.296 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . 0.535 ' CZ ' ' HE2' ' B' ' 48' ' ' LYS . 4.2 p90 -157.24 163.07 39.17 Favored 'General case' 0 C--O 1.234 0.25 0 N-CA-C 104.696 -2.335 . . . . 0.0 104.696 174.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.17 152.88 29.94 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 119.713 -0.795 . . . . 0.0 112.611 -172.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -96.5 148.24 23.02 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.707 166.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 58.5 t -133.98 143.8 37.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -178.439 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -132.21 118.39 19.47 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 120.956 0.408 . . . . 0.0 110.763 -176.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 34.5 m-85 -86.96 161.97 17.93 Favored 'General case' 0 C--N 1.333 -0.115 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -177.436 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -79.98 -27.92 39.59 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.425 174.36 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -138.51 143.51 38.62 Favored Pre-proline 0 C--N 1.34 0.182 0 C-N-CA 123.85 0.86 . . . . 0.0 112.006 179.055 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -73.83 -19.7 20.64 Favored 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 123.281 2.654 . . . . 0.0 111.257 -177.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 78.7 mtt85 -74.18 -25.23 59.59 Favored 'General case' 0 N--CA 1.456 -0.136 0 C-N-CA 122.398 0.279 . . . . 0.0 111.381 -178.154 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -91.96 -21.89 20.3 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.642 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.73 -27.06 66.48 Favored 'General case' 0 N--CA 1.453 -0.276 0 O-C-N 122.274 -0.267 . . . . 0.0 110.282 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -73.55 -26.66 60.95 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 121.9 0.08 . . . . 0.0 110.848 179.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -77.25 -36.23 54.67 Favored 'General case' 0 CA--C 1.521 -0.14 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.84 -29.06 61.92 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 122.259 0.224 . . . . 0.0 110.439 177.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 17.2 t -80.94 -42.81 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 43.8 t -66.97 -21.83 65.95 Favored 'General case' 0 CA--C 1.528 0.108 0 O-C-N 122.177 -0.327 . . . . 0.0 111.063 -178.156 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -89.66 -2.88 75.15 Favored Glycine 0 CA--C 1.531 1.071 0 CA-C-O 119.387 -0.674 . . . . 0.0 112.92 -178.361 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 80.3 mtt85 -141.93 -8.48 0.92 Allowed 'General case' 0 C--N 1.341 0.211 0 CA-C-N 118.181 0.99 . . . . 0.0 112.827 -174.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -67.3 118.64 10.95 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -179.286 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.81 45.37 96.35 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 175.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 53.9 t80 -95.97 135.94 37.06 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -172.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.6 t0 -63.51 105.33 0.76 Allowed 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.52 0.728 . . . . 0.0 112.557 -177.506 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.434 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 62.8 t80 -111.72 171.05 7.72 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.733 0.813 . . . . 0.0 111.301 177.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.434 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 19.7 t0 -60.5 98.83 0.07 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -179.464 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 77.88 -4.69 56.57 Favored Glycine 0 CA--C 1.536 1.35 0 CA-C-O 119.474 -0.626 . . . . 0.0 112.938 177.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -140.93 -171.14 3.19 Favored 'General case' 0 N--CA 1.462 0.148 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 41.7 ttp-105 -145.08 131.07 19.24 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.86 0.864 . . . . 0.0 109.334 -178.107 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.9 mp -66.62 153.79 42.18 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-O 120.923 0.392 . . . . 0.0 110.477 -175.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 52.8 mtm180 -129.47 47.27 2.51 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.457 0.703 . . . . 0.0 110.167 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 88.3 t -77.32 98.43 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 175.088 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -151.09 162.49 40.75 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.629 0.252 . . . . 0.0 110.655 179.178 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -73.05 152.51 90.71 Favored Pre-proline 0 C--O 1.234 0.24 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 178.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo . . . . . 0 C--O 1.251 1.15 0 C-N-CA 123.739 2.959 . . . . 0.0 110.735 177.836 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.944 0 C3'-C2'-C1' 105.006 3.895 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.427 -2.2 0 O4'-C1'-N19 111.411 3.211 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.439 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.352 1 C5'-C4'-C3' 108.176 -4.883 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.402 0 O4'-C1'-N19 112.114 3.914 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.416 0 C5'-C4'-C3' 109.573 -3.951 OUTLIER-DELTA 0.0 OUTLIER delta 0.0 . . . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.415 -3.174 0 O4'-C1'-N19 110.899 2.699 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 111.512 0.189 . . . . 0.0 111.512 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 64.5 mt -79.95 144.61 10.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 177.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 8.5 tmm_? -67.95 164.77 19.18 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 122.902 0.481 . . . . 0.0 110.372 -179.139 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . -44.3 141.33 3.35 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 123.91 0.767 . . . . 0.0 112.114 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -70.41 -2.52 10.78 Favored 'Trans proline' 0 N--CA 1.452 -0.929 0 C-N-CA 123.637 2.891 . . . . 0.0 111.602 178.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -63.82 158.8 20.99 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 122.421 0.288 . . . . 0.0 110.665 179.031 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.66 170.05 49.34 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -178.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -81.56 -162.32 0.51 Allowed 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 123.346 0.659 . . . . 0.0 110.929 -178.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 54.8 m-20 65.26 164.49 0.16 Allowed 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 124.831 1.252 . . . . 0.0 112.464 -177.441 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -73.8 7.23 2.64 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -175.203 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 76.4 m -70.54 -14.59 62.57 Favored 'General case' 0 CA--C 1.532 0.28 0 O-C-N 122.373 -0.205 . . . . 0.0 110.732 178.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 18.4 ttm180 -84.25 152.65 24.05 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 178.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 15.3 pt -136.17 -178.77 2.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.141 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 175.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.434 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.9 OUTLIER -122.58 148.76 44.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.452 -0.794 . . . . 0.0 112.762 177.226 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 21.2 t -137.9 90.47 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 120.451 0.167 . . . . 0.0 110.755 -176.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -80.8 146.5 27.0 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 174.658 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 44.7 t30 58.28 -171.12 0.11 Allowed 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 122.786 0.434 . . . . 0.0 110.292 -174.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -143.77 149.24 45.87 Favored Pre-proline 0 CA--C 1.534 0.338 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 177.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.96 155.62 61.66 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 123.435 2.757 . . . . 0.0 110.633 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_exo -62.5 -28.98 78.16 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 123.118 2.545 . . . . 0.0 111.239 177.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -91.8 123.07 34.9 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.638 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -158.27 140.58 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.11 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.546 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 60.6 mtm180 -136.41 19.56 3.14 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 122.795 0.438 . . . . 0.0 111.267 178.014 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 58.71 18.7 6.15 Favored 'General case' 0 N--CA 1.462 0.169 0 N-CA-C 114.204 1.186 . . . . 0.0 114.204 -176.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.42 ' HE3' ' HB2' ' B' ' 34' ' ' ASP . 30.8 ttpt -150.64 -8.59 0.26 Allowed 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 123.418 0.687 . . . . 0.0 110.072 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -58.83 -23.67 60.91 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -179.004 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 27.7 mm -74.8 -17.49 16.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 122.653 0.381 . . . . 0.0 110.636 179.565 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -126.42 13.53 7.63 Favored 'General case' 0 C--N 1.34 0.159 0 CA-C-N 117.772 0.26 . . . . 0.0 111.052 178.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . 0.42 ' HB2' ' HE3' ' B' ' 30' ' ' LYS . 22.0 t0 -127.93 -60.86 1.14 Allowed 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 173.011 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 95.1 t -69.55 -53.18 26.03 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -65.14 -19.3 65.92 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 175.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 47.5 t -71.57 -28.94 64.19 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 175.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -74.82 -26.93 60.06 Favored 'General case' 0 CA--C 1.529 0.144 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 171.154 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -73.55 -23.78 60.03 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 115.928 1.825 . . . . 0.0 115.928 174.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.57 16.48 0.03 OUTLIER Glycine 0 CA--C 1.53 1.026 0 C-N-CA 120.219 -0.991 . . . . 0.0 114.074 -177.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.21 77.28 0.14 Allowed 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 117.886 0.843 . . . . 0.0 112.191 176.774 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.8 mp -60.07 142.32 15.56 Favored 'Isoleucine or valine' 0 C--O 1.232 0.138 0 C-N-CA 122.742 0.417 . . . . 0.0 110.225 177.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . 0.485 ' HE ' ' HA ' ' B' ' 62' ' ' GLU . 48.6 mtm105 -102.96 -30.99 10.45 Favored 'General case' 0 CA--C 1.523 -0.063 0 C-N-CA 122.393 0.277 . . . . 0.0 111.177 176.272 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -149.67 158.26 44.0 Favored 'General case' 0 C--O 1.232 0.134 0 N-CA-C 114.002 1.112 . . . . 0.0 114.002 -177.057 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 53.4 mt -125.59 150.8 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.149 0 C-N-CA 123.7 0.8 . . . . 0.0 109.098 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -141.01 50.71 1.63 Allowed 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 54.8 tp -60.55 135.58 57.8 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.099 177.034 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 25.3 ttmm -143.77 152.36 41.14 Favored 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 122.886 0.475 . . . . 0.0 110.116 -179.095 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 44.4 p30 -135.09 4.45 3.23 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 122.61 0.364 . . . . 0.0 111.949 -178.345 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 24.3 tpt180 -64.87 -15.75 62.33 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 122.783 0.433 . . . . 0.0 110.096 177.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 66.1 ttt-85 -65.71 -22.38 66.61 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.256 1.023 . . . . 0.0 111.225 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 75.67 165.36 17.22 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -174.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.21 -150.57 46.53 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -177.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -55.79 147.71 59.89 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 123.219 2.613 . . . . 0.0 110.934 175.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.82 167.79 24.81 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 123.48 2.787 . . . . 0.0 110.918 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -154.11 164.5 38.39 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 175.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -153.11 165.5 35.44 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-O 120.935 0.398 . . . . 0.0 111.883 -173.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -121.37 79.52 1.55 Allowed 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.471 175.02 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.5 t -67.49 147.48 12.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 C-N-CA 123.23 0.612 . . . . 0.0 110.19 -174.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -123.84 122.32 37.7 Favored 'General case' 0 CA--C 1.529 0.161 0 CA-C-O 120.825 0.345 . . . . 0.0 110.804 -178.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -94.58 164.92 12.78 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 115.464 1.653 . . . . 0.0 115.464 -175.322 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . 0.485 ' HA ' ' HE ' ' B' ' 43' ' ' ARG . 85.0 tt0 -73.58 -32.18 63.99 Favored 'General case' 0 C--N 1.34 0.183 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.661 174.332 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -141.59 145.82 39.02 Favored Pre-proline 0 CA--C 1.529 0.149 0 C-N-CA 123.771 0.828 . . . . 0.0 111.955 179.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -73.77 -19.58 20.92 Favored 'Trans proline' 0 N--CA 1.452 -0.941 0 C-N-CA 123.179 2.586 . . . . 0.0 110.841 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.74 -35.43 57.77 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 122.122 0.169 . . . . 0.0 110.838 -178.569 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -77.51 -17.72 57.71 Favored 'General case' 0 CA--C 1.527 0.083 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 178.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.53 -20.95 64.59 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 177.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -70.31 -34.25 72.48 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 177.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -75.83 -34.12 60.1 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.03 -31.69 64.6 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 178.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 7.5 t -73.69 -42.37 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 67.0 m -74.78 -0.49 18.43 Favored 'General case' 0 C--O 1.232 0.152 0 C-N-CA 122.136 0.175 . . . . 0.0 111.056 179.278 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -73.16 -35.66 57.02 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 119.487 -0.619 . . . . 0.0 112.756 -175.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 23.6 ttt180 -163.15 30.39 0.09 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.194 0.997 . . . . 0.0 111.631 -176.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -65.0 144.29 57.39 Favored 'General case' 0 C--O 1.232 0.14 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -179.607 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 57.78 46.47 92.27 Favored Glycine 0 C--N 1.338 0.656 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 174.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . 0.541 ' H ' ' HB2' ' B' ' 84' ' ' LEU . 16.7 t80 -98.67 137.42 37.33 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.673 0.736 . . . . 0.0 112.853 -173.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -67.95 83.35 0.21 Allowed 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 124.29 1.036 . . . . 0.0 112.059 -177.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.449 ' CD2' ' N ' ' B' ' 80' ' ' ASP . 54.2 t80 -82.89 171.31 14.02 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 123.199 0.6 . . . . 0.0 111.218 177.532 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.449 ' N ' ' CD2' ' B' ' 79' ' ' TYR . 24.9 t0 -64.5 93.84 0.11 Allowed 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.96 -1.81 88.33 Favored Glycine 0 CA--C 1.53 0.997 0 CA-C-O 119.762 -0.465 . . . . 0.0 112.615 177.244 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -141.93 -172.69 3.62 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 117.876 0.838 . . . . 0.0 112.669 -179.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 4.6 tpt180 -137.59 133.78 34.81 Favored 'General case' 0 C--O 1.232 0.143 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . 0.541 ' HB2' ' H ' ' B' ' 77' ' ' TYR . 4.2 mm? -64.66 139.23 58.74 Favored 'General case' 0 C--N 1.333 -0.117 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 95.3 mtm-85 -129.04 54.98 1.76 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 122.701 0.4 . . . . 0.0 110.288 175.517 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 2.7 p -81.28 97.64 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 175.017 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -153.68 169.49 23.18 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 122.875 0.47 . . . . 0.0 110.686 -179.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -65.26 151.72 93.32 Favored Pre-proline 0 CA--C 1.53 0.203 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo . . . . . 0 C--O 1.25 1.107 0 C-N-CA 123.678 2.918 . . . . 0.0 110.761 177.221 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.07 0 C5'-C4'-C3' 109.934 -3.71 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.446 0 C5'-C4'-C3' 110.149 -3.567 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.434 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.421 -2.652 0 C5'-C4'-C3' 109.719 -3.854 . 0.274 4p . 0.0 . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.412 " H3'" H5'' ' A' ' 94' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.425 -2.369 0 C5'-C4'-C3' 110.343 -3.438 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . 0.412 H5'' " H3'" ' A' ' 93' ' ' ' A' . . . . . . . . 0 P--O5' 1.617 2.383 0 C5'-C4'-C3' 109.74 -3.84 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.498 0 O4'-C1'-N19 112.025 3.825 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 19.5 t . . . . . 0 N--CA 1.476 0.836 0 CA-C-O 119.861 -0.114 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 31.4 mt 52.99 94.5 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 124.722 1.209 . . . . 0.0 111.527 -177.004 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.451 ' HD3' ' H ' ' B' ' 9' ' ' GLY . 17.8 tpp85 62.08 170.36 0.12 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.042 1.337 . . . . 0.0 112.149 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . 0.451 ' H ' ' HD3' ' B' ' 8' ' ' ARG . . . -64.35 166.86 29.07 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.66 -0.576 . . . . 0.0 111.66 -176.696 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -56.8 153.33 37.53 Favored 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 123.949 3.099 . . . . 0.0 111.638 179.144 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 56.67 16.03 2.43 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 123.956 0.902 . . . . 0.0 112.687 -179.314 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 69.72 -168.91 45.88 Favored Glycine 0 CA--C 1.528 0.859 0 N-CA-C 111.763 -0.535 . . . . 0.0 111.763 178.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -71.06 147.53 48.44 Favored 'General case' 0 N--CA 1.453 -0.278 0 O-C-N 122.516 -0.402 . . . . 0.0 111.296 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 63.1 t30 -159.55 170.29 21.98 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 175.561 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 20.5 p30 -77.91 177.06 8.54 Favored 'General case' 0 CA--C 1.533 0.288 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 179.102 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 73.9 m 61.15 13.32 4.65 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 176.155 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 54.6 mtm180 -82.16 145.26 30.2 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 118.422 0.555 . . . . 0.0 111.305 175.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 22.8 pt -138.62 175.73 7.77 Favored 'Isoleucine or valine' 0 C--O 1.231 0.095 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 170.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.452 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.6 OUTLIER -119.34 148.82 42.75 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 114.553 1.316 . . . . 0.0 114.553 -177.839 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 60.7 t -132.88 136.58 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 123.226 0.61 . . . . 0.0 109.634 179.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -140.52 172.15 23.69 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 51.2 t30 57.07 19.74 4.95 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.729 0.812 . . . . 0.0 111.41 -174.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.7 tp -61.42 130.61 91.99 Favored Pre-proline 0 N--CA 1.454 -0.258 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -67.2 146.09 74.89 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 122.545 2.163 . . . . 0.0 110.766 -177.052 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.86 -7.54 21.3 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 C-N-CA 123.815 3.01 . . . . 0.0 111.282 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -73.07 -6.84 48.27 Favored 'General case' 0 CA--C 1.53 0.197 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 179.446 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 10.0 tp -69.04 145.91 13.05 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.335 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 59.3 ttm-85 -161.14 154.41 21.5 Favored 'General case' 0 C--N 1.34 0.167 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -178.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.1 p 51.74 -160.05 0.1 Allowed 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 113.221 0.823 . . . . 0.0 113.221 -177.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -73.27 15.38 0.23 Allowed 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.101 0.56 . . . . 0.0 112.153 -179.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -58.84 -25.48 63.27 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 179.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.9 tt -76.27 -17.87 15.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 C-N-CA 122.335 0.254 . . . . 0.0 110.511 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.1 mt-10 -93.41 -31.04 14.78 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -74.13 -37.26 64.13 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 -177.655 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 62.4 t -69.71 -46.1 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.353 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -68.79 -35.4 76.99 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 113.615 0.969 . . . . 0.0 113.615 178.064 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 33.5 t -60.9 -33.5 73.21 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 178.283 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 16.7 tppt? -73.76 -33.43 64.29 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 122.2 0.2 . . . . 0.0 110.769 177.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -87.04 -13.83 43.28 Favored 'General case' 0 C--O 1.233 0.206 0 N-CA-C 116.739 2.125 . . . . 0.0 116.739 -178.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.08 13.83 0.03 OUTLIER Glycine 0 CA--C 1.527 0.843 0 C-N-CA 119.906 -1.14 . . . . 0.0 114.254 -177.447 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.62 40.54 27.44 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 118.227 1.013 . . . . 0.0 111.806 177.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . 0.407 HD12 ' CE2' ' B' ' 61' ' ' PHE . 1.7 mp -44.25 138.33 0.97 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.182 0 C-N-CA 123.719 0.808 . . . . 0.0 111.114 179.087 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 29.8 mtp-105 -85.51 -38.91 18.03 Favored 'General case' 0 CA--C 1.523 -0.08 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.748 -178.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -144.5 159.48 42.7 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -176.439 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 8.7 tp -137.32 161.74 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -178.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -147.78 70.44 1.16 Allowed 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 177.013 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -64.14 125.53 24.8 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 176.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 39.4 mttp -139.11 164.14 30.57 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 123.547 0.739 . . . . 0.0 111.054 -178.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 51.9 t-20 -159.53 120.04 3.1 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 170.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 43.8 ttt180 -161.91 143.15 10.9 Favored 'General case' 0 C--N 1.338 0.088 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -176.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 35.1 mtm180 50.1 29.83 3.81 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 123.406 0.682 . . . . 0.0 112.24 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -161.22 172.35 37.44 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.387 -0.685 . . . . 0.0 111.387 -178.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -80.21 -83.14 0.72 Allowed Glycine 0 CA--C 1.528 0.875 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -68.96 151.87 73.49 Favored 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.711 2.941 . . . . 0.0 110.817 -179.752 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -68.83 170.96 14.25 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 123.991 3.127 . . . . 0.0 111.629 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -150.67 165.2 34.14 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 104.884 -2.265 . . . . 0.0 104.884 175.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -157.03 163.7 38.78 Favored 'General case' 0 N--CA 1.453 -0.304 0 O-C-N 121.721 -0.612 . . . . 0.0 111.922 -174.409 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . 0.489 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 74.5 m-85 -113.2 151.62 30.75 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 171.154 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 41.5 t -131.1 136.4 57.95 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 -175.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -120.55 111.68 17.98 Favored 'General case' 0 N--CA 1.455 -0.205 0 CA-C-O 120.865 0.364 . . . . 0.0 110.481 -177.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.407 ' CE2' HD12 ' B' ' 42' ' ' ILE . 37.1 m-85 -81.15 159.38 24.66 Favored 'General case' 0 CA--C 1.528 0.125 0 N-CA-C 115.347 1.61 . . . . 0.0 115.347 -176.583 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -87.73 -26.66 22.82 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 169.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -155.44 118.95 2.42 Favored Pre-proline 0 CA--C 1.532 0.258 0 C-N-CA 123.635 0.774 . . . . 0.0 109.691 -179.196 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.52 -10.54 29.08 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.31 2.673 . . . . 0.0 111.942 -174.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 41.0 ttm105 -67.45 -29.29 68.72 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 117.887 0.312 . . . . 0.0 110.542 177.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 -81.24 -16.07 53.72 Favored 'General case' 0 CA--C 1.53 0.176 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.77 -16.43 63.3 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 120.39 0.138 . . . . 0.0 110.75 -179.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -66.7 -20.27 65.93 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 122.363 -0.21 . . . . 0.0 110.6 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -104.29 -33.16 8.76 Favored 'General case' 0 C--N 1.339 0.125 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 178.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.92 -31.49 64.67 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.012 0.525 . . . . 0.0 110.571 -178.614 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 98.0 t -87.44 -48.58 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 36.0 t -67.45 -14.87 63.32 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 122.474 -0.141 . . . . 0.0 111.2 -175.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -79.19 -14.24 81.96 Favored Glycine 0 CA--C 1.529 0.958 0 CA-C-O 119.345 -0.697 . . . . 0.0 112.652 -176.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 23.4 ptt-85 -158.13 3.92 0.11 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 118.623 1.212 . . . . 0.0 113.52 -175.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -73.16 143.39 47.28 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 118.757 0.708 . . . . 0.0 110.11 176.207 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 62.22 35.64 91.86 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.697 -0.561 . . . . 0.0 111.697 175.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 49.8 t80 -96.98 137.51 35.94 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -172.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -64.03 103.86 0.65 Allowed 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 123.382 0.673 . . . . 0.0 112.361 -178.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.457 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 75.7 t80 -109.75 173.33 6.37 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.91 0.884 . . . . 0.0 111.191 179.085 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.457 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 77.2 m-20 -59.88 98.66 0.06 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -179.575 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.58 -5.89 42.54 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-O 119.666 -0.519 . . . . 0.0 112.938 177.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -139.99 -169.33 2.71 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.964 0.882 . . . . 0.0 113.344 -177.36 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 41.6 ttp-105 -143.92 133.96 24.16 Favored 'General case' 0 N--CA 1.457 -0.12 0 C-N-CA 123.615 0.766 . . . . 0.0 109.016 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -62.55 147.96 47.47 Favored 'General case' 0 C--N 1.335 -0.063 0 C-N-CA 122.571 0.348 . . . . 0.0 110.18 -178.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 57.7 ttt180 -130.86 113.74 14.43 Favored 'General case' 0 CA--C 1.517 -0.313 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 37.5 t -132.52 92.57 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.632 178.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 24.0 pt-20 -145.29 159.49 42.96 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.703 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -74.04 153.57 88.69 Favored Pre-proline 0 N--CA 1.454 -0.229 0 N-CA-C 114.854 1.427 . . . . 0.0 114.854 -179.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo . . . . . 0 C--O 1.25 1.118 0 C-N-CA 123.911 3.074 . . . . 0.0 110.714 175.98 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.468 1 O4'-C1'-N19 112.309 4.109 . 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.508 0 C5'-C4'-C3' 111.597 -2.602 . 0.669 6n . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.452 ' C6 ' ' CE1' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.323 1 C5'-C4'-C3' 109.489 -4.007 . 0.289 5p . 0.0 . . . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.489 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.399 0 O4'-C1'-N19 111.75 3.55 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.569 0 C5'-C4'-C3' 111.621 -2.586 OUTLIER-DELTA 0.0 OUTLIER gamma 0.0 . . . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.004 0 C3'-C2'-C1' 104.804 3.671 . 0.0 OUTLIER '7D dist 4p' 0.0 . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 16.5 t . . . . . 0 N--CA 1.475 0.801 0 CA-C-O 120.375 0.131 . . . . 0.0 111.013 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 94.1 mt -67.38 148.16 12.17 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 9.1 tpp180 -66.16 142.61 57.68 Favored 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 122.795 0.438 . . . . 0.0 110.976 -178.089 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . 0.402 ' N ' ' CD ' ' B' ' 10' ' ' PRO . . . 64.52 46.93 88.84 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-O 119.527 -0.596 . . . . 0.0 112.707 175.08 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 72.7 Cg_endo -73.74 -14.71 24.33 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 122.971 2.447 . . . . 0.0 110.957 -177.563 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -158.08 178.76 9.85 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 123.543 0.737 . . . . 0.0 109.863 -177.75 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -155.43 172.59 33.61 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 22.1 m120 58.71 174.22 0.07 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 124.062 0.945 . . . . 0.0 112.238 -176.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 63.8 m-20 57.5 9.5 0.79 Allowed 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 124.154 0.982 . . . . 0.0 112.353 -176.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -126.32 168.87 13.54 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.863 0.865 . . . . 0.0 111.313 -179.497 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 98.6 m -75.0 4.73 6.11 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 122.456 0.302 . . . . 0.0 111.491 177.051 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 92.8 mtt-85 -73.3 147.88 44.07 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-O 120.879 0.371 . . . . 0.0 111.854 179.462 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 20.8 pt -138.67 177.76 4.77 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 C-N-CA 123.852 0.861 . . . . 0.0 108.754 172.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.43 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.7 OUTLIER -116.9 150.54 38.3 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 114.344 1.238 . . . . 0.0 114.344 -177.285 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 47.4 t -138.65 143.3 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 C-N-CA 123.519 0.728 . . . . 0.0 109.187 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.35 178.81 34.43 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.954 -0.459 . . . . 0.0 111.954 -176.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 54.2 t30 58.54 25.52 13.21 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.195 0.998 . . . . 0.0 111.606 -176.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.6 mt -65.11 140.81 98.11 Favored Pre-proline 0 N--CA 1.454 -0.23 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.35 154.09 65.7 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 123.296 2.664 . . . . 0.0 109.898 -179.548 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.19 -17.14 35.82 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.419 2.746 . . . . 0.0 111.067 -179.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -86.98 0.61 54.86 Favored 'General case' 0 CA--C 1.529 0.156 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 tp -67.58 144.1 14.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -178.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 17.1 ttp180 -82.85 150.36 26.6 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 176.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.8 p -65.36 -0.2 1.75 Allowed 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 114.843 1.423 . . . . 0.0 114.843 -177.366 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 48.1 mtpt -136.14 5.74 3.05 Favored 'General case' 0 C--N 1.343 0.315 0 N-CA-C 113.175 0.805 . . . . 0.0 113.175 -179.071 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -62.5 -32.74 73.71 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 118.641 0.655 . . . . 0.0 112.088 175.596 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.9 tt -75.82 -16.81 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 122.787 0.435 . . . . 0.0 110.576 178.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 72.9 mt-10 -97.31 -13.67 21.79 Favored 'General case' 0 C--N 1.34 0.18 0 C-N-CA 122.181 0.193 . . . . 0.0 110.684 -179.456 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -103.17 -67.69 0.87 Allowed 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -175.566 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 3.7 p -73.81 -37.27 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 N-CA-C 112.493 0.553 . . . . 0.0 112.493 -172.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 70.7 m-85 -73.15 -25.98 61.03 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 112.773 0.656 . . . . 0.0 112.773 177.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 42.8 t -72.37 -30.27 64.54 Favored 'General case' 0 N--CA 1.456 -0.166 0 N-CA-C 110.305 -0.257 . . . . 0.0 110.305 176.348 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . 0.583 ' HZ2' ' HB2' ' B' ' 38' ' ' LYS . 0.2 OUTLIER -73.37 -29.48 62.66 Favored 'General case' 0 N--CA 1.455 -0.208 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 174.72 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -81.01 -20.4 41.84 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 116.144 1.905 . . . . 0.0 116.144 179.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.1 14.4 0.76 Allowed Glycine 0 CA--C 1.527 0.783 0 C-N-CA 120.707 -0.758 . . . . 0.0 113.851 -175.113 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.67 38.49 22.88 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 117.858 0.829 . . . . 0.0 111.261 178.002 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 81.8 mt -45.47 138.67 1.3 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.151 0 C-N-CA 123.338 0.655 . . . . 0.0 111.387 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 28.6 mmt180 -104.63 -22.56 13.22 Favored 'General case' 0 N--CA 1.455 -0.204 0 C-N-CA 122.884 0.474 . . . . 0.0 111.668 -178.141 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -152.4 154.16 35.04 Favored 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 118.352 0.524 . . . . 0.0 112.112 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 2.8 mp -136.52 148.03 27.32 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.085 0 C-N-CA 123.884 0.874 . . . . 0.0 109.326 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -140.95 57.2 1.56 Allowed 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 122.694 0.398 . . . . 0.0 110.278 179.297 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 57.8 tp -60.16 129.25 40.79 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.154 175.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 43.0 mttp -120.13 143.59 48.1 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 123.634 0.774 . . . . 0.0 110.672 179.204 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 49.7 p30 -81.35 -149.27 0.07 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 123.402 0.681 . . . . 0.0 110.473 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 5.0 tpp180 -65.13 -4.42 4.93 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.473 0.709 . . . . 0.0 111.746 -177.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 26.4 tpt180 -55.28 134.25 49.84 Favored 'General case' 0 CA--C 1.529 0.138 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 174.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.1 -133.67 22.53 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 -175.096 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -72.94 -164.69 8.34 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 174.283 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -55.34 165.0 3.42 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 123.773 2.982 . . . . 0.0 110.987 174.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -50.84 133.55 39.84 Favored 'Trans proline' 0 N--CA 1.452 -0.96 0 C-N-CA 123.232 2.622 . . . . 0.0 111.197 -178.413 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . 0.443 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 5.8 p90 -160.87 173.86 14.7 Favored 'General case' 0 CA--C 1.53 0.178 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -173.79 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.28 166.11 34.39 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 120.801 0.334 . . . . 0.0 111.668 -175.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . 0.529 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 91.4 m-85 -121.17 154.82 35.72 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 168.581 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 70.5 t -144.2 133.03 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -174.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -106.76 117.97 35.45 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 -85.59 154.65 21.58 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 115.12 1.526 . . . . 0.0 115.12 179.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 38.1 tp10 -75.54 -30.27 59.7 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 172.305 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 58.3 t0 -157.59 117.72 1.97 Allowed Pre-proline 0 N--CA 1.451 -0.415 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.3 -10.3 26.97 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 123.194 2.596 . . . . 0.0 112.112 -176.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 77.4 mtt85 -72.17 -16.16 61.97 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 117.85 0.295 . . . . 0.0 111.026 178.059 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -77.97 -2.73 38.4 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 177.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -64.52 -14.67 58.52 Favored 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 122.435 0.294 . . . . 0.0 111.163 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -65.96 -15.85 63.35 Favored 'General case' 0 CA--C 1.529 0.168 0 O-C-N 122.173 -0.329 . . . . 0.0 111.333 -179.319 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -123.39 -38.28 2.57 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 123.001 0.52 . . . . 0.0 112.181 177.166 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -81.82 -9.57 59.57 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.08 0.552 . . . . 0.0 112.187 -175.486 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 99.5 t -130.99 -49.76 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 CA-C-N 117.729 0.24 . . . . 0.0 110.526 -177.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 69.2 m -66.23 -10.96 46.98 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 117.646 0.203 . . . . 0.0 111.145 -179.462 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.2 -1.16 69.87 Favored Glycine 0 CA--C 1.53 0.975 0 CA-C-O 119.436 -0.646 . . . . 0.0 112.73 -178.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 12.1 tpp180 -151.72 -16.88 0.19 Allowed 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 118.466 1.133 . . . . 0.0 112.705 -176.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 32.9 t0 -65.11 138.34 58.24 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 118.267 0.485 . . . . 0.0 110.634 -178.128 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.51 41.57 99.2 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 111.794 -0.522 . . . . 0.0 111.794 174.091 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -98.61 133.47 42.91 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -174.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.6 t0 -62.63 106.52 0.8 Allowed 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 123.781 0.832 . . . . 0.0 112.341 -177.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.439 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.9 t80 -112.88 171.28 7.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 123.804 0.842 . . . . 0.0 111.445 177.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.439 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 20.6 t0 -60.53 99.82 0.09 Allowed 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.066 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 77.99 -6.32 49.51 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 123.553 0.597 . . . . 0.0 112.761 177.46 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 87.9 m-85 -140.56 -169.54 2.81 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 117.996 0.898 . . . . 0.0 113.269 -177.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 36.1 ttt180 -147.46 129.53 15.48 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.439 0.696 . . . . 0.0 109.474 -177.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -62.57 147.79 48.02 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 122.847 0.459 . . . . 0.0 110.502 -175.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 -120.68 127.68 52.26 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 175.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 11.8 t -145.27 82.02 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.131 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 173.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -148.33 160.7 42.73 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 122.75 0.42 . . . . 0.0 110.43 -175.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -75.25 156.57 85.58 Favored Pre-proline 0 CA--C 1.533 0.324 0 N-CA-C 114.228 1.196 . . . . 0.0 114.228 179.211 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo . . . . . 0 C--O 1.25 1.077 0 C-N-CA 123.739 2.96 . . . . 0.0 111.867 177.349 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.034 0 C5'-C4'-C3' 110.016 -3.656 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.955 1 O4'-C1'-N19 112.3 4.1 . 0.345 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.443 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.422 -2.618 0 C5'-C4'-C3' 110.453 -3.364 . 0.328 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.529 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.425 -2.336 1 C5'-C4'-C3' 108.876 -4.416 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.948 0 O4'-C1'-N19 111.842 3.642 . 0.142 2u . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.053 0 O4'-C1'-N19 111.831 3.631 . 0.175 2[ . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.3 p . . . . . 0 N--CA 1.474 0.774 0 N-CA-C 111.843 0.312 . . . . 0.0 111.843 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 98.6 mt -66.38 144.06 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.174 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 38.1 ttm105 -75.38 154.39 37.22 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 122.662 0.385 . . . . 0.0 111.152 -178.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . 0.519 ' N ' ' CD ' ' B' ' 10' ' ' PRO . . . 103.29 36.52 3.32 Favored Glycine 0 CA--C 1.533 1.192 0 CA-C-O 118.693 -1.059 . . . . 0.0 114.307 170.705 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . 0.519 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 56.9 Cg_endo -68.47 161.48 44.79 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 122.381 2.054 . . . . 0.0 109.853 174.317 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -65.45 154.29 38.91 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.725 -179.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 174.66 -179.66 45.83 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -144.83 161.3 39.62 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 123.457 0.703 . . . . 0.0 110.369 -179.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 54.24 23.61 4.4 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.63 0.772 . . . . 0.0 111.772 -179.061 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 13.4 p30 -74.59 158.15 34.19 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 87.6 m -85.6 -2.06 57.78 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 122.885 0.474 . . . . 0.0 111.334 177.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 73.0 mtm180 -69.03 146.99 52.2 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 122.831 0.452 . . . . 0.0 110.818 -178.546 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.1 pt -132.56 170.06 20.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-O 120.964 0.412 . . . . 0.0 110.08 172.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.454 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.6 OUTLIER -114.99 151.02 34.89 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -176.838 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 59.3 t -138.45 143.61 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -157.36 -178.76 31.73 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 111.934 -0.466 . . . . 0.0 111.934 -177.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 36.3 t30 56.8 23.99 8.65 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 123.825 0.85 . . . . 0.0 111.645 -177.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 93.4 mt -64.2 146.21 97.74 Favored Pre-proline 0 CA--C 1.53 0.207 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.35 157.57 56.46 Favored 'Trans proline' 0 N--CA 1.452 -0.96 0 C-N-CA 123.404 2.736 . . . . 0.0 110.296 -179.272 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -60.43 -20.93 65.85 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.299 2.666 . . . . 0.0 111.699 176.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -84.06 6.82 20.74 Favored 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 8.6 tp -61.49 152.62 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.146 0 C-N-CA 122.416 0.286 . . . . 0.0 110.684 -178.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 60.4 ttt85 -144.62 150.32 37.23 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.8 p -62.17 -18.27 60.49 Favored 'General case' 0 N--CA 1.46 0.069 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 -177.112 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 6.4 ttpt -90.52 -30.01 17.53 Favored 'General case' 0 N--CA 1.456 -0.126 0 C-N-CA 122.429 0.292 . . . . 0.0 111.074 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 -70.72 -36.14 73.06 Favored 'General case' 0 N--CA 1.454 -0.227 0 O-C-N 122.1 -0.375 . . . . 0.0 111.261 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 15.2 tt -75.85 -14.09 15.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.377 -176.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -104.28 -21.85 13.46 Favored 'General case' 0 C--N 1.34 0.164 0 CA-C-N 118.714 0.688 . . . . 0.0 110.687 178.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -74.33 -49.88 21.07 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 178.161 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 m -72.86 -30.8 33.81 Favored 'Isoleucine or valine' 0 C--N 1.338 0.101 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.095 -178.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -75.92 -42.87 47.57 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 177.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 96.7 p -67.58 -21.45 65.42 Favored 'General case' 0 C--N 1.34 0.164 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.49 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 23.7 tptm -73.98 -36.88 64.58 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 173.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -82.12 -11.61 58.66 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 116.659 2.096 . . . . 0.0 116.659 178.175 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.98 179.27 48.92 Favored Glycine 0 C--N 1.338 0.645 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.044 -179.364 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.94 53.7 2.27 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 124.06 0.944 . . . . 0.0 111.626 -177.597 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 2.1 mp -68.75 144.24 14.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.24 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 35.0 mmt180 -124.81 -36.1 2.62 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 119.42 -0.324 . . . . 0.0 111.149 178.246 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 39.9 m-20 -122.38 150.16 42.8 Favored 'General case' 0 N--CA 1.462 0.126 0 N-CA-C 113.944 1.091 . . . . 0.0 113.944 -178.385 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -136.18 150.08 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 C-N-CA 124.236 1.014 . . . . 0.0 109.169 178.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 59.2 t0 -146.9 63.5 1.18 Allowed 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 49.6 tp -64.35 129.06 38.43 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 173.345 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -120.39 146.69 45.94 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 123.698 0.799 . . . . 0.0 109.966 178.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 -111.23 170.09 8.35 Favored 'General case' 0 C--N 1.334 -0.104 0 C-N-CA 122.891 0.476 . . . . 0.0 111.11 -176.183 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 45.8 ttm180 55.47 -96.95 0.07 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 124.149 0.98 . . . . 0.0 111.521 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 15.0 tpt180 56.39 19.89 4.35 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.304 0.642 . . . . 0.0 111.575 -179.061 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.19 12.6 83.81 Favored Glycine 0 CA--C 1.532 1.114 0 CA-C-O 119.665 -0.52 . . . . 0.0 112.697 176.538 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -169.66 -154.13 9.02 Favored Glycine 0 CA--C 1.532 1.112 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -60.19 147.34 93.83 Favored 'Trans proline' 0 N--CA 1.448 -1.164 0 C-N-CA 123.076 2.517 . . . . 0.0 110.191 172.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -65.38 158.38 52.95 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 123.204 2.603 . . . . 0.0 110.414 178.376 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -150.85 167.71 26.68 Favored 'General case' 0 C--O 1.232 0.162 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 -179.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -152.87 166.06 33.48 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.295 0.569 . . . . 0.0 112.426 -171.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . 0.46 ' CE2' ' C6 ' ' A' ' 93' ' ' ' A' . 4.3 m-85 -120.56 153.67 36.43 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 124.042 0.937 . . . . 0.0 112.813 170.85 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 88.9 t -141.1 144.39 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 108.685 -0.858 . . . . 0.0 108.685 -178.17 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 11.7 tp10 -131.14 125.59 33.46 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 122.578 0.351 . . . . 0.0 111.174 -177.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -91.57 151.56 20.68 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 113.974 1.101 . . . . 0.0 113.974 -178.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -82.46 -24.69 34.14 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 169.045 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 36.6 t0 -152.26 114.94 2.9 Favored Pre-proline 0 CA--C 1.534 0.355 0 C-N-CA 123.352 0.661 . . . . 0.0 109.944 -176.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -74.77 -1.37 11.06 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 123.566 2.844 . . . . 0.0 112.742 -173.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 79.5 mtt85 -68.27 -0.49 4.81 Favored 'General case' 0 CA--C 1.53 0.197 0 N-CA-C 112.998 0.74 . . . . 0.0 112.998 -176.212 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 20.4 p30 -134.35 3.12 3.33 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 112.173 0.434 . . . . 0.0 112.173 173.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.76 -22.03 64.33 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 178.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -70.25 -28.45 65.25 Favored 'General case' 0 N--CA 1.456 -0.127 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 178.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -79.63 -35.18 39.8 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 122.337 0.255 . . . . 0.0 111.381 178.025 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.96 -24.72 63.38 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.231 176.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 10.0 t -85.69 -59.03 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.5 t -71.28 -17.6 62.46 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -172.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -93.12 4.07 73.9 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-O 119.247 -0.751 . . . . 0.0 112.588 -177.089 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 46.6 ttm180 -150.19 -16.55 0.25 Allowed 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 118.516 1.158 . . . . 0.0 112.555 -174.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 50.7 p-10 -71.3 156.64 39.29 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.277 0.561 . . . . 0.0 112.306 -176.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 58.85 41.8 96.29 Favored Glycine 0 CA--C 1.526 0.725 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.683 169.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 43.4 t80 -92.38 130.83 37.95 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 118.226 1.013 . . . . 0.0 113.714 -175.153 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -66.12 101.81 0.75 Allowed 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 123.044 0.538 . . . . 0.0 112.025 -178.441 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.515 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 71.4 t80 -93.02 177.98 5.9 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.406 0.682 . . . . 0.0 112.127 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.515 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 74.1 m-20 -66.66 21.84 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.537 0 N-CA-C 114.934 1.457 . . . . 0.0 114.934 -177.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . 0.42 ' H ' ' C ' ' B' ' 79' ' ' TYR . . . 161.5 -10.82 0.12 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-O 119.618 -0.546 . . . . 0.0 112.425 -179.137 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -140.95 -167.05 2.29 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 117.731 0.766 . . . . 0.0 110.893 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 33.8 ttt180 -138.93 122.96 17.89 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -59.81 153.39 20.79 Favored 'General case' 0 N--CA 1.458 -0.043 0 C-N-CA 123.421 0.688 . . . . 0.0 111.096 -176.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 24.0 mtp180 -128.08 125.21 38.81 Favored 'General case' 0 CA--C 1.521 -0.164 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.593 175.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 48.2 t -142.99 82.01 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.171 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 175.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -140.28 160.57 39.67 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.219 0.533 . . . . 0.0 111.809 -173.09 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . 0.468 ' CD1' ' HD2' ' B' ' 89' ' ' PRO . 18.2 t80 -71.84 138.9 82.67 Favored Pre-proline 0 CA--C 1.534 0.335 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . 0.468 ' HD2' ' CD1' ' B' ' 88' ' ' PHE . 43.9 Cg_endo . . . . . 0 C--O 1.248 1.018 0 C-N-CA 123.824 3.016 . . . . 0.0 111.303 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.821 0 C5'-C4'-C3' 110.019 -3.654 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.021 0 C3'-C2'-C1' 104.695 3.55 . 0.109 6p . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.454 ' C6 ' ' CE1' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.334 1 C5'-C4'-C3' 109.47 -4.02 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.484 ' C2 ' ' HA2' ' B' ' 9' ' ' GLY . . . . . . . . 0 O4'--C4' 1.427 -2.176 1 O4'-C1'-N19 112.542 4.342 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.616 1 O4'-C1'-N19 112.412 4.212 OUTLIER-DELTA 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.936 0 O4'-C1'-N19 111.719 3.519 . 0.0 OUTLIER '7D dist 6p' 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.2 p . . . . . 0 N--CA 1.477 0.9 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.08 -6.04 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 C-N-CA 122.312 0.245 . . . . 0.0 110.849 -177.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 16.9 tpp180 61.77 134.58 0.01 OUTLIER 'General case' 0 C--N 1.344 0.348 0 C-N-CA 125.211 1.404 . . . . 0.0 112.573 -176.422 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . 0.664 ' HA2' ' C2 ' ' A' ' 93' ' ' ' A' . . . 104.99 -94.38 1.01 Allowed Glycine 0 CA--C 1.527 0.815 0 CA-C-O 119.171 -0.794 . . . . 0.0 111.129 175.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -59.68 1.8 0.36 Allowed 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 123.985 3.124 . . . . 0.0 113.636 178.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -147.67 176.6 9.96 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 122.821 0.448 . . . . 0.0 110.191 -179.273 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.87 -169.78 30.02 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -178.371 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 28.9 p30 -68.48 174.05 4.46 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.808 0.337 . . . . 0.0 111.547 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 39.2 t30 -149.11 179.12 8.14 Favored 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.333 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 61.23 8.21 1.96 Allowed 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 114.687 1.366 . . . . 0.0 114.687 -178.814 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 61.3 m -132.78 -1.92 3.35 Favored 'General case' 0 C--N 1.339 0.124 0 C-N-CA 123.004 0.521 . . . . 0.0 110.473 176.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 31.4 ttm180 -101.02 147.89 25.67 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 123.046 0.539 . . . . 0.0 109.815 -178.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.5 pt -133.53 174.78 12.67 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.081 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 176.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.465 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.7 OUTLIER -118.92 150.32 40.09 Favored 'General case' 0 C--O 1.231 0.122 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -175.838 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 60.5 t -139.22 142.84 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 C-N-CA 123.509 0.724 . . . . 0.0 109.437 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.81 168.76 31.78 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -178.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 59.4 t30 60.55 36.89 19.81 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 124.073 0.949 . . . . 0.0 111.379 -174.205 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 84.0 mt -61.95 143.44 94.59 Favored Pre-proline 0 CA--C 1.532 0.285 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 176.492 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.37 158.54 55.84 Favored 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 123.511 2.807 . . . . 0.0 109.935 179.195 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.5 -15.81 38.29 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 123.134 2.556 . . . . 0.0 110.851 179.046 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -89.1 5.0 46.54 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 179.026 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 tp -65.45 154.87 7.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 C-N-CA 122.41 0.284 . . . . 0.0 110.432 -178.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 44.9 mtm180 -138.42 161.47 36.89 Favored 'General case' 0 CA--C 1.522 -0.118 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 178.174 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.6 p -66.99 -7.24 20.94 Favored 'General case' 0 C--N 1.338 0.071 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -177.476 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -111.45 -36.22 5.59 Favored 'General case' 0 C--N 1.34 0.182 0 O-C-N 122.421 -0.174 . . . . 0.0 111.218 179.511 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -63.79 -28.39 69.83 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.593 0.235 . . . . 0.0 110.43 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.0 tt -72.1 -13.78 16.9 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.349 -178.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -116.98 -9.94 11.02 Favored 'General case' 0 N--CA 1.456 -0.156 0 CA-C-N 118.291 0.496 . . . . 0.0 110.722 174.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -71.27 -55.3 8.34 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-O 121.025 0.44 . . . . 0.0 110.57 178.016 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 10.0 p -67.68 -34.65 69.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 O-C-N 122.241 -0.287 . . . . 0.0 110.886 179.392 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -69.88 -32.86 71.43 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 113.38 0.882 . . . . 0.0 113.38 176.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 39.2 t -67.48 -28.0 67.48 Favored 'General case' 0 C--N 1.342 0.28 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 176.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -70.68 -34.26 71.8 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 174.532 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -81.68 -15.61 53.95 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 116.225 1.935 . . . . 0.0 116.225 177.124 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.46 179.21 44.92 Favored Glycine 0 C--N 1.338 0.656 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.584 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -83.85 84.61 7.51 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 122.992 0.517 . . . . 0.0 111.249 -178.431 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.7 mp -73.09 150.39 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.123 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 174.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 85.3 mmt-85 -128.35 -25.64 2.91 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 119.25 -0.405 . . . . 0.0 111.972 176.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -150.55 161.43 42.56 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 178.609 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . 0.454 HG23 ' H ' ' B' ' 47' ' ' LEU . 30.8 mm -132.43 156.46 42.42 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.061 0 C-N-CA 124.289 1.036 . . . . 0.0 109.279 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -143.2 55.25 1.36 Allowed 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 175.316 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . 0.454 ' H ' HG23 ' B' ' 45' ' ' ILE . 59.9 tp -55.79 133.13 50.88 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.223 174.468 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -133.79 158.53 43.13 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 123.735 0.814 . . . . 0.0 111.415 -177.483 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 43.0 p30 -145.41 11.45 1.3 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.442 0.697 . . . . 0.0 110.698 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -73.38 165.47 25.0 Favored 'General case' 0 C--O 1.232 0.148 0 C-N-CA 123.323 0.649 . . . . 0.0 110.338 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 43.7 mtt180 61.09 177.7 0.11 Allowed 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.057 0.943 . . . . 0.0 112.264 177.146 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -76.2 173.89 53.69 Favored Glycine 0 CA--C 1.529 0.953 0 N-CA-C 111.881 -0.488 . . . . 0.0 111.881 -177.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.86 177.01 44.39 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -179.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -60.88 160.55 24.97 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 124.059 3.173 . . . . 0.0 111.383 178.286 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -65.6 160.26 44.09 Favored 'Trans proline' 0 N--CA 1.45 -1.038 0 C-N-CA 123.336 2.691 . . . . 0.0 110.195 176.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . 0.48 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 6.1 p90 -153.29 171.38 18.65 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 106.414 -1.699 . . . . 0.0 106.414 -176.61 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -159.61 174.62 14.31 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.242 0.544 . . . . 0.0 111.371 -174.089 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . 0.405 ' CD2' ' C2 ' ' A' ' 93' ' ' ' A' . 90.4 m-85 -131.81 155.94 46.9 Favored 'General case' 0 N--CA 1.452 -0.355 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 172.04 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 66.8 t -132.87 134.24 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -178.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -111.17 123.95 51.23 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 122.465 0.306 . . . . 0.0 110.562 -177.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -97.43 154.95 17.14 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 42.3 tp10 -78.7 -23.63 45.45 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 170.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -152.51 118.87 3.05 Favored Pre-proline 0 CA--C 1.534 0.365 0 C-N-CA 123.162 0.585 . . . . 0.0 109.785 -178.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -66.65 -8.11 20.13 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.188 2.592 . . . . 0.0 112.505 -176.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 72.3 ttt-85 -61.94 -36.05 80.26 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-N 118.111 0.414 . . . . 0.0 110.172 177.19 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 52.8 m-20 -89.87 -16.3 30.36 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-O 120.582 0.23 . . . . 0.0 111.57 -178.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.97 -25.3 64.47 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -71.81 -28.59 63.7 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 177.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 -75.16 -35.48 61.61 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 178.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.97 -29.91 67.13 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 110.279 -0.267 . . . . 0.0 110.279 177.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.93 -30.02 17.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.306 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.368 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 41.5 t -85.79 -12.34 51.19 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 122.587 0.355 . . . . 0.0 111.54 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -68.56 -46.06 64.22 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.609 -0.596 . . . . 0.0 111.609 -175.518 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 38.2 ttt180 -163.08 122.1 2.11 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.274 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -164.24 149.27 10.2 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 123.066 0.229 . . . . 0.0 110.574 -178.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.94 88.88 0.3 Allowed Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.481 0.562 . . . . 0.0 112.857 170.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . 0.443 ' HA ' ' HA ' ' B' ' 83' ' ' ARG . 13.6 t80 60.31 103.09 0.02 OUTLIER 'General case' 0 N--CA 1.457 -0.104 0 N-CA-C 116.478 2.029 . . . . 0.0 116.478 169.579 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -164.71 31.09 0.07 Allowed 'General case' 0 N--CA 1.444 -0.733 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -131.62 178.09 7.01 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -88.89 107.38 18.97 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 114.892 -1.049 . . . . 0.0 111.228 179.378 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 72.11 -2.26 28.26 Favored Glycine 0 CA--C 1.531 1.092 0 N-CA-C 111.522 -0.631 . . . . 0.0 111.522 -178.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 45.1 m-85 -131.47 169.81 15.55 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 124.001 0.92 . . . . 0.0 113.455 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . 0.443 ' HA ' ' HA ' ' B' ' 77' ' ' TYR . 0.0 OUTLIER -135.15 135.83 41.4 Favored 'General case' 0 N--CA 1.44 -0.949 0 CA-C-O 120.803 0.335 . . . . 0.0 111.282 -178.58 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . 0.45 ' CD2' ' N ' ' B' ' 84' ' ' LEU . 2.4 mm? -73.85 142.92 46.06 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 178.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 59.1 mtm180 -132.48 114.57 14.45 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-O 120.943 0.401 . . . . 0.0 110.222 175.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 42.4 t -136.4 86.08 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 C-N-CA 123.543 0.737 . . . . 0.0 109.055 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -149.8 163.21 38.61 Favored 'General case' 0 C--N 1.334 -0.103 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.534 -178.655 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.5 p90 -74.0 152.23 88.62 Favored Pre-proline 0 CA--C 1.531 0.229 0 N-CA-C 114.626 1.343 . . . . 0.0 114.626 179.433 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo . . . . . 0 C--O 1.253 1.266 0 C-N-CA 123.837 3.025 . . . . 0.0 110.781 176.312 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.45 0 C5'-C4'-C3' 109.805 -3.797 OUTLIER-DELTA 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.542 0 C5'-C4'-C3' 110.249 -3.501 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.48 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.423 -2.481 0 C5'-C4'-C3' 110.676 -3.216 . 0.032 4p . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.664 ' C2 ' ' HA2' ' B' ' 9' ' ' GLY . . . . . . . . 0 O4'--C4' 1.421 -2.693 1 C5'-C4'-C3' 109.492 -4.005 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.426 -2.263 0 O4'-C1'-N19 112.007 3.807 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.889 0 C3'-C2'-C1' 104.247 3.052 . 0.167 0b . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 p . . . . . 0 N--CA 1.477 0.896 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 87.5 mt -66.21 148.2 12.2 Favored 'Isoleucine or valine' 0 C--O 1.234 0.237 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 20.5 tpp85 -59.71 140.04 56.78 Favored 'General case' 0 C--N 1.34 0.181 0 C-N-CA 122.722 0.409 . . . . 0.0 110.525 -179.515 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . 0.405 ' HA2' ' C2 ' ' A' ' 93' ' ' ' A' . . . 64.28 58.98 9.01 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -71.22 2.19 4.62 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 124.083 3.189 . . . . 0.0 111.608 179.644 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 57.9 18.72 5.2 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 123.753 0.821 . . . . 0.0 112.008 -177.508 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.5 -173.0 44.1 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 176.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -66.46 152.77 44.47 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 122.553 -0.381 . . . . 0.0 110.465 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 50.1 t30 -75.92 162.5 28.05 Favored 'General case' 0 CA--C 1.529 0.149 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.068 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 15.8 t0 -150.46 -47.81 0.13 Allowed 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 122.537 0.335 . . . . 0.0 111.75 176.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 98.3 m -140.41 5.79 2.07 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 122.804 0.442 . . . . 0.0 111.501 178.438 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -88.86 155.21 19.67 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 120.847 0.356 . . . . 0.0 111.255 -177.733 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 12.2 pt -127.62 -177.29 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 C-N-CA 123.223 0.609 . . . . 0.0 109.477 177.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -142.94 151.29 40.79 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -178.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 62.8 t -142.84 101.15 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.149 0 N-CA-C 110.465 -0.198 . . . . 0.0 110.465 -176.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -92.59 166.95 29.47 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 171.682 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 66.2 t30 55.43 29.37 13.07 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 122.824 0.45 . . . . 0.0 110.725 -177.028 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 23.0 tp -57.0 117.64 18.98 Favored Pre-proline 0 CA--C 1.536 0.405 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -72.86 157.0 52.27 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.104 2.536 . . . . 0.0 110.951 -175.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.01 -4.43 14.84 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 124.074 3.183 . . . . 0.0 111.185 178.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -76.24 -7.02 53.96 Favored 'General case' 0 CA--C 1.529 0.167 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 178.457 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 tp -70.32 151.03 9.59 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.057 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 83.8 mmt-85 -130.59 155.6 46.25 Favored 'General case' 0 N--CA 1.458 -0.054 0 CA-C-O 120.678 0.275 . . . . 0.0 110.382 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.14 10.51 0.3 Allowed 'General case' 0 N--CA 1.462 0.127 0 N-CA-C 114.902 1.445 . . . . 0.0 114.902 -177.353 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.421 ' HE2' ' OD1' ' B' ' 34' ' ' ASP . 23.4 tptm -140.69 -33.46 0.54 Allowed 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 122.326 0.25 . . . . 0.0 110.957 179.685 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -63.87 -24.01 67.58 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 175.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.6 tt -69.51 -15.99 20.06 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 C-N-CA 123.15 0.58 . . . . 0.0 110.902 -179.584 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -125.45 4.35 7.65 Favored 'General case' 0 CA--C 1.53 0.205 0 O-C-N 122.053 -0.404 . . . . 0.0 111.367 179.056 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . 0.421 ' OD1' ' HE2' ' B' ' 30' ' ' LYS . 79.1 m-20 -97.06 -61.93 1.33 Allowed 'General case' 0 C--O 1.233 0.197 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 172.215 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 p -74.84 -41.53 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.087 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -172.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -75.39 -21.49 58.22 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -179.019 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 43.3 t -72.26 -30.18 64.6 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 175.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 29.7 ttpp -72.92 -28.59 62.55 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.638 -0.505 . . . . 0.0 109.638 174.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -79.33 -20.73 47.15 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 116.26 1.948 . . . . 0.0 116.26 177.413 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.88 20.58 0.17 Allowed Glycine 0 CA--C 1.53 0.984 0 C-N-CA 119.887 -1.149 . . . . 0.0 114.717 -175.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 48.7 49.14 19.19 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 117.938 0.869 . . . . 0.0 111.475 175.186 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 75.6 mt -48.97 137.02 5.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.144 0.577 . . . . 0.0 111.008 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 48.0 mtm105 -98.9 -32.14 11.48 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 122.891 0.477 . . . . 0.0 111.527 179.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 32.3 m-20 -148.94 157.01 43.1 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 113.835 1.05 . . . . 0.0 113.835 -177.449 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 3.2 mp -126.78 151.95 34.07 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -148.6 48.02 1.02 Allowed 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -177.032 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 54.0 tp -68.75 110.45 4.32 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 177.632 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 48.1 mttm -93.88 146.57 23.8 Favored 'General case' 0 N--CA 1.456 -0.145 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 175.475 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 31.9 p30 -155.24 12.11 0.35 Allowed 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.003 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 90.0 mmt-85 -134.77 -5.6 2.47 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 117.985 0.357 . . . . 0.0 111.765 179.4 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 51.1 ttt180 -160.31 156.79 26.9 Favored 'General case' 0 CA--C 1.527 0.09 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.89 16.1 63.99 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -178.246 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.67 -161.79 26.21 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -178.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -56.54 163.09 7.28 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 123.852 3.035 . . . . 0.0 111.54 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -54.82 130.53 41.03 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 C-N-CA 123.646 2.897 . . . . 0.0 112.163 -175.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . 0.41 ' CE1' " H4'" ' A' ' 92' ' ' ' C' . 2.9 p90 -164.13 167.22 20.46 Favored 'General case' 0 N--CA 1.455 -0.195 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 178.018 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -144.25 161.01 39.98 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -171.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . 0.492 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 50.9 m-85 -119.71 60.52 0.85 Allowed 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 124.152 0.981 . . . . 0.0 112.769 174.256 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 83.7 t -58.34 143.26 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.108 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -177.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 73.1 tt0 -120.79 120.4 35.49 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.918 0.389 . . . . 0.0 110.956 -175.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -91.53 166.43 12.84 Favored 'General case' 0 N--CA 1.455 -0.179 0 N-CA-C 115.984 1.846 . . . . 0.0 115.984 -174.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 30.4 tp10 -70.99 -35.22 72.01 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 122.757 0.423 . . . . 0.0 110.138 173.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -149.21 148.22 26.03 Favored Pre-proline 0 CA--C 1.527 0.093 0 C-N-CA 124.387 1.075 . . . . 0.0 112.021 178.084 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.1 -17.27 31.73 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.181 2.588 . . . . 0.0 111.089 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 51.9 mmm-85 -77.76 -13.42 59.9 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 122.435 0.294 . . . . 0.0 111.606 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -76.5 -10.31 59.3 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 111.953 0.353 . . . . 0.0 111.953 177.552 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.48 -11.05 60.68 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.592 0.357 . . . . 0.0 111.101 179.563 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -67.93 -17.72 64.54 Favored 'General case' 0 C--O 1.232 0.155 0 O-C-N 122.135 -0.353 . . . . 0.0 111.032 -179.286 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -123.84 -36.24 2.76 Favored 'General case' 0 CA--C 1.528 0.125 0 C-N-CA 123.183 0.593 . . . . 0.0 112.433 178.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -84.28 -8.86 58.9 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -175.605 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 47.3 t -132.68 -46.25 0.64 Allowed 'Isoleucine or valine' 0 C--O 1.228 -0.036 0 CA-C-N 118.062 0.392 . . . . 0.0 110.906 -175.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.3 t -69.5 -15.19 63.2 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-O 120.502 0.192 . . . . 0.0 110.977 -179.282 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.94 -5.82 88.8 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-O 119.647 -0.529 . . . . 0.0 112.711 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 70.2 mtm-85 -138.86 6.07 2.41 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 118.078 0.939 . . . . 0.0 111.869 -178.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -67.3 123.51 20.55 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 117.823 0.283 . . . . 0.0 111.307 -179.101 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 65.19 34.45 89.63 Favored Glycine 0 C--N 1.338 0.669 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 177.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 56.2 t80 -75.91 137.77 40.6 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -173.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 28.2 t0 -66.15 81.02 0.08 Allowed 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.295 1.038 . . . . 0.0 111.964 -177.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . 0.4 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 68.2 t80 -85.03 -179.94 7.15 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 177.784 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.4 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 71.4 m-20 -66.38 91.9 0.18 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 123.246 0.618 . . . . 0.0 112.43 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.73 -2.12 69.81 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-O 119.606 -0.552 . . . . 0.0 112.399 177.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -138.41 176.68 8.49 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 -178.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -125.15 140.1 53.17 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 123.846 0.858 . . . . 0.0 109.376 176.652 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -67.22 152.51 45.6 Favored 'General case' 0 N--CA 1.455 -0.204 0 C-N-CA 122.626 0.37 . . . . 0.0 110.426 177.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -118.43 48.26 1.46 Allowed 'General case' 0 C--N 1.338 0.068 0 C-N-CA 123.3 0.64 . . . . 0.0 109.828 172.012 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 74.7 t -76.43 95.1 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -154.02 158.63 40.86 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.845 178.51 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 8.1 p90 -87.23 145.77 38.64 Favored Pre-proline 0 N--CA 1.456 -0.161 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 177.419 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 C--O 1.253 1.245 0 C-N-CA 123.614 2.876 . . . . 0.0 110.737 175.565 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.42 -2.733 0 C5'-C4'-C3' 110.178 -3.548 OUTLIER-DELTA 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.697 0 C3'-C2'-C1' 103.667 2.408 OUTLIER-DELTA 0.0 OUTLIER delta 0.0 . . . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.41 " H4'" ' CE1' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.392 0 O4'-C1'-N19 111.007 2.807 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.492 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.426 -2.211 0 C5'-C4'-C3' 110.668 -3.221 . 0.21 4b . 0.0 . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.534 0 C5'-C4'-C3' 109.794 -3.804 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.606 0 O4'-C1'-N19 111.185 2.985 . 0.262 6p . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.4 p . . . . . 0 N--CA 1.476 0.872 0 N-CA-C 111.611 0.226 . . . . 0.0 111.611 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.11 137.09 24.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.156 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.661 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 5.0 tpp180 -156.51 131.11 8.84 Favored 'General case' 0 C--O 1.232 0.14 0 C-N-CA 122.241 0.216 . . . . 0.0 110.428 177.172 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . 0.46 ' N ' ' CD ' ' B' ' 10' ' ' PRO . . . 59.17 38.61 93.39 Favored Glycine 0 CA--C 1.533 1.183 0 CA-C-O 118.809 -0.995 . . . . 0.0 113.369 175.472 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 10' ' ' PRO . . . . . 0.46 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 61.8 Cg_endo -70.22 -24.88 27.05 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.693 2.262 . . . . 0.0 110.944 -176.553 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -164.1 170.18 16.82 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 122.755 0.422 . . . . 0.0 110.254 -178.183 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -84.83 5.62 81.6 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.917 -0.473 . . . . 0.0 111.917 179.068 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 46.7 p30 -74.26 -3.14 28.26 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 117.651 0.725 . . . . 0.0 111.931 -177.522 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 71.5 m-80 -69.87 169.35 13.31 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 120.836 0.35 . . . . 0.0 110.84 177.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -137.08 166.85 22.72 Favored 'General case' 0 CA--C 1.528 0.1 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -177.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 74.2 m 58.77 8.09 0.88 Allowed 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.083 0.953 . . . . 0.0 112.53 -177.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 86.3 mtt180 -99.79 148.81 24.01 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 117.96 0.346 . . . . 0.0 111.741 177.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 19.9 pt -134.66 -177.26 1.95 Allowed 'Isoleucine or valine' 0 CA--C 1.524 -0.034 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 19' ' ' TYR . . . . . 0.426 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.4 OUTLIER -119.0 146.64 44.86 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -177.288 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 41.7 t -140.17 139.97 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.54 177.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -143.27 169.75 25.7 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -176.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 59.7 t30 61.07 31.56 19.79 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.741 0.817 . . . . 0.0 111.483 -175.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 81.3 mt -65.08 135.89 96.49 Favored Pre-proline 0 CA--C 1.533 0.301 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.56 146.3 38.87 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.273 2.649 . . . . 0.0 110.153 178.416 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -74.93 -13.04 21.69 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 C-N-CA 123.374 2.716 . . . . 0.0 111.398 177.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 79.8 m-20 -81.07 -2.93 50.17 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -176.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 8.8 tp -68.27 145.58 13.44 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.249 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 48.5 ttt-85 -84.56 151.32 24.62 Favored 'General case' 0 C--N 1.338 0.101 0 N-CA-C 109.965 -0.384 . . . . 0.0 109.965 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -66.21 12.55 0.06 Allowed 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 115.462 1.652 . . . . 0.0 115.462 -177.296 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . 0.411 ' HE2' ' OD2' ' B' ' 34' ' ' ASP . 24.0 tptm -148.69 -28.76 0.29 Allowed 'General case' 0 C--N 1.341 0.198 0 C-N-CA 122.47 0.308 . . . . 0.0 111.004 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 31.2 m-20 -64.06 -19.94 65.59 Favored 'General case' 0 CA--C 1.528 0.103 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 174.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 tt -69.29 -14.14 18.09 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 C-N-CA 123.336 0.654 . . . . 0.0 111.059 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -129.02 -10.32 4.81 Favored 'General case' 0 CA--C 1.529 0.173 0 CA-C-N 118.514 0.597 . . . . 0.0 111.677 176.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . 0.411 ' OD2' ' HE2' ' B' ' 30' ' ' LYS . 77.7 m-20 -74.13 -46.48 42.33 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 113.024 0.75 . . . . 0.0 113.024 174.166 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.6 p -71.91 -30.52 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.117 0 CA-C-O 120.656 0.265 . . . . 0.0 111.045 178.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -75.48 -30.82 60.01 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 177.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 41.4 t -70.37 -30.65 67.63 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 174.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 3.6 tppp? -73.38 -30.81 63.53 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 122.121 0.168 . . . . 0.0 110.672 177.257 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -84.03 -19.18 34.88 Favored 'General case' 0 C--N 1.338 0.103 0 N-CA-C 116.316 1.969 . . . . 0.0 116.316 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.14 22.31 0.07 OUTLIER Glycine 0 CA--C 1.528 0.88 0 C-N-CA 120.035 -1.078 . . . . 0.0 113.531 -177.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 52.32 30.15 7.67 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 117.64 0.72 . . . . 0.0 111.296 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . 0.408 HD11 ' CZ ' ' B' ' 61' ' ' PHE . 17.8 mt -50.72 137.37 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 123.191 0.597 . . . . 0.0 110.131 178.099 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 14.9 mmt180 -105.26 -19.02 13.93 Favored 'General case' 0 N--CA 1.457 -0.078 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -172.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 40.9 t0 -154.94 156.66 36.45 Favored 'General case' 0 C--O 1.233 0.201 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.962 178.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 15.5 mm -131.96 114.86 25.38 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 174.305 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 46' ' ' ASP . . . . . 0.401 ' HB3' ' H ' ' B' ' 58' ' ' PHE . 41.3 t0 -84.53 51.91 2.24 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 177.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 50.8 tp -54.18 120.88 7.09 Favored 'General case' 0 C--O 1.231 0.114 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 175.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.499 ' HZ2' ' HB3' ' B' ' 48' ' ' LYS . 7.0 ttpm? -145.08 146.51 31.88 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-O 120.829 0.347 . . . . 0.0 111.02 -173.407 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 73.9 m-20 -78.98 172.73 13.39 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 122.951 0.501 . . . . 0.0 110.992 -179.198 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 33.3 mtp-105 -137.69 169.02 18.51 Favored 'General case' 0 C--O 1.233 0.218 0 C-N-CA 122.864 0.466 . . . . 0.0 110.059 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 58.9 ttt85 -67.75 -19.83 65.16 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.595 177.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -171.36 169.43 42.48 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 178.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.23 -175.33 45.95 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 -178.197 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.33 160.62 49.11 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 123.866 3.044 . . . . 0.0 110.65 179.183 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.45 166.61 26.63 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.491 2.794 . . . . 0.0 110.564 176.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -149.34 170.16 19.16 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 105.634 -1.987 . . . . 0.0 105.634 -178.141 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.83 155.2 33.98 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-O 120.756 0.312 . . . . 0.0 111.731 -175.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 58' ' ' PHE . . . . . 0.47 ' CE1' ' C4 ' ' A' ' 93' ' ' ' A' . 86.4 m-85 -108.93 107.79 18.3 Favored 'General case' 0 N--CA 1.457 -0.12 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.944 169.395 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 91.2 t -80.54 141.9 14.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -177.685 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -120.09 120.17 35.47 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-O 120.652 0.263 . . . . 0.0 110.424 178.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.408 ' CZ ' HD11 ' B' ' 42' ' ' ILE . 37.0 m-85 -88.08 158.1 18.68 Favored 'General case' 0 N--CA 1.456 -0.148 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -178.441 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -86.3 -29.6 22.91 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 167.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -155.61 110.28 2.19 Favored Pre-proline 0 CA--C 1.535 0.376 0 C-N-CA 123.655 0.782 . . . . 0.0 109.598 178.349 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -58.6 -11.51 11.67 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 124.04 3.16 . . . . 0.0 113.801 -177.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.66 -25.4 67.93 Favored 'General case' 0 CA--C 1.528 0.1 0 CA-C-N 118.191 0.451 . . . . 0.0 110.862 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 78.4 m-20 -76.2 2.7 12.44 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -179.587 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.97 -8.01 26.61 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.538 0.335 . . . . 0.0 111.341 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -62.73 -24.98 67.95 Favored 'General case' 0 N--CA 1.454 -0.26 0 O-C-N 122.149 -0.344 . . . . 0.0 110.969 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -120.78 -34.4 3.58 Favored 'General case' 0 C--O 1.228 -0.063 0 N-CA-C 112.731 0.641 . . . . 0.0 112.731 178.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -79.74 -9.09 59.6 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 123.346 0.658 . . . . 0.0 111.642 -176.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 58.2 t -136.2 -43.99 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 CA-C-N 117.623 0.192 . . . . 0.0 111.111 -177.225 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 68.7 m -83.82 -2.41 56.32 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.985 -0.098 . . . . 0.0 111.197 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -76.61 -30.18 56.72 Favored Glycine 0 C--N 1.34 0.796 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 -178.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 56.2 ttm-85 -162.76 131.8 4.16 Favored 'General case' 0 C--N 1.338 0.07 0 CA-C-N 117.376 0.588 . . . . 0.0 110.762 177.626 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 26.0 p30 -160.11 153.52 22.22 Favored 'General case' 0 C--O 1.232 0.165 0 C-N-CA 123.61 0.764 . . . . 0.0 110.89 175.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 56.37 41.49 87.73 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.71 -0.556 . . . . 0.0 111.71 175.455 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 46.3 t80 -92.71 136.61 33.08 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 -173.102 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -67.51 91.75 0.29 Allowed 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 124.042 0.937 . . . . 0.0 112.224 -177.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -85.09 -175.31 5.69 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.393 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -68.73 77.05 0.3 Allowed 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 123.678 0.791 . . . . 0.0 112.379 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 86.88 5.61 80.79 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 178.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -135.21 -176.86 4.4 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.351 0.66 . . . . 0.0 112.431 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 2.3 tpt180 -139.7 129.08 24.1 Favored 'General case' 0 CA--C 1.522 -0.123 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -179.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.7 mp -70.01 148.33 48.99 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 178.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 43.0 mtp85 -131.12 125.72 33.84 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 173.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 13.8 t -139.65 82.78 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.148 0 C-N-CA 123.562 0.745 . . . . 0.0 109.84 176.235 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -147.37 161.47 40.94 Favored 'General case' 0 C--N 1.333 -0.118 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.038 -177.627 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 6.0 p90 -76.16 151.99 83.95 Favored Pre-proline 0 CA--C 1.53 0.205 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 177.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo . . . . . 0 C--O 1.251 1.128 0 C-N-CA 123.455 2.77 . . . . 0.0 111.015 177.203 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.061 0 C5'-C4'-C3' 110.043 -3.638 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.008 0 O4'-C1'-N19 111.648 3.448 . 0.363 2o . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ' C' . . . . . 0.426 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.352 1 C5'-C4'-C3' 108.074 -4.951 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' ' A' . . . . . 0.47 ' C4 ' ' CE1' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.405 0 C5'-C4'-C3' 110.141 -3.572 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.853 0 C3'-C2'-C1' 104.993 3.882 . 0.0 OUTLIER '7D dist 4p' 0.0 . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -2.967 0 C5'-C4'-C3' 109.604 -3.93 . 0.247 2u . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.1 m . . . . . 0 CA--C 1.533 0.306 0 N-CA-C 111.797 0.295 . . . . 0.0 111.797 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 33.9 mtt180 -84.5 149.7 25.76 Favored 'General case' 0 C--O 1.232 0.135 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -176.109 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 16.6 pt -140.62 174.48 7.8 Favored 'Isoleucine or valine' 0 C--O 1.23 0.07 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.917 173.295 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -109.0 150.39 27.83 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 114.497 1.295 . . . . 0.0 114.497 -177.64 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t -137.4 142.43 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.19 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.221 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.92 179.45 29.35 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -178.339 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 61.9 t30 56.23 39.42 30.25 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 123.666 0.787 . . . . 0.0 110.899 -174.352 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 84.8 mt . . . . . 0 CA--C 1.533 0.295 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.392 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 52.7 tptt . . . . . 0 N--CA 1.454 -0.257 0 N-CA-C 110.83 -0.063 . . . . 0.0 110.83 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 59.2 m-20 -64.6 -28.4 69.6 Favored 'General case' 0 C--O 1.231 0.124 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -176.744 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 31.3 mm -78.12 -23.41 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 177.735 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.4 mt-10 -86.74 -11.44 51.1 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.921 -0.127 . . . . 0.0 110.823 179.083 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 79.0 m-20 -101.33 -66.06 0.94 Allowed 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 177.134 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 41.4 t -73.84 -53.95 16.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.21 0 CA-C-N 116.756 -0.202 . . . . 0.0 111.04 -174.496 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 63.3 m-85 -69.16 -21.38 64.0 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -179.005 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 45.5 t -74.28 -32.18 62.81 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 175.693 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -68.85 -29.71 68.08 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 174.772 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 20.3 m-85 -82.69 -20.17 36.65 Favored 'General case' 0 CA--C 1.528 0.129 0 N-CA-C 116.352 1.982 . . . . 0.0 116.352 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.73 20.52 0.05 OUTLIER Glycine 0 CA--C 1.527 0.782 0 C-N-CA 119.66 -1.257 . . . . 0.0 114.775 -175.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 47.65 59.81 3.92 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 118.203 1.002 . . . . 0.0 111.667 174.34 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 29.2 mm -44.96 132.8 1.83 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 C-N-CA 123.597 0.759 . . . . 0.0 111.496 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -86.64 -37.29 18.18 Favored 'General case' 0 N--CA 1.456 -0.161 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.384 177.824 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 -147.86 150.06 33.44 Favored 'General case' 0 C--O 1.231 0.09 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -176.374 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -109.15 149.91 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 176.647 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -148.11 64.63 1.1 Allowed 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 77.7 mt -63.47 138.12 58.39 Favored 'General case' 0 C--O 1.232 0.156 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 49.3 mttp -130.64 51.76 2.09 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 123.974 0.91 . . . . 0.0 109.832 177.755 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 76.8 m-20 . . . . . 0 N--CA 1.452 -0.329 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.425 174.048 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo . . . . . 0 N--CA 1.45 -1.08 0 N-CA-C 110.535 -0.602 . . . . 0.0 110.535 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -166.32 -178.45 4.54 Favored 'General case' 0 CA--C 1.528 0.127 0 N-CA-C 105.974 -1.862 . . . . 0.0 105.974 176.001 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -158.11 166.39 32.59 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.373 0.606 . . . . 0.0 112.081 -177.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -121.32 157.82 29.55 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.575 171.034 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 75.7 t -138.9 137.21 42.76 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.134 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -178.124 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 69.0 tt0 -116.91 114.04 23.29 Favored 'General case' 0 CA--C 1.529 0.142 0 CA-C-O 120.666 0.27 . . . . 0.0 110.814 -176.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -82.11 168.56 17.62 Favored 'General case' 0 N--CA 1.457 -0.095 0 N-CA-C 115.872 1.804 . . . . 0.0 115.872 -176.074 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 48.7 tp10 -64.74 -35.73 82.01 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 174.222 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 26.1 p30 -159.19 162.92 25.17 Favored Pre-proline 0 CA--C 1.532 0.275 0 C-N-CA 123.536 0.734 . . . . 0.0 110.359 175.478 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -63.61 -18.15 63.05 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 123.116 2.544 . . . . 0.0 112.322 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 4.3 ttp85 -78.44 -40.93 34.29 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 117.849 0.295 . . . . 0.0 110.765 -175.588 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 79.5 m-20 -71.78 -24.35 61.73 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 178.74 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.59 -28.88 68.14 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 44.5 tp10 -68.77 -34.11 75.02 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 110.492 -0.188 . . . . 0.0 110.492 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -73.85 -33.99 64.33 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 178.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.86 -33.33 64.04 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 177.034 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 13.7 t -71.22 -45.23 71.81 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 48.2 t -69.79 -16.65 63.33 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 122.309 -0.244 . . . . 0.0 111.487 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.86 -8.75 41.69 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-O 119.119 -0.823 . . . . 0.0 113.711 -174.155 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -140.25 -12.26 1.07 Allowed 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 118.905 1.352 . . . . 0.0 113.277 -174.818 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -76.61 146.34 38.29 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 118.516 0.598 . . . . 0.0 110.12 -176.763 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.25 39.96 97.92 Favored Glycine 0 CA--C 1.527 0.836 0 CA-C-O 119.526 -0.597 . . . . 0.0 112.068 171.756 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 42.3 t80 -95.67 131.18 42.18 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -174.756 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -61.29 105.87 0.55 Allowed 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 123.663 0.785 . . . . 0.0 112.477 -178.679 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.427 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 46.3 t80 -112.88 169.45 8.9 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 123.738 0.815 . . . . 0.0 111.619 177.691 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.427 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 19.0 t0 -61.02 98.62 0.08 Allowed 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -179.249 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.59 -5.14 61.75 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 123.441 0.543 . . . . 0.0 112.677 177.264 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -141.3 -171.12 3.22 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 117.855 0.828 . . . . 0.0 112.954 -178.323 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 40.5 ttt180 -147.24 128.34 14.64 Favored 'General case' 0 C--O 1.231 0.113 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 -177.717 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -63.92 147.49 51.84 Favored 'General case' 0 N--CA 1.461 0.102 0 C-N-CA 122.694 0.398 . . . . 0.0 110.205 -174.84 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -118.57 119.82 35.65 Favored 'General case' 0 CA--C 1.521 -0.15 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 175.581 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.7 t -145.55 80.11 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 C-N-CA 122.878 0.471 . . . . 0.0 109.84 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -149.33 159.2 44.48 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.692 0.282 . . . . 0.0 110.807 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -74.16 156.04 87.83 Favored Pre-proline 0 CA--C 1.531 0.223 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo . . . . . 0 C--O 1.252 1.187 0 C-N-CA 123.669 2.913 . . . . 0.0 111.727 175.807 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.7 m . . . . . 0 CA--C 1.528 0.106 0 N-CA-C 110.591 -0.151 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 17' ' ' ARG . . . . . 0.423 ' HA ' ' HA ' ' B' ' 60' ' ' GLU . 32.6 ttp-105 -102.81 148.83 25.14 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.324 0.65 . . . . 0.0 110.686 -177.398 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 20.8 pt -131.67 179.23 4.54 Favored 'Isoleucine or valine' 0 C--O 1.23 0.063 0 C-N-CA 123.277 0.631 . . . . 0.0 109.835 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -118.82 156.87 28.67 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 114.248 1.203 . . . . 0.0 114.248 -175.674 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 12.7 t -134.37 123.92 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 C-N-CA 122.917 0.487 . . . . 0.0 110.705 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -130.22 166.61 22.14 Favored Glycine 0 CA--C 1.53 1.02 0 N-CA-C 111.688 -0.565 . . . . 0.0 111.688 -177.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 60.5 t30 63.65 28.61 15.06 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 124.648 1.179 . . . . 0.0 111.765 -176.021 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 87.7 mt . . . . . 0 CA--C 1.532 0.287 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 174.996 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 21.6 tptm . . . . . 0 CA--C 1.533 0.322 0 CA-C-O 120.462 0.173 . . . . 0.0 110.722 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -67.24 -30.38 70.27 Favored 'General case' 0 CA--C 1.528 0.131 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -178.61 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.3 mt -75.28 -33.09 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.503 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 99.3 mt-10 -75.34 -15.49 60.48 Favored 'General case' 0 N--CA 1.456 -0.173 0 C-N-CA 122.451 0.301 . . . . 0.0 110.986 -178.545 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -91.51 -52.18 4.91 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 112.924 0.712 . . . . 0.0 112.924 174.733 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 93.9 t -71.22 -50.91 38.26 Favored 'Isoleucine or valine' 0 C--N 1.34 0.172 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 -174.83 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -68.09 -31.9 71.84 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -177.731 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 43.8 t -66.45 -29.12 69.18 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 110.539 -0.171 . . . . 0.0 110.539 177.11 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -71.23 -31.03 67.07 Favored 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 174.59 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -79.0 -20.88 47.96 Favored 'General case' 0 C--O 1.233 0.219 0 N-CA-C 115.79 1.774 . . . . 0.0 115.79 176.376 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 169.81 -177.11 43.43 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 118.388 0.54 . . . . 0.0 112.289 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.37 95.99 8.92 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 122.838 0.455 . . . . 0.0 110.68 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 42' ' ' ILE . . . . . 0.431 ' N ' HD12 ' B' ' 42' ' ' ILE . 1.8 mp -80.28 149.6 5.13 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 C-N-CA 122.733 0.413 . . . . 0.0 110.225 175.229 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 29.1 mtp-105 -115.0 -34.06 5.2 Favored 'General case' 0 CA--C 1.528 0.119 0 C-N-CA 123.657 0.783 . . . . 0.0 111.313 177.125 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.8 m-20 -146.61 155.8 42.74 Favored 'General case' 0 N--CA 1.457 -0.105 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -176.293 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 4.1 mp -136.1 150.48 28.1 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.137 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 177.248 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -138.96 48.81 1.88 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 120.792 0.33 . . . . 0.0 111.072 179.167 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.6 tp -63.78 124.48 21.6 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 173.794 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 24.4 pttm -152.35 161.72 42.19 Favored 'General case' 0 N--CA 1.458 -0.062 0 C-N-CA 122.53 0.332 . . . . 0.0 110.666 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 18.8 p30 . . . . . 0 N--CA 1.455 -0.22 0 CA-C-O 120.891 0.377 . . . . 0.0 111.061 -177.201 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_exo . . . . . 0 N--CA 1.455 -0.745 0 N-CA-C 113.824 0.663 . . . . 0.0 113.824 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -147.61 163.4 36.75 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 104.385 -2.45 . . . . 0.0 104.385 175.264 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -149.93 163.59 37.67 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 119.997 -0.681 . . . . 0.0 112.737 -171.709 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -122.15 154.67 37.11 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.09 169.078 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 71.9 t -140.12 132.37 33.2 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.266 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.107 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 60' ' ' GLU . . . . . 0.423 ' HA ' ' HA ' ' B' ' 17' ' ' ARG . 68.2 tt0 -117.28 132.54 56.6 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.811 0.339 . . . . 0.0 111.252 -174.546 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -98.47 160.55 14.21 Favored 'General case' 0 C--O 1.231 0.12 0 N-CA-C 114.826 1.417 . . . . 0.0 114.826 -175.745 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -81.89 -17.4 47.36 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.857 0.463 . . . . 0.0 110.382 171.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -152.74 120.58 3.13 Favored Pre-proline 0 C--O 1.233 0.206 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -178.689 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.52 -14.33 44.3 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 123.066 2.51 . . . . 0.0 111.948 -175.687 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 86.7 mtm180 -71.69 -24.49 61.83 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 117.944 0.338 . . . . 0.0 110.669 176.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -87.74 -27.07 22.59 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-O 120.75 0.309 . . . . 0.0 110.751 176.016 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.03 -25.23 65.27 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 177.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -69.86 -31.08 68.73 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 122.218 0.207 . . . . 0.0 110.523 178.448 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -76.48 -35.33 58.45 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 112.308 0.485 . . . . 0.0 112.308 179.027 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.33 -27.72 66.52 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 122.634 0.373 . . . . 0.0 110.059 177.64 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 39.6 t -87.52 -44.09 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.402 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.2 t -65.98 -21.56 66.42 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-N 117.552 0.16 . . . . 0.0 111.127 -176.442 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -90.29 -15.36 57.4 Favored Glycine 0 CA--C 1.53 0.977 0 CA-C-O 119.455 -0.636 . . . . 0.0 113.004 -177.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 61.0 mtm180 -146.22 19.57 1.39 Allowed 'General case' 0 C--N 1.342 0.282 0 CA-C-N 118.24 1.02 . . . . 0.0 113.146 -170.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 18.8 p30 -70.81 -1.42 11.56 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.105 0.779 . . . . 0.0 113.105 178.029 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.82 90.69 0.08 OUTLIER Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -120.58 137.77 54.23 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 176.362 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -68.94 92.26 0.5 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.442 0.697 . . . . 0.0 111.953 -176.448 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -84.68 -175.92 5.99 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -67.89 82.79 0.2 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 123.557 0.743 . . . . 0.0 112.298 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.7 2.83 89.81 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 112.148 -0.381 . . . . 0.0 112.148 178.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -137.86 -174.57 3.82 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -179.081 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 70.5 ttp85 -140.39 135.06 31.71 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.85 151.42 45.55 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 122.666 0.387 . . . . 0.0 110.18 -179.64 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 51.5 mtm180 -134.54 55.71 1.88 Allowed 'General case' 0 C--O 1.231 0.103 0 C-N-CA 122.435 0.294 . . . . 0.0 110.849 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 20.1 t -82.95 94.83 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.188 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 174.392 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -152.31 161.47 42.56 Favored 'General case' 0 C--O 1.226 -0.174 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -76.6 156.05 83.2 Favored Pre-proline 0 CA--C 1.532 0.268 0 N-CA-C 114.666 1.358 . . . . 0.0 114.666 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo . . . . . 0 C--O 1.25 1.119 0 C-N-CA 123.789 2.993 . . . . 0.0 111.723 175.434 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 95.9 m . . . . . 0 CA--C 1.534 0.327 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 84.2 mtt-85 -83.38 146.9 28.21 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 118.272 0.487 . . . . 0.0 111.737 176.195 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 26.9 pt -131.45 172.29 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 173.702 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -120.74 149.72 42.1 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 114.185 1.18 . . . . 0.0 114.185 -178.029 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 19.7 t -137.53 141.83 38.36 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 C-N-CA 123.449 0.699 . . . . 0.0 109.728 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -150.43 171.84 30.26 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -176.107 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 65.6 t30 59.73 30.91 20.51 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.213 1.005 . . . . 0.0 111.688 -175.019 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.9 mt . . . . . 0 N--CA 1.454 -0.257 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 174.892 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 55.0 tptt . . . . . 0 N--CA 1.456 -0.129 0 N-CA-C 111.139 0.051 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -64.53 -29.78 70.81 Favored 'General case' 0 N--CA 1.455 -0.175 0 N-CA-C 112.106 0.409 . . . . 0.0 112.106 -177.089 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 mm -74.69 -21.2 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.18 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 90.2 mt-10 -78.47 -48.74 14.76 Favored 'General case' 0 C--O 1.223 -0.324 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -65.86 -44.7 84.63 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -174.312 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 99.0 t -69.84 -53.04 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.099 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -176.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -75.28 -24.1 57.49 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 113.546 0.943 . . . . 0.0 113.546 -174.736 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 41.8 t -68.89 -31.79 70.96 Favored 'General case' 0 C--N 1.342 0.265 0 CA-C-N 118.008 0.367 . . . . 0.0 110.054 173.149 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 58.3 tptt -68.36 -30.76 69.78 Favored 'General case' 0 C--N 1.341 0.212 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 174.582 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 39.6 m-85 -74.75 -20.36 59.85 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 115.457 1.651 . . . . 0.0 115.457 174.604 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 159.52 -178.0 35.81 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.835 -0.506 . . . . 0.0 111.835 176.617 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -73.79 122.19 22.04 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.65 0.262 . . . . 0.0 110.36 -178.801 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 73.8 mt -92.65 140.0 17.01 Favored 'Isoleucine or valine' 0 C--O 1.233 0.237 0 C-N-CA 122.937 0.495 . . . . 0.0 111.201 -178.43 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -94.14 -38.19 11.21 Favored 'General case' 0 N--CA 1.458 -0.071 0 C-N-CA 123.093 0.557 . . . . 0.0 110.361 170.208 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -155.94 156.76 35.12 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 120.713 0.292 . . . . 0.0 111.101 -173.349 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mt -133.28 143.3 39.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 C-N-CA 124.186 0.994 . . . . 0.0 108.854 175.281 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -144.74 64.88 1.28 Allowed 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 120.644 0.259 . . . . 0.0 111.54 -174.665 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 57.7 tp -58.23 134.75 56.8 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 169.067 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 54.8 tttp -143.23 164.23 30.78 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.841 0.353 . . . . 0.0 111.238 -168.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 44.8 p30 . . . . . 0 CA--C 1.535 0.387 0 C-N-CA 123.383 0.673 . . . . 0.0 110.694 -173.312 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo . . . . . 0 N--CA 1.452 -0.963 0 N-CA-C 110.658 -0.555 . . . . 0.0 110.658 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 3.8 p90 -152.92 173.3 15.55 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 106.281 -1.748 . . . . 0.0 106.281 -175.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.64 168.31 27.78 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 -174.294 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 80.7 m-85 -127.23 157.11 40.7 Favored 'General case' 0 C--O 1.234 0.282 0 C-N-CA 123.618 0.767 . . . . 0.0 110.056 171.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 56.0 t -143.76 142.03 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -119.18 125.26 48.78 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 177.101 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -89.49 161.68 16.11 Favored 'General case' 0 C--O 1.231 0.114 0 N-CA-C 115.272 1.582 . . . . 0.0 115.272 174.764 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 37.3 tp10 -72.18 -23.97 61.35 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.559 175.551 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 48.4 m-20 -144.47 151.86 51.85 Favored Pre-proline 0 N--CA 1.455 -0.176 0 C-N-CA 124.192 0.997 . . . . 0.0 112.292 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -68.6 -18.29 42.9 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.877 2.384 . . . . 0.0 110.615 178.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 73.0 ttt-85 -68.84 -40.04 79.63 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 177.624 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -76.07 -26.12 56.22 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 120.739 0.304 . . . . 0.0 111.664 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.87 -36.24 70.05 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 176.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 41.7 tp10 -69.35 -32.09 70.93 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 110.388 -0.227 . . . . 0.0 110.388 178.546 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -70.94 -35.9 72.4 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.43 -32.73 68.71 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 178.305 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 59.1 t -80.14 -30.48 12.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 45.7 t -79.97 -9.33 59.68 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 122.715 0.406 . . . . 0.0 110.656 178.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -66.57 -77.06 0.31 Allowed Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.217 -0.753 . . . . 0.0 111.217 -178.881 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 4.0 tpm_? -156.69 132.06 9.28 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 51.3 p-10 -153.15 168.79 24.78 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.506 0.722 . . . . 0.0 109.09 176.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 58.67 40.8 95.26 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 174.045 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -98.42 132.93 43.47 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 113.832 1.049 . . . . 0.0 113.832 -172.411 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -62.45 106.69 0.8 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.639 0.776 . . . . 0.0 112.35 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.437 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 50.1 t80 -114.31 170.31 8.39 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 123.585 0.754 . . . . 0.0 111.39 178.341 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.437 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 21.3 t0 -60.0 100.54 0.09 Allowed 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.815 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.33 -5.6 42.49 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-O 119.746 -0.474 . . . . 0.0 112.912 178.213 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 88.1 m-85 -140.34 -170.51 3.0 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 117.871 0.836 . . . . 0.0 113.241 -178.085 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 40.0 ttt180 -148.61 129.9 14.67 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 123.673 0.789 . . . . 0.0 108.953 -177.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -67.51 149.59 49.97 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -176.321 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -129.67 130.35 45.44 Favored 'General case' 0 C--N 1.34 0.181 0 CA-C-O 120.624 0.25 . . . . 0.0 110.52 172.193 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.6 t -145.3 80.36 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.099 0 C-N-CA 123.96 0.904 . . . . 0.0 109.298 173.652 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -144.63 168.36 20.34 Favored 'General case' 0 C--O 1.226 -0.132 0 C-N-CA 122.595 0.358 . . . . 0.0 111.047 -175.042 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 69.9 m-85 -63.67 153.24 84.17 Favored Pre-proline 0 C--O 1.235 0.307 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 179.03 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 C--O 1.251 1.168 0 C-N-CA 123.705 2.937 . . . . 0.0 110.932 175.168 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 69.8 m . . . . . 0 CA--C 1.533 0.292 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 66.1 mtm-85 -71.29 143.86 50.19 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 117.769 0.259 . . . . 0.0 110.796 172.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.6 pt -139.16 171.2 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.102 0 C-N-CA 123.302 0.641 . . . . 0.0 109.4 177.188 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -113.75 151.37 32.03 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 44.1 t -137.38 144.64 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 123.251 0.62 . . . . 0.0 109.462 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -156.2 177.15 33.39 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -177.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 62.1 t30 62.75 169.68 0.14 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.604 1.161 . . . . 0.0 111.406 -172.45 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 85.3 mt . . . . . 0 N--CA 1.454 -0.251 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 177.631 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 47.7 tptt . . . . . 0 CA--C 1.532 0.265 0 CA-C-O 120.554 0.216 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -53.35 -44.66 68.71 Favored 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -177.197 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.3 tt -78.55 -5.26 7.69 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 C-N-CA 122.898 0.479 . . . . 0.0 110.819 -176.445 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 84.5 mt-10 -116.85 1.43 12.7 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 122.55 0.34 . . . . 0.0 111.236 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 11.1 t0 -125.29 -54.04 1.59 Allowed 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 87.2 t -69.7 -41.99 80.2 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.042 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -178.264 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 45.4 m-85 -67.86 -27.85 67.04 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 176.47 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 67.2 m -72.65 -21.88 61.02 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.443 177.292 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 24.7 ttmm -77.75 -30.82 51.75 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 109.684 -0.488 . . . . 0.0 109.684 173.722 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -70.86 -23.13 62.26 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 114.39 1.256 . . . . 0.0 114.39 173.242 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 164.01 174.34 33.71 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 174.138 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -71.53 125.13 26.26 Favored 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 17.1 mt -99.33 138.97 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.164 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 77.8 mtp85 -86.31 -43.1 13.18 Favored 'General case' 0 C--N 1.333 -0.148 0 C-N-CA 122.897 0.479 . . . . 0.0 110.065 174.851 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -152.6 159.13 43.25 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -176.445 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.9 mp -130.02 148.68 33.18 Favored 'Isoleucine or valine' 0 C--N 1.339 0.136 0 C-N-CA 124.172 0.989 . . . . 0.0 109.627 177.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 21.2 t0 -140.72 63.97 1.44 Allowed 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.296 0.238 . . . . 0.0 111.255 176.709 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 61.2 tp -59.81 133.61 56.26 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 170.15 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 15.7 ttmm -143.62 152.2 41.08 Favored 'General case' 0 C--N 1.342 0.24 0 CA-C-O 120.74 0.305 . . . . 0.0 111.024 -173.464 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 . . . . . 0 N--CA 1.455 -0.222 0 C-N-CA 122.996 0.518 . . . . 0.0 110.563 178.891 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo . . . . . 0 N--CA 1.453 -0.883 0 N-CA-C 111.615 -0.187 . . . . 0.0 111.615 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -150.72 169.12 22.38 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 179.211 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -157.96 170.7 21.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 120.916 0.389 . . . . 0.0 111.527 -174.735 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -123.59 154.68 38.95 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.909 169.47 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 71.7 t -137.73 139.85 42.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -178.127 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -121.91 108.32 13.29 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -79.21 160.59 26.84 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 115.004 1.483 . . . . 0.0 115.004 177.6 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 41.1 tp10 -75.76 -31.85 59.71 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.542 175.136 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -133.05 150.75 76.42 Favored Pre-proline 0 CA--C 1.532 0.275 0 C-N-CA 123.707 0.803 . . . . 0.0 112.365 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -70.11 -21.6 31.62 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 123.203 2.602 . . . . 0.0 110.885 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 81.2 mtt85 -72.67 -27.89 62.37 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 178.668 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -79.76 -31.39 40.95 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 122.039 0.136 . . . . 0.0 111.318 179.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.97 -36.68 69.91 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 110.511 -0.181 . . . . 0.0 110.511 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 43.4 tp10 -68.12 -34.29 76.1 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -72.28 -35.23 68.68 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.1 -29.52 64.18 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.561 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.2 t -75.21 -50.97 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.479 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 88.0 p -73.5 -10.22 59.49 Favored 'General case' 0 C--O 1.233 0.217 0 O-C-N 122.199 -0.313 . . . . 0.0 111.661 -176.453 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -98.62 -10.38 50.44 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-O 119.167 -0.796 . . . . 0.0 113.371 -173.49 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -151.51 -13.02 0.2 Allowed 'General case' 0 C--N 1.34 0.159 0 CA-C-N 119.04 1.42 . . . . 0.0 113.206 -173.661 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -66.61 143.9 56.73 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.421 0.555 . . . . 0.0 110.146 -177.02 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 60.22 39.92 96.62 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 173.514 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 41.2 t80 -99.13 133.42 43.44 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 113.635 0.976 . . . . 0.0 113.635 -173.573 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.2 t0 -62.1 105.69 0.62 Allowed 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 123.574 0.749 . . . . 0.0 112.372 -178.186 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.423 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 51.5 t80 -111.26 169.92 8.46 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 123.829 0.852 . . . . 0.0 111.389 178.23 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.423 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 21.0 t0 -61.0 97.41 0.06 Allowed 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.375 0.509 . . . . 0.0 112.375 -179.519 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 80.68 -4.06 71.25 Favored Glycine 0 CA--C 1.53 0.994 0 CA-C-O 119.379 -0.678 . . . . 0.0 112.722 177.643 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -142.46 -170.72 3.25 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 118.142 0.971 . . . . 0.0 112.793 -177.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 36.0 ttt180 -145.89 130.22 17.66 Favored 'General case' 0 C--O 1.231 0.095 0 C-N-CA 123.466 0.706 . . . . 0.0 109.292 -178.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -63.86 152.92 38.33 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 122.952 0.501 . . . . 0.0 111.078 -174.088 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 53.1 mmm-85 -124.92 117.36 23.9 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 173.463 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 19.2 t -145.25 81.31 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.522 -0.103 0 C-N-CA 122.75 0.42 . . . . 0.0 110.252 178.091 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.9 pt-20 -142.8 168.49 19.6 Favored 'General case' 0 C--N 1.333 -0.112 0 C-N-CA 122.429 0.291 . . . . 0.0 111.066 -175.308 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 54.3 m-85 -65.15 151.66 93.27 Favored Pre-proline 0 CA--C 1.532 0.257 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo . . . . . 0 N--CA 1.448 -1.186 0 C-N-CA 123.894 3.063 . . . . 0.0 110.72 175.719 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 85.3 m . . . . . 0 CA--C 1.531 0.236 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 79.6 mtt180 -76.78 147.41 37.28 Favored 'General case' 0 CA--C 1.528 0.108 0 CA-C-N 117.889 0.313 . . . . 0.0 110.668 177.177 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 pt -135.57 167.87 24.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.107 0 C-N-CA 123.216 0.607 . . . . 0.0 109.364 173.235 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -108.61 148.65 30.03 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 114.694 1.368 . . . . 0.0 114.694 -173.309 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 21.7 t -137.13 139.05 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 C-N-CA 123.839 0.856 . . . . 0.0 110.001 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.76 175.65 30.45 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -177.384 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 54.2 t30 59.68 26.07 15.11 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.807 0.843 . . . . 0.0 111.42 -175.459 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 97.3 mt . . . . . 0 N--CA 1.455 -0.218 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 176.455 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.1 tptt . . . . . 0 N--CA 1.454 -0.234 0 CA-C-O 120.019 -0.038 . . . . 0.0 110.974 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 -67.45 -22.92 65.47 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 112.401 0.519 . . . . 0.0 112.401 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 6.4 tp -71.31 -18.18 20.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 C-N-CA 122.64 0.376 . . . . 0.0 110.188 176.719 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -96.16 -26.63 15.39 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 176.416 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -64.93 -49.91 68.54 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.625 0.25 . . . . 0.0 111.67 -177.388 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 99.7 t -67.63 -43.56 86.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -178.467 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -74.6 -32.45 62.36 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 114.52 1.304 . . . . 0.0 114.52 -177.857 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 90.0 p -69.74 -22.48 63.37 Favored 'General case' 0 C--O 1.231 0.107 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.87 175.142 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -72.26 -34.02 67.92 Favored 'General case' 0 C--N 1.34 0.193 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 173.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 49.4 m-85 -68.87 -19.1 64.23 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 170.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.76 169.3 33.14 Favored Glycine 0 CA--C 1.532 1.119 0 C-N-CA 123.183 0.42 . . . . 0.0 112.996 171.263 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 59.56 20.28 8.8 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 124.762 1.225 . . . . 0.0 113.68 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.5 mp -76.51 140.15 17.67 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 173.442 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 20.4 mmt180 -120.3 -21.92 6.74 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 122.488 0.315 . . . . 0.0 111.502 173.524 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -158.13 149.6 21.33 Favored 'General case' 0 C--N 1.339 0.137 0 N-CA-C 113.919 1.081 . . . . 0.0 113.919 176.581 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -120.4 152.24 23.31 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 171.79 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 45.1 t0 -145.16 79.07 1.58 Allowed 'General case' 0 N--CA 1.449 -0.496 0 CA-C-O 120.947 0.404 . . . . 0.0 111.374 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 55.9 tp -66.04 135.73 55.05 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 171.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 14.5 ttmm -151.86 168.29 25.58 Favored 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 -173.218 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 54.3 t30 . . . . . 0 N--CA 1.452 -0.325 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 175.496 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo . . . . . 0 N--CA 1.452 -0.955 0 N-CA-C 111.184 -0.352 . . . . 0.0 111.184 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -149.11 171.76 15.9 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 104.977 -2.231 . . . . 0.0 104.977 177.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.76 169.03 25.32 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.289 0.566 . . . . 0.0 111.941 -174.566 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -121.88 156.95 32.22 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.881 171.228 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 96.8 t -134.8 140.29 45.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -124.1 115.94 21.98 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.019 0.437 . . . . 0.0 110.538 -174.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 38.5 m-85 -91.3 161.74 14.91 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 114.256 1.206 . . . . 0.0 114.256 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -75.65 -28.23 58.67 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 170.545 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 17.2 p30 -154.8 152.55 25.87 Favored Pre-proline 0 CA--C 1.534 0.333 0 C-N-CA 123.326 0.651 . . . . 0.0 111.675 176.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.09 -7.85 22.27 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 123.24 2.626 . . . . 0.0 111.429 179.629 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 45.3 ttm105 -65.24 -38.9 91.8 Favored 'General case' 0 C--N 1.339 0.122 0 C-N-CA 122.444 0.298 . . . . 0.0 111.331 -177.154 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -94.52 -17.81 22.04 Favored 'General case' 0 C--O 1.232 0.177 0 N-CA-C 112.859 0.688 . . . . 0.0 112.859 179.112 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.7 -27.21 67.46 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -69.05 -30.36 68.68 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 110.423 -0.214 . . . . 0.0 110.423 178.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -75.98 -36.81 59.09 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 112.165 0.431 . . . . 0.0 112.165 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.01 -28.01 64.1 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 110.263 -0.273 . . . . 0.0 110.263 176.781 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 16.6 t -77.29 -50.18 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.177 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.61 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 71.1 m -73.59 -7.6 52.59 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 111.656 0.243 . . . . 0.0 111.656 -175.769 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -99.67 -8.05 52.58 Favored Glycine 0 CA--C 1.53 1.023 0 CA-C-O 119.07 -0.85 . . . . 0.0 113.423 -175.088 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 13.6 tpp180 -152.04 -13.73 0.19 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 118.489 1.145 . . . . 0.0 113.332 -174.682 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -66.65 141.86 57.64 Favored 'General case' 0 N--CA 1.456 -0.168 0 O-C-N 121.933 -0.479 . . . . 0.0 110.118 -177.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.49 43.87 97.5 Favored Glycine 0 CA--C 1.53 0.988 0 N-CA-C 111.921 -0.472 . . . . 0.0 111.921 174.61 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -101.86 137.5 40.07 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 114.132 1.16 . . . . 0.0 114.132 -173.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 11.3 t0 -63.23 109.07 1.43 Allowed 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 123.62 0.768 . . . . 0.0 112.491 -176.338 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.41 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 42.3 t80 -116.27 168.11 10.42 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 123.662 0.785 . . . . 0.0 111.524 175.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.41 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.5 t0 -58.99 98.5 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.98 -5.79 61.31 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-O 119.476 -0.624 . . . . 0.0 112.6 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -141.54 -169.32 2.85 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.007 0.904 . . . . 0.0 113.174 -177.268 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 42.3 ttp-105 -145.26 131.05 19.04 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 123.492 0.717 . . . . 0.0 109.48 -178.226 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -63.41 152.07 39.24 Favored 'General case' 0 N--CA 1.461 0.086 0 C-N-CA 122.782 0.433 . . . . 0.0 110.372 -177.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 92.1 mtm-85 -127.98 121.3 29.51 Favored 'General case' 0 CA--C 1.52 -0.177 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 173.302 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 24.2 t -142.46 81.45 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -141.54 164.26 30.71 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 111.798 0.295 . . . . 0.0 111.798 -174.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 88' ' ' PHE . . . . . 0.412 ' CD1' ' HD2' ' B' ' 89' ' ' PRO . 17.0 t80 -72.37 136.14 81.5 Favored Pre-proline 0 CA--C 1.534 0.341 0 N-CA-C 113.365 0.876 . . . . 0.0 113.365 178.494 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 89' ' ' PRO . . . . . 0.412 ' HD2' ' CD1' ' B' ' 88' ' ' PHE . 47.6 Cg_endo . . . . . 0 C--O 1.25 1.081 0 C-N-CA 123.706 2.937 . . . . 0.0 111.076 -179.073 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 72.3 m . . . . . 0 CA--C 1.533 0.291 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 52.8 mtm180 -75.38 151.65 38.15 Favored 'General case' 0 N--CA 1.456 -0.138 0 C-N-CA 122.713 0.405 . . . . 0.0 111.781 178.014 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 pt -136.9 175.52 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 170.743 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -124.76 148.25 48.21 Favored 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 114.541 1.312 . . . . 0.0 114.541 -177.715 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.2 t -135.33 140.89 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.643 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.0 179.38 27.75 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 -178.038 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 60.09 22.23 11.44 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.724 0.81 . . . . 0.0 111.251 -174.093 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 92.8 mt . . . . . 0 N--CA 1.451 -0.377 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 177.763 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.528 0.119 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -70.63 -26.69 63.59 Favored 'General case' 0 C--N 1.333 -0.124 0 O-C-N 121.966 -0.459 . . . . 0.0 110.365 178.762 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 81.0 mt -77.93 -24.03 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.096 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -80.24 -14.39 58.46 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 178.227 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -94.36 -71.45 0.66 Allowed 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 122.865 0.466 . . . . 0.0 111.858 174.11 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 53.5 t -64.12 -55.65 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.254 -171.476 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -68.01 -18.18 64.63 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -177.5 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.8 t -73.33 -31.57 64.07 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 175.456 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -73.08 -27.05 61.5 Favored 'General case' 0 C--N 1.343 0.314 0 O-C-N 122.071 -0.393 . . . . 0.0 110.609 172.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -79.07 -18.11 54.0 Favored 'General case' 0 N--CA 1.456 -0.153 0 N-CA-C 115.253 1.575 . . . . 0.0 115.253 176.1 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.35 167.26 32.9 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.608 -0.597 . . . . 0.0 111.608 177.183 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -75.86 105.57 6.97 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 80.6 mt -79.73 142.29 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.544 -178.816 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -105.94 -32.28 8.4 Favored 'General case' 0 N--CA 1.456 -0.128 0 C-N-CA 122.862 0.465 . . . . 0.0 109.869 172.146 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -152.38 155.46 37.65 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 114.271 1.211 . . . . 0.0 114.271 178.525 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 3.3 mp -117.06 149.95 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 175.191 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -146.28 52.88 1.13 Allowed 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 121.086 0.47 . . . . 0.0 109.801 -178.28 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.0 tp -63.06 135.2 57.11 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 122.678 0.391 . . . . 0.0 110.059 173.455 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 59.0 mttp -127.06 144.83 50.93 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 123.214 0.606 . . . . 0.0 110.645 178.69 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 66.8 m-20 . . . . . 0 C--O 1.232 0.139 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 171.35 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo . . . . . 0 N--CA 1.449 -1.105 0 N-CA-C 110.997 -0.424 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -152.82 165.66 34.69 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 -177.303 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.13 169.64 23.09 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 121.216 0.531 . . . . 0.0 111.46 -172.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -132.17 158.19 42.35 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 171.634 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 73.5 t -140.15 135.05 36.78 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.309 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -178.03 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 64.4 tt0 -110.58 112.03 23.66 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -80.73 162.4 24.13 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 176.825 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 89.2 tt0 -74.36 -37.8 63.38 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 174.082 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -125.24 147.48 57.53 Favored Pre-proline 0 CA--C 1.529 0.17 0 C-N-CA 123.602 0.761 . . . . 0.0 109.917 179.039 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.48 -16.57 30.7 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 123.367 2.711 . . . . 0.0 111.576 -178.416 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 23.3 ptt85 -71.74 -15.92 62.2 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 122.7 0.4 . . . . 0.0 111.314 -177.798 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.65 -21.31 60.32 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 179.163 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -70.79 -18.1 62.76 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -73.93 -17.81 60.97 Favored 'General case' 0 N--CA 1.454 -0.226 0 O-C-N 122.274 -0.266 . . . . 0.0 110.469 179.058 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 -97.85 -39.69 8.89 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.567 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -74.68 -31.35 61.88 Favored 'General case' 0 N--CA 1.453 -0.283 0 O-C-N 122.274 -0.267 . . . . 0.0 110.783 -178.705 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.43 ' O ' HG12 ' B' ' 71' ' ' VAL . 48.2 t -87.99 6.33 3.54 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 122.836 0.455 . . . . 0.0 111.6 -174.812 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.8 t -139.14 -23.04 0.91 Allowed 'General case' 0 C--O 1.232 0.146 0 O-C-N 121.819 -0.551 . . . . 0.0 111.722 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -96.22 -4.2 59.9 Favored Glycine 0 CA--C 1.526 0.737 0 CA-C-O 119.449 -0.639 . . . . 0.0 112.443 -178.713 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 3.9 tpp180 -147.48 -18.5 0.38 Allowed 'General case' 0 CA--C 1.529 0.161 0 CA-C-N 118.219 1.01 . . . . 0.0 111.993 -176.515 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -68.46 146.15 53.43 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.56 42.36 99.75 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-O 119.691 -0.505 . . . . 0.0 112.092 174.703 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 30.7 t80 -87.62 129.13 35.23 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 117.806 0.803 . . . . 0.0 113.028 -177.461 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -69.38 87.42 0.44 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 123.378 0.671 . . . . 0.0 111.442 -177.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 36.7 t80 -81.13 -177.63 6.54 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 31.1 t0 -69.7 85.2 0.46 Allowed 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.144 179.203 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.72 3.45 89.5 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-O 119.843 -0.42 . . . . 0.0 112.113 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 -133.67 -179.1 5.32 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 113.791 1.034 . . . . 0.0 113.791 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -143.19 117.85 9.82 Favored 'General case' 0 N--CA 1.456 -0.13 0 C-N-CA 123.346 0.658 . . . . 0.0 109.357 -176.679 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.77 154.08 37.97 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 122.569 0.348 . . . . 0.0 110.642 -177.398 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -124.35 118.93 27.85 Favored 'General case' 0 CA--C 1.516 -0.352 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 176.143 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 19.9 t -142.52 84.99 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 123.028 0.531 . . . . 0.0 110.109 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -143.58 161.11 39.35 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.175 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.7 p90 -77.74 152.26 80.27 Favored Pre-proline 0 CA--C 1.528 0.116 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 178.736 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo . . . . . 0 C--O 1.251 1.133 0 C-N-CA 123.526 2.817 . . . . 0.0 110.653 177.676 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 78.9 m . . . . . 0 N--CA 1.453 -0.304 0 N-CA-C 110.432 -0.21 . . . . 0.0 110.432 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 41.5 ttm105 -78.51 145.69 34.79 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 123.513 0.725 . . . . 0.0 110.385 -178.527 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.0 pt -142.76 172.87 7.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 CA-C-O 121.087 0.47 . . . . 0.0 110.92 -177.685 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -109.81 153.93 23.71 Favored 'General case' 0 C--O 1.233 0.221 0 C-N-CA 124.909 1.283 . . . . 0.0 113.602 -178.08 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 22.5 t -137.07 139.74 43.81 Favored 'Isoleucine or valine' 0 C--O 1.232 0.17 0 C-N-CA 123.367 0.667 . . . . 0.0 110.701 179.021 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -159.7 -177.7 33.03 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 56.53 26.37 10.9 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.668 0.787 . . . . 0.0 111.107 -173.265 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 91.4 mt . . . . . 0 N--CA 1.454 -0.253 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 177.524 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.4 tptt . . . . . 0 CA--C 1.529 0.139 0 N-CA-C 111.492 0.182 . . . . 0.0 111.492 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -65.35 -24.5 67.27 Favored 'General case' 0 N--CA 1.456 -0.133 0 N-CA-C 112.674 0.62 . . . . 0.0 112.674 -179.099 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 6.9 tp -72.11 -20.93 20.33 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -90.37 -28.87 18.4 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.576 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.32 -32.46 64.6 Favored 'General case' 0 C--N 1.337 0.044 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -178.46 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 53.7 t -71.75 -45.29 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 177.16 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 35.5 m-85 -72.08 -30.41 65.09 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 47.1 t -68.33 -25.58 65.18 Favored 'General case' 0 C--N 1.34 0.179 0 CA-C-N 116.953 -0.112 . . . . 0.0 110.857 174.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -75.98 -32.64 59.56 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 176.061 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 14.6 m-85 -78.57 -15.76 58.2 Favored 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 115.534 1.679 . . . . 0.0 115.534 176.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 170.64 178.89 41.64 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 177.442 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.41 113.78 19.72 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 122.779 -0.247 . . . . 0.0 110.592 -178.169 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.6 mp -86.29 140.97 15.06 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 122.731 0.412 . . . . 0.0 109.9 176.438 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 43' ' ' ARG . . . . . 0.473 ' HE ' ' HA ' ' B' ' 43' ' ' ARG . 1.7 mmp_? -108.05 -31.85 7.78 Favored 'General case' 0 N--CA 1.456 -0.13 0 C-N-CA 122.969 0.508 . . . . 0.0 110.012 174.273 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -151.32 158.8 44.28 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 45' ' ' ILE . . . . . 0.571 HG22 ' H ' ' B' ' 47' ' ' LEU . 29.9 mm -140.2 151.03 21.32 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 124.153 0.981 . . . . 0.0 109.037 179.271 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -135.62 51.9 2.03 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 175.347 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 47' ' ' LEU . . . . . 0.571 ' H ' HG22 ' B' ' 45' ' ' ILE . 51.0 tp -53.38 130.52 35.54 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.101 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 18.3 ttmm -146.46 151.33 37.22 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -172.243 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 . . . . . 0 CA--C 1.532 0.26 0 C-N-CA 122.271 0.229 . . . . 0.0 111.544 -179.304 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo . . . . . 0 N--CA 1.452 -0.918 0 CA-C-O 121.111 0.379 . . . . 0.0 111.807 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -146.9 146.63 30.22 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 124.178 0.991 . . . . 0.0 112.307 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -160.43 157.05 27.05 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -175.653 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -112.69 151.57 30.06 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.854 167.612 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.6 t -135.2 136.63 51.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -176.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 78.8 tt0 -124.25 112.66 17.28 Favored 'General case' 0 N--CA 1.455 -0.176 0 CA-C-O 120.747 0.308 . . . . 0.0 110.637 -177.77 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -84.32 159.29 20.93 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 177.367 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 33.2 tp10 -78.14 -30.33 49.21 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.439 174.542 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -129.09 150.15 74.58 Favored Pre-proline 0 C--O 1.232 0.151 0 C-N-CA 123.573 0.749 . . . . 0.0 112.538 -178.409 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.99 -24.47 24.0 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 123.431 2.754 . . . . 0.0 110.921 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 38.6 mmt180 -76.52 -24.83 53.71 Favored 'General case' 0 C--N 1.339 0.131 0 C-N-CA 121.962 0.105 . . . . 0.0 110.757 179.116 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -75.19 -34.16 61.5 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-O 120.416 0.151 . . . . 0.0 111.271 175.353 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -73.04 -32.54 65.13 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 176.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -65.81 -33.87 76.86 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.151 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -76.06 -35.62 59.35 Favored 'General case' 0 N--CA 1.457 -0.125 0 N-CA-C 113.249 0.833 . . . . 0.0 113.249 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.73 -29.16 63.13 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 122.365 -0.21 . . . . 0.0 110.505 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 55.9 t -81.43 -52.47 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.0 t -70.29 -17.27 63.09 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -174.088 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.03 -1.76 45.28 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-O 119.161 -0.799 . . . . 0.0 113.868 -173.068 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 30.1 ttp-105 -153.23 -14.02 0.15 Allowed 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 119.003 1.402 . . . . 0.0 113.19 -175.048 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -69.28 146.71 52.04 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 118.673 0.67 . . . . 0.0 110.037 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.75 38.25 95.63 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-O 119.562 -0.577 . . . . 0.0 112.313 172.767 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 37.8 t80 -88.24 130.04 35.19 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 118.089 0.945 . . . . 0.0 112.968 -176.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 29.6 t0 -68.75 89.37 0.39 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.369 0.668 . . . . 0.0 111.091 -178.51 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 35.7 t80 -81.17 -174.62 4.99 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -69.49 74.05 0.37 Allowed 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 123.765 0.826 . . . . 0.0 111.997 178.571 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.47 6.83 70.17 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 -179.707 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -133.19 -179.31 5.42 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -179.503 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 9.5 tpp180 -143.08 114.38 7.88 Favored 'General case' 0 CA--C 1.528 0.132 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -175.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -61.9 153.13 29.99 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.811 0.444 . . . . 0.0 110.245 -177.122 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 74.8 mtt180 -129.11 115.31 17.52 Favored 'General case' 0 CA--C 1.52 -0.185 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 177.681 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 38.7 t -143.14 85.14 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.183 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -148.58 165.3 31.66 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.641 0.258 . . . . 0.0 110.589 -174.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -81.79 156.82 70.0 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 113.755 1.021 . . . . 0.0 113.755 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo . . . . . 0 C--O 1.252 1.215 0 C-N-CA 123.895 3.064 . . . . 0.0 111.639 177.684 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 80.9 m . . . . . 0 CA--C 1.53 0.191 0 N-CA-C 111.598 0.221 . . . . 0.0 111.598 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 17' ' ' ARG . . . . . 0.414 ' HA ' ' HA ' ' B' ' 60' ' ' GLU . 27.5 ttm180 -74.38 149.61 40.43 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 122.831 0.452 . . . . 0.0 111.239 -175.002 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.3 pt -131.08 -178.8 2.84 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.09 0 C-N-CA 123.876 0.87 . . . . 0.0 109.645 178.379 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -120.66 150.2 41.3 Favored 'General case' 0 C--O 1.231 0.12 0 N-CA-C 114.462 1.282 . . . . 0.0 114.462 -173.657 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 46.3 t -141.05 142.29 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 C-N-CA 123.928 0.891 . . . . 0.0 109.019 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.54 -178.95 33.03 Favored Glycine 0 C--N 1.338 0.665 0 C-N-CA 121.277 -0.487 . . . . 0.0 112.515 -175.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 48.5 t30 56.48 25.96 10.32 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.245 1.018 . . . . 0.0 111.376 -176.3 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.8 mt . . . . . 0 CA--C 1.531 0.223 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.727 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 58.2 tptt . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 111.132 0.049 . . . . 0.0 111.132 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -65.61 -23.07 66.74 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 122.118 -0.364 . . . . 0.0 111.451 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mp -70.86 -22.47 23.1 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 178.582 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -96.45 -38.4 10.04 Favored 'General case' 0 N--CA 1.453 -0.305 0 O-C-N 122.359 -0.213 . . . . 0.0 110.824 -178.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -67.62 -45.71 74.64 Favored 'General case' 0 N--CA 1.458 -0.057 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -175.514 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 91.1 t -72.26 -42.37 66.06 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -178.192 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -75.32 -26.68 58.85 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -177.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.2 t -70.73 -31.0 67.69 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-O 120.557 0.218 . . . . 0.0 110.43 174.644 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 28.9 tptp -70.82 -31.33 68.02 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -85.22 -13.0 51.28 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 116.082 1.882 . . . . 0.0 116.082 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.18 171.98 38.32 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.303 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -79.1 104.46 9.74 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 122.669 0.387 . . . . 0.0 110.406 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 83.5 mt -75.58 147.27 8.25 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.145 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 176.417 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -131.02 -19.41 2.87 Favored 'General case' 0 C--N 1.34 0.168 0 C-N-CA 122.523 0.329 . . . . 0.0 111.12 175.507 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -153.7 156.03 37.08 Favored 'General case' 0 CA--C 1.528 0.102 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 174.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 18.9 mm -136.19 152.85 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.122 0 C-N-CA 123.737 0.815 . . . . 0.0 109.253 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -145.72 46.73 1.27 Allowed 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 178.707 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 28.6 tp -58.27 133.99 56.16 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 174.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 56.0 mttp -127.56 145.49 50.84 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 123.655 0.782 . . . . 0.0 110.608 178.748 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.4 p-10 . . . . . 0 CA--C 1.533 0.289 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 171.899 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo . . . . . 0 N--CA 1.454 -0.838 0 CA-C-O 120.79 0.246 . . . . 0.0 112.065 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -157.74 166.47 32.68 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.705 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.14 172.68 18.02 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-O 121.174 0.512 . . . . 0.0 112.089 -172.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -131.67 146.58 52.25 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 171.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 96.6 t -132.41 132.41 60.37 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.265 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -174.358 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 60' ' ' GLU . . . . . 0.414 ' HA ' ' HA ' ' B' ' 17' ' ' ARG . 76.2 tt0 -116.36 120.39 38.71 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 120.581 0.229 . . . . 0.0 111.433 -175.525 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -90.49 161.7 15.39 Favored 'General case' 0 C--O 1.232 0.16 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 177.511 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -71.6 -33.4 68.98 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 174.388 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -128.96 150.39 75.12 Favored Pre-proline 0 CA--C 1.53 0.189 0 C-N-CA 123.689 0.795 . . . . 0.0 111.795 -178.678 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.86 -13.89 32.23 Favored 'Trans proline' 0 N--CA 1.452 -0.913 0 C-N-CA 123.214 2.609 . . . . 0.0 110.364 176.499 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 32.5 ttp-105 -65.26 -38.25 89.72 Favored 'General case' 0 CA--C 1.528 0.124 0 C-N-CA 123.323 0.649 . . . . 0.0 110.545 178.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -77.67 -20.3 53.96 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -176.821 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.79 -29.94 65.0 Favored 'General case' 0 N--CA 1.452 -0.364 0 O-C-N 122.527 -0.108 . . . . 0.0 110.711 -177.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -72.89 -27.24 61.77 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.327 -0.233 . . . . 0.0 110.61 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -80.1 -36.45 35.41 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -178.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -76.55 -28.39 56.26 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 110.572 -0.158 . . . . 0.0 110.572 -178.583 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.5 t -79.33 -58.66 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 69.9 m -73.5 -3.33 26.95 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -175.537 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -85.41 -19.94 57.67 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 119.32 -0.711 . . . . 0.0 112.828 -176.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 24.7 ptt-85 -161.64 18.45 0.11 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 118.604 1.202 . . . . 0.0 113.009 -174.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -66.9 140.96 57.8 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.97 0.73 . . . . 0.0 112.97 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 60.28 70.87 0.89 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.828 -0.509 . . . . 0.0 111.828 174.031 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 59.6 t80 -110.73 137.91 47.79 Favored 'General case' 0 C--N 1.339 0.138 0 N-CA-C 113.571 0.952 . . . . 0.0 113.571 179.215 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -64.42 108.47 1.64 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 124.392 1.077 . . . . 0.0 112.988 -175.086 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.412 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.9 t80 -113.9 169.3 9.1 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.849 0.86 . . . . 0.0 111.26 175.266 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.412 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 75.7 m-20 -59.81 97.18 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -179.193 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 80.08 -5.65 62.07 Favored Glycine 0 CA--C 1.534 1.281 0 CA-C-O 119.315 -0.714 . . . . 0.0 112.643 177.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -139.4 -171.02 3.03 Favored 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 118.296 1.048 . . . . 0.0 113.362 -177.4 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -142.04 128.96 20.67 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -177.425 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.6 mp -63.39 150.09 44.34 Favored 'General case' 0 C--N 1.335 -0.049 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -123.11 124.87 44.05 Favored 'General case' 0 CA--C 1.52 -0.194 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.184 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.3 t -147.29 79.73 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.088 0 C-N-CA 123.603 0.761 . . . . 0.0 109.269 178.29 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.9 pt-20 -147.08 165.03 31.17 Favored 'General case' 0 C--O 1.226 -0.155 0 C-N-CA 122.667 0.387 . . . . 0.0 110.442 -177.284 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 88' ' ' PHE . . . . . 0.405 ' HA ' ' HD3' ' B' ' 89' ' ' PRO . 3.7 p90 -80.01 153.72 74.96 Favored Pre-proline 0 C--O 1.234 0.275 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 176.763 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 89' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' B' ' 88' ' ' PHE . 37.1 Cg_exo . . . . . 0 C--O 1.249 1.051 0 C-N-CA 123.746 2.964 . . . . 0.0 111.728 175.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.7 m . . . . . 0 CA--C 1.531 0.247 0 N-CA-C 111.412 0.153 . . . . 0.0 111.412 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 39.9 ttm180 -75.87 148.6 38.19 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 123.943 0.897 . . . . 0.0 110.49 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 14.2 pt -129.6 176.26 8.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 C-N-CA 122.897 0.479 . . . . 0.0 109.923 178.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -115.49 153.42 31.16 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -173.297 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 79.2 t -138.09 100.26 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -82.66 160.03 38.96 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 175.735 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 40.8 t30 60.51 -171.56 0.14 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.153 0.581 . . . . 0.0 110.25 -176.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.6 tp . . . . . 0 CA--C 1.533 0.314 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.645 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.2 tptt . . . . . 0 CA--C 1.528 0.132 0 N-CA-C 111.298 0.11 . . . . 0.0 111.298 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 71.1 m-20 -67.93 -19.76 65.01 Favored 'General case' 0 N--CA 1.457 -0.123 0 O-C-N 122.389 -0.195 . . . . 0.0 111.455 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 7.9 tp -73.19 -14.3 16.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 177.156 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -103.55 -21.25 13.78 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -71.09 -51.46 25.01 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.432 0.293 . . . . 0.0 111.585 -177.049 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 m -67.91 -33.42 61.25 Favored 'Isoleucine or valine' 0 C--N 1.338 0.082 0 CA-C-O 120.515 0.198 . . . . 0.0 110.929 -179.026 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -74.42 -35.15 63.39 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 176.054 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.4 t -66.66 -25.55 66.62 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.575 0.226 . . . . 0.0 110.599 175.59 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 29.2 tptp -77.72 -33.1 53.16 Favored 'General case' 0 N--CA 1.456 -0.149 0 N-CA-C 110.275 -0.268 . . . . 0.0 110.275 177.577 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -85.44 -9.24 57.77 Favored 'General case' 0 CA--C 1.53 0.184 0 N-CA-C 116.394 1.998 . . . . 0.0 116.394 179.1 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.42 178.54 44.4 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.73 177.405 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -79.41 43.26 0.54 Allowed 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.937 0.895 . . . . 0.0 110.99 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 42' ' ' ILE . . . . . 0.584 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.8 mp -55.77 138.25 16.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 122.695 0.398 . . . . 0.0 110.089 179.22 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 56.7 mmm-85 -94.69 -54.64 3.42 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.175 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -133.44 150.62 51.76 Favored 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -170.26 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -112.52 151.04 14.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.203 0 C-N-CA 124.596 1.158 . . . . 0.0 108.26 173.158 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -143.7 68.74 1.28 Allowed 'General case' 0 N--CA 1.452 -0.329 0 CA-C-O 120.694 0.283 . . . . 0.0 111.164 178.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 44.1 tp -70.91 129.54 39.31 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.178 174.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -114.41 140.28 48.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 123.089 0.556 . . . . 0.0 110.085 178.225 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 46.0 p-10 . . . . . 0 CA--C 1.532 0.28 0 C-N-CA 123.877 0.871 . . . . 0.0 111.179 -178.326 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo . . . . . 0 N--CA 1.448 -1.172 0 N-CA-C 110.242 -0.715 . . . . 0.0 110.242 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -157.59 162.98 38.77 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -146.62 173.68 12.12 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-O 121.083 0.468 . . . . 0.0 111.387 -172.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -138.68 160.67 39.06 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.336 175.86 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 81.9 t -137.76 134.75 45.85 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 55.1 tt0 -115.52 127.23 55.14 Favored 'General case' 0 N--CA 1.453 -0.295 0 CA-C-O 120.773 0.32 . . . . 0.0 110.741 -174.1 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.584 ' CE2' HD11 ' B' ' 42' ' ' ILE . 18.4 m-85 -95.17 151.52 19.14 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 115.314 1.598 . . . . 0.0 115.314 -172.718 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 49.8 tp10 -80.49 -26.24 38.33 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 168.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -153.05 117.54 2.85 Favored Pre-proline 0 N--CA 1.453 -0.294 0 C-N-CA 124.125 0.97 . . . . 0.0 109.468 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -66.86 -6.1 14.94 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 123.225 2.616 . . . . 0.0 112.429 -174.357 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 60.1 ttt85 -65.36 -28.88 69.6 Favored 'General case' 0 N--CA 1.456 -0.159 0 CA-C-N 118.022 0.374 . . . . 0.0 110.576 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -78.7 -15.8 58.03 Favored 'General case' 0 CA--C 1.531 0.213 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.21 -20.47 63.97 Favored 'General case' 0 N--CA 1.451 -0.411 0 O-C-N 122.198 -0.314 . . . . 0.0 110.428 -177.76 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -64.75 -26.95 68.58 Favored 'General case' 0 CA--C 1.532 0.266 0 O-C-N 122.055 -0.403 . . . . 0.0 110.336 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -90.88 -36.56 14.1 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 112.561 0.578 . . . . 0.0 112.561 178.691 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.67 -28.44 62.71 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 122.41 0.284 . . . . 0.0 110.723 -177.36 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 49.7 t -75.24 0.0 2.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.354 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 32.5 t -135.35 5.49 3.23 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.763 -0.586 . . . . 0.0 110.943 178.567 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -77.94 -28.87 55.77 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-O 119.694 -0.503 . . . . 0.0 112.129 -177.844 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 50.1 ttt180 -158.45 13.46 0.18 Allowed 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 117.624 0.712 . . . . 0.0 110.89 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 29.9 t0 -69.55 150.07 47.52 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 122.102 -0.374 . . . . 0.0 110.246 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.28 38.13 95.97 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 111.803 -0.519 . . . . 0.0 111.803 175.538 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 31.0 t80 -98.97 132.78 44.03 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 113.149 0.796 . . . . 0.0 113.149 -173.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -61.62 104.35 0.42 Allowed 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 123.559 0.744 . . . . 0.0 112.149 -179.282 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.496 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 66.2 t80 -110.35 173.44 6.33 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 123.586 0.754 . . . . 0.0 111.803 178.617 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.496 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.7 t0 -62.43 100.03 0.17 Allowed 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.67 -8.22 29.15 Favored Glycine 0 CA--C 1.531 1.076 0 C-N-CA 123.435 0.541 . . . . 0.0 112.936 177.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -138.9 -169.92 2.74 Favored 'General case' 0 C--N 1.34 0.172 0 N-CA-C 113.133 0.79 . . . . 0.0 113.133 -178.729 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 38.3 ttt180 -145.46 134.68 22.87 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -177.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -62.71 144.34 56.48 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -178.169 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 56.7 mtm180 -132.43 71.97 1.48 Allowed 'General case' 0 C--N 1.339 0.127 0 C-N-CA 122.728 0.411 . . . . 0.0 110.809 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.83 92.31 3.81 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.103 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 177.338 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.5 pt-20 -151.04 159.72 44.36 Favored 'General case' 0 C--N 1.334 -0.102 0 C-N-CA 122.658 0.383 . . . . 0.0 110.827 178.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -73.65 153.4 89.51 Favored Pre-proline 0 C--O 1.235 0.303 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo . . . . . 0 C--O 1.251 1.173 0 C-N-CA 123.839 3.026 . . . . 0.0 110.543 176.138 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 93.7 m . . . . . 0 CA--C 1.533 0.309 0 CA-C-O 120.483 0.182 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 49.2 mtt180 -73.12 156.61 38.49 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.448 0.699 . . . . 0.0 112.57 -179.128 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.0 pt -132.41 175.96 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.068 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 173.089 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -119.3 147.63 44.08 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -174.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 24.8 t -132.42 138.5 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 C-N-CA 123.312 0.645 . . . . 0.0 110.368 -179.374 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -143.6 -179.43 20.18 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -177.429 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 64.4 t30 59.48 24.4 13.07 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.812 0.845 . . . . 0.0 111.325 -173.346 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 96.1 mt . . . . . 0 CA--C 1.533 0.309 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 176.594 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.456 -0.162 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -75.55 -39.26 58.48 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 117.774 0.261 . . . . 0.0 111.109 179.621 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.412 HG22 ' H ' ' B' ' 32' ' ' ILE . 12.6 tt -78.18 -21.28 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 CA-C-N 116.688 -0.233 . . . . 0.0 110.667 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.4 mt-10 -77.29 -39.39 48.19 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.108 -0.37 . . . . 0.0 110.494 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -74.3 -33.64 63.27 Favored 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -179.287 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 41.3 t -71.3 -48.14 55.86 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -74.58 -31.79 62.18 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 39.1 t -67.81 -30.73 70.22 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.933 177.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -77.66 -26.79 50.64 Favored 'General case' 0 C--O 1.232 0.138 0 O-C-N 122.366 -0.209 . . . . 0.0 111.075 175.529 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -87.45 -8.31 56.63 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 116.435 2.013 . . . . 0.0 116.435 177.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 175.37 174.17 41.73 Favored Glycine 0 CA--C 1.524 0.599 0 C-N-CA 121.1 -0.571 . . . . 0.0 112.483 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.46 40.44 0.57 Allowed 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 123.767 0.827 . . . . 0.0 111.348 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 42' ' ' ILE . . . . . 0.593 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.9 mp -52.8 136.07 13.97 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.066 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 18.8 mmt85 -93.61 -35.18 13.0 Favored 'General case' 0 C--O 1.23 0.073 0 CA-C-O 119.492 -0.289 . . . . 0.0 111.691 -175.556 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -148.54 150.34 33.19 Favored 'General case' 0 C--O 1.232 0.147 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -177.794 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -115.15 151.8 16.84 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 C-N-CA 124.344 1.057 . . . . 0.0 108.278 174.501 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 61.6 t0 -148.16 75.12 1.32 Allowed 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.136 0.493 . . . . 0.0 110.221 179.393 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 53.9 tp -71.05 146.03 49.57 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.526 176.551 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 25.1 ttmm -146.41 141.09 26.82 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 176.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 45.8 p30 . . . . . 0 CA--C 1.53 0.174 0 N-CA-C 111.832 0.308 . . . . 0.0 111.832 -176.048 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_exo . . . . . 0 N--CA 1.451 -0.981 0 CA-C-O 120.839 0.266 . . . . 0.0 112.164 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -162.61 169.4 20.22 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -151.78 159.24 43.99 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.184 0.516 . . . . 0.0 111.68 -174.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -112.72 151.05 30.69 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.11 172.106 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.2 t -135.96 132.33 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.148 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -178.436 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 69.9 tt0 -110.57 116.27 31.07 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 122.445 0.298 . . . . 0.0 111.155 -173.698 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.593 ' CE2' HD11 ' B' ' 42' ' ' ILE . 29.7 m-85 -92.51 154.8 18.24 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -80.71 -29.97 36.38 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 171.669 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -159.93 151.17 16.14 Favored Pre-proline 0 CA--C 1.531 0.212 0 C-N-CA 125.267 1.427 . . . . 0.0 111.589 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.39 -3.04 12.2 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 123.6 2.867 . . . . 0.0 112.484 -176.807 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -63.52 -25.49 68.27 Favored 'General case' 0 CA--C 1.529 0.152 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -176.322 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -89.58 -5.15 57.46 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -177.002 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.15 -14.2 62.85 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 122.408 -0.183 . . . . 0.0 110.818 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -65.86 -17.33 64.57 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 122.419 -0.176 . . . . 0.0 111.17 -178.624 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -123.5 -37.43 2.66 Favored 'General case' 0 C--O 1.231 0.122 0 C-N-CA 122.975 0.51 . . . . 0.0 112.142 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -79.76 -9.92 59.72 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 122.58 0.352 . . . . 0.0 111.634 -175.48 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 60.4 t -131.79 -53.69 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 C-N-CA 122.374 0.27 . . . . 0.0 110.724 -178.507 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 70.5 m -70.71 -6.53 38.0 Favored 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 122.208 0.203 . . . . 0.0 111.343 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -116.09 10.44 17.79 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 119.543 -0.587 . . . . 0.0 111.764 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 74' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' B' ' 74' ' ' ARG . 46.0 ttm180 -145.05 -20.41 0.5 Allowed 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 117.933 0.866 . . . . 0.0 111.984 -176.096 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -68.89 136.16 52.18 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.315 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 67.7 27.49 73.6 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 119.779 -0.456 . . . . 0.0 112.068 176.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 50.4 t80 -79.95 140.62 36.58 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 -172.345 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.7 t0 -59.34 102.52 0.14 Allowed 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -175.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.414 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 73.9 t80 -111.8 172.26 7.0 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 123.71 0.804 . . . . 0.0 110.743 176.026 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.414 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 17.6 t0 -62.4 98.35 0.11 Allowed 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.58 -5.8 55.42 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 119.599 -0.556 . . . . 0.0 112.887 177.347 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -142.2 -175.56 4.48 Favored 'General case' 0 CA--C 1.527 0.072 0 CA-C-N 117.945 0.872 . . . . 0.0 112.882 -178.083 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 93.1 mtt-85 -131.87 138.46 48.45 Favored 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 124.191 0.996 . . . . 0.0 109.829 176.124 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -59.85 154.38 18.64 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 178.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 85' ' ' ARG . . . . . 0.407 ' NE ' ' HA ' ' B' ' 85' ' ' ARG . 1.3 tpm_? -122.42 116.45 24.0 Favored 'General case' 0 CA--C 1.518 -0.255 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 176.012 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 15.2 t -135.1 89.48 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 O-C-N 123.378 0.424 . . . . 0.0 110.063 178.462 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -146.89 158.18 43.85 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.361 178.223 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -76.56 155.09 83.69 Favored Pre-proline 0 CA--C 1.532 0.276 0 N-CA-C 114.224 1.194 . . . . 0.0 114.224 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo . . . . . 0 C--O 1.251 1.14 0 C-N-CA 123.702 2.934 . . . . 0.0 111.46 175.29 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 8.2 p . . . . . 0 C--O 1.233 0.234 0 N-CA-C 111.669 0.248 . . . . 0.0 111.669 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -63.11 144.71 56.66 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 122.857 0.463 . . . . 0.0 111.808 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.7 pt -131.67 173.16 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.885 174.256 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -111.97 150.62 30.29 Favored 'General case' 0 N--CA 1.457 -0.115 0 C-N-CA 124.356 1.062 . . . . 0.0 113.383 -177.667 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 25.9 t -133.32 91.71 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.145 0 C-N-CA 122.964 0.506 . . . . 0.0 110.35 -176.54 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -91.49 165.73 30.06 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 111.594 -0.602 . . . . 0.0 111.594 179.358 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 62.9 t30 59.96 21.09 10.13 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.026 0.93 . . . . 0.0 111.669 -176.398 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 21.0 tp . . . . . 0 CA--C 1.535 0.367 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.204 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.0 tptm . . . . . 0 C--O 1.227 -0.096 0 CA-C-O 119.916 -0.088 . . . . 0.0 111.129 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 -63.71 -19.1 64.66 Favored 'General case' 0 N--CA 1.456 -0.167 0 O-C-N 122.048 -0.407 . . . . 0.0 110.532 175.392 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 tt -67.43 -16.1 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 123.028 0.531 . . . . 0.0 110.908 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -130.66 -22.33 2.69 Favored 'General case' 0 C--N 1.341 0.198 0 CA-C-N 118.162 0.437 . . . . 0.0 111.915 177.759 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 66.4 m-20 -70.9 -29.76 65.92 Favored 'General case' 0 C--O 1.232 0.151 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 176.464 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 52.4 t -67.93 -40.8 84.02 Favored 'Isoleucine or valine' 0 C--N 1.34 0.156 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 174.255 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -67.6 -32.04 72.5 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 113.086 0.772 . . . . 0.0 113.086 176.13 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 54.5 m -65.75 -24.64 67.0 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.993 -0.094 . . . . 0.0 110.819 175.919 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 14.3 tmtt? -74.5 -34.56 63.09 Favored 'General case' 0 CA--C 1.531 0.25 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 173.091 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 39' ' ' TYR . . . . . 0.412 ' CD1' ' HA ' ' B' ' 70' ' ' ALA . 40.0 m-85 -72.04 -20.86 61.62 Favored 'General case' 0 CA--C 1.529 0.169 0 N-CA-C 115.582 1.697 . . . . 0.0 115.582 175.496 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 161.72 -169.43 37.17 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 178.676 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.41 108.51 17.26 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 120.778 0.323 . . . . 0.0 111.174 -177.79 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 42' ' ' ILE . . . . . 0.438 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.8 mp -97.55 147.66 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.157 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 173.308 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -115.3 -24.05 8.63 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 119.384 -0.341 . . . . 0.0 111.209 177.607 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -151.38 158.78 44.2 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 114.071 1.137 . . . . 0.0 114.071 -179.051 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 45' ' ' ILE . . . . . 0.414 HD12 ' HA ' ' B' ' 45' ' ' ILE . 10.9 tp -124.28 159.67 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 176.318 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -153.19 63.28 0.76 Allowed 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.826 0.346 . . . . 0.0 110.752 -177.019 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.1 tp -63.37 135.89 57.28 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 175.198 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 48' ' ' LYS . . . . . 0.528 ' HE2' ' CZ ' ' B' ' 56' ' ' PHE . 35.5 mtmm -141.09 176.43 8.83 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 123.795 0.838 . . . . 0.0 111.239 -178.327 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.5 p30 . . . . . 0 C--O 1.233 0.21 0 C-N-CA 122.928 0.491 . . . . 0.0 110.661 -178.962 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo . . . . . 0 N--CA 1.451 -1.012 0 N-CA-C 110.435 -0.64 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 56' ' ' PHE . . . . . 0.528 ' CZ ' ' HE2' ' B' ' 48' ' ' LYS . 3.1 p90 -155.34 167.34 30.69 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -146.83 156.98 43.54 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.133 0.492 . . . . 0.0 111.74 -175.77 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -106.78 150.85 25.9 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 115.179 -0.919 . . . . 0.0 112.332 170.202 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 72.8 t -131.82 137.98 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.264 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 -179.324 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -122.17 118.42 28.59 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.69 0.281 . . . . 0.0 110.557 -177.234 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.438 ' CE2' HD11 ' B' ' 42' ' ' ILE . 54.2 m-85 -85.52 151.85 23.63 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 115.39 1.626 . . . . 0.0 115.39 -177.498 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 40.3 tp10 -78.53 -18.4 54.78 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.379 0.672 . . . . 0.0 109.851 173.418 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -148.44 119.53 4.32 Favored Pre-proline 0 CA--C 1.532 0.269 0 C-N-CA 123.482 0.713 . . . . 0.0 110.072 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_exo -55.08 -20.5 24.0 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.411 2.741 . . . . 0.0 113.324 -177.402 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 53.3 tpt85 -69.54 -32.55 71.43 Favored 'General case' 0 C--N 1.342 0.243 0 CA-C-N 118.295 0.498 . . . . 0.0 110.971 179.578 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -74.05 -24.39 59.52 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -179.867 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.46 -24.11 64.67 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.239 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -73.79 -27.71 61.27 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 178.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 77.4 m-20 -78.04 -38.43 44.61 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 112.386 0.513 . . . . 0.0 112.386 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 70' ' ' ALA . . . . . 0.412 ' HA ' ' CD1' ' B' ' 39' ' ' TYR . . . -70.77 -31.05 67.71 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 110.343 -0.243 . . . . 0.0 110.343 178.389 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 37.3 t -80.6 -43.91 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.474 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 46.0 t -66.27 -20.97 66.26 Favored 'General case' 0 CA--C 1.533 0.29 0 O-C-N 122.197 -0.315 . . . . 0.0 111.127 -177.467 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -91.03 -15.27 56.43 Favored Glycine 0 CA--C 1.529 0.938 0 CA-C-O 119.307 -0.718 . . . . 0.0 113.17 -177.001 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 62.7 mtt180 -147.62 21.54 1.16 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.448 1.124 . . . . 0.0 113.045 -172.275 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 16.5 p30 -69.32 1.71 3.58 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 177.538 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.24 90.44 0.08 OUTLIER Glycine 0 C--N 1.336 0.582 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -125.53 139.49 53.56 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 178.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -64.39 106.5 1.13 Allowed 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.628 0.771 . . . . 0.0 112.65 -177.066 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.444 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.0 t80 -111.46 170.35 8.18 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 123.677 0.791 . . . . 0.0 111.446 177.348 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.444 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.1 t0 -59.15 100.9 0.08 Allowed 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -179.198 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 75.81 -5.28 40.32 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-O 119.661 -0.522 . . . . 0.0 112.888 177.717 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -141.43 -169.49 2.88 Favored 'General case' 0 C--O 1.232 0.161 0 N-CA-C 113.513 0.931 . . . . 0.0 113.513 -177.723 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 42.2 ttp-105 -142.04 139.31 32.29 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.672 0.789 . . . . 0.0 109.162 179.22 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.72 151.15 45.85 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 -178.414 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 90.1 mtm-85 -133.61 56.17 1.86 Allowed 'General case' 0 C--N 1.339 0.135 0 CA-C-O 120.75 0.31 . . . . 0.0 110.799 177.781 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 23.1 t -82.21 93.95 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 175.676 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.9 pt-20 -151.9 162.72 40.6 Favored 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 122.51 0.324 . . . . 0.0 110.205 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.4 p90 -78.09 157.56 78.4 Favored Pre-proline 0 N--CA 1.453 -0.306 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 177.418 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo . . . . . 0 C--O 1.252 1.219 0 C-N-CA 123.903 3.069 . . . . 0.0 111.658 177.45 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 75.2 m . . . . . 0 CA--C 1.531 0.244 0 N-CA-C 111.34 0.126 . . . . 0.0 111.34 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 48.8 mtt-85 -78.51 151.1 32.73 Favored 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 112.705 0.631 . . . . 0.0 112.705 -177.164 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.4 pt -139.14 171.59 14.44 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 C-N-CA 123.507 0.723 . . . . 0.0 109.524 174.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 19' ' ' TYR . . . . . 0.4 ' HB2' ' CZ ' ' B' ' 58' ' ' PHE . 0.3 OUTLIER -113.21 153.12 28.86 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -175.99 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 58.7 t -136.77 140.89 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.317 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -146.87 174.62 26.63 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.925 -0.47 . . . . 0.0 111.925 -176.504 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 66.3 t30 62.91 157.35 0.06 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.772 1.229 . . . . 0.0 111.463 -172.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.2 tp . . . . . 0 N--CA 1.453 -0.306 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.734 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 30' ' ' LYS . . . . . 0.425 ' HE3' ' HB2' ' B' ' 30' ' ' LYS . 0.0 OUTLIER . . . . . 0 CA--C 1.527 0.085 0 N-CA-C 111.427 0.158 . . . . 0.0 111.427 . . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -64.65 -19.75 65.89 Favored 'General case' 0 N--CA 1.457 -0.112 0 O-C-N 122.116 -0.365 . . . . 0.0 111.979 178.649 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 7.5 tp -71.64 -17.69 19.59 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 175.868 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 81.6 mt-10 -94.96 -36.52 11.55 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -69.52 -39.97 77.2 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -177.023 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 77.1 t -72.14 -41.89 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.075 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.384 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 39.0 m-85 -74.06 -37.78 64.16 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 114.02 1.119 . . . . 0.0 114.02 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 91.7 p -69.21 -22.12 63.9 Favored 'General case' 0 C--N 1.34 0.175 0 CA-C-N 117.729 0.241 . . . . 0.0 110.422 177.54 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -74.73 -34.06 62.49 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.233 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -81.22 -13.26 58.72 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 115.926 1.825 . . . . 0.0 115.926 177.708 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.16 175.37 43.47 Favored Glycine 0 CA--C 1.527 0.819 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.053 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -82.27 80.02 8.58 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.097 0.559 . . . . 0.0 110.601 -178.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.7 mp -65.51 140.22 20.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.105 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 174.495 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 43' ' ' ARG . . . . . 0.43 ' HE ' ' HA ' ' B' ' 43' ' ' ARG . 1.7 mmp_? -109.76 -27.84 9.12 Favored 'General case' 0 N--CA 1.457 -0.082 0 C-N-CA 122.869 0.467 . . . . 0.0 110.739 177.361 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -151.79 163.43 39.18 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 113.815 1.042 . . . . 0.0 113.815 -179.223 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 7.6 tp -142.17 160.56 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -177.653 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -153.95 68.55 0.76 Allowed 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 176.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 49.0 tp -69.3 133.31 47.71 Favored 'General case' 0 CA--C 1.529 0.141 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 175.653 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 48' ' ' LYS . . . . . 0.485 ' HD2' ' CZ ' ' B' ' 56' ' ' PHE . 67.3 mttm -126.5 128.84 47.55 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 122.559 0.344 . . . . 0.0 110.542 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 10.1 p30 . . . . . 0 CA--C 1.533 0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.124 175.879 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo . . . . . 0 N--CA 1.449 -1.142 0 N-CA-C 110.247 -0.713 . . . . 0.0 110.247 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 56' ' ' PHE . . . . . 0.485 ' CZ ' ' HD2' ' B' ' 48' ' ' LYS . 3.3 p90 -161.58 171.69 17.6 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 178.097 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.38 164.37 38.37 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.213 0.53 . . . . 0.0 111.691 -175.743 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 58' ' ' PHE . . . . . 0.4 ' CZ ' ' HB2' ' B' ' 19' ' ' TYR . 9.7 m-85 -116.81 151.62 36.11 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.372 -0.831 . . . . 0.0 113.073 169.396 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 48.2 t -133.41 142.23 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 C-N-CA 123.189 0.596 . . . . 0.0 109.62 -177.212 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -123.99 117.82 25.62 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 110.444 -0.206 . . . . 0.0 110.444 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 49.3 m-85 -90.33 158.27 17.22 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 113.774 1.027 . . . . 0.0 113.774 177.771 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -70.77 -24.28 62.56 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 174.042 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -152.64 155.52 32.64 Favored Pre-proline 0 CA--C 1.533 0.314 0 C-N-CA 123.367 0.667 . . . . 0.0 111.952 178.511 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -71.92 -7.74 21.65 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 123.054 2.502 . . . . 0.0 111.359 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.28 -53.93 14.77 Favored 'General case' 0 C--N 1.339 0.12 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -177.112 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -70.75 -20.22 62.65 Favored 'General case' 0 C--O 1.233 0.185 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -177.564 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.05 -23.92 65.93 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.412 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 45.6 tp10 -72.77 -32.48 65.64 Favored 'General case' 0 N--CA 1.455 -0.2 0 O-C-N 122.273 -0.267 . . . . 0.0 110.318 179.539 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 62.0 m-20 -73.49 -36.8 65.84 Favored 'General case' 0 CA--C 1.522 -0.116 0 N-CA-C 111.979 0.362 . . . . 0.0 111.979 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.8 -27.92 63.26 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 122.164 0.186 . . . . 0.0 110.557 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 42.6 t -83.19 -54.32 9.49 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.2 t -70.68 -18.91 62.83 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 -174.17 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -101.31 0.54 53.91 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-O 119.031 -0.872 . . . . 0.0 113.585 -173.04 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 28.9 ttp-105 -153.78 -13.18 0.14 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-N 118.846 1.323 . . . . 0.0 113.393 -175.664 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -67.68 145.69 54.53 Favored 'General case' 0 C--O 1.233 0.226 0 O-C-N 121.465 -0.772 . . . . 0.0 110.315 179.485 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.51 55.17 26.95 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.554 -0.618 . . . . 0.0 111.554 175.599 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 39.2 t80 -105.96 140.38 39.06 Favored 'General case' 0 N--CA 1.453 -0.288 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -178.094 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -62.91 110.55 1.81 Allowed 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 124.2 1.0 . . . . 0.0 113.012 -175.535 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.421 ' CD2' ' N ' ' B' ' 80' ' ' ASP . 25.6 t80 -118.88 165.93 13.45 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 123.66 0.784 . . . . 0.0 111.941 174.756 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.421 ' N ' ' CD2' ' B' ' 79' ' ' TYR . 19.4 t0 -59.07 98.09 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.436 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -178.661 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.9 -4.91 63.79 Favored Glycine 0 CA--C 1.535 1.285 0 CA-C-O 119.747 -0.474 . . . . 0.0 112.677 177.69 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -140.56 -170.22 2.96 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 117.952 0.876 . . . . 0.0 113.15 -178.185 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 -141.38 133.35 27.59 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 -178.158 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -65.13 152.03 44.6 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.27 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -125.72 126.92 45.39 Favored 'General case' 0 CA--C 1.52 -0.173 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 175.572 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 38.9 t -143.95 81.26 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.245 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 176.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -139.8 158.22 44.45 Favored 'General case' 0 C--O 1.224 -0.281 0 C-N-CA 122.664 0.386 . . . . 0.0 110.551 -175.457 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.0 p90 -74.54 154.79 87.64 Favored Pre-proline 0 N--CA 1.454 -0.269 0 N-CA-C 114.73 1.381 . . . . 0.0 114.73 179.245 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo . . . . . 0 C--O 1.253 1.255 0 C-N-CA 123.646 2.897 . . . . 0.0 110.877 176.937 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 86.6 m . . . . . 0 CA--C 1.533 0.322 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 68.5 mtm-85 -87.76 138.21 31.66 Favored 'General case' 0 N--CA 1.453 -0.316 0 O-C-N 122.1 -0.375 . . . . 0.0 111.336 178.618 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.6 pp -138.05 168.89 19.48 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 C-N-CA 123.148 0.579 . . . . 0.0 110.072 176.128 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -113.33 153.31 28.71 Favored 'General case' 0 CA--C 1.528 0.104 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -177.228 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 93.0 t -133.99 115.21 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -117.56 169.95 13.38 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 177.573 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 61.1 t30 57.99 23.68 10.21 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.704 0.801 . . . . 0.0 111.113 -175.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 21.2 tp . . . . . 0 CA--C 1.535 0.374 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 178.95 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 4.2 ttpt . . . . . 0 C--O 1.226 -0.144 0 N-CA-C 110.714 -0.106 . . . . 0.0 110.714 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -69.23 -31.79 70.58 Favored 'General case' 0 C--O 1.233 0.189 0 O-C-N 122.169 -0.332 . . . . 0.0 111.581 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.4 tt -76.48 -11.24 13.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 O-C-N 123.169 0.293 . . . . 0.0 110.99 -178.459 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -118.97 -0.56 11.14 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 117.833 0.288 . . . . 0.0 110.807 177.471 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -94.49 -62.41 1.33 Allowed 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 122.551 0.34 . . . . 0.0 111.674 177.695 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 62.9 t -65.4 -41.12 90.4 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 -178.518 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -62.94 -31.03 72.03 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.4 t -68.07 -30.8 70.08 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 110.228 -0.286 . . . . 0.0 110.228 177.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 47.1 mmtm -69.35 -28.28 66.08 Favored 'General case' 0 C--N 1.338 0.082 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 173.497 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -80.18 -19.11 47.86 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 116.665 2.098 . . . . 0.0 116.665 176.125 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.49 20.24 0.03 OUTLIER Glycine 0 CA--C 1.53 0.99 0 C-N-CA 119.584 -1.293 . . . . 0.0 114.64 -177.515 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 50.85 66.69 1.1 Allowed 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 118.279 1.039 . . . . 0.0 111.987 176.423 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 42' ' ' ILE . . . . . 0.511 HD11 ' CZ ' ' B' ' 61' ' ' PHE . 1.7 mp -56.02 141.95 11.83 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 C-N-CA 122.951 0.5 . . . . 0.0 110.447 178.054 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 43' ' ' ARG . . . . . 0.421 HH11 ' HD3' ' B' ' 43' ' ' ARG . 10.6 mmm180 -107.05 -24.7 11.88 Favored 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 122.603 0.361 . . . . 0.0 111.262 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -146.59 155.25 42.34 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 45' ' ' ILE . . . . . 0.458 HG22 ' H ' ' B' ' 47' ' ' LEU . 17.7 mm -139.13 154.36 25.5 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 C-N-CA 124.203 1.001 . . . . 0.0 109.407 -178.21 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -142.38 47.67 1.58 Allowed 'General case' 0 CA--C 1.531 0.233 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 177.066 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 47' ' ' LEU . . . . . 0.458 ' H ' HG22 ' B' ' 45' ' ' ILE . 58.7 tp -61.5 128.21 35.19 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.55 177.626 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 48' ' ' LYS . . . . . 0.532 ' HE2' ' CZ ' ' B' ' 56' ' ' PHE . 23.2 pttm -157.74 173.14 17.27 Favored 'General case' 0 CA--C 1.528 0.102 0 C-N-CA 123.551 0.74 . . . . 0.0 109.691 179.04 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 50.8 p30 . . . . . 0 CA--C 1.531 0.219 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -174.445 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo . . . . . 0 N--CA 1.452 -0.923 0 N-CA-C 110.945 -0.444 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 56' ' ' PHE . . . . . 0.532 ' CZ ' ' HE2' ' B' ' 48' ' ' LYS . 4.2 p90 -157.24 163.07 39.17 Favored 'General case' 0 C--O 1.234 0.25 0 N-CA-C 104.696 -2.335 . . . . 0.0 104.696 174.794 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.17 152.88 29.94 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 119.713 -0.795 . . . . 0.0 112.611 -172.755 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -96.5 148.24 23.02 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.707 166.725 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 58.5 t -133.98 143.8 37.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -178.439 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -132.21 118.39 19.47 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 120.956 0.408 . . . . 0.0 110.763 -176.822 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.511 ' CZ ' HD11 ' B' ' 42' ' ' ILE . 34.5 m-85 -86.96 161.97 17.93 Favored 'General case' 0 C--N 1.333 -0.115 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -177.436 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -79.98 -27.92 39.59 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.425 174.36 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -138.51 143.51 38.62 Favored Pre-proline 0 C--N 1.34 0.182 0 C-N-CA 123.85 0.86 . . . . 0.0 112.006 179.055 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -73.83 -19.7 20.64 Favored 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 123.281 2.654 . . . . 0.0 111.257 -177.65 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 78.7 mtt85 -74.18 -25.23 59.59 Favored 'General case' 0 N--CA 1.456 -0.136 0 C-N-CA 122.398 0.279 . . . . 0.0 111.381 -178.154 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -91.96 -21.89 20.3 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.642 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.73 -27.06 66.48 Favored 'General case' 0 N--CA 1.453 -0.276 0 O-C-N 122.274 -0.267 . . . . 0.0 110.282 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -73.55 -26.66 60.95 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 121.9 0.08 . . . . 0.0 110.848 179.001 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -77.25 -36.23 54.67 Favored 'General case' 0 CA--C 1.521 -0.14 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.84 -29.06 61.92 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 122.259 0.224 . . . . 0.0 110.439 177.578 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 17.2 t -80.94 -42.81 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 43.8 t -66.97 -21.83 65.95 Favored 'General case' 0 CA--C 1.528 0.108 0 O-C-N 122.177 -0.327 . . . . 0.0 111.063 -178.156 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -89.66 -2.88 75.15 Favored Glycine 0 CA--C 1.531 1.071 0 CA-C-O 119.387 -0.674 . . . . 0.0 112.92 -178.361 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 80.3 mtt85 -141.93 -8.48 0.92 Allowed 'General case' 0 C--N 1.341 0.211 0 CA-C-N 118.181 0.99 . . . . 0.0 112.827 -174.391 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -67.3 118.64 10.95 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -179.286 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.81 45.37 96.35 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 175.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 53.9 t80 -95.97 135.94 37.06 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -172.693 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.6 t0 -63.51 105.33 0.76 Allowed 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.52 0.728 . . . . 0.0 112.557 -177.506 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.434 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 62.8 t80 -111.72 171.05 7.72 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.733 0.813 . . . . 0.0 111.301 177.766 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.434 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 19.7 t0 -60.5 98.83 0.07 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -179.464 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 77.88 -4.69 56.57 Favored Glycine 0 CA--C 1.536 1.35 0 CA-C-O 119.474 -0.626 . . . . 0.0 112.938 177.405 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -140.93 -171.14 3.19 Favored 'General case' 0 N--CA 1.462 0.148 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 41.7 ttp-105 -145.08 131.07 19.24 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.86 0.864 . . . . 0.0 109.334 -178.107 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.9 mp -66.62 153.79 42.18 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-O 120.923 0.392 . . . . 0.0 110.477 -175.768 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 52.8 mtm180 -129.47 47.27 2.51 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.457 0.703 . . . . 0.0 110.167 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 88.3 t -77.32 98.43 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 175.088 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -151.09 162.49 40.75 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.629 0.252 . . . . 0.0 110.655 179.178 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -73.05 152.51 90.71 Favored Pre-proline 0 C--O 1.234 0.24 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 178.174 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo . . . . . 0 C--O 1.251 1.15 0 C-N-CA 123.739 2.959 . . . . 0.0 110.735 177.836 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 76.4 m . . . . . 0 CA--C 1.532 0.28 0 N-CA-C 110.732 -0.099 . . . . 0.0 110.732 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 18.4 ttm180 -84.25 152.65 24.05 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 178.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 15.3 pt -136.17 -178.77 2.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.141 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 175.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -122.58 148.76 44.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.452 -0.794 . . . . 0.0 112.762 177.226 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 21.2 t -137.9 90.47 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 120.451 0.167 . . . . 0.0 110.755 -176.598 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -80.8 146.5 27.0 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 174.658 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 44.7 t30 58.28 -171.12 0.11 Allowed 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 122.786 0.434 . . . . 0.0 110.292 -174.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.409 ' H ' HD23 ' B' ' 23' ' ' LEU . 2.1 pt? . . . . . 0 CA--C 1.534 0.338 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 177.107 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 30' ' ' LYS . . . . . 0.417 ' HE3' ' HB2' ' B' ' 34' ' ' ASP . 30.8 ttpt . . . . . 0 CA--C 1.529 0.165 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -58.83 -23.67 60.91 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -179.004 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 27.7 mm -74.8 -17.49 16.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 122.653 0.381 . . . . 0.0 110.636 179.565 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -126.42 13.53 7.63 Favored 'General case' 0 C--N 1.34 0.159 0 CA-C-N 117.772 0.26 . . . . 0.0 111.052 178.57 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 34' ' ' ASP . . . . . 0.417 ' HB2' ' HE3' ' B' ' 30' ' ' LYS . 22.0 t0 -127.93 -60.86 1.14 Allowed 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 173.011 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 95.1 t -69.55 -53.18 26.03 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -65.14 -19.3 65.92 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 175.892 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 47.5 t -71.57 -28.94 64.19 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 175.724 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -74.82 -26.93 60.06 Favored 'General case' 0 CA--C 1.529 0.144 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 171.154 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -73.55 -23.78 60.03 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 115.928 1.825 . . . . 0.0 115.928 174.685 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.57 16.48 0.03 OUTLIER Glycine 0 CA--C 1.53 1.026 0 C-N-CA 120.219 -0.991 . . . . 0.0 114.074 -177.383 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.21 77.28 0.14 Allowed 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 117.886 0.843 . . . . 0.0 112.191 176.774 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.8 mp -60.07 142.32 15.56 Favored 'Isoleucine or valine' 0 C--O 1.232 0.138 0 C-N-CA 122.742 0.417 . . . . 0.0 110.225 177.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 43' ' ' ARG . . . . . 0.492 ' HE ' ' HA ' ' B' ' 62' ' ' GLU . 48.6 mtm105 -102.96 -30.99 10.45 Favored 'General case' 0 CA--C 1.523 -0.063 0 C-N-CA 122.393 0.277 . . . . 0.0 111.177 176.272 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -149.67 158.26 44.0 Favored 'General case' 0 C--O 1.232 0.134 0 N-CA-C 114.002 1.112 . . . . 0.0 114.002 -177.057 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 53.4 mt -125.59 150.8 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.149 0 C-N-CA 123.7 0.8 . . . . 0.0 109.098 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -141.01 50.71 1.63 Allowed 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 54.8 tp -60.55 135.58 57.8 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.099 177.034 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 25.3 ttmm -143.77 152.36 41.14 Favored 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 122.886 0.475 . . . . 0.0 110.116 -179.095 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 44.4 p30 . . . . . 0 CA--C 1.534 0.336 0 C-N-CA 122.61 0.364 . . . . 0.0 111.949 -178.345 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo . . . . . 0 N--CA 1.449 -1.097 0 N-CA-C 110.918 -0.455 . . . . 0.0 110.918 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -154.11 164.5 38.39 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 175.523 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -153.11 165.5 35.44 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-O 120.935 0.398 . . . . 0.0 111.883 -173.062 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -121.37 79.52 1.55 Allowed 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.471 175.02 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.5 t -67.49 147.48 12.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 C-N-CA 123.23 0.612 . . . . 0.0 110.19 -174.348 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -123.84 122.32 37.7 Favored 'General case' 0 CA--C 1.529 0.161 0 CA-C-O 120.825 0.345 . . . . 0.0 110.804 -178.146 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -94.58 164.92 12.78 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 115.464 1.653 . . . . 0.0 115.464 -175.322 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 62' ' ' GLU . . . . . 0.492 ' HA ' ' HE ' ' B' ' 43' ' ' ARG . 85.0 tt0 -73.58 -32.18 63.99 Favored 'General case' 0 C--N 1.34 0.183 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.661 174.332 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -141.59 145.82 39.02 Favored Pre-proline 0 CA--C 1.529 0.149 0 C-N-CA 123.771 0.828 . . . . 0.0 111.955 179.772 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -73.77 -19.58 20.92 Favored 'Trans proline' 0 N--CA 1.452 -0.941 0 C-N-CA 123.179 2.586 . . . . 0.0 110.841 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.74 -35.43 57.77 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 122.122 0.169 . . . . 0.0 110.838 -178.569 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -77.51 -17.72 57.71 Favored 'General case' 0 CA--C 1.527 0.083 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 178.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.53 -20.95 64.59 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 177.887 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -70.31 -34.25 72.48 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 177.624 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -75.83 -34.12 60.1 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.03 -31.69 64.6 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 178.646 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 7.5 t -73.69 -42.37 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 67.0 m -74.78 -0.49 18.43 Favored 'General case' 0 C--O 1.232 0.152 0 C-N-CA 122.136 0.175 . . . . 0.0 111.056 179.278 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -73.16 -35.66 57.02 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 119.487 -0.619 . . . . 0.0 112.756 -175.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 23.6 ttt180 -163.15 30.39 0.09 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.194 0.997 . . . . 0.0 111.631 -176.423 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -65.0 144.29 57.39 Favored 'General case' 0 C--O 1.232 0.14 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -179.607 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 57.78 46.47 92.27 Favored Glycine 0 C--N 1.338 0.656 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 174.533 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 77' ' ' TYR . . . . . 0.564 ' H ' ' HB2' ' B' ' 84' ' ' LEU . 16.7 t80 -98.67 137.42 37.33 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.673 0.736 . . . . 0.0 112.853 -173.925 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -67.95 83.35 0.21 Allowed 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 124.29 1.036 . . . . 0.0 112.059 -177.772 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.449 ' CD2' ' N ' ' B' ' 80' ' ' ASP . 54.2 t80 -82.89 171.31 14.02 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 123.199 0.6 . . . . 0.0 111.218 177.532 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.449 ' N ' ' CD2' ' B' ' 79' ' ' TYR . 24.9 t0 -64.5 93.84 0.11 Allowed 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.96 -1.81 88.33 Favored Glycine 0 CA--C 1.53 0.997 0 CA-C-O 119.762 -0.465 . . . . 0.0 112.615 177.244 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -141.93 -172.69 3.62 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 117.876 0.838 . . . . 0.0 112.669 -179.149 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 4.6 tpt180 -137.59 133.78 34.81 Favored 'General case' 0 C--O 1.232 0.143 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 84' ' ' LEU . . . . . 0.564 ' HB2' ' H ' ' B' ' 77' ' ' TYR . 4.2 mm? -64.66 139.23 58.74 Favored 'General case' 0 C--N 1.333 -0.117 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.148 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 95.3 mtm-85 -129.04 54.98 1.76 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 122.701 0.4 . . . . 0.0 110.288 175.517 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 2.7 p -81.28 97.64 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 175.017 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -153.68 169.49 23.18 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 122.875 0.47 . . . . 0.0 110.686 -179.348 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -65.26 151.72 93.32 Favored Pre-proline 0 CA--C 1.53 0.203 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo . . . . . 0 C--O 1.25 1.107 0 C-N-CA 123.678 2.918 . . . . 0.0 110.761 177.221 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 73.9 m . . . . . 0 CA--C 1.532 0.26 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 54.6 mtm180 -82.16 145.26 30.2 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 118.422 0.555 . . . . 0.0 111.305 175.663 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 22.8 pt -138.62 175.73 7.77 Favored 'Isoleucine or valine' 0 C--O 1.231 0.095 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 170.138 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -119.34 148.82 42.75 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 114.553 1.316 . . . . 0.0 114.553 -177.839 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 60.7 t -132.88 136.58 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 123.226 0.61 . . . . 0.0 109.634 179.279 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -140.52 172.15 23.69 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.325 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 51.2 t30 57.07 19.74 4.95 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.729 0.812 . . . . 0.0 111.41 -174.44 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.7 tp . . . . . 0 N--CA 1.454 -0.258 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.723 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt . . . . . 0 CA--C 1.532 0.281 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -58.84 -25.48 63.27 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 179.423 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.9 tt -76.27 -17.87 15.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 C-N-CA 122.335 0.254 . . . . 0.0 110.511 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.1 mt-10 -93.41 -31.04 14.78 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -74.13 -37.26 64.13 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 -177.655 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 62.4 t -69.71 -46.1 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.353 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -68.79 -35.4 76.99 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 113.615 0.969 . . . . 0.0 113.615 178.064 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 33.5 t -60.9 -33.5 73.21 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 178.283 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 16.7 tppt? -73.76 -33.43 64.29 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 122.2 0.2 . . . . 0.0 110.769 177.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -87.04 -13.83 43.28 Favored 'General case' 0 C--O 1.233 0.206 0 N-CA-C 116.739 2.125 . . . . 0.0 116.739 -178.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.08 13.83 0.03 OUTLIER Glycine 0 CA--C 1.527 0.843 0 C-N-CA 119.906 -1.14 . . . . 0.0 114.254 -177.447 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.62 40.54 27.44 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 118.227 1.013 . . . . 0.0 111.806 177.711 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 42' ' ' ILE . . . . . 0.645 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.7 mp -44.25 138.33 0.97 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.182 0 C-N-CA 123.719 0.808 . . . . 0.0 111.114 179.087 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 29.8 mtp-105 -85.51 -38.91 18.03 Favored 'General case' 0 CA--C 1.523 -0.08 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.748 -178.31 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -144.5 159.48 42.7 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -176.439 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 8.7 tp -137.32 161.74 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -178.729 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -147.78 70.44 1.16 Allowed 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 177.013 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 47' ' ' LEU . . . . . 0.472 ' C ' HD13 ' B' ' 47' ' ' LEU . 3.4 tm? -64.14 125.53 24.8 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 176.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 39.4 mttp -139.11 164.14 30.57 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 123.547 0.739 . . . . 0.0 111.054 -178.434 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 51.9 t-20 . . . . . 0 N--CA 1.454 -0.272 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 170.703 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo . . . . . 0 N--CA 1.449 -1.134 0 CA-C-O 121.179 0.408 . . . . 0.0 111.629 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -150.67 165.2 34.14 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 104.884 -2.265 . . . . 0.0 104.884 175.979 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -157.03 163.7 38.78 Favored 'General case' 0 N--CA 1.453 -0.304 0 O-C-N 121.721 -0.612 . . . . 0.0 111.922 -174.409 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -113.2 151.62 30.75 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 171.154 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 41.5 t -131.1 136.4 57.95 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 -175.874 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -120.55 111.68 17.98 Favored 'General case' 0 N--CA 1.455 -0.205 0 CA-C-O 120.865 0.364 . . . . 0.0 110.481 -177.398 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.645 ' CE2' HD11 ' B' ' 42' ' ' ILE . 37.1 m-85 -81.15 159.38 24.66 Favored 'General case' 0 CA--C 1.528 0.125 0 N-CA-C 115.347 1.61 . . . . 0.0 115.347 -176.583 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -87.73 -26.66 22.82 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 169.806 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -155.44 118.95 2.42 Favored Pre-proline 0 CA--C 1.532 0.258 0 C-N-CA 123.635 0.774 . . . . 0.0 109.691 -179.196 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.52 -10.54 29.08 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.31 2.673 . . . . 0.0 111.942 -174.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 41.0 ttm105 -67.45 -29.29 68.72 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 117.887 0.312 . . . . 0.0 110.542 177.676 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 -81.24 -16.07 53.72 Favored 'General case' 0 CA--C 1.53 0.176 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.77 -16.43 63.3 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 120.39 0.138 . . . . 0.0 110.75 -179.346 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -66.7 -20.27 65.93 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 122.363 -0.21 . . . . 0.0 110.6 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -104.29 -33.16 8.76 Favored 'General case' 0 C--N 1.339 0.125 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 178.862 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.92 -31.49 64.67 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.012 0.525 . . . . 0.0 110.571 -178.614 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 98.0 t -87.44 -48.58 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 36.0 t -67.45 -14.87 63.32 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 122.474 -0.141 . . . . 0.0 111.2 -175.915 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -79.19 -14.24 81.96 Favored Glycine 0 CA--C 1.529 0.958 0 CA-C-O 119.345 -0.697 . . . . 0.0 112.652 -176.899 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 23.4 ptt-85 -158.13 3.92 0.11 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 118.623 1.212 . . . . 0.0 113.52 -175.858 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -73.16 143.39 47.28 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 118.757 0.708 . . . . 0.0 110.11 176.207 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 62.22 35.64 91.86 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.697 -0.561 . . . . 0.0 111.697 175.589 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 49.8 t80 -96.98 137.51 35.94 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -172.776 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -64.03 103.86 0.65 Allowed 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 123.382 0.673 . . . . 0.0 112.361 -178.546 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.457 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 75.7 t80 -109.75 173.33 6.37 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.91 0.884 . . . . 0.0 111.191 179.085 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.457 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 77.2 m-20 -59.88 98.66 0.06 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -179.575 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.58 -5.89 42.54 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-O 119.666 -0.519 . . . . 0.0 112.938 177.62 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -139.99 -169.33 2.71 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.964 0.882 . . . . 0.0 113.344 -177.36 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 41.6 ttp-105 -143.92 133.96 24.16 Favored 'General case' 0 N--CA 1.457 -0.12 0 C-N-CA 123.615 0.766 . . . . 0.0 109.016 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -62.55 147.96 47.47 Favored 'General case' 0 C--N 1.335 -0.063 0 C-N-CA 122.571 0.348 . . . . 0.0 110.18 -178.478 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 57.7 ttt180 -130.86 113.74 14.43 Favored 'General case' 0 CA--C 1.517 -0.313 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.475 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 37.5 t -132.52 92.57 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.632 178.782 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 24.0 pt-20 -145.29 159.49 42.96 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.703 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -74.04 153.57 88.69 Favored Pre-proline 0 N--CA 1.454 -0.229 0 N-CA-C 114.854 1.427 . . . . 0.0 114.854 -179.522 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo . . . . . 0 C--O 1.25 1.118 0 C-N-CA 123.911 3.074 . . . . 0.0 110.714 175.98 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 98.6 m . . . . . 0 CA--C 1.532 0.273 0 N-CA-C 111.491 0.182 . . . . 0.0 111.491 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 92.8 mtt-85 -73.3 147.88 44.07 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-O 120.879 0.371 . . . . 0.0 111.854 179.462 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 20.8 pt -138.67 177.76 4.77 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 C-N-CA 123.852 0.861 . . . . 0.0 108.754 172.832 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -116.9 150.54 38.3 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 114.344 1.238 . . . . 0.0 114.344 -177.285 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 47.4 t -138.65 143.3 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 C-N-CA 123.519 0.728 . . . . 0.0 109.187 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.35 178.81 34.43 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.954 -0.459 . . . . 0.0 111.954 -176.538 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 54.2 t30 58.54 25.52 13.21 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.195 0.998 . . . . 0.0 111.606 -176.669 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.6 mt . . . . . 0 N--CA 1.454 -0.23 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.94 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 30' ' ' LYS . . . . . 0.401 ' HE2' ' HB3' ' B' ' 30' ' ' LYS . 48.1 mtpt . . . . . 0 CA--C 1.528 0.112 0 N-CA-C 113.175 0.805 . . . . 0.0 113.175 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -62.5 -32.74 73.71 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 118.641 0.655 . . . . 0.0 112.088 175.596 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.9 tt -75.82 -16.81 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 122.787 0.435 . . . . 0.0 110.576 178.427 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 72.9 mt-10 -97.31 -13.67 21.79 Favored 'General case' 0 C--N 1.34 0.18 0 C-N-CA 122.181 0.193 . . . . 0.0 110.684 -179.456 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -103.17 -67.69 0.87 Allowed 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -175.566 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 3.7 p -73.81 -37.27 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 N-CA-C 112.493 0.553 . . . . 0.0 112.493 -172.853 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 70.7 m-85 -73.15 -25.98 61.03 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 112.773 0.656 . . . . 0.0 112.773 177.603 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 42.8 t -72.37 -30.27 64.54 Favored 'General case' 0 N--CA 1.456 -0.166 0 N-CA-C 110.305 -0.257 . . . . 0.0 110.305 176.348 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.37 -29.48 62.66 Favored 'General case' 0 N--CA 1.455 -0.208 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 174.72 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -81.01 -20.4 41.84 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 116.144 1.905 . . . . 0.0 116.144 179.37 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.1 14.4 0.76 Allowed Glycine 0 CA--C 1.527 0.783 0 C-N-CA 120.707 -0.758 . . . . 0.0 113.851 -175.113 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.67 38.49 22.88 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 117.858 0.829 . . . . 0.0 111.261 178.002 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 81.8 mt -45.47 138.67 1.3 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.151 0 C-N-CA 123.338 0.655 . . . . 0.0 111.387 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 28.6 mmt180 -104.63 -22.56 13.22 Favored 'General case' 0 N--CA 1.455 -0.204 0 C-N-CA 122.884 0.474 . . . . 0.0 111.668 -178.141 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -152.4 154.16 35.04 Favored 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 118.352 0.524 . . . . 0.0 112.112 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 2.8 mp -136.52 148.03 27.32 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.085 0 C-N-CA 123.884 0.874 . . . . 0.0 109.326 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -140.95 57.2 1.56 Allowed 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 122.694 0.398 . . . . 0.0 110.278 179.297 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 57.8 tp -60.16 129.25 40.79 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.154 175.825 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 43.0 mttp -120.13 143.59 48.1 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 123.634 0.774 . . . . 0.0 110.672 179.204 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 49.7 p30 . . . . . 0 N--CA 1.453 -0.307 0 C-N-CA 123.402 0.681 . . . . 0.0 110.473 179.871 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo . . . . . 0 N--CA 1.452 -0.96 0 N-CA-C 111.197 -0.347 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -160.87 173.86 14.7 Favored 'General case' 0 CA--C 1.53 0.178 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -173.79 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.28 166.11 34.39 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 120.801 0.334 . . . . 0.0 111.668 -175.647 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -121.17 154.82 35.72 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 168.581 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 70.5 t -144.2 133.03 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -174.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -106.76 117.97 35.45 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.393 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 -85.59 154.65 21.58 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 115.12 1.526 . . . . 0.0 115.12 179.754 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 38.1 tp10 -75.54 -30.27 59.7 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 172.305 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 58.3 t0 -157.59 117.72 1.97 Allowed Pre-proline 0 N--CA 1.451 -0.415 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.3 -10.3 26.97 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 123.194 2.596 . . . . 0.0 112.112 -176.219 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 77.4 mtt85 -72.17 -16.16 61.97 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 117.85 0.295 . . . . 0.0 111.026 178.059 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -77.97 -2.73 38.4 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 177.703 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -64.52 -14.67 58.52 Favored 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 122.435 0.294 . . . . 0.0 111.163 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -65.96 -15.85 63.35 Favored 'General case' 0 CA--C 1.529 0.168 0 O-C-N 122.173 -0.329 . . . . 0.0 111.333 -179.319 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -123.39 -38.28 2.57 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 123.001 0.52 . . . . 0.0 112.181 177.166 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -81.82 -9.57 59.57 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.08 0.552 . . . . 0.0 112.187 -175.486 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 99.5 t -130.99 -49.76 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 CA-C-N 117.729 0.24 . . . . 0.0 110.526 -177.482 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 69.2 m -66.23 -10.96 46.98 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 117.646 0.203 . . . . 0.0 111.145 -179.462 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.2 -1.16 69.87 Favored Glycine 0 CA--C 1.53 0.975 0 CA-C-O 119.436 -0.646 . . . . 0.0 112.73 -178.756 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 12.1 tpp180 -151.72 -16.88 0.19 Allowed 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 118.466 1.133 . . . . 0.0 112.705 -176.56 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 32.9 t0 -65.11 138.34 58.24 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 118.267 0.485 . . . . 0.0 110.634 -178.128 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.51 41.57 99.2 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 111.794 -0.522 . . . . 0.0 111.794 174.091 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -98.61 133.47 42.91 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -174.329 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.6 t0 -62.63 106.52 0.8 Allowed 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 123.781 0.832 . . . . 0.0 112.341 -177.799 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.439 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.9 t80 -112.88 171.28 7.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 123.804 0.842 . . . . 0.0 111.445 177.926 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.439 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 20.6 t0 -60.53 99.82 0.09 Allowed 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.066 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 77.99 -6.32 49.51 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 123.553 0.597 . . . . 0.0 112.761 177.46 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 87.9 m-85 -140.56 -169.54 2.81 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 117.996 0.898 . . . . 0.0 113.269 -177.324 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 36.1 ttt180 -147.46 129.53 15.48 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.439 0.696 . . . . 0.0 109.474 -177.672 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -62.57 147.79 48.02 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 122.847 0.459 . . . . 0.0 110.502 -175.643 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 -120.68 127.68 52.26 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 175.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 11.8 t -145.27 82.02 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.131 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 173.426 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -148.33 160.7 42.73 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 122.75 0.42 . . . . 0.0 110.43 -175.704 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -75.25 156.57 85.58 Favored Pre-proline 0 CA--C 1.533 0.324 0 N-CA-C 114.228 1.196 . . . . 0.0 114.228 179.211 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo . . . . . 0 C--O 1.25 1.077 0 C-N-CA 123.739 2.96 . . . . 0.0 111.867 177.349 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 87.6 m . . . . . 0 N--CA 1.456 -0.137 0 N-CA-C 111.334 0.124 . . . . 0.0 111.334 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 73.0 mtm180 -69.03 146.99 52.2 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 122.831 0.452 . . . . 0.0 110.818 -178.546 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.1 pt -132.56 170.06 20.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-O 120.964 0.412 . . . . 0.0 110.08 172.536 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -114.99 151.02 34.89 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -176.838 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 59.3 t -138.45 143.61 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -157.36 -178.76 31.73 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 111.934 -0.466 . . . . 0.0 111.934 -177.758 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 9.6 t-20 56.8 23.99 8.65 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 123.825 0.85 . . . . 0.0 111.645 -177.51 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 93.4 mt . . . . . 0 CA--C 1.53 0.207 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -179.992 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 6.4 ttpt . . . . . 0 N--CA 1.456 -0.126 0 CA-C-O 120.449 0.166 . . . . 0.0 111.074 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 -70.72 -36.14 73.06 Favored 'General case' 0 N--CA 1.454 -0.227 0 O-C-N 122.1 -0.375 . . . . 0.0 111.261 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 15.2 tt -75.85 -14.09 15.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.377 -176.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -104.28 -21.85 13.46 Favored 'General case' 0 C--N 1.34 0.164 0 CA-C-N 118.714 0.688 . . . . 0.0 110.687 178.677 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -74.33 -49.88 21.07 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 178.161 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 m -72.86 -30.8 33.81 Favored 'Isoleucine or valine' 0 C--N 1.338 0.101 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.095 -178.664 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 36' ' ' PHE . . . . . 0.408 ' O ' HD13 ' B' ' 42' ' ' ILE . 41.4 m-85 -75.92 -42.87 47.57 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 177.425 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 96.7 p -67.58 -21.45 65.42 Favored 'General case' 0 C--N 1.34 0.164 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.49 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 23.7 tptm -73.98 -36.88 64.58 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 173.0 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -82.12 -11.61 58.66 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 116.659 2.096 . . . . 0.0 116.659 178.175 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.98 179.27 48.92 Favored Glycine 0 C--N 1.338 0.645 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.044 -179.364 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.94 53.7 2.27 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 124.06 0.944 . . . . 0.0 111.626 -177.597 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 42' ' ' ILE . . . . . 0.556 HD11 ' CZ ' ' B' ' 61' ' ' PHE . 2.1 mp -68.75 144.24 14.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.24 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 35.0 mmt180 -124.81 -36.1 2.62 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 119.42 -0.324 . . . . 0.0 111.149 178.246 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 39.9 m-20 -122.38 150.16 42.8 Favored 'General case' 0 N--CA 1.462 0.126 0 N-CA-C 113.944 1.091 . . . . 0.0 113.944 -178.385 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -136.18 150.08 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 C-N-CA 124.236 1.014 . . . . 0.0 109.169 178.837 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 59.2 t0 -146.9 63.5 1.18 Allowed 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.65 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 49.6 tp -64.35 129.06 38.43 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 173.345 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -120.39 146.69 45.94 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 123.698 0.799 . . . . 0.0 109.966 178.743 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 . . . . . 0 C--N 1.334 -0.104 0 C-N-CA 122.891 0.476 . . . . 0.0 111.11 -176.183 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo . . . . . 0 N--CA 1.452 -0.927 0 N-CA-C 110.414 -0.648 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -150.85 167.71 26.68 Favored 'General case' 0 C--O 1.232 0.162 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 -179.478 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -152.87 166.06 33.48 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.295 0.569 . . . . 0.0 112.426 -171.85 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -120.56 153.67 36.43 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 124.042 0.937 . . . . 0.0 112.813 170.85 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 88.9 t -141.1 144.39 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 108.685 -0.858 . . . . 0.0 108.685 -178.17 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 11.7 tp10 -131.14 125.59 33.46 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 122.578 0.351 . . . . 0.0 111.174 -177.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.556 ' CZ ' HD11 ' B' ' 42' ' ' ILE . 9.1 m-85 -91.57 151.56 20.68 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 113.974 1.101 . . . . 0.0 113.974 -178.795 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -82.46 -24.69 34.14 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 169.045 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 36.6 t0 -152.26 114.94 2.9 Favored Pre-proline 0 CA--C 1.534 0.355 0 C-N-CA 123.352 0.661 . . . . 0.0 109.944 -176.886 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -74.77 -1.37 11.06 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 123.566 2.844 . . . . 0.0 112.742 -173.867 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 79.5 mtt85 -68.27 -0.49 4.81 Favored 'General case' 0 CA--C 1.53 0.197 0 N-CA-C 112.998 0.74 . . . . 0.0 112.998 -176.212 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 20.4 p30 -134.35 3.12 3.33 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 112.173 0.434 . . . . 0.0 112.173 173.797 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.76 -22.03 64.33 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 178.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -70.25 -28.45 65.25 Favored 'General case' 0 N--CA 1.456 -0.127 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 178.636 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -79.63 -35.18 39.8 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 122.337 0.255 . . . . 0.0 111.381 178.025 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.96 -24.72 63.38 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.231 176.65 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 10.0 t -85.69 -59.03 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.5 t -71.28 -17.6 62.46 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -172.761 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -93.12 4.07 73.9 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-O 119.247 -0.751 . . . . 0.0 112.588 -177.089 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 46.6 ttm180 -150.19 -16.55 0.25 Allowed 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 118.516 1.158 . . . . 0.0 112.555 -174.714 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 50.7 p-10 -71.3 156.64 39.29 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.277 0.561 . . . . 0.0 112.306 -176.512 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 58.85 41.8 96.29 Favored Glycine 0 CA--C 1.526 0.725 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.683 169.402 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 43.4 t80 -92.38 130.83 37.95 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 118.226 1.013 . . . . 0.0 113.714 -175.153 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -66.12 101.81 0.75 Allowed 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 123.044 0.538 . . . . 0.0 112.025 -178.441 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.515 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 71.4 t80 -93.02 177.98 5.9 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.406 0.682 . . . . 0.0 112.127 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.515 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 74.1 m-20 -66.66 21.84 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.537 0 N-CA-C 114.934 1.457 . . . . 0.0 114.934 -177.27 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 161.5 -10.82 0.12 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-O 119.618 -0.546 . . . . 0.0 112.425 -179.137 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -140.95 -167.05 2.29 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 117.731 0.766 . . . . 0.0 110.893 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 33.8 ttt180 -138.93 122.96 17.89 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -59.81 153.39 20.79 Favored 'General case' 0 N--CA 1.458 -0.043 0 C-N-CA 123.421 0.688 . . . . 0.0 111.096 -176.407 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 24.0 mtp180 -128.08 125.21 38.81 Favored 'General case' 0 CA--C 1.521 -0.164 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.593 175.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 48.2 t -142.99 82.01 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.171 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 175.471 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -140.28 160.57 39.67 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.219 0.533 . . . . 0.0 111.809 -173.09 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 88' ' ' PHE . . . . . 0.467 ' CD1' ' HD2' ' B' ' 89' ' ' PRO . 18.2 t80 -71.84 138.9 82.67 Favored Pre-proline 0 CA--C 1.534 0.335 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 89' ' ' PRO . . . . . 0.467 ' HD2' ' CD1' ' B' ' 88' ' ' PHE . 43.9 Cg_endo . . . . . 0 C--O 1.248 1.018 0 C-N-CA 123.824 3.016 . . . . 0.0 111.303 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 61.3 m . . . . . 0 C--O 1.231 0.093 0 N-CA-C 110.473 -0.195 . . . . 0.0 110.473 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 31.4 ttm180 -101.02 147.89 25.67 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 123.046 0.539 . . . . 0.0 109.815 -178.647 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.5 pt -133.53 174.78 12.67 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.081 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 176.48 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -118.92 150.32 40.09 Favored 'General case' 0 C--O 1.231 0.122 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -175.838 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 60.5 t -139.22 142.84 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 C-N-CA 123.509 0.724 . . . . 0.0 109.437 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.81 168.76 31.78 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -178.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 59.4 t30 60.55 36.89 19.81 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 124.073 0.949 . . . . 0.0 111.379 -174.205 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 84.0 mt . . . . . 0 CA--C 1.532 0.285 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 176.492 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.8 tptt . . . . . 0 N--CA 1.456 -0.174 0 N-CA-C 111.218 0.081 . . . . 0.0 111.218 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -63.79 -28.39 69.83 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.593 0.235 . . . . 0.0 110.43 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.0 tt -72.1 -13.78 16.9 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.349 -178.12 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -116.98 -9.94 11.02 Favored 'General case' 0 N--CA 1.456 -0.156 0 CA-C-N 118.291 0.496 . . . . 0.0 110.722 174.218 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -71.27 -55.3 8.34 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-O 121.025 0.44 . . . . 0.0 110.57 178.016 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 10.0 p -67.68 -34.65 69.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 O-C-N 122.241 -0.287 . . . . 0.0 110.886 179.392 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -69.88 -32.86 71.43 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 113.38 0.882 . . . . 0.0 113.38 176.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 39.2 t -67.48 -28.0 67.48 Favored 'General case' 0 C--N 1.342 0.28 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 176.744 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -70.68 -34.26 71.8 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 174.532 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -81.68 -15.61 53.95 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 116.225 1.935 . . . . 0.0 116.225 177.124 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.46 179.21 44.92 Favored Glycine 0 C--N 1.338 0.656 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.584 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -83.85 84.61 7.51 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 122.992 0.517 . . . . 0.0 111.249 -178.431 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.7 mp -73.09 150.39 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.123 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 174.541 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 85.3 mmt-85 -128.35 -25.64 2.91 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 119.25 -0.405 . . . . 0.0 111.972 176.729 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -150.55 161.43 42.56 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 178.609 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 45' ' ' ILE . . . . . 0.489 HG22 ' H ' ' B' ' 47' ' ' LEU . 30.8 mm -132.43 156.46 42.42 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.061 0 C-N-CA 124.289 1.036 . . . . 0.0 109.279 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -143.2 55.25 1.36 Allowed 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 175.316 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 47' ' ' LEU . . . . . 0.489 ' H ' HG22 ' B' ' 45' ' ' ILE . 59.9 tp -55.79 133.13 50.88 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.223 174.468 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -133.79 158.53 43.13 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 123.735 0.814 . . . . 0.0 111.415 -177.483 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 43.0 p30 . . . . . 0 CA--C 1.533 0.302 0 C-N-CA 123.442 0.697 . . . . 0.0 110.698 177.692 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo . . . . . 0 N--CA 1.45 -1.038 0 N-CA-C 110.195 -0.733 . . . . 0.0 110.195 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 6.1 p90 -153.29 171.38 18.65 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 106.414 -1.699 . . . . 0.0 106.414 -176.61 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -159.61 174.62 14.31 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.242 0.544 . . . . 0.0 111.371 -174.089 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -131.81 155.94 46.9 Favored 'General case' 0 N--CA 1.452 -0.355 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 172.04 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 66.8 t -132.87 134.24 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -178.257 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -111.17 123.95 51.23 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 122.465 0.306 . . . . 0.0 110.562 -177.878 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -97.43 154.95 17.14 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 42.3 tp10 -78.7 -23.63 45.45 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 170.817 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -152.51 118.87 3.05 Favored Pre-proline 0 CA--C 1.534 0.365 0 C-N-CA 123.162 0.585 . . . . 0.0 109.785 -178.727 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -66.65 -8.11 20.13 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.188 2.592 . . . . 0.0 112.505 -176.005 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 72.3 ttt-85 -61.94 -36.05 80.26 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-N 118.111 0.414 . . . . 0.0 110.172 177.19 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 52.8 m-20 -89.87 -16.3 30.36 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-O 120.582 0.23 . . . . 0.0 111.57 -178.52 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.97 -25.3 64.47 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.851 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -71.81 -28.59 63.7 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 177.763 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 -75.16 -35.48 61.61 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 178.753 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.97 -29.91 67.13 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 110.279 -0.267 . . . . 0.0 110.279 177.34 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.93 -30.02 17.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.306 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.368 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 41.5 t -85.79 -12.34 51.19 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 122.587 0.355 . . . . 0.0 111.54 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -68.56 -46.06 64.22 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.609 -0.596 . . . . 0.0 111.609 -175.518 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 38.2 ttt180 -163.08 122.1 2.11 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.274 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -164.24 149.27 10.2 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 123.066 0.229 . . . . 0.0 110.574 -178.68 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.94 88.88 0.3 Allowed Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.481 0.562 . . . . 0.0 112.857 170.84 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 77' ' ' TYR . . . . . 0.449 ' HA ' ' HA ' ' B' ' 83' ' ' ARG . 13.6 t80 60.31 103.09 0.02 OUTLIER 'General case' 0 N--CA 1.457 -0.104 0 N-CA-C 116.478 2.029 . . . . 0.0 116.478 169.579 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -164.71 31.09 0.07 Allowed 'General case' 0 N--CA 1.444 -0.733 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -131.62 178.09 7.01 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -88.89 107.38 18.97 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 114.892 -1.049 . . . . 0.0 111.228 179.378 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 72.11 -2.26 28.26 Favored Glycine 0 CA--C 1.531 1.092 0 N-CA-C 111.522 -0.631 . . . . 0.0 111.522 -178.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 45.1 m-85 -131.47 169.81 15.55 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 124.001 0.92 . . . . 0.0 113.455 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 83' ' ' ARG . . . . . 0.449 ' HA ' ' HA ' ' B' ' 77' ' ' TYR . 0.0 OUTLIER -135.15 135.83 41.4 Favored 'General case' 0 N--CA 1.44 -0.949 0 CA-C-O 120.803 0.335 . . . . 0.0 111.282 -178.58 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 84' ' ' LEU . . . . . 0.592 HD22 ' N ' ' B' ' 84' ' ' LEU . 2.4 mm? -73.85 142.92 46.06 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 178.767 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 59.1 mtm180 -132.48 114.57 14.45 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-O 120.943 0.401 . . . . 0.0 110.222 175.733 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 42.4 t -136.4 86.08 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 C-N-CA 123.543 0.737 . . . . 0.0 109.055 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -149.8 163.21 38.61 Favored 'General case' 0 C--N 1.334 -0.103 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.534 -178.655 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.5 p90 -74.0 152.23 88.62 Favored Pre-proline 0 CA--C 1.531 0.229 0 N-CA-C 114.626 1.343 . . . . 0.0 114.626 179.433 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo . . . . . 0 C--O 1.253 1.266 0 C-N-CA 123.837 3.025 . . . . 0.0 110.781 176.312 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 98.3 m . . . . . 0 C--O 1.231 0.083 0 N-CA-C 111.501 0.185 . . . . 0.0 111.501 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -88.86 155.21 19.67 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 120.847 0.356 . . . . 0.0 111.255 -177.733 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 12.2 pt -127.62 -177.29 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 C-N-CA 123.223 0.609 . . . . 0.0 109.477 177.92 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -142.94 151.29 40.79 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -178.781 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 62.8 t -142.84 101.15 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.149 0 N-CA-C 110.465 -0.198 . . . . 0.0 110.465 -176.642 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -92.59 166.95 29.47 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 171.682 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 66.2 t30 55.43 29.37 13.07 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 122.824 0.45 . . . . 0.0 110.725 -177.028 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 23.0 tp . . . . . 0 CA--C 1.536 0.405 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.911 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 30' ' ' LYS . . . . . 0.424 ' HE2' ' OD1' ' B' ' 34' ' ' ASP . 23.4 tptm . . . . . 0 N--CA 1.455 -0.2 0 CA-C-O 120.221 0.058 . . . . 0.0 110.957 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -63.87 -24.01 67.58 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 175.828 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.6 tt -69.51 -15.99 20.06 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 C-N-CA 123.15 0.58 . . . . 0.0 110.902 -179.584 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -125.45 4.35 7.65 Favored 'General case' 0 CA--C 1.53 0.205 0 O-C-N 122.053 -0.404 . . . . 0.0 111.367 179.056 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 34' ' ' ASP . . . . . 0.424 ' OD1' ' HE2' ' B' ' 30' ' ' LYS . 79.1 m-20 -97.06 -61.93 1.33 Allowed 'General case' 0 C--O 1.233 0.197 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 172.215 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 p -74.84 -41.53 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.087 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -172.408 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -75.39 -21.49 58.22 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -179.019 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 43.3 t -72.26 -30.18 64.6 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 175.495 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 29.7 ttpp -72.92 -28.59 62.55 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.638 -0.505 . . . . 0.0 109.638 174.092 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -79.33 -20.73 47.15 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 116.26 1.948 . . . . 0.0 116.26 177.413 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.88 20.58 0.17 Allowed Glycine 0 CA--C 1.53 0.984 0 C-N-CA 119.887 -1.149 . . . . 0.0 114.717 -175.498 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 48.7 49.14 19.19 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 117.938 0.869 . . . . 0.0 111.475 175.186 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 75.6 mt -48.97 137.02 5.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.144 0.577 . . . . 0.0 111.008 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 48.0 mtm105 -98.9 -32.14 11.48 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 122.891 0.477 . . . . 0.0 111.527 179.226 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 32.3 m-20 -148.94 157.01 43.1 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 113.835 1.05 . . . . 0.0 113.835 -177.449 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 3.2 mp -126.78 151.95 34.07 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.662 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -148.6 48.02 1.02 Allowed 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -177.032 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 54.0 tp -68.75 110.45 4.32 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 177.632 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 48.1 mttm -93.88 146.57 23.8 Favored 'General case' 0 N--CA 1.456 -0.145 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 175.475 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 31.9 p30 . . . . . 0 CA--C 1.532 0.266 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.003 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo . . . . . 0 N--CA 1.454 -0.815 0 CA-C-O 120.78 0.242 . . . . 0.0 112.163 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -164.13 167.22 20.46 Favored 'General case' 0 N--CA 1.455 -0.195 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 178.018 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -144.25 161.01 39.98 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -171.586 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -119.71 60.52 0.85 Allowed 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 124.152 0.981 . . . . 0.0 112.769 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 83.7 t -58.34 143.26 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.108 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -177.308 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 73.1 tt0 -120.79 120.4 35.49 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.918 0.389 . . . . 0.0 110.956 -175.167 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -91.53 166.43 12.84 Favored 'General case' 0 N--CA 1.455 -0.179 0 N-CA-C 115.984 1.846 . . . . 0.0 115.984 -174.417 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 30.4 tp10 -70.99 -35.22 72.01 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 122.757 0.423 . . . . 0.0 110.138 173.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -149.21 148.22 26.03 Favored Pre-proline 0 CA--C 1.527 0.093 0 C-N-CA 124.387 1.075 . . . . 0.0 112.021 178.084 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.1 -17.27 31.73 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.181 2.588 . . . . 0.0 111.089 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 51.9 mmm-85 -77.76 -13.42 59.9 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 122.435 0.294 . . . . 0.0 111.606 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -76.5 -10.31 59.3 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 111.953 0.353 . . . . 0.0 111.953 177.552 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.48 -11.05 60.68 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.592 0.357 . . . . 0.0 111.101 179.563 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -67.93 -17.72 64.54 Favored 'General case' 0 C--O 1.232 0.155 0 O-C-N 122.135 -0.353 . . . . 0.0 111.032 -179.286 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -123.84 -36.24 2.76 Favored 'General case' 0 CA--C 1.528 0.125 0 C-N-CA 123.183 0.593 . . . . 0.0 112.433 178.769 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -84.28 -8.86 58.9 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -175.605 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.43 HG13 HG12 ' B' ' 86' ' ' VAL . 47.3 t -132.68 -46.25 0.64 Allowed 'Isoleucine or valine' 0 C--O 1.228 -0.036 0 CA-C-N 118.062 0.392 . . . . 0.0 110.906 -175.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.3 t -69.5 -15.19 63.2 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-O 120.502 0.192 . . . . 0.0 110.977 -179.282 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.94 -5.82 88.8 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-O 119.647 -0.529 . . . . 0.0 112.711 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 70.2 mtm-85 -138.86 6.07 2.41 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 118.078 0.939 . . . . 0.0 111.869 -178.092 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -67.3 123.51 20.55 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 117.823 0.283 . . . . 0.0 111.307 -179.101 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 65.19 34.45 89.63 Favored Glycine 0 C--N 1.338 0.669 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 177.805 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 56.2 t80 -75.91 137.77 40.6 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -173.645 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 28.2 t0 -66.15 81.02 0.08 Allowed 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.295 1.038 . . . . 0.0 111.964 -177.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 79' ' ' TYR . . . . . 0.4 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 68.2 t80 -85.03 -179.94 7.15 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 177.784 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.4 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 71.4 m-20 -66.38 91.9 0.18 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 123.246 0.618 . . . . 0.0 112.43 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.73 -2.12 69.81 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-O 119.606 -0.552 . . . . 0.0 112.399 177.534 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -138.41 176.68 8.49 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 -178.842 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -125.15 140.1 53.17 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 123.846 0.858 . . . . 0.0 109.376 176.652 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -67.22 152.51 45.6 Favored 'General case' 0 N--CA 1.455 -0.204 0 C-N-CA 122.626 0.37 . . . . 0.0 110.426 177.22 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -118.43 48.26 1.46 Allowed 'General case' 0 C--N 1.338 0.068 0 C-N-CA 123.3 0.64 . . . . 0.0 109.828 172.012 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 86' ' ' VAL . . . . . 0.43 HG12 HG13 ' B' ' 71' ' ' VAL . 74.7 t -76.43 95.1 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.556 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -154.02 158.63 40.86 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.845 178.51 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 8.1 p90 -87.23 145.77 38.64 Favored Pre-proline 0 N--CA 1.456 -0.161 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 177.419 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 C--O 1.253 1.245 0 C-N-CA 123.614 2.876 . . . . 0.0 110.737 175.565 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 74.2 m . . . . . 0 CA--C 1.531 0.225 0 N-CA-C 112.53 0.567 . . . . 0.0 112.53 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 86.3 mtt180 -99.79 148.81 24.01 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 117.96 0.346 . . . . 0.0 111.741 177.71 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 19.9 pt -134.66 -177.26 1.95 Allowed 'Isoleucine or valine' 0 CA--C 1.524 -0.034 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.292 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -119.0 146.64 44.86 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -177.288 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 41.7 t -140.17 139.97 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.54 177.826 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -143.27 169.75 25.7 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -176.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 59.7 t30 61.07 31.56 19.79 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.741 0.817 . . . . 0.0 111.483 -175.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 81.3 mt . . . . . 0 CA--C 1.533 0.301 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.664 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 30' ' ' LYS . . . . . 0.408 ' HE2' ' OD2' ' B' ' 34' ' ' ASP . 24.0 tptm . . . . . 0 C--O 1.227 -0.12 0 CA-C-O 119.915 -0.088 . . . . 0.0 111.004 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 31.2 m-20 -64.06 -19.94 65.59 Favored 'General case' 0 CA--C 1.528 0.103 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 174.15 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 tt -69.29 -14.14 18.09 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 C-N-CA 123.336 0.654 . . . . 0.0 111.059 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -129.02 -10.32 4.81 Favored 'General case' 0 CA--C 1.529 0.173 0 CA-C-N 118.514 0.597 . . . . 0.0 111.677 176.689 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 34' ' ' ASP . . . . . 0.408 ' OD2' ' HE2' ' B' ' 30' ' ' LYS . 77.7 m-20 -74.13 -46.48 42.33 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 113.024 0.75 . . . . 0.0 113.024 174.166 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.6 p -71.91 -30.52 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.117 0 CA-C-O 120.656 0.265 . . . . 0.0 111.045 178.086 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -75.48 -30.82 60.01 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 177.656 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 41.4 t -70.37 -30.65 67.63 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 174.866 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 3.6 tppp? -73.38 -30.81 63.53 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 122.121 0.168 . . . . 0.0 110.672 177.257 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -84.03 -19.18 34.88 Favored 'General case' 0 C--N 1.338 0.103 0 N-CA-C 116.316 1.969 . . . . 0.0 116.316 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.14 22.31 0.07 OUTLIER Glycine 0 CA--C 1.528 0.88 0 C-N-CA 120.035 -1.078 . . . . 0.0 113.531 -177.594 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 52.32 30.15 7.67 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 117.64 0.72 . . . . 0.0 111.296 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 42' ' ' ILE . . . . . 0.417 HD11 ' CZ ' ' B' ' 61' ' ' PHE . 17.8 mt -50.72 137.37 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 123.191 0.597 . . . . 0.0 110.131 178.099 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 14.9 mmt180 -105.26 -19.02 13.93 Favored 'General case' 0 N--CA 1.457 -0.078 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -172.148 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 40.9 t0 -154.94 156.66 36.45 Favored 'General case' 0 C--O 1.233 0.201 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.962 178.554 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 15.5 mm -131.96 114.86 25.38 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 174.305 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 46' ' ' ASP . . . . . 0.453 ' HB3' ' H ' ' B' ' 58' ' ' PHE . 41.3 t0 -84.53 51.91 2.24 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 177.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 50.8 tp -54.18 120.88 7.09 Favored 'General case' 0 C--O 1.231 0.114 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 175.629 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -145.08 146.51 31.88 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-O 120.829 0.347 . . . . 0.0 111.02 -173.407 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 73.9 m-20 . . . . . 0 N--CA 1.454 -0.249 0 C-N-CA 122.951 0.501 . . . . 0.0 110.992 -179.198 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo . . . . . 0 N--CA 1.45 -1.079 0 N-CA-C 110.564 -0.591 . . . . 0.0 110.564 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -149.34 170.16 19.16 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 105.634 -1.987 . . . . 0.0 105.634 -178.141 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.83 155.2 33.98 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-O 120.756 0.312 . . . . 0.0 111.731 -175.295 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 58' ' ' PHE . . . . . 0.453 ' H ' ' HB3' ' B' ' 46' ' ' ASP . 86.4 m-85 -108.93 107.79 18.3 Favored 'General case' 0 N--CA 1.457 -0.12 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.944 169.395 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 91.2 t -80.54 141.9 14.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -177.685 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -120.09 120.17 35.47 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-O 120.652 0.263 . . . . 0.0 110.424 178.806 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.417 ' CZ ' HD11 ' B' ' 42' ' ' ILE . 37.0 m-85 -88.08 158.1 18.68 Favored 'General case' 0 N--CA 1.456 -0.148 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -178.441 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -86.3 -29.6 22.91 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 167.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -155.61 110.28 2.19 Favored Pre-proline 0 CA--C 1.535 0.376 0 C-N-CA 123.655 0.782 . . . . 0.0 109.598 178.349 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -58.6 -11.51 11.67 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 124.04 3.16 . . . . 0.0 113.801 -177.73 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.66 -25.4 67.93 Favored 'General case' 0 CA--C 1.528 0.1 0 CA-C-N 118.191 0.451 . . . . 0.0 110.862 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 78.4 m-20 -76.2 2.7 12.44 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -179.587 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.97 -8.01 26.61 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.538 0.335 . . . . 0.0 111.341 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -62.73 -24.98 67.95 Favored 'General case' 0 N--CA 1.454 -0.26 0 O-C-N 122.149 -0.344 . . . . 0.0 110.969 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -120.78 -34.4 3.58 Favored 'General case' 0 C--O 1.228 -0.063 0 N-CA-C 112.731 0.641 . . . . 0.0 112.731 178.744 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -79.74 -9.09 59.6 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 123.346 0.658 . . . . 0.0 111.642 -176.025 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 58.2 t -136.2 -43.99 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 CA-C-N 117.623 0.192 . . . . 0.0 111.111 -177.225 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 68.7 m -83.82 -2.41 56.32 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.985 -0.098 . . . . 0.0 111.197 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -76.61 -30.18 56.72 Favored Glycine 0 C--N 1.34 0.796 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 -178.584 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 56.2 ttm-85 -162.76 131.8 4.16 Favored 'General case' 0 C--N 1.338 0.07 0 CA-C-N 117.376 0.588 . . . . 0.0 110.762 177.626 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 26.0 p30 -160.11 153.52 22.22 Favored 'General case' 0 C--O 1.232 0.165 0 C-N-CA 123.61 0.764 . . . . 0.0 110.89 175.584 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 56.37 41.49 87.73 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.71 -0.556 . . . . 0.0 111.71 175.455 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 46.3 t80 -92.71 136.61 33.08 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 -173.102 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -67.51 91.75 0.29 Allowed 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 124.042 0.937 . . . . 0.0 112.224 -177.673 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -85.09 -175.31 5.69 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.393 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -68.73 77.05 0.3 Allowed 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 123.678 0.791 . . . . 0.0 112.379 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 86.88 5.61 80.79 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 178.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -135.21 -176.86 4.4 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.351 0.66 . . . . 0.0 112.431 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 2.3 tpt180 -139.7 129.08 24.1 Favored 'General case' 0 CA--C 1.522 -0.123 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -179.436 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.7 mp -70.01 148.33 48.99 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 178.75 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 43.0 mtp85 -131.12 125.72 33.84 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 173.657 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 13.8 t -139.65 82.78 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.148 0 C-N-CA 123.562 0.745 . . . . 0.0 109.84 176.235 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -147.37 161.47 40.94 Favored 'General case' 0 C--N 1.333 -0.118 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.038 -177.627 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 6.0 p90 -76.16 151.99 83.95 Favored Pre-proline 0 CA--C 1.53 0.205 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 177.883 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo . . . . . 0 C--O 1.251 1.128 0 C-N-CA 123.455 2.77 . . . . 0.0 111.015 177.203 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 3.0 m . . . . . 0 N--CA 1.479 1.016 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 85.9 mt -70.75 140.24 18.71 Favored 'Isoleucine or valine' 0 C--O 1.232 0.181 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 178.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 17.6 tpp85 -159.69 167.28 28.75 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 122.538 0.335 . . . . 0.0 110.313 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 9' ' ' GLY . . . . . 0.422 ' N ' ' C2 ' ' A' ' 93' ' ' ' A' . . . -74.15 -123.11 0.1 OUTLIER Glycine 0 CA--C 1.531 1.09 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 176.703 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -71.75 -162.82 0.12 Allowed 'Trans proline' 0 N--CA 1.45 -1.06 0 C-N-CA 123.396 2.73 . . . . 0.0 109.502 172.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.7 7.49 0.35 Allowed 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -177.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -74.99 70.08 1.82 Allowed Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 177.782 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 72.3 m-20 -80.58 0.42 34.07 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.183 0.593 . . . . 0.0 112.165 -177.181 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 79.6 m-20 -68.1 152.97 44.68 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 122.253 -0.279 . . . . 0.0 110.624 -178.092 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 20.1 p30 -80.76 3.25 22.97 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -179.168 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.1 m -78.33 3.64 15.05 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 122.93 0.492 . . . . 0.0 111.797 -178.556 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 33.9 mtt180 -84.5 149.7 25.76 Favored 'General case' 0 C--O 1.232 0.135 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -176.109 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 16.6 pt -140.62 174.48 7.8 Favored 'Isoleucine or valine' 0 C--O 1.23 0.07 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.917 173.295 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.436 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.6 OUTLIER -109.0 150.39 27.83 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 114.497 1.295 . . . . 0.0 114.497 -177.64 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t -137.4 142.43 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.19 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.221 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.92 179.45 29.35 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -178.339 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 61.9 t30 56.23 39.42 30.25 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 123.666 0.787 . . . . 0.0 110.899 -174.352 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 84.8 mt -60.27 139.59 91.65 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.392 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 24' ' ' PRO . . . . . 0.412 ' HA ' ' HD3' ' B' ' 25' ' ' PRO . 57.5 Cg_endo -70.47 159.47 52.75 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 123.441 2.761 . . . . 0.0 110.885 -178.312 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 25' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' B' ' 24' ' ' PRO . 26.2 Cg_exo -62.1 -5.87 7.11 Favored 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 123.957 3.104 . . . . 0.0 113.302 -179.067 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -129.21 25.3 5.51 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -177.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 7.3 tp -57.71 150.8 3.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 122.504 0.322 . . . . 0.0 110.178 178.315 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 28' ' ' ARG . . . . . 0.441 ' HG2' ' H ' ' B' ' 30' ' ' LYS . 38.1 ttm105 -143.26 145.68 32.95 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -177.695 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -60.66 -26.66 67.24 Favored 'General case' 0 C--N 1.333 -0.118 0 N-CA-C 114.173 1.175 . . . . 0.0 114.173 -178.474 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 30' ' ' LYS . . . . . 0.441 ' H ' ' HG2' ' B' ' 28' ' ' ARG . 52.7 tptt -81.02 -19.17 44.5 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 122.269 0.228 . . . . 0.0 110.83 -178.081 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 59.2 m-20 -64.6 -28.4 69.6 Favored 'General case' 0 C--O 1.231 0.124 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -176.744 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 31.3 mm -78.12 -23.41 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 177.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.4 mt-10 -86.74 -11.44 51.1 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.921 -0.127 . . . . 0.0 110.823 179.083 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 79.0 m-20 -101.33 -66.06 0.94 Allowed 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 177.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 41.4 t -73.84 -53.95 16.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.21 0 CA-C-N 116.756 -0.202 . . . . 0.0 111.04 -174.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 63.3 m-85 -69.16 -21.38 64.0 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -179.005 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 45.5 t -74.28 -32.18 62.81 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 175.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -68.85 -29.71 68.08 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 174.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 20.3 m-85 -82.69 -20.17 36.65 Favored 'General case' 0 CA--C 1.528 0.129 0 N-CA-C 116.352 1.982 . . . . 0.0 116.352 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.73 20.52 0.05 OUTLIER Glycine 0 CA--C 1.527 0.782 0 C-N-CA 119.66 -1.257 . . . . 0.0 114.775 -175.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 47.65 59.81 3.92 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 118.203 1.002 . . . . 0.0 111.667 174.34 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 29.2 mm -44.96 132.8 1.83 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 C-N-CA 123.597 0.759 . . . . 0.0 111.496 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -86.64 -37.29 18.18 Favored 'General case' 0 N--CA 1.456 -0.161 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.384 177.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 -147.86 150.06 33.44 Favored 'General case' 0 C--O 1.231 0.09 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -176.374 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -109.15 149.91 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 176.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -148.11 64.63 1.1 Allowed 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 77.7 mt -63.47 138.12 58.39 Favored 'General case' 0 C--O 1.232 0.156 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 49.3 mttp -130.64 51.76 2.09 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 123.974 0.91 . . . . 0.0 109.832 177.755 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 76.8 m-20 -80.84 5.18 16.77 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.425 174.048 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 58.8 ttt180 -58.8 150.5 23.7 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 123.755 0.822 . . . . 0.0 110.623 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.95 170.08 5.95 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.136 0.574 . . . . 0.0 110.987 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.98 -2.12 65.88 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 111.273 -0.731 . . . . 0.0 111.273 -179.354 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -175.42 175.75 47.25 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 178.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -67.79 148.19 76.68 Favored 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 123.652 2.901 . . . . 0.0 110.067 178.744 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.9 138.5 34.34 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 123.167 2.578 . . . . 0.0 110.535 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 56' ' ' PHE . . . . . 0.451 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 2.9 p90 -166.32 -178.45 4.54 Favored 'General case' 0 CA--C 1.528 0.127 0 N-CA-C 105.974 -1.862 . . . . 0.0 105.974 176.001 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -158.11 166.39 32.59 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.373 0.606 . . . . 0.0 112.081 -177.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 58' ' ' PHE . . . . . 0.425 ' CE1' ' C4 ' ' A' ' 93' ' ' ' A' . 85.2 m-85 -121.32 157.82 29.55 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.575 171.034 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 75.7 t -138.9 137.21 42.76 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.134 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -178.124 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 69.0 tt0 -116.91 114.04 23.29 Favored 'General case' 0 CA--C 1.529 0.142 0 CA-C-O 120.666 0.27 . . . . 0.0 110.814 -176.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -82.11 168.56 17.62 Favored 'General case' 0 N--CA 1.457 -0.095 0 N-CA-C 115.872 1.804 . . . . 0.0 115.872 -176.074 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 48.7 tp10 -64.74 -35.73 82.01 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 174.222 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 26.1 p30 -159.19 162.92 25.17 Favored Pre-proline 0 CA--C 1.532 0.275 0 C-N-CA 123.536 0.734 . . . . 0.0 110.359 175.478 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -63.61 -18.15 63.05 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 123.116 2.544 . . . . 0.0 112.322 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 4.3 ttp85 -78.44 -40.93 34.29 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 117.849 0.295 . . . . 0.0 110.765 -175.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 79.5 m-20 -71.78 -24.35 61.73 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 178.74 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.59 -28.88 68.14 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 44.5 tp10 -68.77 -34.11 75.02 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 110.492 -0.188 . . . . 0.0 110.492 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -73.85 -33.99 64.33 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 178.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.86 -33.33 64.04 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 177.034 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 13.7 t -71.22 -45.23 71.81 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 48.2 t -69.79 -16.65 63.33 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 122.309 -0.244 . . . . 0.0 111.487 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.86 -8.75 41.69 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-O 119.119 -0.823 . . . . 0.0 113.711 -174.155 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -140.25 -12.26 1.07 Allowed 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 118.905 1.352 . . . . 0.0 113.277 -174.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -76.61 146.34 38.29 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 118.516 0.598 . . . . 0.0 110.12 -176.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.25 39.96 97.92 Favored Glycine 0 CA--C 1.527 0.836 0 CA-C-O 119.526 -0.597 . . . . 0.0 112.068 171.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 42.3 t80 -95.67 131.18 42.18 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -174.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -61.29 105.87 0.55 Allowed 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 123.663 0.785 . . . . 0.0 112.477 -178.679 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.427 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 46.3 t80 -112.88 169.45 8.9 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 123.738 0.815 . . . . 0.0 111.619 177.691 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.427 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 19.0 t0 -61.02 98.62 0.08 Allowed 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -179.249 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.59 -5.14 61.75 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 123.441 0.543 . . . . 0.0 112.677 177.264 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -141.3 -171.12 3.22 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 117.855 0.828 . . . . 0.0 112.954 -178.323 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 40.5 ttt180 -147.24 128.34 14.64 Favored 'General case' 0 C--O 1.231 0.113 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 -177.717 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -63.92 147.49 51.84 Favored 'General case' 0 N--CA 1.461 0.102 0 C-N-CA 122.694 0.398 . . . . 0.0 110.205 -174.84 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -118.57 119.82 35.65 Favored 'General case' 0 CA--C 1.521 -0.15 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 175.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.7 t -145.55 80.11 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 C-N-CA 122.878 0.471 . . . . 0.0 109.84 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -149.33 159.2 44.48 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.692 0.282 . . . . 0.0 110.807 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -74.16 156.04 87.83 Favored Pre-proline 0 CA--C 1.531 0.223 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo . . . . . 0 C--O 1.252 1.187 0 C-N-CA 123.669 2.913 . . . . 0.0 111.727 175.807 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . 0.404 " H3'" H5'' ' A' ' 91' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.418 -2.884 0 C5'-C4'-C3' 110.058 -3.628 . 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . 0.404 H5'' " H3'" ' A' ' 90' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.422 -2.623 1 O4'-C1'-N19 113.215 5.015 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.451 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.378 0 O4'-C1'-N19 111.594 3.394 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.425 ' C4 ' ' CE1' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.421 -2.663 0 C5'-C4'-C3' 109.922 -3.719 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.69 1 O4'-C1'-N19 112.443 4.243 . 0.01 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.563 0 C5'-C4'-C3' 111.391 -2.739 . 0.0 OUTLIER delta 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 N--CA 1.477 0.924 0 N-CA-C 111.406 0.15 . . . . 0.0 111.406 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 84.0 mt -69.26 142.77 15.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 4.4 tmm_? -70.9 133.75 46.7 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 122.686 0.394 . . . . 0.0 110.396 179.245 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 57.78 -159.54 12.77 Favored Glycine 0 CA--C 1.528 0.905 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 175.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -72.96 164.6 35.11 Favored 'Trans proline' 0 N--CA 1.449 -1.118 0 C-N-CA 123.249 2.633 . . . . 0.0 109.704 175.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.57 -6.34 43.35 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 122.319 0.248 . . . . 0.0 111.648 -178.736 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -77.08 168.26 54.64 Favored Glycine 0 CA--C 1.529 0.913 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 76.8 m-20 -76.87 148.67 36.35 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 122.553 0.341 . . . . 0.0 111.031 -178.381 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -76.92 -9.62 58.81 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 122.504 0.322 . . . . 0.0 110.456 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -70.43 -9.12 55.55 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 -176.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.7 m -133.37 9.67 4.05 Favored 'General case' 0 CA--C 1.528 0.106 0 C-N-CA 122.746 0.419 . . . . 0.0 110.591 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 17' ' ' ARG . . . . . 0.423 ' HA ' ' HA ' ' B' ' 60' ' ' GLU . 32.6 ttp-105 -102.81 148.83 25.14 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.324 0.65 . . . . 0.0 110.686 -177.398 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 20.8 pt -131.67 179.23 4.54 Favored 'Isoleucine or valine' 0 C--O 1.23 0.063 0 C-N-CA 123.277 0.631 . . . . 0.0 109.835 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.44 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.7 OUTLIER -118.82 156.87 28.67 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 114.248 1.203 . . . . 0.0 114.248 -175.674 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 12.7 t -134.37 123.92 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 C-N-CA 122.917 0.487 . . . . 0.0 110.705 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -130.22 166.61 22.14 Favored Glycine 0 CA--C 1.53 1.02 0 N-CA-C 111.688 -0.565 . . . . 0.0 111.688 -177.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 60.5 t30 63.65 28.61 15.06 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 124.648 1.179 . . . . 0.0 111.765 -176.021 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 87.7 mt -69.38 143.11 92.99 Favored Pre-proline 0 CA--C 1.532 0.287 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -60.46 157.36 36.65 Favored 'Trans proline' 0 N--CA 1.452 -0.96 0 C-N-CA 123.247 2.632 . . . . 0.0 110.783 174.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.99 -18.99 35.59 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 123.377 2.718 . . . . 0.0 110.537 177.594 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -96.37 14.11 25.48 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.727 0.639 . . . . 0.0 112.727 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 7.8 tp -61.24 153.09 5.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 122.546 0.338 . . . . 0.0 110.691 -177.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 22.9 tpp85 -143.29 149.95 38.55 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.34 -26.19 62.83 Favored 'General case' 0 C--N 1.333 -0.14 0 N-CA-C 114.64 1.348 . . . . 0.0 114.64 -174.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 21.6 tptm -71.94 -29.82 64.67 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 122.364 -0.21 . . . . 0.0 110.722 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -67.24 -30.38 70.27 Favored 'General case' 0 CA--C 1.528 0.131 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -178.61 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.3 mt -75.28 -33.09 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.503 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 99.3 mt-10 -75.34 -15.49 60.48 Favored 'General case' 0 N--CA 1.456 -0.173 0 C-N-CA 122.451 0.301 . . . . 0.0 110.986 -178.545 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -91.51 -52.18 4.91 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 112.924 0.712 . . . . 0.0 112.924 174.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 93.9 t -71.22 -50.91 38.26 Favored 'Isoleucine or valine' 0 C--N 1.34 0.172 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 -174.83 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -68.09 -31.9 71.84 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -177.731 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 43.8 t -66.45 -29.12 69.18 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 110.539 -0.171 . . . . 0.0 110.539 177.11 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -71.23 -31.03 67.07 Favored 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 174.59 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -79.0 -20.88 47.96 Favored 'General case' 0 C--O 1.233 0.219 0 N-CA-C 115.79 1.774 . . . . 0.0 115.79 176.376 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 169.81 -177.11 43.43 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 118.388 0.54 . . . . 0.0 112.289 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.37 95.99 8.92 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 122.838 0.455 . . . . 0.0 110.68 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 42' ' ' ILE . . . . . 0.431 ' N ' HD12 ' B' ' 42' ' ' ILE . 1.8 mp -80.28 149.6 5.13 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 C-N-CA 122.733 0.413 . . . . 0.0 110.225 175.229 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 29.1 mtp-105 -115.0 -34.06 5.2 Favored 'General case' 0 CA--C 1.528 0.119 0 C-N-CA 123.657 0.783 . . . . 0.0 111.313 177.125 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.8 m-20 -146.61 155.8 42.74 Favored 'General case' 0 N--CA 1.457 -0.105 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -176.293 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 4.1 mp -136.1 150.48 28.1 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.137 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 177.248 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -138.96 48.81 1.88 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 120.792 0.33 . . . . 0.0 111.072 179.167 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.6 tp -63.78 124.48 21.6 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 173.794 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 24.4 pttm -152.35 161.72 42.19 Favored 'General case' 0 N--CA 1.458 -0.062 0 C-N-CA 122.53 0.332 . . . . 0.0 110.666 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 18.8 p30 -69.74 158.06 36.13 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-O 120.891 0.377 . . . . 0.0 111.061 -177.201 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 28.7 ttm-85 -96.65 76.96 2.86 Favored 'General case' 0 N--CA 1.457 -0.11 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 18.7 mmt-85 56.36 26.39 10.59 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 122.761 0.424 . . . . 0.0 110.32 -174.289 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.2 -8.97 61.04 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 123.777 0.703 . . . . 0.0 111.733 -177.455 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -86.65 -168.09 44.42 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 176.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 54' ' ' PRO . . . . . 0.465 ' HA ' ' HD3' ' B' ' 55' ' ' PRO . 51.4 Cg_exo -52.68 119.41 5.92 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 124.232 3.288 . . . . 0.0 110.944 -179.056 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 55' ' ' PRO . . . . . 0.465 ' HD3' ' HA ' ' B' ' 54' ' ' PRO . 40.4 Cg_exo -56.45 163.05 7.17 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 124.09 3.193 . . . . 0.0 113.824 -174.011 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -147.61 163.4 36.75 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 104.385 -2.45 . . . . 0.0 104.385 175.264 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -149.93 163.59 37.67 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 119.997 -0.681 . . . . 0.0 112.737 -171.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 58' ' ' PHE . . . . . 0.445 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 88.6 m-85 -122.15 154.67 37.11 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.09 169.078 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 71.9 t -140.12 132.37 33.2 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.266 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.107 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 60' ' ' GLU . . . . . 0.423 ' HA ' ' HA ' ' B' ' 17' ' ' ARG . 68.2 tt0 -117.28 132.54 56.6 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.811 0.339 . . . . 0.0 111.252 -174.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -98.47 160.55 14.21 Favored 'General case' 0 C--O 1.231 0.12 0 N-CA-C 114.826 1.417 . . . . 0.0 114.826 -175.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -81.89 -17.4 47.36 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.857 0.463 . . . . 0.0 110.382 171.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -152.74 120.58 3.13 Favored Pre-proline 0 C--O 1.233 0.206 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -178.689 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.52 -14.33 44.3 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 123.066 2.51 . . . . 0.0 111.948 -175.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 86.7 mtm180 -71.69 -24.49 61.83 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 117.944 0.338 . . . . 0.0 110.669 176.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -87.74 -27.07 22.59 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-O 120.75 0.309 . . . . 0.0 110.751 176.016 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.03 -25.23 65.27 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 177.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -69.86 -31.08 68.73 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 122.218 0.207 . . . . 0.0 110.523 178.448 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -76.48 -35.33 58.45 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 112.308 0.485 . . . . 0.0 112.308 179.027 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.33 -27.72 66.52 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 122.634 0.373 . . . . 0.0 110.059 177.64 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 39.6 t -87.52 -44.09 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.402 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.2 t -65.98 -21.56 66.42 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-N 117.552 0.16 . . . . 0.0 111.127 -176.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -90.29 -15.36 57.4 Favored Glycine 0 CA--C 1.53 0.977 0 CA-C-O 119.455 -0.636 . . . . 0.0 113.004 -177.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 61.0 mtm180 -146.22 19.57 1.39 Allowed 'General case' 0 C--N 1.342 0.282 0 CA-C-N 118.24 1.02 . . . . 0.0 113.146 -170.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 18.8 p30 -70.81 -1.42 11.56 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.105 0.779 . . . . 0.0 113.105 178.029 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.82 90.69 0.08 OUTLIER Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -120.58 137.77 54.23 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 176.362 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -68.94 92.26 0.5 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.442 0.697 . . . . 0.0 111.953 -176.448 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -84.68 -175.92 5.99 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -67.89 82.79 0.2 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 123.557 0.743 . . . . 0.0 112.298 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.7 2.83 89.81 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 112.148 -0.381 . . . . 0.0 112.148 178.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -137.86 -174.57 3.82 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -179.081 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 70.5 ttp85 -140.39 135.06 31.71 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.85 151.42 45.55 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 122.666 0.387 . . . . 0.0 110.18 -179.64 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 51.5 mtm180 -134.54 55.71 1.88 Allowed 'General case' 0 C--O 1.231 0.103 0 C-N-CA 122.435 0.294 . . . . 0.0 110.849 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 20.1 t -82.95 94.83 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.188 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 174.392 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -152.31 161.47 42.56 Favored 'General case' 0 C--O 1.226 -0.174 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -76.6 156.05 83.2 Favored Pre-proline 0 CA--C 1.532 0.268 0 N-CA-C 114.666 1.358 . . . . 0.0 114.666 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo . . . . . 0 C--O 1.25 1.119 0 C-N-CA 123.789 2.993 . . . . 0.0 111.723 175.434 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.426 -2.287 0 C5'-C4'-C3' 110.589 -3.274 OUTLIER-DELTA 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.948 1 C5'-C4'-C3' 108.908 -4.395 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.44 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.323 0 C5'-C4'-C3' 110.337 -3.442 . 0.259 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.445 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.426 -2.241 1 C5'-C4'-C3' 109.102 -4.266 . 0.01 6n . 0.0 . . . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.568 1 O4'-C1'-N19 112.762 4.562 . 0.01 5z . 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.601 0 C5'-C4'-C3' 109.838 -3.775 . 0.0 OUTLIER delta 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 11.8 t . . . . . 0 N--CA 1.476 0.833 0 N-CA-C 111.302 0.112 . . . . 0.0 111.302 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 7' ' ' ILE . . . . . 0.435 ' N ' HD12 ' B' ' 7' ' ' ILE . 1.8 mp -68.07 153.13 9.08 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.58 172.21 2.81 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.078 0.466 . . . . 0.0 112.2 -176.643 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 9' ' ' GLY . . . . . 0.528 ' N ' ' CD ' ' B' ' 10' ' ' PRO . . . 70.99 27.66 71.8 Favored Glycine 0 CA--C 1.535 1.318 0 CA-C-O 118.232 -1.315 . . . . 0.0 114.695 175.565 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 10' ' ' PRO . . . . . 0.528 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 61.5 Cg_endo -70.54 -25.02 25.44 Favored 'Trans proline' 0 N--CA 1.454 -0.8 0 CA-C-N 120.489 2.145 . . . . 0.0 110.334 179.259 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -161.1 158.71 28.1 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 123.371 0.669 . . . . 0.0 109.909 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -81.71 -6.04 89.38 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.928 -0.469 . . . . 0.0 111.928 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 35.9 p30 -87.04 8.76 22.07 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 117.408 0.604 . . . . 0.0 111.804 -177.689 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -65.05 148.61 51.35 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -178.027 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 82.5 m-20 -78.67 148.98 32.94 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -174.011 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 95.9 m 58.22 2.4 0.2 Allowed 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 125.152 1.381 . . . . 0.0 114.343 174.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 84.2 mtt-85 -83.38 146.9 28.21 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 118.272 0.487 . . . . 0.0 111.737 176.195 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 26.9 pt -131.45 172.29 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 173.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.442 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.4 OUTLIER -120.74 149.72 42.1 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 114.185 1.18 . . . . 0.0 114.185 -178.029 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 19.7 t -137.53 141.83 38.36 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 C-N-CA 123.449 0.699 . . . . 0.0 109.728 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -150.43 171.84 30.26 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -176.107 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 65.6 t30 59.73 30.91 20.51 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.213 1.005 . . . . 0.0 111.688 -175.019 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.9 mt -64.17 149.15 94.66 Favored Pre-proline 0 N--CA 1.454 -0.257 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 174.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 24' ' ' PRO . . . . . 0.431 ' HA ' ' HD3' ' B' ' 25' ' ' PRO . 37.0 Cg_endo -65.29 155.45 68.51 Favored 'Trans proline' 0 N--CA 1.452 -0.944 0 C-N-CA 122.996 2.464 . . . . 0.0 111.218 -177.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 25' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 24' ' ' PRO . 23.7 Cg_exo -62.85 -3.21 4.31 Favored 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 124.271 3.314 . . . . 0.0 113.191 -179.495 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -136.52 30.61 2.89 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -176.549 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 6.3 tp -61.56 137.39 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 177.735 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 47.2 mtm180 -97.55 153.93 17.84 Favored 'General case' 0 N--CA 1.457 -0.124 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.6 p -68.24 -22.0 64.8 Favored 'General case' 0 C--O 1.232 0.155 0 N-CA-C 112.914 0.709 . . . . 0.0 112.914 177.21 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -82.02 -26.47 33.78 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 122.798 0.439 . . . . 0.0 111.139 -179.119 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -64.53 -29.78 70.81 Favored 'General case' 0 N--CA 1.455 -0.175 0 N-CA-C 112.106 0.409 . . . . 0.0 112.106 -177.089 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 mm -74.69 -21.2 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.18 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 90.2 mt-10 -78.47 -48.74 14.76 Favored 'General case' 0 C--O 1.223 -0.324 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -65.86 -44.7 84.63 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -174.312 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 99.0 t -69.84 -53.04 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.099 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -176.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -75.28 -24.1 57.49 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 113.546 0.943 . . . . 0.0 113.546 -174.736 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 41.8 t -68.89 -31.79 70.96 Favored 'General case' 0 C--N 1.342 0.265 0 CA-C-N 118.008 0.367 . . . . 0.0 110.054 173.149 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 58.3 tptt -68.36 -30.76 69.78 Favored 'General case' 0 C--N 1.341 0.212 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 174.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 39.6 m-85 -74.75 -20.36 59.85 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 115.457 1.651 . . . . 0.0 115.457 174.604 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 159.52 -178.0 35.81 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.835 -0.506 . . . . 0.0 111.835 176.617 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -73.79 122.19 22.04 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.65 0.262 . . . . 0.0 110.36 -178.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 73.8 mt -92.65 140.0 17.01 Favored 'Isoleucine or valine' 0 C--O 1.233 0.237 0 C-N-CA 122.937 0.495 . . . . 0.0 111.201 -178.43 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -94.14 -38.19 11.21 Favored 'General case' 0 N--CA 1.458 -0.071 0 C-N-CA 123.093 0.557 . . . . 0.0 110.361 170.208 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -155.94 156.76 35.12 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 120.713 0.292 . . . . 0.0 111.101 -173.349 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mt -133.28 143.3 39.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 C-N-CA 124.186 0.994 . . . . 0.0 108.854 175.281 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -144.74 64.88 1.28 Allowed 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 120.644 0.259 . . . . 0.0 111.54 -174.665 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 57.7 tp -58.23 134.75 56.8 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 169.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 54.8 tttp -143.23 164.23 30.78 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.841 0.353 . . . . 0.0 111.238 -168.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 44.8 p30 -142.67 -155.97 0.64 Allowed 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 123.383 0.673 . . . . 0.0 110.694 -173.312 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 55.0 mtm180 63.61 175.31 0.17 Allowed 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.837 1.255 . . . . 0.0 111.618 -172.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 61.81 159.18 0.06 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.659 1.184 . . . . 0.0 110.789 -170.31 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -67.01 170.9 32.58 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.07 -176.77 53.01 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 111.449 -0.66 . . . . 0.0 111.449 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -68.33 161.24 45.59 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 124.348 3.365 . . . . 0.0 111.122 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -64.8 167.21 16.09 Favored 'Trans proline' 0 N--CA 1.452 -0.963 0 C-N-CA 123.684 2.922 . . . . 0.0 110.658 177.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 56' ' ' PHE . . . . . 0.46 ' CE1' " H4'" ' A' ' 92' ' ' ' C' . 3.8 p90 -152.92 173.3 15.55 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 106.281 -1.748 . . . . 0.0 106.281 -175.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.64 168.31 27.78 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 -174.294 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 58' ' ' PHE . . . . . 0.498 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 80.7 m-85 -127.23 157.11 40.7 Favored 'General case' 0 C--O 1.234 0.282 0 C-N-CA 123.618 0.767 . . . . 0.0 110.056 171.287 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 56.0 t -143.76 142.03 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -119.18 125.26 48.78 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 177.101 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -89.49 161.68 16.11 Favored 'General case' 0 C--O 1.231 0.114 0 N-CA-C 115.272 1.582 . . . . 0.0 115.272 174.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 37.3 tp10 -72.18 -23.97 61.35 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.559 175.551 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 48.4 m-20 -144.47 151.86 51.85 Favored Pre-proline 0 N--CA 1.455 -0.176 0 C-N-CA 124.192 0.997 . . . . 0.0 112.292 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -68.6 -18.29 42.9 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.877 2.384 . . . . 0.0 110.615 178.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 73.0 ttt-85 -68.84 -40.04 79.63 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 177.624 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -76.07 -26.12 56.22 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 120.739 0.304 . . . . 0.0 111.664 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.87 -36.24 70.05 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 176.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 41.7 tp10 -69.35 -32.09 70.93 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 110.388 -0.227 . . . . 0.0 110.388 178.546 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -70.94 -35.9 72.4 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.43 -32.73 68.71 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 178.305 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 59.1 t -80.14 -30.48 12.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 45.7 t -79.97 -9.33 59.68 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 122.715 0.406 . . . . 0.0 110.656 178.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -66.57 -77.06 0.31 Allowed Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.217 -0.753 . . . . 0.0 111.217 -178.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 4.0 tpm_? -156.69 132.06 9.28 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 51.3 p-10 -153.15 168.79 24.78 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.506 0.722 . . . . 0.0 109.09 176.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 58.67 40.8 95.26 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 174.045 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -98.42 132.93 43.47 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 113.832 1.049 . . . . 0.0 113.832 -172.411 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -62.45 106.69 0.8 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.639 0.776 . . . . 0.0 112.35 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.437 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 50.1 t80 -114.31 170.31 8.39 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 123.585 0.754 . . . . 0.0 111.39 178.341 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.437 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 21.3 t0 -60.0 100.54 0.09 Allowed 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.815 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.33 -5.6 42.49 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-O 119.746 -0.474 . . . . 0.0 112.912 178.213 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 88.1 m-85 -140.34 -170.51 3.0 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 117.871 0.836 . . . . 0.0 113.241 -178.085 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 40.0 ttt180 -148.61 129.9 14.67 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 123.673 0.789 . . . . 0.0 108.953 -177.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -67.51 149.59 49.97 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -176.321 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -129.67 130.35 45.44 Favored 'General case' 0 C--N 1.34 0.181 0 CA-C-O 120.624 0.25 . . . . 0.0 110.52 172.193 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.6 t -145.3 80.36 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.099 0 C-N-CA 123.96 0.904 . . . . 0.0 109.298 173.652 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -144.63 168.36 20.34 Favored 'General case' 0 C--O 1.226 -0.132 0 C-N-CA 122.595 0.358 . . . . 0.0 111.047 -175.042 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 69.9 m-85 -63.67 153.24 84.17 Favored Pre-proline 0 C--O 1.235 0.307 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 179.03 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 C--O 1.251 1.168 0 C-N-CA 123.705 2.937 . . . . 0.0 110.932 175.168 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.664 0 C5'-C4'-C3' 109.925 -3.717 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.472 1 O4'-C1'-N19 112.32 4.12 . 0.344 2[ . 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.46 " H4'" ' CE1' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.42 -2.732 0 O4'-C1'-N19 111.112 2.912 . 0.687 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.498 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.385 0 C5'-C4'-C3' 110.111 -3.593 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.42 -2.743 0 O4'-C1'-N19 111.496 3.296 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.479 1 C5'-C4'-C3' 109.402 -4.065 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.476 0.825 0 N-CA-C 111.79 0.293 . . . . 0.0 111.79 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 32.3 mm -71.14 149.4 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 2.4 tmm_? -62.71 -47.33 84.07 Favored 'General case' 0 C--N 1.337 0.062 0 C-N-CA 122.723 0.409 . . . . 0.0 111.059 -179.214 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . -157.92 -161.5 10.99 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 -172.417 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.52 -28.1 53.3 Favored 'Trans proline' 0 N--CA 1.452 -0.957 0 C-N-CA 123.933 3.088 . . . . 0.0 111.853 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 53.62 19.39 1.76 Allowed 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 123.91 0.884 . . . . 0.0 113.109 175.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.1 152.52 50.13 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -73.85 -15.1 61.17 Favored 'General case' 0 N--CA 1.457 -0.114 0 CA-C-N 116.773 0.286 . . . . 0.0 111.709 -178.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 63.4 t30 -88.22 160.83 17.54 Favored 'General case' 0 N--CA 1.456 -0.125 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 50.1 m-20 -82.4 -139.62 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 172.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 69.8 m 62.58 15.33 7.85 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 123.554 0.742 . . . . 0.0 112.855 175.508 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 66.1 mtm-85 -71.29 143.86 50.19 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 117.769 0.259 . . . . 0.0 110.796 172.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.6 pt -139.16 171.2 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.102 0 C-N-CA 123.302 0.641 . . . . 0.0 109.4 177.188 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.424 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.2 OUTLIER -113.75 151.37 32.03 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -179.327 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 44.1 t -137.38 144.64 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 123.251 0.62 . . . . 0.0 109.462 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -156.2 177.15 33.39 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -177.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 62.1 t30 62.75 169.68 0.14 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.604 1.161 . . . . 0.0 111.406 -172.45 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 85.3 mt -61.36 146.26 89.41 Favored Pre-proline 0 N--CA 1.454 -0.251 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 177.631 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -69.31 159.87 52.05 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 C-N-CA 123.553 2.835 . . . . 0.0 110.838 -176.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.42 -9.06 25.06 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 124.104 3.202 . . . . 0.0 110.775 178.182 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 55.5 t0 -149.94 133.65 16.78 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 177.378 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 3.0 tp -80.01 80.21 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-O 121.618 0.723 . . . . 0.0 111.344 -172.315 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 16.3 ptt180 -159.17 145.91 16.91 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.665 171.443 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.8 p -71.81 -13.7 61.77 Favored 'General case' 0 C--O 1.231 0.086 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -179.121 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 47.7 tptt -82.24 -5.27 58.4 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.577 0.351 . . . . 0.0 110.517 179.186 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -53.35 -44.66 68.71 Favored 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -177.197 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.3 tt -78.55 -5.26 7.69 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 C-N-CA 122.898 0.479 . . . . 0.0 110.819 -176.445 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 84.5 mt-10 -116.85 1.43 12.7 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 122.55 0.34 . . . . 0.0 111.236 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 11.1 t0 -125.29 -54.04 1.59 Allowed 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 87.2 t -69.7 -41.99 80.2 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.042 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -178.264 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 45.4 m-85 -67.86 -27.85 67.04 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 176.47 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 67.2 m -72.65 -21.88 61.02 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.443 177.292 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 24.7 ttmm -77.75 -30.82 51.75 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 109.684 -0.488 . . . . 0.0 109.684 173.722 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -70.86 -23.13 62.26 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 114.39 1.256 . . . . 0.0 114.39 173.242 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 164.01 174.34 33.71 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 174.138 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -71.53 125.13 26.26 Favored 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 17.1 mt -99.33 138.97 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.164 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 77.8 mtp85 -86.31 -43.1 13.18 Favored 'General case' 0 C--N 1.333 -0.148 0 C-N-CA 122.897 0.479 . . . . 0.0 110.065 174.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -152.6 159.13 43.25 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -176.445 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.9 mp -130.02 148.68 33.18 Favored 'Isoleucine or valine' 0 C--N 1.339 0.136 0 C-N-CA 124.172 0.989 . . . . 0.0 109.627 177.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 21.2 t0 -140.72 63.97 1.44 Allowed 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.296 0.238 . . . . 0.0 111.255 176.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 61.2 tp -59.81 133.61 56.26 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 170.15 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 15.7 ttmm -143.62 152.2 41.08 Favored 'General case' 0 C--N 1.342 0.24 0 CA-C-O 120.74 0.305 . . . . 0.0 111.024 -173.464 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -75.96 159.77 30.54 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 122.996 0.518 . . . . 0.0 110.563 178.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 9.2 tpt180 -148.69 146.7 28.26 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.381 0.672 . . . . 0.0 109.767 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 55.7 mtt180 -106.07 149.37 26.78 Favored 'General case' 0 C--O 1.231 0.099 0 C-N-CA 122.888 0.475 . . . . 0.0 110.198 -179.542 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.59 6.55 62.81 Favored Glycine 0 CA--C 1.532 1.116 0 N-CA-C 112.357 -0.297 . . . . 0.0 112.357 176.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -173.67 174.63 46.24 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 54' ' ' PRO . . . . . 0.401 ' HA ' ' HD3' ' B' ' 55' ' ' PRO . 39.0 Cg_exo -59.08 157.63 28.82 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.981 3.12 . . . . 0.0 111.633 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 55' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' B' ' 54' ' ' PRO . 39.7 Cg_exo -58.63 168.53 4.02 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.828 3.019 . . . . 0.0 111.615 175.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 56' ' ' PHE . . . . . 0.429 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 2.9 p90 -150.72 169.12 22.38 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 179.211 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -157.96 170.7 21.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 120.916 0.389 . . . . 0.0 111.527 -174.735 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -123.59 154.68 38.95 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.909 169.47 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 71.7 t -137.73 139.85 42.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -178.127 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -121.91 108.32 13.29 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -79.21 160.59 26.84 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 115.004 1.483 . . . . 0.0 115.004 177.6 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 41.1 tp10 -75.76 -31.85 59.71 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.542 175.136 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -133.05 150.75 76.42 Favored Pre-proline 0 CA--C 1.532 0.275 0 C-N-CA 123.707 0.803 . . . . 0.0 112.365 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -70.11 -21.6 31.62 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 123.203 2.602 . . . . 0.0 110.885 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 81.2 mtt85 -72.67 -27.89 62.37 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 178.668 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -79.76 -31.39 40.95 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 122.039 0.136 . . . . 0.0 111.318 179.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.97 -36.68 69.91 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 110.511 -0.181 . . . . 0.0 110.511 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 43.4 tp10 -68.12 -34.29 76.1 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -72.28 -35.23 68.68 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.1 -29.52 64.18 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.561 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.2 t -75.21 -50.97 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.479 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 88.0 p -73.5 -10.22 59.49 Favored 'General case' 0 C--O 1.233 0.217 0 O-C-N 122.199 -0.313 . . . . 0.0 111.661 -176.453 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -98.62 -10.38 50.44 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-O 119.167 -0.796 . . . . 0.0 113.371 -173.49 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -151.51 -13.02 0.2 Allowed 'General case' 0 C--N 1.34 0.159 0 CA-C-N 119.04 1.42 . . . . 0.0 113.206 -173.661 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -66.61 143.9 56.73 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.421 0.555 . . . . 0.0 110.146 -177.02 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 60.22 39.92 96.62 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 173.514 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 41.2 t80 -99.13 133.42 43.44 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 113.635 0.976 . . . . 0.0 113.635 -173.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.2 t0 -62.1 105.69 0.62 Allowed 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 123.574 0.749 . . . . 0.0 112.372 -178.186 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.423 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 51.5 t80 -111.26 169.92 8.46 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 123.829 0.852 . . . . 0.0 111.389 178.23 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.423 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 21.0 t0 -61.0 97.41 0.06 Allowed 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.375 0.509 . . . . 0.0 112.375 -179.519 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 80.68 -4.06 71.25 Favored Glycine 0 CA--C 1.53 0.994 0 CA-C-O 119.379 -0.678 . . . . 0.0 112.722 177.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -142.46 -170.72 3.25 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 118.142 0.971 . . . . 0.0 112.793 -177.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 36.0 ttt180 -145.89 130.22 17.66 Favored 'General case' 0 C--O 1.231 0.095 0 C-N-CA 123.466 0.706 . . . . 0.0 109.292 -178.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -63.86 152.92 38.33 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 122.952 0.501 . . . . 0.0 111.078 -174.088 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 53.1 mmm-85 -124.92 117.36 23.9 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 173.463 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 19.2 t -145.25 81.31 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.522 -0.103 0 C-N-CA 122.75 0.42 . . . . 0.0 110.252 178.091 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.9 pt-20 -142.8 168.49 19.6 Favored 'General case' 0 C--N 1.333 -0.112 0 C-N-CA 122.429 0.291 . . . . 0.0 111.066 -175.308 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 54.3 m-85 -65.15 151.66 93.27 Favored Pre-proline 0 CA--C 1.532 0.257 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo . . . . . 0 N--CA 1.448 -1.186 0 C-N-CA 123.894 3.063 . . . . 0.0 110.72 175.719 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.529 0 O4'-C1'-N19 111.414 3.214 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.293 0 C5'-C4'-C3' 111.623 -2.585 OUTLIER-DELTA 0.072 8d . 0.0 . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.429 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.423 -2.528 0 C5'-C4'-C3' 111.559 -2.627 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.643 0 C5'-C4'-C3' 109.634 -3.911 . 0.01 6n . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.42 -2.721 0 C5'-C4'-C3' 109.825 -3.784 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.354 0 O4'-C1'-N19 111.954 3.754 . 0.13 2u . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 12.4 t . . . . . 0 N--CA 1.477 0.878 0 N-CA-C 111.499 0.185 . . . . 0.0 111.499 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 44.9 mm -66.02 149.21 11.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.009 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 41.0 ttm-85 -68.42 142.79 55.28 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.95 -73.2 0.23 Allowed Glycine 0 CA--C 1.527 0.817 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -58.1 -10.97 9.07 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 123.777 2.984 . . . . 0.0 112.176 174.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -147.51 160.45 42.59 Favored 'General case' 0 C--O 1.234 0.279 0 C-N-CA 123.112 0.565 . . . . 0.0 109.976 177.339 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.39 179.93 43.55 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 13.3 m120 -139.49 3.54 2.11 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 122.749 0.42 . . . . 0.0 110.919 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -144.82 147.59 33.04 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -95.73 8.93 42.08 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.038 0.535 . . . . 0.0 112.326 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 85.3 m -76.46 8.67 3.26 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -176.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 79.6 mtt180 -76.78 147.41 37.28 Favored 'General case' 0 CA--C 1.528 0.108 0 CA-C-N 117.889 0.313 . . . . 0.0 110.668 177.177 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 pt -135.57 167.87 24.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.107 0 C-N-CA 123.216 0.607 . . . . 0.0 109.364 173.235 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.423 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.6 OUTLIER -108.61 148.65 30.03 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 114.694 1.368 . . . . 0.0 114.694 -173.309 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 21.7 t -137.13 139.05 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 C-N-CA 123.839 0.856 . . . . 0.0 110.001 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.76 175.65 30.45 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -177.384 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 54.2 t30 59.68 26.07 15.11 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.807 0.843 . . . . 0.0 111.42 -175.459 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 97.3 mt -64.9 152.25 91.22 Favored Pre-proline 0 N--CA 1.455 -0.218 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 176.455 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_exo -53.47 140.8 63.6 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.247 2.631 . . . . 0.0 111.388 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_exo -60.32 -7.26 6.47 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 123.694 2.93 . . . . 0.0 112.579 177.374 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 27.5 p30 -135.73 26.56 3.36 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 123.448 0.699 . . . . 0.0 111.879 -177.524 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 7.2 tp -54.96 141.69 10.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.681 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 28' ' ' ARG . . . . . 0.403 HH11 ' HD3' ' B' ' 28' ' ' ARG . 41.8 ttt-85 -80.44 147.55 30.9 Favored 'General case' 0 N--CA 1.455 -0.19 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 -176.698 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.82 17.36 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 114.908 1.447 . . . . 0.0 114.908 -178.303 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -146.0 -22.2 0.45 Allowed 'General case' 0 N--CA 1.454 -0.234 0 C-N-CA 122.968 0.507 . . . . 0.0 110.974 -178.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 -67.45 -22.92 65.47 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 112.401 0.519 . . . . 0.0 112.401 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 6.4 tp -71.31 -18.18 20.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 C-N-CA 122.64 0.376 . . . . 0.0 110.188 176.719 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -96.16 -26.63 15.39 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 176.416 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -64.93 -49.91 68.54 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.625 0.25 . . . . 0.0 111.67 -177.388 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 99.7 t -67.63 -43.56 86.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -178.467 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -74.6 -32.45 62.36 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 114.52 1.304 . . . . 0.0 114.52 -177.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 90.0 p -69.74 -22.48 63.37 Favored 'General case' 0 C--O 1.231 0.107 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.87 175.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -72.26 -34.02 67.92 Favored 'General case' 0 C--N 1.34 0.193 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 173.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 49.4 m-85 -68.87 -19.1 64.23 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 170.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.76 169.3 33.14 Favored Glycine 0 CA--C 1.532 1.119 0 C-N-CA 123.183 0.42 . . . . 0.0 112.996 171.263 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 59.56 20.28 8.8 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 124.762 1.225 . . . . 0.0 113.68 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.5 mp -76.51 140.15 17.67 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 173.442 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 20.4 mmt180 -120.3 -21.92 6.74 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 122.488 0.315 . . . . 0.0 111.502 173.524 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -158.13 149.6 21.33 Favored 'General case' 0 C--N 1.339 0.137 0 N-CA-C 113.919 1.081 . . . . 0.0 113.919 176.581 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -120.4 152.24 23.31 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 171.79 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 45.1 t0 -145.16 79.07 1.58 Allowed 'General case' 0 N--CA 1.449 -0.496 0 CA-C-O 120.947 0.404 . . . . 0.0 111.374 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 55.9 tp -66.04 135.73 55.05 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 171.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 14.5 ttmm -151.86 168.29 25.58 Favored 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 -173.218 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 54.3 t30 -155.12 156.89 36.6 Favored 'General case' 0 N--CA 1.452 -0.325 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 175.496 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 11.0 tpp180 -151.98 6.08 0.44 Allowed 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.274 0.63 . . . . 0.0 110.325 -178.163 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 6.5 ptp85 -150.18 166.16 30.69 Favored 'General case' 0 CA--C 1.529 0.136 0 O-C-N 122.035 -0.415 . . . . 0.0 110.891 -172.557 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -78.4 -9.54 86.92 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 178.086 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -78.1 -172.4 39.63 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.096 -0.801 . . . . 0.0 111.096 176.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -57.22 151.13 53.42 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 123.822 3.015 . . . . 0.0 111.621 179.019 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.07 172.88 13.83 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.753 2.969 . . . . 0.0 111.184 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 56' ' ' PHE . . . . . 0.499 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 1.9 p90 -149.11 171.76 15.9 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 104.977 -2.231 . . . . 0.0 104.977 177.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.76 169.03 25.32 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.289 0.566 . . . . 0.0 111.941 -174.566 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 58' ' ' PHE . . . . . 0.534 ' CE1' ' C4 ' ' A' ' 93' ' ' ' A' . 90.9 m-85 -121.88 156.95 32.22 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.881 171.228 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 96.8 t -134.8 140.29 45.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -124.1 115.94 21.98 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.019 0.437 . . . . 0.0 110.538 -174.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 38.5 m-85 -91.3 161.74 14.91 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 114.256 1.206 . . . . 0.0 114.256 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -75.65 -28.23 58.67 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 170.545 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 17.2 p30 -154.8 152.55 25.87 Favored Pre-proline 0 CA--C 1.534 0.333 0 C-N-CA 123.326 0.651 . . . . 0.0 111.675 176.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.09 -7.85 22.27 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 123.24 2.626 . . . . 0.0 111.429 179.629 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 45.3 ttm105 -65.24 -38.9 91.8 Favored 'General case' 0 C--N 1.339 0.122 0 C-N-CA 122.444 0.298 . . . . 0.0 111.331 -177.154 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -94.52 -17.81 22.04 Favored 'General case' 0 C--O 1.232 0.177 0 N-CA-C 112.859 0.688 . . . . 0.0 112.859 179.112 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.7 -27.21 67.46 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -69.05 -30.36 68.68 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 110.423 -0.214 . . . . 0.0 110.423 178.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -75.98 -36.81 59.09 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 112.165 0.431 . . . . 0.0 112.165 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.01 -28.01 64.1 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 110.263 -0.273 . . . . 0.0 110.263 176.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 16.6 t -77.29 -50.18 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.177 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.61 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 71.1 m -73.59 -7.6 52.59 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 111.656 0.243 . . . . 0.0 111.656 -175.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -99.67 -8.05 52.58 Favored Glycine 0 CA--C 1.53 1.023 0 CA-C-O 119.07 -0.85 . . . . 0.0 113.423 -175.088 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 13.6 tpp180 -152.04 -13.73 0.19 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 118.489 1.145 . . . . 0.0 113.332 -174.682 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -66.65 141.86 57.64 Favored 'General case' 0 N--CA 1.456 -0.168 0 O-C-N 121.933 -0.479 . . . . 0.0 110.118 -177.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.49 43.87 97.5 Favored Glycine 0 CA--C 1.53 0.988 0 N-CA-C 111.921 -0.472 . . . . 0.0 111.921 174.61 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -101.86 137.5 40.07 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 114.132 1.16 . . . . 0.0 114.132 -173.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 11.3 t0 -63.23 109.07 1.43 Allowed 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 123.62 0.768 . . . . 0.0 112.491 -176.338 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.41 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 42.3 t80 -116.27 168.11 10.42 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 123.662 0.785 . . . . 0.0 111.524 175.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.41 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.5 t0 -58.99 98.5 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.98 -5.79 61.31 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-O 119.476 -0.624 . . . . 0.0 112.6 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -141.54 -169.32 2.85 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.007 0.904 . . . . 0.0 113.174 -177.268 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 42.3 ttp-105 -145.26 131.05 19.04 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 123.492 0.717 . . . . 0.0 109.48 -178.226 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -63.41 152.07 39.24 Favored 'General case' 0 N--CA 1.461 0.086 0 C-N-CA 122.782 0.433 . . . . 0.0 110.372 -177.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 92.1 mtm-85 -127.98 121.3 29.51 Favored 'General case' 0 CA--C 1.52 -0.177 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 173.302 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 24.2 t -142.46 81.45 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -141.54 164.26 30.71 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 111.798 0.295 . . . . 0.0 111.798 -174.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 88' ' ' PHE . . . . . 0.412 ' CD1' ' HD2' ' B' ' 89' ' ' PRO . 17.0 t80 -72.37 136.14 81.5 Favored Pre-proline 0 CA--C 1.534 0.341 0 N-CA-C 113.365 0.876 . . . . 0.0 113.365 178.494 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 89' ' ' PRO . . . . . 0.412 ' HD2' ' CD1' ' B' ' 88' ' ' PHE . 47.6 Cg_endo . . . . . 0 C--O 1.25 1.081 0 C-N-CA 123.706 2.937 . . . . 0.0 111.076 -179.073 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.087 0 C3'-C2'-C1' 104.832 3.702 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.63 0 O4'-C1'-N19 111.428 3.228 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.499 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.421 -2.701 0 O4'-C1'-N19 111.235 3.035 . 0.057 2z . 0.0 . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.534 ' C4 ' ' CE1' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.427 -2.172 1 O4'-C1'-N19 112.699 4.499 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . 0.47 H5'' " H3'" ' A' ' 93' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.422 -2.604 0 O4'-C1'-N19 111.582 3.382 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.859 0 C5'-C4'-C3' 110.158 -3.561 . 0.282 2u . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m . . . . . 0 N--CA 1.477 0.925 0 N-CA-C 111.531 0.197 . . . . 0.0 111.531 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 8.7 pt -72.77 166.04 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 C-N-CA 122.846 0.458 . . . . 0.0 110.214 -178.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 33.0 ttm105 -67.68 138.7 56.52 Favored 'General case' 0 N--CA 1.457 -0.086 0 C-N-CA 122.921 0.488 . . . . 0.0 110.598 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.77 -66.84 0.31 Allowed Glycine 0 CA--C 1.529 0.946 0 CA-C-O 119.324 -0.709 . . . . 0.0 111.896 174.613 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.23 -6.78 3.14 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 124.073 3.182 . . . . 0.0 113.309 178.552 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -147.65 155.88 42.22 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 118.01 0.368 . . . . 0.0 110.773 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -84.29 22.18 9.03 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 111.624 -0.59 . . . . 0.0 111.624 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -71.27 3.14 3.88 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.353 0.577 . . . . 0.0 112.25 -176.336 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -133.25 138.24 46.39 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 122.46 0.304 . . . . 0.0 110.824 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -113.25 177.52 4.6 Favored 'General case' 0 C--N 1.334 -0.074 0 C-N-CA 123.883 0.873 . . . . 0.0 111.008 -178.375 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 72.3 m 57.31 16.95 3.39 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 123.657 0.783 . . . . 0.0 112.641 177.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 52.8 mtm180 -75.38 151.65 38.15 Favored 'General case' 0 N--CA 1.456 -0.138 0 C-N-CA 122.713 0.405 . . . . 0.0 111.781 178.014 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 pt -136.9 175.52 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 170.743 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.417 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.5 OUTLIER -124.76 148.25 48.21 Favored 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 114.541 1.312 . . . . 0.0 114.541 -177.715 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.2 t -135.33 140.89 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.643 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.0 179.38 27.75 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 -178.038 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 60.09 22.23 11.44 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.724 0.81 . . . . 0.0 111.251 -174.093 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 92.8 mt -68.39 147.01 98.17 Favored Pre-proline 0 N--CA 1.451 -0.377 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 177.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 24' ' ' PRO . . . . . 0.409 ' HA ' ' HD3' ' B' ' 25' ' ' PRO . 59.1 Cg_endo -71.59 156.62 57.51 Favored 'Trans proline' 0 N--CA 1.452 -0.938 0 C-N-CA 123.257 2.638 . . . . 0.0 110.218 178.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 25' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' B' ' 24' ' ' PRO . 29.8 Cg_exo -60.02 -20.72 62.0 Favored 'Trans proline' 0 N--CA 1.453 -0.906 0 C-N-CA 123.217 2.611 . . . . 0.0 111.622 176.17 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -85.3 8.56 18.15 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.077 0.769 . . . . 0.0 113.077 -179.1 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 8.1 tp -59.98 150.47 6.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.237 0 CA-C-O 120.828 0.347 . . . . 0.0 110.528 -179.1 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 53.1 ttt180 -144.05 150.93 38.96 Favored 'General case' 0 N--CA 1.456 -0.137 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 177.42 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -57.49 -28.92 63.83 Favored 'General case' 0 CA--C 1.527 0.059 0 N-CA-C 114.908 1.447 . . . . 0.0 114.908 -173.809 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -79.91 -13.74 59.15 Favored 'General case' 0 CA--C 1.528 0.119 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -177.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -70.63 -26.69 63.59 Favored 'General case' 0 C--N 1.333 -0.124 0 O-C-N 121.966 -0.459 . . . . 0.0 110.365 178.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 81.0 mt -77.93 -24.03 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.096 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -80.24 -14.39 58.46 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 178.227 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -94.36 -71.45 0.66 Allowed 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 122.865 0.466 . . . . 0.0 111.858 174.11 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 53.5 t -64.12 -55.65 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.254 -171.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -68.01 -18.18 64.63 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -177.5 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.8 t -73.33 -31.57 64.07 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 175.456 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -73.08 -27.05 61.5 Favored 'General case' 0 C--N 1.343 0.314 0 O-C-N 122.071 -0.393 . . . . 0.0 110.609 172.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -79.07 -18.11 54.0 Favored 'General case' 0 N--CA 1.456 -0.153 0 N-CA-C 115.253 1.575 . . . . 0.0 115.253 176.1 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.35 167.26 32.9 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.608 -0.597 . . . . 0.0 111.608 177.183 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -75.86 105.57 6.97 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 80.6 mt -79.73 142.29 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.544 -178.816 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -105.94 -32.28 8.4 Favored 'General case' 0 N--CA 1.456 -0.128 0 C-N-CA 122.862 0.465 . . . . 0.0 109.869 172.146 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -152.38 155.46 37.65 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 114.271 1.211 . . . . 0.0 114.271 178.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 3.3 mp -117.06 149.95 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 175.191 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -146.28 52.88 1.13 Allowed 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 121.086 0.47 . . . . 0.0 109.801 -178.28 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.0 tp -63.06 135.2 57.11 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 122.678 0.391 . . . . 0.0 110.059 173.455 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.49 ' HE3' ' C2 ' ' A' ' 94' ' ' ' A' . 59.0 mttp -127.06 144.83 50.93 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 123.214 0.606 . . . . 0.0 110.645 178.69 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 66.8 m-20 -76.51 169.21 18.68 Favored 'General case' 0 C--O 1.232 0.139 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 171.35 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 18.6 tpt85 -156.0 152.16 27.79 Favored 'General case' 0 C--O 1.231 0.105 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 82.2 mtt85 -119.56 151.8 38.04 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 123.938 0.895 . . . . 0.0 109.365 178.521 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.49 5.57 60.27 Favored Glycine 0 CA--C 1.533 1.162 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 -178.64 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -176.34 175.93 47.62 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -179.121 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -68.44 157.28 62.5 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 123.886 3.057 . . . . 0.0 111.012 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.13 167.81 17.26 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 123.869 3.046 . . . . 0.0 110.997 177.444 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 56' ' ' PHE . . . . . 0.455 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 3.9 p90 -152.82 165.66 34.69 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 -177.303 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.13 169.64 23.09 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 121.216 0.531 . . . . 0.0 111.46 -172.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -132.17 158.19 42.35 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 171.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 73.5 t -140.15 135.05 36.78 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.309 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -178.03 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 64.4 tt0 -110.58 112.03 23.66 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -80.73 162.4 24.13 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 176.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 89.2 tt0 -74.36 -37.8 63.38 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 174.082 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -125.24 147.48 57.53 Favored Pre-proline 0 CA--C 1.529 0.17 0 C-N-CA 123.602 0.761 . . . . 0.0 109.917 179.039 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.48 -16.57 30.7 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 123.367 2.711 . . . . 0.0 111.576 -178.416 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 23.3 ptt85 -71.74 -15.92 62.2 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 122.7 0.4 . . . . 0.0 111.314 -177.798 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.65 -21.31 60.32 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 179.163 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -70.79 -18.1 62.76 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -73.93 -17.81 60.97 Favored 'General case' 0 N--CA 1.454 -0.226 0 O-C-N 122.274 -0.266 . . . . 0.0 110.469 179.058 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 -97.85 -39.69 8.89 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.567 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -74.68 -31.35 61.88 Favored 'General case' 0 N--CA 1.453 -0.283 0 O-C-N 122.274 -0.267 . . . . 0.0 110.783 -178.705 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.43 ' O ' HG12 ' B' ' 71' ' ' VAL . 48.2 t -87.99 6.33 3.54 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 122.836 0.455 . . . . 0.0 111.6 -174.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.8 t -139.14 -23.04 0.91 Allowed 'General case' 0 C--O 1.232 0.146 0 O-C-N 121.819 -0.551 . . . . 0.0 111.722 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -96.22 -4.2 59.9 Favored Glycine 0 CA--C 1.526 0.737 0 CA-C-O 119.449 -0.639 . . . . 0.0 112.443 -178.713 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 3.9 tpp180 -147.48 -18.5 0.38 Allowed 'General case' 0 CA--C 1.529 0.161 0 CA-C-N 118.219 1.01 . . . . 0.0 111.993 -176.515 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -68.46 146.15 53.43 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.56 42.36 99.75 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-O 119.691 -0.505 . . . . 0.0 112.092 174.703 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 30.7 t80 -87.62 129.13 35.23 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 117.806 0.803 . . . . 0.0 113.028 -177.461 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -69.38 87.42 0.44 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 123.378 0.671 . . . . 0.0 111.442 -177.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 36.7 t80 -81.13 -177.63 6.54 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 31.1 t0 -69.7 85.2 0.46 Allowed 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.144 179.203 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.72 3.45 89.5 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-O 119.843 -0.42 . . . . 0.0 112.113 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 -133.67 -179.1 5.32 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 113.791 1.034 . . . . 0.0 113.791 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -143.19 117.85 9.82 Favored 'General case' 0 N--CA 1.456 -0.13 0 C-N-CA 123.346 0.658 . . . . 0.0 109.357 -176.679 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.77 154.08 37.97 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 122.569 0.348 . . . . 0.0 110.642 -177.398 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -124.35 118.93 27.85 Favored 'General case' 0 CA--C 1.516 -0.352 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 176.143 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 19.9 t -142.52 84.99 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 123.028 0.531 . . . . 0.0 110.109 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -143.58 161.11 39.35 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.175 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.7 p90 -77.74 152.26 80.27 Favored Pre-proline 0 CA--C 1.528 0.116 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 178.736 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo . . . . . 0 C--O 1.251 1.133 0 C-N-CA 123.526 2.817 . . . . 0.0 110.653 177.676 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -2.985 0 C3'-C2'-C1' 104.823 3.692 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.821 1 C5'-C4'-C3' 109.014 -4.324 OUTLIER-DELTA 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.455 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.379 0 C5'-C4'-C3' 110.64 -3.24 . 0.01 2z . 0.0 . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.426 -2.248 1 C5'-C4'-C3' 108.97 -4.354 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . 0.49 ' C2 ' ' HE3' ' B' ' 48' ' ' LYS . . . . . . . . 0 O4'--C4' 1.425 -2.324 1 O4'-C1'-N19 112.721 4.521 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.825 0 C5'-C4'-C3' 110.282 -3.479 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.3 t . . . . . 0 N--CA 1.477 0.878 0 CA-C-O 120.772 0.32 . . . . 0.0 111.569 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 93.2 mt -68.18 144.84 13.98 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.407 ' C ' ' HD2' ' B' ' 8' ' ' ARG . 2.1 tmm_? -152.62 127.4 9.53 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 116.907 -0.133 . . . . 0.0 110.792 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.13 -170.59 5.41 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 123.62 0.629 . . . . 0.0 112.664 172.391 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.38 -28.82 3.39 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.534 2.822 . . . . 0.0 110.631 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -165.24 166.83 18.55 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 123.244 0.618 . . . . 0.0 109.958 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -89.7 -168.49 43.23 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 176.171 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 34.3 t30 57.95 -176.26 0.07 Allowed 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 123.87 0.868 . . . . 0.0 111.222 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 30.3 t-20 63.09 162.04 0.1 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.404 1.081 . . . . 0.0 111.342 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 19.1 p30 -139.51 -0.74 1.74 Allowed 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 123.358 0.663 . . . . 0.0 112.113 179.325 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 78.9 m -77.26 0.31 22.5 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 122.686 0.395 . . . . 0.0 110.432 174.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 41.5 ttm105 -78.51 145.69 34.79 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 123.513 0.725 . . . . 0.0 110.385 -178.527 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.0 pt -142.76 172.87 7.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 CA-C-O 121.087 0.47 . . . . 0.0 110.92 -177.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -109.81 153.93 23.71 Favored 'General case' 0 C--O 1.233 0.221 0 C-N-CA 124.909 1.283 . . . . 0.0 113.602 -178.08 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 22.5 t -137.07 139.74 43.81 Favored 'Isoleucine or valine' 0 C--O 1.232 0.17 0 C-N-CA 123.367 0.667 . . . . 0.0 110.701 179.021 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -159.7 -177.7 33.03 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 56.53 26.37 10.9 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.668 0.787 . . . . 0.0 111.107 -173.265 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 91.4 mt -63.97 152.59 86.97 Favored Pre-proline 0 N--CA 1.454 -0.253 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 177.524 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -64.34 159.74 42.35 Favored 'Trans proline' 0 N--CA 1.45 -1.066 0 C-N-CA 123.461 2.774 . . . . 0.0 110.805 -177.1 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.53 -2.15 9.51 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 124.218 3.279 . . . . 0.0 111.563 -178.574 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -146.12 116.94 7.68 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 122.695 0.398 . . . . 0.0 111.415 178.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 8.1 tp -157.79 147.33 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.177 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 15.0 mmp_? -80.58 158.08 25.84 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 120.783 0.325 . . . . 0.0 110.365 -179.03 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.5 p -72.57 10.24 0.88 Allowed 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 114.168 1.173 . . . . 0.0 114.168 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.4 tptt -140.1 -22.75 0.84 Allowed 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 122.473 0.309 . . . . 0.0 111.492 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -65.35 -24.5 67.27 Favored 'General case' 0 N--CA 1.456 -0.133 0 N-CA-C 112.674 0.62 . . . . 0.0 112.674 -179.099 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 6.9 tp -72.11 -20.93 20.33 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -90.37 -28.87 18.4 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.576 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.32 -32.46 64.6 Favored 'General case' 0 C--N 1.337 0.044 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -178.46 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 53.7 t -71.75 -45.29 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 177.16 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 35.5 m-85 -72.08 -30.41 65.09 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 47.1 t -68.33 -25.58 65.18 Favored 'General case' 0 C--N 1.34 0.179 0 CA-C-N 116.953 -0.112 . . . . 0.0 110.857 174.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -75.98 -32.64 59.56 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 176.061 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 14.6 m-85 -78.57 -15.76 58.2 Favored 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 115.534 1.679 . . . . 0.0 115.534 176.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 170.64 178.89 41.64 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 177.442 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.41 113.78 19.72 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 122.779 -0.247 . . . . 0.0 110.592 -178.169 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.6 mp -86.29 140.97 15.06 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 122.731 0.412 . . . . 0.0 109.9 176.438 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 43' ' ' ARG . . . . . 0.473 ' HE ' ' HA ' ' B' ' 43' ' ' ARG . 1.7 mmp_? -108.05 -31.85 7.78 Favored 'General case' 0 N--CA 1.456 -0.13 0 C-N-CA 122.969 0.508 . . . . 0.0 110.012 174.273 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -151.32 158.8 44.28 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 45' ' ' ILE . . . . . 0.571 HG22 ' H ' ' B' ' 47' ' ' LEU . 29.9 mm -140.2 151.03 21.32 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 124.153 0.981 . . . . 0.0 109.037 179.271 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -135.62 51.9 2.03 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 175.347 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 47' ' ' LEU . . . . . 0.571 ' H ' HG22 ' B' ' 45' ' ' ILE . 51.0 tp -53.38 130.52 35.54 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.101 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 18.3 ttmm -146.46 151.33 37.22 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -172.243 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 -141.29 -1.08 1.37 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 122.271 0.229 . . . . 0.0 111.544 -179.304 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 50' ' ' ARG . . . . . 0.408 HH22 ' P ' ' A' ' 93' ' ' ' A' . 44.8 ttm105 49.11 -102.97 0.1 Allowed 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 123.709 0.804 . . . . 0.0 111.235 179.334 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 51' ' ' ARG . . . . . 0.411 HH11 ' HD3' ' B' ' 51' ' ' ARG . 54.8 mtt180 -142.71 4.52 1.52 Allowed 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 123.077 0.551 . . . . 0.0 111.302 -178.525 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 167.71 -176.49 42.38 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.488 -0.645 . . . . 0.0 111.488 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.03 178.41 48.98 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -178.377 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 54' ' ' PRO . . . . . 0.422 ' HA ' ' HD3' ' B' ' 55' ' ' PRO . 43.3 Cg_endo -67.58 154.1 74.46 Favored 'Trans proline' 0 N--CA 1.451 -0.983 0 C-N-CA 123.4 2.733 . . . . 0.0 109.882 178.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 55' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' B' ' 54' ' ' PRO . 24.0 Cg_exo -60.38 153.17 62.05 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 122.956 2.438 . . . . 0.0 111.807 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -146.9 146.63 30.22 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 124.178 0.991 . . . . 0.0 112.307 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -160.43 157.05 27.05 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -175.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -112.69 151.57 30.06 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.854 167.612 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.6 t -135.2 136.63 51.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -176.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 78.8 tt0 -124.25 112.66 17.28 Favored 'General case' 0 N--CA 1.455 -0.176 0 CA-C-O 120.747 0.308 . . . . 0.0 110.637 -177.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -84.32 159.29 20.93 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 177.367 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 33.2 tp10 -78.14 -30.33 49.21 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.439 174.542 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -129.09 150.15 74.58 Favored Pre-proline 0 C--O 1.232 0.151 0 C-N-CA 123.573 0.749 . . . . 0.0 112.538 -178.409 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.99 -24.47 24.0 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 123.431 2.754 . . . . 0.0 110.921 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 38.6 mmt180 -76.52 -24.83 53.71 Favored 'General case' 0 C--N 1.339 0.131 0 C-N-CA 121.962 0.105 . . . . 0.0 110.757 179.116 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -75.19 -34.16 61.5 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-O 120.416 0.151 . . . . 0.0 111.271 175.353 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -73.04 -32.54 65.13 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 176.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -65.81 -33.87 76.86 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.151 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -76.06 -35.62 59.35 Favored 'General case' 0 N--CA 1.457 -0.125 0 N-CA-C 113.249 0.833 . . . . 0.0 113.249 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.73 -29.16 63.13 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 122.365 -0.21 . . . . 0.0 110.505 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 55.9 t -81.43 -52.47 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.0 t -70.29 -17.27 63.09 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -174.088 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.03 -1.76 45.28 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-O 119.161 -0.799 . . . . 0.0 113.868 -173.068 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 30.1 ttp-105 -153.23 -14.02 0.15 Allowed 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 119.003 1.402 . . . . 0.0 113.19 -175.048 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -69.28 146.71 52.04 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 118.673 0.67 . . . . 0.0 110.037 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.75 38.25 95.63 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-O 119.562 -0.577 . . . . 0.0 112.313 172.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 37.8 t80 -88.24 130.04 35.19 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 118.089 0.945 . . . . 0.0 112.968 -176.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 29.6 t0 -68.75 89.37 0.39 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.369 0.668 . . . . 0.0 111.091 -178.51 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 35.7 t80 -81.17 -174.62 4.99 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -69.49 74.05 0.37 Allowed 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 123.765 0.826 . . . . 0.0 111.997 178.571 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.47 6.83 70.17 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 -179.707 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -133.19 -179.31 5.42 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -179.503 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 9.5 tpp180 -143.08 114.38 7.88 Favored 'General case' 0 CA--C 1.528 0.132 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -175.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -61.9 153.13 29.99 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.811 0.444 . . . . 0.0 110.245 -177.122 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 74.8 mtt180 -129.11 115.31 17.52 Favored 'General case' 0 CA--C 1.52 -0.185 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 177.681 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 38.7 t -143.14 85.14 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.183 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -148.58 165.3 31.66 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.641 0.258 . . . . 0.0 110.589 -174.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -81.79 156.82 70.0 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 113.755 1.021 . . . . 0.0 113.755 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo . . . . . 0 C--O 1.252 1.215 0 C-N-CA 123.895 3.064 . . . . 0.0 111.639 177.684 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.649 1 O4'-C1'-N19 112.447 4.247 . 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.46 1 C5'-C4'-C3' 109.311 -4.126 . 0.118 6n . 0.0 . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.547 0 O4'-C1'-N19 111.91 3.71 . 0.078 1z . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.5 ' C8 ' H5'' ' A' ' 93' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.421 -2.654 1 C3'-C2'-C1' 105.188 4.098 OUTLIER-DELTA 0.0 OUTLIER . 0.0 . . . . . . . . . . 4 4 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.845 0 O4'-C1'-N19 111.558 3.358 . 0.142 2u . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.417 2 C5'-C4'-C3' 109.421 -4.052 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 11.1 t . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 111.535 0.198 . . . . 0.0 111.535 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 73.3 mt -68.53 150.51 10.75 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.497 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.497 ' HD3' ' N ' ' B' ' 9' ' ' GLY . 3.0 tmt_? -144.0 158.34 43.77 Favored 'General case' 0 N--CA 1.457 -0.097 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 9' ' ' GLY . . . . . 0.497 ' N ' ' HD3' ' B' ' 8' ' ' ARG . . . -45.45 145.33 2.73 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 178.271 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.73 176.88 6.89 Favored 'Trans proline' 0 N--CA 1.452 -0.93 0 C-N-CA 123.766 2.977 . . . . 0.0 111.769 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 62.39 15.63 7.89 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.481 1.112 . . . . 0.0 113.492 176.398 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 166.33 160.99 14.37 Favored Glycine 0 CA--C 1.527 0.808 0 CA-C-N 118.41 0.55 . . . . 0.0 112.304 174.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 73.5 m-80 -137.44 -5.81 1.79 Allowed 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 123.525 0.73 . . . . 0.0 110.525 176.15 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -155.48 106.64 2.55 Favored 'General case' 0 N--CA 1.456 -0.14 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 176.173 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 6.7 p30 -160.69 176.38 11.59 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -169.385 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 80.9 m -75.47 18.67 0.21 Allowed 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 123.321 0.649 . . . . 0.0 111.598 177.377 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 17' ' ' ARG . . . . . 0.414 ' HA ' ' HA ' ' B' ' 60' ' ' GLU . 27.5 ttm180 -74.38 149.61 40.43 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 122.831 0.452 . . . . 0.0 111.239 -175.002 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.3 pt -131.08 -178.8 2.84 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.09 0 C-N-CA 123.876 0.87 . . . . 0.0 109.645 178.379 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -120.66 150.2 41.3 Favored 'General case' 0 C--O 1.231 0.12 0 N-CA-C 114.462 1.282 . . . . 0.0 114.462 -173.657 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 46.3 t -141.05 142.29 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 C-N-CA 123.928 0.891 . . . . 0.0 109.019 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.54 -178.95 33.03 Favored Glycine 0 C--N 1.338 0.665 0 C-N-CA 121.277 -0.487 . . . . 0.0 112.515 -175.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 48.5 t30 56.48 25.96 10.32 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.245 1.018 . . . . 0.0 111.376 -176.3 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.8 mt -66.32 127.34 93.22 Favored Pre-proline 0 CA--C 1.531 0.223 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -57.73 152.64 47.94 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 123.302 2.668 . . . . 0.0 110.905 174.214 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -69.24 -14.83 38.42 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.527 2.818 . . . . 0.0 111.194 -179.469 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 -82.5 -6.66 59.45 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 112.921 0.711 . . . . 0.0 112.921 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 19.5 mm -71.59 138.77 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 C-N-CA 122.421 0.288 . . . . 0.0 110.517 -178.552 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 65.9 mtm180 -88.06 154.53 20.41 Favored 'General case' 0 C--N 1.334 -0.065 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 177.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 2.7 p -65.74 -18.1 65.09 Favored 'General case' 0 C--N 1.333 -0.147 0 N-CA-C 113.246 0.832 . . . . 0.0 113.246 179.227 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 58.2 tptt -87.71 -21.09 25.4 Favored 'General case' 0 C--N 1.342 0.25 0 C-N-CA 122.669 0.388 . . . . 0.0 111.132 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -65.61 -23.07 66.74 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 122.118 -0.364 . . . . 0.0 111.451 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mp -70.86 -22.47 23.1 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 178.582 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -96.45 -38.4 10.04 Favored 'General case' 0 N--CA 1.453 -0.305 0 O-C-N 122.359 -0.213 . . . . 0.0 110.824 -178.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -67.62 -45.71 74.64 Favored 'General case' 0 N--CA 1.458 -0.057 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -175.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 91.1 t -72.26 -42.37 66.06 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -178.192 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -75.32 -26.68 58.85 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -177.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.2 t -70.73 -31.0 67.69 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-O 120.557 0.218 . . . . 0.0 110.43 174.644 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 28.9 tptp -70.82 -31.33 68.02 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -85.22 -13.0 51.28 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 116.082 1.882 . . . . 0.0 116.082 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.18 171.98 38.32 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.303 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -79.1 104.46 9.74 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 122.669 0.387 . . . . 0.0 110.406 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 83.5 mt -75.58 147.27 8.25 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.145 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 176.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -131.02 -19.41 2.87 Favored 'General case' 0 C--N 1.34 0.168 0 C-N-CA 122.523 0.329 . . . . 0.0 111.12 175.507 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -153.7 156.03 37.08 Favored 'General case' 0 CA--C 1.528 0.102 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 174.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 18.9 mm -136.19 152.85 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.122 0 C-N-CA 123.737 0.815 . . . . 0.0 109.253 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -145.72 46.73 1.27 Allowed 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 178.707 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 28.6 tp -58.27 133.99 56.16 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 174.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 56.0 mttp -127.56 145.49 50.84 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 123.655 0.782 . . . . 0.0 110.608 178.748 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.4 p-10 -81.38 -12.77 58.87 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 171.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 52.1 ttt85 62.4 154.56 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 125.437 1.495 . . . . 0.0 112.125 -177.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 33.3 ttp-105 -72.8 -11.18 60.5 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.185 0.594 . . . . 0.0 111.155 -178.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.41 162.69 33.05 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.93 -176.86 42.83 Favored Glycine 0 CA--C 1.53 0.978 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -177.742 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -66.76 157.64 60.17 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 123.798 2.998 . . . . 0.0 111.055 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -59.81 160.08 22.68 Favored 'Trans proline' 0 N--CA 1.454 -0.838 0 C-N-CA 123.808 3.005 . . . . 0.0 112.065 177.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 56' ' ' PHE . . . . . 0.429 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 1.8 p90 -157.74 166.47 32.68 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.705 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.14 172.68 18.02 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-O 121.174 0.512 . . . . 0.0 112.089 -172.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -131.67 146.58 52.25 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 171.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 96.6 t -132.41 132.41 60.37 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.265 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -174.358 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 60' ' ' GLU . . . . . 0.414 ' HA ' ' HA ' ' B' ' 17' ' ' ARG . 76.2 tt0 -116.36 120.39 38.71 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 120.581 0.229 . . . . 0.0 111.433 -175.525 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -90.49 161.7 15.39 Favored 'General case' 0 C--O 1.232 0.16 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 177.511 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -71.6 -33.4 68.98 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 174.388 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -128.96 150.39 75.12 Favored Pre-proline 0 CA--C 1.53 0.189 0 C-N-CA 123.689 0.795 . . . . 0.0 111.795 -178.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.86 -13.89 32.23 Favored 'Trans proline' 0 N--CA 1.452 -0.913 0 C-N-CA 123.214 2.609 . . . . 0.0 110.364 176.499 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 32.5 ttp-105 -65.26 -38.25 89.72 Favored 'General case' 0 CA--C 1.528 0.124 0 C-N-CA 123.323 0.649 . . . . 0.0 110.545 178.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -77.67 -20.3 53.96 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -176.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.79 -29.94 65.0 Favored 'General case' 0 N--CA 1.452 -0.364 0 O-C-N 122.527 -0.108 . . . . 0.0 110.711 -177.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -72.89 -27.24 61.77 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.327 -0.233 . . . . 0.0 110.61 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -80.1 -36.45 35.41 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -178.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -76.55 -28.39 56.26 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 110.572 -0.158 . . . . 0.0 110.572 -178.583 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.5 t -79.33 -58.66 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 69.9 m -73.5 -3.33 26.95 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -175.537 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -85.41 -19.94 57.67 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 119.32 -0.711 . . . . 0.0 112.828 -176.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 24.7 ptt-85 -161.64 18.45 0.11 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 118.604 1.202 . . . . 0.0 113.009 -174.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -66.9 140.96 57.8 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.97 0.73 . . . . 0.0 112.97 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 60.28 70.87 0.89 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.828 -0.509 . . . . 0.0 111.828 174.031 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 59.6 t80 -110.73 137.91 47.79 Favored 'General case' 0 C--N 1.339 0.138 0 N-CA-C 113.571 0.952 . . . . 0.0 113.571 179.215 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -64.42 108.47 1.64 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 124.392 1.077 . . . . 0.0 112.988 -175.086 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.412 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.9 t80 -113.9 169.3 9.1 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.849 0.86 . . . . 0.0 111.26 175.266 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.412 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 75.7 m-20 -59.81 97.18 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -179.193 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 80.08 -5.65 62.07 Favored Glycine 0 CA--C 1.534 1.281 0 CA-C-O 119.315 -0.714 . . . . 0.0 112.643 177.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -139.4 -171.02 3.03 Favored 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 118.296 1.048 . . . . 0.0 113.362 -177.4 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -142.04 128.96 20.67 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -177.425 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.6 mp -63.39 150.09 44.34 Favored 'General case' 0 C--N 1.335 -0.049 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -123.11 124.87 44.05 Favored 'General case' 0 CA--C 1.52 -0.194 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.184 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.3 t -147.29 79.73 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.088 0 C-N-CA 123.603 0.761 . . . . 0.0 109.269 178.29 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.9 pt-20 -147.08 165.03 31.17 Favored 'General case' 0 C--O 1.226 -0.155 0 C-N-CA 122.667 0.387 . . . . 0.0 110.442 -177.284 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 88' ' ' PHE . . . . . 0.405 ' HA ' ' HD3' ' B' ' 89' ' ' PRO . 3.7 p90 -80.01 153.72 74.96 Favored Pre-proline 0 C--O 1.234 0.275 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 176.763 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 89' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' B' ' 88' ' ' PHE . 37.1 Cg_exo . . . . . 0 C--O 1.249 1.051 0 C-N-CA 123.746 2.964 . . . . 0.0 111.728 175.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.472 2 O4'-C1'-N19 112.967 4.767 . 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . 0.429 " H4'" " H5'" ' A' ' 92' ' ' ' C' . . . . . . . . 0 O4'--C4' 1.424 -2.433 0 C5'-C4'-C3' 110.304 -3.464 OUTLIER-DELTA 0.0 OUTLIER delta 0.0 . . . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.429 " H5'" " H4'" ' A' ' 91' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.42 -2.747 0 C5'-C4'-C3' 109.756 -3.829 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.515 1 C3'-C2'-C1' 105.21 4.122 . 0.145 4b . 0.0 . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.563 1 O4'-C1'-N19 112.564 4.364 OUTLIER-EPSILON 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.895 0 C5'-C4'-C3' 109.585 -3.943 . 0.0 OUTLIER epsilon-1 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 4.6 p . . . . . 0 N--CA 1.48 1.037 0 N-CA-C 111.862 0.319 . . . . 0.0 111.862 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 44.3 mm -71.49 152.89 8.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 36.5 ttm-85 -62.85 145.5 54.91 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 122.666 0.387 . . . . 0.0 110.711 -179.149 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 9' ' ' GLY . . . . . 0.74 ' HA2' ' C2 ' ' A' ' 93' ' ' ' A' . . . 148.56 -25.71 1.35 Allowed Glycine 0 CA--C 1.533 1.185 0 CA-C-O 118.312 -1.271 . . . . 0.0 113.641 172.266 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 10' ' ' PRO . . . . . 0.531 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 32.4 Cg_exo -58.07 161.32 13.64 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 CA-C-N 120.111 1.956 . . . . 0.0 111.01 169.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.77 155.55 40.63 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.021 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 154.88 173.61 23.88 Favored Glycine 0 C--N 1.337 0.599 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.32 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 52.77 42.7 31.88 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.098 0.559 . . . . 0.0 111.28 179.48 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 68.0 m-20 57.17 20.37 5.59 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.792 0.837 . . . . 0.0 112.398 179.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 53.86 34.3 19.03 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 177.196 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.7 m -68.92 -1.08 6.47 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 122.739 0.416 . . . . 0.0 111.412 177.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 39.9 ttm180 -75.87 148.6 38.19 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 123.943 0.897 . . . . 0.0 110.49 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 14.2 pt -129.6 176.26 8.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 C-N-CA 122.897 0.479 . . . . 0.0 109.923 178.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.478 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 1.0 OUTLIER -115.49 153.42 31.16 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -173.297 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 79.2 t -138.09 100.26 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -82.66 160.03 38.96 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 175.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 40.8 t30 60.51 -171.56 0.14 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.153 0.581 . . . . 0.0 110.25 -176.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.6 tp -144.52 132.62 10.74 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.645 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -68.64 157.67 60.89 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.23 2.62 . . . . 0.0 111.501 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.59 -4.5 15.34 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 124.337 3.358 . . . . 0.0 111.821 -175.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 9.9 p30 -126.82 25.19 6.39 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -177.636 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 5.5 tp -58.78 139.97 17.75 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 C-N-CA 122.855 0.462 . . . . 0.0 110.95 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 39.0 ttm105 -155.83 160.56 40.32 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 175.405 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.05 3.68 0.16 Allowed 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 116.279 1.955 . . . . 0.0 116.279 -173.678 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -148.72 -22.49 0.32 Allowed 'General case' 0 CA--C 1.528 0.132 0 O-C-N 122.092 -0.38 . . . . 0.0 111.298 177.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 71.1 m-20 -67.93 -19.76 65.01 Favored 'General case' 0 N--CA 1.457 -0.123 0 O-C-N 122.389 -0.195 . . . . 0.0 111.455 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 7.9 tp -73.19 -14.3 16.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 177.156 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -103.55 -21.25 13.78 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -71.09 -51.46 25.01 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.432 0.293 . . . . 0.0 111.585 -177.049 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 m -67.91 -33.42 61.25 Favored 'Isoleucine or valine' 0 C--N 1.338 0.082 0 CA-C-O 120.515 0.198 . . . . 0.0 110.929 -179.026 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -74.42 -35.15 63.39 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 176.054 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.4 t -66.66 -25.55 66.62 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.575 0.226 . . . . 0.0 110.599 175.59 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 29.2 tptp -77.72 -33.1 53.16 Favored 'General case' 0 N--CA 1.456 -0.149 0 N-CA-C 110.275 -0.268 . . . . 0.0 110.275 177.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -85.44 -9.24 57.77 Favored 'General case' 0 CA--C 1.53 0.184 0 N-CA-C 116.394 1.998 . . . . 0.0 116.394 179.1 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.42 178.54 44.4 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.73 177.405 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -79.41 43.26 0.54 Allowed 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.937 0.895 . . . . 0.0 110.99 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 42' ' ' ILE . . . . . 0.584 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.8 mp -55.77 138.25 16.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 122.695 0.398 . . . . 0.0 110.089 179.22 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 56.7 mmm-85 -94.69 -54.64 3.42 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.175 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -133.44 150.62 51.76 Favored 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -170.26 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -112.52 151.04 14.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.203 0 C-N-CA 124.596 1.158 . . . . 0.0 108.26 173.158 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -143.7 68.74 1.28 Allowed 'General case' 0 N--CA 1.452 -0.329 0 CA-C-O 120.694 0.283 . . . . 0.0 111.164 178.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 44.1 tp -70.91 129.54 39.31 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.178 174.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.555 ' HE3' " H1'" ' A' ' 93' ' ' ' A' . 68.8 mttm -114.41 140.28 48.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 123.089 0.556 . . . . 0.0 110.085 178.225 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 46.0 p-10 -81.53 -163.81 0.68 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 123.877 0.871 . . . . 0.0 111.179 -178.326 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 22.7 tpp85 -49.6 131.06 21.31 Favored 'General case' 0 C--N 1.339 0.114 0 C-N-CA 123.182 0.593 . . . . 0.0 109.883 177.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 57.6 ttt-85 -150.39 42.32 0.82 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 122.86 0.464 . . . . 0.0 110.049 -174.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.7 6.09 83.41 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -176.492 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -167.03 -172.09 33.87 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 -179.729 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -63.97 159.05 44.2 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 123.158 2.572 . . . . 0.0 110.348 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -65.36 152.07 83.17 Favored 'Trans proline' 0 N--CA 1.448 -1.172 0 C-N-CA 123.086 2.524 . . . . 0.0 110.242 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 56' ' ' PHE . . . . . 0.479 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 2.1 p90 -157.59 162.98 38.77 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -178.301 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -146.62 173.68 12.12 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-O 121.083 0.468 . . . . 0.0 111.387 -172.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 58' ' ' PHE . . . . . 0.411 ' CD2' ' C2 ' ' A' ' 93' ' ' ' A' . 94.5 m-85 -138.68 160.67 39.06 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.336 175.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 81.9 t -137.76 134.75 45.85 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 55.1 tt0 -115.52 127.23 55.14 Favored 'General case' 0 N--CA 1.453 -0.295 0 CA-C-O 120.773 0.32 . . . . 0.0 110.741 -174.1 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.584 ' CE2' HD11 ' B' ' 42' ' ' ILE . 18.4 m-85 -95.17 151.52 19.14 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 115.314 1.598 . . . . 0.0 115.314 -172.718 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 49.8 tp10 -80.49 -26.24 38.33 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 168.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -153.05 117.54 2.85 Favored Pre-proline 0 N--CA 1.453 -0.294 0 C-N-CA 124.125 0.97 . . . . 0.0 109.468 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -66.86 -6.1 14.94 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 123.225 2.616 . . . . 0.0 112.429 -174.357 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 60.1 ttt85 -65.36 -28.88 69.6 Favored 'General case' 0 N--CA 1.456 -0.159 0 CA-C-N 118.022 0.374 . . . . 0.0 110.576 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -78.7 -15.8 58.03 Favored 'General case' 0 CA--C 1.531 0.213 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.21 -20.47 63.97 Favored 'General case' 0 N--CA 1.451 -0.411 0 O-C-N 122.198 -0.314 . . . . 0.0 110.428 -177.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -64.75 -26.95 68.58 Favored 'General case' 0 CA--C 1.532 0.266 0 O-C-N 122.055 -0.403 . . . . 0.0 110.336 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -90.88 -36.56 14.1 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 112.561 0.578 . . . . 0.0 112.561 178.691 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.67 -28.44 62.71 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 122.41 0.284 . . . . 0.0 110.723 -177.36 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 49.7 t -75.24 0.0 2.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.354 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 32.5 t -135.35 5.49 3.23 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.763 -0.586 . . . . 0.0 110.943 178.567 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -77.94 -28.87 55.77 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-O 119.694 -0.503 . . . . 0.0 112.129 -177.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 50.1 ttt180 -158.45 13.46 0.18 Allowed 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 117.624 0.712 . . . . 0.0 110.89 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 29.9 t0 -69.55 150.07 47.52 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 122.102 -0.374 . . . . 0.0 110.246 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.28 38.13 95.97 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 111.803 -0.519 . . . . 0.0 111.803 175.538 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 31.0 t80 -98.97 132.78 44.03 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 113.149 0.796 . . . . 0.0 113.149 -173.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -61.62 104.35 0.42 Allowed 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 123.559 0.744 . . . . 0.0 112.149 -179.282 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.496 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 66.2 t80 -110.35 173.44 6.33 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 123.586 0.754 . . . . 0.0 111.803 178.617 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.496 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.7 t0 -62.43 100.03 0.17 Allowed 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.67 -8.22 29.15 Favored Glycine 0 CA--C 1.531 1.076 0 C-N-CA 123.435 0.541 . . . . 0.0 112.936 177.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -138.9 -169.92 2.74 Favored 'General case' 0 C--N 1.34 0.172 0 N-CA-C 113.133 0.79 . . . . 0.0 113.133 -178.729 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 38.3 ttt180 -145.46 134.68 22.87 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -177.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -62.71 144.34 56.48 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -178.169 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 56.7 mtm180 -132.43 71.97 1.48 Allowed 'General case' 0 C--N 1.339 0.127 0 C-N-CA 122.728 0.411 . . . . 0.0 110.809 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.83 92.31 3.81 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.103 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 177.338 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.5 pt-20 -151.04 159.72 44.36 Favored 'General case' 0 C--N 1.334 -0.102 0 C-N-CA 122.658 0.383 . . . . 0.0 110.827 178.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -73.65 153.4 89.51 Favored Pre-proline 0 C--O 1.235 0.303 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo . . . . . 0 C--O 1.251 1.173 0 C-N-CA 123.839 3.026 . . . . 0.0 110.543 176.138 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.443 0 C5'-C4'-C3' 112.174 -2.218 OUTLIER-DELTA 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.619 0 O4'-C1'-N19 111.882 3.682 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.479 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.422 -2.608 0 O4'-C1'-N19 111.391 3.191 . 0.202 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.74 ' C2 ' ' HA2' ' B' ' 9' ' ' GLY . . . . . . . . 0 O4'--C4' 1.422 -2.605 0 C5'-C4'-C3' 110.2 -3.534 . 0.14 6n . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.662 0 C5'-C4'-C3' 110.337 -3.442 OUTLIER-DELTA 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.42 -2.739 0 C3'-C2'-C1' 104.523 3.359 . 0.0 OUTLIER '7D dist 2[' 0.0 . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 14.1 t . . . . . 0 N--CA 1.477 0.894 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 15.8 mt 61.91 -38.96 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 C-N-CA 125.777 1.631 . . . . 0.0 113.364 -176.241 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.87 -31.87 0.05 Allowed 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.254 0.621 . . . . 0.0 110.481 178.478 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . -171.43 -56.0 0.04 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-O 119.482 -0.621 . . . . 0.0 112.209 -174.488 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -59.31 135.77 67.66 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 123.666 2.911 . . . . 0.0 112.859 -176.747 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 57.47 170.71 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.901 1.28 . . . . 0.0 113.562 176.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.58 172.41 32.05 Favored Glycine 0 CA--C 1.525 0.711 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.22 178.057 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -77.81 162.73 26.68 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.764 0.426 . . . . 0.0 110.351 178.062 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -73.84 144.98 45.26 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 120.696 0.284 . . . . 0.0 110.641 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 15' ' ' ASP . . . . . 0.418 ' C ' ' H ' ' B' ' 17' ' ' ARG . 68.0 m-20 -87.08 -157.73 0.4 Allowed 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.496 0.719 . . . . 0.0 109.826 174.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 93.7 m -68.36 8.72 0.41 Allowed 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 122.608 0.363 . . . . 0.0 111.18 174.02 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 17' ' ' ARG . . . . . 0.418 ' H ' ' C ' ' B' ' 15' ' ' ASP . 49.2 mtt180 -73.12 156.61 38.49 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.448 0.699 . . . . 0.0 112.57 -179.128 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.0 pt -132.41 175.96 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.068 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 173.089 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.435 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.7 OUTLIER -119.3 147.63 44.08 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -174.981 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 24.8 t -132.42 138.5 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 C-N-CA 123.312 0.645 . . . . 0.0 110.368 -179.374 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -143.6 -179.43 20.18 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -177.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 64.4 t30 59.48 24.4 13.07 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.812 0.845 . . . . 0.0 111.325 -173.346 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 96.1 mt -71.5 142.04 86.06 Favored Pre-proline 0 CA--C 1.533 0.309 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 176.594 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -59.68 157.82 30.89 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 123.256 2.638 . . . . 0.0 111.116 176.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -69.97 -17.57 36.55 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.269 2.646 . . . . 0.0 110.58 177.245 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 79.1 m-20 -88.93 11.9 16.81 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 123.385 0.674 . . . . 0.0 112.724 178.015 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 7.7 tp -59.75 151.29 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 C-N-CA 122.63 0.372 . . . . 0.0 110.507 -178.303 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 16.1 ttp180 -142.68 147.69 36.11 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -59.78 -28.39 67.38 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -176.42 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -83.01 -19.62 36.63 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -75.55 -39.26 58.48 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 117.774 0.261 . . . . 0.0 111.109 179.621 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.412 HG22 ' H ' ' B' ' 32' ' ' ILE . 12.6 tt -78.18 -21.28 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 CA-C-N 116.688 -0.233 . . . . 0.0 110.667 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.4 mt-10 -77.29 -39.39 48.19 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.108 -0.37 . . . . 0.0 110.494 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -74.3 -33.64 63.27 Favored 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -179.287 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 41.3 t -71.3 -48.14 55.86 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -74.58 -31.79 62.18 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 39.1 t -67.81 -30.73 70.22 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.933 177.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -77.66 -26.79 50.64 Favored 'General case' 0 C--O 1.232 0.138 0 O-C-N 122.366 -0.209 . . . . 0.0 111.075 175.529 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -87.45 -8.31 56.63 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 116.435 2.013 . . . . 0.0 116.435 177.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 175.37 174.17 41.73 Favored Glycine 0 CA--C 1.524 0.599 0 C-N-CA 121.1 -0.571 . . . . 0.0 112.483 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.46 40.44 0.57 Allowed 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 123.767 0.827 . . . . 0.0 111.348 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 42' ' ' ILE . . . . . 0.593 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.9 mp -52.8 136.07 13.97 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.066 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 18.8 mmt85 -93.61 -35.18 13.0 Favored 'General case' 0 C--O 1.23 0.073 0 CA-C-O 119.492 -0.289 . . . . 0.0 111.691 -175.556 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -148.54 150.34 33.19 Favored 'General case' 0 C--O 1.232 0.147 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -177.794 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -115.15 151.8 16.84 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 C-N-CA 124.344 1.057 . . . . 0.0 108.278 174.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 61.6 t0 -148.16 75.12 1.32 Allowed 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.136 0.493 . . . . 0.0 110.221 179.393 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 53.9 tp -71.05 146.03 49.57 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.526 176.551 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 25.1 ttmm -146.41 141.09 26.82 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 176.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 45.8 p30 -147.42 15.12 1.12 Allowed 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 111.832 0.308 . . . . 0.0 111.832 -176.048 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 50' ' ' ARG . . . . . 0.432 ' C ' ' H ' ' B' ' 52' ' ' GLY . 35.3 ptt-85 -154.7 165.68 35.8 Favored 'General case' 0 CA--C 1.52 -0.176 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -178.397 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 64.35 -28.85 0.1 Allowed 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 125.144 1.378 . . . . 0.0 112.734 -176.585 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 52' ' ' GLY . . . . . 0.432 ' H ' ' C ' ' B' ' 50' ' ' ARG . . . -102.75 -155.07 25.13 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 175.55 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -74.85 -156.84 5.41 Favored Glycine 0 CA--C 1.534 1.277 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 176.421 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -63.48 164.91 19.16 Favored 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 123.618 2.879 . . . . 0.0 110.191 178.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_exo -50.5 131.47 32.62 Favored 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 123.569 2.846 . . . . 0.0 112.164 -173.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -162.61 169.4 20.22 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -151.78 159.24 43.99 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.184 0.516 . . . . 0.0 111.68 -174.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 58' ' ' PHE . . . . . 0.513 ' CE1' ' C4 ' ' A' ' 93' ' ' ' A' . 86.2 m-85 -112.72 151.05 30.69 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.11 172.106 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.2 t -135.96 132.33 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.148 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -178.436 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 69.9 tt0 -110.57 116.27 31.07 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 122.445 0.298 . . . . 0.0 111.155 -173.698 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.593 ' CE2' HD11 ' B' ' 42' ' ' ILE . 29.7 m-85 -92.51 154.8 18.24 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -80.71 -29.97 36.38 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 171.669 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -159.93 151.17 16.14 Favored Pre-proline 0 CA--C 1.531 0.212 0 C-N-CA 125.267 1.427 . . . . 0.0 111.589 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.39 -3.04 12.2 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 123.6 2.867 . . . . 0.0 112.484 -176.807 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -63.52 -25.49 68.27 Favored 'General case' 0 CA--C 1.529 0.152 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -176.322 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -89.58 -5.15 57.46 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -177.002 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.15 -14.2 62.85 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 122.408 -0.183 . . . . 0.0 110.818 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -65.86 -17.33 64.57 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 122.419 -0.176 . . . . 0.0 111.17 -178.624 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -123.5 -37.43 2.66 Favored 'General case' 0 C--O 1.231 0.122 0 C-N-CA 122.975 0.51 . . . . 0.0 112.142 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -79.76 -9.92 59.72 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 122.58 0.352 . . . . 0.0 111.634 -175.48 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 60.4 t -131.79 -53.69 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 C-N-CA 122.374 0.27 . . . . 0.0 110.724 -178.507 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 70.5 m -70.71 -6.53 38.0 Favored 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 122.208 0.203 . . . . 0.0 111.343 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -116.09 10.44 17.79 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 119.543 -0.587 . . . . 0.0 111.764 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 74' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' B' ' 74' ' ' ARG . 46.0 ttm180 -145.05 -20.41 0.5 Allowed 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 117.933 0.866 . . . . 0.0 111.984 -176.096 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -68.89 136.16 52.18 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.315 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 67.7 27.49 73.6 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 119.779 -0.456 . . . . 0.0 112.068 176.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 50.4 t80 -79.95 140.62 36.58 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 -172.345 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.7 t0 -59.34 102.52 0.14 Allowed 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -175.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.414 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 73.9 t80 -111.8 172.26 7.0 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 123.71 0.804 . . . . 0.0 110.743 176.026 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.414 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 17.6 t0 -62.4 98.35 0.11 Allowed 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.58 -5.8 55.42 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 119.599 -0.556 . . . . 0.0 112.887 177.347 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -142.2 -175.56 4.48 Favored 'General case' 0 CA--C 1.527 0.072 0 CA-C-N 117.945 0.872 . . . . 0.0 112.882 -178.083 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 93.1 mtt-85 -131.87 138.46 48.45 Favored 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 124.191 0.996 . . . . 0.0 109.829 176.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -59.85 154.38 18.64 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 178.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 85' ' ' ARG . . . . . 0.407 ' NE ' ' HA ' ' B' ' 85' ' ' ARG . 1.3 tpm_? -122.42 116.45 24.0 Favored 'General case' 0 CA--C 1.518 -0.255 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 176.012 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 15.2 t -135.1 89.48 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 O-C-N 123.378 0.424 . . . . 0.0 110.063 178.462 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -146.89 158.18 43.85 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.361 178.223 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -76.56 155.09 83.69 Favored Pre-proline 0 CA--C 1.532 0.276 0 N-CA-C 114.224 1.194 . . . . 0.0 114.224 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo . . . . . 0 C--O 1.251 1.14 0 C-N-CA 123.702 2.934 . . . . 0.0 111.46 175.29 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.036 0 O4'-C1'-N19 111.689 3.489 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.891 0 C5'-C4'-C3' 111.221 -2.853 . 0.571 6n . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.435 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.422 -2.585 0 C5'-C4'-C3' 110.537 -3.308 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.513 ' C4 ' ' CE1' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.426 -2.238 2 C5'-C4'-C3' 109.095 -4.27 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . 0.4 H5'' " H3'" ' A' ' 93' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.425 -2.319 0 C5'-C4'-C3' 112.531 -1.979 OUTLIER-DELTA 0.0 OUTLIER '7D dist 8d' 0.0 . . . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.319 0 O4'-C1'-N19 111.853 3.653 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.477 0.896 0 CA-C-O 120.567 0.222 . . . . 0.0 111.303 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 85.7 mt -74.35 147.1 9.13 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.144 0 C-N-CA 122.845 0.458 . . . . 0.0 110.496 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 53.52 -98.05 0.07 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.431 1.092 . . . . 0.0 112.427 178.126 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 9' ' ' GLY . . . . . 0.462 ' HA3' ' C4 ' ' A' ' 93' ' ' ' A' . . . -79.01 132.2 11.3 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 111.932 -0.467 . . . . 0.0 111.932 -169.111 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -75.03 175.41 11.28 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 123.919 3.079 . . . . 0.0 110.265 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.27 -12.28 61.53 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 122.201 0.201 . . . . 0.0 110.674 176.458 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 169.39 151.51 7.34 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 110.104 -1.199 . . . . 0.0 110.104 177.136 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 31.1 p-10 -159.3 174.74 14.32 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 116.855 0.327 . . . . 0.0 110.659 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 41.8 p30 -135.62 26.99 3.38 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 123.377 0.671 . . . . 0.0 110.366 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -69.63 -177.67 1.28 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.352 0.661 . . . . 0.0 110.024 -179.38 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 8.2 p -64.06 -9.77 18.16 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 122.62 0.368 . . . . 0.0 111.669 176.134 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -63.11 144.71 56.66 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 122.857 0.463 . . . . 0.0 111.808 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.7 pt -131.67 173.16 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.885 174.256 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -111.97 150.62 30.29 Favored 'General case' 0 N--CA 1.457 -0.115 0 C-N-CA 124.356 1.062 . . . . 0.0 113.383 -177.667 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 25.9 t -133.32 91.71 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.145 0 C-N-CA 122.964 0.506 . . . . 0.0 110.35 -176.54 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -91.49 165.73 30.06 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 111.594 -0.602 . . . . 0.0 111.594 179.358 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 62.9 t30 59.96 21.09 10.13 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.026 0.93 . . . . 0.0 111.669 -176.398 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 21.0 tp -67.35 118.7 59.03 Favored Pre-proline 0 CA--C 1.535 0.367 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.204 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.36 146.95 46.15 Favored 'Trans proline' 0 N--CA 1.45 -1.039 0 C-N-CA 122.658 2.239 . . . . 0.0 110.26 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.41 -14.47 30.97 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 123.401 2.734 . . . . 0.0 110.881 178.219 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 78.1 m-20 -80.13 0.8 30.61 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 113.479 0.918 . . . . 0.0 113.479 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 tp -64.98 144.3 14.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 24.7 ttp85 -73.91 155.66 38.46 Favored 'General case' 0 C--O 1.231 0.127 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.8 p -66.01 7.82 0.25 Allowed 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 114.537 1.31 . . . . 0.0 114.537 -178.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.0 tptm -142.02 -29.43 0.6 Allowed 'General case' 0 C--O 1.227 -0.096 0 C-N-CA 122.354 0.262 . . . . 0.0 111.129 -179.061 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 -63.71 -19.1 64.66 Favored 'General case' 0 N--CA 1.456 -0.167 0 O-C-N 122.048 -0.407 . . . . 0.0 110.532 175.392 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 tt -67.43 -16.1 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 123.028 0.531 . . . . 0.0 110.908 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -130.66 -22.33 2.69 Favored 'General case' 0 C--N 1.341 0.198 0 CA-C-N 118.162 0.437 . . . . 0.0 111.915 177.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 66.4 m-20 -70.9 -29.76 65.92 Favored 'General case' 0 C--O 1.232 0.151 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 176.464 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 52.4 t -67.93 -40.8 84.02 Favored 'Isoleucine or valine' 0 C--N 1.34 0.156 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 174.255 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -67.6 -32.04 72.5 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 113.086 0.772 . . . . 0.0 113.086 176.13 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 54.5 m -65.75 -24.64 67.0 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.993 -0.094 . . . . 0.0 110.819 175.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 14.3 tmtt? -74.5 -34.56 63.09 Favored 'General case' 0 CA--C 1.531 0.25 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 173.091 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 39' ' ' TYR . . . . . 0.412 ' CD1' ' HA ' ' B' ' 70' ' ' ALA . 40.0 m-85 -72.04 -20.86 61.62 Favored 'General case' 0 CA--C 1.529 0.169 0 N-CA-C 115.582 1.697 . . . . 0.0 115.582 175.496 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 161.72 -169.43 37.17 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 178.676 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.41 108.51 17.26 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 120.778 0.323 . . . . 0.0 111.174 -177.79 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 42' ' ' ILE . . . . . 0.438 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.8 mp -97.55 147.66 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.157 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 173.308 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -115.3 -24.05 8.63 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 119.384 -0.341 . . . . 0.0 111.209 177.607 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -151.38 158.78 44.2 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 114.071 1.137 . . . . 0.0 114.071 -179.051 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 45' ' ' ILE . . . . . 0.414 HD12 ' HA ' ' B' ' 45' ' ' ILE . 10.9 tp -124.28 159.67 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 176.318 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -153.19 63.28 0.76 Allowed 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.826 0.346 . . . . 0.0 110.752 -177.019 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.1 tp -63.37 135.89 57.28 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 175.198 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.528 ' HE2' ' CZ ' ' B' ' 56' ' ' PHE . 35.5 mtmm -141.09 176.43 8.83 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 123.795 0.838 . . . . 0.0 111.239 -178.327 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -144.16 177.85 8.3 Favored 'General case' 0 C--O 1.233 0.21 0 C-N-CA 122.928 0.491 . . . . 0.0 110.661 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 52.6 ttp180 -146.88 161.17 41.27 Favored 'General case' 0 C--O 1.232 0.171 0 C-N-CA 123.15 0.58 . . . . 0.0 109.601 -177.615 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 23.1 mmm180 -69.14 1.0 3.98 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 123.259 0.624 . . . . 0.0 112.218 -178.258 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -167.28 158.77 31.86 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 178.711 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.54 178.97 37.6 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 111.641 -0.584 . . . . 0.0 111.641 -178.456 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.82 160.59 49.12 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 123.649 2.9 . . . . 0.0 110.684 178.798 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.12 172.74 12.42 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 123.837 3.025 . . . . 0.0 110.435 176.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 56' ' ' PHE . . . . . 0.528 ' CZ ' ' HE2' ' B' ' 48' ' ' LYS . 3.1 p90 -155.34 167.34 30.69 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -146.83 156.98 43.54 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.133 0.492 . . . . 0.0 111.74 -175.77 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -106.78 150.85 25.9 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 115.179 -0.919 . . . . 0.0 112.332 170.202 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 72.8 t -131.82 137.98 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.264 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 -179.324 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -122.17 118.42 28.59 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.69 0.281 . . . . 0.0 110.557 -177.234 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.438 ' CE2' HD11 ' B' ' 42' ' ' ILE . 54.2 m-85 -85.52 151.85 23.63 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 115.39 1.626 . . . . 0.0 115.39 -177.498 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 40.3 tp10 -78.53 -18.4 54.78 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.379 0.672 . . . . 0.0 109.851 173.418 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -148.44 119.53 4.32 Favored Pre-proline 0 CA--C 1.532 0.269 0 C-N-CA 123.482 0.713 . . . . 0.0 110.072 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_exo -55.08 -20.5 24.0 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.411 2.741 . . . . 0.0 113.324 -177.402 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 53.3 tpt85 -69.54 -32.55 71.43 Favored 'General case' 0 C--N 1.342 0.243 0 CA-C-N 118.295 0.498 . . . . 0.0 110.971 179.578 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -74.05 -24.39 59.52 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -179.867 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.46 -24.11 64.67 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.239 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -73.79 -27.71 61.27 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 178.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 77.4 m-20 -78.04 -38.43 44.61 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 112.386 0.513 . . . . 0.0 112.386 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 70' ' ' ALA . . . . . 0.412 ' HA ' ' CD1' ' B' ' 39' ' ' TYR . . . -70.77 -31.05 67.71 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 110.343 -0.243 . . . . 0.0 110.343 178.389 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 37.3 t -80.6 -43.91 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.474 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 46.0 t -66.27 -20.97 66.26 Favored 'General case' 0 CA--C 1.533 0.29 0 O-C-N 122.197 -0.315 . . . . 0.0 111.127 -177.467 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -91.03 -15.27 56.43 Favored Glycine 0 CA--C 1.529 0.938 0 CA-C-O 119.307 -0.718 . . . . 0.0 113.17 -177.001 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 62.7 mtt180 -147.62 21.54 1.16 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.448 1.124 . . . . 0.0 113.045 -172.275 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 16.5 p30 -69.32 1.71 3.58 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 177.538 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.24 90.44 0.08 OUTLIER Glycine 0 C--N 1.336 0.582 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -125.53 139.49 53.56 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 178.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -64.39 106.5 1.13 Allowed 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.628 0.771 . . . . 0.0 112.65 -177.066 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.444 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.0 t80 -111.46 170.35 8.18 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 123.677 0.791 . . . . 0.0 111.446 177.348 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.444 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.1 t0 -59.15 100.9 0.08 Allowed 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -179.198 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 75.81 -5.28 40.32 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-O 119.661 -0.522 . . . . 0.0 112.888 177.717 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -141.43 -169.49 2.88 Favored 'General case' 0 C--O 1.232 0.161 0 N-CA-C 113.513 0.931 . . . . 0.0 113.513 -177.723 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 42.2 ttp-105 -142.04 139.31 32.29 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.672 0.789 . . . . 0.0 109.162 179.22 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.72 151.15 45.85 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 -178.414 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 90.1 mtm-85 -133.61 56.17 1.86 Allowed 'General case' 0 C--N 1.339 0.135 0 CA-C-O 120.75 0.31 . . . . 0.0 110.799 177.781 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 23.1 t -82.21 93.95 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 175.676 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.9 pt-20 -151.9 162.72 40.6 Favored 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 122.51 0.324 . . . . 0.0 110.205 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.4 p90 -78.09 157.56 78.4 Favored Pre-proline 0 N--CA 1.453 -0.306 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 177.418 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo . . . . . 0 C--O 1.252 1.219 0 C-N-CA 123.903 3.069 . . . . 0.0 111.658 177.45 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.379 1 O4'-C1'-N19 112.554 4.354 . 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.908 0 O4'-C1'-N19 111.828 3.628 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.441 " H4'" ' CE1' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.421 -2.643 0 O4'-C1'-N19 111.395 3.195 . 0.133 2z . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.462 ' C4 ' ' HA3' ' B' ' 9' ' ' GLY . . . . . . . . 0 O4'--C4' 1.42 -2.75 0 O4'-C1'-N19 111.098 2.898 . 0.368 4g . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.298 0 C5'-C4'-C3' 110.208 -3.528 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.025 0 C5'-C4'-C3' 109.924 -3.717 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.4 HG22 ' H ' ' B' ' 8' ' ' ARG . 4.6 p . . . . . 0 N--CA 1.477 0.909 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 1.7 mt -86.05 -2.16 7.75 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 C-N-CA 122.61 0.364 . . . . 0.0 111.24 -177.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.4 ' H ' HG22 ' B' ' 6' ' ' VAL . 1.2 tmm_? -60.79 141.8 56.64 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 122.474 0.31 . . . . 0.0 110.457 -179.604 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 57.8 -145.88 39.35 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 176.665 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -76.31 43.24 1.14 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 124.27 3.313 . . . . 0.0 110.273 175.388 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 59.39 13.36 3.14 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 124.2 1.0 . . . . 0.0 112.064 -173.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -93.15 175.95 36.88 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 176.589 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -154.86 125.46 6.96 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 122.404 -0.468 . . . . 0.0 110.168 178.498 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 56.4 t-20 -163.61 139.41 6.58 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 177.507 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -77.52 -11.07 59.81 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.074 0.398 . . . . 0.0 112.074 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 75.2 m -79.24 1.76 23.6 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 122.835 0.454 . . . . 0.0 111.34 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 48.8 mtt-85 -78.51 151.1 32.73 Favored 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 112.705 0.631 . . . . 0.0 112.705 -177.164 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.4 pt -139.14 171.59 14.44 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 C-N-CA 123.507 0.723 . . . . 0.0 109.524 174.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.441 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.3 OUTLIER -113.21 153.12 28.86 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -175.99 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 58.7 t -136.77 140.89 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.317 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -146.87 174.62 26.63 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.925 -0.47 . . . . 0.0 111.925 -176.504 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 66.3 t30 62.91 157.35 0.06 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.772 1.229 . . . . 0.0 111.463 -172.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.2 tp -81.65 130.41 61.49 Favored Pre-proline 0 N--CA 1.453 -0.306 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -69.93 165.17 32.07 Favored 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.344 2.696 . . . . 0.0 110.822 176.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -56.59 -26.16 63.01 Favored 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 123.737 2.958 . . . . 0.0 111.894 179.022 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 40.4 p-10 -157.14 162.85 39.39 Favored 'General case' 0 C--O 1.233 0.192 0 C-N-CA 123.368 0.667 . . . . 0.0 110.457 175.535 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 6.4 tp -151.99 142.63 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 110.105 -0.332 . . . . 0.0 110.105 -179.644 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 81.8 mtt85 -140.02 31.15 1.99 Allowed 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 123.558 0.743 . . . . 0.0 110.135 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . 0.25 1.0 OUTLIER 59.59 7.78 1.1 Allowed 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 115.749 1.759 . . . . 0.0 115.749 -178.916 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 30' ' ' LYS . . . . . 0.425 ' HE3' ' HB2' ' B' ' 30' ' ' LYS . 0.0 OUTLIER -151.43 -6.6 0.25 Allowed 'General case' 0 C--N 1.339 0.126 0 O-C-N 122.435 -0.166 . . . . 0.0 111.427 177.359 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -64.65 -19.75 65.89 Favored 'General case' 0 N--CA 1.457 -0.112 0 O-C-N 122.116 -0.365 . . . . 0.0 111.979 178.649 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 7.5 tp -71.64 -17.69 19.59 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 175.868 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 81.6 mt-10 -94.96 -36.52 11.55 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -69.52 -39.97 77.2 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -177.023 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 77.1 t -72.14 -41.89 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.075 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.384 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 39.0 m-85 -74.06 -37.78 64.16 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 114.02 1.119 . . . . 0.0 114.02 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 91.7 p -69.21 -22.12 63.9 Favored 'General case' 0 C--N 1.34 0.175 0 CA-C-N 117.729 0.241 . . . . 0.0 110.422 177.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -74.73 -34.06 62.49 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.233 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -81.22 -13.26 58.72 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 115.926 1.825 . . . . 0.0 115.926 177.708 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.16 175.37 43.47 Favored Glycine 0 CA--C 1.527 0.819 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.053 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -82.27 80.02 8.58 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.097 0.559 . . . . 0.0 110.601 -178.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.7 mp -65.51 140.22 20.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.105 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 174.495 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 43' ' ' ARG . . . . . 0.43 ' HE ' ' HA ' ' B' ' 43' ' ' ARG . 1.7 mmp_? -109.76 -27.84 9.12 Favored 'General case' 0 N--CA 1.457 -0.082 0 C-N-CA 122.869 0.467 . . . . 0.0 110.739 177.361 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -151.79 163.43 39.18 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 113.815 1.042 . . . . 0.0 113.815 -179.223 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 7.6 tp -142.17 160.56 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -177.653 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -153.95 68.55 0.76 Allowed 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 176.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 49.0 tp -69.3 133.31 47.71 Favored 'General case' 0 CA--C 1.529 0.141 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 175.653 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.485 ' HD2' ' CZ ' ' B' ' 56' ' ' PHE . 67.3 mttm -126.5 128.84 47.55 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 122.559 0.344 . . . . 0.0 110.542 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -161.2 -36.41 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.124 175.879 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 51.5 tpt85 -84.03 -21.16 31.71 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 122.719 0.408 . . . . 0.0 110.62 177.2 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 82.9 mtm180 -82.89 14.12 3.47 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.263 0.625 . . . . 0.0 111.621 179.47 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.73 174.57 44.32 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 111.671 -0.572 . . . . 0.0 111.671 176.37 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.53 176.47 32.81 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.504 -0.639 . . . . 0.0 111.504 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.24 161.3 45.2 Favored 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 123.639 2.892 . . . . 0.0 109.772 176.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -68.0 120.82 7.8 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 123.021 2.48 . . . . 0.0 110.247 178.637 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 56' ' ' PHE . . . . . 0.485 ' CZ ' ' HD2' ' B' ' 48' ' ' LYS . 3.3 p90 -161.58 171.69 17.6 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 178.097 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.38 164.37 38.37 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.213 0.53 . . . . 0.0 111.691 -175.743 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 58' ' ' PHE . . . . . 0.4 ' CZ ' ' HB2' ' B' ' 19' ' ' TYR . 9.7 m-85 -116.81 151.62 36.11 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.372 -0.831 . . . . 0.0 113.073 169.396 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 48.2 t -133.41 142.23 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 C-N-CA 123.189 0.596 . . . . 0.0 109.62 -177.212 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -123.99 117.82 25.62 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 110.444 -0.206 . . . . 0.0 110.444 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 49.3 m-85 -90.33 158.27 17.22 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 113.774 1.027 . . . . 0.0 113.774 177.771 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -70.77 -24.28 62.56 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 174.042 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -152.64 155.52 32.64 Favored Pre-proline 0 CA--C 1.533 0.314 0 C-N-CA 123.367 0.667 . . . . 0.0 111.952 178.511 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -71.92 -7.74 21.65 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 123.054 2.502 . . . . 0.0 111.359 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.28 -53.93 14.77 Favored 'General case' 0 C--N 1.339 0.12 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -177.112 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -70.75 -20.22 62.65 Favored 'General case' 0 C--O 1.233 0.185 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -177.564 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.05 -23.92 65.93 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.412 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 45.6 tp10 -72.77 -32.48 65.64 Favored 'General case' 0 N--CA 1.455 -0.2 0 O-C-N 122.273 -0.267 . . . . 0.0 110.318 179.539 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 62.0 m-20 -73.49 -36.8 65.84 Favored 'General case' 0 CA--C 1.522 -0.116 0 N-CA-C 111.979 0.362 . . . . 0.0 111.979 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.8 -27.92 63.26 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 122.164 0.186 . . . . 0.0 110.557 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 42.6 t -83.19 -54.32 9.49 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.2 t -70.68 -18.91 62.83 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 -174.17 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -101.31 0.54 53.91 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-O 119.031 -0.872 . . . . 0.0 113.585 -173.04 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 28.9 ttp-105 -153.78 -13.18 0.14 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-N 118.846 1.323 . . . . 0.0 113.393 -175.664 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -67.68 145.69 54.53 Favored 'General case' 0 C--O 1.233 0.226 0 O-C-N 121.465 -0.772 . . . . 0.0 110.315 179.485 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.51 55.17 26.95 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.554 -0.618 . . . . 0.0 111.554 175.599 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 39.2 t80 -105.96 140.38 39.06 Favored 'General case' 0 N--CA 1.453 -0.288 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -178.094 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -62.91 110.55 1.81 Allowed 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 124.2 1.0 . . . . 0.0 113.012 -175.535 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.421 ' CD2' ' N ' ' B' ' 80' ' ' ASP . 25.6 t80 -118.88 165.93 13.45 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 123.66 0.784 . . . . 0.0 111.941 174.756 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.421 ' N ' ' CD2' ' B' ' 79' ' ' TYR . 19.4 t0 -59.07 98.09 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.436 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -178.661 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.9 -4.91 63.79 Favored Glycine 0 CA--C 1.535 1.285 0 CA-C-O 119.747 -0.474 . . . . 0.0 112.677 177.69 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -140.56 -170.22 2.96 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 117.952 0.876 . . . . 0.0 113.15 -178.185 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 -141.38 133.35 27.59 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 -178.158 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -65.13 152.03 44.6 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.27 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -125.72 126.92 45.39 Favored 'General case' 0 CA--C 1.52 -0.173 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 175.572 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 38.9 t -143.95 81.26 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.245 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 176.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -139.8 158.22 44.45 Favored 'General case' 0 C--O 1.224 -0.281 0 C-N-CA 122.664 0.386 . . . . 0.0 110.551 -175.457 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.0 p90 -74.54 154.79 87.64 Favored Pre-proline 0 N--CA 1.454 -0.269 0 N-CA-C 114.73 1.381 . . . . 0.0 114.73 179.245 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo . . . . . 0 C--O 1.253 1.255 0 C-N-CA 123.646 2.897 . . . . 0.0 110.877 176.937 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -2.987 0 C3'-C2'-C1' 104.46 3.289 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.063 0 C3'-C2'-C1' 104.673 3.525 . 0.171 0b . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.441 ' C6 ' ' CE1' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.422 -2.607 0 C5'-C4'-C3' 110.752 -3.165 . 0.048 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.358 0 C5'-C4'-C3' 110.079 -3.614 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.518 0 O4'-C1'-N19 110.745 2.545 OUTLIER-DELTA 0.0 OUTLIER delta 0.0 . . . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.792 0 C5'-C4'-C3' 110.208 -3.528 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.2 t . . . . . 0 N--CA 1.476 0.87 0 N-CA-C 111.585 0.217 . . . . 0.0 111.585 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 85.7 mt -66.4 -31.69 54.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 122.261 0.224 . . . . 0.0 111.438 -175.191 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 7.0 tpp180 -158.25 159.5 36.08 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 122.436 0.294 . . . . 0.0 110.267 -178.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . -64.12 167.91 25.9 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 176.777 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.42 149.4 84.71 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 123.292 2.661 . . . . 0.0 109.433 174.337 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -156.94 164.35 38.13 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-O 120.878 0.37 . . . . 0.0 111.442 -176.21 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -157.65 5.86 0.17 Allowed Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 177.456 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 59.4 t30 -148.1 158.88 44.31 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.895 0.878 . . . . 0.0 109.364 -179.175 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 74.8 m-20 -73.66 140.95 46.46 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 178.729 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 40.75 -134.05 0.26 Allowed 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.876 0.695 . . . . 0.0 112.876 -178.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 86.6 m 59.27 7.58 0.94 Allowed 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 178.085 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 68.5 mtm-85 -87.76 138.21 31.66 Favored 'General case' 0 N--CA 1.453 -0.316 0 O-C-N 122.1 -0.375 . . . . 0.0 111.336 178.618 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.6 pp -138.05 168.89 19.48 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 C-N-CA 123.148 0.579 . . . . 0.0 110.072 176.128 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.439 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.4 OUTLIER -113.33 153.31 28.71 Favored 'General case' 0 CA--C 1.528 0.104 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -177.228 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 93.0 t -133.99 115.21 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -117.56 169.95 13.38 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 177.573 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 61.1 t30 57.99 23.68 10.21 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.704 0.801 . . . . 0.0 111.113 -175.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 21.2 tp -65.39 127.05 92.61 Favored Pre-proline 0 CA--C 1.535 0.374 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 178.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -71.21 154.46 61.76 Favored 'Trans proline' 0 N--CA 1.451 -0.98 0 C-N-CA 123.075 2.516 . . . . 0.0 110.824 -178.08 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -71.26 -12.52 30.03 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 123.44 2.76 . . . . 0.0 111.233 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 -77.56 -1.91 33.04 Favored 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 178.8 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 9.1 tp -67.12 158.62 5.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 C-N-CA 122.596 0.358 . . . . 0.0 110.321 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 76.5 mtt85 -132.19 152.58 51.22 Favored 'General case' 0 N--CA 1.457 -0.09 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 176.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.43 -17.78 60.15 Favored 'General case' 0 C--N 1.334 -0.101 0 N-CA-C 114.262 1.208 . . . . 0.0 114.262 -177.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 4.2 ttpt -97.03 -30.56 12.99 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 122.329 0.251 . . . . 0.0 110.714 178.082 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -69.23 -31.79 70.58 Favored 'General case' 0 C--O 1.233 0.189 0 O-C-N 122.169 -0.332 . . . . 0.0 111.581 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.4 tt -76.48 -11.24 13.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 O-C-N 123.169 0.293 . . . . 0.0 110.99 -178.459 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -118.97 -0.56 11.14 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 117.833 0.288 . . . . 0.0 110.807 177.471 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -94.49 -62.41 1.33 Allowed 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 122.551 0.34 . . . . 0.0 111.674 177.695 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 62.9 t -65.4 -41.12 90.4 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 -178.518 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -62.94 -31.03 72.03 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.4 t -68.07 -30.8 70.08 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 110.228 -0.286 . . . . 0.0 110.228 177.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 47.1 mmtm -69.35 -28.28 66.08 Favored 'General case' 0 C--N 1.338 0.082 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 173.497 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -80.18 -19.11 47.86 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 116.665 2.098 . . . . 0.0 116.665 176.125 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.49 20.24 0.03 OUTLIER Glycine 0 CA--C 1.53 0.99 0 C-N-CA 119.584 -1.293 . . . . 0.0 114.64 -177.515 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 50.85 66.69 1.1 Allowed 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 118.279 1.039 . . . . 0.0 111.987 176.423 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 42' ' ' ILE . . . . . 0.511 HD11 ' CZ ' ' B' ' 61' ' ' PHE . 1.7 mp -56.02 141.95 11.83 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 C-N-CA 122.951 0.5 . . . . 0.0 110.447 178.054 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 43' ' ' ARG . . . . . 0.421 HH11 ' HD3' ' B' ' 43' ' ' ARG . 10.6 mmm180 -107.05 -24.7 11.88 Favored 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 122.603 0.361 . . . . 0.0 111.262 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -146.59 155.25 42.34 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 45' ' ' ILE . . . . . 0.458 HG22 ' H ' ' B' ' 47' ' ' LEU . 17.7 mm -139.13 154.36 25.5 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 C-N-CA 124.203 1.001 . . . . 0.0 109.407 -178.21 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -142.38 47.67 1.58 Allowed 'General case' 0 CA--C 1.531 0.233 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 177.066 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 47' ' ' LEU . . . . . 0.458 ' H ' HG22 ' B' ' 45' ' ' ILE . 58.7 tp -61.5 128.21 35.19 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.55 177.626 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.532 ' HE2' ' CZ ' ' B' ' 56' ' ' PHE . 23.2 pttm -157.74 173.14 17.27 Favored 'General case' 0 CA--C 1.528 0.102 0 C-N-CA 123.551 0.74 . . . . 0.0 109.691 179.04 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 50.8 p30 -146.78 11.28 1.08 Allowed 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -174.445 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 19.5 mtp180 50.53 24.46 1.63 Allowed 'General case' 0 C--N 1.341 0.219 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -179.054 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 63.6 mtm-85 56.1 19.93 4.07 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.399 0.68 . . . . 0.0 112.586 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.88 145.42 7.91 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.43 -179.03 49.15 Favored Glycine 0 CA--C 1.53 0.97 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -176.39 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -68.0 147.16 73.35 Favored 'Trans proline' 0 N--CA 1.451 -1.001 0 C-N-CA 123.665 2.91 . . . . 0.0 110.397 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.22 164.69 34.87 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 123.362 2.708 . . . . 0.0 110.945 -179.296 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 56' ' ' PHE . . . . . 0.532 ' CZ ' ' HE2' ' B' ' 48' ' ' LYS . 4.2 p90 -157.24 163.07 39.17 Favored 'General case' 0 C--O 1.234 0.25 0 N-CA-C 104.696 -2.335 . . . . 0.0 104.696 174.794 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.17 152.88 29.94 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 119.713 -0.795 . . . . 0.0 112.611 -172.755 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -96.5 148.24 23.02 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.707 166.725 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 58.5 t -133.98 143.8 37.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -178.439 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -132.21 118.39 19.47 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 120.956 0.408 . . . . 0.0 110.763 -176.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.511 ' CZ ' HD11 ' B' ' 42' ' ' ILE . 34.5 m-85 -86.96 161.97 17.93 Favored 'General case' 0 C--N 1.333 -0.115 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -177.436 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -79.98 -27.92 39.59 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.425 174.36 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -138.51 143.51 38.62 Favored Pre-proline 0 C--N 1.34 0.182 0 C-N-CA 123.85 0.86 . . . . 0.0 112.006 179.055 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -73.83 -19.7 20.64 Favored 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 123.281 2.654 . . . . 0.0 111.257 -177.65 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 78.7 mtt85 -74.18 -25.23 59.59 Favored 'General case' 0 N--CA 1.456 -0.136 0 C-N-CA 122.398 0.279 . . . . 0.0 111.381 -178.154 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -91.96 -21.89 20.3 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.642 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.73 -27.06 66.48 Favored 'General case' 0 N--CA 1.453 -0.276 0 O-C-N 122.274 -0.267 . . . . 0.0 110.282 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -73.55 -26.66 60.95 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 121.9 0.08 . . . . 0.0 110.848 179.001 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -77.25 -36.23 54.67 Favored 'General case' 0 CA--C 1.521 -0.14 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.84 -29.06 61.92 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 122.259 0.224 . . . . 0.0 110.439 177.578 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 17.2 t -80.94 -42.81 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 43.8 t -66.97 -21.83 65.95 Favored 'General case' 0 CA--C 1.528 0.108 0 O-C-N 122.177 -0.327 . . . . 0.0 111.063 -178.156 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -89.66 -2.88 75.15 Favored Glycine 0 CA--C 1.531 1.071 0 CA-C-O 119.387 -0.674 . . . . 0.0 112.92 -178.361 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 80.3 mtt85 -141.93 -8.48 0.92 Allowed 'General case' 0 C--N 1.341 0.211 0 CA-C-N 118.181 0.99 . . . . 0.0 112.827 -174.391 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -67.3 118.64 10.95 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -179.286 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.81 45.37 96.35 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 175.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 53.9 t80 -95.97 135.94 37.06 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -172.693 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.6 t0 -63.51 105.33 0.76 Allowed 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.52 0.728 . . . . 0.0 112.557 -177.506 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.434 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 62.8 t80 -111.72 171.05 7.72 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.733 0.813 . . . . 0.0 111.301 177.766 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.434 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 19.7 t0 -60.5 98.83 0.07 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -179.464 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 77.88 -4.69 56.57 Favored Glycine 0 CA--C 1.536 1.35 0 CA-C-O 119.474 -0.626 . . . . 0.0 112.938 177.405 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -140.93 -171.14 3.19 Favored 'General case' 0 N--CA 1.462 0.148 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 41.7 ttp-105 -145.08 131.07 19.24 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.86 0.864 . . . . 0.0 109.334 -178.107 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.9 mp -66.62 153.79 42.18 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-O 120.923 0.392 . . . . 0.0 110.477 -175.768 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 52.8 mtm180 -129.47 47.27 2.51 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.457 0.703 . . . . 0.0 110.167 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 88.3 t -77.32 98.43 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 175.088 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -151.09 162.49 40.75 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.629 0.252 . . . . 0.0 110.655 179.178 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -73.05 152.51 90.71 Favored Pre-proline 0 C--O 1.234 0.24 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 178.174 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo . . . . . 0 C--O 1.251 1.15 0 C-N-CA 123.739 2.959 . . . . 0.0 110.735 177.836 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.944 0 C3'-C2'-C1' 105.006 3.895 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.427 -2.2 0 O4'-C1'-N19 111.411 3.211 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.439 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.352 1 C5'-C4'-C3' 108.176 -4.883 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.402 0 O4'-C1'-N19 112.114 3.914 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.416 0 C5'-C4'-C3' 109.573 -3.951 OUTLIER-DELTA 0.0 OUTLIER delta 0.0 . . . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.415 -3.174 0 O4'-C1'-N19 110.899 2.699 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 111.512 0.189 . . . . 0.0 111.512 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 64.5 mt -79.95 144.61 10.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 177.75 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 8.5 tmm_? -67.95 164.77 19.18 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 122.902 0.481 . . . . 0.0 110.372 -179.139 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . -44.3 141.33 3.35 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 123.91 0.767 . . . . 0.0 112.114 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -70.41 -2.52 10.78 Favored 'Trans proline' 0 N--CA 1.452 -0.929 0 C-N-CA 123.637 2.891 . . . . 0.0 111.602 178.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -63.82 158.8 20.99 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 122.421 0.288 . . . . 0.0 110.665 179.031 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.66 170.05 49.34 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -178.458 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -81.56 -162.32 0.51 Allowed 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 123.346 0.659 . . . . 0.0 110.929 -178.516 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 54.8 m-20 65.26 164.49 0.16 Allowed 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 124.831 1.252 . . . . 0.0 112.464 -177.441 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -73.8 7.23 2.64 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -175.203 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 76.4 m -70.54 -14.59 62.57 Favored 'General case' 0 CA--C 1.532 0.28 0 O-C-N 122.373 -0.205 . . . . 0.0 110.732 178.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 18.4 ttm180 -84.25 152.65 24.05 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 178.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 15.3 pt -136.17 -178.77 2.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.141 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 175.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.434 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.9 OUTLIER -122.58 148.76 44.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.452 -0.794 . . . . 0.0 112.762 177.226 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 21.2 t -137.9 90.47 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 120.451 0.167 . . . . 0.0 110.755 -176.598 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -80.8 146.5 27.0 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 174.658 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 44.7 t30 58.28 -171.12 0.11 Allowed 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 122.786 0.434 . . . . 0.0 110.292 -174.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.409 ' H ' HD23 ' B' ' 23' ' ' LEU . 2.1 pt? -143.77 149.24 45.87 Favored Pre-proline 0 CA--C 1.534 0.338 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 177.107 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 24' ' ' PRO . . . . . 0.437 ' HA ' ' HD3' ' B' ' 25' ' ' PRO . 55.2 Cg_endo -70.96 155.62 61.66 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 123.435 2.757 . . . . 0.0 110.633 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 25' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' B' ' 24' ' ' PRO . 22.1 Cg_exo -62.5 -28.98 78.16 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 123.118 2.545 . . . . 0.0 111.239 177.296 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -91.8 123.07 34.9 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.638 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -158.27 140.58 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.11 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.546 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 60.6 mtm180 -136.41 19.56 3.14 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 122.795 0.438 . . . . 0.0 111.267 178.014 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 58.71 18.7 6.15 Favored 'General case' 0 N--CA 1.462 0.169 0 N-CA-C 114.204 1.186 . . . . 0.0 114.204 -176.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 30' ' ' LYS . . . . . 0.417 ' HE3' ' HB2' ' B' ' 34' ' ' ASP . 30.8 ttpt -150.64 -8.59 0.26 Allowed 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 123.418 0.687 . . . . 0.0 110.072 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -58.83 -23.67 60.91 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -179.004 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 27.7 mm -74.8 -17.49 16.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 122.653 0.381 . . . . 0.0 110.636 179.565 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -126.42 13.53 7.63 Favored 'General case' 0 C--N 1.34 0.159 0 CA-C-N 117.772 0.26 . . . . 0.0 111.052 178.57 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 34' ' ' ASP . . . . . 0.417 ' HB2' ' HE3' ' B' ' 30' ' ' LYS . 22.0 t0 -127.93 -60.86 1.14 Allowed 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 173.011 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 95.1 t -69.55 -53.18 26.03 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -65.14 -19.3 65.92 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 175.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 47.5 t -71.57 -28.94 64.19 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 175.724 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -74.82 -26.93 60.06 Favored 'General case' 0 CA--C 1.529 0.144 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 171.154 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -73.55 -23.78 60.03 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 115.928 1.825 . . . . 0.0 115.928 174.685 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.57 16.48 0.03 OUTLIER Glycine 0 CA--C 1.53 1.026 0 C-N-CA 120.219 -0.991 . . . . 0.0 114.074 -177.383 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.21 77.28 0.14 Allowed 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 117.886 0.843 . . . . 0.0 112.191 176.774 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.8 mp -60.07 142.32 15.56 Favored 'Isoleucine or valine' 0 C--O 1.232 0.138 0 C-N-CA 122.742 0.417 . . . . 0.0 110.225 177.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 43' ' ' ARG . . . . . 0.492 ' HE ' ' HA ' ' B' ' 62' ' ' GLU . 48.6 mtm105 -102.96 -30.99 10.45 Favored 'General case' 0 CA--C 1.523 -0.063 0 C-N-CA 122.393 0.277 . . . . 0.0 111.177 176.272 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -149.67 158.26 44.0 Favored 'General case' 0 C--O 1.232 0.134 0 N-CA-C 114.002 1.112 . . . . 0.0 114.002 -177.057 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 53.4 mt -125.59 150.8 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.149 0 C-N-CA 123.7 0.8 . . . . 0.0 109.098 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -141.01 50.71 1.63 Allowed 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 54.8 tp -60.55 135.58 57.8 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.099 177.034 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 25.3 ttmm -143.77 152.36 41.14 Favored 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 122.886 0.475 . . . . 0.0 110.116 -179.095 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 44.4 p30 -135.09 4.45 3.23 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 122.61 0.364 . . . . 0.0 111.949 -178.345 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 24.3 tpt180 -64.87 -15.75 62.33 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 122.783 0.433 . . . . 0.0 110.096 177.186 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 66.1 ttt-85 -65.71 -22.38 66.61 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.256 1.023 . . . . 0.0 111.225 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 75.67 165.36 17.22 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -174.009 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.21 -150.57 46.53 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -177.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -55.79 147.71 59.89 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 123.219 2.613 . . . . 0.0 110.934 175.595 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.82 167.79 24.81 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 123.48 2.787 . . . . 0.0 110.918 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -154.11 164.5 38.39 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 175.523 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -153.11 165.5 35.44 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-O 120.935 0.398 . . . . 0.0 111.883 -173.062 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -121.37 79.52 1.55 Allowed 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.471 175.02 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.5 t -67.49 147.48 12.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 C-N-CA 123.23 0.612 . . . . 0.0 110.19 -174.348 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -123.84 122.32 37.7 Favored 'General case' 0 CA--C 1.529 0.161 0 CA-C-O 120.825 0.345 . . . . 0.0 110.804 -178.146 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -94.58 164.92 12.78 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 115.464 1.653 . . . . 0.0 115.464 -175.322 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 62' ' ' GLU . . . . . 0.492 ' HA ' ' HE ' ' B' ' 43' ' ' ARG . 85.0 tt0 -73.58 -32.18 63.99 Favored 'General case' 0 C--N 1.34 0.183 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.661 174.332 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -141.59 145.82 39.02 Favored Pre-proline 0 CA--C 1.529 0.149 0 C-N-CA 123.771 0.828 . . . . 0.0 111.955 179.772 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -73.77 -19.58 20.92 Favored 'Trans proline' 0 N--CA 1.452 -0.941 0 C-N-CA 123.179 2.586 . . . . 0.0 110.841 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.74 -35.43 57.77 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 122.122 0.169 . . . . 0.0 110.838 -178.569 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -77.51 -17.72 57.71 Favored 'General case' 0 CA--C 1.527 0.083 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 178.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.53 -20.95 64.59 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 177.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -70.31 -34.25 72.48 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 177.624 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -75.83 -34.12 60.1 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.03 -31.69 64.6 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 178.646 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 7.5 t -73.69 -42.37 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 67.0 m -74.78 -0.49 18.43 Favored 'General case' 0 C--O 1.232 0.152 0 C-N-CA 122.136 0.175 . . . . 0.0 111.056 179.278 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -73.16 -35.66 57.02 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 119.487 -0.619 . . . . 0.0 112.756 -175.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 23.6 ttt180 -163.15 30.39 0.09 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.194 0.997 . . . . 0.0 111.631 -176.423 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -65.0 144.29 57.39 Favored 'General case' 0 C--O 1.232 0.14 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -179.607 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 57.78 46.47 92.27 Favored Glycine 0 C--N 1.338 0.656 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 174.533 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 77' ' ' TYR . . . . . 0.564 ' H ' ' HB2' ' B' ' 84' ' ' LEU . 16.7 t80 -98.67 137.42 37.33 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.673 0.736 . . . . 0.0 112.853 -173.925 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -67.95 83.35 0.21 Allowed 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 124.29 1.036 . . . . 0.0 112.059 -177.772 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.449 ' CD2' ' N ' ' B' ' 80' ' ' ASP . 54.2 t80 -82.89 171.31 14.02 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 123.199 0.6 . . . . 0.0 111.218 177.532 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.449 ' N ' ' CD2' ' B' ' 79' ' ' TYR . 24.9 t0 -64.5 93.84 0.11 Allowed 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.96 -1.81 88.33 Favored Glycine 0 CA--C 1.53 0.997 0 CA-C-O 119.762 -0.465 . . . . 0.0 112.615 177.244 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -141.93 -172.69 3.62 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 117.876 0.838 . . . . 0.0 112.669 -179.149 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 4.6 tpt180 -137.59 133.78 34.81 Favored 'General case' 0 C--O 1.232 0.143 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 84' ' ' LEU . . . . . 0.564 ' HB2' ' H ' ' B' ' 77' ' ' TYR . 4.2 mm? -64.66 139.23 58.74 Favored 'General case' 0 C--N 1.333 -0.117 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.148 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 95.3 mtm-85 -129.04 54.98 1.76 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 122.701 0.4 . . . . 0.0 110.288 175.517 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 2.7 p -81.28 97.64 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 175.017 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -153.68 169.49 23.18 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 122.875 0.47 . . . . 0.0 110.686 -179.348 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -65.26 151.72 93.32 Favored Pre-proline 0 CA--C 1.53 0.203 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo . . . . . 0 C--O 1.25 1.107 0 C-N-CA 123.678 2.918 . . . . 0.0 110.761 177.221 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.07 0 C5'-C4'-C3' 109.934 -3.71 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.446 0 C5'-C4'-C3' 110.149 -3.567 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.434 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.421 -2.652 0 C5'-C4'-C3' 109.719 -3.854 . 0.274 4p . 0.0 . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.482 " H3'" H5'' ' A' ' 94' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.425 -2.369 0 C5'-C4'-C3' 110.343 -3.438 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . 0.482 H5'' " H3'" ' A' ' 93' ' ' ' A' . . . . . . . . 0 P--O5' 1.617 2.383 0 C5'-C4'-C3' 109.74 -3.84 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.498 0 O4'-C1'-N19 112.025 3.825 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 19.5 t . . . . . 0 N--CA 1.476 0.836 0 CA-C-O 119.861 -0.114 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 31.4 mt 52.99 94.5 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 124.722 1.209 . . . . 0.0 111.527 -177.004 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.416 ' HD3' ' H ' ' B' ' 9' ' ' GLY . 17.8 tpp85 62.08 170.36 0.12 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.042 1.337 . . . . 0.0 112.149 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 9' ' ' GLY . . . . . 0.416 ' H ' ' HD3' ' B' ' 8' ' ' ARG . . . -64.35 166.86 29.07 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.66 -0.576 . . . . 0.0 111.66 -176.696 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -56.8 153.33 37.53 Favored 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 123.949 3.099 . . . . 0.0 111.638 179.144 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 56.67 16.03 2.43 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 123.956 0.902 . . . . 0.0 112.687 -179.314 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 69.72 -168.91 45.88 Favored Glycine 0 CA--C 1.528 0.859 0 N-CA-C 111.763 -0.535 . . . . 0.0 111.763 178.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -71.06 147.53 48.44 Favored 'General case' 0 N--CA 1.453 -0.278 0 O-C-N 122.516 -0.402 . . . . 0.0 111.296 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 63.1 t30 -159.55 170.29 21.98 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 175.561 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 20.5 p30 -77.91 177.06 8.54 Favored 'General case' 0 CA--C 1.533 0.288 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 179.102 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 73.9 m 61.15 13.32 4.65 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 176.155 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 54.6 mtm180 -82.16 145.26 30.2 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 118.422 0.555 . . . . 0.0 111.305 175.663 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 22.8 pt -138.62 175.73 7.77 Favored 'Isoleucine or valine' 0 C--O 1.231 0.095 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 170.138 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.452 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.6 OUTLIER -119.34 148.82 42.75 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 114.553 1.316 . . . . 0.0 114.553 -177.839 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 60.7 t -132.88 136.58 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 123.226 0.61 . . . . 0.0 109.634 179.279 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -140.52 172.15 23.69 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.325 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 51.2 t30 57.07 19.74 4.95 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.729 0.812 . . . . 0.0 111.41 -174.44 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.7 tp -61.42 130.61 91.99 Favored Pre-proline 0 N--CA 1.454 -0.258 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -67.2 146.09 74.89 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 122.545 2.163 . . . . 0.0 110.766 -177.052 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.86 -7.54 21.3 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 C-N-CA 123.815 3.01 . . . . 0.0 111.282 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -73.07 -6.84 48.27 Favored 'General case' 0 CA--C 1.53 0.197 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 179.446 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 10.0 tp -69.04 145.91 13.05 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.335 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 59.3 ttm-85 -161.14 154.41 21.5 Favored 'General case' 0 C--N 1.34 0.167 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -178.556 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.1 p 51.74 -160.05 0.1 Allowed 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 113.221 0.823 . . . . 0.0 113.221 -177.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -73.27 15.38 0.23 Allowed 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.101 0.56 . . . . 0.0 112.153 -179.119 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -58.84 -25.48 63.27 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 179.423 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.9 tt -76.27 -17.87 15.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 C-N-CA 122.335 0.254 . . . . 0.0 110.511 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.1 mt-10 -93.41 -31.04 14.78 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -74.13 -37.26 64.13 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 -177.655 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 62.4 t -69.71 -46.1 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.353 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -68.79 -35.4 76.99 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 113.615 0.969 . . . . 0.0 113.615 178.064 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 33.5 t -60.9 -33.5 73.21 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 178.283 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 16.7 tppt? -73.76 -33.43 64.29 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 122.2 0.2 . . . . 0.0 110.769 177.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -87.04 -13.83 43.28 Favored 'General case' 0 C--O 1.233 0.206 0 N-CA-C 116.739 2.125 . . . . 0.0 116.739 -178.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.08 13.83 0.03 OUTLIER Glycine 0 CA--C 1.527 0.843 0 C-N-CA 119.906 -1.14 . . . . 0.0 114.254 -177.447 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.62 40.54 27.44 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 118.227 1.013 . . . . 0.0 111.806 177.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 42' ' ' ILE . . . . . 0.645 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.7 mp -44.25 138.33 0.97 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.182 0 C-N-CA 123.719 0.808 . . . . 0.0 111.114 179.087 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 29.8 mtp-105 -85.51 -38.91 18.03 Favored 'General case' 0 CA--C 1.523 -0.08 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.748 -178.31 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -144.5 159.48 42.7 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -176.439 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 8.7 tp -137.32 161.74 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -178.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -147.78 70.44 1.16 Allowed 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 177.013 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 47' ' ' LEU . . . . . 0.472 ' C ' HD13 ' B' ' 47' ' ' LEU . 3.4 tm? -64.14 125.53 24.8 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 176.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 39.4 mttp -139.11 164.14 30.57 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 123.547 0.739 . . . . 0.0 111.054 -178.434 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 51.9 t-20 -159.53 120.04 3.1 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 170.703 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 43.8 ttt180 -161.91 143.15 10.9 Favored 'General case' 0 C--N 1.338 0.088 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -176.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 35.1 mtm180 50.1 29.83 3.81 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 123.406 0.682 . . . . 0.0 112.24 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -161.22 172.35 37.44 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.387 -0.685 . . . . 0.0 111.387 -178.874 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -80.21 -83.14 0.72 Allowed Glycine 0 CA--C 1.528 0.875 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -68.96 151.87 73.49 Favored 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.711 2.941 . . . . 0.0 110.817 -179.752 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -68.83 170.96 14.25 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 123.991 3.127 . . . . 0.0 111.629 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -150.67 165.2 34.14 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 104.884 -2.265 . . . . 0.0 104.884 175.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -157.03 163.7 38.78 Favored 'General case' 0 N--CA 1.453 -0.304 0 O-C-N 121.721 -0.612 . . . . 0.0 111.922 -174.409 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 58' ' ' PHE . . . . . 0.489 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 74.5 m-85 -113.2 151.62 30.75 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 171.154 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 41.5 t -131.1 136.4 57.95 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 -175.874 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -120.55 111.68 17.98 Favored 'General case' 0 N--CA 1.455 -0.205 0 CA-C-O 120.865 0.364 . . . . 0.0 110.481 -177.398 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.645 ' CE2' HD11 ' B' ' 42' ' ' ILE . 37.1 m-85 -81.15 159.38 24.66 Favored 'General case' 0 CA--C 1.528 0.125 0 N-CA-C 115.347 1.61 . . . . 0.0 115.347 -176.583 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -87.73 -26.66 22.82 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 169.806 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -155.44 118.95 2.42 Favored Pre-proline 0 CA--C 1.532 0.258 0 C-N-CA 123.635 0.774 . . . . 0.0 109.691 -179.196 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.52 -10.54 29.08 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.31 2.673 . . . . 0.0 111.942 -174.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 41.0 ttm105 -67.45 -29.29 68.72 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 117.887 0.312 . . . . 0.0 110.542 177.676 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 -81.24 -16.07 53.72 Favored 'General case' 0 CA--C 1.53 0.176 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.77 -16.43 63.3 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 120.39 0.138 . . . . 0.0 110.75 -179.346 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -66.7 -20.27 65.93 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 122.363 -0.21 . . . . 0.0 110.6 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -104.29 -33.16 8.76 Favored 'General case' 0 C--N 1.339 0.125 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 178.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.92 -31.49 64.67 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.012 0.525 . . . . 0.0 110.571 -178.614 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 98.0 t -87.44 -48.58 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 36.0 t -67.45 -14.87 63.32 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 122.474 -0.141 . . . . 0.0 111.2 -175.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -79.19 -14.24 81.96 Favored Glycine 0 CA--C 1.529 0.958 0 CA-C-O 119.345 -0.697 . . . . 0.0 112.652 -176.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 23.4 ptt-85 -158.13 3.92 0.11 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 118.623 1.212 . . . . 0.0 113.52 -175.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -73.16 143.39 47.28 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 118.757 0.708 . . . . 0.0 110.11 176.207 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 62.22 35.64 91.86 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.697 -0.561 . . . . 0.0 111.697 175.589 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 49.8 t80 -96.98 137.51 35.94 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -172.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -64.03 103.86 0.65 Allowed 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 123.382 0.673 . . . . 0.0 112.361 -178.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.457 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 75.7 t80 -109.75 173.33 6.37 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.91 0.884 . . . . 0.0 111.191 179.085 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.457 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 77.2 m-20 -59.88 98.66 0.06 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -179.575 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.58 -5.89 42.54 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-O 119.666 -0.519 . . . . 0.0 112.938 177.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -139.99 -169.33 2.71 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.964 0.882 . . . . 0.0 113.344 -177.36 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 41.6 ttp-105 -143.92 133.96 24.16 Favored 'General case' 0 N--CA 1.457 -0.12 0 C-N-CA 123.615 0.766 . . . . 0.0 109.016 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -62.55 147.96 47.47 Favored 'General case' 0 C--N 1.335 -0.063 0 C-N-CA 122.571 0.348 . . . . 0.0 110.18 -178.478 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 57.7 ttt180 -130.86 113.74 14.43 Favored 'General case' 0 CA--C 1.517 -0.313 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.475 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 37.5 t -132.52 92.57 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.632 178.782 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 24.0 pt-20 -145.29 159.49 42.96 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.703 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -74.04 153.57 88.69 Favored Pre-proline 0 N--CA 1.454 -0.229 0 N-CA-C 114.854 1.427 . . . . 0.0 114.854 -179.522 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo . . . . . 0 C--O 1.25 1.118 0 C-N-CA 123.911 3.074 . . . . 0.0 110.714 175.98 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.468 1 O4'-C1'-N19 112.309 4.109 . 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.508 0 C5'-C4'-C3' 111.597 -2.602 . 0.669 6n . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.452 ' C6 ' ' CE1' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.323 1 C5'-C4'-C3' 109.489 -4.007 . 0.289 5p . 0.0 . . . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.489 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.399 0 O4'-C1'-N19 111.75 3.55 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . 0.424 H5'' " H3'" ' A' ' 93' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.422 -2.569 0 C5'-C4'-C3' 111.621 -2.586 OUTLIER-DELTA 0.0 OUTLIER gamma 0.0 . . . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.004 0 C3'-C2'-C1' 104.804 3.671 . 0.0 OUTLIER '7D dist 4p' 0.0 . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 16.5 t . . . . . 0 N--CA 1.475 0.801 0 CA-C-O 120.375 0.131 . . . . 0.0 111.013 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 94.1 mt -67.38 148.16 12.17 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 9.1 tpp180 -66.16 142.61 57.68 Favored 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 122.795 0.438 . . . . 0.0 110.976 -178.089 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 9' ' ' GLY . . . . . 0.402 ' N ' ' CD ' ' B' ' 10' ' ' PRO . . . 64.52 46.93 88.84 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-O 119.527 -0.596 . . . . 0.0 112.707 175.08 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 10' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 72.7 Cg_endo -73.74 -14.71 24.33 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 122.971 2.447 . . . . 0.0 110.957 -177.563 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -158.08 178.76 9.85 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 123.543 0.737 . . . . 0.0 109.863 -177.75 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -155.43 172.59 33.61 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 22.1 m120 58.71 174.22 0.07 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 124.062 0.945 . . . . 0.0 112.238 -176.8 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 63.8 m-20 57.5 9.5 0.79 Allowed 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 124.154 0.982 . . . . 0.0 112.353 -176.808 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -126.32 168.87 13.54 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.863 0.865 . . . . 0.0 111.313 -179.497 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 98.6 m -75.0 4.73 6.11 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 122.456 0.302 . . . . 0.0 111.491 177.051 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 92.8 mtt-85 -73.3 147.88 44.07 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-O 120.879 0.371 . . . . 0.0 111.854 179.462 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 20.8 pt -138.67 177.76 4.77 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 C-N-CA 123.852 0.861 . . . . 0.0 108.754 172.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.43 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.7 OUTLIER -116.9 150.54 38.3 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 114.344 1.238 . . . . 0.0 114.344 -177.285 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 47.4 t -138.65 143.3 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 C-N-CA 123.519 0.728 . . . . 0.0 109.187 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.35 178.81 34.43 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.954 -0.459 . . . . 0.0 111.954 -176.538 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 54.2 t30 58.54 25.52 13.21 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.195 0.998 . . . . 0.0 111.606 -176.669 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.6 mt -65.11 140.81 98.11 Favored Pre-proline 0 N--CA 1.454 -0.23 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.35 154.09 65.7 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 123.296 2.664 . . . . 0.0 109.898 -179.548 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.19 -17.14 35.82 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.419 2.746 . . . . 0.0 111.067 -179.387 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -86.98 0.61 54.86 Favored 'General case' 0 CA--C 1.529 0.156 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 tp -67.58 144.1 14.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -178.402 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 17.1 ttp180 -82.85 150.36 26.6 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 176.775 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.8 p -65.36 -0.2 1.75 Allowed 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 114.843 1.423 . . . . 0.0 114.843 -177.366 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 30' ' ' LYS . . . . . 0.401 ' HE2' ' HB3' ' B' ' 30' ' ' LYS . 48.1 mtpt -136.14 5.74 3.05 Favored 'General case' 0 C--N 1.343 0.315 0 N-CA-C 113.175 0.805 . . . . 0.0 113.175 -179.071 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -62.5 -32.74 73.71 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 118.641 0.655 . . . . 0.0 112.088 175.596 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.9 tt -75.82 -16.81 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 122.787 0.435 . . . . 0.0 110.576 178.427 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 72.9 mt-10 -97.31 -13.67 21.79 Favored 'General case' 0 C--N 1.34 0.18 0 C-N-CA 122.181 0.193 . . . . 0.0 110.684 -179.456 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -103.17 -67.69 0.87 Allowed 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -175.566 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 3.7 p -73.81 -37.27 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 N-CA-C 112.493 0.553 . . . . 0.0 112.493 -172.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 70.7 m-85 -73.15 -25.98 61.03 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 112.773 0.656 . . . . 0.0 112.773 177.603 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 42.8 t -72.37 -30.27 64.54 Favored 'General case' 0 N--CA 1.456 -0.166 0 N-CA-C 110.305 -0.257 . . . . 0.0 110.305 176.348 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.37 -29.48 62.66 Favored 'General case' 0 N--CA 1.455 -0.208 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 174.72 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -81.01 -20.4 41.84 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 116.144 1.905 . . . . 0.0 116.144 179.37 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.1 14.4 0.76 Allowed Glycine 0 CA--C 1.527 0.783 0 C-N-CA 120.707 -0.758 . . . . 0.0 113.851 -175.113 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.67 38.49 22.88 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 117.858 0.829 . . . . 0.0 111.261 178.002 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 81.8 mt -45.47 138.67 1.3 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.151 0 C-N-CA 123.338 0.655 . . . . 0.0 111.387 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 28.6 mmt180 -104.63 -22.56 13.22 Favored 'General case' 0 N--CA 1.455 -0.204 0 C-N-CA 122.884 0.474 . . . . 0.0 111.668 -178.141 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -152.4 154.16 35.04 Favored 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 118.352 0.524 . . . . 0.0 112.112 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 2.8 mp -136.52 148.03 27.32 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.085 0 C-N-CA 123.884 0.874 . . . . 0.0 109.326 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -140.95 57.2 1.56 Allowed 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 122.694 0.398 . . . . 0.0 110.278 179.297 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 57.8 tp -60.16 129.25 40.79 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.154 175.825 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 43.0 mttp -120.13 143.59 48.1 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 123.634 0.774 . . . . 0.0 110.672 179.204 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 49.7 p30 -81.35 -149.27 0.07 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 123.402 0.681 . . . . 0.0 110.473 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 5.0 tpp180 -65.13 -4.42 4.93 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.473 0.709 . . . . 0.0 111.746 -177.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 26.4 tpt180 -55.28 134.25 49.84 Favored 'General case' 0 CA--C 1.529 0.138 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 174.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.1 -133.67 22.53 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 -175.096 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -72.94 -164.69 8.34 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 174.283 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -55.34 165.0 3.42 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 123.773 2.982 . . . . 0.0 110.987 174.31 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -50.84 133.55 39.84 Favored 'Trans proline' 0 N--CA 1.452 -0.96 0 C-N-CA 123.232 2.622 . . . . 0.0 111.197 -178.413 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 56' ' ' PHE . . . . . 0.433 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 5.8 p90 -160.87 173.86 14.7 Favored 'General case' 0 CA--C 1.53 0.178 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -173.79 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.28 166.11 34.39 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 120.801 0.334 . . . . 0.0 111.668 -175.647 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 58' ' ' PHE . . . . . 0.529 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 91.4 m-85 -121.17 154.82 35.72 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 168.581 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 70.5 t -144.2 133.03 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -174.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -106.76 117.97 35.45 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.393 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 -85.59 154.65 21.58 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 115.12 1.526 . . . . 0.0 115.12 179.754 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 38.1 tp10 -75.54 -30.27 59.7 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 172.305 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 58.3 t0 -157.59 117.72 1.97 Allowed Pre-proline 0 N--CA 1.451 -0.415 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.3 -10.3 26.97 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 123.194 2.596 . . . . 0.0 112.112 -176.219 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 77.4 mtt85 -72.17 -16.16 61.97 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 117.85 0.295 . . . . 0.0 111.026 178.059 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -77.97 -2.73 38.4 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 177.703 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -64.52 -14.67 58.52 Favored 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 122.435 0.294 . . . . 0.0 111.163 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -65.96 -15.85 63.35 Favored 'General case' 0 CA--C 1.529 0.168 0 O-C-N 122.173 -0.329 . . . . 0.0 111.333 -179.319 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -123.39 -38.28 2.57 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 123.001 0.52 . . . . 0.0 112.181 177.166 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -81.82 -9.57 59.57 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.08 0.552 . . . . 0.0 112.187 -175.486 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 99.5 t -130.99 -49.76 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 CA-C-N 117.729 0.24 . . . . 0.0 110.526 -177.482 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 69.2 m -66.23 -10.96 46.98 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 117.646 0.203 . . . . 0.0 111.145 -179.462 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.2 -1.16 69.87 Favored Glycine 0 CA--C 1.53 0.975 0 CA-C-O 119.436 -0.646 . . . . 0.0 112.73 -178.756 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 12.1 tpp180 -151.72 -16.88 0.19 Allowed 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 118.466 1.133 . . . . 0.0 112.705 -176.56 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 32.9 t0 -65.11 138.34 58.24 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 118.267 0.485 . . . . 0.0 110.634 -178.128 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.51 41.57 99.2 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 111.794 -0.522 . . . . 0.0 111.794 174.091 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -98.61 133.47 42.91 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -174.329 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.6 t0 -62.63 106.52 0.8 Allowed 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 123.781 0.832 . . . . 0.0 112.341 -177.799 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.439 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.9 t80 -112.88 171.28 7.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 123.804 0.842 . . . . 0.0 111.445 177.926 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.439 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 20.6 t0 -60.53 99.82 0.09 Allowed 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.066 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 77.99 -6.32 49.51 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 123.553 0.597 . . . . 0.0 112.761 177.46 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 87.9 m-85 -140.56 -169.54 2.81 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 117.996 0.898 . . . . 0.0 113.269 -177.324 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 36.1 ttt180 -147.46 129.53 15.48 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.439 0.696 . . . . 0.0 109.474 -177.672 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -62.57 147.79 48.02 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 122.847 0.459 . . . . 0.0 110.502 -175.643 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 -120.68 127.68 52.26 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 175.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 11.8 t -145.27 82.02 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.131 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 173.426 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -148.33 160.7 42.73 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 122.75 0.42 . . . . 0.0 110.43 -175.704 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -75.25 156.57 85.58 Favored Pre-proline 0 CA--C 1.533 0.324 0 N-CA-C 114.228 1.196 . . . . 0.0 114.228 179.211 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo . . . . . 0 C--O 1.25 1.077 0 C-N-CA 123.739 2.96 . . . . 0.0 111.867 177.349 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.034 0 C5'-C4'-C3' 110.016 -3.656 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.955 1 O4'-C1'-N19 112.3 4.1 . 0.345 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.433 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.422 -2.618 0 C5'-C4'-C3' 110.453 -3.364 . 0.328 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.529 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.425 -2.336 1 C5'-C4'-C3' 108.876 -4.416 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.948 0 O4'-C1'-N19 111.842 3.642 . 0.142 2u . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.053 0 O4'-C1'-N19 111.831 3.631 . 0.175 2[ . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.3 p . . . . . 0 N--CA 1.474 0.774 0 N-CA-C 111.843 0.312 . . . . 0.0 111.843 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 98.6 mt -66.38 144.06 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.174 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 38.1 ttm105 -75.38 154.39 37.22 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 122.662 0.385 . . . . 0.0 111.152 -178.43 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 9' ' ' GLY . . . . . 0.519 ' N ' ' CD ' ' B' ' 10' ' ' PRO . . . 103.29 36.52 3.32 Favored Glycine 0 CA--C 1.533 1.192 0 CA-C-O 118.693 -1.059 . . . . 0.0 114.307 170.705 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 10' ' ' PRO . . . . . 0.519 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 56.9 Cg_endo -68.47 161.48 44.79 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 122.381 2.054 . . . . 0.0 109.853 174.317 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -65.45 154.29 38.91 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.725 -179.506 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 174.66 -179.66 45.83 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -144.83 161.3 39.62 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 123.457 0.703 . . . . 0.0 110.369 -179.141 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 54.24 23.61 4.4 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.63 0.772 . . . . 0.0 111.772 -179.061 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 13.4 p30 -74.59 158.15 34.19 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 87.6 m -85.6 -2.06 57.78 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 122.885 0.474 . . . . 0.0 111.334 177.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 73.0 mtm180 -69.03 146.99 52.2 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 122.831 0.452 . . . . 0.0 110.818 -178.546 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.1 pt -132.56 170.06 20.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-O 120.964 0.412 . . . . 0.0 110.08 172.536 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.454 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.6 OUTLIER -114.99 151.02 34.89 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -176.838 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 59.3 t -138.45 143.61 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -157.36 -178.76 31.73 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 111.934 -0.466 . . . . 0.0 111.934 -177.758 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 9.6 t-20 56.8 23.99 8.65 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 123.825 0.85 . . . . 0.0 111.645 -177.51 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 93.4 mt -64.2 146.21 97.74 Favored Pre-proline 0 CA--C 1.53 0.207 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.35 157.57 56.46 Favored 'Trans proline' 0 N--CA 1.452 -0.96 0 C-N-CA 123.404 2.736 . . . . 0.0 110.296 -179.272 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -60.43 -20.93 65.85 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.299 2.666 . . . . 0.0 111.699 176.157 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -84.06 6.82 20.74 Favored 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 8.6 tp -61.49 152.62 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.146 0 C-N-CA 122.416 0.286 . . . . 0.0 110.684 -178.523 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 60.4 ttt85 -144.62 150.32 37.23 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.438 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.8 p -62.17 -18.27 60.49 Favored 'General case' 0 N--CA 1.46 0.069 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 -177.112 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 6.4 ttpt -90.52 -30.01 17.53 Favored 'General case' 0 N--CA 1.456 -0.126 0 C-N-CA 122.429 0.292 . . . . 0.0 111.074 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 -70.72 -36.14 73.06 Favored 'General case' 0 N--CA 1.454 -0.227 0 O-C-N 122.1 -0.375 . . . . 0.0 111.261 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 15.2 tt -75.85 -14.09 15.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.377 -176.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -104.28 -21.85 13.46 Favored 'General case' 0 C--N 1.34 0.164 0 CA-C-N 118.714 0.688 . . . . 0.0 110.687 178.677 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -74.33 -49.88 21.07 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 178.161 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 m -72.86 -30.8 33.81 Favored 'Isoleucine or valine' 0 C--N 1.338 0.101 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.095 -178.664 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 36' ' ' PHE . . . . . 0.408 ' O ' HD13 ' B' ' 42' ' ' ILE . 41.4 m-85 -75.92 -42.87 47.57 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 177.425 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 96.7 p -67.58 -21.45 65.42 Favored 'General case' 0 C--N 1.34 0.164 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.49 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 23.7 tptm -73.98 -36.88 64.58 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 173.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -82.12 -11.61 58.66 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 116.659 2.096 . . . . 0.0 116.659 178.175 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.98 179.27 48.92 Favored Glycine 0 C--N 1.338 0.645 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.044 -179.364 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.94 53.7 2.27 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 124.06 0.944 . . . . 0.0 111.626 -177.597 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 42' ' ' ILE . . . . . 0.556 HD11 ' CZ ' ' B' ' 61' ' ' PHE . 2.1 mp -68.75 144.24 14.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.24 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 35.0 mmt180 -124.81 -36.1 2.62 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 119.42 -0.324 . . . . 0.0 111.149 178.246 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 39.9 m-20 -122.38 150.16 42.8 Favored 'General case' 0 N--CA 1.462 0.126 0 N-CA-C 113.944 1.091 . . . . 0.0 113.944 -178.385 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -136.18 150.08 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 C-N-CA 124.236 1.014 . . . . 0.0 109.169 178.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 59.2 t0 -146.9 63.5 1.18 Allowed 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.65 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 49.6 tp -64.35 129.06 38.43 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 173.345 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -120.39 146.69 45.94 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 123.698 0.799 . . . . 0.0 109.966 178.743 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 -111.23 170.09 8.35 Favored 'General case' 0 C--N 1.334 -0.104 0 C-N-CA 122.891 0.476 . . . . 0.0 111.11 -176.183 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 50' ' ' ARG . . . . . 0.41 HH11 ' HD2' ' B' ' 50' ' ' ARG . 45.8 ttm180 55.47 -96.95 0.07 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 124.149 0.98 . . . . 0.0 111.521 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 15.0 tpt180 56.39 19.89 4.35 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.304 0.642 . . . . 0.0 111.575 -179.061 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.19 12.6 83.81 Favored Glycine 0 CA--C 1.532 1.114 0 CA-C-O 119.665 -0.52 . . . . 0.0 112.697 176.538 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -169.66 -154.13 9.02 Favored Glycine 0 CA--C 1.532 1.112 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.442 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -60.19 147.34 93.83 Favored 'Trans proline' 0 N--CA 1.448 -1.164 0 C-N-CA 123.076 2.517 . . . . 0.0 110.191 172.265 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -65.38 158.38 52.95 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 123.204 2.603 . . . . 0.0 110.414 178.376 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -150.85 167.71 26.68 Favored 'General case' 0 C--O 1.232 0.162 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 -179.478 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -152.87 166.06 33.48 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.295 0.569 . . . . 0.0 112.426 -171.85 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 58' ' ' PHE . . . . . 0.46 ' CE2' ' C6 ' ' A' ' 93' ' ' ' A' . 4.3 m-85 -120.56 153.67 36.43 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 124.042 0.937 . . . . 0.0 112.813 170.85 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 88.9 t -141.1 144.39 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 108.685 -0.858 . . . . 0.0 108.685 -178.17 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 11.7 tp10 -131.14 125.59 33.46 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 122.578 0.351 . . . . 0.0 111.174 -177.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.556 ' CZ ' HD11 ' B' ' 42' ' ' ILE . 9.1 m-85 -91.57 151.56 20.68 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 113.974 1.101 . . . . 0.0 113.974 -178.795 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -82.46 -24.69 34.14 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 169.045 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 36.6 t0 -152.26 114.94 2.9 Favored Pre-proline 0 CA--C 1.534 0.355 0 C-N-CA 123.352 0.661 . . . . 0.0 109.944 -176.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -74.77 -1.37 11.06 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 123.566 2.844 . . . . 0.0 112.742 -173.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 79.5 mtt85 -68.27 -0.49 4.81 Favored 'General case' 0 CA--C 1.53 0.197 0 N-CA-C 112.998 0.74 . . . . 0.0 112.998 -176.212 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 20.4 p30 -134.35 3.12 3.33 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 112.173 0.434 . . . . 0.0 112.173 173.797 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.76 -22.03 64.33 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 178.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -70.25 -28.45 65.25 Favored 'General case' 0 N--CA 1.456 -0.127 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 178.636 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -79.63 -35.18 39.8 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 122.337 0.255 . . . . 0.0 111.381 178.025 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.96 -24.72 63.38 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.231 176.65 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 10.0 t -85.69 -59.03 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.5 t -71.28 -17.6 62.46 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -172.761 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -93.12 4.07 73.9 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-O 119.247 -0.751 . . . . 0.0 112.588 -177.089 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 46.6 ttm180 -150.19 -16.55 0.25 Allowed 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 118.516 1.158 . . . . 0.0 112.555 -174.714 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 50.7 p-10 -71.3 156.64 39.29 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.277 0.561 . . . . 0.0 112.306 -176.512 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 58.85 41.8 96.29 Favored Glycine 0 CA--C 1.526 0.725 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.683 169.402 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 43.4 t80 -92.38 130.83 37.95 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 118.226 1.013 . . . . 0.0 113.714 -175.153 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -66.12 101.81 0.75 Allowed 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 123.044 0.538 . . . . 0.0 112.025 -178.441 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.515 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 71.4 t80 -93.02 177.98 5.9 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.406 0.682 . . . . 0.0 112.127 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.515 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 74.1 m-20 -66.66 21.84 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.537 0 N-CA-C 114.934 1.457 . . . . 0.0 114.934 -177.27 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 161.5 -10.82 0.12 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-O 119.618 -0.546 . . . . 0.0 112.425 -179.137 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -140.95 -167.05 2.29 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 117.731 0.766 . . . . 0.0 110.893 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 33.8 ttt180 -138.93 122.96 17.89 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -59.81 153.39 20.79 Favored 'General case' 0 N--CA 1.458 -0.043 0 C-N-CA 123.421 0.688 . . . . 0.0 111.096 -176.407 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 24.0 mtp180 -128.08 125.21 38.81 Favored 'General case' 0 CA--C 1.521 -0.164 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.593 175.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 48.2 t -142.99 82.01 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.171 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 175.471 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -140.28 160.57 39.67 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.219 0.533 . . . . 0.0 111.809 -173.09 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 88' ' ' PHE . . . . . 0.467 ' CD1' ' HD2' ' B' ' 89' ' ' PRO . 18.2 t80 -71.84 138.9 82.67 Favored Pre-proline 0 CA--C 1.534 0.335 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 89' ' ' PRO . . . . . 0.467 ' HD2' ' CD1' ' B' ' 88' ' ' PHE . 43.9 Cg_endo . . . . . 0 C--O 1.248 1.018 0 C-N-CA 123.824 3.016 . . . . 0.0 111.303 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.821 0 C5'-C4'-C3' 110.019 -3.654 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.021 0 C3'-C2'-C1' 104.695 3.55 . 0.109 6p . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.454 ' C6 ' ' CE1' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.334 1 C5'-C4'-C3' 109.47 -4.02 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.506 ' C2 ' ' HA2' ' B' ' 9' ' ' GLY . . . . . . . . 0 O4'--C4' 1.427 -2.176 1 O4'-C1'-N19 112.542 4.342 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.616 1 O4'-C1'-N19 112.412 4.212 OUTLIER-DELTA 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.936 0 O4'-C1'-N19 111.719 3.519 . 0.0 OUTLIER '7D dist 6p' 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.2 p . . . . . 0 N--CA 1.477 0.9 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.08 -6.04 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 C-N-CA 122.312 0.245 . . . . 0.0 110.849 -177.67 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 16.9 tpp180 61.77 134.58 0.01 OUTLIER 'General case' 0 C--N 1.344 0.348 0 C-N-CA 125.211 1.404 . . . . 0.0 112.573 -176.422 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 9' ' ' GLY . . . . . 0.702 ' HA2' ' C2 ' ' A' ' 93' ' ' ' A' . . . 104.99 -94.38 1.01 Allowed Glycine 0 CA--C 1.527 0.815 0 CA-C-O 119.171 -0.794 . . . . 0.0 111.129 175.863 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -59.68 1.8 0.36 Allowed 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 123.985 3.124 . . . . 0.0 113.636 178.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -147.67 176.6 9.96 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 122.821 0.448 . . . . 0.0 110.191 -179.273 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.87 -169.78 30.02 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -178.371 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 28.9 p30 -68.48 174.05 4.46 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.808 0.337 . . . . 0.0 111.547 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 39.2 t30 -149.11 179.12 8.14 Favored 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.333 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 61.23 8.21 1.96 Allowed 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 114.687 1.366 . . . . 0.0 114.687 -178.814 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 61.3 m -132.78 -1.92 3.35 Favored 'General case' 0 C--N 1.339 0.124 0 C-N-CA 123.004 0.521 . . . . 0.0 110.473 176.391 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 31.4 ttm180 -101.02 147.89 25.67 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 123.046 0.539 . . . . 0.0 109.815 -178.647 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.5 pt -133.53 174.78 12.67 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.081 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 176.48 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.465 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.7 OUTLIER -118.92 150.32 40.09 Favored 'General case' 0 C--O 1.231 0.122 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -175.838 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 60.5 t -139.22 142.84 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 C-N-CA 123.509 0.724 . . . . 0.0 109.437 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.81 168.76 31.78 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -178.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 59.4 t30 60.55 36.89 19.81 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 124.073 0.949 . . . . 0.0 111.379 -174.205 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 84.0 mt -61.95 143.44 94.59 Favored Pre-proline 0 CA--C 1.532 0.285 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 176.492 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.37 158.54 55.84 Favored 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 123.511 2.807 . . . . 0.0 109.935 179.195 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.5 -15.81 38.29 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 123.134 2.556 . . . . 0.0 110.851 179.046 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -89.1 5.0 46.54 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 179.026 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 tp -65.45 154.87 7.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 C-N-CA 122.41 0.284 . . . . 0.0 110.432 -178.149 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 44.9 mtm180 -138.42 161.47 36.89 Favored 'General case' 0 CA--C 1.522 -0.118 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 178.174 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.6 p -66.99 -7.24 20.94 Favored 'General case' 0 C--N 1.338 0.071 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -177.476 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -111.45 -36.22 5.59 Favored 'General case' 0 C--N 1.34 0.182 0 O-C-N 122.421 -0.174 . . . . 0.0 111.218 179.511 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -63.79 -28.39 69.83 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.593 0.235 . . . . 0.0 110.43 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.0 tt -72.1 -13.78 16.9 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.349 -178.12 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -116.98 -9.94 11.02 Favored 'General case' 0 N--CA 1.456 -0.156 0 CA-C-N 118.291 0.496 . . . . 0.0 110.722 174.218 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -71.27 -55.3 8.34 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-O 121.025 0.44 . . . . 0.0 110.57 178.016 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 10.0 p -67.68 -34.65 69.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 O-C-N 122.241 -0.287 . . . . 0.0 110.886 179.392 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -69.88 -32.86 71.43 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 113.38 0.882 . . . . 0.0 113.38 176.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 39.2 t -67.48 -28.0 67.48 Favored 'General case' 0 C--N 1.342 0.28 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 176.744 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -70.68 -34.26 71.8 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 174.532 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -81.68 -15.61 53.95 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 116.225 1.935 . . . . 0.0 116.225 177.124 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.46 179.21 44.92 Favored Glycine 0 C--N 1.338 0.656 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.584 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -83.85 84.61 7.51 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 122.992 0.517 . . . . 0.0 111.249 -178.431 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.7 mp -73.09 150.39 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.123 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 174.541 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 85.3 mmt-85 -128.35 -25.64 2.91 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 119.25 -0.405 . . . . 0.0 111.972 176.729 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -150.55 161.43 42.56 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 178.609 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 45' ' ' ILE . . . . . 0.489 HG22 ' H ' ' B' ' 47' ' ' LEU . 30.8 mm -132.43 156.46 42.42 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.061 0 C-N-CA 124.289 1.036 . . . . 0.0 109.279 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -143.2 55.25 1.36 Allowed 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 175.316 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 47' ' ' LEU . . . . . 0.489 ' H ' HG22 ' B' ' 45' ' ' ILE . 59.9 tp -55.79 133.13 50.88 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.223 174.468 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -133.79 158.53 43.13 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 123.735 0.814 . . . . 0.0 111.415 -177.483 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 43.0 p30 -145.41 11.45 1.3 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.442 0.697 . . . . 0.0 110.698 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -73.38 165.47 25.0 Favored 'General case' 0 C--O 1.232 0.148 0 C-N-CA 123.323 0.649 . . . . 0.0 110.338 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 43.7 mtt180 61.09 177.7 0.11 Allowed 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.057 0.943 . . . . 0.0 112.264 177.146 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -76.2 173.89 53.69 Favored Glycine 0 CA--C 1.529 0.953 0 N-CA-C 111.881 -0.488 . . . . 0.0 111.881 -177.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.86 177.01 44.39 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -179.079 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -60.88 160.55 24.97 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 124.059 3.173 . . . . 0.0 111.383 178.286 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -65.6 160.26 44.09 Favored 'Trans proline' 0 N--CA 1.45 -1.038 0 C-N-CA 123.336 2.691 . . . . 0.0 110.195 176.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 56' ' ' PHE . . . . . 0.47 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 6.1 p90 -153.29 171.38 18.65 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 106.414 -1.699 . . . . 0.0 106.414 -176.61 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -159.61 174.62 14.31 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.242 0.544 . . . . 0.0 111.371 -174.089 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 58' ' ' PHE . . . . . 0.405 ' CD2' ' C2 ' ' A' ' 93' ' ' ' A' . 90.4 m-85 -131.81 155.94 46.9 Favored 'General case' 0 N--CA 1.452 -0.355 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 172.04 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 66.8 t -132.87 134.24 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -178.257 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -111.17 123.95 51.23 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 122.465 0.306 . . . . 0.0 110.562 -177.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -97.43 154.95 17.14 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 42.3 tp10 -78.7 -23.63 45.45 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 170.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -152.51 118.87 3.05 Favored Pre-proline 0 CA--C 1.534 0.365 0 C-N-CA 123.162 0.585 . . . . 0.0 109.785 -178.727 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -66.65 -8.11 20.13 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.188 2.592 . . . . 0.0 112.505 -176.005 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 72.3 ttt-85 -61.94 -36.05 80.26 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-N 118.111 0.414 . . . . 0.0 110.172 177.19 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 52.8 m-20 -89.87 -16.3 30.36 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-O 120.582 0.23 . . . . 0.0 111.57 -178.52 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.97 -25.3 64.47 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.851 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -71.81 -28.59 63.7 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 177.763 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 -75.16 -35.48 61.61 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 178.753 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.97 -29.91 67.13 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 110.279 -0.267 . . . . 0.0 110.279 177.34 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.93 -30.02 17.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.306 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.368 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 41.5 t -85.79 -12.34 51.19 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 122.587 0.355 . . . . 0.0 111.54 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -68.56 -46.06 64.22 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.609 -0.596 . . . . 0.0 111.609 -175.518 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 38.2 ttt180 -163.08 122.1 2.11 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.274 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -164.24 149.27 10.2 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 123.066 0.229 . . . . 0.0 110.574 -178.68 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.94 88.88 0.3 Allowed Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.481 0.562 . . . . 0.0 112.857 170.84 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 77' ' ' TYR . . . . . 0.449 ' HA ' ' HA ' ' B' ' 83' ' ' ARG . 13.6 t80 60.31 103.09 0.02 OUTLIER 'General case' 0 N--CA 1.457 -0.104 0 N-CA-C 116.478 2.029 . . . . 0.0 116.478 169.579 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -164.71 31.09 0.07 Allowed 'General case' 0 N--CA 1.444 -0.733 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -131.62 178.09 7.01 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -88.89 107.38 18.97 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 114.892 -1.049 . . . . 0.0 111.228 179.378 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 72.11 -2.26 28.26 Favored Glycine 0 CA--C 1.531 1.092 0 N-CA-C 111.522 -0.631 . . . . 0.0 111.522 -178.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 45.1 m-85 -131.47 169.81 15.55 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 124.001 0.92 . . . . 0.0 113.455 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 83' ' ' ARG . . . . . 0.449 ' HA ' ' HA ' ' B' ' 77' ' ' TYR . 0.0 OUTLIER -135.15 135.83 41.4 Favored 'General case' 0 N--CA 1.44 -0.949 0 CA-C-O 120.803 0.335 . . . . 0.0 111.282 -178.58 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 84' ' ' LEU . . . . . 0.592 HD22 ' N ' ' B' ' 84' ' ' LEU . 2.4 mm? -73.85 142.92 46.06 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 178.767 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 59.1 mtm180 -132.48 114.57 14.45 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-O 120.943 0.401 . . . . 0.0 110.222 175.733 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 42.4 t -136.4 86.08 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 C-N-CA 123.543 0.737 . . . . 0.0 109.055 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -149.8 163.21 38.61 Favored 'General case' 0 C--N 1.334 -0.103 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.534 -178.655 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.5 p90 -74.0 152.23 88.62 Favored Pre-proline 0 CA--C 1.531 0.229 0 N-CA-C 114.626 1.343 . . . . 0.0 114.626 179.433 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo . . . . . 0 C--O 1.253 1.266 0 C-N-CA 123.837 3.025 . . . . 0.0 110.781 176.312 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.45 0 C5'-C4'-C3' 109.805 -3.797 OUTLIER-DELTA 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.542 0 C5'-C4'-C3' 110.249 -3.501 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.47 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.423 -2.481 0 C5'-C4'-C3' 110.676 -3.216 . 0.032 4p . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.702 ' C2 ' ' HA2' ' B' ' 9' ' ' GLY . . . . . . . . 0 O4'--C4' 1.421 -2.693 1 C5'-C4'-C3' 109.492 -4.005 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.426 -2.263 0 O4'-C1'-N19 112.007 3.807 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.889 0 C3'-C2'-C1' 104.247 3.052 . 0.167 0b . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 p . . . . . 0 N--CA 1.477 0.896 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 87.5 mt -66.21 148.2 12.2 Favored 'Isoleucine or valine' 0 C--O 1.234 0.237 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 20.5 tpp85 -59.71 140.04 56.78 Favored 'General case' 0 C--N 1.34 0.181 0 C-N-CA 122.722 0.409 . . . . 0.0 110.525 -179.515 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 9' ' ' GLY . . . . . 0.426 ' HA2' ' C2 ' ' A' ' 93' ' ' ' A' . . . 64.28 58.98 9.01 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -71.22 2.19 4.62 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 124.083 3.189 . . . . 0.0 111.608 179.644 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 57.9 18.72 5.2 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 123.753 0.821 . . . . 0.0 112.008 -177.508 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.5 -173.0 44.1 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 176.788 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -66.46 152.77 44.47 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 122.553 -0.381 . . . . 0.0 110.465 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 50.1 t30 -75.92 162.5 28.05 Favored 'General case' 0 CA--C 1.529 0.149 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.068 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 15.8 t0 -150.46 -47.81 0.13 Allowed 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 122.537 0.335 . . . . 0.0 111.75 176.866 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 98.3 m -140.41 5.79 2.07 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 122.804 0.442 . . . . 0.0 111.501 178.438 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -88.86 155.21 19.67 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 120.847 0.356 . . . . 0.0 111.255 -177.733 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 12.2 pt -127.62 -177.29 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 C-N-CA 123.223 0.609 . . . . 0.0 109.477 177.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -142.94 151.29 40.79 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -178.781 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 62.8 t -142.84 101.15 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.149 0 N-CA-C 110.465 -0.198 . . . . 0.0 110.465 -176.642 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -92.59 166.95 29.47 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 171.682 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 66.2 t30 55.43 29.37 13.07 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 122.824 0.45 . . . . 0.0 110.725 -177.028 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 23.0 tp -57.0 117.64 18.98 Favored Pre-proline 0 CA--C 1.536 0.405 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -72.86 157.0 52.27 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.104 2.536 . . . . 0.0 110.951 -175.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.01 -4.43 14.84 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 124.074 3.183 . . . . 0.0 111.185 178.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -76.24 -7.02 53.96 Favored 'General case' 0 CA--C 1.529 0.167 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 178.457 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 tp -70.32 151.03 9.59 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.057 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 83.8 mmt-85 -130.59 155.6 46.25 Favored 'General case' 0 N--CA 1.458 -0.054 0 CA-C-O 120.678 0.275 . . . . 0.0 110.382 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.14 10.51 0.3 Allowed 'General case' 0 N--CA 1.462 0.127 0 N-CA-C 114.902 1.445 . . . . 0.0 114.902 -177.353 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 30' ' ' LYS . . . . . 0.424 ' HE2' ' OD1' ' B' ' 34' ' ' ASP . 23.4 tptm -140.69 -33.46 0.54 Allowed 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 122.326 0.25 . . . . 0.0 110.957 179.685 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -63.87 -24.01 67.58 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 175.828 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.6 tt -69.51 -15.99 20.06 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 C-N-CA 123.15 0.58 . . . . 0.0 110.902 -179.584 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -125.45 4.35 7.65 Favored 'General case' 0 CA--C 1.53 0.205 0 O-C-N 122.053 -0.404 . . . . 0.0 111.367 179.056 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 34' ' ' ASP . . . . . 0.424 ' OD1' ' HE2' ' B' ' 30' ' ' LYS . 79.1 m-20 -97.06 -61.93 1.33 Allowed 'General case' 0 C--O 1.233 0.197 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 172.215 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 p -74.84 -41.53 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.087 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -172.408 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -75.39 -21.49 58.22 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -179.019 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 43.3 t -72.26 -30.18 64.6 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 175.495 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 29.7 ttpp -72.92 -28.59 62.55 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.638 -0.505 . . . . 0.0 109.638 174.092 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -79.33 -20.73 47.15 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 116.26 1.948 . . . . 0.0 116.26 177.413 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.88 20.58 0.17 Allowed Glycine 0 CA--C 1.53 0.984 0 C-N-CA 119.887 -1.149 . . . . 0.0 114.717 -175.498 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 48.7 49.14 19.19 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 117.938 0.869 . . . . 0.0 111.475 175.186 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 75.6 mt -48.97 137.02 5.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.144 0.577 . . . . 0.0 111.008 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 48.0 mtm105 -98.9 -32.14 11.48 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 122.891 0.477 . . . . 0.0 111.527 179.226 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 32.3 m-20 -148.94 157.01 43.1 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 113.835 1.05 . . . . 0.0 113.835 -177.449 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 3.2 mp -126.78 151.95 34.07 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.662 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -148.6 48.02 1.02 Allowed 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -177.032 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 54.0 tp -68.75 110.45 4.32 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 177.632 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 48.1 mttm -93.88 146.57 23.8 Favored 'General case' 0 N--CA 1.456 -0.145 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 175.475 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 31.9 p30 -155.24 12.11 0.35 Allowed 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.003 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 90.0 mmt-85 -134.77 -5.6 2.47 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 117.985 0.357 . . . . 0.0 111.765 179.4 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 51.1 ttt180 -160.31 156.79 26.9 Favored 'General case' 0 CA--C 1.527 0.09 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.89 16.1 63.99 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -178.246 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.67 -161.79 26.21 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -178.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -56.54 163.09 7.28 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 123.852 3.035 . . . . 0.0 111.54 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -54.82 130.53 41.03 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 C-N-CA 123.646 2.897 . . . . 0.0 112.163 -175.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -164.13 167.22 20.46 Favored 'General case' 0 N--CA 1.455 -0.195 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 178.018 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -144.25 161.01 39.98 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -171.586 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 58' ' ' PHE . . . . . 0.492 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 50.9 m-85 -119.71 60.52 0.85 Allowed 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 124.152 0.981 . . . . 0.0 112.769 174.256 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 83.7 t -58.34 143.26 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.108 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -177.308 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 73.1 tt0 -120.79 120.4 35.49 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.918 0.389 . . . . 0.0 110.956 -175.167 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -91.53 166.43 12.84 Favored 'General case' 0 N--CA 1.455 -0.179 0 N-CA-C 115.984 1.846 . . . . 0.0 115.984 -174.417 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 30.4 tp10 -70.99 -35.22 72.01 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 122.757 0.423 . . . . 0.0 110.138 173.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -149.21 148.22 26.03 Favored Pre-proline 0 CA--C 1.527 0.093 0 C-N-CA 124.387 1.075 . . . . 0.0 112.021 178.084 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.1 -17.27 31.73 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.181 2.588 . . . . 0.0 111.089 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 51.9 mmm-85 -77.76 -13.42 59.9 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 122.435 0.294 . . . . 0.0 111.606 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -76.5 -10.31 59.3 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 111.953 0.353 . . . . 0.0 111.953 177.552 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.48 -11.05 60.68 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.592 0.357 . . . . 0.0 111.101 179.563 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -67.93 -17.72 64.54 Favored 'General case' 0 C--O 1.232 0.155 0 O-C-N 122.135 -0.353 . . . . 0.0 111.032 -179.286 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -123.84 -36.24 2.76 Favored 'General case' 0 CA--C 1.528 0.125 0 C-N-CA 123.183 0.593 . . . . 0.0 112.433 178.769 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -84.28 -8.86 58.9 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -175.605 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.43 HG13 HG12 ' B' ' 86' ' ' VAL . 47.3 t -132.68 -46.25 0.64 Allowed 'Isoleucine or valine' 0 C--O 1.228 -0.036 0 CA-C-N 118.062 0.392 . . . . 0.0 110.906 -175.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.3 t -69.5 -15.19 63.2 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-O 120.502 0.192 . . . . 0.0 110.977 -179.282 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.94 -5.82 88.8 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-O 119.647 -0.529 . . . . 0.0 112.711 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 70.2 mtm-85 -138.86 6.07 2.41 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 118.078 0.939 . . . . 0.0 111.869 -178.092 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -67.3 123.51 20.55 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 117.823 0.283 . . . . 0.0 111.307 -179.101 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 65.19 34.45 89.63 Favored Glycine 0 C--N 1.338 0.669 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 177.805 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 56.2 t80 -75.91 137.77 40.6 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -173.645 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 28.2 t0 -66.15 81.02 0.08 Allowed 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.295 1.038 . . . . 0.0 111.964 -177.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 79' ' ' TYR . . . . . 0.4 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 68.2 t80 -85.03 -179.94 7.15 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 177.784 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.4 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 71.4 m-20 -66.38 91.9 0.18 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 123.246 0.618 . . . . 0.0 112.43 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.73 -2.12 69.81 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-O 119.606 -0.552 . . . . 0.0 112.399 177.534 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -138.41 176.68 8.49 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 -178.842 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -125.15 140.1 53.17 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 123.846 0.858 . . . . 0.0 109.376 176.652 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -67.22 152.51 45.6 Favored 'General case' 0 N--CA 1.455 -0.204 0 C-N-CA 122.626 0.37 . . . . 0.0 110.426 177.22 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -118.43 48.26 1.46 Allowed 'General case' 0 C--N 1.338 0.068 0 C-N-CA 123.3 0.64 . . . . 0.0 109.828 172.012 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 86' ' ' VAL . . . . . 0.43 HG12 HG13 ' B' ' 71' ' ' VAL . 74.7 t -76.43 95.1 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.556 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -154.02 158.63 40.86 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.845 178.51 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 8.1 p90 -87.23 145.77 38.64 Favored Pre-proline 0 N--CA 1.456 -0.161 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 177.419 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 C--O 1.253 1.245 0 C-N-CA 123.614 2.876 . . . . 0.0 110.737 175.565 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . 0.471 " H3'" H5'' ' A' ' 91' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.42 -2.733 0 C5'-C4'-C3' 110.178 -3.548 OUTLIER-DELTA 0.0 '__' . 0.0 . . . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . 0.471 H5'' " H3'" ' A' ' 90' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.421 -2.697 0 C3'-C2'-C1' 103.667 2.408 OUTLIER-DELTA 0.0 OUTLIER delta 0.0 . . . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.392 0 O4'-C1'-N19 111.007 2.807 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.492 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.426 -2.211 0 C5'-C4'-C3' 110.668 -3.221 . 0.21 4b . 0.0 . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.534 0 C5'-C4'-C3' 109.794 -3.804 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.606 0 O4'-C1'-N19 111.185 2.985 . 0.262 6p . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.4 p . . . . . 0 N--CA 1.476 0.872 0 N-CA-C 111.611 0.226 . . . . 0.0 111.611 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.11 137.09 24.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.156 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.661 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 5.0 tpp180 -156.51 131.11 8.84 Favored 'General case' 0 C--O 1.232 0.14 0 C-N-CA 122.241 0.216 . . . . 0.0 110.428 177.172 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 9' ' ' GLY . . . . . 0.46 ' N ' ' CD ' ' B' ' 10' ' ' PRO . . . 59.17 38.61 93.39 Favored Glycine 0 CA--C 1.533 1.183 0 CA-C-O 118.809 -0.995 . . . . 0.0 113.369 175.472 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 10' ' ' PRO . . . . . 0.46 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 61.8 Cg_endo -70.22 -24.88 27.05 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.693 2.262 . . . . 0.0 110.944 -176.553 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -164.1 170.18 16.82 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 122.755 0.422 . . . . 0.0 110.254 -178.183 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -84.83 5.62 81.6 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.917 -0.473 . . . . 0.0 111.917 179.068 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 46.7 p30 -74.26 -3.14 28.26 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 117.651 0.725 . . . . 0.0 111.931 -177.522 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 71.5 m-80 -69.87 169.35 13.31 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 120.836 0.35 . . . . 0.0 110.84 177.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -137.08 166.85 22.72 Favored 'General case' 0 CA--C 1.528 0.1 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -177.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 74.2 m 58.77 8.09 0.88 Allowed 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.083 0.953 . . . . 0.0 112.53 -177.154 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 86.3 mtt180 -99.79 148.81 24.01 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 117.96 0.346 . . . . 0.0 111.741 177.71 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 19.9 pt -134.66 -177.26 1.95 Allowed 'Isoleucine or valine' 0 CA--C 1.524 -0.034 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.292 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 19' ' ' TYR . . . . . 0.426 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.4 OUTLIER -119.0 146.64 44.86 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -177.288 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 41.7 t -140.17 139.97 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.54 177.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -143.27 169.75 25.7 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -176.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 59.7 t30 61.07 31.56 19.79 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.741 0.817 . . . . 0.0 111.483 -175.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 81.3 mt -65.08 135.89 96.49 Favored Pre-proline 0 CA--C 1.533 0.301 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.56 146.3 38.87 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.273 2.649 . . . . 0.0 110.153 178.416 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -74.93 -13.04 21.69 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 C-N-CA 123.374 2.716 . . . . 0.0 111.398 177.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 79.8 m-20 -81.07 -2.93 50.17 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -176.618 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 8.8 tp -68.27 145.58 13.44 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.249 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 48.5 ttt-85 -84.56 151.32 24.62 Favored 'General case' 0 C--N 1.338 0.101 0 N-CA-C 109.965 -0.384 . . . . 0.0 109.965 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -66.21 12.55 0.06 Allowed 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 115.462 1.652 . . . . 0.0 115.462 -177.296 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 30' ' ' LYS . . . . . 0.408 ' HE2' ' OD2' ' B' ' 34' ' ' ASP . 24.0 tptm -148.69 -28.76 0.29 Allowed 'General case' 0 C--N 1.341 0.198 0 C-N-CA 122.47 0.308 . . . . 0.0 111.004 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 31.2 m-20 -64.06 -19.94 65.59 Favored 'General case' 0 CA--C 1.528 0.103 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 174.15 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 tt -69.29 -14.14 18.09 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 C-N-CA 123.336 0.654 . . . . 0.0 111.059 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -129.02 -10.32 4.81 Favored 'General case' 0 CA--C 1.529 0.173 0 CA-C-N 118.514 0.597 . . . . 0.0 111.677 176.689 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 34' ' ' ASP . . . . . 0.408 ' OD2' ' HE2' ' B' ' 30' ' ' LYS . 77.7 m-20 -74.13 -46.48 42.33 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 113.024 0.75 . . . . 0.0 113.024 174.166 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.6 p -71.91 -30.52 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.117 0 CA-C-O 120.656 0.265 . . . . 0.0 111.045 178.086 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -75.48 -30.82 60.01 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 177.656 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 41.4 t -70.37 -30.65 67.63 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 174.866 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 3.6 tppp? -73.38 -30.81 63.53 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 122.121 0.168 . . . . 0.0 110.672 177.257 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -84.03 -19.18 34.88 Favored 'General case' 0 C--N 1.338 0.103 0 N-CA-C 116.316 1.969 . . . . 0.0 116.316 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.14 22.31 0.07 OUTLIER Glycine 0 CA--C 1.528 0.88 0 C-N-CA 120.035 -1.078 . . . . 0.0 113.531 -177.594 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 52.32 30.15 7.67 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 117.64 0.72 . . . . 0.0 111.296 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 42' ' ' ILE . . . . . 0.417 HD11 ' CZ ' ' B' ' 61' ' ' PHE . 17.8 mt -50.72 137.37 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 123.191 0.597 . . . . 0.0 110.131 178.099 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 14.9 mmt180 -105.26 -19.02 13.93 Favored 'General case' 0 N--CA 1.457 -0.078 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -172.148 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 40.9 t0 -154.94 156.66 36.45 Favored 'General case' 0 C--O 1.233 0.201 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.962 178.554 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 15.5 mm -131.96 114.86 25.38 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 174.305 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 46' ' ' ASP . . . . . 0.453 ' HB3' ' H ' ' B' ' 58' ' ' PHE . 41.3 t0 -84.53 51.91 2.24 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 177.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 50.8 tp -54.18 120.88 7.09 Favored 'General case' 0 C--O 1.231 0.114 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 175.629 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -145.08 146.51 31.88 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-O 120.829 0.347 . . . . 0.0 111.02 -173.407 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 73.9 m-20 -78.98 172.73 13.39 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 122.951 0.501 . . . . 0.0 110.992 -179.198 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 33.3 mtp-105 -137.69 169.02 18.51 Favored 'General case' 0 C--O 1.233 0.218 0 C-N-CA 122.864 0.466 . . . . 0.0 110.059 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 58.9 ttt85 -67.75 -19.83 65.16 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.595 177.808 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -171.36 169.43 42.48 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 178.618 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.23 -175.33 45.95 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 -178.197 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.33 160.62 49.11 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 123.866 3.044 . . . . 0.0 110.65 179.183 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.45 166.61 26.63 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.491 2.794 . . . . 0.0 110.564 176.781 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -149.34 170.16 19.16 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 105.634 -1.987 . . . . 0.0 105.634 -178.141 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.83 155.2 33.98 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-O 120.756 0.312 . . . . 0.0 111.731 -175.295 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 58' ' ' PHE . . . . . 0.47 ' CE1' ' C4 ' ' A' ' 93' ' ' ' A' . 86.4 m-85 -108.93 107.79 18.3 Favored 'General case' 0 N--CA 1.457 -0.12 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.944 169.395 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 91.2 t -80.54 141.9 14.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -177.685 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -120.09 120.17 35.47 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-O 120.652 0.263 . . . . 0.0 110.424 178.806 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.417 ' CZ ' HD11 ' B' ' 42' ' ' ILE . 37.0 m-85 -88.08 158.1 18.68 Favored 'General case' 0 N--CA 1.456 -0.148 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -178.441 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -86.3 -29.6 22.91 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 167.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -155.61 110.28 2.19 Favored Pre-proline 0 CA--C 1.535 0.376 0 C-N-CA 123.655 0.782 . . . . 0.0 109.598 178.349 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -58.6 -11.51 11.67 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 124.04 3.16 . . . . 0.0 113.801 -177.73 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.66 -25.4 67.93 Favored 'General case' 0 CA--C 1.528 0.1 0 CA-C-N 118.191 0.451 . . . . 0.0 110.862 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 78.4 m-20 -76.2 2.7 12.44 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -179.587 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.97 -8.01 26.61 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.538 0.335 . . . . 0.0 111.341 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -62.73 -24.98 67.95 Favored 'General case' 0 N--CA 1.454 -0.26 0 O-C-N 122.149 -0.344 . . . . 0.0 110.969 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -120.78 -34.4 3.58 Favored 'General case' 0 C--O 1.228 -0.063 0 N-CA-C 112.731 0.641 . . . . 0.0 112.731 178.744 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -79.74 -9.09 59.6 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 123.346 0.658 . . . . 0.0 111.642 -176.025 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 58.2 t -136.2 -43.99 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 CA-C-N 117.623 0.192 . . . . 0.0 111.111 -177.225 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 68.7 m -83.82 -2.41 56.32 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.985 -0.098 . . . . 0.0 111.197 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -76.61 -30.18 56.72 Favored Glycine 0 C--N 1.34 0.796 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 -178.584 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 56.2 ttm-85 -162.76 131.8 4.16 Favored 'General case' 0 C--N 1.338 0.07 0 CA-C-N 117.376 0.588 . . . . 0.0 110.762 177.626 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 26.0 p30 -160.11 153.52 22.22 Favored 'General case' 0 C--O 1.232 0.165 0 C-N-CA 123.61 0.764 . . . . 0.0 110.89 175.584 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 56.37 41.49 87.73 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.71 -0.556 . . . . 0.0 111.71 175.455 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 46.3 t80 -92.71 136.61 33.08 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 -173.102 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -67.51 91.75 0.29 Allowed 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 124.042 0.937 . . . . 0.0 112.224 -177.673 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -85.09 -175.31 5.69 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.393 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -68.73 77.05 0.3 Allowed 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 123.678 0.791 . . . . 0.0 112.379 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 86.88 5.61 80.79 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 178.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -135.21 -176.86 4.4 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.351 0.66 . . . . 0.0 112.431 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 2.3 tpt180 -139.7 129.08 24.1 Favored 'General case' 0 CA--C 1.522 -0.123 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -179.436 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.7 mp -70.01 148.33 48.99 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 178.75 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 43.0 mtp85 -131.12 125.72 33.84 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 173.657 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 13.8 t -139.65 82.78 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.148 0 C-N-CA 123.562 0.745 . . . . 0.0 109.84 176.235 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -147.37 161.47 40.94 Favored 'General case' 0 C--N 1.333 -0.118 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.038 -177.627 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 6.0 p90 -76.16 151.99 83.95 Favored Pre-proline 0 CA--C 1.53 0.205 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 177.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo . . . . . 0 C--O 1.251 1.128 0 C-N-CA 123.455 2.77 . . . . 0.0 111.015 177.203 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.061 0 C5'-C4'-C3' 110.043 -3.638 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.008 0 O4'-C1'-N19 111.648 3.448 . 0.363 2o . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ' C' . . . . . 0.426 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.352 1 C5'-C4'-C3' 108.074 -4.951 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 93' ' ' ' A' . . . . . 0.47 ' C4 ' ' CE1' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.405 0 C5'-C4'-C3' 110.141 -3.572 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.853 0 C3'-C2'-C1' 104.993 3.882 . 0.0 OUTLIER '7D dist 4p' 0.0 . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -2.967 0 C5'-C4'-C3' 109.604 -3.93 . 0.247 2u . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.1 m . . . . . 0 CA--C 1.533 0.306 0 N-CA-C 111.797 0.295 . . . . 0.0 111.797 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 33.9 mtt180 -84.5 149.7 25.76 Favored 'General case' 0 C--O 1.232 0.135 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -176.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 16.6 pt -140.62 174.48 7.8 Favored 'Isoleucine or valine' 0 C--O 1.23 0.07 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.917 173.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -109.0 150.39 27.83 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 114.497 1.295 . . . . 0.0 114.497 -177.64 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t -137.4 142.43 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.19 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.221 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.92 179.45 29.35 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -178.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 61.9 t30 56.23 39.42 30.25 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 123.666 0.787 . . . . 0.0 110.899 -174.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 84.8 mt . . . . . 0 CA--C 1.533 0.295 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.392 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 52.7 tptt . . . . . 0 N--CA 1.454 -0.257 0 N-CA-C 110.83 -0.063 . . . . 0.0 110.83 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 59.2 m-20 -64.6 -28.4 69.6 Favored 'General case' 0 C--O 1.231 0.124 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -176.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 31.3 mm -78.12 -23.41 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 177.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.4 mt-10 -86.74 -11.44 51.1 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.921 -0.127 . . . . 0.0 110.823 179.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 79.0 m-20 -101.33 -66.06 0.94 Allowed 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 177.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 41.4 t -73.84 -53.95 16.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.21 0 CA-C-N 116.756 -0.202 . . . . 0.0 111.04 -174.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 63.3 m-85 -69.16 -21.38 64.0 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -179.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 45.5 t -74.28 -32.18 62.81 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 175.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -68.85 -29.71 68.08 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 174.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 20.3 m-85 -82.69 -20.17 36.65 Favored 'General case' 0 CA--C 1.528 0.129 0 N-CA-C 116.352 1.982 . . . . 0.0 116.352 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.73 20.52 0.05 OUTLIER Glycine 0 CA--C 1.527 0.782 0 C-N-CA 119.66 -1.257 . . . . 0.0 114.775 -175.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 47.65 59.81 3.92 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 118.203 1.002 . . . . 0.0 111.667 174.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 29.2 mm -44.96 132.8 1.83 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 C-N-CA 123.597 0.759 . . . . 0.0 111.496 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -86.64 -37.29 18.18 Favored 'General case' 0 N--CA 1.456 -0.161 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.384 177.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 -147.86 150.06 33.44 Favored 'General case' 0 C--O 1.231 0.09 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -176.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -109.15 149.91 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 176.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -148.11 64.63 1.1 Allowed 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 77.7 mt -63.47 138.12 58.39 Favored 'General case' 0 C--O 1.232 0.156 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 49.3 mttp -130.64 51.76 2.09 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 123.974 0.91 . . . . 0.0 109.832 177.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 76.8 m-20 . . . . . 0 N--CA 1.452 -0.329 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.425 174.048 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo . . . . . 0 N--CA 1.45 -1.08 0 N-CA-C 110.535 -0.602 . . . . 0.0 110.535 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -166.32 -178.45 4.54 Favored 'General case' 0 CA--C 1.528 0.127 0 N-CA-C 105.974 -1.862 . . . . 0.0 105.974 176.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -158.11 166.39 32.59 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.373 0.606 . . . . 0.0 112.081 -177.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -121.32 157.82 29.55 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.575 171.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 75.7 t -138.9 137.21 42.76 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.134 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -178.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 69.0 tt0 -116.91 114.04 23.29 Favored 'General case' 0 CA--C 1.529 0.142 0 CA-C-O 120.666 0.27 . . . . 0.0 110.814 -176.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -82.11 168.56 17.62 Favored 'General case' 0 N--CA 1.457 -0.095 0 N-CA-C 115.872 1.804 . . . . 0.0 115.872 -176.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 48.7 tp10 -64.74 -35.73 82.01 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 174.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 26.1 p30 -159.19 162.92 25.17 Favored Pre-proline 0 CA--C 1.532 0.275 0 C-N-CA 123.536 0.734 . . . . 0.0 110.359 175.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -63.61 -18.15 63.05 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 123.116 2.544 . . . . 0.0 112.322 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 4.3 ttp85 -78.44 -40.93 34.29 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 117.849 0.295 . . . . 0.0 110.765 -175.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 79.5 m-20 -71.78 -24.35 61.73 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 178.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.59 -28.88 68.14 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 44.5 tp10 -68.77 -34.11 75.02 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 110.492 -0.188 . . . . 0.0 110.492 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -73.85 -33.99 64.33 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 178.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.86 -33.33 64.04 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 177.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 13.7 t -71.22 -45.23 71.81 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 48.2 t -69.79 -16.65 63.33 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 122.309 -0.244 . . . . 0.0 111.487 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.86 -8.75 41.69 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-O 119.119 -0.823 . . . . 0.0 113.711 -174.155 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -140.25 -12.26 1.07 Allowed 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 118.905 1.352 . . . . 0.0 113.277 -174.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -76.61 146.34 38.29 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 118.516 0.598 . . . . 0.0 110.12 -176.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.25 39.96 97.92 Favored Glycine 0 CA--C 1.527 0.836 0 CA-C-O 119.526 -0.597 . . . . 0.0 112.068 171.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 42.3 t80 -95.67 131.18 42.18 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -174.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -61.29 105.87 0.55 Allowed 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 123.663 0.785 . . . . 0.0 112.477 -178.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.427 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 46.3 t80 -112.88 169.45 8.9 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 123.738 0.815 . . . . 0.0 111.619 177.691 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.427 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 19.0 t0 -61.02 98.62 0.08 Allowed 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -179.249 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.59 -5.14 61.75 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 123.441 0.543 . . . . 0.0 112.677 177.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -141.3 -171.12 3.22 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 117.855 0.828 . . . . 0.0 112.954 -178.323 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 40.5 ttt180 -147.24 128.34 14.64 Favored 'General case' 0 C--O 1.231 0.113 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 -177.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -63.92 147.49 51.84 Favored 'General case' 0 N--CA 1.461 0.102 0 C-N-CA 122.694 0.398 . . . . 0.0 110.205 -174.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -118.57 119.82 35.65 Favored 'General case' 0 CA--C 1.521 -0.15 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 175.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.7 t -145.55 80.11 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 C-N-CA 122.878 0.471 . . . . 0.0 109.84 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -149.33 159.2 44.48 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.692 0.282 . . . . 0.0 110.807 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -74.16 156.04 87.83 Favored Pre-proline 0 CA--C 1.531 0.223 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo . . . . . 0 C--O 1.252 1.187 0 C-N-CA 123.669 2.913 . . . . 0.0 111.727 175.807 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.7 m . . . . . 0 CA--C 1.528 0.106 0 N-CA-C 110.591 -0.151 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . 0.423 ' HA ' ' HA ' ' B' ' 60' ' ' GLU . 32.6 ttp-105 -102.81 148.83 25.14 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.324 0.65 . . . . 0.0 110.686 -177.398 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 20.8 pt -131.67 179.23 4.54 Favored 'Isoleucine or valine' 0 C--O 1.23 0.063 0 C-N-CA 123.277 0.631 . . . . 0.0 109.835 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -118.82 156.87 28.67 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 114.248 1.203 . . . . 0.0 114.248 -175.674 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 12.7 t -134.37 123.92 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 C-N-CA 122.917 0.487 . . . . 0.0 110.705 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -130.22 166.61 22.14 Favored Glycine 0 CA--C 1.53 1.02 0 N-CA-C 111.688 -0.565 . . . . 0.0 111.688 -177.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 60.5 t30 63.65 28.61 15.06 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 124.648 1.179 . . . . 0.0 111.765 -176.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 87.7 mt . . . . . 0 CA--C 1.532 0.287 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 174.996 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 21.6 tptm . . . . . 0 CA--C 1.533 0.322 0 CA-C-O 120.462 0.173 . . . . 0.0 110.722 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -67.24 -30.38 70.27 Favored 'General case' 0 CA--C 1.528 0.131 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -178.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.3 mt -75.28 -33.09 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 99.3 mt-10 -75.34 -15.49 60.48 Favored 'General case' 0 N--CA 1.456 -0.173 0 C-N-CA 122.451 0.301 . . . . 0.0 110.986 -178.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -91.51 -52.18 4.91 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 112.924 0.712 . . . . 0.0 112.924 174.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 93.9 t -71.22 -50.91 38.26 Favored 'Isoleucine or valine' 0 C--N 1.34 0.172 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 -174.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -68.09 -31.9 71.84 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -177.731 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 43.8 t -66.45 -29.12 69.18 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 110.539 -0.171 . . . . 0.0 110.539 177.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -71.23 -31.03 67.07 Favored 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 174.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -79.0 -20.88 47.96 Favored 'General case' 0 C--O 1.233 0.219 0 N-CA-C 115.79 1.774 . . . . 0.0 115.79 176.376 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 169.81 -177.11 43.43 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 118.388 0.54 . . . . 0.0 112.289 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.37 95.99 8.92 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 122.838 0.455 . . . . 0.0 110.68 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . 0.431 ' N ' HD12 ' B' ' 42' ' ' ILE . 1.8 mp -80.28 149.6 5.13 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 C-N-CA 122.733 0.413 . . . . 0.0 110.225 175.229 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 29.1 mtp-105 -115.0 -34.06 5.2 Favored 'General case' 0 CA--C 1.528 0.119 0 C-N-CA 123.657 0.783 . . . . 0.0 111.313 177.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.8 m-20 -146.61 155.8 42.74 Favored 'General case' 0 N--CA 1.457 -0.105 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -176.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 4.1 mp -136.1 150.48 28.1 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.137 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 177.248 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -138.96 48.81 1.88 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 120.792 0.33 . . . . 0.0 111.072 179.167 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.6 tp -63.78 124.48 21.6 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 173.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 24.4 pttm -152.35 161.72 42.19 Favored 'General case' 0 N--CA 1.458 -0.062 0 C-N-CA 122.53 0.332 . . . . 0.0 110.666 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 18.8 p30 . . . . . 0 N--CA 1.455 -0.22 0 CA-C-O 120.891 0.377 . . . . 0.0 111.061 -177.201 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_exo . . . . . 0 N--CA 1.455 -0.745 0 N-CA-C 113.824 0.663 . . . . 0.0 113.824 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -147.61 163.4 36.75 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 104.385 -2.45 . . . . 0.0 104.385 175.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -149.93 163.59 37.67 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 119.997 -0.681 . . . . 0.0 112.737 -171.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -122.15 154.67 37.11 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.09 169.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 71.9 t -140.12 132.37 33.2 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.266 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . 0.423 ' HA ' ' HA ' ' B' ' 17' ' ' ARG . 68.2 tt0 -117.28 132.54 56.6 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.811 0.339 . . . . 0.0 111.252 -174.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -98.47 160.55 14.21 Favored 'General case' 0 C--O 1.231 0.12 0 N-CA-C 114.826 1.417 . . . . 0.0 114.826 -175.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -81.89 -17.4 47.36 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.857 0.463 . . . . 0.0 110.382 171.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -152.74 120.58 3.13 Favored Pre-proline 0 C--O 1.233 0.206 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -178.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.52 -14.33 44.3 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 123.066 2.51 . . . . 0.0 111.948 -175.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 86.7 mtm180 -71.69 -24.49 61.83 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 117.944 0.338 . . . . 0.0 110.669 176.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -87.74 -27.07 22.59 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-O 120.75 0.309 . . . . 0.0 110.751 176.016 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.03 -25.23 65.27 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 177.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -69.86 -31.08 68.73 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 122.218 0.207 . . . . 0.0 110.523 178.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -76.48 -35.33 58.45 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 112.308 0.485 . . . . 0.0 112.308 179.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.33 -27.72 66.52 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 122.634 0.373 . . . . 0.0 110.059 177.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 39.6 t -87.52 -44.09 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.2 t -65.98 -21.56 66.42 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-N 117.552 0.16 . . . . 0.0 111.127 -176.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -90.29 -15.36 57.4 Favored Glycine 0 CA--C 1.53 0.977 0 CA-C-O 119.455 -0.636 . . . . 0.0 113.004 -177.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 61.0 mtm180 -146.22 19.57 1.39 Allowed 'General case' 0 C--N 1.342 0.282 0 CA-C-N 118.24 1.02 . . . . 0.0 113.146 -170.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 18.8 p30 -70.81 -1.42 11.56 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.105 0.779 . . . . 0.0 113.105 178.029 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.82 90.69 0.08 OUTLIER Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -120.58 137.77 54.23 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 176.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -68.94 92.26 0.5 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.442 0.697 . . . . 0.0 111.953 -176.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -84.68 -175.92 5.99 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -67.89 82.79 0.2 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 123.557 0.743 . . . . 0.0 112.298 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.7 2.83 89.81 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 112.148 -0.381 . . . . 0.0 112.148 178.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -137.86 -174.57 3.82 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -179.081 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 70.5 ttp85 -140.39 135.06 31.71 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.85 151.42 45.55 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 122.666 0.387 . . . . 0.0 110.18 -179.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 51.5 mtm180 -134.54 55.71 1.88 Allowed 'General case' 0 C--O 1.231 0.103 0 C-N-CA 122.435 0.294 . . . . 0.0 110.849 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 20.1 t -82.95 94.83 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.188 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 174.392 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -152.31 161.47 42.56 Favored 'General case' 0 C--O 1.226 -0.174 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -76.6 156.05 83.2 Favored Pre-proline 0 CA--C 1.532 0.268 0 N-CA-C 114.666 1.358 . . . . 0.0 114.666 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo . . . . . 0 C--O 1.25 1.119 0 C-N-CA 123.789 2.993 . . . . 0.0 111.723 175.434 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 95.9 m . . . . . 0 CA--C 1.534 0.327 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 84.2 mtt-85 -83.38 146.9 28.21 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 118.272 0.487 . . . . 0.0 111.737 176.195 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 26.9 pt -131.45 172.29 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 173.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -120.74 149.72 42.1 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 114.185 1.18 . . . . 0.0 114.185 -178.029 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 19.7 t -137.53 141.83 38.36 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 C-N-CA 123.449 0.699 . . . . 0.0 109.728 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -150.43 171.84 30.26 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -176.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 65.6 t30 59.73 30.91 20.51 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.213 1.005 . . . . 0.0 111.688 -175.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.9 mt . . . . . 0 N--CA 1.454 -0.257 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 174.892 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 55.0 tptt . . . . . 0 N--CA 1.456 -0.129 0 N-CA-C 111.139 0.051 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -64.53 -29.78 70.81 Favored 'General case' 0 N--CA 1.455 -0.175 0 N-CA-C 112.106 0.409 . . . . 0.0 112.106 -177.089 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 mm -74.69 -21.2 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.18 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 90.2 mt-10 -78.47 -48.74 14.76 Favored 'General case' 0 C--O 1.223 -0.324 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -65.86 -44.7 84.63 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -174.312 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 99.0 t -69.84 -53.04 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.099 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -176.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -75.28 -24.1 57.49 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 113.546 0.943 . . . . 0.0 113.546 -174.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 41.8 t -68.89 -31.79 70.96 Favored 'General case' 0 C--N 1.342 0.265 0 CA-C-N 118.008 0.367 . . . . 0.0 110.054 173.149 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 58.3 tptt -68.36 -30.76 69.78 Favored 'General case' 0 C--N 1.341 0.212 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 174.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 39.6 m-85 -74.75 -20.36 59.85 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 115.457 1.651 . . . . 0.0 115.457 174.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 159.52 -178.0 35.81 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.835 -0.506 . . . . 0.0 111.835 176.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -73.79 122.19 22.04 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.65 0.262 . . . . 0.0 110.36 -178.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 73.8 mt -92.65 140.0 17.01 Favored 'Isoleucine or valine' 0 C--O 1.233 0.237 0 C-N-CA 122.937 0.495 . . . . 0.0 111.201 -178.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -94.14 -38.19 11.21 Favored 'General case' 0 N--CA 1.458 -0.071 0 C-N-CA 123.093 0.557 . . . . 0.0 110.361 170.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -155.94 156.76 35.12 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 120.713 0.292 . . . . 0.0 111.101 -173.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mt -133.28 143.3 39.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 C-N-CA 124.186 0.994 . . . . 0.0 108.854 175.281 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -144.74 64.88 1.28 Allowed 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 120.644 0.259 . . . . 0.0 111.54 -174.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 57.7 tp -58.23 134.75 56.8 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 169.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 54.8 tttp -143.23 164.23 30.78 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.841 0.353 . . . . 0.0 111.238 -168.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 44.8 p30 . . . . . 0 CA--C 1.535 0.387 0 C-N-CA 123.383 0.673 . . . . 0.0 110.694 -173.312 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo . . . . . 0 N--CA 1.452 -0.963 0 N-CA-C 110.658 -0.555 . . . . 0.0 110.658 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 3.8 p90 -152.92 173.3 15.55 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 106.281 -1.748 . . . . 0.0 106.281 -175.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.64 168.31 27.78 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 -174.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 80.7 m-85 -127.23 157.11 40.7 Favored 'General case' 0 C--O 1.234 0.282 0 C-N-CA 123.618 0.767 . . . . 0.0 110.056 171.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 56.0 t -143.76 142.03 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -119.18 125.26 48.78 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 177.101 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -89.49 161.68 16.11 Favored 'General case' 0 C--O 1.231 0.114 0 N-CA-C 115.272 1.582 . . . . 0.0 115.272 174.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 37.3 tp10 -72.18 -23.97 61.35 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.559 175.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 48.4 m-20 -144.47 151.86 51.85 Favored Pre-proline 0 N--CA 1.455 -0.176 0 C-N-CA 124.192 0.997 . . . . 0.0 112.292 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -68.6 -18.29 42.9 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.877 2.384 . . . . 0.0 110.615 178.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 73.0 ttt-85 -68.84 -40.04 79.63 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 177.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -76.07 -26.12 56.22 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 120.739 0.304 . . . . 0.0 111.664 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.87 -36.24 70.05 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 176.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 41.7 tp10 -69.35 -32.09 70.93 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 110.388 -0.227 . . . . 0.0 110.388 178.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -70.94 -35.9 72.4 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.43 -32.73 68.71 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 178.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 59.1 t -80.14 -30.48 12.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 45.7 t -79.97 -9.33 59.68 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 122.715 0.406 . . . . 0.0 110.656 178.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -66.57 -77.06 0.31 Allowed Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.217 -0.753 . . . . 0.0 111.217 -178.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 4.0 tpm_? -156.69 132.06 9.28 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 51.3 p-10 -153.15 168.79 24.78 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.506 0.722 . . . . 0.0 109.09 176.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 58.67 40.8 95.26 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 174.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -98.42 132.93 43.47 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 113.832 1.049 . . . . 0.0 113.832 -172.411 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -62.45 106.69 0.8 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.639 0.776 . . . . 0.0 112.35 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.437 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 50.1 t80 -114.31 170.31 8.39 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 123.585 0.754 . . . . 0.0 111.39 178.341 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.437 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 21.3 t0 -60.0 100.54 0.09 Allowed 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.33 -5.6 42.49 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-O 119.746 -0.474 . . . . 0.0 112.912 178.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 88.1 m-85 -140.34 -170.51 3.0 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 117.871 0.836 . . . . 0.0 113.241 -178.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 40.0 ttt180 -148.61 129.9 14.67 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 123.673 0.789 . . . . 0.0 108.953 -177.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -67.51 149.59 49.97 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -176.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -129.67 130.35 45.44 Favored 'General case' 0 C--N 1.34 0.181 0 CA-C-O 120.624 0.25 . . . . 0.0 110.52 172.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.6 t -145.3 80.36 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.099 0 C-N-CA 123.96 0.904 . . . . 0.0 109.298 173.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -144.63 168.36 20.34 Favored 'General case' 0 C--O 1.226 -0.132 0 C-N-CA 122.595 0.358 . . . . 0.0 111.047 -175.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 69.9 m-85 -63.67 153.24 84.17 Favored Pre-proline 0 C--O 1.235 0.307 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 179.03 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 C--O 1.251 1.168 0 C-N-CA 123.705 2.937 . . . . 0.0 110.932 175.168 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 69.8 m . . . . . 0 CA--C 1.533 0.292 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 66.1 mtm-85 -71.29 143.86 50.19 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 117.769 0.259 . . . . 0.0 110.796 172.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.6 pt -139.16 171.2 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.102 0 C-N-CA 123.302 0.641 . . . . 0.0 109.4 177.188 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -113.75 151.37 32.03 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 44.1 t -137.38 144.64 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 123.251 0.62 . . . . 0.0 109.462 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -156.2 177.15 33.39 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -177.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 62.1 t30 62.75 169.68 0.14 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.604 1.161 . . . . 0.0 111.406 -172.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 85.3 mt . . . . . 0 N--CA 1.454 -0.251 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 177.631 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 47.7 tptt . . . . . 0 CA--C 1.532 0.265 0 CA-C-O 120.554 0.216 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -53.35 -44.66 68.71 Favored 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -177.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.3 tt -78.55 -5.26 7.69 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 C-N-CA 122.898 0.479 . . . . 0.0 110.819 -176.445 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 84.5 mt-10 -116.85 1.43 12.7 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 122.55 0.34 . . . . 0.0 111.236 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 11.1 t0 -125.29 -54.04 1.59 Allowed 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 87.2 t -69.7 -41.99 80.2 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.042 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -178.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 45.4 m-85 -67.86 -27.85 67.04 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 176.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 67.2 m -72.65 -21.88 61.02 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.443 177.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 24.7 ttmm -77.75 -30.82 51.75 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 109.684 -0.488 . . . . 0.0 109.684 173.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -70.86 -23.13 62.26 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 114.39 1.256 . . . . 0.0 114.39 173.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 164.01 174.34 33.71 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 174.138 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -71.53 125.13 26.26 Favored 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 17.1 mt -99.33 138.97 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.164 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 77.8 mtp85 -86.31 -43.1 13.18 Favored 'General case' 0 C--N 1.333 -0.148 0 C-N-CA 122.897 0.479 . . . . 0.0 110.065 174.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -152.6 159.13 43.25 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -176.445 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.9 mp -130.02 148.68 33.18 Favored 'Isoleucine or valine' 0 C--N 1.339 0.136 0 C-N-CA 124.172 0.989 . . . . 0.0 109.627 177.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 21.2 t0 -140.72 63.97 1.44 Allowed 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.296 0.238 . . . . 0.0 111.255 176.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 61.2 tp -59.81 133.61 56.26 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 170.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 15.7 ttmm -143.62 152.2 41.08 Favored 'General case' 0 C--N 1.342 0.24 0 CA-C-O 120.74 0.305 . . . . 0.0 111.024 -173.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 . . . . . 0 N--CA 1.455 -0.222 0 C-N-CA 122.996 0.518 . . . . 0.0 110.563 178.891 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo . . . . . 0 N--CA 1.453 -0.883 0 N-CA-C 111.615 -0.187 . . . . 0.0 111.615 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -150.72 169.12 22.38 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 179.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -157.96 170.7 21.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 120.916 0.389 . . . . 0.0 111.527 -174.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -123.59 154.68 38.95 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.909 169.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 71.7 t -137.73 139.85 42.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -178.127 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -121.91 108.32 13.29 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -79.21 160.59 26.84 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 115.004 1.483 . . . . 0.0 115.004 177.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 41.1 tp10 -75.76 -31.85 59.71 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.542 175.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -133.05 150.75 76.42 Favored Pre-proline 0 CA--C 1.532 0.275 0 C-N-CA 123.707 0.803 . . . . 0.0 112.365 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -70.11 -21.6 31.62 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 123.203 2.602 . . . . 0.0 110.885 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 81.2 mtt85 -72.67 -27.89 62.37 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 178.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -79.76 -31.39 40.95 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 122.039 0.136 . . . . 0.0 111.318 179.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.97 -36.68 69.91 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 110.511 -0.181 . . . . 0.0 110.511 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 43.4 tp10 -68.12 -34.29 76.1 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -72.28 -35.23 68.68 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.1 -29.52 64.18 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.2 t -75.21 -50.97 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.479 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 88.0 p -73.5 -10.22 59.49 Favored 'General case' 0 C--O 1.233 0.217 0 O-C-N 122.199 -0.313 . . . . 0.0 111.661 -176.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -98.62 -10.38 50.44 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-O 119.167 -0.796 . . . . 0.0 113.371 -173.49 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -151.51 -13.02 0.2 Allowed 'General case' 0 C--N 1.34 0.159 0 CA-C-N 119.04 1.42 . . . . 0.0 113.206 -173.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -66.61 143.9 56.73 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.421 0.555 . . . . 0.0 110.146 -177.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 60.22 39.92 96.62 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 173.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 41.2 t80 -99.13 133.42 43.44 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 113.635 0.976 . . . . 0.0 113.635 -173.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.2 t0 -62.1 105.69 0.62 Allowed 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 123.574 0.749 . . . . 0.0 112.372 -178.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.423 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 51.5 t80 -111.26 169.92 8.46 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 123.829 0.852 . . . . 0.0 111.389 178.23 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.423 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 21.0 t0 -61.0 97.41 0.06 Allowed 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.375 0.509 . . . . 0.0 112.375 -179.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 80.68 -4.06 71.25 Favored Glycine 0 CA--C 1.53 0.994 0 CA-C-O 119.379 -0.678 . . . . 0.0 112.722 177.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -142.46 -170.72 3.25 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 118.142 0.971 . . . . 0.0 112.793 -177.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 36.0 ttt180 -145.89 130.22 17.66 Favored 'General case' 0 C--O 1.231 0.095 0 C-N-CA 123.466 0.706 . . . . 0.0 109.292 -178.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -63.86 152.92 38.33 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 122.952 0.501 . . . . 0.0 111.078 -174.088 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 53.1 mmm-85 -124.92 117.36 23.9 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 173.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 19.2 t -145.25 81.31 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.522 -0.103 0 C-N-CA 122.75 0.42 . . . . 0.0 110.252 178.091 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.9 pt-20 -142.8 168.49 19.6 Favored 'General case' 0 C--N 1.333 -0.112 0 C-N-CA 122.429 0.291 . . . . 0.0 111.066 -175.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 54.3 m-85 -65.15 151.66 93.27 Favored Pre-proline 0 CA--C 1.532 0.257 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo . . . . . 0 N--CA 1.448 -1.186 0 C-N-CA 123.894 3.063 . . . . 0.0 110.72 175.719 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 85.3 m . . . . . 0 CA--C 1.531 0.236 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 79.6 mtt180 -76.78 147.41 37.28 Favored 'General case' 0 CA--C 1.528 0.108 0 CA-C-N 117.889 0.313 . . . . 0.0 110.668 177.177 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 pt -135.57 167.87 24.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.107 0 C-N-CA 123.216 0.607 . . . . 0.0 109.364 173.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -108.61 148.65 30.03 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 114.694 1.368 . . . . 0.0 114.694 -173.309 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 21.7 t -137.13 139.05 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 C-N-CA 123.839 0.856 . . . . 0.0 110.001 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.76 175.65 30.45 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -177.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 54.2 t30 59.68 26.07 15.11 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.807 0.843 . . . . 0.0 111.42 -175.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 97.3 mt . . . . . 0 N--CA 1.455 -0.218 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 176.455 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.1 tptt . . . . . 0 N--CA 1.454 -0.234 0 CA-C-O 120.019 -0.038 . . . . 0.0 110.974 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 -67.45 -22.92 65.47 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 112.401 0.519 . . . . 0.0 112.401 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 6.4 tp -71.31 -18.18 20.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 C-N-CA 122.64 0.376 . . . . 0.0 110.188 176.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -96.16 -26.63 15.39 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 176.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -64.93 -49.91 68.54 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.625 0.25 . . . . 0.0 111.67 -177.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 99.7 t -67.63 -43.56 86.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -178.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -74.6 -32.45 62.36 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 114.52 1.304 . . . . 0.0 114.52 -177.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 90.0 p -69.74 -22.48 63.37 Favored 'General case' 0 C--O 1.231 0.107 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.87 175.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -72.26 -34.02 67.92 Favored 'General case' 0 C--N 1.34 0.193 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 173.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 49.4 m-85 -68.87 -19.1 64.23 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 170.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.76 169.3 33.14 Favored Glycine 0 CA--C 1.532 1.119 0 C-N-CA 123.183 0.42 . . . . 0.0 112.996 171.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 59.56 20.28 8.8 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 124.762 1.225 . . . . 0.0 113.68 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.5 mp -76.51 140.15 17.67 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 173.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 20.4 mmt180 -120.3 -21.92 6.74 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 122.488 0.315 . . . . 0.0 111.502 173.524 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -158.13 149.6 21.33 Favored 'General case' 0 C--N 1.339 0.137 0 N-CA-C 113.919 1.081 . . . . 0.0 113.919 176.581 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -120.4 152.24 23.31 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 171.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 45.1 t0 -145.16 79.07 1.58 Allowed 'General case' 0 N--CA 1.449 -0.496 0 CA-C-O 120.947 0.404 . . . . 0.0 111.374 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 55.9 tp -66.04 135.73 55.05 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 171.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 14.5 ttmm -151.86 168.29 25.58 Favored 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 -173.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 54.3 t30 . . . . . 0 N--CA 1.452 -0.325 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 175.496 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo . . . . . 0 N--CA 1.452 -0.955 0 N-CA-C 111.184 -0.352 . . . . 0.0 111.184 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -149.11 171.76 15.9 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 104.977 -2.231 . . . . 0.0 104.977 177.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.76 169.03 25.32 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.289 0.566 . . . . 0.0 111.941 -174.566 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -121.88 156.95 32.22 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.881 171.228 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 96.8 t -134.8 140.29 45.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -124.1 115.94 21.98 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.019 0.437 . . . . 0.0 110.538 -174.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 38.5 m-85 -91.3 161.74 14.91 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 114.256 1.206 . . . . 0.0 114.256 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -75.65 -28.23 58.67 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 170.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 17.2 p30 -154.8 152.55 25.87 Favored Pre-proline 0 CA--C 1.534 0.333 0 C-N-CA 123.326 0.651 . . . . 0.0 111.675 176.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.09 -7.85 22.27 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 123.24 2.626 . . . . 0.0 111.429 179.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 45.3 ttm105 -65.24 -38.9 91.8 Favored 'General case' 0 C--N 1.339 0.122 0 C-N-CA 122.444 0.298 . . . . 0.0 111.331 -177.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -94.52 -17.81 22.04 Favored 'General case' 0 C--O 1.232 0.177 0 N-CA-C 112.859 0.688 . . . . 0.0 112.859 179.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.7 -27.21 67.46 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -69.05 -30.36 68.68 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 110.423 -0.214 . . . . 0.0 110.423 178.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -75.98 -36.81 59.09 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 112.165 0.431 . . . . 0.0 112.165 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.01 -28.01 64.1 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 110.263 -0.273 . . . . 0.0 110.263 176.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 16.6 t -77.29 -50.18 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.177 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 71.1 m -73.59 -7.6 52.59 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 111.656 0.243 . . . . 0.0 111.656 -175.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -99.67 -8.05 52.58 Favored Glycine 0 CA--C 1.53 1.023 0 CA-C-O 119.07 -0.85 . . . . 0.0 113.423 -175.088 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 13.6 tpp180 -152.04 -13.73 0.19 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 118.489 1.145 . . . . 0.0 113.332 -174.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -66.65 141.86 57.64 Favored 'General case' 0 N--CA 1.456 -0.168 0 O-C-N 121.933 -0.479 . . . . 0.0 110.118 -177.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.49 43.87 97.5 Favored Glycine 0 CA--C 1.53 0.988 0 N-CA-C 111.921 -0.472 . . . . 0.0 111.921 174.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -101.86 137.5 40.07 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 114.132 1.16 . . . . 0.0 114.132 -173.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 11.3 t0 -63.23 109.07 1.43 Allowed 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 123.62 0.768 . . . . 0.0 112.491 -176.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.41 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 42.3 t80 -116.27 168.11 10.42 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 123.662 0.785 . . . . 0.0 111.524 175.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.41 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.5 t0 -58.99 98.5 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.98 -5.79 61.31 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-O 119.476 -0.624 . . . . 0.0 112.6 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -141.54 -169.32 2.85 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.007 0.904 . . . . 0.0 113.174 -177.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 42.3 ttp-105 -145.26 131.05 19.04 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 123.492 0.717 . . . . 0.0 109.48 -178.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -63.41 152.07 39.24 Favored 'General case' 0 N--CA 1.461 0.086 0 C-N-CA 122.782 0.433 . . . . 0.0 110.372 -177.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 92.1 mtm-85 -127.98 121.3 29.51 Favored 'General case' 0 CA--C 1.52 -0.177 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 173.302 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 24.2 t -142.46 81.45 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -141.54 164.26 30.71 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 111.798 0.295 . . . . 0.0 111.798 -174.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . 0.412 ' CD1' ' HD2' ' B' ' 89' ' ' PRO . 17.0 t80 -72.37 136.14 81.5 Favored Pre-proline 0 CA--C 1.534 0.341 0 N-CA-C 113.365 0.876 . . . . 0.0 113.365 178.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . 0.412 ' HD2' ' CD1' ' B' ' 88' ' ' PHE . 47.6 Cg_endo . . . . . 0 C--O 1.25 1.081 0 C-N-CA 123.706 2.937 . . . . 0.0 111.076 -179.073 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 72.3 m . . . . . 0 CA--C 1.533 0.291 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 52.8 mtm180 -75.38 151.65 38.15 Favored 'General case' 0 N--CA 1.456 -0.138 0 C-N-CA 122.713 0.405 . . . . 0.0 111.781 178.014 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 pt -136.9 175.52 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 170.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -124.76 148.25 48.21 Favored 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 114.541 1.312 . . . . 0.0 114.541 -177.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.2 t -135.33 140.89 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.643 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.0 179.38 27.75 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 -178.038 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 57.4 t30 60.09 22.23 11.44 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.724 0.81 . . . . 0.0 111.251 -174.093 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 92.8 mt . . . . . 0 N--CA 1.451 -0.377 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 177.763 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.528 0.119 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -70.63 -26.69 63.59 Favored 'General case' 0 C--N 1.333 -0.124 0 O-C-N 121.966 -0.459 . . . . 0.0 110.365 178.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 81.0 mt -77.93 -24.03 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.096 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -80.24 -14.39 58.46 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 178.227 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -94.36 -71.45 0.66 Allowed 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 122.865 0.466 . . . . 0.0 111.858 174.11 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 53.5 t -64.12 -55.65 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.254 -171.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -68.01 -18.18 64.63 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -177.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.8 t -73.33 -31.57 64.07 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 175.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -73.08 -27.05 61.5 Favored 'General case' 0 C--N 1.343 0.314 0 O-C-N 122.071 -0.393 . . . . 0.0 110.609 172.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -79.07 -18.11 54.0 Favored 'General case' 0 N--CA 1.456 -0.153 0 N-CA-C 115.253 1.575 . . . . 0.0 115.253 176.1 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.35 167.26 32.9 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.608 -0.597 . . . . 0.0 111.608 177.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -75.86 105.57 6.97 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 80.6 mt -79.73 142.29 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.544 -178.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -105.94 -32.28 8.4 Favored 'General case' 0 N--CA 1.456 -0.128 0 C-N-CA 122.862 0.465 . . . . 0.0 109.869 172.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -152.38 155.46 37.65 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 114.271 1.211 . . . . 0.0 114.271 178.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 3.3 mp -117.06 149.95 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 175.191 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -146.28 52.88 1.13 Allowed 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 121.086 0.47 . . . . 0.0 109.801 -178.28 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.0 tp -63.06 135.2 57.11 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 122.678 0.391 . . . . 0.0 110.059 173.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 59.0 mttp -127.06 144.83 50.93 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 123.214 0.606 . . . . 0.0 110.645 178.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 66.8 m-20 . . . . . 0 C--O 1.232 0.139 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 171.35 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo . . . . . 0 N--CA 1.449 -1.105 0 N-CA-C 110.997 -0.424 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -152.82 165.66 34.69 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 -177.303 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.13 169.64 23.09 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 121.216 0.531 . . . . 0.0 111.46 -172.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -132.17 158.19 42.35 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 171.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 73.5 t -140.15 135.05 36.78 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.309 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -178.03 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 64.4 tt0 -110.58 112.03 23.66 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -80.73 162.4 24.13 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 176.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 89.2 tt0 -74.36 -37.8 63.38 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 174.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -125.24 147.48 57.53 Favored Pre-proline 0 CA--C 1.529 0.17 0 C-N-CA 123.602 0.761 . . . . 0.0 109.917 179.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.48 -16.57 30.7 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 123.367 2.711 . . . . 0.0 111.576 -178.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 23.3 ptt85 -71.74 -15.92 62.2 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 122.7 0.4 . . . . 0.0 111.314 -177.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.65 -21.31 60.32 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 179.163 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -70.79 -18.1 62.76 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -73.93 -17.81 60.97 Favored 'General case' 0 N--CA 1.454 -0.226 0 O-C-N 122.274 -0.266 . . . . 0.0 110.469 179.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 -97.85 -39.69 8.89 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.567 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -74.68 -31.35 61.88 Favored 'General case' 0 N--CA 1.453 -0.283 0 O-C-N 122.274 -0.267 . . . . 0.0 110.783 -178.705 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.43 ' O ' HG12 ' B' ' 71' ' ' VAL . 48.2 t -87.99 6.33 3.54 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 122.836 0.455 . . . . 0.0 111.6 -174.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.8 t -139.14 -23.04 0.91 Allowed 'General case' 0 C--O 1.232 0.146 0 O-C-N 121.819 -0.551 . . . . 0.0 111.722 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -96.22 -4.2 59.9 Favored Glycine 0 CA--C 1.526 0.737 0 CA-C-O 119.449 -0.639 . . . . 0.0 112.443 -178.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 3.9 tpp180 -147.48 -18.5 0.38 Allowed 'General case' 0 CA--C 1.529 0.161 0 CA-C-N 118.219 1.01 . . . . 0.0 111.993 -176.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -68.46 146.15 53.43 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.56 42.36 99.75 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-O 119.691 -0.505 . . . . 0.0 112.092 174.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 30.7 t80 -87.62 129.13 35.23 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 117.806 0.803 . . . . 0.0 113.028 -177.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -69.38 87.42 0.44 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 123.378 0.671 . . . . 0.0 111.442 -177.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 36.7 t80 -81.13 -177.63 6.54 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 31.1 t0 -69.7 85.2 0.46 Allowed 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.144 179.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.72 3.45 89.5 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-O 119.843 -0.42 . . . . 0.0 112.113 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 -133.67 -179.1 5.32 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 113.791 1.034 . . . . 0.0 113.791 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -143.19 117.85 9.82 Favored 'General case' 0 N--CA 1.456 -0.13 0 C-N-CA 123.346 0.658 . . . . 0.0 109.357 -176.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.77 154.08 37.97 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 122.569 0.348 . . . . 0.0 110.642 -177.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -124.35 118.93 27.85 Favored 'General case' 0 CA--C 1.516 -0.352 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 176.143 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 19.9 t -142.52 84.99 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 123.028 0.531 . . . . 0.0 110.109 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -143.58 161.11 39.35 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.175 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.7 p90 -77.74 152.26 80.27 Favored Pre-proline 0 CA--C 1.528 0.116 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 178.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo . . . . . 0 C--O 1.251 1.133 0 C-N-CA 123.526 2.817 . . . . 0.0 110.653 177.676 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 78.9 m . . . . . 0 N--CA 1.453 -0.304 0 N-CA-C 110.432 -0.21 . . . . 0.0 110.432 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 41.5 ttm105 -78.51 145.69 34.79 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 123.513 0.725 . . . . 0.0 110.385 -178.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.0 pt -142.76 172.87 7.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 CA-C-O 121.087 0.47 . . . . 0.0 110.92 -177.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -109.81 153.93 23.71 Favored 'General case' 0 C--O 1.233 0.221 0 C-N-CA 124.909 1.283 . . . . 0.0 113.602 -178.08 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 22.5 t -137.07 139.74 43.81 Favored 'Isoleucine or valine' 0 C--O 1.232 0.17 0 C-N-CA 123.367 0.667 . . . . 0.0 110.701 179.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -159.7 -177.7 33.03 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 40.2 t30 56.53 26.37 10.9 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.668 0.787 . . . . 0.0 111.107 -173.265 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 91.4 mt . . . . . 0 N--CA 1.454 -0.253 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 177.524 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.4 tptt . . . . . 0 CA--C 1.529 0.139 0 N-CA-C 111.492 0.182 . . . . 0.0 111.492 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -65.35 -24.5 67.27 Favored 'General case' 0 N--CA 1.456 -0.133 0 N-CA-C 112.674 0.62 . . . . 0.0 112.674 -179.099 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 6.9 tp -72.11 -20.93 20.33 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -90.37 -28.87 18.4 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.32 -32.46 64.6 Favored 'General case' 0 C--N 1.337 0.044 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -178.46 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 53.7 t -71.75 -45.29 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 177.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 35.5 m-85 -72.08 -30.41 65.09 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 47.1 t -68.33 -25.58 65.18 Favored 'General case' 0 C--N 1.34 0.179 0 CA-C-N 116.953 -0.112 . . . . 0.0 110.857 174.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -75.98 -32.64 59.56 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 176.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 14.6 m-85 -78.57 -15.76 58.2 Favored 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 115.534 1.679 . . . . 0.0 115.534 176.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 170.64 178.89 41.64 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 177.442 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.41 113.78 19.72 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 122.779 -0.247 . . . . 0.0 110.592 -178.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.6 mp -86.29 140.97 15.06 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 122.731 0.412 . . . . 0.0 109.9 176.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . 0.473 ' HE ' ' HA ' ' B' ' 43' ' ' ARG . 1.7 mmp_? -108.05 -31.85 7.78 Favored 'General case' 0 N--CA 1.456 -0.13 0 C-N-CA 122.969 0.508 . . . . 0.0 110.012 174.273 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -151.32 158.8 44.28 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . 0.571 HG22 ' H ' ' B' ' 47' ' ' LEU . 29.9 mm -140.2 151.03 21.32 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 124.153 0.981 . . . . 0.0 109.037 179.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -135.62 51.9 2.03 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 175.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . 0.571 ' H ' HG22 ' B' ' 45' ' ' ILE . 51.0 tp -53.38 130.52 35.54 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.101 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 18.3 ttmm -146.46 151.33 37.22 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -172.243 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 . . . . . 0 CA--C 1.532 0.26 0 C-N-CA 122.271 0.229 . . . . 0.0 111.544 -179.304 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo . . . . . 0 N--CA 1.452 -0.918 0 CA-C-O 121.111 0.379 . . . . 0.0 111.807 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -146.9 146.63 30.22 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 124.178 0.991 . . . . 0.0 112.307 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -160.43 157.05 27.05 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -175.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -112.69 151.57 30.06 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.854 167.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.6 t -135.2 136.63 51.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -176.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 78.8 tt0 -124.25 112.66 17.28 Favored 'General case' 0 N--CA 1.455 -0.176 0 CA-C-O 120.747 0.308 . . . . 0.0 110.637 -177.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -84.32 159.29 20.93 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 177.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 33.2 tp10 -78.14 -30.33 49.21 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.439 174.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -129.09 150.15 74.58 Favored Pre-proline 0 C--O 1.232 0.151 0 C-N-CA 123.573 0.749 . . . . 0.0 112.538 -178.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.99 -24.47 24.0 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 123.431 2.754 . . . . 0.0 110.921 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 38.6 mmt180 -76.52 -24.83 53.71 Favored 'General case' 0 C--N 1.339 0.131 0 C-N-CA 121.962 0.105 . . . . 0.0 110.757 179.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -75.19 -34.16 61.5 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-O 120.416 0.151 . . . . 0.0 111.271 175.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -73.04 -32.54 65.13 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 176.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -65.81 -33.87 76.86 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.151 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -76.06 -35.62 59.35 Favored 'General case' 0 N--CA 1.457 -0.125 0 N-CA-C 113.249 0.833 . . . . 0.0 113.249 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.73 -29.16 63.13 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 122.365 -0.21 . . . . 0.0 110.505 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 55.9 t -81.43 -52.47 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.0 t -70.29 -17.27 63.09 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -174.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.03 -1.76 45.28 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-O 119.161 -0.799 . . . . 0.0 113.868 -173.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 30.1 ttp-105 -153.23 -14.02 0.15 Allowed 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 119.003 1.402 . . . . 0.0 113.19 -175.048 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -69.28 146.71 52.04 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 118.673 0.67 . . . . 0.0 110.037 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.75 38.25 95.63 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-O 119.562 -0.577 . . . . 0.0 112.313 172.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 37.8 t80 -88.24 130.04 35.19 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 118.089 0.945 . . . . 0.0 112.968 -176.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 29.6 t0 -68.75 89.37 0.39 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.369 0.668 . . . . 0.0 111.091 -178.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 35.7 t80 -81.17 -174.62 4.99 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -69.49 74.05 0.37 Allowed 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 123.765 0.826 . . . . 0.0 111.997 178.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.47 6.83 70.17 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 -179.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -133.19 -179.31 5.42 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -179.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 9.5 tpp180 -143.08 114.38 7.88 Favored 'General case' 0 CA--C 1.528 0.132 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -175.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -61.9 153.13 29.99 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.811 0.444 . . . . 0.0 110.245 -177.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 74.8 mtt180 -129.11 115.31 17.52 Favored 'General case' 0 CA--C 1.52 -0.185 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 177.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 38.7 t -143.14 85.14 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.183 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -148.58 165.3 31.66 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.641 0.258 . . . . 0.0 110.589 -174.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -81.79 156.82 70.0 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 113.755 1.021 . . . . 0.0 113.755 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo . . . . . 0 C--O 1.252 1.215 0 C-N-CA 123.895 3.064 . . . . 0.0 111.639 177.684 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 80.9 m . . . . . 0 CA--C 1.53 0.191 0 N-CA-C 111.598 0.221 . . . . 0.0 111.598 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . 0.414 ' HA ' ' HA ' ' B' ' 60' ' ' GLU . 27.5 ttm180 -74.38 149.61 40.43 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 122.831 0.452 . . . . 0.0 111.239 -175.002 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.3 pt -131.08 -178.8 2.84 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.09 0 C-N-CA 123.876 0.87 . . . . 0.0 109.645 178.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -120.66 150.2 41.3 Favored 'General case' 0 C--O 1.231 0.12 0 N-CA-C 114.462 1.282 . . . . 0.0 114.462 -173.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 46.3 t -141.05 142.29 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 C-N-CA 123.928 0.891 . . . . 0.0 109.019 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.54 -178.95 33.03 Favored Glycine 0 C--N 1.338 0.665 0 C-N-CA 121.277 -0.487 . . . . 0.0 112.515 -175.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 48.5 t30 56.48 25.96 10.32 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.245 1.018 . . . . 0.0 111.376 -176.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.8 mt . . . . . 0 CA--C 1.531 0.223 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.727 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 58.2 tptt . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 111.132 0.049 . . . . 0.0 111.132 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -65.61 -23.07 66.74 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 122.118 -0.364 . . . . 0.0 111.451 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mp -70.86 -22.47 23.1 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 178.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -96.45 -38.4 10.04 Favored 'General case' 0 N--CA 1.453 -0.305 0 O-C-N 122.359 -0.213 . . . . 0.0 110.824 -178.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -67.62 -45.71 74.64 Favored 'General case' 0 N--CA 1.458 -0.057 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -175.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 91.1 t -72.26 -42.37 66.06 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -178.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -75.32 -26.68 58.85 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -177.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.2 t -70.73 -31.0 67.69 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-O 120.557 0.218 . . . . 0.0 110.43 174.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 28.9 tptp -70.82 -31.33 68.02 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -85.22 -13.0 51.28 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 116.082 1.882 . . . . 0.0 116.082 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.18 171.98 38.32 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.303 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -79.1 104.46 9.74 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 122.669 0.387 . . . . 0.0 110.406 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 83.5 mt -75.58 147.27 8.25 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.145 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 176.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -131.02 -19.41 2.87 Favored 'General case' 0 C--N 1.34 0.168 0 C-N-CA 122.523 0.329 . . . . 0.0 111.12 175.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -153.7 156.03 37.08 Favored 'General case' 0 CA--C 1.528 0.102 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 174.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 18.9 mm -136.19 152.85 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.122 0 C-N-CA 123.737 0.815 . . . . 0.0 109.253 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -145.72 46.73 1.27 Allowed 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 178.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 28.6 tp -58.27 133.99 56.16 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 174.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 56.0 mttp -127.56 145.49 50.84 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 123.655 0.782 . . . . 0.0 110.608 178.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.4 p-10 . . . . . 0 CA--C 1.533 0.289 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 171.899 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo . . . . . 0 N--CA 1.454 -0.838 0 CA-C-O 120.79 0.246 . . . . 0.0 112.065 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -157.74 166.47 32.68 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.14 172.68 18.02 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-O 121.174 0.512 . . . . 0.0 112.089 -172.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -131.67 146.58 52.25 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 171.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 96.6 t -132.41 132.41 60.37 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.265 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -174.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . 0.414 ' HA ' ' HA ' ' B' ' 17' ' ' ARG . 76.2 tt0 -116.36 120.39 38.71 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 120.581 0.229 . . . . 0.0 111.433 -175.525 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -90.49 161.7 15.39 Favored 'General case' 0 C--O 1.232 0.16 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 177.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -71.6 -33.4 68.98 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 174.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -128.96 150.39 75.12 Favored Pre-proline 0 CA--C 1.53 0.189 0 C-N-CA 123.689 0.795 . . . . 0.0 111.795 -178.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.86 -13.89 32.23 Favored 'Trans proline' 0 N--CA 1.452 -0.913 0 C-N-CA 123.214 2.609 . . . . 0.0 110.364 176.499 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 32.5 ttp-105 -65.26 -38.25 89.72 Favored 'General case' 0 CA--C 1.528 0.124 0 C-N-CA 123.323 0.649 . . . . 0.0 110.545 178.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -77.67 -20.3 53.96 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -176.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.79 -29.94 65.0 Favored 'General case' 0 N--CA 1.452 -0.364 0 O-C-N 122.527 -0.108 . . . . 0.0 110.711 -177.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -72.89 -27.24 61.77 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.327 -0.233 . . . . 0.0 110.61 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -80.1 -36.45 35.41 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -178.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -76.55 -28.39 56.26 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 110.572 -0.158 . . . . 0.0 110.572 -178.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.5 t -79.33 -58.66 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 69.9 m -73.5 -3.33 26.95 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -175.537 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -85.41 -19.94 57.67 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 119.32 -0.711 . . . . 0.0 112.828 -176.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 24.7 ptt-85 -161.64 18.45 0.11 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 118.604 1.202 . . . . 0.0 113.009 -174.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -66.9 140.96 57.8 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.97 0.73 . . . . 0.0 112.97 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 60.28 70.87 0.89 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.828 -0.509 . . . . 0.0 111.828 174.031 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 59.6 t80 -110.73 137.91 47.79 Favored 'General case' 0 C--N 1.339 0.138 0 N-CA-C 113.571 0.952 . . . . 0.0 113.571 179.215 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -64.42 108.47 1.64 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 124.392 1.077 . . . . 0.0 112.988 -175.086 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.412 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.9 t80 -113.9 169.3 9.1 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.849 0.86 . . . . 0.0 111.26 175.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.412 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 75.7 m-20 -59.81 97.18 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -179.193 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 80.08 -5.65 62.07 Favored Glycine 0 CA--C 1.534 1.281 0 CA-C-O 119.315 -0.714 . . . . 0.0 112.643 177.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -139.4 -171.02 3.03 Favored 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 118.296 1.048 . . . . 0.0 113.362 -177.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -142.04 128.96 20.67 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -177.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.6 mp -63.39 150.09 44.34 Favored 'General case' 0 C--N 1.335 -0.049 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -123.11 124.87 44.05 Favored 'General case' 0 CA--C 1.52 -0.194 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.184 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.3 t -147.29 79.73 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.088 0 C-N-CA 123.603 0.761 . . . . 0.0 109.269 178.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.9 pt-20 -147.08 165.03 31.17 Favored 'General case' 0 C--O 1.226 -0.155 0 C-N-CA 122.667 0.387 . . . . 0.0 110.442 -177.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . 0.405 ' HA ' ' HD3' ' B' ' 89' ' ' PRO . 3.7 p90 -80.01 153.72 74.96 Favored Pre-proline 0 C--O 1.234 0.275 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 176.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' B' ' 88' ' ' PHE . 37.1 Cg_exo . . . . . 0 C--O 1.249 1.051 0 C-N-CA 123.746 2.964 . . . . 0.0 111.728 175.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.7 m . . . . . 0 CA--C 1.531 0.247 0 N-CA-C 111.412 0.153 . . . . 0.0 111.412 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 39.9 ttm180 -75.87 148.6 38.19 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 123.943 0.897 . . . . 0.0 110.49 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 14.2 pt -129.6 176.26 8.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 C-N-CA 122.897 0.479 . . . . 0.0 109.923 178.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -115.49 153.42 31.16 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -173.297 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 79.2 t -138.09 100.26 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -82.66 160.03 38.96 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 175.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 40.8 t30 60.51 -171.56 0.14 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.153 0.581 . . . . 0.0 110.25 -176.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.6 tp . . . . . 0 CA--C 1.533 0.314 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.645 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.2 tptt . . . . . 0 CA--C 1.528 0.132 0 N-CA-C 111.298 0.11 . . . . 0.0 111.298 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 71.1 m-20 -67.93 -19.76 65.01 Favored 'General case' 0 N--CA 1.457 -0.123 0 O-C-N 122.389 -0.195 . . . . 0.0 111.455 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 7.9 tp -73.19 -14.3 16.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 177.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -103.55 -21.25 13.78 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -71.09 -51.46 25.01 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.432 0.293 . . . . 0.0 111.585 -177.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 m -67.91 -33.42 61.25 Favored 'Isoleucine or valine' 0 C--N 1.338 0.082 0 CA-C-O 120.515 0.198 . . . . 0.0 110.929 -179.026 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -74.42 -35.15 63.39 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 176.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.4 t -66.66 -25.55 66.62 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.575 0.226 . . . . 0.0 110.599 175.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 29.2 tptp -77.72 -33.1 53.16 Favored 'General case' 0 N--CA 1.456 -0.149 0 N-CA-C 110.275 -0.268 . . . . 0.0 110.275 177.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -85.44 -9.24 57.77 Favored 'General case' 0 CA--C 1.53 0.184 0 N-CA-C 116.394 1.998 . . . . 0.0 116.394 179.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.42 178.54 44.4 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.73 177.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -79.41 43.26 0.54 Allowed 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.937 0.895 . . . . 0.0 110.99 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . 0.584 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.8 mp -55.77 138.25 16.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 122.695 0.398 . . . . 0.0 110.089 179.22 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 56.7 mmm-85 -94.69 -54.64 3.42 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.175 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -133.44 150.62 51.76 Favored 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -170.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -112.52 151.04 14.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.203 0 C-N-CA 124.596 1.158 . . . . 0.0 108.26 173.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -143.7 68.74 1.28 Allowed 'General case' 0 N--CA 1.452 -0.329 0 CA-C-O 120.694 0.283 . . . . 0.0 111.164 178.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 44.1 tp -70.91 129.54 39.31 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.178 174.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -114.41 140.28 48.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 123.089 0.556 . . . . 0.0 110.085 178.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 46.0 p-10 . . . . . 0 CA--C 1.532 0.28 0 C-N-CA 123.877 0.871 . . . . 0.0 111.179 -178.326 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo . . . . . 0 N--CA 1.448 -1.172 0 N-CA-C 110.242 -0.715 . . . . 0.0 110.242 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -157.59 162.98 38.77 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -178.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -146.62 173.68 12.12 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-O 121.083 0.468 . . . . 0.0 111.387 -172.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -138.68 160.67 39.06 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.336 175.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 81.9 t -137.76 134.75 45.85 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 55.1 tt0 -115.52 127.23 55.14 Favored 'General case' 0 N--CA 1.453 -0.295 0 CA-C-O 120.773 0.32 . . . . 0.0 110.741 -174.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.584 ' CE2' HD11 ' B' ' 42' ' ' ILE . 18.4 m-85 -95.17 151.52 19.14 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 115.314 1.598 . . . . 0.0 115.314 -172.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 49.8 tp10 -80.49 -26.24 38.33 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 168.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -153.05 117.54 2.85 Favored Pre-proline 0 N--CA 1.453 -0.294 0 C-N-CA 124.125 0.97 . . . . 0.0 109.468 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -66.86 -6.1 14.94 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 123.225 2.616 . . . . 0.0 112.429 -174.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 60.1 ttt85 -65.36 -28.88 69.6 Favored 'General case' 0 N--CA 1.456 -0.159 0 CA-C-N 118.022 0.374 . . . . 0.0 110.576 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -78.7 -15.8 58.03 Favored 'General case' 0 CA--C 1.531 0.213 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.21 -20.47 63.97 Favored 'General case' 0 N--CA 1.451 -0.411 0 O-C-N 122.198 -0.314 . . . . 0.0 110.428 -177.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -64.75 -26.95 68.58 Favored 'General case' 0 CA--C 1.532 0.266 0 O-C-N 122.055 -0.403 . . . . 0.0 110.336 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -90.88 -36.56 14.1 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 112.561 0.578 . . . . 0.0 112.561 178.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.67 -28.44 62.71 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 122.41 0.284 . . . . 0.0 110.723 -177.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 49.7 t -75.24 0.0 2.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 32.5 t -135.35 5.49 3.23 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.763 -0.586 . . . . 0.0 110.943 178.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -77.94 -28.87 55.77 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-O 119.694 -0.503 . . . . 0.0 112.129 -177.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 50.1 ttt180 -158.45 13.46 0.18 Allowed 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 117.624 0.712 . . . . 0.0 110.89 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 29.9 t0 -69.55 150.07 47.52 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 122.102 -0.374 . . . . 0.0 110.246 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.28 38.13 95.97 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 111.803 -0.519 . . . . 0.0 111.803 175.538 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 31.0 t80 -98.97 132.78 44.03 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 113.149 0.796 . . . . 0.0 113.149 -173.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -61.62 104.35 0.42 Allowed 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 123.559 0.744 . . . . 0.0 112.149 -179.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.496 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 66.2 t80 -110.35 173.44 6.33 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 123.586 0.754 . . . . 0.0 111.803 178.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.496 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.7 t0 -62.43 100.03 0.17 Allowed 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.67 -8.22 29.15 Favored Glycine 0 CA--C 1.531 1.076 0 C-N-CA 123.435 0.541 . . . . 0.0 112.936 177.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -138.9 -169.92 2.74 Favored 'General case' 0 C--N 1.34 0.172 0 N-CA-C 113.133 0.79 . . . . 0.0 113.133 -178.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 38.3 ttt180 -145.46 134.68 22.87 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -177.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -62.71 144.34 56.48 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -178.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 56.7 mtm180 -132.43 71.97 1.48 Allowed 'General case' 0 C--N 1.339 0.127 0 C-N-CA 122.728 0.411 . . . . 0.0 110.809 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.83 92.31 3.81 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.103 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 177.338 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.5 pt-20 -151.04 159.72 44.36 Favored 'General case' 0 C--N 1.334 -0.102 0 C-N-CA 122.658 0.383 . . . . 0.0 110.827 178.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -73.65 153.4 89.51 Favored Pre-proline 0 C--O 1.235 0.303 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo . . . . . 0 C--O 1.251 1.173 0 C-N-CA 123.839 3.026 . . . . 0.0 110.543 176.138 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 93.7 m . . . . . 0 CA--C 1.533 0.309 0 CA-C-O 120.483 0.182 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 49.2 mtt180 -73.12 156.61 38.49 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.448 0.699 . . . . 0.0 112.57 -179.128 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.0 pt -132.41 175.96 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.068 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 173.089 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -119.3 147.63 44.08 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -174.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 24.8 t -132.42 138.5 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 C-N-CA 123.312 0.645 . . . . 0.0 110.368 -179.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -143.6 -179.43 20.18 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -177.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 64.4 t30 59.48 24.4 13.07 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.812 0.845 . . . . 0.0 111.325 -173.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 96.1 mt . . . . . 0 CA--C 1.533 0.309 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 176.594 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.456 -0.162 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -75.55 -39.26 58.48 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 117.774 0.261 . . . . 0.0 111.109 179.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.412 HG22 ' H ' ' B' ' 32' ' ' ILE . 12.6 tt -78.18 -21.28 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 CA-C-N 116.688 -0.233 . . . . 0.0 110.667 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.4 mt-10 -77.29 -39.39 48.19 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.108 -0.37 . . . . 0.0 110.494 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -74.3 -33.64 63.27 Favored 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -179.287 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 41.3 t -71.3 -48.14 55.86 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -74.58 -31.79 62.18 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 39.1 t -67.81 -30.73 70.22 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.933 177.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -77.66 -26.79 50.64 Favored 'General case' 0 C--O 1.232 0.138 0 O-C-N 122.366 -0.209 . . . . 0.0 111.075 175.529 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -87.45 -8.31 56.63 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 116.435 2.013 . . . . 0.0 116.435 177.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 175.37 174.17 41.73 Favored Glycine 0 CA--C 1.524 0.599 0 C-N-CA 121.1 -0.571 . . . . 0.0 112.483 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.46 40.44 0.57 Allowed 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 123.767 0.827 . . . . 0.0 111.348 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . 0.593 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.9 mp -52.8 136.07 13.97 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.066 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 18.8 mmt85 -93.61 -35.18 13.0 Favored 'General case' 0 C--O 1.23 0.073 0 CA-C-O 119.492 -0.289 . . . . 0.0 111.691 -175.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -148.54 150.34 33.19 Favored 'General case' 0 C--O 1.232 0.147 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -177.794 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -115.15 151.8 16.84 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 C-N-CA 124.344 1.057 . . . . 0.0 108.278 174.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 61.6 t0 -148.16 75.12 1.32 Allowed 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.136 0.493 . . . . 0.0 110.221 179.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 53.9 tp -71.05 146.03 49.57 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.526 176.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 25.1 ttmm -146.41 141.09 26.82 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 176.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 45.8 p30 . . . . . 0 CA--C 1.53 0.174 0 N-CA-C 111.832 0.308 . . . . 0.0 111.832 -176.048 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_exo . . . . . 0 N--CA 1.451 -0.981 0 CA-C-O 120.839 0.266 . . . . 0.0 112.164 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -162.61 169.4 20.22 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -151.78 159.24 43.99 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.184 0.516 . . . . 0.0 111.68 -174.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -112.72 151.05 30.69 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.11 172.106 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.2 t -135.96 132.33 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.148 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -178.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 69.9 tt0 -110.57 116.27 31.07 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 122.445 0.298 . . . . 0.0 111.155 -173.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.593 ' CE2' HD11 ' B' ' 42' ' ' ILE . 29.7 m-85 -92.51 154.8 18.24 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -80.71 -29.97 36.38 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 171.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -159.93 151.17 16.14 Favored Pre-proline 0 CA--C 1.531 0.212 0 C-N-CA 125.267 1.427 . . . . 0.0 111.589 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.39 -3.04 12.2 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 123.6 2.867 . . . . 0.0 112.484 -176.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -63.52 -25.49 68.27 Favored 'General case' 0 CA--C 1.529 0.152 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -176.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -89.58 -5.15 57.46 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -177.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.15 -14.2 62.85 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 122.408 -0.183 . . . . 0.0 110.818 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -65.86 -17.33 64.57 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 122.419 -0.176 . . . . 0.0 111.17 -178.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -123.5 -37.43 2.66 Favored 'General case' 0 C--O 1.231 0.122 0 C-N-CA 122.975 0.51 . . . . 0.0 112.142 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -79.76 -9.92 59.72 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 122.58 0.352 . . . . 0.0 111.634 -175.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 60.4 t -131.79 -53.69 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 C-N-CA 122.374 0.27 . . . . 0.0 110.724 -178.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 70.5 m -70.71 -6.53 38.0 Favored 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 122.208 0.203 . . . . 0.0 111.343 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -116.09 10.44 17.79 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 119.543 -0.587 . . . . 0.0 111.764 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' B' ' 74' ' ' ARG . 46.0 ttm180 -145.05 -20.41 0.5 Allowed 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 117.933 0.866 . . . . 0.0 111.984 -176.096 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -68.89 136.16 52.18 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.315 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 67.7 27.49 73.6 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 119.779 -0.456 . . . . 0.0 112.068 176.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 50.4 t80 -79.95 140.62 36.58 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 -172.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.7 t0 -59.34 102.52 0.14 Allowed 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -175.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.414 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 73.9 t80 -111.8 172.26 7.0 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 123.71 0.804 . . . . 0.0 110.743 176.026 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.414 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 17.6 t0 -62.4 98.35 0.11 Allowed 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.58 -5.8 55.42 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 119.599 -0.556 . . . . 0.0 112.887 177.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -142.2 -175.56 4.48 Favored 'General case' 0 CA--C 1.527 0.072 0 CA-C-N 117.945 0.872 . . . . 0.0 112.882 -178.083 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 93.1 mtt-85 -131.87 138.46 48.45 Favored 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 124.191 0.996 . . . . 0.0 109.829 176.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -59.85 154.38 18.64 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 178.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . 0.407 ' NE ' ' HA ' ' B' ' 85' ' ' ARG . 1.3 tpm_? -122.42 116.45 24.0 Favored 'General case' 0 CA--C 1.518 -0.255 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 176.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 15.2 t -135.1 89.48 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 O-C-N 123.378 0.424 . . . . 0.0 110.063 178.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -146.89 158.18 43.85 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.361 178.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -76.56 155.09 83.69 Favored Pre-proline 0 CA--C 1.532 0.276 0 N-CA-C 114.224 1.194 . . . . 0.0 114.224 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo . . . . . 0 C--O 1.251 1.14 0 C-N-CA 123.702 2.934 . . . . 0.0 111.46 175.29 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 8.2 p . . . . . 0 C--O 1.233 0.234 0 N-CA-C 111.669 0.248 . . . . 0.0 111.669 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -63.11 144.71 56.66 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 122.857 0.463 . . . . 0.0 111.808 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.7 pt -131.67 173.16 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.885 174.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -111.97 150.62 30.29 Favored 'General case' 0 N--CA 1.457 -0.115 0 C-N-CA 124.356 1.062 . . . . 0.0 113.383 -177.667 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 25.9 t -133.32 91.71 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.145 0 C-N-CA 122.964 0.506 . . . . 0.0 110.35 -176.54 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -91.49 165.73 30.06 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 111.594 -0.602 . . . . 0.0 111.594 179.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 62.9 t30 59.96 21.09 10.13 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.026 0.93 . . . . 0.0 111.669 -176.398 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 21.0 tp . . . . . 0 CA--C 1.535 0.367 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.204 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.0 tptm . . . . . 0 C--O 1.227 -0.096 0 CA-C-O 119.916 -0.088 . . . . 0.0 111.129 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 -63.71 -19.1 64.66 Favored 'General case' 0 N--CA 1.456 -0.167 0 O-C-N 122.048 -0.407 . . . . 0.0 110.532 175.392 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 tt -67.43 -16.1 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 123.028 0.531 . . . . 0.0 110.908 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -130.66 -22.33 2.69 Favored 'General case' 0 C--N 1.341 0.198 0 CA-C-N 118.162 0.437 . . . . 0.0 111.915 177.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 66.4 m-20 -70.9 -29.76 65.92 Favored 'General case' 0 C--O 1.232 0.151 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 176.464 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 52.4 t -67.93 -40.8 84.02 Favored 'Isoleucine or valine' 0 C--N 1.34 0.156 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 174.255 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -67.6 -32.04 72.5 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 113.086 0.772 . . . . 0.0 113.086 176.13 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 54.5 m -65.75 -24.64 67.0 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.993 -0.094 . . . . 0.0 110.819 175.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 14.3 tmtt? -74.5 -34.56 63.09 Favored 'General case' 0 CA--C 1.531 0.25 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 173.091 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . 0.412 ' CD1' ' HA ' ' B' ' 70' ' ' ALA . 40.0 m-85 -72.04 -20.86 61.62 Favored 'General case' 0 CA--C 1.529 0.169 0 N-CA-C 115.582 1.697 . . . . 0.0 115.582 175.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 161.72 -169.43 37.17 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 178.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.41 108.51 17.26 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 120.778 0.323 . . . . 0.0 111.174 -177.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . 0.438 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.8 mp -97.55 147.66 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.157 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 173.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -115.3 -24.05 8.63 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 119.384 -0.341 . . . . 0.0 111.209 177.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -151.38 158.78 44.2 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 114.071 1.137 . . . . 0.0 114.071 -179.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . 0.414 HD12 ' HA ' ' B' ' 45' ' ' ILE . 10.9 tp -124.28 159.67 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 176.318 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -153.19 63.28 0.76 Allowed 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.826 0.346 . . . . 0.0 110.752 -177.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.1 tp -63.37 135.89 57.28 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 175.198 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . 0.528 ' HE2' ' CZ ' ' B' ' 56' ' ' PHE . 35.5 mtmm -141.09 176.43 8.83 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 123.795 0.838 . . . . 0.0 111.239 -178.327 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.5 p30 . . . . . 0 C--O 1.233 0.21 0 C-N-CA 122.928 0.491 . . . . 0.0 110.661 -178.962 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo . . . . . 0 N--CA 1.451 -1.012 0 N-CA-C 110.435 -0.64 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . 0.528 ' CZ ' ' HE2' ' B' ' 48' ' ' LYS . 3.1 p90 -155.34 167.34 30.69 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -146.83 156.98 43.54 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.133 0.492 . . . . 0.0 111.74 -175.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -106.78 150.85 25.9 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 115.179 -0.919 . . . . 0.0 112.332 170.202 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 72.8 t -131.82 137.98 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.264 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 -179.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -122.17 118.42 28.59 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.69 0.281 . . . . 0.0 110.557 -177.234 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.438 ' CE2' HD11 ' B' ' 42' ' ' ILE . 54.2 m-85 -85.52 151.85 23.63 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 115.39 1.626 . . . . 0.0 115.39 -177.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 40.3 tp10 -78.53 -18.4 54.78 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.379 0.672 . . . . 0.0 109.851 173.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -148.44 119.53 4.32 Favored Pre-proline 0 CA--C 1.532 0.269 0 C-N-CA 123.482 0.713 . . . . 0.0 110.072 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_exo -55.08 -20.5 24.0 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.411 2.741 . . . . 0.0 113.324 -177.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 53.3 tpt85 -69.54 -32.55 71.43 Favored 'General case' 0 C--N 1.342 0.243 0 CA-C-N 118.295 0.498 . . . . 0.0 110.971 179.578 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -74.05 -24.39 59.52 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -179.867 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.46 -24.11 64.67 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.239 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -73.79 -27.71 61.27 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 178.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 77.4 m-20 -78.04 -38.43 44.61 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 112.386 0.513 . . . . 0.0 112.386 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . 0.412 ' HA ' ' CD1' ' B' ' 39' ' ' TYR . . . -70.77 -31.05 67.71 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 110.343 -0.243 . . . . 0.0 110.343 178.389 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 37.3 t -80.6 -43.91 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 46.0 t -66.27 -20.97 66.26 Favored 'General case' 0 CA--C 1.533 0.29 0 O-C-N 122.197 -0.315 . . . . 0.0 111.127 -177.467 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -91.03 -15.27 56.43 Favored Glycine 0 CA--C 1.529 0.938 0 CA-C-O 119.307 -0.718 . . . . 0.0 113.17 -177.001 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 62.7 mtt180 -147.62 21.54 1.16 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.448 1.124 . . . . 0.0 113.045 -172.275 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 16.5 p30 -69.32 1.71 3.58 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 177.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.24 90.44 0.08 OUTLIER Glycine 0 C--N 1.336 0.582 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -125.53 139.49 53.56 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 178.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -64.39 106.5 1.13 Allowed 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.628 0.771 . . . . 0.0 112.65 -177.066 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.444 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.0 t80 -111.46 170.35 8.18 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 123.677 0.791 . . . . 0.0 111.446 177.348 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.444 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.1 t0 -59.15 100.9 0.08 Allowed 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -179.198 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 75.81 -5.28 40.32 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-O 119.661 -0.522 . . . . 0.0 112.888 177.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -141.43 -169.49 2.88 Favored 'General case' 0 C--O 1.232 0.161 0 N-CA-C 113.513 0.931 . . . . 0.0 113.513 -177.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 42.2 ttp-105 -142.04 139.31 32.29 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.672 0.789 . . . . 0.0 109.162 179.22 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.72 151.15 45.85 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 -178.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 90.1 mtm-85 -133.61 56.17 1.86 Allowed 'General case' 0 C--N 1.339 0.135 0 CA-C-O 120.75 0.31 . . . . 0.0 110.799 177.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 23.1 t -82.21 93.95 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 175.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.9 pt-20 -151.9 162.72 40.6 Favored 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 122.51 0.324 . . . . 0.0 110.205 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.4 p90 -78.09 157.56 78.4 Favored Pre-proline 0 N--CA 1.453 -0.306 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 177.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo . . . . . 0 C--O 1.252 1.219 0 C-N-CA 123.903 3.069 . . . . 0.0 111.658 177.45 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 75.2 m . . . . . 0 CA--C 1.531 0.244 0 N-CA-C 111.34 0.126 . . . . 0.0 111.34 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 48.8 mtt-85 -78.51 151.1 32.73 Favored 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 112.705 0.631 . . . . 0.0 112.705 -177.164 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.4 pt -139.14 171.59 14.44 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 C-N-CA 123.507 0.723 . . . . 0.0 109.524 174.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . 0.4 ' HB2' ' CZ ' ' B' ' 58' ' ' PHE . 0.3 OUTLIER -113.21 153.12 28.86 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -175.99 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 58.7 t -136.77 140.89 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.317 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -146.87 174.62 26.63 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.925 -0.47 . . . . 0.0 111.925 -176.504 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 66.3 t30 62.91 157.35 0.06 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.772 1.229 . . . . 0.0 111.463 -172.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.2 tp . . . . . 0 N--CA 1.453 -0.306 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.734 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . 0.425 ' HE3' ' HB2' ' B' ' 30' ' ' LYS . 0.0 OUTLIER . . . . . 0 CA--C 1.527 0.085 0 N-CA-C 111.427 0.158 . . . . 0.0 111.427 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -64.65 -19.75 65.89 Favored 'General case' 0 N--CA 1.457 -0.112 0 O-C-N 122.116 -0.365 . . . . 0.0 111.979 178.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 7.5 tp -71.64 -17.69 19.59 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 175.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 81.6 mt-10 -94.96 -36.52 11.55 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -69.52 -39.97 77.2 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -177.023 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 77.1 t -72.14 -41.89 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.075 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 39.0 m-85 -74.06 -37.78 64.16 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 114.02 1.119 . . . . 0.0 114.02 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 91.7 p -69.21 -22.12 63.9 Favored 'General case' 0 C--N 1.34 0.175 0 CA-C-N 117.729 0.241 . . . . 0.0 110.422 177.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -74.73 -34.06 62.49 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -81.22 -13.26 58.72 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 115.926 1.825 . . . . 0.0 115.926 177.708 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.16 175.37 43.47 Favored Glycine 0 CA--C 1.527 0.819 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.053 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -82.27 80.02 8.58 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.097 0.559 . . . . 0.0 110.601 -178.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.7 mp -65.51 140.22 20.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.105 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 174.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . 0.43 ' HE ' ' HA ' ' B' ' 43' ' ' ARG . 1.7 mmp_? -109.76 -27.84 9.12 Favored 'General case' 0 N--CA 1.457 -0.082 0 C-N-CA 122.869 0.467 . . . . 0.0 110.739 177.361 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -151.79 163.43 39.18 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 113.815 1.042 . . . . 0.0 113.815 -179.223 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 7.6 tp -142.17 160.56 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -177.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -153.95 68.55 0.76 Allowed 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 176.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 49.0 tp -69.3 133.31 47.71 Favored 'General case' 0 CA--C 1.529 0.141 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 175.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . 0.485 ' HD2' ' CZ ' ' B' ' 56' ' ' PHE . 67.3 mttm -126.5 128.84 47.55 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 122.559 0.344 . . . . 0.0 110.542 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 10.1 p30 . . . . . 0 CA--C 1.533 0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.124 175.879 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo . . . . . 0 N--CA 1.449 -1.142 0 N-CA-C 110.247 -0.713 . . . . 0.0 110.247 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . 0.485 ' CZ ' ' HD2' ' B' ' 48' ' ' LYS . 3.3 p90 -161.58 171.69 17.6 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 178.097 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.38 164.37 38.37 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.213 0.53 . . . . 0.0 111.691 -175.743 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . 0.4 ' CZ ' ' HB2' ' B' ' 19' ' ' TYR . 9.7 m-85 -116.81 151.62 36.11 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.372 -0.831 . . . . 0.0 113.073 169.396 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 48.2 t -133.41 142.23 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 C-N-CA 123.189 0.596 . . . . 0.0 109.62 -177.212 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -123.99 117.82 25.62 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 110.444 -0.206 . . . . 0.0 110.444 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 49.3 m-85 -90.33 158.27 17.22 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 113.774 1.027 . . . . 0.0 113.774 177.771 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -70.77 -24.28 62.56 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 174.042 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -152.64 155.52 32.64 Favored Pre-proline 0 CA--C 1.533 0.314 0 C-N-CA 123.367 0.667 . . . . 0.0 111.952 178.511 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -71.92 -7.74 21.65 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 123.054 2.502 . . . . 0.0 111.359 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.28 -53.93 14.77 Favored 'General case' 0 C--N 1.339 0.12 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -177.112 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -70.75 -20.22 62.65 Favored 'General case' 0 C--O 1.233 0.185 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -177.564 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.05 -23.92 65.93 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 45.6 tp10 -72.77 -32.48 65.64 Favored 'General case' 0 N--CA 1.455 -0.2 0 O-C-N 122.273 -0.267 . . . . 0.0 110.318 179.539 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 62.0 m-20 -73.49 -36.8 65.84 Favored 'General case' 0 CA--C 1.522 -0.116 0 N-CA-C 111.979 0.362 . . . . 0.0 111.979 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.8 -27.92 63.26 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 122.164 0.186 . . . . 0.0 110.557 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 42.6 t -83.19 -54.32 9.49 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.2 t -70.68 -18.91 62.83 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 -174.17 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -101.31 0.54 53.91 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-O 119.031 -0.872 . . . . 0.0 113.585 -173.04 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 28.9 ttp-105 -153.78 -13.18 0.14 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-N 118.846 1.323 . . . . 0.0 113.393 -175.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -67.68 145.69 54.53 Favored 'General case' 0 C--O 1.233 0.226 0 O-C-N 121.465 -0.772 . . . . 0.0 110.315 179.485 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.51 55.17 26.95 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.554 -0.618 . . . . 0.0 111.554 175.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 39.2 t80 -105.96 140.38 39.06 Favored 'General case' 0 N--CA 1.453 -0.288 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -178.094 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -62.91 110.55 1.81 Allowed 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 124.2 1.0 . . . . 0.0 113.012 -175.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.421 ' CD2' ' N ' ' B' ' 80' ' ' ASP . 25.6 t80 -118.88 165.93 13.45 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 123.66 0.784 . . . . 0.0 111.941 174.756 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.421 ' N ' ' CD2' ' B' ' 79' ' ' TYR . 19.4 t0 -59.07 98.09 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.436 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -178.661 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.9 -4.91 63.79 Favored Glycine 0 CA--C 1.535 1.285 0 CA-C-O 119.747 -0.474 . . . . 0.0 112.677 177.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -140.56 -170.22 2.96 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 117.952 0.876 . . . . 0.0 113.15 -178.185 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 -141.38 133.35 27.59 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 -178.158 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -65.13 152.03 44.6 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.27 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -125.72 126.92 45.39 Favored 'General case' 0 CA--C 1.52 -0.173 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 175.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 38.9 t -143.95 81.26 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.245 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 176.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -139.8 158.22 44.45 Favored 'General case' 0 C--O 1.224 -0.281 0 C-N-CA 122.664 0.386 . . . . 0.0 110.551 -175.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.0 p90 -74.54 154.79 87.64 Favored Pre-proline 0 N--CA 1.454 -0.269 0 N-CA-C 114.73 1.381 . . . . 0.0 114.73 179.245 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo . . . . . 0 C--O 1.253 1.255 0 C-N-CA 123.646 2.897 . . . . 0.0 110.877 176.937 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 86.6 m . . . . . 0 CA--C 1.533 0.322 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 68.5 mtm-85 -87.76 138.21 31.66 Favored 'General case' 0 N--CA 1.453 -0.316 0 O-C-N 122.1 -0.375 . . . . 0.0 111.336 178.618 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.6 pp -138.05 168.89 19.48 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 C-N-CA 123.148 0.579 . . . . 0.0 110.072 176.128 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -113.33 153.31 28.71 Favored 'General case' 0 CA--C 1.528 0.104 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -177.228 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 93.0 t -133.99 115.21 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -117.56 169.95 13.38 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 177.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 61.1 t30 57.99 23.68 10.21 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.704 0.801 . . . . 0.0 111.113 -175.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 21.2 tp . . . . . 0 CA--C 1.535 0.374 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 178.95 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 4.2 ttpt . . . . . 0 C--O 1.226 -0.144 0 N-CA-C 110.714 -0.106 . . . . 0.0 110.714 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -69.23 -31.79 70.58 Favored 'General case' 0 C--O 1.233 0.189 0 O-C-N 122.169 -0.332 . . . . 0.0 111.581 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.4 tt -76.48 -11.24 13.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 O-C-N 123.169 0.293 . . . . 0.0 110.99 -178.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -118.97 -0.56 11.14 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 117.833 0.288 . . . . 0.0 110.807 177.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -94.49 -62.41 1.33 Allowed 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 122.551 0.34 . . . . 0.0 111.674 177.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 62.9 t -65.4 -41.12 90.4 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 -178.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -62.94 -31.03 72.03 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.4 t -68.07 -30.8 70.08 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 110.228 -0.286 . . . . 0.0 110.228 177.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 47.1 mmtm -69.35 -28.28 66.08 Favored 'General case' 0 C--N 1.338 0.082 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 173.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -80.18 -19.11 47.86 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 116.665 2.098 . . . . 0.0 116.665 176.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.49 20.24 0.03 OUTLIER Glycine 0 CA--C 1.53 0.99 0 C-N-CA 119.584 -1.293 . . . . 0.0 114.64 -177.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 50.85 66.69 1.1 Allowed 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 118.279 1.039 . . . . 0.0 111.987 176.423 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . 0.511 HD11 ' CZ ' ' B' ' 61' ' ' PHE . 1.7 mp -56.02 141.95 11.83 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 C-N-CA 122.951 0.5 . . . . 0.0 110.447 178.054 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . 0.421 HH11 ' HD3' ' B' ' 43' ' ' ARG . 10.6 mmm180 -107.05 -24.7 11.88 Favored 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 122.603 0.361 . . . . 0.0 111.262 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -146.59 155.25 42.34 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . 0.458 HG22 ' H ' ' B' ' 47' ' ' LEU . 17.7 mm -139.13 154.36 25.5 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 C-N-CA 124.203 1.001 . . . . 0.0 109.407 -178.21 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -142.38 47.67 1.58 Allowed 'General case' 0 CA--C 1.531 0.233 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 177.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . 0.458 ' H ' HG22 ' B' ' 45' ' ' ILE . 58.7 tp -61.5 128.21 35.19 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.55 177.626 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . 0.532 ' HE2' ' CZ ' ' B' ' 56' ' ' PHE . 23.2 pttm -157.74 173.14 17.27 Favored 'General case' 0 CA--C 1.528 0.102 0 C-N-CA 123.551 0.74 . . . . 0.0 109.691 179.04 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 50.8 p30 . . . . . 0 CA--C 1.531 0.219 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -174.445 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo . . . . . 0 N--CA 1.452 -0.923 0 N-CA-C 110.945 -0.444 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . 0.532 ' CZ ' ' HE2' ' B' ' 48' ' ' LYS . 4.2 p90 -157.24 163.07 39.17 Favored 'General case' 0 C--O 1.234 0.25 0 N-CA-C 104.696 -2.335 . . . . 0.0 104.696 174.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.17 152.88 29.94 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 119.713 -0.795 . . . . 0.0 112.611 -172.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -96.5 148.24 23.02 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.707 166.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 58.5 t -133.98 143.8 37.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -178.439 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -132.21 118.39 19.47 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 120.956 0.408 . . . . 0.0 110.763 -176.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.511 ' CZ ' HD11 ' B' ' 42' ' ' ILE . 34.5 m-85 -86.96 161.97 17.93 Favored 'General case' 0 C--N 1.333 -0.115 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -177.436 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -79.98 -27.92 39.59 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.425 174.36 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -138.51 143.51 38.62 Favored Pre-proline 0 C--N 1.34 0.182 0 C-N-CA 123.85 0.86 . . . . 0.0 112.006 179.055 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -73.83 -19.7 20.64 Favored 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 123.281 2.654 . . . . 0.0 111.257 -177.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 78.7 mtt85 -74.18 -25.23 59.59 Favored 'General case' 0 N--CA 1.456 -0.136 0 C-N-CA 122.398 0.279 . . . . 0.0 111.381 -178.154 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -91.96 -21.89 20.3 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.642 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.73 -27.06 66.48 Favored 'General case' 0 N--CA 1.453 -0.276 0 O-C-N 122.274 -0.267 . . . . 0.0 110.282 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -73.55 -26.66 60.95 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 121.9 0.08 . . . . 0.0 110.848 179.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -77.25 -36.23 54.67 Favored 'General case' 0 CA--C 1.521 -0.14 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.84 -29.06 61.92 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 122.259 0.224 . . . . 0.0 110.439 177.578 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 17.2 t -80.94 -42.81 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 43.8 t -66.97 -21.83 65.95 Favored 'General case' 0 CA--C 1.528 0.108 0 O-C-N 122.177 -0.327 . . . . 0.0 111.063 -178.156 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -89.66 -2.88 75.15 Favored Glycine 0 CA--C 1.531 1.071 0 CA-C-O 119.387 -0.674 . . . . 0.0 112.92 -178.361 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 80.3 mtt85 -141.93 -8.48 0.92 Allowed 'General case' 0 C--N 1.341 0.211 0 CA-C-N 118.181 0.99 . . . . 0.0 112.827 -174.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -67.3 118.64 10.95 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -179.286 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.81 45.37 96.35 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 175.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 53.9 t80 -95.97 135.94 37.06 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -172.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.6 t0 -63.51 105.33 0.76 Allowed 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.52 0.728 . . . . 0.0 112.557 -177.506 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.434 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 62.8 t80 -111.72 171.05 7.72 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.733 0.813 . . . . 0.0 111.301 177.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.434 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 19.7 t0 -60.5 98.83 0.07 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -179.464 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 77.88 -4.69 56.57 Favored Glycine 0 CA--C 1.536 1.35 0 CA-C-O 119.474 -0.626 . . . . 0.0 112.938 177.405 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -140.93 -171.14 3.19 Favored 'General case' 0 N--CA 1.462 0.148 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 41.7 ttp-105 -145.08 131.07 19.24 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.86 0.864 . . . . 0.0 109.334 -178.107 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.9 mp -66.62 153.79 42.18 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-O 120.923 0.392 . . . . 0.0 110.477 -175.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 52.8 mtm180 -129.47 47.27 2.51 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.457 0.703 . . . . 0.0 110.167 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 88.3 t -77.32 98.43 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 175.088 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -151.09 162.49 40.75 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.629 0.252 . . . . 0.0 110.655 179.178 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -73.05 152.51 90.71 Favored Pre-proline 0 C--O 1.234 0.24 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 178.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo . . . . . 0 C--O 1.251 1.15 0 C-N-CA 123.739 2.959 . . . . 0.0 110.735 177.836 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 76.4 m . . . . . 0 CA--C 1.532 0.28 0 N-CA-C 110.732 -0.099 . . . . 0.0 110.732 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 18.4 ttm180 -84.25 152.65 24.05 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 178.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 15.3 pt -136.17 -178.77 2.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.141 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 175.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -122.58 148.76 44.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.452 -0.794 . . . . 0.0 112.762 177.226 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 21.2 t -137.9 90.47 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 120.451 0.167 . . . . 0.0 110.755 -176.598 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -80.8 146.5 27.0 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 174.658 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 44.7 t30 58.28 -171.12 0.11 Allowed 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 122.786 0.434 . . . . 0.0 110.292 -174.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.409 ' H ' HD23 ' B' ' 23' ' ' LEU . 2.1 pt? . . . . . 0 CA--C 1.534 0.338 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 177.107 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . 0.417 ' HE3' ' HB2' ' B' ' 34' ' ' ASP . 30.8 ttpt . . . . . 0 CA--C 1.529 0.165 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -58.83 -23.67 60.91 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -179.004 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 27.7 mm -74.8 -17.49 16.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 122.653 0.381 . . . . 0.0 110.636 179.565 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -126.42 13.53 7.63 Favored 'General case' 0 C--N 1.34 0.159 0 CA-C-N 117.772 0.26 . . . . 0.0 111.052 178.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . 0.417 ' HB2' ' HE3' ' B' ' 30' ' ' LYS . 22.0 t0 -127.93 -60.86 1.14 Allowed 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 173.011 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 95.1 t -69.55 -53.18 26.03 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -65.14 -19.3 65.92 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 175.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 47.5 t -71.57 -28.94 64.19 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 175.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -74.82 -26.93 60.06 Favored 'General case' 0 CA--C 1.529 0.144 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 171.154 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -73.55 -23.78 60.03 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 115.928 1.825 . . . . 0.0 115.928 174.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.57 16.48 0.03 OUTLIER Glycine 0 CA--C 1.53 1.026 0 C-N-CA 120.219 -0.991 . . . . 0.0 114.074 -177.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.21 77.28 0.14 Allowed 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 117.886 0.843 . . . . 0.0 112.191 176.774 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.8 mp -60.07 142.32 15.56 Favored 'Isoleucine or valine' 0 C--O 1.232 0.138 0 C-N-CA 122.742 0.417 . . . . 0.0 110.225 177.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . 0.492 ' HE ' ' HA ' ' B' ' 62' ' ' GLU . 48.6 mtm105 -102.96 -30.99 10.45 Favored 'General case' 0 CA--C 1.523 -0.063 0 C-N-CA 122.393 0.277 . . . . 0.0 111.177 176.272 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -149.67 158.26 44.0 Favored 'General case' 0 C--O 1.232 0.134 0 N-CA-C 114.002 1.112 . . . . 0.0 114.002 -177.057 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 53.4 mt -125.59 150.8 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.149 0 C-N-CA 123.7 0.8 . . . . 0.0 109.098 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -141.01 50.71 1.63 Allowed 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 54.8 tp -60.55 135.58 57.8 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.099 177.034 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 25.3 ttmm -143.77 152.36 41.14 Favored 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 122.886 0.475 . . . . 0.0 110.116 -179.095 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 44.4 p30 . . . . . 0 CA--C 1.534 0.336 0 C-N-CA 122.61 0.364 . . . . 0.0 111.949 -178.345 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo . . . . . 0 N--CA 1.449 -1.097 0 N-CA-C 110.918 -0.455 . . . . 0.0 110.918 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -154.11 164.5 38.39 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 175.523 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -153.11 165.5 35.44 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-O 120.935 0.398 . . . . 0.0 111.883 -173.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -121.37 79.52 1.55 Allowed 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.471 175.02 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.5 t -67.49 147.48 12.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 C-N-CA 123.23 0.612 . . . . 0.0 110.19 -174.348 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -123.84 122.32 37.7 Favored 'General case' 0 CA--C 1.529 0.161 0 CA-C-O 120.825 0.345 . . . . 0.0 110.804 -178.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -94.58 164.92 12.78 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 115.464 1.653 . . . . 0.0 115.464 -175.322 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . 0.492 ' HA ' ' HE ' ' B' ' 43' ' ' ARG . 85.0 tt0 -73.58 -32.18 63.99 Favored 'General case' 0 C--N 1.34 0.183 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.661 174.332 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -141.59 145.82 39.02 Favored Pre-proline 0 CA--C 1.529 0.149 0 C-N-CA 123.771 0.828 . . . . 0.0 111.955 179.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -73.77 -19.58 20.92 Favored 'Trans proline' 0 N--CA 1.452 -0.941 0 C-N-CA 123.179 2.586 . . . . 0.0 110.841 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.74 -35.43 57.77 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 122.122 0.169 . . . . 0.0 110.838 -178.569 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -77.51 -17.72 57.71 Favored 'General case' 0 CA--C 1.527 0.083 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 178.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.53 -20.95 64.59 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 177.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -70.31 -34.25 72.48 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 177.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -75.83 -34.12 60.1 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.03 -31.69 64.6 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 178.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 7.5 t -73.69 -42.37 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 67.0 m -74.78 -0.49 18.43 Favored 'General case' 0 C--O 1.232 0.152 0 C-N-CA 122.136 0.175 . . . . 0.0 111.056 179.278 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -73.16 -35.66 57.02 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 119.487 -0.619 . . . . 0.0 112.756 -175.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 23.6 ttt180 -163.15 30.39 0.09 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.194 0.997 . . . . 0.0 111.631 -176.423 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -65.0 144.29 57.39 Favored 'General case' 0 C--O 1.232 0.14 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -179.607 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 57.78 46.47 92.27 Favored Glycine 0 C--N 1.338 0.656 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 174.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . 0.564 ' H ' ' HB2' ' B' ' 84' ' ' LEU . 16.7 t80 -98.67 137.42 37.33 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.673 0.736 . . . . 0.0 112.853 -173.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -67.95 83.35 0.21 Allowed 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 124.29 1.036 . . . . 0.0 112.059 -177.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.449 ' CD2' ' N ' ' B' ' 80' ' ' ASP . 54.2 t80 -82.89 171.31 14.02 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 123.199 0.6 . . . . 0.0 111.218 177.532 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.449 ' N ' ' CD2' ' B' ' 79' ' ' TYR . 24.9 t0 -64.5 93.84 0.11 Allowed 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.96 -1.81 88.33 Favored Glycine 0 CA--C 1.53 0.997 0 CA-C-O 119.762 -0.465 . . . . 0.0 112.615 177.244 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -141.93 -172.69 3.62 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 117.876 0.838 . . . . 0.0 112.669 -179.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 4.6 tpt180 -137.59 133.78 34.81 Favored 'General case' 0 C--O 1.232 0.143 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . 0.564 ' HB2' ' H ' ' B' ' 77' ' ' TYR . 4.2 mm? -64.66 139.23 58.74 Favored 'General case' 0 C--N 1.333 -0.117 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 95.3 mtm-85 -129.04 54.98 1.76 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 122.701 0.4 . . . . 0.0 110.288 175.517 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 2.7 p -81.28 97.64 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 175.017 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -153.68 169.49 23.18 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 122.875 0.47 . . . . 0.0 110.686 -179.348 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -65.26 151.72 93.32 Favored Pre-proline 0 CA--C 1.53 0.203 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo . . . . . 0 C--O 1.25 1.107 0 C-N-CA 123.678 2.918 . . . . 0.0 110.761 177.221 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 73.9 m . . . . . 0 CA--C 1.532 0.26 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 54.6 mtm180 -82.16 145.26 30.2 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 118.422 0.555 . . . . 0.0 111.305 175.663 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 22.8 pt -138.62 175.73 7.77 Favored 'Isoleucine or valine' 0 C--O 1.231 0.095 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 170.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -119.34 148.82 42.75 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 114.553 1.316 . . . . 0.0 114.553 -177.839 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 60.7 t -132.88 136.58 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 123.226 0.61 . . . . 0.0 109.634 179.279 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -140.52 172.15 23.69 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 51.2 t30 57.07 19.74 4.95 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.729 0.812 . . . . 0.0 111.41 -174.44 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.7 tp . . . . . 0 N--CA 1.454 -0.258 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.723 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt . . . . . 0 CA--C 1.532 0.281 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -58.84 -25.48 63.27 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 179.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.9 tt -76.27 -17.87 15.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 C-N-CA 122.335 0.254 . . . . 0.0 110.511 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.1 mt-10 -93.41 -31.04 14.78 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -74.13 -37.26 64.13 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 -177.655 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 62.4 t -69.71 -46.1 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.353 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -68.79 -35.4 76.99 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 113.615 0.969 . . . . 0.0 113.615 178.064 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 33.5 t -60.9 -33.5 73.21 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 178.283 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 16.7 tppt? -73.76 -33.43 64.29 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 122.2 0.2 . . . . 0.0 110.769 177.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -87.04 -13.83 43.28 Favored 'General case' 0 C--O 1.233 0.206 0 N-CA-C 116.739 2.125 . . . . 0.0 116.739 -178.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.08 13.83 0.03 OUTLIER Glycine 0 CA--C 1.527 0.843 0 C-N-CA 119.906 -1.14 . . . . 0.0 114.254 -177.447 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.62 40.54 27.44 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 118.227 1.013 . . . . 0.0 111.806 177.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . 0.645 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.7 mp -44.25 138.33 0.97 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.182 0 C-N-CA 123.719 0.808 . . . . 0.0 111.114 179.087 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 29.8 mtp-105 -85.51 -38.91 18.03 Favored 'General case' 0 CA--C 1.523 -0.08 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.748 -178.31 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -144.5 159.48 42.7 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -176.439 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 8.7 tp -137.32 161.74 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -178.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -147.78 70.44 1.16 Allowed 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 177.013 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . 0.472 ' C ' HD13 ' B' ' 47' ' ' LEU . 3.4 tm? -64.14 125.53 24.8 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 176.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 39.4 mttp -139.11 164.14 30.57 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 123.547 0.739 . . . . 0.0 111.054 -178.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 51.9 t-20 . . . . . 0 N--CA 1.454 -0.272 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 170.703 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo . . . . . 0 N--CA 1.449 -1.134 0 CA-C-O 121.179 0.408 . . . . 0.0 111.629 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -150.67 165.2 34.14 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 104.884 -2.265 . . . . 0.0 104.884 175.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -157.03 163.7 38.78 Favored 'General case' 0 N--CA 1.453 -0.304 0 O-C-N 121.721 -0.612 . . . . 0.0 111.922 -174.409 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -113.2 151.62 30.75 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 171.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 41.5 t -131.1 136.4 57.95 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 -175.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -120.55 111.68 17.98 Favored 'General case' 0 N--CA 1.455 -0.205 0 CA-C-O 120.865 0.364 . . . . 0.0 110.481 -177.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.645 ' CE2' HD11 ' B' ' 42' ' ' ILE . 37.1 m-85 -81.15 159.38 24.66 Favored 'General case' 0 CA--C 1.528 0.125 0 N-CA-C 115.347 1.61 . . . . 0.0 115.347 -176.583 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -87.73 -26.66 22.82 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 169.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -155.44 118.95 2.42 Favored Pre-proline 0 CA--C 1.532 0.258 0 C-N-CA 123.635 0.774 . . . . 0.0 109.691 -179.196 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.52 -10.54 29.08 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.31 2.673 . . . . 0.0 111.942 -174.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 41.0 ttm105 -67.45 -29.29 68.72 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 117.887 0.312 . . . . 0.0 110.542 177.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 -81.24 -16.07 53.72 Favored 'General case' 0 CA--C 1.53 0.176 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.77 -16.43 63.3 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 120.39 0.138 . . . . 0.0 110.75 -179.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -66.7 -20.27 65.93 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 122.363 -0.21 . . . . 0.0 110.6 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -104.29 -33.16 8.76 Favored 'General case' 0 C--N 1.339 0.125 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 178.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.92 -31.49 64.67 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.012 0.525 . . . . 0.0 110.571 -178.614 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 98.0 t -87.44 -48.58 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 36.0 t -67.45 -14.87 63.32 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 122.474 -0.141 . . . . 0.0 111.2 -175.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -79.19 -14.24 81.96 Favored Glycine 0 CA--C 1.529 0.958 0 CA-C-O 119.345 -0.697 . . . . 0.0 112.652 -176.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 23.4 ptt-85 -158.13 3.92 0.11 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 118.623 1.212 . . . . 0.0 113.52 -175.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -73.16 143.39 47.28 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 118.757 0.708 . . . . 0.0 110.11 176.207 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 62.22 35.64 91.86 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.697 -0.561 . . . . 0.0 111.697 175.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 49.8 t80 -96.98 137.51 35.94 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -172.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -64.03 103.86 0.65 Allowed 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 123.382 0.673 . . . . 0.0 112.361 -178.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.457 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 75.7 t80 -109.75 173.33 6.37 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.91 0.884 . . . . 0.0 111.191 179.085 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.457 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 77.2 m-20 -59.88 98.66 0.06 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -179.575 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.58 -5.89 42.54 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-O 119.666 -0.519 . . . . 0.0 112.938 177.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -139.99 -169.33 2.71 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.964 0.882 . . . . 0.0 113.344 -177.36 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 41.6 ttp-105 -143.92 133.96 24.16 Favored 'General case' 0 N--CA 1.457 -0.12 0 C-N-CA 123.615 0.766 . . . . 0.0 109.016 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -62.55 147.96 47.47 Favored 'General case' 0 C--N 1.335 -0.063 0 C-N-CA 122.571 0.348 . . . . 0.0 110.18 -178.478 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 57.7 ttt180 -130.86 113.74 14.43 Favored 'General case' 0 CA--C 1.517 -0.313 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 37.5 t -132.52 92.57 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.632 178.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 24.0 pt-20 -145.29 159.49 42.96 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.703 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -74.04 153.57 88.69 Favored Pre-proline 0 N--CA 1.454 -0.229 0 N-CA-C 114.854 1.427 . . . . 0.0 114.854 -179.522 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo . . . . . 0 C--O 1.25 1.118 0 C-N-CA 123.911 3.074 . . . . 0.0 110.714 175.98 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 98.6 m . . . . . 0 CA--C 1.532 0.273 0 N-CA-C 111.491 0.182 . . . . 0.0 111.491 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 92.8 mtt-85 -73.3 147.88 44.07 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-O 120.879 0.371 . . . . 0.0 111.854 179.462 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 20.8 pt -138.67 177.76 4.77 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 C-N-CA 123.852 0.861 . . . . 0.0 108.754 172.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -116.9 150.54 38.3 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 114.344 1.238 . . . . 0.0 114.344 -177.285 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 47.4 t -138.65 143.3 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 C-N-CA 123.519 0.728 . . . . 0.0 109.187 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.35 178.81 34.43 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.954 -0.459 . . . . 0.0 111.954 -176.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 54.2 t30 58.54 25.52 13.21 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.195 0.998 . . . . 0.0 111.606 -176.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.6 mt . . . . . 0 N--CA 1.454 -0.23 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.94 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . 0.401 ' HE2' ' HB3' ' B' ' 30' ' ' LYS . 48.1 mtpt . . . . . 0 CA--C 1.528 0.112 0 N-CA-C 113.175 0.805 . . . . 0.0 113.175 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -62.5 -32.74 73.71 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 118.641 0.655 . . . . 0.0 112.088 175.596 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.9 tt -75.82 -16.81 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 122.787 0.435 . . . . 0.0 110.576 178.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 72.9 mt-10 -97.31 -13.67 21.79 Favored 'General case' 0 C--N 1.34 0.18 0 C-N-CA 122.181 0.193 . . . . 0.0 110.684 -179.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -103.17 -67.69 0.87 Allowed 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -175.566 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 3.7 p -73.81 -37.27 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 N-CA-C 112.493 0.553 . . . . 0.0 112.493 -172.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 70.7 m-85 -73.15 -25.98 61.03 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 112.773 0.656 . . . . 0.0 112.773 177.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 42.8 t -72.37 -30.27 64.54 Favored 'General case' 0 N--CA 1.456 -0.166 0 N-CA-C 110.305 -0.257 . . . . 0.0 110.305 176.348 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.37 -29.48 62.66 Favored 'General case' 0 N--CA 1.455 -0.208 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 174.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -81.01 -20.4 41.84 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 116.144 1.905 . . . . 0.0 116.144 179.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.1 14.4 0.76 Allowed Glycine 0 CA--C 1.527 0.783 0 C-N-CA 120.707 -0.758 . . . . 0.0 113.851 -175.113 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.67 38.49 22.88 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 117.858 0.829 . . . . 0.0 111.261 178.002 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 81.8 mt -45.47 138.67 1.3 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.151 0 C-N-CA 123.338 0.655 . . . . 0.0 111.387 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 28.6 mmt180 -104.63 -22.56 13.22 Favored 'General case' 0 N--CA 1.455 -0.204 0 C-N-CA 122.884 0.474 . . . . 0.0 111.668 -178.141 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -152.4 154.16 35.04 Favored 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 118.352 0.524 . . . . 0.0 112.112 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 2.8 mp -136.52 148.03 27.32 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.085 0 C-N-CA 123.884 0.874 . . . . 0.0 109.326 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -140.95 57.2 1.56 Allowed 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 122.694 0.398 . . . . 0.0 110.278 179.297 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 57.8 tp -60.16 129.25 40.79 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.154 175.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 43.0 mttp -120.13 143.59 48.1 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 123.634 0.774 . . . . 0.0 110.672 179.204 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 49.7 p30 . . . . . 0 N--CA 1.453 -0.307 0 C-N-CA 123.402 0.681 . . . . 0.0 110.473 179.871 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo . . . . . 0 N--CA 1.452 -0.96 0 N-CA-C 111.197 -0.347 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -160.87 173.86 14.7 Favored 'General case' 0 CA--C 1.53 0.178 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -173.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.28 166.11 34.39 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 120.801 0.334 . . . . 0.0 111.668 -175.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -121.17 154.82 35.72 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 168.581 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 70.5 t -144.2 133.03 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -174.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -106.76 117.97 35.45 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.393 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 -85.59 154.65 21.58 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 115.12 1.526 . . . . 0.0 115.12 179.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 38.1 tp10 -75.54 -30.27 59.7 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 172.305 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 58.3 t0 -157.59 117.72 1.97 Allowed Pre-proline 0 N--CA 1.451 -0.415 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.3 -10.3 26.97 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 123.194 2.596 . . . . 0.0 112.112 -176.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 77.4 mtt85 -72.17 -16.16 61.97 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 117.85 0.295 . . . . 0.0 111.026 178.059 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -77.97 -2.73 38.4 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 177.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -64.52 -14.67 58.52 Favored 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 122.435 0.294 . . . . 0.0 111.163 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -65.96 -15.85 63.35 Favored 'General case' 0 CA--C 1.529 0.168 0 O-C-N 122.173 -0.329 . . . . 0.0 111.333 -179.319 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -123.39 -38.28 2.57 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 123.001 0.52 . . . . 0.0 112.181 177.166 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -81.82 -9.57 59.57 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.08 0.552 . . . . 0.0 112.187 -175.486 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 99.5 t -130.99 -49.76 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 CA-C-N 117.729 0.24 . . . . 0.0 110.526 -177.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 69.2 m -66.23 -10.96 46.98 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 117.646 0.203 . . . . 0.0 111.145 -179.462 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.2 -1.16 69.87 Favored Glycine 0 CA--C 1.53 0.975 0 CA-C-O 119.436 -0.646 . . . . 0.0 112.73 -178.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 12.1 tpp180 -151.72 -16.88 0.19 Allowed 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 118.466 1.133 . . . . 0.0 112.705 -176.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 32.9 t0 -65.11 138.34 58.24 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 118.267 0.485 . . . . 0.0 110.634 -178.128 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.51 41.57 99.2 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 111.794 -0.522 . . . . 0.0 111.794 174.091 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -98.61 133.47 42.91 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -174.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.6 t0 -62.63 106.52 0.8 Allowed 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 123.781 0.832 . . . . 0.0 112.341 -177.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.439 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.9 t80 -112.88 171.28 7.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 123.804 0.842 . . . . 0.0 111.445 177.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.439 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 20.6 t0 -60.53 99.82 0.09 Allowed 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.066 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 77.99 -6.32 49.51 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 123.553 0.597 . . . . 0.0 112.761 177.46 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 87.9 m-85 -140.56 -169.54 2.81 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 117.996 0.898 . . . . 0.0 113.269 -177.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 36.1 ttt180 -147.46 129.53 15.48 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.439 0.696 . . . . 0.0 109.474 -177.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -62.57 147.79 48.02 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 122.847 0.459 . . . . 0.0 110.502 -175.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 -120.68 127.68 52.26 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 175.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 11.8 t -145.27 82.02 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.131 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 173.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -148.33 160.7 42.73 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 122.75 0.42 . . . . 0.0 110.43 -175.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -75.25 156.57 85.58 Favored Pre-proline 0 CA--C 1.533 0.324 0 N-CA-C 114.228 1.196 . . . . 0.0 114.228 179.211 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo . . . . . 0 C--O 1.25 1.077 0 C-N-CA 123.739 2.96 . . . . 0.0 111.867 177.349 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 87.6 m . . . . . 0 N--CA 1.456 -0.137 0 N-CA-C 111.334 0.124 . . . . 0.0 111.334 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 73.0 mtm180 -69.03 146.99 52.2 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 122.831 0.452 . . . . 0.0 110.818 -178.546 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.1 pt -132.56 170.06 20.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-O 120.964 0.412 . . . . 0.0 110.08 172.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -114.99 151.02 34.89 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -176.838 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 59.3 t -138.45 143.61 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -157.36 -178.76 31.73 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 111.934 -0.466 . . . . 0.0 111.934 -177.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 36.3 t30 56.8 23.99 8.65 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 123.825 0.85 . . . . 0.0 111.645 -177.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 93.4 mt . . . . . 0 CA--C 1.53 0.207 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -179.992 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 6.4 ttpt . . . . . 0 N--CA 1.456 -0.126 0 CA-C-O 120.449 0.166 . . . . 0.0 111.074 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 -70.72 -36.14 73.06 Favored 'General case' 0 N--CA 1.454 -0.227 0 O-C-N 122.1 -0.375 . . . . 0.0 111.261 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 15.2 tt -75.85 -14.09 15.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.377 -176.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -104.28 -21.85 13.46 Favored 'General case' 0 C--N 1.34 0.164 0 CA-C-N 118.714 0.688 . . . . 0.0 110.687 178.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -74.33 -49.88 21.07 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 178.161 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 m -72.86 -30.8 33.81 Favored 'Isoleucine or valine' 0 C--N 1.338 0.101 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.095 -178.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . 0.408 ' O ' HD13 ' B' ' 42' ' ' ILE . 41.4 m-85 -75.92 -42.87 47.57 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 177.425 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 96.7 p -67.58 -21.45 65.42 Favored 'General case' 0 C--N 1.34 0.164 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.49 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 23.7 tptm -73.98 -36.88 64.58 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 173.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -82.12 -11.61 58.66 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 116.659 2.096 . . . . 0.0 116.659 178.175 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.98 179.27 48.92 Favored Glycine 0 C--N 1.338 0.645 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.044 -179.364 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.94 53.7 2.27 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 124.06 0.944 . . . . 0.0 111.626 -177.597 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . 0.556 HD11 ' CZ ' ' B' ' 61' ' ' PHE . 2.1 mp -68.75 144.24 14.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.24 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 35.0 mmt180 -124.81 -36.1 2.62 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 119.42 -0.324 . . . . 0.0 111.149 178.246 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 39.9 m-20 -122.38 150.16 42.8 Favored 'General case' 0 N--CA 1.462 0.126 0 N-CA-C 113.944 1.091 . . . . 0.0 113.944 -178.385 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -136.18 150.08 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 C-N-CA 124.236 1.014 . . . . 0.0 109.169 178.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 59.2 t0 -146.9 63.5 1.18 Allowed 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 49.6 tp -64.35 129.06 38.43 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 173.345 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -120.39 146.69 45.94 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 123.698 0.799 . . . . 0.0 109.966 178.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 . . . . . 0 C--N 1.334 -0.104 0 C-N-CA 122.891 0.476 . . . . 0.0 111.11 -176.183 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo . . . . . 0 N--CA 1.452 -0.927 0 N-CA-C 110.414 -0.648 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -150.85 167.71 26.68 Favored 'General case' 0 C--O 1.232 0.162 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 -179.478 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -152.87 166.06 33.48 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.295 0.569 . . . . 0.0 112.426 -171.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -120.56 153.67 36.43 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 124.042 0.937 . . . . 0.0 112.813 170.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 88.9 t -141.1 144.39 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 108.685 -0.858 . . . . 0.0 108.685 -178.17 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 11.7 tp10 -131.14 125.59 33.46 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 122.578 0.351 . . . . 0.0 111.174 -177.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.556 ' CZ ' HD11 ' B' ' 42' ' ' ILE . 9.1 m-85 -91.57 151.56 20.68 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 113.974 1.101 . . . . 0.0 113.974 -178.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -82.46 -24.69 34.14 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 169.045 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 36.6 t0 -152.26 114.94 2.9 Favored Pre-proline 0 CA--C 1.534 0.355 0 C-N-CA 123.352 0.661 . . . . 0.0 109.944 -176.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -74.77 -1.37 11.06 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 123.566 2.844 . . . . 0.0 112.742 -173.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 79.5 mtt85 -68.27 -0.49 4.81 Favored 'General case' 0 CA--C 1.53 0.197 0 N-CA-C 112.998 0.74 . . . . 0.0 112.998 -176.212 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 20.4 p30 -134.35 3.12 3.33 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 112.173 0.434 . . . . 0.0 112.173 173.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.76 -22.03 64.33 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 178.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -70.25 -28.45 65.25 Favored 'General case' 0 N--CA 1.456 -0.127 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 178.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -79.63 -35.18 39.8 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 122.337 0.255 . . . . 0.0 111.381 178.025 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.96 -24.72 63.38 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.231 176.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 10.0 t -85.69 -59.03 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.5 t -71.28 -17.6 62.46 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -172.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -93.12 4.07 73.9 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-O 119.247 -0.751 . . . . 0.0 112.588 -177.089 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 46.6 ttm180 -150.19 -16.55 0.25 Allowed 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 118.516 1.158 . . . . 0.0 112.555 -174.714 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 50.7 p-10 -71.3 156.64 39.29 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.277 0.561 . . . . 0.0 112.306 -176.512 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 58.85 41.8 96.29 Favored Glycine 0 CA--C 1.526 0.725 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.683 169.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 43.4 t80 -92.38 130.83 37.95 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 118.226 1.013 . . . . 0.0 113.714 -175.153 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -66.12 101.81 0.75 Allowed 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 123.044 0.538 . . . . 0.0 112.025 -178.441 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.515 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 71.4 t80 -93.02 177.98 5.9 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.406 0.682 . . . . 0.0 112.127 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.515 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 74.1 m-20 -66.66 21.84 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.537 0 N-CA-C 114.934 1.457 . . . . 0.0 114.934 -177.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 161.5 -10.82 0.12 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-O 119.618 -0.546 . . . . 0.0 112.425 -179.137 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -140.95 -167.05 2.29 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 117.731 0.766 . . . . 0.0 110.893 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 33.8 ttt180 -138.93 122.96 17.89 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -59.81 153.39 20.79 Favored 'General case' 0 N--CA 1.458 -0.043 0 C-N-CA 123.421 0.688 . . . . 0.0 111.096 -176.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 24.0 mtp180 -128.08 125.21 38.81 Favored 'General case' 0 CA--C 1.521 -0.164 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.593 175.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 48.2 t -142.99 82.01 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.171 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 175.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -140.28 160.57 39.67 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.219 0.533 . . . . 0.0 111.809 -173.09 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . 0.467 ' CD1' ' HD2' ' B' ' 89' ' ' PRO . 18.2 t80 -71.84 138.9 82.67 Favored Pre-proline 0 CA--C 1.534 0.335 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . 0.467 ' HD2' ' CD1' ' B' ' 88' ' ' PHE . 43.9 Cg_endo . . . . . 0 C--O 1.248 1.018 0 C-N-CA 123.824 3.016 . . . . 0.0 111.303 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 61.3 m . . . . . 0 C--O 1.231 0.093 0 N-CA-C 110.473 -0.195 . . . . 0.0 110.473 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 31.4 ttm180 -101.02 147.89 25.67 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 123.046 0.539 . . . . 0.0 109.815 -178.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.5 pt -133.53 174.78 12.67 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.081 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 176.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -118.92 150.32 40.09 Favored 'General case' 0 C--O 1.231 0.122 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -175.838 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 60.5 t -139.22 142.84 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 C-N-CA 123.509 0.724 . . . . 0.0 109.437 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.81 168.76 31.78 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -178.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 59.4 t30 60.55 36.89 19.81 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 124.073 0.949 . . . . 0.0 111.379 -174.205 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 84.0 mt . . . . . 0 CA--C 1.532 0.285 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 176.492 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.8 tptt . . . . . 0 N--CA 1.456 -0.174 0 N-CA-C 111.218 0.081 . . . . 0.0 111.218 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -63.79 -28.39 69.83 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.593 0.235 . . . . 0.0 110.43 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.0 tt -72.1 -13.78 16.9 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.349 -178.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -116.98 -9.94 11.02 Favored 'General case' 0 N--CA 1.456 -0.156 0 CA-C-N 118.291 0.496 . . . . 0.0 110.722 174.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -71.27 -55.3 8.34 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-O 121.025 0.44 . . . . 0.0 110.57 178.016 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 10.0 p -67.68 -34.65 69.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 O-C-N 122.241 -0.287 . . . . 0.0 110.886 179.392 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -69.88 -32.86 71.43 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 113.38 0.882 . . . . 0.0 113.38 176.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 39.2 t -67.48 -28.0 67.48 Favored 'General case' 0 C--N 1.342 0.28 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 176.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -70.68 -34.26 71.8 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 174.532 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -81.68 -15.61 53.95 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 116.225 1.935 . . . . 0.0 116.225 177.124 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.46 179.21 44.92 Favored Glycine 0 C--N 1.338 0.656 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.584 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -83.85 84.61 7.51 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 122.992 0.517 . . . . 0.0 111.249 -178.431 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.7 mp -73.09 150.39 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.123 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 174.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 85.3 mmt-85 -128.35 -25.64 2.91 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 119.25 -0.405 . . . . 0.0 111.972 176.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -150.55 161.43 42.56 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 178.609 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . 0.489 HG22 ' H ' ' B' ' 47' ' ' LEU . 30.8 mm -132.43 156.46 42.42 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.061 0 C-N-CA 124.289 1.036 . . . . 0.0 109.279 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -143.2 55.25 1.36 Allowed 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 175.316 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . 0.489 ' H ' HG22 ' B' ' 45' ' ' ILE . 59.9 tp -55.79 133.13 50.88 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.223 174.468 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -133.79 158.53 43.13 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 123.735 0.814 . . . . 0.0 111.415 -177.483 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 43.0 p30 . . . . . 0 CA--C 1.533 0.302 0 C-N-CA 123.442 0.697 . . . . 0.0 110.698 177.692 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo . . . . . 0 N--CA 1.45 -1.038 0 N-CA-C 110.195 -0.733 . . . . 0.0 110.195 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 6.1 p90 -153.29 171.38 18.65 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 106.414 -1.699 . . . . 0.0 106.414 -176.61 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -159.61 174.62 14.31 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.242 0.544 . . . . 0.0 111.371 -174.089 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -131.81 155.94 46.9 Favored 'General case' 0 N--CA 1.452 -0.355 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 172.04 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 66.8 t -132.87 134.24 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -178.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -111.17 123.95 51.23 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 122.465 0.306 . . . . 0.0 110.562 -177.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -97.43 154.95 17.14 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 42.3 tp10 -78.7 -23.63 45.45 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 170.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -152.51 118.87 3.05 Favored Pre-proline 0 CA--C 1.534 0.365 0 C-N-CA 123.162 0.585 . . . . 0.0 109.785 -178.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -66.65 -8.11 20.13 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.188 2.592 . . . . 0.0 112.505 -176.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 72.3 ttt-85 -61.94 -36.05 80.26 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-N 118.111 0.414 . . . . 0.0 110.172 177.19 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 52.8 m-20 -89.87 -16.3 30.36 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-O 120.582 0.23 . . . . 0.0 111.57 -178.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.97 -25.3 64.47 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.851 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -71.81 -28.59 63.7 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 177.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 -75.16 -35.48 61.61 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 178.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.97 -29.91 67.13 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 110.279 -0.267 . . . . 0.0 110.279 177.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.93 -30.02 17.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.306 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.368 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 41.5 t -85.79 -12.34 51.19 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 122.587 0.355 . . . . 0.0 111.54 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -68.56 -46.06 64.22 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.609 -0.596 . . . . 0.0 111.609 -175.518 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 38.2 ttt180 -163.08 122.1 2.11 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.274 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -164.24 149.27 10.2 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 123.066 0.229 . . . . 0.0 110.574 -178.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.94 88.88 0.3 Allowed Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.481 0.562 . . . . 0.0 112.857 170.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . 0.449 ' HA ' ' HA ' ' B' ' 83' ' ' ARG . 13.6 t80 60.31 103.09 0.02 OUTLIER 'General case' 0 N--CA 1.457 -0.104 0 N-CA-C 116.478 2.029 . . . . 0.0 116.478 169.579 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -164.71 31.09 0.07 Allowed 'General case' 0 N--CA 1.444 -0.733 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -131.62 178.09 7.01 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -88.89 107.38 18.97 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 114.892 -1.049 . . . . 0.0 111.228 179.378 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 72.11 -2.26 28.26 Favored Glycine 0 CA--C 1.531 1.092 0 N-CA-C 111.522 -0.631 . . . . 0.0 111.522 -178.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 45.1 m-85 -131.47 169.81 15.55 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 124.001 0.92 . . . . 0.0 113.455 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . 0.449 ' HA ' ' HA ' ' B' ' 77' ' ' TYR . 0.0 OUTLIER -135.15 135.83 41.4 Favored 'General case' 0 N--CA 1.44 -0.949 0 CA-C-O 120.803 0.335 . . . . 0.0 111.282 -178.58 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . 0.592 HD22 ' N ' ' B' ' 84' ' ' LEU . 2.4 mm? -73.85 142.92 46.06 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 178.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 59.1 mtm180 -132.48 114.57 14.45 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-O 120.943 0.401 . . . . 0.0 110.222 175.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 42.4 t -136.4 86.08 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 C-N-CA 123.543 0.737 . . . . 0.0 109.055 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -149.8 163.21 38.61 Favored 'General case' 0 C--N 1.334 -0.103 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.534 -178.655 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.5 p90 -74.0 152.23 88.62 Favored Pre-proline 0 CA--C 1.531 0.229 0 N-CA-C 114.626 1.343 . . . . 0.0 114.626 179.433 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo . . . . . 0 C--O 1.253 1.266 0 C-N-CA 123.837 3.025 . . . . 0.0 110.781 176.312 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 98.3 m . . . . . 0 C--O 1.231 0.083 0 N-CA-C 111.501 0.185 . . . . 0.0 111.501 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -88.86 155.21 19.67 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 120.847 0.356 . . . . 0.0 111.255 -177.733 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 12.2 pt -127.62 -177.29 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 C-N-CA 123.223 0.609 . . . . 0.0 109.477 177.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -142.94 151.29 40.79 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -178.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 62.8 t -142.84 101.15 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.149 0 N-CA-C 110.465 -0.198 . . . . 0.0 110.465 -176.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -92.59 166.95 29.47 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 171.682 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 66.2 t30 55.43 29.37 13.07 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 122.824 0.45 . . . . 0.0 110.725 -177.028 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 23.0 tp . . . . . 0 CA--C 1.536 0.405 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.911 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . 0.424 ' HE2' ' OD1' ' B' ' 34' ' ' ASP . 23.4 tptm . . . . . 0 N--CA 1.455 -0.2 0 CA-C-O 120.221 0.058 . . . . 0.0 110.957 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -63.87 -24.01 67.58 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 175.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.6 tt -69.51 -15.99 20.06 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 C-N-CA 123.15 0.58 . . . . 0.0 110.902 -179.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -125.45 4.35 7.65 Favored 'General case' 0 CA--C 1.53 0.205 0 O-C-N 122.053 -0.404 . . . . 0.0 111.367 179.056 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . 0.424 ' OD1' ' HE2' ' B' ' 30' ' ' LYS . 79.1 m-20 -97.06 -61.93 1.33 Allowed 'General case' 0 C--O 1.233 0.197 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 172.215 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 p -74.84 -41.53 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.087 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -172.408 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -75.39 -21.49 58.22 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -179.019 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 43.3 t -72.26 -30.18 64.6 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 175.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 29.7 ttpp -72.92 -28.59 62.55 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.638 -0.505 . . . . 0.0 109.638 174.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -79.33 -20.73 47.15 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 116.26 1.948 . . . . 0.0 116.26 177.413 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.88 20.58 0.17 Allowed Glycine 0 CA--C 1.53 0.984 0 C-N-CA 119.887 -1.149 . . . . 0.0 114.717 -175.498 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 48.7 49.14 19.19 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 117.938 0.869 . . . . 0.0 111.475 175.186 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 75.6 mt -48.97 137.02 5.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.144 0.577 . . . . 0.0 111.008 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 48.0 mtm105 -98.9 -32.14 11.48 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 122.891 0.477 . . . . 0.0 111.527 179.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 32.3 m-20 -148.94 157.01 43.1 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 113.835 1.05 . . . . 0.0 113.835 -177.449 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 3.2 mp -126.78 151.95 34.07 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -148.6 48.02 1.02 Allowed 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -177.032 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 54.0 tp -68.75 110.45 4.32 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 177.632 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 48.1 mttm -93.88 146.57 23.8 Favored 'General case' 0 N--CA 1.456 -0.145 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 175.475 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 31.9 p30 . . . . . 0 CA--C 1.532 0.266 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.003 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo . . . . . 0 N--CA 1.454 -0.815 0 CA-C-O 120.78 0.242 . . . . 0.0 112.163 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -164.13 167.22 20.46 Favored 'General case' 0 N--CA 1.455 -0.195 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 178.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -144.25 161.01 39.98 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -171.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -119.71 60.52 0.85 Allowed 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 124.152 0.981 . . . . 0.0 112.769 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 83.7 t -58.34 143.26 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.108 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -177.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 73.1 tt0 -120.79 120.4 35.49 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.918 0.389 . . . . 0.0 110.956 -175.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -91.53 166.43 12.84 Favored 'General case' 0 N--CA 1.455 -0.179 0 N-CA-C 115.984 1.846 . . . . 0.0 115.984 -174.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 30.4 tp10 -70.99 -35.22 72.01 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 122.757 0.423 . . . . 0.0 110.138 173.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -149.21 148.22 26.03 Favored Pre-proline 0 CA--C 1.527 0.093 0 C-N-CA 124.387 1.075 . . . . 0.0 112.021 178.084 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.1 -17.27 31.73 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.181 2.588 . . . . 0.0 111.089 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 51.9 mmm-85 -77.76 -13.42 59.9 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 122.435 0.294 . . . . 0.0 111.606 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -76.5 -10.31 59.3 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 111.953 0.353 . . . . 0.0 111.953 177.552 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.48 -11.05 60.68 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.592 0.357 . . . . 0.0 111.101 179.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -67.93 -17.72 64.54 Favored 'General case' 0 C--O 1.232 0.155 0 O-C-N 122.135 -0.353 . . . . 0.0 111.032 -179.286 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -123.84 -36.24 2.76 Favored 'General case' 0 CA--C 1.528 0.125 0 C-N-CA 123.183 0.593 . . . . 0.0 112.433 178.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -84.28 -8.86 58.9 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -175.605 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.43 HG13 HG12 ' B' ' 86' ' ' VAL . 47.3 t -132.68 -46.25 0.64 Allowed 'Isoleucine or valine' 0 C--O 1.228 -0.036 0 CA-C-N 118.062 0.392 . . . . 0.0 110.906 -175.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.3 t -69.5 -15.19 63.2 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-O 120.502 0.192 . . . . 0.0 110.977 -179.282 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.94 -5.82 88.8 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-O 119.647 -0.529 . . . . 0.0 112.711 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 70.2 mtm-85 -138.86 6.07 2.41 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 118.078 0.939 . . . . 0.0 111.869 -178.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -67.3 123.51 20.55 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 117.823 0.283 . . . . 0.0 111.307 -179.101 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 65.19 34.45 89.63 Favored Glycine 0 C--N 1.338 0.669 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 177.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 56.2 t80 -75.91 137.77 40.6 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -173.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 28.2 t0 -66.15 81.02 0.08 Allowed 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.295 1.038 . . . . 0.0 111.964 -177.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . 0.4 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 68.2 t80 -85.03 -179.94 7.15 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 177.784 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.4 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 71.4 m-20 -66.38 91.9 0.18 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 123.246 0.618 . . . . 0.0 112.43 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.73 -2.12 69.81 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-O 119.606 -0.552 . . . . 0.0 112.399 177.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -138.41 176.68 8.49 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 -178.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -125.15 140.1 53.17 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 123.846 0.858 . . . . 0.0 109.376 176.652 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -67.22 152.51 45.6 Favored 'General case' 0 N--CA 1.455 -0.204 0 C-N-CA 122.626 0.37 . . . . 0.0 110.426 177.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -118.43 48.26 1.46 Allowed 'General case' 0 C--N 1.338 0.068 0 C-N-CA 123.3 0.64 . . . . 0.0 109.828 172.012 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . 0.43 HG12 HG13 ' B' ' 71' ' ' VAL . 74.7 t -76.43 95.1 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.556 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -154.02 158.63 40.86 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.845 178.51 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 8.1 p90 -87.23 145.77 38.64 Favored Pre-proline 0 N--CA 1.456 -0.161 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 177.419 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 C--O 1.253 1.245 0 C-N-CA 123.614 2.876 . . . . 0.0 110.737 175.565 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 74.2 m . . . . . 0 CA--C 1.531 0.225 0 N-CA-C 112.53 0.567 . . . . 0.0 112.53 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 86.3 mtt180 -99.79 148.81 24.01 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 117.96 0.346 . . . . 0.0 111.741 177.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 19.9 pt -134.66 -177.26 1.95 Allowed 'Isoleucine or valine' 0 CA--C 1.524 -0.034 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -119.0 146.64 44.86 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -177.288 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 41.7 t -140.17 139.97 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.54 177.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -143.27 169.75 25.7 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -176.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 59.7 t30 61.07 31.56 19.79 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.741 0.817 . . . . 0.0 111.483 -175.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 81.3 mt . . . . . 0 CA--C 1.533 0.301 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.664 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 30' ' ' LYS . . . . . 0.408 ' HE2' ' OD2' ' B' ' 34' ' ' ASP . 24.0 tptm . . . . . 0 C--O 1.227 -0.12 0 CA-C-O 119.915 -0.088 . . . . 0.0 111.004 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 31.2 m-20 -64.06 -19.94 65.59 Favored 'General case' 0 CA--C 1.528 0.103 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 174.15 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 tt -69.29 -14.14 18.09 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 C-N-CA 123.336 0.654 . . . . 0.0 111.059 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -129.02 -10.32 4.81 Favored 'General case' 0 CA--C 1.529 0.173 0 CA-C-N 118.514 0.597 . . . . 0.0 111.677 176.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . 0.408 ' OD2' ' HE2' ' B' ' 30' ' ' LYS . 77.7 m-20 -74.13 -46.48 42.33 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 113.024 0.75 . . . . 0.0 113.024 174.166 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.6 p -71.91 -30.52 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.117 0 CA-C-O 120.656 0.265 . . . . 0.0 111.045 178.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -75.48 -30.82 60.01 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 177.656 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 41.4 t -70.37 -30.65 67.63 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 174.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 3.6 tppp? -73.38 -30.81 63.53 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 122.121 0.168 . . . . 0.0 110.672 177.257 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -84.03 -19.18 34.88 Favored 'General case' 0 C--N 1.338 0.103 0 N-CA-C 116.316 1.969 . . . . 0.0 116.316 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.14 22.31 0.07 OUTLIER Glycine 0 CA--C 1.528 0.88 0 C-N-CA 120.035 -1.078 . . . . 0.0 113.531 -177.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 52.32 30.15 7.67 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 117.64 0.72 . . . . 0.0 111.296 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 42' ' ' ILE . . . . . 0.417 HD11 ' CZ ' ' B' ' 61' ' ' PHE . 17.8 mt -50.72 137.37 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 123.191 0.597 . . . . 0.0 110.131 178.099 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 14.9 mmt180 -105.26 -19.02 13.93 Favored 'General case' 0 N--CA 1.457 -0.078 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -172.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 40.9 t0 -154.94 156.66 36.45 Favored 'General case' 0 C--O 1.233 0.201 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.962 178.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 15.5 mm -131.96 114.86 25.38 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 174.305 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 46' ' ' ASP . . . . . 0.453 ' HB3' ' H ' ' B' ' 58' ' ' PHE . 41.3 t0 -84.53 51.91 2.24 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 177.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 50.8 tp -54.18 120.88 7.09 Favored 'General case' 0 C--O 1.231 0.114 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 175.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -145.08 146.51 31.88 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-O 120.829 0.347 . . . . 0.0 111.02 -173.407 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 73.9 m-20 . . . . . 0 N--CA 1.454 -0.249 0 C-N-CA 122.951 0.501 . . . . 0.0 110.992 -179.198 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo . . . . . 0 N--CA 1.45 -1.079 0 N-CA-C 110.564 -0.591 . . . . 0.0 110.564 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -149.34 170.16 19.16 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 105.634 -1.987 . . . . 0.0 105.634 -178.141 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.83 155.2 33.98 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-O 120.756 0.312 . . . . 0.0 111.731 -175.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 58' ' ' PHE . . . . . 0.453 ' H ' ' HB3' ' B' ' 46' ' ' ASP . 86.4 m-85 -108.93 107.79 18.3 Favored 'General case' 0 N--CA 1.457 -0.12 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.944 169.395 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 91.2 t -80.54 141.9 14.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -177.685 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -120.09 120.17 35.47 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-O 120.652 0.263 . . . . 0.0 110.424 178.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.417 ' CZ ' HD11 ' B' ' 42' ' ' ILE . 37.0 m-85 -88.08 158.1 18.68 Favored 'General case' 0 N--CA 1.456 -0.148 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -178.441 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -86.3 -29.6 22.91 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 167.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -155.61 110.28 2.19 Favored Pre-proline 0 CA--C 1.535 0.376 0 C-N-CA 123.655 0.782 . . . . 0.0 109.598 178.349 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -58.6 -11.51 11.67 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 124.04 3.16 . . . . 0.0 113.801 -177.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.66 -25.4 67.93 Favored 'General case' 0 CA--C 1.528 0.1 0 CA-C-N 118.191 0.451 . . . . 0.0 110.862 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 78.4 m-20 -76.2 2.7 12.44 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -179.587 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.97 -8.01 26.61 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.538 0.335 . . . . 0.0 111.341 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -62.73 -24.98 67.95 Favored 'General case' 0 N--CA 1.454 -0.26 0 O-C-N 122.149 -0.344 . . . . 0.0 110.969 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -120.78 -34.4 3.58 Favored 'General case' 0 C--O 1.228 -0.063 0 N-CA-C 112.731 0.641 . . . . 0.0 112.731 178.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -79.74 -9.09 59.6 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 123.346 0.658 . . . . 0.0 111.642 -176.025 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 58.2 t -136.2 -43.99 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 CA-C-N 117.623 0.192 . . . . 0.0 111.111 -177.225 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 68.7 m -83.82 -2.41 56.32 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.985 -0.098 . . . . 0.0 111.197 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -76.61 -30.18 56.72 Favored Glycine 0 C--N 1.34 0.796 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 -178.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 56.2 ttm-85 -162.76 131.8 4.16 Favored 'General case' 0 C--N 1.338 0.07 0 CA-C-N 117.376 0.588 . . . . 0.0 110.762 177.626 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 26.0 p30 -160.11 153.52 22.22 Favored 'General case' 0 C--O 1.232 0.165 0 C-N-CA 123.61 0.764 . . . . 0.0 110.89 175.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 56.37 41.49 87.73 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.71 -0.556 . . . . 0.0 111.71 175.455 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 46.3 t80 -92.71 136.61 33.08 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 -173.102 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -67.51 91.75 0.29 Allowed 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 124.042 0.937 . . . . 0.0 112.224 -177.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -85.09 -175.31 5.69 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.393 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -68.73 77.05 0.3 Allowed 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 123.678 0.791 . . . . 0.0 112.379 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 86.88 5.61 80.79 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 178.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -135.21 -176.86 4.4 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.351 0.66 . . . . 0.0 112.431 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 2.3 tpt180 -139.7 129.08 24.1 Favored 'General case' 0 CA--C 1.522 -0.123 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -179.436 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.7 mp -70.01 148.33 48.99 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 178.75 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 43.0 mtp85 -131.12 125.72 33.84 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 173.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 13.8 t -139.65 82.78 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.148 0 C-N-CA 123.562 0.745 . . . . 0.0 109.84 176.235 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -147.37 161.47 40.94 Favored 'General case' 0 C--N 1.333 -0.118 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.038 -177.627 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 6.0 p90 -76.16 151.99 83.95 Favored Pre-proline 0 CA--C 1.53 0.205 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 177.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo . . . . . 0 C--O 1.251 1.128 0 C-N-CA 123.455 2.77 . . . . 0.0 111.015 177.203 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 3.0 m . . . . . 0 N--CA 1.479 1.016 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 85.9 mt -70.75 140.24 18.71 Favored 'Isoleucine or valine' 0 C--O 1.232 0.181 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 178.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 17.6 tpp85 -159.69 167.28 28.75 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 122.538 0.335 . . . . 0.0 110.313 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . 0.422 ' N ' ' C2 ' ' A' ' 93' ' ' ' A' . . . -74.15 -123.11 0.1 OUTLIER Glycine 0 CA--C 1.531 1.09 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 176.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -71.75 -162.82 0.12 Allowed 'Trans proline' 0 N--CA 1.45 -1.06 0 C-N-CA 123.396 2.73 . . . . 0.0 109.502 172.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.7 7.49 0.35 Allowed 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -177.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -74.99 70.08 1.82 Allowed Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 177.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 72.3 m-20 -80.58 0.42 34.07 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.183 0.593 . . . . 0.0 112.165 -177.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 79.6 m-20 -68.1 152.97 44.68 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 122.253 -0.279 . . . . 0.0 110.624 -178.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 20.1 p30 -80.76 3.25 22.97 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -179.168 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.1 m -78.33 3.64 15.05 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 122.93 0.492 . . . . 0.0 111.797 -178.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 33.9 mtt180 -84.5 149.7 25.76 Favored 'General case' 0 C--O 1.232 0.135 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -176.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 16.6 pt -140.62 174.48 7.8 Favored 'Isoleucine or valine' 0 C--O 1.23 0.07 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.917 173.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.436 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.6 OUTLIER -109.0 150.39 27.83 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 114.497 1.295 . . . . 0.0 114.497 -177.64 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t -137.4 142.43 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.19 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.221 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.92 179.45 29.35 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -178.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 61.9 t30 56.23 39.42 30.25 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 123.666 0.787 . . . . 0.0 110.899 -174.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 84.8 mt -60.27 139.59 91.65 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.392 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . 0.412 ' HA ' ' HD3' ' B' ' 25' ' ' PRO . 57.5 Cg_endo -70.47 159.47 52.75 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 123.441 2.761 . . . . 0.0 110.885 -178.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' B' ' 24' ' ' PRO . 26.2 Cg_exo -62.1 -5.87 7.11 Favored 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 123.957 3.104 . . . . 0.0 113.302 -179.067 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 19.8 p30 -129.21 25.3 5.51 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -177.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 7.3 tp -57.71 150.8 3.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 C-N-CA 122.504 0.322 . . . . 0.0 110.178 178.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . 0.441 ' HG2' ' H ' ' B' ' 30' ' ' LYS . 38.1 ttm105 -143.26 145.68 32.95 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -177.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -60.66 -26.66 67.24 Favored 'General case' 0 C--N 1.333 -0.118 0 N-CA-C 114.173 1.175 . . . . 0.0 114.173 -178.474 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . 0.441 ' H ' ' HG2' ' B' ' 28' ' ' ARG . 52.7 tptt -81.02 -19.17 44.5 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 122.269 0.228 . . . . 0.0 110.83 -178.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 59.2 m-20 -64.6 -28.4 69.6 Favored 'General case' 0 C--O 1.231 0.124 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -176.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 31.3 mm -78.12 -23.41 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 177.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.4 mt-10 -86.74 -11.44 51.1 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.921 -0.127 . . . . 0.0 110.823 179.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 79.0 m-20 -101.33 -66.06 0.94 Allowed 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 177.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 41.4 t -73.84 -53.95 16.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.21 0 CA-C-N 116.756 -0.202 . . . . 0.0 111.04 -174.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 63.3 m-85 -69.16 -21.38 64.0 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -179.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 45.5 t -74.28 -32.18 62.81 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 175.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -68.85 -29.71 68.08 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 174.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 20.3 m-85 -82.69 -20.17 36.65 Favored 'General case' 0 CA--C 1.528 0.129 0 N-CA-C 116.352 1.982 . . . . 0.0 116.352 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.73 20.52 0.05 OUTLIER Glycine 0 CA--C 1.527 0.782 0 C-N-CA 119.66 -1.257 . . . . 0.0 114.775 -175.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 47.65 59.81 3.92 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 118.203 1.002 . . . . 0.0 111.667 174.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 29.2 mm -44.96 132.8 1.83 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 C-N-CA 123.597 0.759 . . . . 0.0 111.496 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -86.64 -37.29 18.18 Favored 'General case' 0 N--CA 1.456 -0.161 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.384 177.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 -147.86 150.06 33.44 Favored 'General case' 0 C--O 1.231 0.09 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -176.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -109.15 149.91 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 176.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -148.11 64.63 1.1 Allowed 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 77.7 mt -63.47 138.12 58.39 Favored 'General case' 0 C--O 1.232 0.156 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 175.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 49.3 mttp -130.64 51.76 2.09 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 123.974 0.91 . . . . 0.0 109.832 177.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 76.8 m-20 -80.84 5.18 16.77 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.425 174.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 58.8 ttt180 -58.8 150.5 23.7 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 123.755 0.822 . . . . 0.0 110.623 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.95 170.08 5.95 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.136 0.574 . . . . 0.0 110.987 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 94.98 -2.12 65.88 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 111.273 -0.731 . . . . 0.0 111.273 -179.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -175.42 175.75 47.25 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 178.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -67.79 148.19 76.68 Favored 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 123.652 2.901 . . . . 0.0 110.067 178.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.9 138.5 34.34 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 123.167 2.578 . . . . 0.0 110.535 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . 0.451 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 2.9 p90 -166.32 -178.45 4.54 Favored 'General case' 0 CA--C 1.528 0.127 0 N-CA-C 105.974 -1.862 . . . . 0.0 105.974 176.001 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -158.11 166.39 32.59 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 121.373 0.606 . . . . 0.0 112.081 -177.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . 0.425 ' CE1' ' C4 ' ' A' ' 93' ' ' ' A' . 85.2 m-85 -121.32 157.82 29.55 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.575 171.034 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 75.7 t -138.9 137.21 42.76 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.134 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -178.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 69.0 tt0 -116.91 114.04 23.29 Favored 'General case' 0 CA--C 1.529 0.142 0 CA-C-O 120.666 0.27 . . . . 0.0 110.814 -176.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 43.2 m-85 -82.11 168.56 17.62 Favored 'General case' 0 N--CA 1.457 -0.095 0 N-CA-C 115.872 1.804 . . . . 0.0 115.872 -176.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 48.7 tp10 -64.74 -35.73 82.01 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 174.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 26.1 p30 -159.19 162.92 25.17 Favored Pre-proline 0 CA--C 1.532 0.275 0 C-N-CA 123.536 0.734 . . . . 0.0 110.359 175.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -63.61 -18.15 63.05 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 123.116 2.544 . . . . 0.0 112.322 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 4.3 ttp85 -78.44 -40.93 34.29 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 117.849 0.295 . . . . 0.0 110.765 -175.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 79.5 m-20 -71.78 -24.35 61.73 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 178.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.59 -28.88 68.14 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 44.5 tp10 -68.77 -34.11 75.02 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 110.492 -0.188 . . . . 0.0 110.492 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -73.85 -33.99 64.33 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 178.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.86 -33.33 64.04 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 177.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 13.7 t -71.22 -45.23 71.81 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 48.2 t -69.79 -16.65 63.33 Favored 'General case' 0 N--CA 1.452 -0.341 0 O-C-N 122.309 -0.244 . . . . 0.0 111.487 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.86 -8.75 41.69 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-O 119.119 -0.823 . . . . 0.0 113.711 -174.155 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -140.25 -12.26 1.07 Allowed 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 118.905 1.352 . . . . 0.0 113.277 -174.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -76.61 146.34 38.29 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 118.516 0.598 . . . . 0.0 110.12 -176.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.25 39.96 97.92 Favored Glycine 0 CA--C 1.527 0.836 0 CA-C-O 119.526 -0.597 . . . . 0.0 112.068 171.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 42.3 t80 -95.67 131.18 42.18 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 113.463 0.912 . . . . 0.0 113.463 -174.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -61.29 105.87 0.55 Allowed 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 123.663 0.785 . . . . 0.0 112.477 -178.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.427 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 46.3 t80 -112.88 169.45 8.9 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 123.738 0.815 . . . . 0.0 111.619 177.691 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.427 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 19.0 t0 -61.02 98.62 0.08 Allowed 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -179.249 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.59 -5.14 61.75 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 123.441 0.543 . . . . 0.0 112.677 177.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -141.3 -171.12 3.22 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 117.855 0.828 . . . . 0.0 112.954 -178.323 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 40.5 ttt180 -147.24 128.34 14.64 Favored 'General case' 0 C--O 1.231 0.113 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 -177.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -63.92 147.49 51.84 Favored 'General case' 0 N--CA 1.461 0.102 0 C-N-CA 122.694 0.398 . . . . 0.0 110.205 -174.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -118.57 119.82 35.65 Favored 'General case' 0 CA--C 1.521 -0.15 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 175.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.7 t -145.55 80.11 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 C-N-CA 122.878 0.471 . . . . 0.0 109.84 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -149.33 159.2 44.48 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.692 0.282 . . . . 0.0 110.807 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -74.16 156.04 87.83 Favored Pre-proline 0 CA--C 1.531 0.223 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo . . . . . 0 C--O 1.252 1.187 0 C-N-CA 123.669 2.913 . . . . 0.0 111.727 175.807 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . 0.404 " H3'" H5'' ' A' ' 91' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.418 -2.884 0 C5'-C4'-C3' 110.058 -3.628 . 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . 0.404 H5'' " H3'" ' A' ' 90' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.422 -2.623 1 O4'-C1'-N19 113.215 5.015 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.451 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.378 0 O4'-C1'-N19 111.594 3.394 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.425 ' C4 ' ' CE1' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.421 -2.663 0 C5'-C4'-C3' 109.922 -3.719 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.69 1 O4'-C1'-N19 112.443 4.243 . 0.01 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.563 0 C5'-C4'-C3' 111.391 -2.739 . 0.0 OUTLIER delta 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 N--CA 1.477 0.924 0 N-CA-C 111.406 0.15 . . . . 0.0 111.406 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 84.0 mt -69.26 142.77 15.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 4.4 tmm_? -70.9 133.75 46.7 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 122.686 0.394 . . . . 0.0 110.396 179.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 57.78 -159.54 12.77 Favored Glycine 0 CA--C 1.528 0.905 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 175.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -72.96 164.6 35.11 Favored 'Trans proline' 0 N--CA 1.449 -1.118 0 C-N-CA 123.249 2.633 . . . . 0.0 109.704 175.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.57 -6.34 43.35 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 122.319 0.248 . . . . 0.0 111.648 -178.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -77.08 168.26 54.64 Favored Glycine 0 CA--C 1.529 0.913 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 76.8 m-20 -76.87 148.67 36.35 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 122.553 0.341 . . . . 0.0 111.031 -178.381 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -76.92 -9.62 58.81 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 122.504 0.322 . . . . 0.0 110.456 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -70.43 -9.12 55.55 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 -176.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.7 m -133.37 9.67 4.05 Favored 'General case' 0 CA--C 1.528 0.106 0 C-N-CA 122.746 0.419 . . . . 0.0 110.591 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . 0.423 ' HA ' ' HA ' ' B' ' 60' ' ' GLU . 32.6 ttp-105 -102.81 148.83 25.14 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.324 0.65 . . . . 0.0 110.686 -177.398 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 20.8 pt -131.67 179.23 4.54 Favored 'Isoleucine or valine' 0 C--O 1.23 0.063 0 C-N-CA 123.277 0.631 . . . . 0.0 109.835 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.44 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.7 OUTLIER -118.82 156.87 28.67 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 114.248 1.203 . . . . 0.0 114.248 -175.674 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 12.7 t -134.37 123.92 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 C-N-CA 122.917 0.487 . . . . 0.0 110.705 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -130.22 166.61 22.14 Favored Glycine 0 CA--C 1.53 1.02 0 N-CA-C 111.688 -0.565 . . . . 0.0 111.688 -177.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 60.5 t30 63.65 28.61 15.06 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 124.648 1.179 . . . . 0.0 111.765 -176.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 87.7 mt -69.38 143.11 92.99 Favored Pre-proline 0 CA--C 1.532 0.287 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -60.46 157.36 36.65 Favored 'Trans proline' 0 N--CA 1.452 -0.96 0 C-N-CA 123.247 2.632 . . . . 0.0 110.783 174.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.99 -18.99 35.59 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 123.377 2.718 . . . . 0.0 110.537 177.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -96.37 14.11 25.48 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.727 0.639 . . . . 0.0 112.727 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 7.8 tp -61.24 153.09 5.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 122.546 0.338 . . . . 0.0 110.691 -177.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 22.9 tpp85 -143.29 149.95 38.55 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -58.34 -26.19 62.83 Favored 'General case' 0 C--N 1.333 -0.14 0 N-CA-C 114.64 1.348 . . . . 0.0 114.64 -174.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 21.6 tptm -71.94 -29.82 64.67 Favored 'General case' 0 CA--C 1.533 0.322 0 O-C-N 122.364 -0.21 . . . . 0.0 110.722 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -67.24 -30.38 70.27 Favored 'General case' 0 CA--C 1.528 0.131 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -178.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.3 mt -75.28 -33.09 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 99.3 mt-10 -75.34 -15.49 60.48 Favored 'General case' 0 N--CA 1.456 -0.173 0 C-N-CA 122.451 0.301 . . . . 0.0 110.986 -178.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -91.51 -52.18 4.91 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 112.924 0.712 . . . . 0.0 112.924 174.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 93.9 t -71.22 -50.91 38.26 Favored 'Isoleucine or valine' 0 C--N 1.34 0.172 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 -174.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -68.09 -31.9 71.84 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -177.731 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 43.8 t -66.45 -29.12 69.18 Favored 'General case' 0 C--O 1.232 0.138 0 N-CA-C 110.539 -0.171 . . . . 0.0 110.539 177.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -71.23 -31.03 67.07 Favored 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 174.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -79.0 -20.88 47.96 Favored 'General case' 0 C--O 1.233 0.219 0 N-CA-C 115.79 1.774 . . . . 0.0 115.79 176.376 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 169.81 -177.11 43.43 Favored Glycine 0 CA--C 1.524 0.602 0 CA-C-N 118.388 0.54 . . . . 0.0 112.289 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.37 95.99 8.92 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 122.838 0.455 . . . . 0.0 110.68 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . 0.431 ' N ' HD12 ' B' ' 42' ' ' ILE . 1.8 mp -80.28 149.6 5.13 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 C-N-CA 122.733 0.413 . . . . 0.0 110.225 175.229 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 29.1 mtp-105 -115.0 -34.06 5.2 Favored 'General case' 0 CA--C 1.528 0.119 0 C-N-CA 123.657 0.783 . . . . 0.0 111.313 177.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.8 m-20 -146.61 155.8 42.74 Favored 'General case' 0 N--CA 1.457 -0.105 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -176.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 4.1 mp -136.1 150.48 28.1 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.137 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 177.248 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -138.96 48.81 1.88 Allowed 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 120.792 0.33 . . . . 0.0 111.072 179.167 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.6 tp -63.78 124.48 21.6 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 173.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 24.4 pttm -152.35 161.72 42.19 Favored 'General case' 0 N--CA 1.458 -0.062 0 C-N-CA 122.53 0.332 . . . . 0.0 110.666 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 18.8 p30 -69.74 158.06 36.13 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-O 120.891 0.377 . . . . 0.0 111.061 -177.201 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 28.7 ttm-85 -96.65 76.96 2.86 Favored 'General case' 0 N--CA 1.457 -0.11 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 18.7 mmt-85 56.36 26.39 10.59 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 122.761 0.424 . . . . 0.0 110.32 -174.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.2 -8.97 61.04 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 123.777 0.703 . . . . 0.0 111.733 -177.455 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -86.65 -168.09 44.42 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 176.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . 0.465 ' HA ' ' HD3' ' B' ' 55' ' ' PRO . 51.4 Cg_exo -52.68 119.41 5.92 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 124.232 3.288 . . . . 0.0 110.944 -179.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . 0.465 ' HD3' ' HA ' ' B' ' 54' ' ' PRO . 40.4 Cg_exo -56.45 163.05 7.17 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 124.09 3.193 . . . . 0.0 113.824 -174.011 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -147.61 163.4 36.75 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 104.385 -2.45 . . . . 0.0 104.385 175.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -149.93 163.59 37.67 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 119.997 -0.681 . . . . 0.0 112.737 -171.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . 0.445 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 88.6 m-85 -122.15 154.67 37.11 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.09 169.078 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 71.9 t -140.12 132.37 33.2 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.266 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . 0.423 ' HA ' ' HA ' ' B' ' 17' ' ' ARG . 68.2 tt0 -117.28 132.54 56.6 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.811 0.339 . . . . 0.0 111.252 -174.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -98.47 160.55 14.21 Favored 'General case' 0 C--O 1.231 0.12 0 N-CA-C 114.826 1.417 . . . . 0.0 114.826 -175.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -81.89 -17.4 47.36 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.857 0.463 . . . . 0.0 110.382 171.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -152.74 120.58 3.13 Favored Pre-proline 0 C--O 1.233 0.206 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 -178.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -65.52 -14.33 44.3 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 123.066 2.51 . . . . 0.0 111.948 -175.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 86.7 mtm180 -71.69 -24.49 61.83 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 117.944 0.338 . . . . 0.0 110.669 176.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -87.74 -27.07 22.59 Favored 'General case' 0 C--O 1.232 0.167 0 CA-C-O 120.75 0.309 . . . . 0.0 110.751 176.016 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.03 -25.23 65.27 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 177.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -69.86 -31.08 68.73 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 122.218 0.207 . . . . 0.0 110.523 178.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -76.48 -35.33 58.45 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 112.308 0.485 . . . . 0.0 112.308 179.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.33 -27.72 66.52 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 122.634 0.373 . . . . 0.0 110.059 177.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 39.6 t -87.52 -44.09 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.2 t -65.98 -21.56 66.42 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-N 117.552 0.16 . . . . 0.0 111.127 -176.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -90.29 -15.36 57.4 Favored Glycine 0 CA--C 1.53 0.977 0 CA-C-O 119.455 -0.636 . . . . 0.0 113.004 -177.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 61.0 mtm180 -146.22 19.57 1.39 Allowed 'General case' 0 C--N 1.342 0.282 0 CA-C-N 118.24 1.02 . . . . 0.0 113.146 -170.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 18.8 p30 -70.81 -1.42 11.56 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.105 0.779 . . . . 0.0 113.105 178.029 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.82 90.69 0.08 OUTLIER Glycine 0 C--N 1.335 0.524 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -120.58 137.77 54.23 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 112.999 0.74 . . . . 0.0 112.999 176.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -68.94 92.26 0.5 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.442 0.697 . . . . 0.0 111.953 -176.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -84.68 -175.92 5.99 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -67.89 82.79 0.2 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 123.557 0.743 . . . . 0.0 112.298 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.7 2.83 89.81 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 112.148 -0.381 . . . . 0.0 112.148 178.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -137.86 -174.57 3.82 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -179.081 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 70.5 ttp85 -140.39 135.06 31.71 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.85 151.42 45.55 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 122.666 0.387 . . . . 0.0 110.18 -179.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 51.5 mtm180 -134.54 55.71 1.88 Allowed 'General case' 0 C--O 1.231 0.103 0 C-N-CA 122.435 0.294 . . . . 0.0 110.849 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 20.1 t -82.95 94.83 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.188 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 174.392 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -152.31 161.47 42.56 Favored 'General case' 0 C--O 1.226 -0.174 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -76.6 156.05 83.2 Favored Pre-proline 0 CA--C 1.532 0.268 0 N-CA-C 114.666 1.358 . . . . 0.0 114.666 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo . . . . . 0 C--O 1.25 1.119 0 C-N-CA 123.789 2.993 . . . . 0.0 111.723 175.434 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.426 -2.287 0 C5'-C4'-C3' 110.589 -3.274 OUTLIER-DELTA 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.948 1 C5'-C4'-C3' 108.908 -4.395 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.44 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.323 0 C5'-C4'-C3' 110.337 -3.442 . 0.259 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.445 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.426 -2.241 1 C5'-C4'-C3' 109.102 -4.266 . 0.01 6n . 0.0 . . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.568 1 O4'-C1'-N19 112.762 4.562 . 0.01 5z . 0.0 . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.601 0 C5'-C4'-C3' 109.838 -3.775 . 0.0 OUTLIER delta 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 11.8 t . . . . . 0 N--CA 1.476 0.833 0 N-CA-C 111.302 0.112 . . . . 0.0 111.302 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . 0.435 ' N ' HD12 ' B' ' 7' ' ' ILE . 1.8 mp -68.07 153.13 9.08 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.58 172.21 2.81 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.078 0.466 . . . . 0.0 112.2 -176.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . 0.528 ' N ' ' CD ' ' B' ' 10' ' ' PRO . . . 70.99 27.66 71.8 Favored Glycine 0 CA--C 1.535 1.318 0 CA-C-O 118.232 -1.315 . . . . 0.0 114.695 175.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . 0.528 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 61.5 Cg_endo -70.54 -25.02 25.44 Favored 'Trans proline' 0 N--CA 1.454 -0.8 0 CA-C-N 120.489 2.145 . . . . 0.0 110.334 179.259 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -161.1 158.71 28.1 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 123.371 0.669 . . . . 0.0 109.909 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -81.71 -6.04 89.38 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.928 -0.469 . . . . 0.0 111.928 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 35.9 p30 -87.04 8.76 22.07 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 117.408 0.604 . . . . 0.0 111.804 -177.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -65.05 148.61 51.35 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -178.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 82.5 m-20 -78.67 148.98 32.94 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -174.011 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 95.9 m 58.22 2.4 0.2 Allowed 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 125.152 1.381 . . . . 0.0 114.343 174.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 84.2 mtt-85 -83.38 146.9 28.21 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 118.272 0.487 . . . . 0.0 111.737 176.195 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 26.9 pt -131.45 172.29 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 173.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.442 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.4 OUTLIER -120.74 149.72 42.1 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 114.185 1.18 . . . . 0.0 114.185 -178.029 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 19.7 t -137.53 141.83 38.36 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 C-N-CA 123.449 0.699 . . . . 0.0 109.728 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -150.43 171.84 30.26 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -176.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 65.6 t30 59.73 30.91 20.51 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.213 1.005 . . . . 0.0 111.688 -175.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.9 mt -64.17 149.15 94.66 Favored Pre-proline 0 N--CA 1.454 -0.257 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 174.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . 0.431 ' HA ' ' HD3' ' B' ' 25' ' ' PRO . 37.0 Cg_endo -65.29 155.45 68.51 Favored 'Trans proline' 0 N--CA 1.452 -0.944 0 C-N-CA 122.996 2.464 . . . . 0.0 111.218 -177.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 24' ' ' PRO . 23.7 Cg_exo -62.85 -3.21 4.31 Favored 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 124.271 3.314 . . . . 0.0 113.191 -179.495 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -136.52 30.61 2.89 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -176.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 6.3 tp -61.56 137.39 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 177.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 47.2 mtm180 -97.55 153.93 17.84 Favored 'General case' 0 N--CA 1.457 -0.124 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.6 p -68.24 -22.0 64.8 Favored 'General case' 0 C--O 1.232 0.155 0 N-CA-C 112.914 0.709 . . . . 0.0 112.914 177.21 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -82.02 -26.47 33.78 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 122.798 0.439 . . . . 0.0 111.139 -179.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -64.53 -29.78 70.81 Favored 'General case' 0 N--CA 1.455 -0.175 0 N-CA-C 112.106 0.409 . . . . 0.0 112.106 -177.089 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 mm -74.69 -21.2 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.18 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 90.2 mt-10 -78.47 -48.74 14.76 Favored 'General case' 0 C--O 1.223 -0.324 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -65.86 -44.7 84.63 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -174.312 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 99.0 t -69.84 -53.04 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.099 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -176.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -75.28 -24.1 57.49 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 113.546 0.943 . . . . 0.0 113.546 -174.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 41.8 t -68.89 -31.79 70.96 Favored 'General case' 0 C--N 1.342 0.265 0 CA-C-N 118.008 0.367 . . . . 0.0 110.054 173.149 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 58.3 tptt -68.36 -30.76 69.78 Favored 'General case' 0 C--N 1.341 0.212 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 174.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 39.6 m-85 -74.75 -20.36 59.85 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 115.457 1.651 . . . . 0.0 115.457 174.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 159.52 -178.0 35.81 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 111.835 -0.506 . . . . 0.0 111.835 176.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -73.79 122.19 22.04 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-O 120.65 0.262 . . . . 0.0 110.36 -178.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 73.8 mt -92.65 140.0 17.01 Favored 'Isoleucine or valine' 0 C--O 1.233 0.237 0 C-N-CA 122.937 0.495 . . . . 0.0 111.201 -178.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -94.14 -38.19 11.21 Favored 'General case' 0 N--CA 1.458 -0.071 0 C-N-CA 123.093 0.557 . . . . 0.0 110.361 170.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -155.94 156.76 35.12 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 120.713 0.292 . . . . 0.0 111.101 -173.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mt -133.28 143.3 39.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 C-N-CA 124.186 0.994 . . . . 0.0 108.854 175.281 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -144.74 64.88 1.28 Allowed 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 120.644 0.259 . . . . 0.0 111.54 -174.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 57.7 tp -58.23 134.75 56.8 Favored 'General case' 0 C--O 1.234 0.272 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 169.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 54.8 tttp -143.23 164.23 30.78 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.841 0.353 . . . . 0.0 111.238 -168.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 44.8 p30 -142.67 -155.97 0.64 Allowed 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 123.383 0.673 . . . . 0.0 110.694 -173.312 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 55.0 mtm180 63.61 175.31 0.17 Allowed 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.837 1.255 . . . . 0.0 111.618 -172.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 61.81 159.18 0.06 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.659 1.184 . . . . 0.0 110.789 -170.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -67.01 170.9 32.58 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.07 -176.77 53.01 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 111.449 -0.66 . . . . 0.0 111.449 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -68.33 161.24 45.59 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 124.348 3.365 . . . . 0.0 111.122 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -64.8 167.21 16.09 Favored 'Trans proline' 0 N--CA 1.452 -0.963 0 C-N-CA 123.684 2.922 . . . . 0.0 110.658 177.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . 0.46 ' CE1' " H4'" ' A' ' 92' ' ' ' C' . 3.8 p90 -152.92 173.3 15.55 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 106.281 -1.748 . . . . 0.0 106.281 -175.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.64 168.31 27.78 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 -174.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . 0.498 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 80.7 m-85 -127.23 157.11 40.7 Favored 'General case' 0 C--O 1.234 0.282 0 C-N-CA 123.618 0.767 . . . . 0.0 110.056 171.287 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 56.0 t -143.76 142.03 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -119.18 125.26 48.78 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 177.101 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -89.49 161.68 16.11 Favored 'General case' 0 C--O 1.231 0.114 0 N-CA-C 115.272 1.582 . . . . 0.0 115.272 174.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 37.3 tp10 -72.18 -23.97 61.35 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.559 175.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 48.4 m-20 -144.47 151.86 51.85 Favored Pre-proline 0 N--CA 1.455 -0.176 0 C-N-CA 124.192 0.997 . . . . 0.0 112.292 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -68.6 -18.29 42.9 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.877 2.384 . . . . 0.0 110.615 178.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 73.0 ttt-85 -68.84 -40.04 79.63 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 177.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -76.07 -26.12 56.22 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 120.739 0.304 . . . . 0.0 111.664 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.87 -36.24 70.05 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 176.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 41.7 tp10 -69.35 -32.09 70.93 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 110.388 -0.227 . . . . 0.0 110.388 178.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -70.94 -35.9 72.4 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.43 -32.73 68.71 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 178.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 59.1 t -80.14 -30.48 12.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 45.7 t -79.97 -9.33 59.68 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 122.715 0.406 . . . . 0.0 110.656 178.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -66.57 -77.06 0.31 Allowed Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.217 -0.753 . . . . 0.0 111.217 -178.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 4.0 tpm_? -156.69 132.06 9.28 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 51.3 p-10 -153.15 168.79 24.78 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.506 0.722 . . . . 0.0 109.09 176.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 58.67 40.8 95.26 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 174.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -98.42 132.93 43.47 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 113.832 1.049 . . . . 0.0 113.832 -172.411 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -62.45 106.69 0.8 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.639 0.776 . . . . 0.0 112.35 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.437 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 50.1 t80 -114.31 170.31 8.39 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 123.585 0.754 . . . . 0.0 111.39 178.341 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.437 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 21.3 t0 -60.0 100.54 0.09 Allowed 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.33 -5.6 42.49 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-O 119.746 -0.474 . . . . 0.0 112.912 178.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 88.1 m-85 -140.34 -170.51 3.0 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 117.871 0.836 . . . . 0.0 113.241 -178.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 40.0 ttt180 -148.61 129.9 14.67 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 123.673 0.789 . . . . 0.0 108.953 -177.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -67.51 149.59 49.97 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -176.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -129.67 130.35 45.44 Favored 'General case' 0 C--N 1.34 0.181 0 CA-C-O 120.624 0.25 . . . . 0.0 110.52 172.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.6 t -145.3 80.36 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.231 0.099 0 C-N-CA 123.96 0.904 . . . . 0.0 109.298 173.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -144.63 168.36 20.34 Favored 'General case' 0 C--O 1.226 -0.132 0 C-N-CA 122.595 0.358 . . . . 0.0 111.047 -175.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 69.9 m-85 -63.67 153.24 84.17 Favored Pre-proline 0 C--O 1.235 0.307 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 179.03 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 C--O 1.251 1.168 0 C-N-CA 123.705 2.937 . . . . 0.0 110.932 175.168 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.664 0 C5'-C4'-C3' 109.925 -3.717 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.472 1 O4'-C1'-N19 112.32 4.12 . 0.344 2[ . 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.46 " H4'" ' CE1' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.42 -2.732 0 O4'-C1'-N19 111.112 2.912 . 0.687 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.498 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.385 0 C5'-C4'-C3' 110.111 -3.593 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.42 -2.743 0 O4'-C1'-N19 111.496 3.296 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.479 1 C5'-C4'-C3' 109.402 -4.065 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.476 0.825 0 N-CA-C 111.79 0.293 . . . . 0.0 111.79 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 32.3 mm -71.14 149.4 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 2.4 tmm_? -62.71 -47.33 84.07 Favored 'General case' 0 C--N 1.337 0.062 0 C-N-CA 122.723 0.409 . . . . 0.0 111.059 -179.214 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . -157.92 -161.5 10.99 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 -172.417 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.52 -28.1 53.3 Favored 'Trans proline' 0 N--CA 1.452 -0.957 0 C-N-CA 123.933 3.088 . . . . 0.0 111.853 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 53.62 19.39 1.76 Allowed 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 123.91 0.884 . . . . 0.0 113.109 175.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.1 152.52 50.13 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -73.85 -15.1 61.17 Favored 'General case' 0 N--CA 1.457 -0.114 0 CA-C-N 116.773 0.286 . . . . 0.0 111.709 -178.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 63.4 t30 -88.22 160.83 17.54 Favored 'General case' 0 N--CA 1.456 -0.125 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 50.1 m-20 -82.4 -139.62 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 172.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 69.8 m 62.58 15.33 7.85 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 123.554 0.742 . . . . 0.0 112.855 175.508 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 66.1 mtm-85 -71.29 143.86 50.19 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 117.769 0.259 . . . . 0.0 110.796 172.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.6 pt -139.16 171.2 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.102 0 C-N-CA 123.302 0.641 . . . . 0.0 109.4 177.188 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.424 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.2 OUTLIER -113.75 151.37 32.03 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -179.327 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 44.1 t -137.38 144.64 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 123.251 0.62 . . . . 0.0 109.462 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -156.2 177.15 33.39 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -177.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 62.1 t30 62.75 169.68 0.14 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.604 1.161 . . . . 0.0 111.406 -172.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 85.3 mt -61.36 146.26 89.41 Favored Pre-proline 0 N--CA 1.454 -0.251 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 177.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -69.31 159.87 52.05 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 C-N-CA 123.553 2.835 . . . . 0.0 110.838 -176.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.42 -9.06 25.06 Favored 'Trans proline' 0 N--CA 1.453 -0.897 0 C-N-CA 124.104 3.202 . . . . 0.0 110.775 178.182 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 55.5 t0 -149.94 133.65 16.78 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 177.378 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 3.0 tp -80.01 80.21 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-O 121.618 0.723 . . . . 0.0 111.344 -172.315 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 16.3 ptt180 -159.17 145.91 16.91 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.665 171.443 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.8 p -71.81 -13.7 61.77 Favored 'General case' 0 C--O 1.231 0.086 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -179.121 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 47.7 tptt -82.24 -5.27 58.4 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.577 0.351 . . . . 0.0 110.517 179.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -53.35 -44.66 68.71 Favored 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -177.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.3 tt -78.55 -5.26 7.69 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 C-N-CA 122.898 0.479 . . . . 0.0 110.819 -176.445 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 84.5 mt-10 -116.85 1.43 12.7 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 122.55 0.34 . . . . 0.0 111.236 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 11.1 t0 -125.29 -54.04 1.59 Allowed 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 179.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 87.2 t -69.7 -41.99 80.2 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.042 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -178.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 45.4 m-85 -67.86 -27.85 67.04 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 176.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 67.2 m -72.65 -21.88 61.02 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.443 177.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 24.7 ttmm -77.75 -30.82 51.75 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 109.684 -0.488 . . . . 0.0 109.684 173.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -70.86 -23.13 62.26 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 114.39 1.256 . . . . 0.0 114.39 173.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 164.01 174.34 33.71 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 174.138 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -71.53 125.13 26.26 Favored 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 17.1 mt -99.33 138.97 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.164 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 77.8 mtp85 -86.31 -43.1 13.18 Favored 'General case' 0 C--N 1.333 -0.148 0 C-N-CA 122.897 0.479 . . . . 0.0 110.065 174.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -152.6 159.13 43.25 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -176.445 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.9 mp -130.02 148.68 33.18 Favored 'Isoleucine or valine' 0 C--N 1.339 0.136 0 C-N-CA 124.172 0.989 . . . . 0.0 109.627 177.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 21.2 t0 -140.72 63.97 1.44 Allowed 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.296 0.238 . . . . 0.0 111.255 176.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 61.2 tp -59.81 133.61 56.26 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 170.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 15.7 ttmm -143.62 152.2 41.08 Favored 'General case' 0 C--N 1.342 0.24 0 CA-C-O 120.74 0.305 . . . . 0.0 111.024 -173.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -75.96 159.77 30.54 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 122.996 0.518 . . . . 0.0 110.563 178.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 9.2 tpt180 -148.69 146.7 28.26 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.381 0.672 . . . . 0.0 109.767 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 55.7 mtt180 -106.07 149.37 26.78 Favored 'General case' 0 C--O 1.231 0.099 0 C-N-CA 122.888 0.475 . . . . 0.0 110.198 -179.542 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.59 6.55 62.81 Favored Glycine 0 CA--C 1.532 1.116 0 N-CA-C 112.357 -0.297 . . . . 0.0 112.357 176.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -173.67 174.63 46.24 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . 0.401 ' HA ' ' HD3' ' B' ' 55' ' ' PRO . 39.0 Cg_exo -59.08 157.63 28.82 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.981 3.12 . . . . 0.0 111.633 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' B' ' 54' ' ' PRO . 39.7 Cg_exo -58.63 168.53 4.02 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.828 3.019 . . . . 0.0 111.615 175.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . 0.429 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 2.9 p90 -150.72 169.12 22.38 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 179.211 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -157.96 170.7 21.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 120.916 0.389 . . . . 0.0 111.527 -174.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -123.59 154.68 38.95 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.909 169.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 71.7 t -137.73 139.85 42.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -178.127 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -121.91 108.32 13.29 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -79.21 160.59 26.84 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 115.004 1.483 . . . . 0.0 115.004 177.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 41.1 tp10 -75.76 -31.85 59.71 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.542 175.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -133.05 150.75 76.42 Favored Pre-proline 0 CA--C 1.532 0.275 0 C-N-CA 123.707 0.803 . . . . 0.0 112.365 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -70.11 -21.6 31.62 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 123.203 2.602 . . . . 0.0 110.885 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 81.2 mtt85 -72.67 -27.89 62.37 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 178.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 64.5 m-20 -79.76 -31.39 40.95 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 122.039 0.136 . . . . 0.0 111.318 179.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.97 -36.68 69.91 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 110.511 -0.181 . . . . 0.0 110.511 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 43.4 tp10 -68.12 -34.29 76.1 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 78.9 m-20 -72.28 -35.23 68.68 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.1 -29.52 64.18 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.2 t -75.21 -50.97 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.479 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 88.0 p -73.5 -10.22 59.49 Favored 'General case' 0 C--O 1.233 0.217 0 O-C-N 122.199 -0.313 . . . . 0.0 111.661 -176.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -98.62 -10.38 50.44 Favored Glycine 0 CA--C 1.529 0.943 0 CA-C-O 119.167 -0.796 . . . . 0.0 113.371 -173.49 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -151.51 -13.02 0.2 Allowed 'General case' 0 C--N 1.34 0.159 0 CA-C-N 119.04 1.42 . . . . 0.0 113.206 -173.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -66.61 143.9 56.73 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.421 0.555 . . . . 0.0 110.146 -177.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 60.22 39.92 96.62 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 173.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 41.2 t80 -99.13 133.42 43.44 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 113.635 0.976 . . . . 0.0 113.635 -173.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.2 t0 -62.1 105.69 0.62 Allowed 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 123.574 0.749 . . . . 0.0 112.372 -178.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.423 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 51.5 t80 -111.26 169.92 8.46 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 123.829 0.852 . . . . 0.0 111.389 178.23 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.423 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 21.0 t0 -61.0 97.41 0.06 Allowed 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.375 0.509 . . . . 0.0 112.375 -179.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 80.68 -4.06 71.25 Favored Glycine 0 CA--C 1.53 0.994 0 CA-C-O 119.379 -0.678 . . . . 0.0 112.722 177.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -142.46 -170.72 3.25 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 118.142 0.971 . . . . 0.0 112.793 -177.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 36.0 ttt180 -145.89 130.22 17.66 Favored 'General case' 0 C--O 1.231 0.095 0 C-N-CA 123.466 0.706 . . . . 0.0 109.292 -178.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -63.86 152.92 38.33 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 122.952 0.501 . . . . 0.0 111.078 -174.088 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 53.1 mmm-85 -124.92 117.36 23.9 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 173.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 19.2 t -145.25 81.31 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.522 -0.103 0 C-N-CA 122.75 0.42 . . . . 0.0 110.252 178.091 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.9 pt-20 -142.8 168.49 19.6 Favored 'General case' 0 C--N 1.333 -0.112 0 C-N-CA 122.429 0.291 . . . . 0.0 111.066 -175.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 54.3 m-85 -65.15 151.66 93.27 Favored Pre-proline 0 CA--C 1.532 0.257 0 N-CA-C 113.962 1.097 . . . . 0.0 113.962 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo . . . . . 0 N--CA 1.448 -1.186 0 C-N-CA 123.894 3.063 . . . . 0.0 110.72 175.719 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.529 0 O4'-C1'-N19 111.414 3.214 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.293 0 C5'-C4'-C3' 111.623 -2.585 OUTLIER-DELTA 0.072 8d . 0.0 . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.429 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.423 -2.528 0 C5'-C4'-C3' 111.559 -2.627 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.643 0 C5'-C4'-C3' 109.634 -3.911 . 0.01 6n . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.42 -2.721 0 C5'-C4'-C3' 109.825 -3.784 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.354 0 O4'-C1'-N19 111.954 3.754 . 0.13 2u . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 12.4 t . . . . . 0 N--CA 1.477 0.878 0 N-CA-C 111.499 0.185 . . . . 0.0 111.499 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 44.9 mm -66.02 149.21 11.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 179.009 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 41.0 ttm-85 -68.42 142.79 55.28 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.95 -73.2 0.23 Allowed Glycine 0 CA--C 1.527 0.817 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -58.1 -10.97 9.07 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 123.777 2.984 . . . . 0.0 112.176 174.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -147.51 160.45 42.59 Favored 'General case' 0 C--O 1.234 0.279 0 C-N-CA 123.112 0.565 . . . . 0.0 109.976 177.339 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.39 179.93 43.55 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 13.3 m120 -139.49 3.54 2.11 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 122.749 0.42 . . . . 0.0 110.919 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -144.82 147.59 33.04 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -95.73 8.93 42.08 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.038 0.535 . . . . 0.0 112.326 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 85.3 m -76.46 8.67 3.26 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -176.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 79.6 mtt180 -76.78 147.41 37.28 Favored 'General case' 0 CA--C 1.528 0.108 0 CA-C-N 117.889 0.313 . . . . 0.0 110.668 177.177 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 30.3 pt -135.57 167.87 24.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.107 0 C-N-CA 123.216 0.607 . . . . 0.0 109.364 173.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.423 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.6 OUTLIER -108.61 148.65 30.03 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 114.694 1.368 . . . . 0.0 114.694 -173.309 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 21.7 t -137.13 139.05 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 C-N-CA 123.839 0.856 . . . . 0.0 110.001 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.76 175.65 30.45 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -177.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 54.2 t30 59.68 26.07 15.11 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.807 0.843 . . . . 0.0 111.42 -175.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 97.3 mt -64.9 152.25 91.22 Favored Pre-proline 0 N--CA 1.455 -0.218 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 176.455 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_exo -53.47 140.8 63.6 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.247 2.631 . . . . 0.0 111.388 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_exo -60.32 -7.26 6.47 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 123.694 2.93 . . . . 0.0 112.579 177.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 27.5 p30 -135.73 26.56 3.36 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 123.448 0.699 . . . . 0.0 111.879 -177.524 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 7.2 tp -54.96 141.69 10.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . 0.403 HH11 ' HD3' ' B' ' 28' ' ' ARG . 41.8 ttt-85 -80.44 147.55 30.9 Favored 'General case' 0 N--CA 1.455 -0.19 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 -176.698 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.82 17.36 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 114.908 1.447 . . . . 0.0 114.908 -178.303 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -146.0 -22.2 0.45 Allowed 'General case' 0 N--CA 1.454 -0.234 0 C-N-CA 122.968 0.507 . . . . 0.0 110.974 -178.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 -67.45 -22.92 65.47 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 112.401 0.519 . . . . 0.0 112.401 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 6.4 tp -71.31 -18.18 20.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 C-N-CA 122.64 0.376 . . . . 0.0 110.188 176.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -96.16 -26.63 15.39 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 176.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -64.93 -49.91 68.54 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.625 0.25 . . . . 0.0 111.67 -177.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 99.7 t -67.63 -43.56 86.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -178.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -74.6 -32.45 62.36 Favored 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 114.52 1.304 . . . . 0.0 114.52 -177.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 90.0 p -69.74 -22.48 63.37 Favored 'General case' 0 C--O 1.231 0.107 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.87 175.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -72.26 -34.02 67.92 Favored 'General case' 0 C--N 1.34 0.193 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 173.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 49.4 m-85 -68.87 -19.1 64.23 Favored 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 170.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.76 169.3 33.14 Favored Glycine 0 CA--C 1.532 1.119 0 C-N-CA 123.183 0.42 . . . . 0.0 112.996 171.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 59.56 20.28 8.8 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 124.762 1.225 . . . . 0.0 113.68 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.5 mp -76.51 140.15 17.67 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 173.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 20.4 mmt180 -120.3 -21.92 6.74 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 122.488 0.315 . . . . 0.0 111.502 173.524 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -158.13 149.6 21.33 Favored 'General case' 0 C--N 1.339 0.137 0 N-CA-C 113.919 1.081 . . . . 0.0 113.919 176.581 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -120.4 152.24 23.31 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 171.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 45.1 t0 -145.16 79.07 1.58 Allowed 'General case' 0 N--CA 1.449 -0.496 0 CA-C-O 120.947 0.404 . . . . 0.0 111.374 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 55.9 tp -66.04 135.73 55.05 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 171.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 14.5 ttmm -151.86 168.29 25.58 Favored 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 -173.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 54.3 t30 -155.12 156.89 36.6 Favored 'General case' 0 N--CA 1.452 -0.325 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 175.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 11.0 tpp180 -151.98 6.08 0.44 Allowed 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.274 0.63 . . . . 0.0 110.325 -178.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 6.5 ptp85 -150.18 166.16 30.69 Favored 'General case' 0 CA--C 1.529 0.136 0 O-C-N 122.035 -0.415 . . . . 0.0 110.891 -172.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -78.4 -9.54 86.92 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 178.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -78.1 -172.4 39.63 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.096 -0.801 . . . . 0.0 111.096 176.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -57.22 151.13 53.42 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 123.822 3.015 . . . . 0.0 111.621 179.019 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.07 172.88 13.83 Favored 'Trans proline' 0 N--CA 1.452 -0.955 0 C-N-CA 123.753 2.969 . . . . 0.0 111.184 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . 0.499 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 1.9 p90 -149.11 171.76 15.9 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 104.977 -2.231 . . . . 0.0 104.977 177.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.76 169.03 25.32 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.289 0.566 . . . . 0.0 111.941 -174.566 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . 0.534 ' CE1' ' C4 ' ' A' ' 93' ' ' ' A' . 90.9 m-85 -121.88 156.95 32.22 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.881 171.228 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 96.8 t -134.8 140.29 45.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -124.1 115.94 21.98 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.019 0.437 . . . . 0.0 110.538 -174.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 38.5 m-85 -91.3 161.74 14.91 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 114.256 1.206 . . . . 0.0 114.256 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -75.65 -28.23 58.67 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 170.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 17.2 p30 -154.8 152.55 25.87 Favored Pre-proline 0 CA--C 1.534 0.333 0 C-N-CA 123.326 0.651 . . . . 0.0 111.675 176.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.09 -7.85 22.27 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 123.24 2.626 . . . . 0.0 111.429 179.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 45.3 ttm105 -65.24 -38.9 91.8 Favored 'General case' 0 C--N 1.339 0.122 0 C-N-CA 122.444 0.298 . . . . 0.0 111.331 -177.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -94.52 -17.81 22.04 Favored 'General case' 0 C--O 1.232 0.177 0 N-CA-C 112.859 0.688 . . . . 0.0 112.859 179.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.7 -27.21 67.46 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -69.05 -30.36 68.68 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 110.423 -0.214 . . . . 0.0 110.423 178.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -75.98 -36.81 59.09 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 112.165 0.431 . . . . 0.0 112.165 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.01 -28.01 64.1 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 110.263 -0.273 . . . . 0.0 110.263 176.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 16.6 t -77.29 -50.18 21.07 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.177 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 71.1 m -73.59 -7.6 52.59 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 111.656 0.243 . . . . 0.0 111.656 -175.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -99.67 -8.05 52.58 Favored Glycine 0 CA--C 1.53 1.023 0 CA-C-O 119.07 -0.85 . . . . 0.0 113.423 -175.088 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 13.6 tpp180 -152.04 -13.73 0.19 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 118.489 1.145 . . . . 0.0 113.332 -174.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -66.65 141.86 57.64 Favored 'General case' 0 N--CA 1.456 -0.168 0 O-C-N 121.933 -0.479 . . . . 0.0 110.118 -177.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.49 43.87 97.5 Favored Glycine 0 CA--C 1.53 0.988 0 N-CA-C 111.921 -0.472 . . . . 0.0 111.921 174.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -101.86 137.5 40.07 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 114.132 1.16 . . . . 0.0 114.132 -173.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 11.3 t0 -63.23 109.07 1.43 Allowed 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 123.62 0.768 . . . . 0.0 112.491 -176.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.41 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 42.3 t80 -116.27 168.11 10.42 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 123.662 0.785 . . . . 0.0 111.524 175.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.41 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.5 t0 -58.99 98.5 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.98 -5.79 61.31 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-O 119.476 -0.624 . . . . 0.0 112.6 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -141.54 -169.32 2.85 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.007 0.904 . . . . 0.0 113.174 -177.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 42.3 ttp-105 -145.26 131.05 19.04 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 123.492 0.717 . . . . 0.0 109.48 -178.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -63.41 152.07 39.24 Favored 'General case' 0 N--CA 1.461 0.086 0 C-N-CA 122.782 0.433 . . . . 0.0 110.372 -177.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 92.1 mtm-85 -127.98 121.3 29.51 Favored 'General case' 0 CA--C 1.52 -0.177 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 173.302 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 24.2 t -142.46 81.45 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -141.54 164.26 30.71 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 111.798 0.295 . . . . 0.0 111.798 -174.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . 0.412 ' CD1' ' HD2' ' B' ' 89' ' ' PRO . 17.0 t80 -72.37 136.14 81.5 Favored Pre-proline 0 CA--C 1.534 0.341 0 N-CA-C 113.365 0.876 . . . . 0.0 113.365 178.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . 0.412 ' HD2' ' CD1' ' B' ' 88' ' ' PHE . 47.6 Cg_endo . . . . . 0 C--O 1.25 1.081 0 C-N-CA 123.706 2.937 . . . . 0.0 111.076 -179.073 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.087 0 C3'-C2'-C1' 104.832 3.702 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.63 0 O4'-C1'-N19 111.428 3.228 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.499 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.421 -2.701 0 O4'-C1'-N19 111.235 3.035 . 0.057 2z . 0.0 . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.534 ' C4 ' ' CE1' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.427 -2.172 1 O4'-C1'-N19 112.699 4.499 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . 0.47 H5'' " H3'" ' A' ' 93' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.422 -2.604 0 O4'-C1'-N19 111.582 3.382 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.859 0 C5'-C4'-C3' 110.158 -3.561 . 0.282 2u . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m . . . . . 0 N--CA 1.477 0.925 0 N-CA-C 111.531 0.197 . . . . 0.0 111.531 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 8.7 pt -72.77 166.04 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 C-N-CA 122.846 0.458 . . . . 0.0 110.214 -178.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 33.0 ttm105 -67.68 138.7 56.52 Favored 'General case' 0 N--CA 1.457 -0.086 0 C-N-CA 122.921 0.488 . . . . 0.0 110.598 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.77 -66.84 0.31 Allowed Glycine 0 CA--C 1.529 0.946 0 CA-C-O 119.324 -0.709 . . . . 0.0 111.896 174.613 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.23 -6.78 3.14 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 124.073 3.182 . . . . 0.0 113.309 178.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -147.65 155.88 42.22 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 118.01 0.368 . . . . 0.0 110.773 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -84.29 22.18 9.03 Favored Glycine 0 CA--C 1.528 0.899 0 N-CA-C 111.624 -0.59 . . . . 0.0 111.624 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -71.27 3.14 3.88 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.353 0.577 . . . . 0.0 112.25 -176.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 9.5 m120 -133.25 138.24 46.39 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 122.46 0.304 . . . . 0.0 110.824 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -113.25 177.52 4.6 Favored 'General case' 0 C--N 1.334 -0.074 0 C-N-CA 123.883 0.873 . . . . 0.0 111.008 -178.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 72.3 m 57.31 16.95 3.39 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 123.657 0.783 . . . . 0.0 112.641 177.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 52.8 mtm180 -75.38 151.65 38.15 Favored 'General case' 0 N--CA 1.456 -0.138 0 C-N-CA 122.713 0.405 . . . . 0.0 111.781 178.014 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 pt -136.9 175.52 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 170.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.417 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.5 OUTLIER -124.76 148.25 48.21 Favored 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 114.541 1.312 . . . . 0.0 114.541 -177.715 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.2 t -135.33 140.89 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.643 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -151.0 179.38 27.75 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 -178.038 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 57.4 t30 60.09 22.23 11.44 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.724 0.81 . . . . 0.0 111.251 -174.093 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 92.8 mt -68.39 147.01 98.17 Favored Pre-proline 0 N--CA 1.451 -0.377 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 177.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . 0.409 ' HA ' ' HD3' ' B' ' 25' ' ' PRO . 59.1 Cg_endo -71.59 156.62 57.51 Favored 'Trans proline' 0 N--CA 1.452 -0.938 0 C-N-CA 123.257 2.638 . . . . 0.0 110.218 178.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' B' ' 24' ' ' PRO . 29.8 Cg_exo -60.02 -20.72 62.0 Favored 'Trans proline' 0 N--CA 1.453 -0.906 0 C-N-CA 123.217 2.611 . . . . 0.0 111.622 176.17 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -85.3 8.56 18.15 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.077 0.769 . . . . 0.0 113.077 -179.1 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 8.1 tp -59.98 150.47 6.2 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.237 0 CA-C-O 120.828 0.347 . . . . 0.0 110.528 -179.1 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 53.1 ttt180 -144.05 150.93 38.96 Favored 'General case' 0 N--CA 1.456 -0.137 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 177.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -57.49 -28.92 63.83 Favored 'General case' 0 CA--C 1.527 0.059 0 N-CA-C 114.908 1.447 . . . . 0.0 114.908 -173.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -79.91 -13.74 59.15 Favored 'General case' 0 CA--C 1.528 0.119 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -177.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -70.63 -26.69 63.59 Favored 'General case' 0 C--N 1.333 -0.124 0 O-C-N 121.966 -0.459 . . . . 0.0 110.365 178.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 81.0 mt -77.93 -24.03 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.096 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -80.24 -14.39 58.46 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 178.227 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -94.36 -71.45 0.66 Allowed 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 122.865 0.466 . . . . 0.0 111.858 174.11 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 53.5 t -64.12 -55.65 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.254 -171.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -68.01 -18.18 64.63 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 -177.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.8 t -73.33 -31.57 64.07 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 175.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -73.08 -27.05 61.5 Favored 'General case' 0 C--N 1.343 0.314 0 O-C-N 122.071 -0.393 . . . . 0.0 110.609 172.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -79.07 -18.11 54.0 Favored 'General case' 0 N--CA 1.456 -0.153 0 N-CA-C 115.253 1.575 . . . . 0.0 115.253 176.1 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.35 167.26 32.9 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.608 -0.597 . . . . 0.0 111.608 177.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -75.86 105.57 6.97 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 80.6 mt -79.73 142.29 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.544 -178.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -105.94 -32.28 8.4 Favored 'General case' 0 N--CA 1.456 -0.128 0 C-N-CA 122.862 0.465 . . . . 0.0 109.869 172.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -152.38 155.46 37.65 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 114.271 1.211 . . . . 0.0 114.271 178.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 3.3 mp -117.06 149.95 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 175.191 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -146.28 52.88 1.13 Allowed 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 121.086 0.47 . . . . 0.0 109.801 -178.28 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.0 tp -63.06 135.2 57.11 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 122.678 0.391 . . . . 0.0 110.059 173.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.49 ' HE3' ' C2 ' ' A' ' 94' ' ' ' A' . 59.0 mttp -127.06 144.83 50.93 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 123.214 0.606 . . . . 0.0 110.645 178.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 66.8 m-20 -76.51 169.21 18.68 Favored 'General case' 0 C--O 1.232 0.139 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 171.35 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 18.6 tpt85 -156.0 152.16 27.79 Favored 'General case' 0 C--O 1.231 0.105 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 82.2 mtt85 -119.56 151.8 38.04 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 123.938 0.895 . . . . 0.0 109.365 178.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.49 5.57 60.27 Favored Glycine 0 CA--C 1.533 1.162 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 -178.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -176.34 175.93 47.62 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -179.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -68.44 157.28 62.5 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 123.886 3.057 . . . . 0.0 111.012 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.13 167.81 17.26 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 123.869 3.046 . . . . 0.0 110.997 177.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . 0.455 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 3.9 p90 -152.82 165.66 34.69 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 -177.303 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.13 169.64 23.09 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 121.216 0.531 . . . . 0.0 111.46 -172.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -132.17 158.19 42.35 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 171.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 73.5 t -140.15 135.05 36.78 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.309 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 -178.03 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 64.4 tt0 -110.58 112.03 23.66 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -80.73 162.4 24.13 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 113.681 0.993 . . . . 0.0 113.681 176.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 89.2 tt0 -74.36 -37.8 63.38 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 174.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -125.24 147.48 57.53 Favored Pre-proline 0 CA--C 1.529 0.17 0 C-N-CA 123.602 0.761 . . . . 0.0 109.917 179.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.48 -16.57 30.7 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 123.367 2.711 . . . . 0.0 111.576 -178.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 23.3 ptt85 -71.74 -15.92 62.2 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 122.7 0.4 . . . . 0.0 111.314 -177.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.65 -21.31 60.32 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 179.163 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -70.79 -18.1 62.76 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -73.93 -17.81 60.97 Favored 'General case' 0 N--CA 1.454 -0.226 0 O-C-N 122.274 -0.266 . . . . 0.0 110.469 179.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 76.9 m-20 -97.85 -39.69 8.89 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.567 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -74.68 -31.35 61.88 Favored 'General case' 0 N--CA 1.453 -0.283 0 O-C-N 122.274 -0.267 . . . . 0.0 110.783 -178.705 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.43 ' O ' HG12 ' B' ' 71' ' ' VAL . 48.2 t -87.99 6.33 3.54 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 C-N-CA 122.836 0.455 . . . . 0.0 111.6 -174.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.8 t -139.14 -23.04 0.91 Allowed 'General case' 0 C--O 1.232 0.146 0 O-C-N 121.819 -0.551 . . . . 0.0 111.722 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -96.22 -4.2 59.9 Favored Glycine 0 CA--C 1.526 0.737 0 CA-C-O 119.449 -0.639 . . . . 0.0 112.443 -178.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 3.9 tpp180 -147.48 -18.5 0.38 Allowed 'General case' 0 CA--C 1.529 0.161 0 CA-C-N 118.219 1.01 . . . . 0.0 111.993 -176.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -68.46 146.15 53.43 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.56 42.36 99.75 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-O 119.691 -0.505 . . . . 0.0 112.092 174.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 30.7 t80 -87.62 129.13 35.23 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 117.806 0.803 . . . . 0.0 113.028 -177.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -69.38 87.42 0.44 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 123.378 0.671 . . . . 0.0 111.442 -177.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 36.7 t80 -81.13 -177.63 6.54 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 31.1 t0 -69.7 85.2 0.46 Allowed 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.144 179.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.72 3.45 89.5 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-O 119.843 -0.42 . . . . 0.0 112.113 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 78.6 m-85 -133.67 -179.1 5.32 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 113.791 1.034 . . . . 0.0 113.791 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -143.19 117.85 9.82 Favored 'General case' 0 N--CA 1.456 -0.13 0 C-N-CA 123.346 0.658 . . . . 0.0 109.357 -176.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.77 154.08 37.97 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 122.569 0.348 . . . . 0.0 110.642 -177.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -124.35 118.93 27.85 Favored 'General case' 0 CA--C 1.516 -0.352 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 176.143 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 19.9 t -142.52 84.99 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 123.028 0.531 . . . . 0.0 110.109 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -143.58 161.11 39.35 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.175 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.7 p90 -77.74 152.26 80.27 Favored Pre-proline 0 CA--C 1.528 0.116 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 178.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo . . . . . 0 C--O 1.251 1.133 0 C-N-CA 123.526 2.817 . . . . 0.0 110.653 177.676 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -2.985 0 C3'-C2'-C1' 104.823 3.692 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.821 1 C5'-C4'-C3' 109.014 -4.324 OUTLIER-DELTA 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.455 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.379 0 C5'-C4'-C3' 110.64 -3.24 . 0.01 2z . 0.0 . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.426 -2.248 1 C5'-C4'-C3' 108.97 -4.354 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . 0.49 ' C2 ' ' HE3' ' B' ' 48' ' ' LYS . . . . . . . . 0 O4'--C4' 1.425 -2.324 1 O4'-C1'-N19 112.721 4.521 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.825 0 C5'-C4'-C3' 110.282 -3.479 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.3 t . . . . . 0 N--CA 1.477 0.878 0 CA-C-O 120.772 0.32 . . . . 0.0 111.569 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 93.2 mt -68.18 144.84 13.98 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.407 ' C ' ' HD2' ' B' ' 8' ' ' ARG . 2.1 tmm_? -152.62 127.4 9.53 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 116.907 -0.133 . . . . 0.0 110.792 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.13 -170.59 5.41 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 123.62 0.629 . . . . 0.0 112.664 172.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.38 -28.82 3.39 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.534 2.822 . . . . 0.0 110.631 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -165.24 166.83 18.55 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 123.244 0.618 . . . . 0.0 109.958 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -89.7 -168.49 43.23 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 176.171 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 34.3 t30 57.95 -176.26 0.07 Allowed 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 123.87 0.868 . . . . 0.0 111.222 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 30.3 t-20 63.09 162.04 0.1 Allowed 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.404 1.081 . . . . 0.0 111.342 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 19.1 p30 -139.51 -0.74 1.74 Allowed 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 123.358 0.663 . . . . 0.0 112.113 179.325 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 78.9 m -77.26 0.31 22.5 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 122.686 0.395 . . . . 0.0 110.432 174.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 41.5 ttm105 -78.51 145.69 34.79 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 123.513 0.725 . . . . 0.0 110.385 -178.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 33.0 pt -142.76 172.87 7.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 CA-C-O 121.087 0.47 . . . . 0.0 110.92 -177.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -109.81 153.93 23.71 Favored 'General case' 0 C--O 1.233 0.221 0 C-N-CA 124.909 1.283 . . . . 0.0 113.602 -178.08 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 22.5 t -137.07 139.74 43.81 Favored 'Isoleucine or valine' 0 C--O 1.232 0.17 0 C-N-CA 123.367 0.667 . . . . 0.0 110.701 179.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -159.7 -177.7 33.03 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -178.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 40.2 t30 56.53 26.37 10.9 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.668 0.787 . . . . 0.0 111.107 -173.265 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 91.4 mt -63.97 152.59 86.97 Favored Pre-proline 0 N--CA 1.454 -0.253 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 177.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -64.34 159.74 42.35 Favored 'Trans proline' 0 N--CA 1.45 -1.066 0 C-N-CA 123.461 2.774 . . . . 0.0 110.805 -177.1 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.53 -2.15 9.51 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 124.218 3.279 . . . . 0.0 111.563 -178.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -146.12 116.94 7.68 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 122.695 0.398 . . . . 0.0 111.415 178.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 8.1 tp -157.79 147.33 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.177 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 15.0 mmp_? -80.58 158.08 25.84 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 120.783 0.325 . . . . 0.0 110.365 -179.03 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.5 p -72.57 10.24 0.88 Allowed 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 114.168 1.173 . . . . 0.0 114.168 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.4 tptt -140.1 -22.75 0.84 Allowed 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 122.473 0.309 . . . . 0.0 111.492 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -65.35 -24.5 67.27 Favored 'General case' 0 N--CA 1.456 -0.133 0 N-CA-C 112.674 0.62 . . . . 0.0 112.674 -179.099 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 6.9 tp -72.11 -20.93 20.33 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 178.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -90.37 -28.87 18.4 Favored 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.32 -32.46 64.6 Favored 'General case' 0 C--N 1.337 0.044 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -178.46 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 53.7 t -71.75 -45.29 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 177.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 35.5 m-85 -72.08 -30.41 65.09 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 47.1 t -68.33 -25.58 65.18 Favored 'General case' 0 C--N 1.34 0.179 0 CA-C-N 116.953 -0.112 . . . . 0.0 110.857 174.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -75.98 -32.64 59.56 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 176.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 14.6 m-85 -78.57 -15.76 58.2 Favored 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 115.534 1.679 . . . . 0.0 115.534 176.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 170.64 178.89 41.64 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 177.442 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.41 113.78 19.72 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 122.779 -0.247 . . . . 0.0 110.592 -178.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.6 mp -86.29 140.97 15.06 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 122.731 0.412 . . . . 0.0 109.9 176.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . 0.473 ' HE ' ' HA ' ' B' ' 43' ' ' ARG . 1.7 mmp_? -108.05 -31.85 7.78 Favored 'General case' 0 N--CA 1.456 -0.13 0 C-N-CA 122.969 0.508 . . . . 0.0 110.012 174.273 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -151.32 158.8 44.28 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 113.925 1.083 . . . . 0.0 113.925 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . 0.571 HG22 ' H ' ' B' ' 47' ' ' LEU . 29.9 mm -140.2 151.03 21.32 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 124.153 0.981 . . . . 0.0 109.037 179.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -135.62 51.9 2.03 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 175.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . 0.571 ' H ' HG22 ' B' ' 45' ' ' ILE . 51.0 tp -53.38 130.52 35.54 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.101 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 18.3 ttmm -146.46 151.33 37.22 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 -172.243 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 -141.29 -1.08 1.37 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 122.271 0.229 . . . . 0.0 111.544 -179.304 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . 0.408 HH22 ' P ' ' A' ' 93' ' ' ' A' . 44.8 ttm105 49.11 -102.97 0.1 Allowed 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 123.709 0.804 . . . . 0.0 111.235 179.334 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . 0.411 HH11 ' HD3' ' B' ' 51' ' ' ARG . 54.8 mtt180 -142.71 4.52 1.52 Allowed 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 123.077 0.551 . . . . 0.0 111.302 -178.525 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 167.71 -176.49 42.38 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.488 -0.645 . . . . 0.0 111.488 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.03 178.41 48.98 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -178.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . 0.422 ' HA ' ' HD3' ' B' ' 55' ' ' PRO . 43.3 Cg_endo -67.58 154.1 74.46 Favored 'Trans proline' 0 N--CA 1.451 -0.983 0 C-N-CA 123.4 2.733 . . . . 0.0 109.882 178.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' B' ' 54' ' ' PRO . 24.0 Cg_exo -60.38 153.17 62.05 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 122.956 2.438 . . . . 0.0 111.807 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -146.9 146.63 30.22 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 124.178 0.991 . . . . 0.0 112.307 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -160.43 157.05 27.05 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -175.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -112.69 151.57 30.06 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.854 167.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.6 t -135.2 136.63 51.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -176.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 78.8 tt0 -124.25 112.66 17.28 Favored 'General case' 0 N--CA 1.455 -0.176 0 CA-C-O 120.747 0.308 . . . . 0.0 110.637 -177.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -84.32 159.29 20.93 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 114.297 1.221 . . . . 0.0 114.297 177.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 33.2 tp10 -78.14 -30.33 49.21 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.439 174.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -129.09 150.15 74.58 Favored Pre-proline 0 C--O 1.232 0.151 0 C-N-CA 123.573 0.749 . . . . 0.0 112.538 -178.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.99 -24.47 24.0 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 123.431 2.754 . . . . 0.0 110.921 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 38.6 mmt180 -76.52 -24.83 53.71 Favored 'General case' 0 C--N 1.339 0.131 0 C-N-CA 121.962 0.105 . . . . 0.0 110.757 179.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -75.19 -34.16 61.5 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-O 120.416 0.151 . . . . 0.0 111.271 175.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -73.04 -32.54 65.13 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 176.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -65.81 -33.87 76.86 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.151 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -76.06 -35.62 59.35 Favored 'General case' 0 N--CA 1.457 -0.125 0 N-CA-C 113.249 0.833 . . . . 0.0 113.249 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.73 -29.16 63.13 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 122.365 -0.21 . . . . 0.0 110.505 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 55.9 t -81.43 -52.47 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.0 t -70.29 -17.27 63.09 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 -174.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.03 -1.76 45.28 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-O 119.161 -0.799 . . . . 0.0 113.868 -173.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 30.1 ttp-105 -153.23 -14.02 0.15 Allowed 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 119.003 1.402 . . . . 0.0 113.19 -175.048 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -69.28 146.71 52.04 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 118.673 0.67 . . . . 0.0 110.037 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.75 38.25 95.63 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-O 119.562 -0.577 . . . . 0.0 112.313 172.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 37.8 t80 -88.24 130.04 35.19 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 118.089 0.945 . . . . 0.0 112.968 -176.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 29.6 t0 -68.75 89.37 0.39 Allowed 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.369 0.668 . . . . 0.0 111.091 -178.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 35.7 t80 -81.17 -174.62 4.99 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -69.49 74.05 0.37 Allowed 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 123.765 0.826 . . . . 0.0 111.997 178.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.47 6.83 70.17 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 -179.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -133.19 -179.31 5.42 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -179.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 9.5 tpp180 -143.08 114.38 7.88 Favored 'General case' 0 CA--C 1.528 0.132 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -175.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -61.9 153.13 29.99 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.811 0.444 . . . . 0.0 110.245 -177.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 74.8 mtt180 -129.11 115.31 17.52 Favored 'General case' 0 CA--C 1.52 -0.185 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 177.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 38.7 t -143.14 85.14 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.183 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -148.58 165.3 31.66 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.641 0.258 . . . . 0.0 110.589 -174.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -81.79 156.82 70.0 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 113.755 1.021 . . . . 0.0 113.755 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo . . . . . 0 C--O 1.252 1.215 0 C-N-CA 123.895 3.064 . . . . 0.0 111.639 177.684 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.649 1 O4'-C1'-N19 112.447 4.247 . 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.46 1 C5'-C4'-C3' 109.311 -4.126 . 0.118 6n . 0.0 . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.547 0 O4'-C1'-N19 111.91 3.71 . 0.078 1z . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.5 ' C8 ' H5'' ' A' ' 93' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.421 -2.654 1 C3'-C2'-C1' 105.188 4.098 OUTLIER-DELTA 0.0 OUTLIER . 0.0 . . . . . . . . . . 4 4 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.845 0 O4'-C1'-N19 111.558 3.358 . 0.142 2u . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.417 2 C5'-C4'-C3' 109.421 -4.052 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 11.1 t . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 111.535 0.198 . . . . 0.0 111.535 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 73.3 mt -68.53 150.51 10.75 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.497 ' HD3' ' N ' ' B' ' 9' ' ' GLY . 3.0 tmt_? -144.0 158.34 43.77 Favored 'General case' 0 N--CA 1.457 -0.097 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . 0.497 ' N ' ' HD3' ' B' ' 8' ' ' ARG . . . -45.45 145.33 2.73 Favored Glycine 0 CA--C 1.529 0.964 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 178.271 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.73 176.88 6.89 Favored 'Trans proline' 0 N--CA 1.452 -0.93 0 C-N-CA 123.766 2.977 . . . . 0.0 111.769 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 62.39 15.63 7.89 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 124.481 1.112 . . . . 0.0 113.492 176.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 166.33 160.99 14.37 Favored Glycine 0 CA--C 1.527 0.808 0 CA-C-N 118.41 0.55 . . . . 0.0 112.304 174.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 73.5 m-80 -137.44 -5.81 1.79 Allowed 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 123.525 0.73 . . . . 0.0 110.525 176.15 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -155.48 106.64 2.55 Favored 'General case' 0 N--CA 1.456 -0.14 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 176.173 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 6.7 p30 -160.69 176.38 11.59 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -169.385 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 80.9 m -75.47 18.67 0.21 Allowed 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 123.321 0.649 . . . . 0.0 111.598 177.377 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . 0.414 ' HA ' ' HA ' ' B' ' 60' ' ' GLU . 27.5 ttm180 -74.38 149.61 40.43 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 122.831 0.452 . . . . 0.0 111.239 -175.002 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.3 pt -131.08 -178.8 2.84 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.09 0 C-N-CA 123.876 0.87 . . . . 0.0 109.645 178.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -120.66 150.2 41.3 Favored 'General case' 0 C--O 1.231 0.12 0 N-CA-C 114.462 1.282 . . . . 0.0 114.462 -173.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 46.3 t -141.05 142.29 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 C-N-CA 123.928 0.891 . . . . 0.0 109.019 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.54 -178.95 33.03 Favored Glycine 0 C--N 1.338 0.665 0 C-N-CA 121.277 -0.487 . . . . 0.0 112.515 -175.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 48.5 t30 56.48 25.96 10.32 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.245 1.018 . . . . 0.0 111.376 -176.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.8 mt -66.32 127.34 93.22 Favored Pre-proline 0 CA--C 1.531 0.223 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -57.73 152.64 47.94 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 123.302 2.668 . . . . 0.0 110.905 174.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -69.24 -14.83 38.42 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.527 2.818 . . . . 0.0 111.194 -179.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 -82.5 -6.66 59.45 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 112.921 0.711 . . . . 0.0 112.921 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 19.5 mm -71.59 138.77 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 C-N-CA 122.421 0.288 . . . . 0.0 110.517 -178.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 65.9 mtm180 -88.06 154.53 20.41 Favored 'General case' 0 C--N 1.334 -0.065 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 177.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 2.7 p -65.74 -18.1 65.09 Favored 'General case' 0 C--N 1.333 -0.147 0 N-CA-C 113.246 0.832 . . . . 0.0 113.246 179.227 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 58.2 tptt -87.71 -21.09 25.4 Favored 'General case' 0 C--N 1.342 0.25 0 C-N-CA 122.669 0.388 . . . . 0.0 111.132 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -65.61 -23.07 66.74 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 122.118 -0.364 . . . . 0.0 111.451 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mp -70.86 -22.47 23.1 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.108 0 N-CA-C 109.921 -0.399 . . . . 0.0 109.921 178.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -96.45 -38.4 10.04 Favored 'General case' 0 N--CA 1.453 -0.305 0 O-C-N 122.359 -0.213 . . . . 0.0 110.824 -178.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -67.62 -45.71 74.64 Favored 'General case' 0 N--CA 1.458 -0.057 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -175.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 91.1 t -72.26 -42.37 66.06 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -178.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 54.4 m-85 -75.32 -26.68 58.85 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -177.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.2 t -70.73 -31.0 67.69 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-O 120.557 0.218 . . . . 0.0 110.43 174.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 28.9 tptp -70.82 -31.33 68.02 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -85.22 -13.0 51.28 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 116.082 1.882 . . . . 0.0 116.082 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.18 171.98 38.32 Favored Glycine 0 C--N 1.336 0.566 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.303 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -79.1 104.46 9.74 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 122.669 0.387 . . . . 0.0 110.406 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 83.5 mt -75.58 147.27 8.25 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.145 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 176.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -131.02 -19.41 2.87 Favored 'General case' 0 C--N 1.34 0.168 0 C-N-CA 122.523 0.329 . . . . 0.0 111.12 175.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -153.7 156.03 37.08 Favored 'General case' 0 CA--C 1.528 0.102 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 174.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 18.9 mm -136.19 152.85 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.122 0 C-N-CA 123.737 0.815 . . . . 0.0 109.253 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -145.72 46.73 1.27 Allowed 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 178.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 28.6 tp -58.27 133.99 56.16 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 174.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 56.0 mttp -127.56 145.49 50.84 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 123.655 0.782 . . . . 0.0 110.608 178.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.4 p-10 -81.38 -12.77 58.87 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 171.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 52.1 ttt85 62.4 154.56 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 125.437 1.495 . . . . 0.0 112.125 -177.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 33.3 ttp-105 -72.8 -11.18 60.5 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.185 0.594 . . . . 0.0 111.155 -178.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.41 162.69 33.05 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.93 -176.86 42.83 Favored Glycine 0 CA--C 1.53 0.978 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -177.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -66.76 157.64 60.17 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 123.798 2.998 . . . . 0.0 111.055 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -59.81 160.08 22.68 Favored 'Trans proline' 0 N--CA 1.454 -0.838 0 C-N-CA 123.808 3.005 . . . . 0.0 112.065 177.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . 0.429 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 1.8 p90 -157.74 166.47 32.68 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.14 172.68 18.02 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-O 121.174 0.512 . . . . 0.0 112.089 -172.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -131.67 146.58 52.25 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 171.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 96.6 t -132.41 132.41 60.37 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.265 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -174.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . 0.414 ' HA ' ' HA ' ' B' ' 17' ' ' ARG . 76.2 tt0 -116.36 120.39 38.71 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 120.581 0.229 . . . . 0.0 111.433 -175.525 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -90.49 161.7 15.39 Favored 'General case' 0 C--O 1.232 0.16 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 177.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -71.6 -33.4 68.98 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 174.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -128.96 150.39 75.12 Favored Pre-proline 0 CA--C 1.53 0.189 0 C-N-CA 123.689 0.795 . . . . 0.0 111.795 -178.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.86 -13.89 32.23 Favored 'Trans proline' 0 N--CA 1.452 -0.913 0 C-N-CA 123.214 2.609 . . . . 0.0 110.364 176.499 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 32.5 ttp-105 -65.26 -38.25 89.72 Favored 'General case' 0 CA--C 1.528 0.124 0 C-N-CA 123.323 0.649 . . . . 0.0 110.545 178.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -77.67 -20.3 53.96 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -176.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.79 -29.94 65.0 Favored 'General case' 0 N--CA 1.452 -0.364 0 O-C-N 122.527 -0.108 . . . . 0.0 110.711 -177.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -72.89 -27.24 61.77 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.327 -0.233 . . . . 0.0 110.61 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -80.1 -36.45 35.41 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -178.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -76.55 -28.39 56.26 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 110.572 -0.158 . . . . 0.0 110.572 -178.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 35.5 t -79.33 -58.66 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 69.9 m -73.5 -3.33 26.95 Favored 'General case' 0 CA--C 1.528 0.107 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -175.537 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -85.41 -19.94 57.67 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 119.32 -0.711 . . . . 0.0 112.828 -176.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 24.7 ptt-85 -161.64 18.45 0.11 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 118.604 1.202 . . . . 0.0 113.009 -174.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -66.9 140.96 57.8 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.97 0.73 . . . . 0.0 112.97 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 60.28 70.87 0.89 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.828 -0.509 . . . . 0.0 111.828 174.031 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 59.6 t80 -110.73 137.91 47.79 Favored 'General case' 0 C--N 1.339 0.138 0 N-CA-C 113.571 0.952 . . . . 0.0 113.571 179.215 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -64.42 108.47 1.64 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 124.392 1.077 . . . . 0.0 112.988 -175.086 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.412 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.9 t80 -113.9 169.3 9.1 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.849 0.86 . . . . 0.0 111.26 175.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.412 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 75.7 m-20 -59.81 97.18 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -179.193 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 80.08 -5.65 62.07 Favored Glycine 0 CA--C 1.534 1.281 0 CA-C-O 119.315 -0.714 . . . . 0.0 112.643 177.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -139.4 -171.02 3.03 Favored 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 118.296 1.048 . . . . 0.0 113.362 -177.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 1.5 tpp180 -142.04 128.96 20.67 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -177.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.6 mp -63.39 150.09 44.34 Favored 'General case' 0 C--N 1.335 -0.049 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -123.11 124.87 44.05 Favored 'General case' 0 CA--C 1.52 -0.194 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.184 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 21.3 t -147.29 79.73 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.088 0 C-N-CA 123.603 0.761 . . . . 0.0 109.269 178.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.9 pt-20 -147.08 165.03 31.17 Favored 'General case' 0 C--O 1.226 -0.155 0 C-N-CA 122.667 0.387 . . . . 0.0 110.442 -177.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . 0.405 ' HA ' ' HD3' ' B' ' 89' ' ' PRO . 3.7 p90 -80.01 153.72 74.96 Favored Pre-proline 0 C--O 1.234 0.275 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 176.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' B' ' 88' ' ' PHE . 37.1 Cg_exo . . . . . 0 C--O 1.249 1.051 0 C-N-CA 123.746 2.964 . . . . 0.0 111.728 175.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.472 2 O4'-C1'-N19 112.967 4.767 . 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . 0.429 " H4'" " H5'" ' A' ' 92' ' ' ' C' . . . . . . . . 0 O4'--C4' 1.424 -2.433 0 C5'-C4'-C3' 110.304 -3.464 OUTLIER-DELTA 0.0 OUTLIER delta 0.0 . . . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.429 " H5'" " H4'" ' A' ' 91' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.42 -2.747 0 C5'-C4'-C3' 109.756 -3.829 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.515 1 C3'-C2'-C1' 105.21 4.122 . 0.145 4b . 0.0 . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.563 1 O4'-C1'-N19 112.564 4.364 OUTLIER-EPSILON 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.895 0 C5'-C4'-C3' 109.585 -3.943 . 0.0 OUTLIER epsilon-1 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 4.6 p . . . . . 0 N--CA 1.48 1.037 0 N-CA-C 111.862 0.319 . . . . 0.0 111.862 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 44.3 mm -71.49 152.89 8.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 36.5 ttm-85 -62.85 145.5 54.91 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 122.666 0.387 . . . . 0.0 110.711 -179.149 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . 0.74 ' HA2' ' C2 ' ' A' ' 93' ' ' ' A' . . . 148.56 -25.71 1.35 Allowed Glycine 0 CA--C 1.533 1.185 0 CA-C-O 118.312 -1.271 . . . . 0.0 113.641 172.266 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . 0.531 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 32.4 Cg_exo -58.07 161.32 13.64 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 CA-C-N 120.111 1.956 . . . . 0.0 111.01 169.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.77 155.55 40.63 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.021 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 154.88 173.61 23.88 Favored Glycine 0 C--N 1.337 0.599 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 52.77 42.7 31.88 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.098 0.559 . . . . 0.0 111.28 179.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 68.0 m-20 57.17 20.37 5.59 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.792 0.837 . . . . 0.0 112.398 179.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 53.86 34.3 19.03 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 177.196 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 71.7 m -68.92 -1.08 6.47 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 122.739 0.416 . . . . 0.0 111.412 177.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 39.9 ttm180 -75.87 148.6 38.19 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 123.943 0.897 . . . . 0.0 110.49 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 14.2 pt -129.6 176.26 8.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 C-N-CA 122.897 0.479 . . . . 0.0 109.923 178.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.478 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 1.0 OUTLIER -115.49 153.42 31.16 Favored 'General case' 0 N--CA 1.456 -0.175 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -173.297 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 79.2 t -138.09 100.26 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -82.66 160.03 38.96 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 175.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 40.8 t30 60.51 -171.56 0.14 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.153 0.581 . . . . 0.0 110.25 -176.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.6 tp -144.52 132.62 10.74 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -179.645 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -68.64 157.67 60.89 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.23 2.62 . . . . 0.0 111.501 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.59 -4.5 15.34 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 124.337 3.358 . . . . 0.0 111.821 -175.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 9.9 p30 -126.82 25.19 6.39 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -177.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 5.5 tp -58.78 139.97 17.75 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 C-N-CA 122.855 0.462 . . . . 0.0 110.95 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 39.0 ttm105 -155.83 160.56 40.32 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 175.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.05 3.68 0.16 Allowed 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 116.279 1.955 . . . . 0.0 116.279 -173.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -148.72 -22.49 0.32 Allowed 'General case' 0 CA--C 1.528 0.132 0 O-C-N 122.092 -0.38 . . . . 0.0 111.298 177.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 71.1 m-20 -67.93 -19.76 65.01 Favored 'General case' 0 N--CA 1.457 -0.123 0 O-C-N 122.389 -0.195 . . . . 0.0 111.455 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 7.9 tp -73.19 -14.3 16.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 177.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -103.55 -21.25 13.78 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -71.09 -51.46 25.01 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.432 0.293 . . . . 0.0 111.585 -177.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 m -67.91 -33.42 61.25 Favored 'Isoleucine or valine' 0 C--N 1.338 0.082 0 CA-C-O 120.515 0.198 . . . . 0.0 110.929 -179.026 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -74.42 -35.15 63.39 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 176.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.4 t -66.66 -25.55 66.62 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.575 0.226 . . . . 0.0 110.599 175.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 29.2 tptp -77.72 -33.1 53.16 Favored 'General case' 0 N--CA 1.456 -0.149 0 N-CA-C 110.275 -0.268 . . . . 0.0 110.275 177.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -85.44 -9.24 57.77 Favored 'General case' 0 CA--C 1.53 0.184 0 N-CA-C 116.394 1.998 . . . . 0.0 116.394 179.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.42 178.54 44.4 Favored Glycine 0 C--N 1.339 0.703 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.73 177.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -79.41 43.26 0.54 Allowed 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.937 0.895 . . . . 0.0 110.99 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . 0.584 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.8 mp -55.77 138.25 16.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 122.695 0.398 . . . . 0.0 110.089 179.22 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 56.7 mmm-85 -94.69 -54.64 3.42 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.175 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -133.44 150.62 51.76 Favored 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -170.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -112.52 151.04 14.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.203 0 C-N-CA 124.596 1.158 . . . . 0.0 108.26 173.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -143.7 68.74 1.28 Allowed 'General case' 0 N--CA 1.452 -0.329 0 CA-C-O 120.694 0.283 . . . . 0.0 111.164 178.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 44.1 tp -70.91 129.54 39.31 Favored 'General case' 0 CA--C 1.531 0.238 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.178 174.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.555 ' HE3' " H1'" ' A' ' 93' ' ' ' A' . 68.8 mttm -114.41 140.28 48.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 123.089 0.556 . . . . 0.0 110.085 178.225 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 46.0 p-10 -81.53 -163.81 0.68 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 123.877 0.871 . . . . 0.0 111.179 -178.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 22.7 tpp85 -49.6 131.06 21.31 Favored 'General case' 0 C--N 1.339 0.114 0 C-N-CA 123.182 0.593 . . . . 0.0 109.883 177.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 57.6 ttt-85 -150.39 42.32 0.82 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 122.86 0.464 . . . . 0.0 110.049 -174.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.7 6.09 83.41 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -176.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -167.03 -172.09 33.87 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 -179.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -63.97 159.05 44.2 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 123.158 2.572 . . . . 0.0 110.348 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -65.36 152.07 83.17 Favored 'Trans proline' 0 N--CA 1.448 -1.172 0 C-N-CA 123.086 2.524 . . . . 0.0 110.242 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . 0.479 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 2.1 p90 -157.59 162.98 38.77 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -178.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -146.62 173.68 12.12 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-O 121.083 0.468 . . . . 0.0 111.387 -172.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . 0.411 ' CD2' ' C2 ' ' A' ' 93' ' ' ' A' . 94.5 m-85 -138.68 160.67 39.06 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.336 175.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 81.9 t -137.76 134.75 45.85 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 55.1 tt0 -115.52 127.23 55.14 Favored 'General case' 0 N--CA 1.453 -0.295 0 CA-C-O 120.773 0.32 . . . . 0.0 110.741 -174.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.584 ' CE2' HD11 ' B' ' 42' ' ' ILE . 18.4 m-85 -95.17 151.52 19.14 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 115.314 1.598 . . . . 0.0 115.314 -172.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 49.8 tp10 -80.49 -26.24 38.33 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 168.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -153.05 117.54 2.85 Favored Pre-proline 0 N--CA 1.453 -0.294 0 C-N-CA 124.125 0.97 . . . . 0.0 109.468 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -66.86 -6.1 14.94 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 123.225 2.616 . . . . 0.0 112.429 -174.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 60.1 ttt85 -65.36 -28.88 69.6 Favored 'General case' 0 N--CA 1.456 -0.159 0 CA-C-N 118.022 0.374 . . . . 0.0 110.576 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -78.7 -15.8 58.03 Favored 'General case' 0 CA--C 1.531 0.213 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.21 -20.47 63.97 Favored 'General case' 0 N--CA 1.451 -0.411 0 O-C-N 122.198 -0.314 . . . . 0.0 110.428 -177.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -64.75 -26.95 68.58 Favored 'General case' 0 CA--C 1.532 0.266 0 O-C-N 122.055 -0.403 . . . . 0.0 110.336 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 -90.88 -36.56 14.1 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 112.561 0.578 . . . . 0.0 112.561 178.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.67 -28.44 62.71 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 122.41 0.284 . . . . 0.0 110.723 -177.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 49.7 t -75.24 0.0 2.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 32.5 t -135.35 5.49 3.23 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.763 -0.586 . . . . 0.0 110.943 178.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -77.94 -28.87 55.77 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-O 119.694 -0.503 . . . . 0.0 112.129 -177.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 50.1 ttt180 -158.45 13.46 0.18 Allowed 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 117.624 0.712 . . . . 0.0 110.89 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 29.9 t0 -69.55 150.07 47.52 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 122.102 -0.374 . . . . 0.0 110.246 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.28 38.13 95.97 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 111.803 -0.519 . . . . 0.0 111.803 175.538 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 31.0 t80 -98.97 132.78 44.03 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 113.149 0.796 . . . . 0.0 113.149 -173.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -61.62 104.35 0.42 Allowed 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 123.559 0.744 . . . . 0.0 112.149 -179.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.496 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 66.2 t80 -110.35 173.44 6.33 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 123.586 0.754 . . . . 0.0 111.803 178.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.496 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.7 t0 -62.43 100.03 0.17 Allowed 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.67 -8.22 29.15 Favored Glycine 0 CA--C 1.531 1.076 0 C-N-CA 123.435 0.541 . . . . 0.0 112.936 177.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -138.9 -169.92 2.74 Favored 'General case' 0 C--N 1.34 0.172 0 N-CA-C 113.133 0.79 . . . . 0.0 113.133 -178.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 38.3 ttt180 -145.46 134.68 22.87 Favored 'General case' 0 N--CA 1.454 -0.269 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -177.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -62.71 144.34 56.48 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -178.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 56.7 mtm180 -132.43 71.97 1.48 Allowed 'General case' 0 C--N 1.339 0.127 0 C-N-CA 122.728 0.411 . . . . 0.0 110.809 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.83 92.31 3.81 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.103 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 177.338 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.5 pt-20 -151.04 159.72 44.36 Favored 'General case' 0 C--N 1.334 -0.102 0 C-N-CA 122.658 0.383 . . . . 0.0 110.827 178.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -73.65 153.4 89.51 Favored Pre-proline 0 C--O 1.235 0.303 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo . . . . . 0 C--O 1.251 1.173 0 C-N-CA 123.839 3.026 . . . . 0.0 110.543 176.138 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.443 0 C5'-C4'-C3' 112.174 -2.218 OUTLIER-DELTA 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.619 0 O4'-C1'-N19 111.882 3.682 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.479 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.422 -2.608 0 O4'-C1'-N19 111.391 3.191 . 0.202 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.74 ' C2 ' ' HA2' ' B' ' 9' ' ' GLY . . . . . . . . 0 O4'--C4' 1.422 -2.605 0 C5'-C4'-C3' 110.2 -3.534 . 0.14 6n . 0.0 . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.421 -2.662 0 C5'-C4'-C3' 110.337 -3.442 OUTLIER-DELTA 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.42 -2.739 0 C3'-C2'-C1' 104.523 3.359 . 0.0 OUTLIER '7D dist 2[' 0.0 . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 14.1 t . . . . . 0 N--CA 1.477 0.894 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 15.8 mt 61.91 -38.96 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 C-N-CA 125.777 1.631 . . . . 0.0 113.364 -176.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.87 -31.87 0.05 Allowed 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.254 0.621 . . . . 0.0 110.481 178.478 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . -171.43 -56.0 0.04 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-O 119.482 -0.621 . . . . 0.0 112.209 -174.488 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -59.31 135.77 67.66 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 123.666 2.911 . . . . 0.0 112.859 -176.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 57.47 170.71 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.901 1.28 . . . . 0.0 113.562 176.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.58 172.41 32.05 Favored Glycine 0 CA--C 1.525 0.711 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.22 178.057 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -77.81 162.73 26.68 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.764 0.426 . . . . 0.0 110.351 178.062 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -73.84 144.98 45.26 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-O 120.696 0.284 . . . . 0.0 110.641 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . 0.418 ' C ' ' H ' ' B' ' 17' ' ' ARG . 68.0 m-20 -87.08 -157.73 0.4 Allowed 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.496 0.719 . . . . 0.0 109.826 174.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 93.7 m -68.36 8.72 0.41 Allowed 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 122.608 0.363 . . . . 0.0 111.18 174.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . 0.418 ' H ' ' C ' ' B' ' 15' ' ' ASP . 49.2 mtt180 -73.12 156.61 38.49 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.448 0.699 . . . . 0.0 112.57 -179.128 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.0 pt -132.41 175.96 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.068 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 173.089 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.435 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.7 OUTLIER -119.3 147.63 44.08 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -174.981 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 24.8 t -132.42 138.5 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 C-N-CA 123.312 0.645 . . . . 0.0 110.368 -179.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -143.6 -179.43 20.18 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -177.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 64.4 t30 59.48 24.4 13.07 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.812 0.845 . . . . 0.0 111.325 -173.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 96.1 mt -71.5 142.04 86.06 Favored Pre-proline 0 CA--C 1.533 0.309 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 176.594 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -59.68 157.82 30.89 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 123.256 2.638 . . . . 0.0 111.116 176.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -69.97 -17.57 36.55 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.269 2.646 . . . . 0.0 110.58 177.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 79.1 m-20 -88.93 11.9 16.81 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 123.385 0.674 . . . . 0.0 112.724 178.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 7.7 tp -59.75 151.29 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 C-N-CA 122.63 0.372 . . . . 0.0 110.507 -178.303 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 16.1 ttp180 -142.68 147.69 36.11 Favored 'General case' 0 N--CA 1.454 -0.245 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -59.78 -28.39 67.38 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -176.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -83.01 -19.62 36.63 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -75.55 -39.26 58.48 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 117.774 0.261 . . . . 0.0 111.109 179.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.412 HG22 ' H ' ' B' ' 32' ' ' ILE . 12.6 tt -78.18 -21.28 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 CA-C-N 116.688 -0.233 . . . . 0.0 110.667 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.4 mt-10 -77.29 -39.39 48.19 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.108 -0.37 . . . . 0.0 110.494 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -74.3 -33.64 63.27 Favored 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -179.287 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 41.3 t -71.3 -48.14 55.86 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -74.58 -31.79 62.18 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 39.1 t -67.81 -30.73 70.22 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.933 177.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -77.66 -26.79 50.64 Favored 'General case' 0 C--O 1.232 0.138 0 O-C-N 122.366 -0.209 . . . . 0.0 111.075 175.529 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -87.45 -8.31 56.63 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 116.435 2.013 . . . . 0.0 116.435 177.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 175.37 174.17 41.73 Favored Glycine 0 CA--C 1.524 0.599 0 C-N-CA 121.1 -0.571 . . . . 0.0 112.483 179.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.46 40.44 0.57 Allowed 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 123.767 0.827 . . . . 0.0 111.348 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . 0.593 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.9 mp -52.8 136.07 13.97 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.066 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 18.8 mmt85 -93.61 -35.18 13.0 Favored 'General case' 0 C--O 1.23 0.073 0 CA-C-O 119.492 -0.289 . . . . 0.0 111.691 -175.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -148.54 150.34 33.19 Favored 'General case' 0 C--O 1.232 0.147 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -177.794 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -115.15 151.8 16.84 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 C-N-CA 124.344 1.057 . . . . 0.0 108.278 174.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 61.6 t0 -148.16 75.12 1.32 Allowed 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.136 0.493 . . . . 0.0 110.221 179.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 53.9 tp -71.05 146.03 49.57 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.526 176.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 25.1 ttmm -146.41 141.09 26.82 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 176.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 45.8 p30 -147.42 15.12 1.12 Allowed 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 111.832 0.308 . . . . 0.0 111.832 -176.048 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . 0.432 ' C ' ' H ' ' B' ' 52' ' ' GLY . 35.3 ptt-85 -154.7 165.68 35.8 Favored 'General case' 0 CA--C 1.52 -0.176 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -178.397 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 64.35 -28.85 0.1 Allowed 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 125.144 1.378 . . . . 0.0 112.734 -176.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . 0.432 ' H ' ' C ' ' B' ' 50' ' ' ARG . . . -102.75 -155.07 25.13 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 175.55 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -74.85 -156.84 5.41 Favored Glycine 0 CA--C 1.534 1.277 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 176.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -63.48 164.91 19.16 Favored 'Trans proline' 0 N--CA 1.456 -0.731 0 C-N-CA 123.618 2.879 . . . . 0.0 110.191 178.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_exo -50.5 131.47 32.62 Favored 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 123.569 2.846 . . . . 0.0 112.164 -173.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -162.61 169.4 20.22 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -151.78 159.24 43.99 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.184 0.516 . . . . 0.0 111.68 -174.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . 0.513 ' CE1' ' C4 ' ' A' ' 93' ' ' ' A' . 86.2 m-85 -112.72 151.05 30.69 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.11 172.106 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.2 t -135.96 132.33 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.148 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -178.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 69.9 tt0 -110.57 116.27 31.07 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 122.445 0.298 . . . . 0.0 111.155 -173.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.593 ' CE2' HD11 ' B' ' 42' ' ' ILE . 29.7 m-85 -92.51 154.8 18.24 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -80.71 -29.97 36.38 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 171.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -159.93 151.17 16.14 Favored Pre-proline 0 CA--C 1.531 0.212 0 C-N-CA 125.267 1.427 . . . . 0.0 111.589 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.39 -3.04 12.2 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 123.6 2.867 . . . . 0.0 112.484 -176.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -63.52 -25.49 68.27 Favored 'General case' 0 CA--C 1.529 0.152 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -176.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -89.58 -5.15 57.46 Favored 'General case' 0 CA--C 1.53 0.189 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -177.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.15 -14.2 62.85 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 122.408 -0.183 . . . . 0.0 110.818 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -65.86 -17.33 64.57 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 122.419 -0.176 . . . . 0.0 111.17 -178.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -123.5 -37.43 2.66 Favored 'General case' 0 C--O 1.231 0.122 0 C-N-CA 122.975 0.51 . . . . 0.0 112.142 177.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -79.76 -9.92 59.72 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 122.58 0.352 . . . . 0.0 111.634 -175.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 60.4 t -131.79 -53.69 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 C-N-CA 122.374 0.27 . . . . 0.0 110.724 -178.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 70.5 m -70.71 -6.53 38.0 Favored 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 122.208 0.203 . . . . 0.0 111.343 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -116.09 10.44 17.79 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 119.543 -0.587 . . . . 0.0 111.764 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' B' ' 74' ' ' ARG . 46.0 ttm180 -145.05 -20.41 0.5 Allowed 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 117.933 0.866 . . . . 0.0 111.984 -176.096 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 39.8 t0 -68.89 136.16 52.18 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.315 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 67.7 27.49 73.6 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-O 119.779 -0.456 . . . . 0.0 112.068 176.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 50.4 t80 -79.95 140.62 36.58 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 -172.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.7 t0 -59.34 102.52 0.14 Allowed 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -175.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.414 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 73.9 t80 -111.8 172.26 7.0 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 123.71 0.804 . . . . 0.0 110.743 176.026 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.414 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 17.6 t0 -62.4 98.35 0.11 Allowed 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 179.752 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.58 -5.8 55.42 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 119.599 -0.556 . . . . 0.0 112.887 177.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -142.2 -175.56 4.48 Favored 'General case' 0 CA--C 1.527 0.072 0 CA-C-N 117.945 0.872 . . . . 0.0 112.882 -178.083 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 93.1 mtt-85 -131.87 138.46 48.45 Favored 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 124.191 0.996 . . . . 0.0 109.829 176.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -59.85 154.38 18.64 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 178.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . 0.407 ' NE ' ' HA ' ' B' ' 85' ' ' ARG . 1.3 tpm_? -122.42 116.45 24.0 Favored 'General case' 0 CA--C 1.518 -0.255 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 176.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 15.2 t -135.1 89.48 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.279 0 O-C-N 123.378 0.424 . . . . 0.0 110.063 178.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -146.89 158.18 43.85 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.361 178.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -76.56 155.09 83.69 Favored Pre-proline 0 CA--C 1.532 0.276 0 N-CA-C 114.224 1.194 . . . . 0.0 114.224 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo . . . . . 0 C--O 1.251 1.14 0 C-N-CA 123.702 2.934 . . . . 0.0 111.46 175.29 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.036 0 O4'-C1'-N19 111.689 3.489 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.891 0 C5'-C4'-C3' 111.221 -2.853 . 0.571 6n . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.435 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.422 -2.585 0 C5'-C4'-C3' 110.537 -3.308 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.513 ' C4 ' ' CE1' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.426 -2.238 2 C5'-C4'-C3' 109.095 -4.27 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . 0.4 H5'' " H3'" ' A' ' 93' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.425 -2.319 0 C5'-C4'-C3' 112.531 -1.979 OUTLIER-DELTA 0.0 OUTLIER '7D dist 8d' 0.0 . . . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.319 0 O4'-C1'-N19 111.853 3.653 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.477 0.896 0 CA-C-O 120.567 0.222 . . . . 0.0 111.303 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 85.7 mt -74.35 147.1 9.13 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.144 0 C-N-CA 122.845 0.458 . . . . 0.0 110.496 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 9.3 tpp180 53.52 -98.05 0.07 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.431 1.092 . . . . 0.0 112.427 178.126 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . 0.462 ' HA3' ' C4 ' ' A' ' 93' ' ' ' A' . . . -79.01 132.2 11.3 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 111.932 -0.467 . . . . 0.0 111.932 -169.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -75.03 175.41 11.28 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 123.919 3.079 . . . . 0.0 110.265 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -69.27 -12.28 61.53 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 122.201 0.201 . . . . 0.0 110.674 176.458 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 169.39 151.51 7.34 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 110.104 -1.199 . . . . 0.0 110.104 177.136 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 31.1 p-10 -159.3 174.74 14.32 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 116.855 0.327 . . . . 0.0 110.659 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 41.8 p30 -135.62 26.99 3.38 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 123.377 0.671 . . . . 0.0 110.366 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -69.63 -177.67 1.28 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.352 0.661 . . . . 0.0 110.024 -179.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 8.2 p -64.06 -9.77 18.16 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 122.62 0.368 . . . . 0.0 111.669 176.134 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -63.11 144.71 56.66 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 122.857 0.463 . . . . 0.0 111.808 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 27.7 pt -131.67 173.16 15.12 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.885 174.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -111.97 150.62 30.29 Favored 'General case' 0 N--CA 1.457 -0.115 0 C-N-CA 124.356 1.062 . . . . 0.0 113.383 -177.667 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 25.9 t -133.32 91.71 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.145 0 C-N-CA 122.964 0.506 . . . . 0.0 110.35 -176.54 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -91.49 165.73 30.06 Favored Glycine 0 C--N 1.336 0.535 0 N-CA-C 111.594 -0.602 . . . . 0.0 111.594 179.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 62.9 t30 59.96 21.09 10.13 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.026 0.93 . . . . 0.0 111.669 -176.398 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 21.0 tp -67.35 118.7 59.03 Favored Pre-proline 0 CA--C 1.535 0.367 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.36 146.95 46.15 Favored 'Trans proline' 0 N--CA 1.45 -1.039 0 C-N-CA 122.658 2.239 . . . . 0.0 110.26 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.41 -14.47 30.97 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 123.401 2.734 . . . . 0.0 110.881 178.219 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 78.1 m-20 -80.13 0.8 30.61 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 113.479 0.918 . . . . 0.0 113.479 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 tp -64.98 144.3 14.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 24.7 ttp85 -73.91 155.66 38.46 Favored 'General case' 0 C--O 1.231 0.127 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.8 p -66.01 7.82 0.25 Allowed 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 114.537 1.31 . . . . 0.0 114.537 -178.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 19.0 tptm -142.02 -29.43 0.6 Allowed 'General case' 0 C--O 1.227 -0.096 0 C-N-CA 122.354 0.262 . . . . 0.0 111.129 -179.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 -63.71 -19.1 64.66 Favored 'General case' 0 N--CA 1.456 -0.167 0 O-C-N 122.048 -0.407 . . . . 0.0 110.532 175.392 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 tt -67.43 -16.1 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 123.028 0.531 . . . . 0.0 110.908 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -130.66 -22.33 2.69 Favored 'General case' 0 C--N 1.341 0.198 0 CA-C-N 118.162 0.437 . . . . 0.0 111.915 177.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 66.4 m-20 -70.9 -29.76 65.92 Favored 'General case' 0 C--O 1.232 0.151 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 176.464 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 52.4 t -67.93 -40.8 84.02 Favored 'Isoleucine or valine' 0 C--N 1.34 0.156 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 174.255 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -67.6 -32.04 72.5 Favored 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 113.086 0.772 . . . . 0.0 113.086 176.13 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 54.5 m -65.75 -24.64 67.0 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.993 -0.094 . . . . 0.0 110.819 175.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 14.3 tmtt? -74.5 -34.56 63.09 Favored 'General case' 0 CA--C 1.531 0.25 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 173.091 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . 0.412 ' CD1' ' HA ' ' B' ' 70' ' ' ALA . 40.0 m-85 -72.04 -20.86 61.62 Favored 'General case' 0 CA--C 1.529 0.169 0 N-CA-C 115.582 1.697 . . . . 0.0 115.582 175.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 161.72 -169.43 37.17 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 178.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.41 108.51 17.26 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-O 120.778 0.323 . . . . 0.0 111.174 -177.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . 0.438 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.8 mp -97.55 147.66 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.157 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 173.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -115.3 -24.05 8.63 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 119.384 -0.341 . . . . 0.0 111.209 177.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -151.38 158.78 44.2 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 114.071 1.137 . . . . 0.0 114.071 -179.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . 0.414 HD12 ' HA ' ' B' ' 45' ' ' ILE . 10.9 tp -124.28 159.67 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 176.318 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -153.19 63.28 0.76 Allowed 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.826 0.346 . . . . 0.0 110.752 -177.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 45.1 tp -63.37 135.89 57.28 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 175.198 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.528 ' HE2' ' CZ ' ' B' ' 56' ' ' PHE . 35.5 mtmm -141.09 176.43 8.83 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 123.795 0.838 . . . . 0.0 111.239 -178.327 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -144.16 177.85 8.3 Favored 'General case' 0 C--O 1.233 0.21 0 C-N-CA 122.928 0.491 . . . . 0.0 110.661 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 52.6 ttp180 -146.88 161.17 41.27 Favored 'General case' 0 C--O 1.232 0.171 0 C-N-CA 123.15 0.58 . . . . 0.0 109.601 -177.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 23.1 mmm180 -69.14 1.0 3.98 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 123.259 0.624 . . . . 0.0 112.218 -178.258 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -167.28 158.77 31.86 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 178.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.54 178.97 37.6 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 111.641 -0.584 . . . . 0.0 111.641 -178.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.82 160.59 49.12 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 123.649 2.9 . . . . 0.0 110.684 178.798 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.12 172.74 12.42 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 123.837 3.025 . . . . 0.0 110.435 176.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . 0.528 ' CZ ' ' HE2' ' B' ' 48' ' ' LYS . 3.1 p90 -155.34 167.34 30.69 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -146.83 156.98 43.54 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.133 0.492 . . . . 0.0 111.74 -175.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -106.78 150.85 25.9 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 115.179 -0.919 . . . . 0.0 112.332 170.202 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 72.8 t -131.82 137.98 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.264 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 -179.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -122.17 118.42 28.59 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.69 0.281 . . . . 0.0 110.557 -177.234 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.438 ' CE2' HD11 ' B' ' 42' ' ' ILE . 54.2 m-85 -85.52 151.85 23.63 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 115.39 1.626 . . . . 0.0 115.39 -177.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 40.3 tp10 -78.53 -18.4 54.78 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.379 0.672 . . . . 0.0 109.851 173.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -148.44 119.53 4.32 Favored Pre-proline 0 CA--C 1.532 0.269 0 C-N-CA 123.482 0.713 . . . . 0.0 110.072 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_exo -55.08 -20.5 24.0 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.411 2.741 . . . . 0.0 113.324 -177.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 53.3 tpt85 -69.54 -32.55 71.43 Favored 'General case' 0 C--N 1.342 0.243 0 CA-C-N 118.295 0.498 . . . . 0.0 110.971 179.578 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -74.05 -24.39 59.52 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -179.867 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.46 -24.11 64.67 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.239 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -73.79 -27.71 61.27 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 178.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 77.4 m-20 -78.04 -38.43 44.61 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 112.386 0.513 . . . . 0.0 112.386 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . 0.412 ' HA ' ' CD1' ' B' ' 39' ' ' TYR . . . -70.77 -31.05 67.71 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 110.343 -0.243 . . . . 0.0 110.343 178.389 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 37.3 t -80.6 -43.91 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 46.0 t -66.27 -20.97 66.26 Favored 'General case' 0 CA--C 1.533 0.29 0 O-C-N 122.197 -0.315 . . . . 0.0 111.127 -177.467 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -91.03 -15.27 56.43 Favored Glycine 0 CA--C 1.529 0.938 0 CA-C-O 119.307 -0.718 . . . . 0.0 113.17 -177.001 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 62.7 mtt180 -147.62 21.54 1.16 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.448 1.124 . . . . 0.0 113.045 -172.275 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 16.5 p30 -69.32 1.71 3.58 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 177.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.24 90.44 0.08 OUTLIER Glycine 0 C--N 1.336 0.582 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -125.53 139.49 53.56 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 178.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 13.0 t0 -64.39 106.5 1.13 Allowed 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.628 0.771 . . . . 0.0 112.65 -177.066 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.444 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.0 t80 -111.46 170.35 8.18 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 123.677 0.791 . . . . 0.0 111.446 177.348 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.444 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 18.1 t0 -59.15 100.9 0.08 Allowed 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -179.198 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 75.81 -5.28 40.32 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-O 119.661 -0.522 . . . . 0.0 112.888 177.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -141.43 -169.49 2.88 Favored 'General case' 0 C--O 1.232 0.161 0 N-CA-C 113.513 0.931 . . . . 0.0 113.513 -177.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 42.2 ttp-105 -142.04 139.31 32.29 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.672 0.789 . . . . 0.0 109.162 179.22 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -64.72 151.15 45.85 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 -178.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 90.1 mtm-85 -133.61 56.17 1.86 Allowed 'General case' 0 C--N 1.339 0.135 0 CA-C-O 120.75 0.31 . . . . 0.0 110.799 177.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 23.1 t -82.21 93.95 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 175.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.9 pt-20 -151.9 162.72 40.6 Favored 'General case' 0 N--CA 1.456 -0.14 0 C-N-CA 122.51 0.324 . . . . 0.0 110.205 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.4 p90 -78.09 157.56 78.4 Favored Pre-proline 0 N--CA 1.453 -0.306 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 177.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo . . . . . 0 C--O 1.252 1.219 0 C-N-CA 123.903 3.069 . . . . 0.0 111.658 177.45 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.379 1 O4'-C1'-N19 112.554 4.354 . 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.908 0 O4'-C1'-N19 111.828 3.628 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.441 " H4'" ' CE1' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.421 -2.643 0 O4'-C1'-N19 111.395 3.195 . 0.133 2z . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.462 ' C4 ' ' HA3' ' B' ' 9' ' ' GLY . . . . . . . . 0 O4'--C4' 1.42 -2.75 0 O4'-C1'-N19 111.098 2.898 . 0.368 4g . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.298 0 C5'-C4'-C3' 110.208 -3.528 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.025 0 C5'-C4'-C3' 109.924 -3.717 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.4 HG22 ' H ' ' B' ' 8' ' ' ARG . 4.6 p . . . . . 0 N--CA 1.477 0.909 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 1.7 mt -86.05 -2.16 7.75 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 C-N-CA 122.61 0.364 . . . . 0.0 111.24 -177.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.4 ' H ' HG22 ' B' ' 6' ' ' VAL . 1.2 tmm_? -60.79 141.8 56.64 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 122.474 0.31 . . . . 0.0 110.457 -179.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 57.8 -145.88 39.35 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 176.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -76.31 43.24 1.14 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 124.27 3.313 . . . . 0.0 110.273 175.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 59.39 13.36 3.14 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 124.2 1.0 . . . . 0.0 112.064 -173.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -93.15 175.95 36.88 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 176.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -154.86 125.46 6.96 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 122.404 -0.468 . . . . 0.0 110.168 178.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 56.4 t-20 -163.61 139.41 6.58 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 177.507 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -77.52 -11.07 59.81 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.074 0.398 . . . . 0.0 112.074 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 75.2 m -79.24 1.76 23.6 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 122.835 0.454 . . . . 0.0 111.34 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 48.8 mtt-85 -78.51 151.1 32.73 Favored 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 112.705 0.631 . . . . 0.0 112.705 -177.164 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 34.4 pt -139.14 171.59 14.44 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 C-N-CA 123.507 0.723 . . . . 0.0 109.524 174.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.441 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.3 OUTLIER -113.21 153.12 28.86 Favored 'General case' 0 C--O 1.231 0.107 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -175.99 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 58.7 t -136.77 140.89 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.317 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -146.87 174.62 26.63 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 111.925 -0.47 . . . . 0.0 111.925 -176.504 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 66.3 t30 62.91 157.35 0.06 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.772 1.229 . . . . 0.0 111.463 -172.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.2 tp -81.65 130.41 61.49 Favored Pre-proline 0 N--CA 1.453 -0.306 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -69.93 165.17 32.07 Favored 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.344 2.696 . . . . 0.0 110.822 176.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -56.59 -26.16 63.01 Favored 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 123.737 2.958 . . . . 0.0 111.894 179.022 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 40.4 p-10 -157.14 162.85 39.39 Favored 'General case' 0 C--O 1.233 0.192 0 C-N-CA 123.368 0.667 . . . . 0.0 110.457 175.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 6.4 tp -151.99 142.63 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 110.105 -0.332 . . . . 0.0 110.105 -179.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 81.8 mtt85 -140.02 31.15 1.99 Allowed 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 123.558 0.743 . . . . 0.0 110.135 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . 0.25 1.0 OUTLIER 59.59 7.78 1.1 Allowed 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 115.749 1.759 . . . . 0.0 115.749 -178.916 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . 0.425 ' HE3' ' HB2' ' B' ' 30' ' ' LYS . 0.0 OUTLIER -151.43 -6.6 0.25 Allowed 'General case' 0 C--N 1.339 0.126 0 O-C-N 122.435 -0.166 . . . . 0.0 111.427 177.359 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -64.65 -19.75 65.89 Favored 'General case' 0 N--CA 1.457 -0.112 0 O-C-N 122.116 -0.365 . . . . 0.0 111.979 178.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 7.5 tp -71.64 -17.69 19.59 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 175.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 81.6 mt-10 -94.96 -36.52 11.55 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -69.52 -39.97 77.2 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -177.023 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 77.1 t -72.14 -41.89 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.075 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 39.0 m-85 -74.06 -37.78 64.16 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 114.02 1.119 . . . . 0.0 114.02 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 91.7 p -69.21 -22.12 63.9 Favored 'General case' 0 C--N 1.34 0.175 0 CA-C-N 117.729 0.241 . . . . 0.0 110.422 177.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -74.73 -34.06 62.49 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -81.22 -13.26 58.72 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 115.926 1.825 . . . . 0.0 115.926 177.708 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.16 175.37 43.47 Favored Glycine 0 CA--C 1.527 0.819 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.053 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -82.27 80.02 8.58 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.097 0.559 . . . . 0.0 110.601 -178.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.7 mp -65.51 140.22 20.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.105 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 174.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . 0.43 ' HE ' ' HA ' ' B' ' 43' ' ' ARG . 1.7 mmp_? -109.76 -27.84 9.12 Favored 'General case' 0 N--CA 1.457 -0.082 0 C-N-CA 122.869 0.467 . . . . 0.0 110.739 177.361 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -151.79 163.43 39.18 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 113.815 1.042 . . . . 0.0 113.815 -179.223 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 7.6 tp -142.17 160.56 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -177.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -153.95 68.55 0.76 Allowed 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 176.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 49.0 tp -69.3 133.31 47.71 Favored 'General case' 0 CA--C 1.529 0.141 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 175.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.485 ' HD2' ' CZ ' ' B' ' 56' ' ' PHE . 67.3 mttm -126.5 128.84 47.55 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 122.559 0.344 . . . . 0.0 110.542 -178.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -161.2 -36.41 0.05 OUTLIER 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.124 175.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 51.5 tpt85 -84.03 -21.16 31.71 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 122.719 0.408 . . . . 0.0 110.62 177.2 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 82.9 mtm180 -82.89 14.12 3.47 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.263 0.625 . . . . 0.0 111.621 179.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.73 174.57 44.32 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 111.671 -0.572 . . . . 0.0 111.671 176.37 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.53 176.47 32.81 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.504 -0.639 . . . . 0.0 111.504 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.24 161.3 45.2 Favored 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 123.639 2.892 . . . . 0.0 109.772 176.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -68.0 120.82 7.8 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 123.021 2.48 . . . . 0.0 110.247 178.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . 0.485 ' CZ ' ' HD2' ' B' ' 48' ' ' LYS . 3.3 p90 -161.58 171.69 17.6 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 178.097 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.38 164.37 38.37 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.213 0.53 . . . . 0.0 111.691 -175.743 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . 0.4 ' CZ ' ' HB2' ' B' ' 19' ' ' TYR . 9.7 m-85 -116.81 151.62 36.11 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 115.372 -0.831 . . . . 0.0 113.073 169.396 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 48.2 t -133.41 142.23 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 C-N-CA 123.189 0.596 . . . . 0.0 109.62 -177.212 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -123.99 117.82 25.62 Favored 'General case' 0 N--CA 1.454 -0.262 0 N-CA-C 110.444 -0.206 . . . . 0.0 110.444 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 49.3 m-85 -90.33 158.27 17.22 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 113.774 1.027 . . . . 0.0 113.774 177.771 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -70.77 -24.28 62.56 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 174.042 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -152.64 155.52 32.64 Favored Pre-proline 0 CA--C 1.533 0.314 0 C-N-CA 123.367 0.667 . . . . 0.0 111.952 178.511 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -71.92 -7.74 21.65 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 123.054 2.502 . . . . 0.0 111.359 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.28 -53.93 14.77 Favored 'General case' 0 C--N 1.339 0.12 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -177.112 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -70.75 -20.22 62.65 Favored 'General case' 0 C--O 1.233 0.185 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -177.564 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.05 -23.92 65.93 Favored 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 45.6 tp10 -72.77 -32.48 65.64 Favored 'General case' 0 N--CA 1.455 -0.2 0 O-C-N 122.273 -0.267 . . . . 0.0 110.318 179.539 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 62.0 m-20 -73.49 -36.8 65.84 Favored 'General case' 0 CA--C 1.522 -0.116 0 N-CA-C 111.979 0.362 . . . . 0.0 111.979 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.8 -27.92 63.26 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 122.164 0.186 . . . . 0.0 110.557 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 42.6 t -83.19 -54.32 9.49 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.2 t -70.68 -18.91 62.83 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 -174.17 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -101.31 0.54 53.91 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-O 119.031 -0.872 . . . . 0.0 113.585 -173.04 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 28.9 ttp-105 -153.78 -13.18 0.14 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-N 118.846 1.323 . . . . 0.0 113.393 -175.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -67.68 145.69 54.53 Favored 'General case' 0 C--O 1.233 0.226 0 O-C-N 121.465 -0.772 . . . . 0.0 110.315 179.485 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.51 55.17 26.95 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.554 -0.618 . . . . 0.0 111.554 175.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 39.2 t80 -105.96 140.38 39.06 Favored 'General case' 0 N--CA 1.453 -0.288 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -178.094 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -62.91 110.55 1.81 Allowed 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 124.2 1.0 . . . . 0.0 113.012 -175.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.421 ' CD2' ' N ' ' B' ' 80' ' ' ASP . 25.6 t80 -118.88 165.93 13.45 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 123.66 0.784 . . . . 0.0 111.941 174.756 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.421 ' N ' ' CD2' ' B' ' 79' ' ' TYR . 19.4 t0 -59.07 98.09 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.436 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -178.661 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 79.9 -4.91 63.79 Favored Glycine 0 CA--C 1.535 1.285 0 CA-C-O 119.747 -0.474 . . . . 0.0 112.677 177.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -140.56 -170.22 2.96 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 117.952 0.876 . . . . 0.0 113.15 -178.185 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 -141.38 133.35 27.59 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 -178.158 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -65.13 152.03 44.6 Favored 'General case' 0 C--O 1.231 0.109 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.27 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -125.72 126.92 45.39 Favored 'General case' 0 CA--C 1.52 -0.173 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 175.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 38.9 t -143.95 81.26 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.224 -0.245 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 176.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -139.8 158.22 44.45 Favored 'General case' 0 C--O 1.224 -0.281 0 C-N-CA 122.664 0.386 . . . . 0.0 110.551 -175.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 3.0 p90 -74.54 154.79 87.64 Favored Pre-proline 0 N--CA 1.454 -0.269 0 N-CA-C 114.73 1.381 . . . . 0.0 114.73 179.245 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo . . . . . 0 C--O 1.253 1.255 0 C-N-CA 123.646 2.897 . . . . 0.0 110.877 176.937 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -2.987 0 C3'-C2'-C1' 104.46 3.289 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.063 0 C3'-C2'-C1' 104.673 3.525 . 0.171 0b . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.441 ' C6 ' ' CE1' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.422 -2.607 0 C5'-C4'-C3' 110.752 -3.165 . 0.048 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.425 -2.358 0 C5'-C4'-C3' 110.079 -3.614 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.518 0 O4'-C1'-N19 110.745 2.545 OUTLIER-DELTA 0.0 OUTLIER delta 0.0 . . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.792 0 C5'-C4'-C3' 110.208 -3.528 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.2 t . . . . . 0 N--CA 1.476 0.87 0 N-CA-C 111.585 0.217 . . . . 0.0 111.585 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 85.7 mt -66.4 -31.69 54.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 122.261 0.224 . . . . 0.0 111.438 -175.191 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 7.0 tpp180 -158.25 159.5 36.08 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 122.436 0.294 . . . . 0.0 110.267 -178.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . -64.12 167.91 25.9 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 176.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.42 149.4 84.71 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 123.292 2.661 . . . . 0.0 109.433 174.337 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -156.94 164.35 38.13 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-O 120.878 0.37 . . . . 0.0 111.442 -176.21 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -157.65 5.86 0.17 Allowed Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 177.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 59.4 t30 -148.1 158.88 44.31 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.895 0.878 . . . . 0.0 109.364 -179.175 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 74.8 m-20 -73.66 140.95 46.46 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 178.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 40.75 -134.05 0.26 Allowed 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.876 0.695 . . . . 0.0 112.876 -178.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 86.6 m 59.27 7.58 0.94 Allowed 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 178.085 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 68.5 mtm-85 -87.76 138.21 31.66 Favored 'General case' 0 N--CA 1.453 -0.316 0 O-C-N 122.1 -0.375 . . . . 0.0 111.336 178.618 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 2.6 pp -138.05 168.89 19.48 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 C-N-CA 123.148 0.579 . . . . 0.0 110.072 176.128 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.439 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.4 OUTLIER -113.33 153.31 28.71 Favored 'General case' 0 CA--C 1.528 0.104 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -177.228 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 93.0 t -133.99 115.21 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 -178.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -117.56 169.95 13.38 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 177.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 61.1 t30 57.99 23.68 10.21 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.704 0.801 . . . . 0.0 111.113 -175.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 21.2 tp -65.39 127.05 92.61 Favored Pre-proline 0 CA--C 1.535 0.374 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 178.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -71.21 154.46 61.76 Favored 'Trans proline' 0 N--CA 1.451 -0.98 0 C-N-CA 123.075 2.516 . . . . 0.0 110.824 -178.08 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -71.26 -12.52 30.03 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 123.44 2.76 . . . . 0.0 111.233 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 -77.56 -1.91 33.04 Favored 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 178.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 9.1 tp -67.12 158.62 5.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 C-N-CA 122.596 0.358 . . . . 0.0 110.321 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 76.5 mtt85 -132.19 152.58 51.22 Favored 'General case' 0 N--CA 1.457 -0.09 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 176.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.43 -17.78 60.15 Favored 'General case' 0 C--N 1.334 -0.101 0 N-CA-C 114.262 1.208 . . . . 0.0 114.262 -177.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 4.2 ttpt -97.03 -30.56 12.99 Favored 'General case' 0 C--O 1.226 -0.144 0 C-N-CA 122.329 0.251 . . . . 0.0 110.714 178.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -69.23 -31.79 70.58 Favored 'General case' 0 C--O 1.233 0.189 0 O-C-N 122.169 -0.332 . . . . 0.0 111.581 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.4 tt -76.48 -11.24 13.79 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 O-C-N 123.169 0.293 . . . . 0.0 110.99 -178.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 24.1 pt-20 -118.97 -0.56 11.14 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 117.833 0.288 . . . . 0.0 110.807 177.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -94.49 -62.41 1.33 Allowed 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 122.551 0.34 . . . . 0.0 111.674 177.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 62.9 t -65.4 -41.12 90.4 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 -178.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -62.94 -31.03 72.03 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 40.4 t -68.07 -30.8 70.08 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 110.228 -0.286 . . . . 0.0 110.228 177.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 47.1 mmtm -69.35 -28.28 66.08 Favored 'General case' 0 C--N 1.338 0.082 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 173.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -80.18 -19.11 47.86 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 116.665 2.098 . . . . 0.0 116.665 176.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.49 20.24 0.03 OUTLIER Glycine 0 CA--C 1.53 0.99 0 C-N-CA 119.584 -1.293 . . . . 0.0 114.64 -177.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 50.85 66.69 1.1 Allowed 'General case' 0 CA--C 1.533 0.313 0 CA-C-N 118.279 1.039 . . . . 0.0 111.987 176.423 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . 0.511 HD11 ' CZ ' ' B' ' 61' ' ' PHE . 1.7 mp -56.02 141.95 11.83 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 C-N-CA 122.951 0.5 . . . . 0.0 110.447 178.054 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . 0.421 HH11 ' HD3' ' B' ' 43' ' ' ARG . 10.6 mmm180 -107.05 -24.7 11.88 Favored 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 122.603 0.361 . . . . 0.0 111.262 179.804 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -146.59 155.25 42.34 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . 0.458 HG22 ' H ' ' B' ' 47' ' ' LEU . 17.7 mm -139.13 154.36 25.5 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 C-N-CA 124.203 1.001 . . . . 0.0 109.407 -178.21 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -142.38 47.67 1.58 Allowed 'General case' 0 CA--C 1.531 0.233 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 177.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . 0.458 ' H ' HG22 ' B' ' 45' ' ' ILE . 58.7 tp -61.5 128.21 35.19 Favored 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.55 177.626 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.532 ' HE2' ' CZ ' ' B' ' 56' ' ' PHE . 23.2 pttm -157.74 173.14 17.27 Favored 'General case' 0 CA--C 1.528 0.102 0 C-N-CA 123.551 0.74 . . . . 0.0 109.691 179.04 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 50.8 p30 -146.78 11.28 1.08 Allowed 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -174.445 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 19.5 mtp180 50.53 24.46 1.63 Allowed 'General case' 0 C--N 1.341 0.219 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -179.054 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 63.6 mtm-85 56.1 19.93 4.07 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.399 0.68 . . . . 0.0 112.586 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.88 145.42 7.91 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.43 -179.03 49.15 Favored Glycine 0 CA--C 1.53 0.97 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -176.39 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -68.0 147.16 73.35 Favored 'Trans proline' 0 N--CA 1.451 -1.001 0 C-N-CA 123.665 2.91 . . . . 0.0 110.397 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.22 164.69 34.87 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 123.362 2.708 . . . . 0.0 110.945 -179.296 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . 0.532 ' CZ ' ' HE2' ' B' ' 48' ' ' LYS . 4.2 p90 -157.24 163.07 39.17 Favored 'General case' 0 C--O 1.234 0.25 0 N-CA-C 104.696 -2.335 . . . . 0.0 104.696 174.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.17 152.88 29.94 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 119.713 -0.795 . . . . 0.0 112.611 -172.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -96.5 148.24 23.02 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.707 166.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 58.5 t -133.98 143.8 37.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -178.439 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -132.21 118.39 19.47 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 120.956 0.408 . . . . 0.0 110.763 -176.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.511 ' CZ ' HD11 ' B' ' 42' ' ' ILE . 34.5 m-85 -86.96 161.97 17.93 Favored 'General case' 0 C--N 1.333 -0.115 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -177.436 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 72.9 tt0 -79.98 -27.92 39.59 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.425 174.36 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -138.51 143.51 38.62 Favored Pre-proline 0 C--N 1.34 0.182 0 C-N-CA 123.85 0.86 . . . . 0.0 112.006 179.055 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -73.83 -19.7 20.64 Favored 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 123.281 2.654 . . . . 0.0 111.257 -177.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 78.7 mtt85 -74.18 -25.23 59.59 Favored 'General case' 0 N--CA 1.456 -0.136 0 C-N-CA 122.398 0.279 . . . . 0.0 111.381 -178.154 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -91.96 -21.89 20.3 Favored 'General case' 0 N--CA 1.457 -0.122 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.642 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -67.73 -27.06 66.48 Favored 'General case' 0 N--CA 1.453 -0.276 0 O-C-N 122.274 -0.267 . . . . 0.0 110.282 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -73.55 -26.66 60.95 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 121.9 0.08 . . . . 0.0 110.848 179.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -77.25 -36.23 54.67 Favored 'General case' 0 CA--C 1.521 -0.14 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.84 -29.06 61.92 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 122.259 0.224 . . . . 0.0 110.439 177.578 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 17.2 t -80.94 -42.81 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.246 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 43.8 t -66.97 -21.83 65.95 Favored 'General case' 0 CA--C 1.528 0.108 0 O-C-N 122.177 -0.327 . . . . 0.0 111.063 -178.156 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -89.66 -2.88 75.15 Favored Glycine 0 CA--C 1.531 1.071 0 CA-C-O 119.387 -0.674 . . . . 0.0 112.92 -178.361 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 80.3 mtt85 -141.93 -8.48 0.92 Allowed 'General case' 0 C--N 1.341 0.211 0 CA-C-N 118.181 0.99 . . . . 0.0 112.827 -174.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -67.3 118.64 10.95 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -179.286 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 61.81 45.37 96.35 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 175.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 53.9 t80 -95.97 135.94 37.06 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -172.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.6 t0 -63.51 105.33 0.76 Allowed 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.52 0.728 . . . . 0.0 112.557 -177.506 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.434 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 62.8 t80 -111.72 171.05 7.72 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.733 0.813 . . . . 0.0 111.301 177.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.434 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 19.7 t0 -60.5 98.83 0.07 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -179.464 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 77.88 -4.69 56.57 Favored Glycine 0 CA--C 1.536 1.35 0 CA-C-O 119.474 -0.626 . . . . 0.0 112.938 177.405 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -140.93 -171.14 3.19 Favored 'General case' 0 N--CA 1.462 0.148 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 41.7 ttp-105 -145.08 131.07 19.24 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.86 0.864 . . . . 0.0 109.334 -178.107 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.9 mp -66.62 153.79 42.18 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-O 120.923 0.392 . . . . 0.0 110.477 -175.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 52.8 mtm180 -129.47 47.27 2.51 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.457 0.703 . . . . 0.0 110.167 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 88.3 t -77.32 98.43 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 175.088 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -151.09 162.49 40.75 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.629 0.252 . . . . 0.0 110.655 179.178 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -73.05 152.51 90.71 Favored Pre-proline 0 C--O 1.234 0.24 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 178.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo . . . . . 0 C--O 1.251 1.15 0 C-N-CA 123.739 2.959 . . . . 0.0 110.735 177.836 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.944 0 C3'-C2'-C1' 105.006 3.895 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.427 -2.2 0 O4'-C1'-N19 111.411 3.211 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.439 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.352 1 C5'-C4'-C3' 108.176 -4.883 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.402 0 O4'-C1'-N19 112.114 3.914 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.416 0 C5'-C4'-C3' 109.573 -3.951 OUTLIER-DELTA 0.0 OUTLIER delta 0.0 . . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.415 -3.174 0 O4'-C1'-N19 110.899 2.699 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 111.512 0.189 . . . . 0.0 111.512 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 64.5 mt -79.95 144.61 10.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 177.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 8.5 tmm_? -67.95 164.77 19.18 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 122.902 0.481 . . . . 0.0 110.372 -179.139 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . -44.3 141.33 3.35 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 123.91 0.767 . . . . 0.0 112.114 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -70.41 -2.52 10.78 Favored 'Trans proline' 0 N--CA 1.452 -0.929 0 C-N-CA 123.637 2.891 . . . . 0.0 111.602 178.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -63.82 158.8 20.99 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 122.421 0.288 . . . . 0.0 110.665 179.031 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.66 170.05 49.34 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -178.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -81.56 -162.32 0.51 Allowed 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 123.346 0.659 . . . . 0.0 110.929 -178.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 54.8 m-20 65.26 164.49 0.16 Allowed 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 124.831 1.252 . . . . 0.0 112.464 -177.441 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 77.9 m-20 -73.8 7.23 2.64 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -175.203 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 76.4 m -70.54 -14.59 62.57 Favored 'General case' 0 CA--C 1.532 0.28 0 O-C-N 122.373 -0.205 . . . . 0.0 110.732 178.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 18.4 ttm180 -84.25 152.65 24.05 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 178.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 15.3 pt -136.17 -178.77 2.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.141 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 175.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.434 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.9 OUTLIER -122.58 148.76 44.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.452 -0.794 . . . . 0.0 112.762 177.226 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 21.2 t -137.9 90.47 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 120.451 0.167 . . . . 0.0 110.755 -176.598 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -80.8 146.5 27.0 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 174.658 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 44.7 t30 58.28 -171.12 0.11 Allowed 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 122.786 0.434 . . . . 0.0 110.292 -174.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.409 ' H ' HD23 ' B' ' 23' ' ' LEU . 2.1 pt? -143.77 149.24 45.87 Favored Pre-proline 0 CA--C 1.534 0.338 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 177.107 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . 0.437 ' HA ' ' HD3' ' B' ' 25' ' ' PRO . 55.2 Cg_endo -70.96 155.62 61.66 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 123.435 2.757 . . . . 0.0 110.633 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' B' ' 24' ' ' PRO . 22.1 Cg_exo -62.5 -28.98 78.16 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 123.118 2.545 . . . . 0.0 111.239 177.296 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -91.8 123.07 34.9 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.638 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -158.27 140.58 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.11 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.546 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 60.6 mtm180 -136.41 19.56 3.14 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 122.795 0.438 . . . . 0.0 111.267 178.014 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 58.71 18.7 6.15 Favored 'General case' 0 N--CA 1.462 0.169 0 N-CA-C 114.204 1.186 . . . . 0.0 114.204 -176.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . 0.417 ' HE3' ' HB2' ' B' ' 34' ' ' ASP . 30.8 ttpt -150.64 -8.59 0.26 Allowed 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 123.418 0.687 . . . . 0.0 110.072 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -58.83 -23.67 60.91 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 113.092 0.775 . . . . 0.0 113.092 -179.004 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 27.7 mm -74.8 -17.49 16.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 122.653 0.381 . . . . 0.0 110.636 179.565 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -126.42 13.53 7.63 Favored 'General case' 0 C--N 1.34 0.159 0 CA-C-N 117.772 0.26 . . . . 0.0 111.052 178.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . 0.417 ' HB2' ' HE3' ' B' ' 30' ' ' LYS . 22.0 t0 -127.93 -60.86 1.14 Allowed 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 173.011 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 95.1 t -69.55 -53.18 26.03 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 51.1 m-85 -65.14 -19.3 65.92 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 175.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 47.5 t -71.57 -28.94 64.19 Favored 'General case' 0 N--CA 1.454 -0.242 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 175.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -74.82 -26.93 60.06 Favored 'General case' 0 CA--C 1.529 0.144 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 171.154 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -73.55 -23.78 60.03 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 115.928 1.825 . . . . 0.0 115.928 174.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.57 16.48 0.03 OUTLIER Glycine 0 CA--C 1.53 1.026 0 C-N-CA 120.219 -0.991 . . . . 0.0 114.074 -177.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.21 77.28 0.14 Allowed 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 117.886 0.843 . . . . 0.0 112.191 176.774 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.8 mp -60.07 142.32 15.56 Favored 'Isoleucine or valine' 0 C--O 1.232 0.138 0 C-N-CA 122.742 0.417 . . . . 0.0 110.225 177.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . 0.492 ' HE ' ' HA ' ' B' ' 62' ' ' GLU . 48.6 mtm105 -102.96 -30.99 10.45 Favored 'General case' 0 CA--C 1.523 -0.063 0 C-N-CA 122.393 0.277 . . . . 0.0 111.177 176.272 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -149.67 158.26 44.0 Favored 'General case' 0 C--O 1.232 0.134 0 N-CA-C 114.002 1.112 . . . . 0.0 114.002 -177.057 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 53.4 mt -125.59 150.8 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.149 0 C-N-CA 123.7 0.8 . . . . 0.0 109.098 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -141.01 50.71 1.63 Allowed 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 54.8 tp -60.55 135.58 57.8 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.099 177.034 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 25.3 ttmm -143.77 152.36 41.14 Favored 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 122.886 0.475 . . . . 0.0 110.116 -179.095 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 44.4 p30 -135.09 4.45 3.23 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 122.61 0.364 . . . . 0.0 111.949 -178.345 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 24.3 tpt180 -64.87 -15.75 62.33 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 122.783 0.433 . . . . 0.0 110.096 177.186 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 66.1 ttt-85 -65.71 -22.38 66.61 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.256 1.023 . . . . 0.0 111.225 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 75.67 165.36 17.22 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -174.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.21 -150.57 46.53 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -177.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -55.79 147.71 59.89 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 123.219 2.613 . . . . 0.0 110.934 175.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.82 167.79 24.81 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 123.48 2.787 . . . . 0.0 110.918 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -154.11 164.5 38.39 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 175.523 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -153.11 165.5 35.44 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-O 120.935 0.398 . . . . 0.0 111.883 -173.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -121.37 79.52 1.55 Allowed 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.471 175.02 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 97.5 t -67.49 147.48 12.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 C-N-CA 123.23 0.612 . . . . 0.0 110.19 -174.348 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -123.84 122.32 37.7 Favored 'General case' 0 CA--C 1.529 0.161 0 CA-C-O 120.825 0.345 . . . . 0.0 110.804 -178.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -94.58 164.92 12.78 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 115.464 1.653 . . . . 0.0 115.464 -175.322 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . 0.492 ' HA ' ' HE ' ' B' ' 43' ' ' ARG . 85.0 tt0 -73.58 -32.18 63.99 Favored 'General case' 0 C--N 1.34 0.183 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.661 174.332 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -141.59 145.82 39.02 Favored Pre-proline 0 CA--C 1.529 0.149 0 C-N-CA 123.771 0.828 . . . . 0.0 111.955 179.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -73.77 -19.58 20.92 Favored 'Trans proline' 0 N--CA 1.452 -0.941 0 C-N-CA 123.179 2.586 . . . . 0.0 110.841 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.74 -35.43 57.77 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 122.122 0.169 . . . . 0.0 110.838 -178.569 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -77.51 -17.72 57.71 Favored 'General case' 0 CA--C 1.527 0.083 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 178.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.53 -20.95 64.59 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 177.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -70.31 -34.25 72.48 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 177.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -75.83 -34.12 60.1 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -73.03 -31.69 64.6 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 178.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 7.5 t -73.69 -42.37 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.272 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 67.0 m -74.78 -0.49 18.43 Favored 'General case' 0 C--O 1.232 0.152 0 C-N-CA 122.136 0.175 . . . . 0.0 111.056 179.278 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -73.16 -35.66 57.02 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 119.487 -0.619 . . . . 0.0 112.756 -175.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 23.6 ttt180 -163.15 30.39 0.09 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.194 0.997 . . . . 0.0 111.631 -176.423 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 14.9 p-10 -65.0 144.29 57.39 Favored 'General case' 0 C--O 1.232 0.14 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -179.607 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 57.78 46.47 92.27 Favored Glycine 0 C--N 1.338 0.656 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 174.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . 0.564 ' H ' ' HB2' ' B' ' 84' ' ' LEU . 16.7 t80 -98.67 137.42 37.33 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.673 0.736 . . . . 0.0 112.853 -173.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -67.95 83.35 0.21 Allowed 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 124.29 1.036 . . . . 0.0 112.059 -177.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.449 ' CD2' ' N ' ' B' ' 80' ' ' ASP . 54.2 t80 -82.89 171.31 14.02 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 123.199 0.6 . . . . 0.0 111.218 177.532 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.449 ' N ' ' CD2' ' B' ' 79' ' ' TYR . 24.9 t0 -64.5 93.84 0.11 Allowed 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 83.96 -1.81 88.33 Favored Glycine 0 CA--C 1.53 0.997 0 CA-C-O 119.762 -0.465 . . . . 0.0 112.615 177.244 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -141.93 -172.69 3.62 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 117.876 0.838 . . . . 0.0 112.669 -179.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 4.6 tpt180 -137.59 133.78 34.81 Favored 'General case' 0 C--O 1.232 0.143 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . 0.564 ' HB2' ' H ' ' B' ' 77' ' ' TYR . 4.2 mm? -64.66 139.23 58.74 Favored 'General case' 0 C--N 1.333 -0.117 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 95.3 mtm-85 -129.04 54.98 1.76 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 122.701 0.4 . . . . 0.0 110.288 175.517 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 2.7 p -81.28 97.64 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 175.017 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -153.68 169.49 23.18 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 122.875 0.47 . . . . 0.0 110.686 -179.348 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -65.26 151.72 93.32 Favored Pre-proline 0 CA--C 1.53 0.203 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo . . . . . 0 C--O 1.25 1.107 0 C-N-CA 123.678 2.918 . . . . 0.0 110.761 177.221 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.07 0 C5'-C4'-C3' 109.934 -3.71 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.446 0 C5'-C4'-C3' 110.149 -3.567 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.434 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.421 -2.652 0 C5'-C4'-C3' 109.719 -3.854 . 0.274 4p . 0.0 . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.482 " H3'" H5'' ' A' ' 94' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.425 -2.369 0 C5'-C4'-C3' 110.343 -3.438 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . 0.482 H5'' " H3'" ' A' ' 93' ' ' ' A' . . . . . . . . 0 P--O5' 1.617 2.383 0 C5'-C4'-C3' 109.74 -3.84 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.498 0 O4'-C1'-N19 112.025 3.825 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 19.5 t . . . . . 0 N--CA 1.476 0.836 0 CA-C-O 119.861 -0.114 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 31.4 mt 52.99 94.5 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 124.722 1.209 . . . . 0.0 111.527 -177.004 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.416 ' HD3' ' H ' ' B' ' 9' ' ' GLY . 17.8 tpp85 62.08 170.36 0.12 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.042 1.337 . . . . 0.0 112.149 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . 0.416 ' H ' ' HD3' ' B' ' 8' ' ' ARG . . . -64.35 166.86 29.07 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.66 -0.576 . . . . 0.0 111.66 -176.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -56.8 153.33 37.53 Favored 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 123.949 3.099 . . . . 0.0 111.638 179.144 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 56.67 16.03 2.43 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 123.956 0.902 . . . . 0.0 112.687 -179.314 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 69.72 -168.91 45.88 Favored Glycine 0 CA--C 1.528 0.859 0 N-CA-C 111.763 -0.535 . . . . 0.0 111.763 178.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -71.06 147.53 48.44 Favored 'General case' 0 N--CA 1.453 -0.278 0 O-C-N 122.516 -0.402 . . . . 0.0 111.296 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 63.1 t30 -159.55 170.29 21.98 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 175.561 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 20.5 p30 -77.91 177.06 8.54 Favored 'General case' 0 CA--C 1.533 0.288 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 179.102 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 73.9 m 61.15 13.32 4.65 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 176.155 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 54.6 mtm180 -82.16 145.26 30.2 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 118.422 0.555 . . . . 0.0 111.305 175.663 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 22.8 pt -138.62 175.73 7.77 Favored 'Isoleucine or valine' 0 C--O 1.231 0.095 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 170.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.452 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.6 OUTLIER -119.34 148.82 42.75 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 114.553 1.316 . . . . 0.0 114.553 -177.839 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 60.7 t -132.88 136.58 55.39 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 C-N-CA 123.226 0.61 . . . . 0.0 109.634 179.279 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -140.52 172.15 23.69 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 51.2 t30 57.07 19.74 4.95 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.729 0.812 . . . . 0.0 111.41 -174.44 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 15.7 tp -61.42 130.61 91.99 Favored Pre-proline 0 N--CA 1.454 -0.258 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -67.2 146.09 74.89 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 122.545 2.163 . . . . 0.0 110.766 -177.052 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.86 -7.54 21.3 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 C-N-CA 123.815 3.01 . . . . 0.0 111.282 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -73.07 -6.84 48.27 Favored 'General case' 0 CA--C 1.53 0.197 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 179.446 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 10.0 tp -69.04 145.91 13.05 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.335 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 59.3 ttm-85 -161.14 154.41 21.5 Favored 'General case' 0 C--N 1.34 0.167 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -178.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.1 p 51.74 -160.05 0.1 Allowed 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 113.221 0.823 . . . . 0.0 113.221 -177.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -73.27 15.38 0.23 Allowed 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.101 0.56 . . . . 0.0 112.153 -179.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -58.84 -25.48 63.27 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 179.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.9 tt -76.27 -17.87 15.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 C-N-CA 122.335 0.254 . . . . 0.0 110.511 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 86.1 mt-10 -93.41 -31.04 14.78 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -74.13 -37.26 64.13 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 112.863 0.69 . . . . 0.0 112.863 -177.655 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 62.4 t -69.71 -46.1 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.353 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -68.79 -35.4 76.99 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 113.615 0.969 . . . . 0.0 113.615 178.064 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 33.5 t -60.9 -33.5 73.21 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 178.283 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 16.7 tppt? -73.76 -33.43 64.29 Favored 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 122.2 0.2 . . . . 0.0 110.769 177.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -87.04 -13.83 43.28 Favored 'General case' 0 C--O 1.233 0.206 0 N-CA-C 116.739 2.125 . . . . 0.0 116.739 -178.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.08 13.83 0.03 OUTLIER Glycine 0 CA--C 1.527 0.843 0 C-N-CA 119.906 -1.14 . . . . 0.0 114.254 -177.447 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.62 40.54 27.44 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 118.227 1.013 . . . . 0.0 111.806 177.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . 0.645 HD11 ' CE2' ' B' ' 61' ' ' PHE . 1.7 mp -44.25 138.33 0.97 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.182 0 C-N-CA 123.719 0.808 . . . . 0.0 111.114 179.087 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 29.8 mtp-105 -85.51 -38.91 18.03 Favored 'General case' 0 CA--C 1.523 -0.08 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.748 -178.31 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -144.5 159.48 42.7 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -176.439 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 8.7 tp -137.32 161.74 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -178.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -147.78 70.44 1.16 Allowed 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 177.013 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . 0.472 ' C ' HD13 ' B' ' 47' ' ' LEU . 3.4 tm? -64.14 125.53 24.8 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 176.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 39.4 mttp -139.11 164.14 30.57 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 123.547 0.739 . . . . 0.0 111.054 -178.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 51.9 t-20 -159.53 120.04 3.1 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 170.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 43.8 ttt180 -161.91 143.15 10.9 Favored 'General case' 0 C--N 1.338 0.088 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -176.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 35.1 mtm180 50.1 29.83 3.81 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 123.406 0.682 . . . . 0.0 112.24 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -161.22 172.35 37.44 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.387 -0.685 . . . . 0.0 111.387 -178.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -80.21 -83.14 0.72 Allowed Glycine 0 CA--C 1.528 0.875 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -68.96 151.87 73.49 Favored 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.711 2.941 . . . . 0.0 110.817 -179.752 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -68.83 170.96 14.25 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 123.991 3.127 . . . . 0.0 111.629 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -150.67 165.2 34.14 Favored 'General case' 0 N--CA 1.457 -0.088 0 N-CA-C 104.884 -2.265 . . . . 0.0 104.884 175.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -157.03 163.7 38.78 Favored 'General case' 0 N--CA 1.453 -0.304 0 O-C-N 121.721 -0.612 . . . . 0.0 111.922 -174.409 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . 0.489 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 74.5 m-85 -113.2 151.62 30.75 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 171.154 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 41.5 t -131.1 136.4 57.95 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 -175.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -120.55 111.68 17.98 Favored 'General case' 0 N--CA 1.455 -0.205 0 CA-C-O 120.865 0.364 . . . . 0.0 110.481 -177.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.645 ' CE2' HD11 ' B' ' 42' ' ' ILE . 37.1 m-85 -81.15 159.38 24.66 Favored 'General case' 0 CA--C 1.528 0.125 0 N-CA-C 115.347 1.61 . . . . 0.0 115.347 -176.583 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -87.73 -26.66 22.82 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 169.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -155.44 118.95 2.42 Favored Pre-proline 0 CA--C 1.532 0.258 0 C-N-CA 123.635 0.774 . . . . 0.0 109.691 -179.196 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.52 -10.54 29.08 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.31 2.673 . . . . 0.0 111.942 -174.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 41.0 ttm105 -67.45 -29.29 68.72 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 117.887 0.312 . . . . 0.0 110.542 177.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 -81.24 -16.07 53.72 Favored 'General case' 0 CA--C 1.53 0.176 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -69.77 -16.43 63.3 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-O 120.39 0.138 . . . . 0.0 110.75 -179.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -66.7 -20.27 65.93 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 122.363 -0.21 . . . . 0.0 110.6 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 79.2 m-20 -104.29 -33.16 8.76 Favored 'General case' 0 C--N 1.339 0.125 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 178.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -72.92 -31.49 64.67 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 123.012 0.525 . . . . 0.0 110.571 -178.614 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 98.0 t -87.44 -48.58 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 36.0 t -67.45 -14.87 63.32 Favored 'General case' 0 CA--C 1.532 0.259 0 O-C-N 122.474 -0.141 . . . . 0.0 111.2 -175.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -79.19 -14.24 81.96 Favored Glycine 0 CA--C 1.529 0.958 0 CA-C-O 119.345 -0.697 . . . . 0.0 112.652 -176.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 23.4 ptt-85 -158.13 3.92 0.11 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 118.623 1.212 . . . . 0.0 113.52 -175.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 24.6 t0 -73.16 143.39 47.28 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 118.757 0.708 . . . . 0.0 110.11 176.207 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 62.22 35.64 91.86 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.697 -0.561 . . . . 0.0 111.697 175.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 49.8 t80 -96.98 137.51 35.94 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -172.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -64.03 103.86 0.65 Allowed 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 123.382 0.673 . . . . 0.0 112.361 -178.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.457 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 75.7 t80 -109.75 173.33 6.37 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.91 0.884 . . . . 0.0 111.191 179.085 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.457 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 77.2 m-20 -59.88 98.66 0.06 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -179.575 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 76.58 -5.89 42.54 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-O 119.666 -0.519 . . . . 0.0 112.938 177.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -139.99 -169.33 2.71 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.964 0.882 . . . . 0.0 113.344 -177.36 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 41.6 ttp-105 -143.92 133.96 24.16 Favored 'General case' 0 N--CA 1.457 -0.12 0 C-N-CA 123.615 0.766 . . . . 0.0 109.016 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -62.55 147.96 47.47 Favored 'General case' 0 C--N 1.335 -0.063 0 C-N-CA 122.571 0.348 . . . . 0.0 110.18 -178.478 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 57.7 ttt180 -130.86 113.74 14.43 Favored 'General case' 0 CA--C 1.517 -0.313 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 37.5 t -132.52 92.57 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.412 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.632 178.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 24.0 pt-20 -145.29 159.49 42.96 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.703 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -74.04 153.57 88.69 Favored Pre-proline 0 N--CA 1.454 -0.229 0 N-CA-C 114.854 1.427 . . . . 0.0 114.854 -179.522 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo . . . . . 0 C--O 1.25 1.118 0 C-N-CA 123.911 3.074 . . . . 0.0 110.714 175.98 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.468 1 O4'-C1'-N19 112.309 4.109 . 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.508 0 C5'-C4'-C3' 111.597 -2.602 . 0.669 6n . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.452 ' C6 ' ' CE1' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.323 1 C5'-C4'-C3' 109.489 -4.007 . 0.289 5p . 0.0 . . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.489 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.399 0 O4'-C1'-N19 111.75 3.55 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . 0.424 H5'' " H3'" ' A' ' 93' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.422 -2.569 0 C5'-C4'-C3' 111.621 -2.586 OUTLIER-DELTA 0.0 OUTLIER gamma 0.0 . . . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.004 0 C3'-C2'-C1' 104.804 3.671 . 0.0 OUTLIER '7D dist 4p' 0.0 . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 16.5 t . . . . . 0 N--CA 1.475 0.801 0 CA-C-O 120.375 0.131 . . . . 0.0 111.013 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 94.1 mt -67.38 148.16 12.17 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 9.1 tpp180 -66.16 142.61 57.68 Favored 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 122.795 0.438 . . . . 0.0 110.976 -178.089 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . 0.402 ' N ' ' CD ' ' B' ' 10' ' ' PRO . . . 64.52 46.93 88.84 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-O 119.527 -0.596 . . . . 0.0 112.707 175.08 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 72.7 Cg_endo -73.74 -14.71 24.33 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 122.971 2.447 . . . . 0.0 110.957 -177.563 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -158.08 178.76 9.85 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 123.543 0.737 . . . . 0.0 109.863 -177.75 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -155.43 172.59 33.61 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 22.1 m120 58.71 174.22 0.07 Allowed 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 124.062 0.945 . . . . 0.0 112.238 -176.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 63.8 m-20 57.5 9.5 0.79 Allowed 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 124.154 0.982 . . . . 0.0 112.353 -176.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -126.32 168.87 13.54 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.863 0.865 . . . . 0.0 111.313 -179.497 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 98.6 m -75.0 4.73 6.11 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 122.456 0.302 . . . . 0.0 111.491 177.051 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 92.8 mtt-85 -73.3 147.88 44.07 Favored 'General case' 0 N--CA 1.455 -0.181 0 CA-C-O 120.879 0.371 . . . . 0.0 111.854 179.462 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 20.8 pt -138.67 177.76 4.77 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 C-N-CA 123.852 0.861 . . . . 0.0 108.754 172.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.43 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.7 OUTLIER -116.9 150.54 38.3 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 114.344 1.238 . . . . 0.0 114.344 -177.285 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 47.4 t -138.65 143.3 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 C-N-CA 123.519 0.728 . . . . 0.0 109.187 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.35 178.81 34.43 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.954 -0.459 . . . . 0.0 111.954 -176.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 54.2 t30 58.54 25.52 13.21 Favored 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.195 0.998 . . . . 0.0 111.606 -176.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 95.6 mt -65.11 140.81 98.11 Favored Pre-proline 0 N--CA 1.454 -0.23 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.35 154.09 65.7 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 123.296 2.664 . . . . 0.0 109.898 -179.548 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.19 -17.14 35.82 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.419 2.746 . . . . 0.0 111.067 -179.387 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -86.98 0.61 54.86 Favored 'General case' 0 CA--C 1.529 0.156 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 tp -67.58 144.1 14.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -178.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 17.1 ttp180 -82.85 150.36 26.6 Favored 'General case' 0 N--CA 1.456 -0.17 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 176.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.8 p -65.36 -0.2 1.75 Allowed 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 114.843 1.423 . . . . 0.0 114.843 -177.366 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . 0.401 ' HE2' ' HB3' ' B' ' 30' ' ' LYS . 48.1 mtpt -136.14 5.74 3.05 Favored 'General case' 0 C--N 1.343 0.315 0 N-CA-C 113.175 0.805 . . . . 0.0 113.175 -179.071 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -62.5 -32.74 73.71 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 118.641 0.655 . . . . 0.0 112.088 175.596 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.9 tt -75.82 -16.81 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 122.787 0.435 . . . . 0.0 110.576 178.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 72.9 mt-10 -97.31 -13.67 21.79 Favored 'General case' 0 C--N 1.34 0.18 0 C-N-CA 122.181 0.193 . . . . 0.0 110.684 -179.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 79.6 m-20 -103.17 -67.69 0.87 Allowed 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -175.566 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 3.7 p -73.81 -37.27 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 N-CA-C 112.493 0.553 . . . . 0.0 112.493 -172.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 70.7 m-85 -73.15 -25.98 61.03 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 112.773 0.656 . . . . 0.0 112.773 177.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 42.8 t -72.37 -30.27 64.54 Favored 'General case' 0 N--CA 1.456 -0.166 0 N-CA-C 110.305 -0.257 . . . . 0.0 110.305 176.348 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.37 -29.48 62.66 Favored 'General case' 0 N--CA 1.455 -0.208 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 174.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -81.01 -20.4 41.84 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 116.144 1.905 . . . . 0.0 116.144 179.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.1 14.4 0.76 Allowed Glycine 0 CA--C 1.527 0.783 0 C-N-CA 120.707 -0.758 . . . . 0.0 113.851 -175.113 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 51.67 38.49 22.88 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 117.858 0.829 . . . . 0.0 111.261 178.002 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 81.8 mt -45.47 138.67 1.3 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.151 0 C-N-CA 123.338 0.655 . . . . 0.0 111.387 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 28.6 mmt180 -104.63 -22.56 13.22 Favored 'General case' 0 N--CA 1.455 -0.204 0 C-N-CA 122.884 0.474 . . . . 0.0 111.668 -178.141 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -152.4 154.16 35.04 Favored 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 118.352 0.524 . . . . 0.0 112.112 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 2.8 mp -136.52 148.03 27.32 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.085 0 C-N-CA 123.884 0.874 . . . . 0.0 109.326 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -140.95 57.2 1.56 Allowed 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 122.694 0.398 . . . . 0.0 110.278 179.297 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 57.8 tp -60.16 129.25 40.79 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.154 175.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 43.0 mttp -120.13 143.59 48.1 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 123.634 0.774 . . . . 0.0 110.672 179.204 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 49.7 p30 -81.35 -149.27 0.07 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 123.402 0.681 . . . . 0.0 110.473 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 5.0 tpp180 -65.13 -4.42 4.93 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 123.473 0.709 . . . . 0.0 111.746 -177.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 26.4 tpt180 -55.28 134.25 49.84 Favored 'General case' 0 CA--C 1.529 0.138 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 174.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 71.1 -133.67 22.53 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 -175.096 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -72.94 -164.69 8.34 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 174.283 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -55.34 165.0 3.42 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 123.773 2.982 . . . . 0.0 110.987 174.31 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -50.84 133.55 39.84 Favored 'Trans proline' 0 N--CA 1.452 -0.96 0 C-N-CA 123.232 2.622 . . . . 0.0 111.197 -178.413 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . 0.433 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 5.8 p90 -160.87 173.86 14.7 Favored 'General case' 0 CA--C 1.53 0.178 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -173.79 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.28 166.11 34.39 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 120.801 0.334 . . . . 0.0 111.668 -175.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . 0.529 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 91.4 m-85 -121.17 154.82 35.72 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 168.581 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 70.5 t -144.2 133.03 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -174.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -106.76 117.97 35.45 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.393 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 -85.59 154.65 21.58 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 115.12 1.526 . . . . 0.0 115.12 179.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 38.1 tp10 -75.54 -30.27 59.7 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 172.305 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 58.3 t0 -157.59 117.72 1.97 Allowed Pre-proline 0 N--CA 1.451 -0.415 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.3 -10.3 26.97 Favored 'Trans proline' 0 N--CA 1.456 -0.69 0 C-N-CA 123.194 2.596 . . . . 0.0 112.112 -176.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 77.4 mtt85 -72.17 -16.16 61.97 Favored 'General case' 0 CA--C 1.529 0.166 0 CA-C-N 117.85 0.295 . . . . 0.0 111.026 178.059 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -77.97 -2.73 38.4 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 177.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -64.52 -14.67 58.52 Favored 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 122.435 0.294 . . . . 0.0 111.163 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -65.96 -15.85 63.35 Favored 'General case' 0 CA--C 1.529 0.168 0 O-C-N 122.173 -0.329 . . . . 0.0 111.333 -179.319 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -123.39 -38.28 2.57 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 123.001 0.52 . . . . 0.0 112.181 177.166 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -81.82 -9.57 59.57 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.08 0.552 . . . . 0.0 112.187 -175.486 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 99.5 t -130.99 -49.76 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 CA-C-N 117.729 0.24 . . . . 0.0 110.526 -177.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 69.2 m -66.23 -10.96 46.98 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 117.646 0.203 . . . . 0.0 111.145 -179.462 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.2 -1.16 69.87 Favored Glycine 0 CA--C 1.53 0.975 0 CA-C-O 119.436 -0.646 . . . . 0.0 112.73 -178.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 12.1 tpp180 -151.72 -16.88 0.19 Allowed 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 118.466 1.133 . . . . 0.0 112.705 -176.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 32.9 t0 -65.11 138.34 58.24 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-N 118.267 0.485 . . . . 0.0 110.634 -178.128 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 63.51 41.57 99.2 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 111.794 -0.522 . . . . 0.0 111.794 174.091 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -98.61 133.47 42.91 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -174.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 14.6 t0 -62.63 106.52 0.8 Allowed 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 123.781 0.832 . . . . 0.0 112.341 -177.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.439 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 57.9 t80 -112.88 171.28 7.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 123.804 0.842 . . . . 0.0 111.445 177.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.439 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 20.6 t0 -60.53 99.82 0.09 Allowed 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.066 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 77.99 -6.32 49.51 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 123.553 0.597 . . . . 0.0 112.761 177.46 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 87.9 m-85 -140.56 -169.54 2.81 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 117.996 0.898 . . . . 0.0 113.269 -177.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 36.1 ttt180 -147.46 129.53 15.48 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.439 0.696 . . . . 0.0 109.474 -177.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -62.57 147.79 48.02 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 122.847 0.459 . . . . 0.0 110.502 -175.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 93.8 mtt180 -120.68 127.68 52.26 Favored 'General case' 0 N--CA 1.455 -0.186 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 175.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 11.8 t -145.27 82.02 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.131 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 173.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -148.33 160.7 42.73 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 122.75 0.42 . . . . 0.0 110.43 -175.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -75.25 156.57 85.58 Favored Pre-proline 0 CA--C 1.533 0.324 0 N-CA-C 114.228 1.196 . . . . 0.0 114.228 179.211 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo . . . . . 0 C--O 1.25 1.077 0 C-N-CA 123.739 2.96 . . . . 0.0 111.867 177.349 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.034 0 C5'-C4'-C3' 110.016 -3.656 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.955 1 O4'-C1'-N19 112.3 4.1 . 0.345 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.433 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.422 -2.618 0 C5'-C4'-C3' 110.453 -3.364 . 0.328 6p . 0.0 . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.529 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.425 -2.336 1 C5'-C4'-C3' 108.876 -4.416 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.948 0 O4'-C1'-N19 111.842 3.642 . 0.142 2u . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.053 0 O4'-C1'-N19 111.831 3.631 . 0.175 2[ . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.3 p . . . . . 0 N--CA 1.474 0.774 0 N-CA-C 111.843 0.312 . . . . 0.0 111.843 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 98.6 mt -66.38 144.06 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.174 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 38.1 ttm105 -75.38 154.39 37.22 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 122.662 0.385 . . . . 0.0 111.152 -178.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . 0.519 ' N ' ' CD ' ' B' ' 10' ' ' PRO . . . 103.29 36.52 3.32 Favored Glycine 0 CA--C 1.533 1.192 0 CA-C-O 118.693 -1.059 . . . . 0.0 114.307 170.705 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . 0.519 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 56.9 Cg_endo -68.47 161.48 44.79 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 122.381 2.054 . . . . 0.0 109.853 174.317 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -65.45 154.29 38.91 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.725 -179.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 174.66 -179.66 45.83 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -144.83 161.3 39.62 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 123.457 0.703 . . . . 0.0 110.369 -179.141 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 54.24 23.61 4.4 Favored 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.63 0.772 . . . . 0.0 111.772 -179.061 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 13.4 p30 -74.59 158.15 34.19 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 87.6 m -85.6 -2.06 57.78 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 122.885 0.474 . . . . 0.0 111.334 177.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 73.0 mtm180 -69.03 146.99 52.2 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 122.831 0.452 . . . . 0.0 110.818 -178.546 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 28.1 pt -132.56 170.06 20.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-O 120.964 0.412 . . . . 0.0 110.08 172.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.454 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.6 OUTLIER -114.99 151.02 34.89 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -176.838 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 59.3 t -138.45 143.61 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -157.36 -178.76 31.73 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 111.934 -0.466 . . . . 0.0 111.934 -177.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 36.3 t30 56.8 23.99 8.65 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 123.825 0.85 . . . . 0.0 111.645 -177.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 93.4 mt -64.2 146.21 97.74 Favored Pre-proline 0 CA--C 1.53 0.207 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.35 157.57 56.46 Favored 'Trans proline' 0 N--CA 1.452 -0.96 0 C-N-CA 123.404 2.736 . . . . 0.0 110.296 -179.272 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -60.43 -20.93 65.85 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.299 2.666 . . . . 0.0 111.699 176.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -84.06 6.82 20.74 Favored 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 113.321 0.86 . . . . 0.0 113.321 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 8.6 tp -61.49 152.62 6.11 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.146 0 C-N-CA 122.416 0.286 . . . . 0.0 110.684 -178.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 60.4 ttt85 -144.62 150.32 37.23 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.8 p -62.17 -18.27 60.49 Favored 'General case' 0 N--CA 1.46 0.069 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 -177.112 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 6.4 ttpt -90.52 -30.01 17.53 Favored 'General case' 0 N--CA 1.456 -0.126 0 C-N-CA 122.429 0.292 . . . . 0.0 111.074 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 72.4 m-20 -70.72 -36.14 73.06 Favored 'General case' 0 N--CA 1.454 -0.227 0 O-C-N 122.1 -0.375 . . . . 0.0 111.261 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 15.2 tt -75.85 -14.09 15.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.377 -176.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.4 pt-20 -104.28 -21.85 13.46 Favored 'General case' 0 C--N 1.34 0.164 0 CA-C-N 118.714 0.688 . . . . 0.0 110.687 178.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -74.33 -49.88 21.07 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 113.137 0.791 . . . . 0.0 113.137 178.161 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 m -72.86 -30.8 33.81 Favored 'Isoleucine or valine' 0 C--N 1.338 0.101 0 C-N-CA 121.098 -0.241 . . . . 0.0 111.095 -178.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . 0.408 ' O ' HD13 ' B' ' 42' ' ' ILE . 41.4 m-85 -75.92 -42.87 47.57 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 177.425 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 96.7 p -67.58 -21.45 65.42 Favored 'General case' 0 C--N 1.34 0.164 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.49 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 23.7 tptm -73.98 -36.88 64.58 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 173.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -82.12 -11.61 58.66 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 116.659 2.096 . . . . 0.0 116.659 178.175 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.98 179.27 48.92 Favored Glycine 0 C--N 1.338 0.645 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.044 -179.364 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.94 53.7 2.27 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 124.06 0.944 . . . . 0.0 111.626 -177.597 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . 0.556 HD11 ' CZ ' ' B' ' 61' ' ' PHE . 2.1 mp -68.75 144.24 14.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.24 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 35.0 mmt180 -124.81 -36.1 2.62 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 119.42 -0.324 . . . . 0.0 111.149 178.246 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 39.9 m-20 -122.38 150.16 42.8 Favored 'General case' 0 N--CA 1.462 0.126 0 N-CA-C 113.944 1.091 . . . . 0.0 113.944 -178.385 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -136.18 150.08 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 C-N-CA 124.236 1.014 . . . . 0.0 109.169 178.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 59.2 t0 -146.9 63.5 1.18 Allowed 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 49.6 tp -64.35 129.06 38.43 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 173.345 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -120.39 146.69 45.94 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 123.698 0.799 . . . . 0.0 109.966 178.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 -111.23 170.09 8.35 Favored 'General case' 0 C--N 1.334 -0.104 0 C-N-CA 122.891 0.476 . . . . 0.0 111.11 -176.183 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . 0.41 HH11 ' HD2' ' B' ' 50' ' ' ARG . 45.8 ttm180 55.47 -96.95 0.07 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 124.149 0.98 . . . . 0.0 111.521 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 15.0 tpt180 56.39 19.89 4.35 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.304 0.642 . . . . 0.0 111.575 -179.061 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.19 12.6 83.81 Favored Glycine 0 CA--C 1.532 1.114 0 CA-C-O 119.665 -0.52 . . . . 0.0 112.697 176.538 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . -169.66 -154.13 9.02 Favored Glycine 0 CA--C 1.532 1.112 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo -60.19 147.34 93.83 Favored 'Trans proline' 0 N--CA 1.448 -1.164 0 C-N-CA 123.076 2.517 . . . . 0.0 110.191 172.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -65.38 158.38 52.95 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 123.204 2.603 . . . . 0.0 110.414 178.376 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -150.85 167.71 26.68 Favored 'General case' 0 C--O 1.232 0.162 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 -179.478 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -152.87 166.06 33.48 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.295 0.569 . . . . 0.0 112.426 -171.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . 0.46 ' CE2' ' C6 ' ' A' ' 93' ' ' ' A' . 4.3 m-85 -120.56 153.67 36.43 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 124.042 0.937 . . . . 0.0 112.813 170.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 88.9 t -141.1 144.39 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 108.685 -0.858 . . . . 0.0 108.685 -178.17 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 11.7 tp10 -131.14 125.59 33.46 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 122.578 0.351 . . . . 0.0 111.174 -177.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.556 ' CZ ' HD11 ' B' ' 42' ' ' ILE . 9.1 m-85 -91.57 151.56 20.68 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 113.974 1.101 . . . . 0.0 113.974 -178.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -82.46 -24.69 34.14 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 169.045 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 36.6 t0 -152.26 114.94 2.9 Favored Pre-proline 0 CA--C 1.534 0.355 0 C-N-CA 123.352 0.661 . . . . 0.0 109.944 -176.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -74.77 -1.37 11.06 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 123.566 2.844 . . . . 0.0 112.742 -173.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 79.5 mtt85 -68.27 -0.49 4.81 Favored 'General case' 0 CA--C 1.53 0.197 0 N-CA-C 112.998 0.74 . . . . 0.0 112.998 -176.212 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 20.4 p30 -134.35 3.12 3.33 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 112.173 0.434 . . . . 0.0 112.173 173.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.76 -22.03 64.33 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 178.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -70.25 -28.45 65.25 Favored 'General case' 0 N--CA 1.456 -0.127 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 178.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -79.63 -35.18 39.8 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 122.337 0.255 . . . . 0.0 111.381 178.025 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.96 -24.72 63.38 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.231 176.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 10.0 t -85.69 -59.03 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.338 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 44.5 t -71.28 -17.6 62.46 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -172.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -93.12 4.07 73.9 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-O 119.247 -0.751 . . . . 0.0 112.588 -177.089 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 46.6 ttm180 -150.19 -16.55 0.25 Allowed 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 118.516 1.158 . . . . 0.0 112.555 -174.714 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 50.7 p-10 -71.3 156.64 39.29 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.277 0.561 . . . . 0.0 112.306 -176.512 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 58.85 41.8 96.29 Favored Glycine 0 CA--C 1.526 0.725 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.683 169.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 43.4 t80 -92.38 130.83 37.95 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 118.226 1.013 . . . . 0.0 113.714 -175.153 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -66.12 101.81 0.75 Allowed 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 123.044 0.538 . . . . 0.0 112.025 -178.441 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.515 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 71.4 t80 -93.02 177.98 5.9 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.406 0.682 . . . . 0.0 112.127 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.515 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 74.1 m-20 -66.66 21.84 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.537 0 N-CA-C 114.934 1.457 . . . . 0.0 114.934 -177.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 161.5 -10.82 0.12 Allowed Glycine 0 CA--C 1.527 0.834 0 CA-C-O 119.618 -0.546 . . . . 0.0 112.425 -179.137 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -140.95 -167.05 2.29 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 117.731 0.766 . . . . 0.0 110.893 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 33.8 ttt180 -138.93 122.96 17.89 Favored 'General case' 0 N--CA 1.455 -0.182 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -59.81 153.39 20.79 Favored 'General case' 0 N--CA 1.458 -0.043 0 C-N-CA 123.421 0.688 . . . . 0.0 111.096 -176.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 24.0 mtp180 -128.08 125.21 38.81 Favored 'General case' 0 CA--C 1.521 -0.164 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.593 175.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 48.2 t -142.99 82.01 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.226 -0.171 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 175.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -140.28 160.57 39.67 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.219 0.533 . . . . 0.0 111.809 -173.09 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . 0.467 ' CD1' ' HD2' ' B' ' 89' ' ' PRO . 18.2 t80 -71.84 138.9 82.67 Favored Pre-proline 0 CA--C 1.534 0.335 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . 0.467 ' HD2' ' CD1' ' B' ' 88' ' ' PHE . 43.9 Cg_endo . . . . . 0 C--O 1.248 1.018 0 C-N-CA 123.824 3.016 . . . . 0.0 111.303 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.821 0 C5'-C4'-C3' 110.019 -3.654 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.021 0 C3'-C2'-C1' 104.695 3.55 . 0.109 6p . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.454 ' C6 ' ' CE1' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.334 1 C5'-C4'-C3' 109.47 -4.02 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.506 ' C2 ' ' HA2' ' B' ' 9' ' ' GLY . . . . . . . . 0 O4'--C4' 1.427 -2.176 1 O4'-C1'-N19 112.542 4.342 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.616 1 O4'-C1'-N19 112.412 4.212 OUTLIER-DELTA 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.936 0 O4'-C1'-N19 111.719 3.519 . 0.0 OUTLIER '7D dist 6p' 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.2 p . . . . . 0 N--CA 1.477 0.9 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -78.08 -6.04 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 C-N-CA 122.312 0.245 . . . . 0.0 110.849 -177.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 16.9 tpp180 61.77 134.58 0.01 OUTLIER 'General case' 0 C--N 1.344 0.348 0 C-N-CA 125.211 1.404 . . . . 0.0 112.573 -176.422 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . 0.702 ' HA2' ' C2 ' ' A' ' 93' ' ' ' A' . . . 104.99 -94.38 1.01 Allowed Glycine 0 CA--C 1.527 0.815 0 CA-C-O 119.171 -0.794 . . . . 0.0 111.129 175.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -59.68 1.8 0.36 Allowed 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 123.985 3.124 . . . . 0.0 113.636 178.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -147.67 176.6 9.96 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 122.821 0.448 . . . . 0.0 110.191 -179.273 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.87 -169.78 30.02 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -178.371 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 28.9 p30 -68.48 174.05 4.46 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-O 120.808 0.337 . . . . 0.0 111.547 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 39.2 t30 -149.11 179.12 8.14 Favored 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.333 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 61.23 8.21 1.96 Allowed 'General case' 0 CA--C 1.532 0.263 0 N-CA-C 114.687 1.366 . . . . 0.0 114.687 -178.814 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 61.3 m -132.78 -1.92 3.35 Favored 'General case' 0 C--N 1.339 0.124 0 C-N-CA 123.004 0.521 . . . . 0.0 110.473 176.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 31.4 ttm180 -101.02 147.89 25.67 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 123.046 0.539 . . . . 0.0 109.815 -178.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 25.5 pt -133.53 174.78 12.67 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.081 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 176.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.465 ' CE1' ' C6 ' ' A' ' 92' ' ' ' C' . 0.7 OUTLIER -118.92 150.32 40.09 Favored 'General case' 0 C--O 1.231 0.122 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -175.838 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 60.5 t -139.22 142.84 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 C-N-CA 123.509 0.724 . . . . 0.0 109.437 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -152.81 168.76 31.78 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -178.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 59.4 t30 60.55 36.89 19.81 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 124.073 0.949 . . . . 0.0 111.379 -174.205 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 84.0 mt -61.95 143.44 94.59 Favored Pre-proline 0 CA--C 1.532 0.285 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 176.492 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.37 158.54 55.84 Favored 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 123.511 2.807 . . . . 0.0 109.935 179.195 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.5 -15.81 38.29 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 123.134 2.556 . . . . 0.0 110.851 179.046 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -89.1 5.0 46.54 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 179.026 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 tp -65.45 154.87 7.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 C-N-CA 122.41 0.284 . . . . 0.0 110.432 -178.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 44.9 mtm180 -138.42 161.47 36.89 Favored 'General case' 0 CA--C 1.522 -0.118 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 178.174 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 1.6 p -66.99 -7.24 20.94 Favored 'General case' 0 C--N 1.338 0.071 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -177.476 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -111.45 -36.22 5.59 Favored 'General case' 0 C--N 1.34 0.182 0 O-C-N 122.421 -0.174 . . . . 0.0 111.218 179.511 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -63.79 -28.39 69.83 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.593 0.235 . . . . 0.0 110.43 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.0 tt -72.1 -13.78 16.9 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.349 -178.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -116.98 -9.94 11.02 Favored 'General case' 0 N--CA 1.456 -0.156 0 CA-C-N 118.291 0.496 . . . . 0.0 110.722 174.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -71.27 -55.3 8.34 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-O 121.025 0.44 . . . . 0.0 110.57 178.016 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 10.0 p -67.68 -34.65 69.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 O-C-N 122.241 -0.287 . . . . 0.0 110.886 179.392 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -69.88 -32.86 71.43 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 113.38 0.882 . . . . 0.0 113.38 176.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 39.2 t -67.48 -28.0 67.48 Favored 'General case' 0 C--N 1.342 0.28 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 176.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -70.68 -34.26 71.8 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 174.532 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -81.68 -15.61 53.95 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 116.225 1.935 . . . . 0.0 116.225 177.124 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.46 179.21 44.92 Favored Glycine 0 C--N 1.338 0.656 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.584 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . -83.85 84.61 7.51 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 122.992 0.517 . . . . 0.0 111.249 -178.431 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 1.7 mp -73.09 150.39 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.123 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 174.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 85.3 mmt-85 -128.35 -25.64 2.91 Favored 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 119.25 -0.405 . . . . 0.0 111.972 176.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -150.55 161.43 42.56 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 178.609 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . 0.489 HG22 ' H ' ' B' ' 47' ' ' LEU . 30.8 mm -132.43 156.46 42.42 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.061 0 C-N-CA 124.289 1.036 . . . . 0.0 109.279 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -143.2 55.25 1.36 Allowed 'General case' 0 N--CA 1.452 -0.328 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 175.316 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . 0.489 ' H ' HG22 ' B' ' 45' ' ' ILE . 59.9 tp -55.79 133.13 50.88 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.223 174.468 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -133.79 158.53 43.13 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 123.735 0.814 . . . . 0.0 111.415 -177.483 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 43.0 p30 -145.41 11.45 1.3 Allowed 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.442 0.697 . . . . 0.0 110.698 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -73.38 165.47 25.0 Favored 'General case' 0 C--O 1.232 0.148 0 C-N-CA 123.323 0.649 . . . . 0.0 110.338 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 43.7 mtt180 61.09 177.7 0.11 Allowed 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.057 0.943 . . . . 0.0 112.264 177.146 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -76.2 173.89 53.69 Favored Glycine 0 CA--C 1.529 0.953 0 N-CA-C 111.881 -0.488 . . . . 0.0 111.881 -177.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.86 177.01 44.39 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -179.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -60.88 160.55 24.97 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 124.059 3.173 . . . . 0.0 111.383 178.286 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -65.6 160.26 44.09 Favored 'Trans proline' 0 N--CA 1.45 -1.038 0 C-N-CA 123.336 2.691 . . . . 0.0 110.195 176.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . 0.47 ' CE2' " H4'" ' A' ' 92' ' ' ' C' . 6.1 p90 -153.29 171.38 18.65 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 106.414 -1.699 . . . . 0.0 106.414 -176.61 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -159.61 174.62 14.31 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 121.242 0.544 . . . . 0.0 111.371 -174.089 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . 0.405 ' CD2' ' C2 ' ' A' ' 93' ' ' ' A' . 90.4 m-85 -131.81 155.94 46.9 Favored 'General case' 0 N--CA 1.452 -0.355 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 172.04 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 66.8 t -132.87 134.24 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -178.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -111.17 123.95 51.23 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 122.465 0.306 . . . . 0.0 110.562 -177.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -97.43 154.95 17.14 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 42.3 tp10 -78.7 -23.63 45.45 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 170.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -152.51 118.87 3.05 Favored Pre-proline 0 CA--C 1.534 0.365 0 C-N-CA 123.162 0.585 . . . . 0.0 109.785 -178.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -66.65 -8.11 20.13 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.188 2.592 . . . . 0.0 112.505 -176.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 72.3 ttt-85 -61.94 -36.05 80.26 Favored 'General case' 0 N--CA 1.456 -0.168 0 CA-C-N 118.111 0.414 . . . . 0.0 110.172 177.19 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 52.8 m-20 -89.87 -16.3 30.36 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-O 120.582 0.23 . . . . 0.0 111.57 -178.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -68.97 -25.3 64.47 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.851 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -71.81 -28.59 63.7 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 177.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 -75.16 -35.48 61.61 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 178.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.97 -29.91 67.13 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 110.279 -0.267 . . . . 0.0 110.279 177.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.93 -30.02 17.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.306 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.368 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 41.5 t -85.79 -12.34 51.19 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 122.587 0.355 . . . . 0.0 111.54 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -68.56 -46.06 64.22 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.609 -0.596 . . . . 0.0 111.609 -175.518 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 38.2 ttt180 -163.08 122.1 2.11 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.274 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -164.24 149.27 10.2 Favored 'General case' 0 CA--C 1.531 0.214 0 O-C-N 123.066 0.229 . . . . 0.0 110.574 -178.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.94 88.88 0.3 Allowed Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.481 0.562 . . . . 0.0 112.857 170.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . 0.449 ' HA ' ' HA ' ' B' ' 83' ' ' ARG . 13.6 t80 60.31 103.09 0.02 OUTLIER 'General case' 0 N--CA 1.457 -0.104 0 N-CA-C 116.478 2.029 . . . . 0.0 116.478 169.579 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -164.71 31.09 0.07 Allowed 'General case' 0 N--CA 1.444 -0.733 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -131.62 178.09 7.01 Favored 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -88.89 107.38 18.97 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 114.892 -1.049 . . . . 0.0 111.228 179.378 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 72.11 -2.26 28.26 Favored Glycine 0 CA--C 1.531 1.092 0 N-CA-C 111.522 -0.631 . . . . 0.0 111.522 -178.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 45.1 m-85 -131.47 169.81 15.55 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 124.001 0.92 . . . . 0.0 113.455 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . 0.449 ' HA ' ' HA ' ' B' ' 77' ' ' TYR . 0.0 OUTLIER -135.15 135.83 41.4 Favored 'General case' 0 N--CA 1.44 -0.949 0 CA-C-O 120.803 0.335 . . . . 0.0 111.282 -178.58 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . 0.592 HD22 ' N ' ' B' ' 84' ' ' LEU . 2.4 mm? -73.85 142.92 46.06 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 178.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 59.1 mtm180 -132.48 114.57 14.45 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-O 120.943 0.401 . . . . 0.0 110.222 175.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 42.4 t -136.4 86.08 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 C-N-CA 123.543 0.737 . . . . 0.0 109.055 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.2 pt-20 -149.8 163.21 38.61 Favored 'General case' 0 C--N 1.334 -0.103 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.534 -178.655 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 4.5 p90 -74.0 152.23 88.62 Favored Pre-proline 0 CA--C 1.531 0.229 0 N-CA-C 114.626 1.343 . . . . 0.0 114.626 179.433 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo . . . . . 0 C--O 1.253 1.266 0 C-N-CA 123.837 3.025 . . . . 0.0 110.781 176.312 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.45 0 C5'-C4'-C3' 109.805 -3.797 OUTLIER-DELTA 0.0 '__' . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.542 0 C5'-C4'-C3' 110.249 -3.501 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.47 " H4'" ' CE2' ' B' ' 56' ' ' PHE . . . . . . . . 0 O4'--C4' 1.423 -2.481 0 C5'-C4'-C3' 110.676 -3.216 . 0.032 4p . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.702 ' C2 ' ' HA2' ' B' ' 9' ' ' GLY . . . . . . . . 0 O4'--C4' 1.421 -2.693 1 C5'-C4'-C3' 109.492 -4.005 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.426 -2.263 0 O4'-C1'-N19 112.007 3.807 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.418 -2.889 0 C3'-C2'-C1' 104.247 3.052 . 0.167 0b . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 p . . . . . 0 N--CA 1.477 0.896 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 87.5 mt -66.21 148.2 12.2 Favored 'Isoleucine or valine' 0 C--O 1.234 0.237 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 20.5 tpp85 -59.71 140.04 56.78 Favored 'General case' 0 C--N 1.34 0.181 0 C-N-CA 122.722 0.409 . . . . 0.0 110.525 -179.515 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . 0.426 ' HA2' ' C2 ' ' A' ' 93' ' ' ' A' . . . 64.28 58.98 9.01 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -71.22 2.19 4.62 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 124.083 3.189 . . . . 0.0 111.608 179.644 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . 57.9 18.72 5.2 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 123.753 0.821 . . . . 0.0 112.008 -177.508 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.5 -173.0 44.1 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 176.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -66.46 152.77 44.47 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 122.553 -0.381 . . . . 0.0 110.465 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 50.1 t30 -75.92 162.5 28.05 Favored 'General case' 0 CA--C 1.529 0.149 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.068 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 15.8 t0 -150.46 -47.81 0.13 Allowed 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 122.537 0.335 . . . . 0.0 111.75 176.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 98.3 m -140.41 5.79 2.07 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 122.804 0.442 . . . . 0.0 111.501 178.438 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -88.86 155.21 19.67 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 120.847 0.356 . . . . 0.0 111.255 -177.733 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 12.2 pt -127.62 -177.29 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 C-N-CA 123.223 0.609 . . . . 0.0 109.477 177.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -142.94 151.29 40.79 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -178.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 62.8 t -142.84 101.15 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.149 0 N-CA-C 110.465 -0.198 . . . . 0.0 110.465 -176.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -92.59 166.95 29.47 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 171.682 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 66.2 t30 55.43 29.37 13.07 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 122.824 0.45 . . . . 0.0 110.725 -177.028 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 23.0 tp -57.0 117.64 18.98 Favored Pre-proline 0 CA--C 1.536 0.405 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -72.86 157.0 52.27 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.104 2.536 . . . . 0.0 110.951 -175.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.01 -4.43 14.84 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 124.074 3.183 . . . . 0.0 111.185 178.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -76.24 -7.02 53.96 Favored 'General case' 0 CA--C 1.529 0.167 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 178.457 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 tp -70.32 151.03 9.59 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.057 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 83.8 mmt-85 -130.59 155.6 46.25 Favored 'General case' 0 N--CA 1.458 -0.054 0 CA-C-O 120.678 0.275 . . . . 0.0 110.382 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.14 10.51 0.3 Allowed 'General case' 0 N--CA 1.462 0.127 0 N-CA-C 114.902 1.445 . . . . 0.0 114.902 -177.353 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . 0.424 ' HE2' ' OD1' ' B' ' 34' ' ' ASP . 23.4 tptm -140.69 -33.46 0.54 Allowed 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 122.326 0.25 . . . . 0.0 110.957 179.685 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -63.87 -24.01 67.58 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 175.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.6 tt -69.51 -15.99 20.06 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 C-N-CA 123.15 0.58 . . . . 0.0 110.902 -179.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -125.45 4.35 7.65 Favored 'General case' 0 CA--C 1.53 0.205 0 O-C-N 122.053 -0.404 . . . . 0.0 111.367 179.056 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . 0.424 ' OD1' ' HE2' ' B' ' 30' ' ' LYS . 79.1 m-20 -97.06 -61.93 1.33 Allowed 'General case' 0 C--O 1.233 0.197 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 172.215 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.0 p -74.84 -41.53 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.087 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -172.408 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -75.39 -21.49 58.22 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -179.019 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 43.3 t -72.26 -30.18 64.6 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 175.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 29.7 ttpp -72.92 -28.59 62.55 Favored 'General case' 0 CA--C 1.533 0.29 0 N-CA-C 109.638 -0.505 . . . . 0.0 109.638 174.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -79.33 -20.73 47.15 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 116.26 1.948 . . . . 0.0 116.26 177.413 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.88 20.58 0.17 Allowed Glycine 0 CA--C 1.53 0.984 0 C-N-CA 119.887 -1.149 . . . . 0.0 114.717 -175.498 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 48.7 49.14 19.19 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 117.938 0.869 . . . . 0.0 111.475 175.186 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 75.6 mt -48.97 137.02 5.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.144 0.577 . . . . 0.0 111.008 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 48.0 mtm105 -98.9 -32.14 11.48 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 122.891 0.477 . . . . 0.0 111.527 179.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 32.3 m-20 -148.94 157.01 43.1 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 113.835 1.05 . . . . 0.0 113.835 -177.449 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 3.2 mp -126.78 151.95 34.07 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -148.6 48.02 1.02 Allowed 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -177.032 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 54.0 tp -68.75 110.45 4.32 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 177.632 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 48.1 mttm -93.88 146.57 23.8 Favored 'General case' 0 N--CA 1.456 -0.145 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 175.475 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 31.9 p30 -155.24 12.11 0.35 Allowed 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.003 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 90.0 mmt-85 -134.77 -5.6 2.47 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 117.985 0.357 . . . . 0.0 111.765 179.4 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 51.1 ttt180 -160.31 156.79 26.9 Favored 'General case' 0 CA--C 1.527 0.09 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.89 16.1 63.99 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -178.246 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.67 -161.79 26.21 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -178.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -56.54 163.09 7.28 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 123.852 3.035 . . . . 0.0 111.54 179.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -54.82 130.53 41.03 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 C-N-CA 123.646 2.897 . . . . 0.0 112.163 -175.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -164.13 167.22 20.46 Favored 'General case' 0 N--CA 1.455 -0.195 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 178.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -144.25 161.01 39.98 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -171.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . 0.492 ' CE2' ' C4 ' ' A' ' 93' ' ' ' A' . 50.9 m-85 -119.71 60.52 0.85 Allowed 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 124.152 0.981 . . . . 0.0 112.769 174.256 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 83.7 t -58.34 143.26 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.108 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -177.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 73.1 tt0 -120.79 120.4 35.49 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-O 120.918 0.389 . . . . 0.0 110.956 -175.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -91.53 166.43 12.84 Favored 'General case' 0 N--CA 1.455 -0.179 0 N-CA-C 115.984 1.846 . . . . 0.0 115.984 -174.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 30.4 tp10 -70.99 -35.22 72.01 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 122.757 0.423 . . . . 0.0 110.138 173.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -149.21 148.22 26.03 Favored Pre-proline 0 CA--C 1.527 0.093 0 C-N-CA 124.387 1.075 . . . . 0.0 112.021 178.084 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -71.1 -17.27 31.73 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.181 2.588 . . . . 0.0 111.089 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 51.9 mmm-85 -77.76 -13.42 59.9 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 122.435 0.294 . . . . 0.0 111.606 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -76.5 -10.31 59.3 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 111.953 0.353 . . . . 0.0 111.953 177.552 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -71.48 -11.05 60.68 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.592 0.357 . . . . 0.0 111.101 179.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -67.93 -17.72 64.54 Favored 'General case' 0 C--O 1.232 0.155 0 O-C-N 122.135 -0.353 . . . . 0.0 111.032 -179.286 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -123.84 -36.24 2.76 Favored 'General case' 0 CA--C 1.528 0.125 0 C-N-CA 123.183 0.593 . . . . 0.0 112.433 178.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -84.28 -8.86 58.9 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -175.605 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.43 HG13 HG12 ' B' ' 86' ' ' VAL . 47.3 t -132.68 -46.25 0.64 Allowed 'Isoleucine or valine' 0 C--O 1.228 -0.036 0 CA-C-N 118.062 0.392 . . . . 0.0 110.906 -175.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 47.3 t -69.5 -15.19 63.2 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-O 120.502 0.192 . . . . 0.0 110.977 -179.282 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.94 -5.82 88.8 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-O 119.647 -0.529 . . . . 0.0 112.711 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 70.2 mtm-85 -138.86 6.07 2.41 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 118.078 0.939 . . . . 0.0 111.869 -178.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 23.1 t0 -67.3 123.51 20.55 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 117.823 0.283 . . . . 0.0 111.307 -179.101 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 65.19 34.45 89.63 Favored Glycine 0 C--N 1.338 0.669 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 177.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 56.2 t80 -75.91 137.77 40.6 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -173.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 28.2 t0 -66.15 81.02 0.08 Allowed 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.295 1.038 . . . . 0.0 111.964 -177.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . 0.4 ' CG ' ' N ' ' B' ' 80' ' ' ASP . 68.2 t80 -85.03 -179.94 7.15 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 177.784 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.4 ' N ' ' CG ' ' B' ' 79' ' ' TYR . 71.4 m-20 -66.38 91.9 0.18 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 123.246 0.618 . . . . 0.0 112.43 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 78.73 -2.12 69.81 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-O 119.606 -0.552 . . . . 0.0 112.399 177.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -138.41 176.68 8.49 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 -178.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -125.15 140.1 53.17 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 123.846 0.858 . . . . 0.0 109.376 176.652 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -67.22 152.51 45.6 Favored 'General case' 0 N--CA 1.455 -0.204 0 C-N-CA 122.626 0.37 . . . . 0.0 110.426 177.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -118.43 48.26 1.46 Allowed 'General case' 0 C--N 1.338 0.068 0 C-N-CA 123.3 0.64 . . . . 0.0 109.828 172.012 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . 0.43 HG12 HG13 ' B' ' 71' ' ' VAL . 74.7 t -76.43 95.1 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.556 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -154.02 158.63 40.86 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.845 178.51 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 8.1 p90 -87.23 145.77 38.64 Favored Pre-proline 0 N--CA 1.456 -0.161 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 177.419 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 C--O 1.253 1.245 0 C-N-CA 123.614 2.876 . . . . 0.0 110.737 175.565 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . 0.471 " H3'" H5'' ' A' ' 91' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.42 -2.733 0 C5'-C4'-C3' 110.178 -3.548 OUTLIER-DELTA 0.0 '__' . 0.0 . . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . 0.471 H5'' " H3'" ' A' ' 90' ' ' ' A' . . . . . . . . 0 O4'--C4' 1.421 -2.697 0 C3'-C2'-C1' 103.667 2.408 OUTLIER-DELTA 0.0 OUTLIER delta 0.0 . . . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.424 -2.392 0 O4'-C1'-N19 111.007 2.807 . 0.0 OUTLIER delta-1 0.0 . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.492 ' C4 ' ' CE2' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.426 -2.211 0 C5'-C4'-C3' 110.668 -3.221 . 0.21 4b . 0.0 . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.423 -2.534 0 C5'-C4'-C3' 109.794 -3.804 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.422 -2.606 0 O4'-C1'-N19 111.185 2.985 . 0.262 6p . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . . . . . . . . . 5.4 p . . . . . 0 N--CA 1.476 0.872 0 N-CA-C 111.611 0.226 . . . . 0.0 111.611 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 7' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.11 137.09 24.73 Favored 'Isoleucine or valine' 0 C--O 1.232 0.156 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.661 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 5.0 tpp180 -156.51 131.11 8.84 Favored 'General case' 0 C--O 1.232 0.14 0 C-N-CA 122.241 0.216 . . . . 0.0 110.428 177.172 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . 0.46 ' N ' ' CD ' ' B' ' 10' ' ' PRO . . . 59.17 38.61 93.39 Favored Glycine 0 CA--C 1.533 1.183 0 CA-C-O 118.809 -0.995 . . . . 0.0 113.369 175.472 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 10' ' ' PRO . . . . . 0.46 ' CD ' ' N ' ' B' ' 9' ' ' GLY . 61.8 Cg_endo -70.22 -24.88 27.05 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.693 2.262 . . . . 0.0 110.944 -176.553 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 11' ' ' ALA . . . . . . . . . . . . . . . -164.1 170.18 16.82 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 122.755 0.422 . . . . 0.0 110.254 -178.183 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -84.83 5.62 81.6 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.917 -0.473 . . . . 0.0 111.917 179.068 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 13' ' ' ASN . . . . . . . . . . . . . 46.7 p30 -74.26 -3.14 28.26 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 117.651 0.725 . . . . 0.0 111.931 -177.522 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 14' ' ' ASN . . . . . . . . . . . . . 71.5 m-80 -69.87 169.35 13.31 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 120.836 0.35 . . . . 0.0 110.84 177.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 15' ' ' ASP . . . . . . . . . . . . . 14.2 p30 -137.08 166.85 22.72 Favored 'General case' 0 CA--C 1.528 0.1 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -177.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 16' ' ' CYS . . . . . . . . . . . . . 74.2 m 58.77 8.09 0.88 Allowed 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.083 0.953 . . . . 0.0 112.53 -177.154 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 17' ' ' ARG . . . . . . . . . . . . . 86.3 mtt180 -99.79 148.81 24.01 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 117.96 0.346 . . . . 0.0 111.741 177.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . . . . . . . . . 19.9 pt -134.66 -177.26 1.95 Allowed 'Isoleucine or valine' 0 CA--C 1.524 -0.034 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 19' ' ' TYR . . . . . 0.426 ' CE2' ' C6 ' ' A' ' 92' ' ' ' C' . 0.4 OUTLIER -119.0 146.64 44.86 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -177.288 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 41.7 t -140.17 139.97 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.54 177.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . -143.27 169.75 25.7 Favored Glycine 0 CA--C 1.522 0.508 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -176.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 22' ' ' ASN . . . . . . . . . . . . . 59.7 t30 61.07 31.56 19.79 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.741 0.817 . . . . 0.0 111.483 -175.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . . . . . . . . . 81.3 mt -65.08 135.89 96.49 Favored Pre-proline 0 CA--C 1.533 0.301 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 24' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.56 146.3 38.87 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.273 2.649 . . . . 0.0 110.153 178.416 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -74.93 -13.04 21.69 Favored 'Trans proline' 0 N--CA 1.453 -0.892 0 C-N-CA 123.374 2.716 . . . . 0.0 111.398 177.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 26' ' ' ASP . . . . . . . . . . . . . 79.8 m-20 -81.07 -2.93 50.17 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -176.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 8.8 tp -68.27 145.58 13.44 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.249 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 28' ' ' ARG . . . . . . . . . . . . . 48.5 ttt-85 -84.56 151.32 24.62 Favored 'General case' 0 C--N 1.338 0.101 0 N-CA-C 109.965 -0.384 . . . . 0.0 109.965 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 29' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -66.21 12.55 0.06 Allowed 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 115.462 1.652 . . . . 0.0 115.462 -177.296 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . 0.408 ' HE2' ' OD2' ' B' ' 34' ' ' ASP . 24.0 tptm -148.69 -28.76 0.29 Allowed 'General case' 0 C--N 1.341 0.198 0 C-N-CA 122.47 0.308 . . . . 0.0 111.004 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 31' ' ' ASP . . . . . . . . . . . . . 31.2 m-20 -64.06 -19.94 65.59 Favored 'General case' 0 CA--C 1.528 0.103 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 174.15 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 tt -69.29 -14.14 18.09 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 C-N-CA 123.336 0.654 . . . . 0.0 111.059 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 33' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -129.02 -10.32 4.81 Favored 'General case' 0 CA--C 1.529 0.173 0 CA-C-N 118.514 0.597 . . . . 0.0 111.677 176.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . 0.408 ' OD2' ' HE2' ' B' ' 30' ' ' LYS . 77.7 m-20 -74.13 -46.48 42.33 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 113.024 0.75 . . . . 0.0 113.024 174.166 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . . . . . . . . . 4.6 p -71.91 -30.52 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.117 0 CA-C-O 120.656 0.265 . . . . 0.0 111.045 178.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 36' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -75.48 -30.82 60.01 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 177.656 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 41.4 t -70.37 -30.65 67.63 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 174.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 38' ' ' LYS . . . . . . . . . . . . . 3.6 tppp? -73.38 -30.81 63.53 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 122.121 0.168 . . . . 0.0 110.672 177.257 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 39' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -84.03 -19.18 34.88 Favored 'General case' 0 C--N 1.338 0.103 0 N-CA-C 116.316 1.969 . . . . 0.0 116.316 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.14 22.31 0.07 OUTLIER Glycine 0 CA--C 1.528 0.88 0 C-N-CA 120.035 -1.078 . . . . 0.0 113.531 -177.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 41' ' ' ALA . . . . . . . . . . . . . . . 52.32 30.15 7.67 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 117.64 0.72 . . . . 0.0 111.296 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . 0.417 HD11 ' CZ ' ' B' ' 61' ' ' PHE . 17.8 mt -50.72 137.37 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.205 0 C-N-CA 123.191 0.597 . . . . 0.0 110.131 178.099 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 43' ' ' ARG . . . . . . . . . . . . . 14.9 mmt180 -105.26 -19.02 13.93 Favored 'General case' 0 N--CA 1.457 -0.078 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -172.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 40.9 t0 -154.94 156.66 36.45 Favored 'General case' 0 C--O 1.233 0.201 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.962 178.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . . . . . . . . . 15.5 mm -131.96 114.86 25.38 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 174.305 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 46' ' ' ASP . . . . . 0.453 ' HB3' ' H ' ' B' ' 58' ' ' PHE . 41.3 t0 -84.53 51.91 2.24 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 177.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 47' ' ' LEU . . . . . . . . . . . . . 50.8 tp -54.18 120.88 7.09 Favored 'General case' 0 C--O 1.231 0.114 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 175.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -145.08 146.51 31.88 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-O 120.829 0.347 . . . . 0.0 111.02 -173.407 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 49' ' ' ASN . . . . . . . . . . . . . 73.9 m-20 -78.98 172.73 13.39 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 122.951 0.501 . . . . 0.0 110.992 -179.198 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 50' ' ' ARG . . . . . . . . . . . . . 33.3 mtp-105 -137.69 169.02 18.51 Favored 'General case' 0 C--O 1.233 0.218 0 C-N-CA 122.864 0.466 . . . . 0.0 110.059 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 58.9 ttt85 -67.75 -19.83 65.16 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.595 177.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -171.36 169.43 42.48 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 178.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.23 -175.33 45.95 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 111.338 -0.705 . . . . 0.0 111.338 -178.197 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 54' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.33 160.62 49.11 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 123.866 3.044 . . . . 0.0 110.65 179.183 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 55' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.45 166.61 26.63 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.491 2.794 . . . . 0.0 110.564 176.781 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 56' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -149.34 170.16 19.16 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 105.634 -1.987 . . . . 0.0 105.634 -178.141 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.83 155.2 33.98 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-O 120.756 0.312 . . . . 0.0 111.731 -175.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 58' ' ' PHE . . . . . 0.47 ' CE1' ' C4 ' ' A' ' 93' ' ' ' A' . 86.4 m-85 -108.93 107.79 18.3 Favored 'General case' 0 N--CA 1.457 -0.12 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.944 169.395 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . . . . . . . . . 91.2 t -80.54 141.9 14.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -177.685 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -120.09 120.17 35.47 Favored 'General case' 0 C--O 1.232 0.166 0 CA-C-O 120.652 0.263 . . . . 0.0 110.424 178.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.417 ' CZ ' HD11 ' B' ' 42' ' ' ILE . 37.0 m-85 -88.08 158.1 18.68 Favored 'General case' 0 N--CA 1.456 -0.148 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -178.441 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 62' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -86.3 -29.6 22.91 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 167.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 63' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -155.61 110.28 2.19 Favored Pre-proline 0 CA--C 1.535 0.376 0 C-N-CA 123.655 0.782 . . . . 0.0 109.598 178.349 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 64' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -58.6 -11.51 11.67 Favored 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 124.04 3.16 . . . . 0.0 113.801 -177.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.66 -25.4 67.93 Favored 'General case' 0 CA--C 1.528 0.1 0 CA-C-N 118.191 0.451 . . . . 0.0 110.862 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 66' ' ' ASP . . . . . . . . . . . . . 78.4 m-20 -76.2 2.7 12.44 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -179.587 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 67' ' ' ALA . . . . . . . . . . . . . . . -66.97 -8.01 26.61 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.538 0.335 . . . . 0.0 111.341 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -62.73 -24.98 67.95 Favored 'General case' 0 N--CA 1.454 -0.26 0 O-C-N 122.149 -0.344 . . . . 0.0 110.969 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 69' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -120.78 -34.4 3.58 Favored 'General case' 0 C--O 1.228 -0.063 0 N-CA-C 112.731 0.641 . . . . 0.0 112.731 178.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 70' ' ' ALA . . . . . . . . . . . . . . . -79.74 -9.09 59.6 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 123.346 0.658 . . . . 0.0 111.642 -176.025 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . . . . . . . . . 58.2 t -136.2 -43.99 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 CA-C-N 117.623 0.192 . . . . 0.0 111.111 -177.225 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 72' ' ' SER . . . . . . . . . . . . . 68.7 m -83.82 -2.41 56.32 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.985 -0.098 . . . . 0.0 111.197 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -76.61 -30.18 56.72 Favored Glycine 0 C--N 1.34 0.796 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 -178.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 74' ' ' ARG . . . . . . . . . . . . . 56.2 ttm-85 -162.76 131.8 4.16 Favored 'General case' 0 C--N 1.338 0.07 0 CA-C-N 117.376 0.588 . . . . 0.0 110.762 177.626 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . . . . . . . . . 26.0 p30 -160.11 153.52 22.22 Favored 'General case' 0 C--O 1.232 0.165 0 C-N-CA 123.61 0.764 . . . . 0.0 110.89 175.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 76' ' ' GLY . . . . . . . . . . . . . . . 56.37 41.49 87.73 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.71 -0.556 . . . . 0.0 111.71 175.455 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 77' ' ' TYR . . . . . . . . . . . . . 46.3 t80 -92.71 136.61 33.08 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 -173.102 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 78' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -67.51 91.75 0.29 Allowed 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 124.042 0.937 . . . . 0.0 112.224 -177.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 79' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -85.09 -175.31 5.69 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.393 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -68.73 77.05 0.3 Allowed 'General case' 0 N--CA 1.449 -0.524 0 C-N-CA 123.678 0.791 . . . . 0.0 112.379 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 81' ' ' GLY . . . . . . . . . . . . . . . 86.88 5.61 80.79 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 178.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 82' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -135.21 -176.86 4.4 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.351 0.66 . . . . 0.0 112.431 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 83' ' ' ARG . . . . . . . . . . . . . 2.3 tpt180 -139.7 129.08 24.1 Favored 'General case' 0 CA--C 1.522 -0.123 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -179.436 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 84' ' ' LEU . . . . . . . . . . . . . 10.7 mp -70.01 148.33 48.99 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 178.75 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 85' ' ' ARG . . . . . . . . . . . . . 43.0 mtp85 -131.12 125.72 33.84 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 173.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 86' ' ' VAL . . . . . . . . . . . . . 13.8 t -139.65 82.78 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.148 0 C-N-CA 123.562 0.745 . . . . 0.0 109.84 176.235 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 87' ' ' GLU . . . . . . . . . . . . . 23.8 pt-20 -147.37 161.47 40.94 Favored 'General case' 0 C--N 1.333 -0.118 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.038 -177.627 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 88' ' ' PHE . . . . . . . . . . . . . 6.0 p90 -76.16 151.99 83.95 Favored Pre-proline 0 CA--C 1.53 0.205 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 177.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 89' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo . . . . . 0 C--O 1.251 1.128 0 C-N-CA 123.455 2.77 . . . . 0.0 111.015 177.203 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.416 -3.061 0 C5'-C4'-C3' 110.043 -3.638 . 0.0 '__' . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -3.008 0 O4'-C1'-N19 111.648 3.448 . 0.363 2o . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ' C' . . . . . 0.426 ' C6 ' ' CE2' ' B' ' 19' ' ' TYR . . . . . . . . 0 O4'--C4' 1.425 -2.352 1 C5'-C4'-C3' 108.074 -4.951 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' ' A' . . . . . 0.47 ' C4 ' ' CE1' ' B' ' 58' ' ' PHE . . . . . . . . 0 O4'--C4' 1.424 -2.405 0 C5'-C4'-C3' 110.141 -3.572 . 0.0 OUTLIER . 0.0 . . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.419 -2.853 0 C3'-C2'-C1' 104.993 3.882 . 0.0 OUTLIER '7D dist 4p' 0.0 . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ' A' . . . . . . . . . . . . . . . . . . . . 0 O4'--C4' 1.417 -2.967 0 C5'-C4'-C3' 109.604 -3.93 . 0.247 2u . 0.0 . . . . . . . . . . 0 0 . 1 stop_ save_